PUBLIC COMMENT DRAFT
Toxicity Assessment and Proposed Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) in Drinking Water
PUBLIC COMMENT DRAFT
Toxicity Assessment and Proposed Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) in Drinking Water

Prepared by:

U.S. Environmental Protection Agency
Office of Water (4304T)
Health and Ecological Criteria Division
Washington, DC 20460

EPA Document Number: EPA 822P23005

March 2023
Disclaimer

This document is a public comment draft for review purposes only. This information is distributed solely for the purpose of public comment. It has not been formally disseminated by the U.S. Environmental Protection Agency. It does not represent and should not be construed to represent any agency determination or policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.
Acknowledgments

This document was prepared by the Health and Ecological Criteria Division, Office of Science and Technology, Office of Water (OW) of the U.S. Environmental Protection Agency (EPA). The agency gratefully acknowledges the valuable contributions of EPA scientists from the OW, Office of Research and Development (ORD), the Office of Children’s Health Protection (OCHP), and the Office of Land and Emergency Management (OLEM). OW authors of the document include Brittany Jacobs; Casey Lindberg; Carlye Austin; Kelly Cunningham; Barbara Soares; Ruth Etzel; and Colleen Flaherty. ORD authors of the document include J. Michael Wright; Elizabeth Radke; Michael Dzierlenga; Todd Zurlinden; Jacqueline Weinberger; Thomas Bateson; Hongyu Ru; and Kelly Garcia. OCHP authors of the document include Chris Brinkerhoff; and Greg Miller (formerly OW). EPA scientists who provided valuable contributions to the development of the document from OW include Adrienne Keel; Joyce Donohue (now retired); Amanda Jarvis; James R. Justice; from ORD include Timothy Buckley; Allen Davis; Peter Egeghy; Elaine Cohen Hubal; Pamela Noyes; Kathleen Newhouse; Ingrid Druwe; Michelle Angrish; Christopher Lau; Catherine Gibbons; and Paul Schlosser; and from OLEM includes Stiven Foster. Additional contributions to draft document review from managers and other scientific experts, including the ORD Toxicity Pathways Workgroup and experts from the Office of Chemical Safety and Pollution Prevention (OSCPP), are greatly appreciated. The agency gratefully acknowledges the valuable management oversight and review provided by Elizabeth Behl (OW); Jamie Strong (formerly OW; currently ORD); Susan Euling (OW); Kristina Thayer (ORD); Andrew Kraft (ORD); Viktor Morozov (ORD); Vicki Soto (ORD); and Garland Waleko (ORD).

The systematic review work included in this assessment was prepared in collaboration with ICF under the U.S. EPA Contracts EP-C-16-011 (Work Assignment Nos. 4-16 and 5-16) and PR-OW-21-00612 (TO-0060). ICF authors serving as the toxicology and epidemiology technical leads were Samantha Snow and Sorina Eftim. ICF and subcontractor authors of the assessment include Kezia Addo; Barrett Allen; Robyn Blain; Lauren Browning; Grace Chappell; Meredith Clemons; Jonathan Cohen; Grace Cooney; Ryan Cronk; Katherine Duke; Hannah Eglington; Zhenyu Gan; Sagi Enicole Gillera; Rebecca Gray; Joanna Greig; Samantha Goodman; Anthony Hannani; Samantha Hall; Jessica Jimenez; Anna Kolanowski; Madison Lee; Cynthia Lin; Alexander Lindahl; Nathan Lothrop; Melissa Miller; Rachel O’Neal; Ashley Pepriell; Mia Peng; Lisa Prince; Johanna Rochester; Courtney Rosenthal; Amanda Ross; Karen Setty; Sheerin Shirajian; Raquel Silva; Jenna Sprowles; Wren Tracy; Joanne Trgovcich; Janielle Vidal; Maricruz Zarco; and Pradeep Rajan (subcontractor).

ICF contributors to this assessment include Sarah Abosede Alli; Tonia Aminone; Caelen Caspers; Laura Charney; Kathleen Clark; Sarah Colley; Kaylyn Dinh; Julia Finver; Lauren Fitzharris; Caroline Foster; Jeremy Frye; Angelina Guiducci; Pamela Hartman; Cara Henning; Audrey Ichida; Caroline Jasperse; Kaedra Jones; Michele Justice; Afrodit Katsigiannakis; Gillian Laidlaw; Yi Lu; Denyse Marquez Sanchez; Alicia Murphy; Emily Pak; Joei Robertson; Lucas Rocha Melogno; Andrea Santa-Rios; Alessandria Schumacher; Nkoli Ukpabi; and Wanchen Xiong.
# Contents

Disclaimer ................................................................................................................................. i  
Acknowledgments .................................................................................................................... ii  
Contents ........................................................................................................................................ iii  
Figures ........................................................................................................................................ vi  
Tables ......................................................................................................................................... xi  
Acronyms and Abbreviations ....................................................................................................... xiii  

## 1 Background ......................................................................................................................... 1-1  
1.1 National Primary Drinking Water Regulation for Per- and Polyfluoroalkyl Substances under the Safe Drinking Water Act ................................................................. 1-1  
1.2 Background on PFAS ........................................................................................................ 1-1  
1.3 Evaluation of PFOA Under SDWA .................................................................................. 1-2  
1.4 Purpose of this Document ............................................................................................... 1-3  
1.5 Chemical Identity ............................................................................................................. 1-5  
1.6 Occurrence Summary ......................................................................................................... 1-6  
1.6.1 Biomonitoring ................................................................................................................ 1-6  
1.6.2 Ambient Water .............................................................................................................. 1-7  
1.6.3 Drinking Water ............................................................................................................. 1-8  

## 2 Summary of Assessment Methods ...................................................................................... 2-10  
2.1 Introduction to the Systematic Review Assessment Methods ....................................... 2-10  
2.1.1 Literature Search ......................................................................................................... 2-11  
2.1.2 Literature Screening .................................................................................................... 2-12  
2.1.3 Study Quality Evaluation for Epidemiological Studies and Animal Toxicological Studies ......................................................................................................................... 2-13  
2.1.4 Data Extraction ........................................................................................................... 2-13  
2.1.5 Evidence Synthesis and Integration .......................................................................... 2-14  
2.2 Dose-Response Assessment .............................................................................................. 2-15  
2.2.1 Approach to POD and RfD Derivation for Non-Cancer Health Outcomes ............... 2-15  
2.2.2 Cancer Assessment ..................................................................................................... 2-17  
2.3 MCLG Derivation .............................................................................................................. 2-19  

## 3 Results of the Health Effects Systematic Review and Toxicokinetics Methods ............. 3-1  
3.1 Literature Search and Screening Results .......................................................................... 3-1  
3.1.1 Results for Epidemiology Studies of PFOA by Health Outcome ......................... 3-4  
3.1.2 Results for Animal Toxicological Studies of PFOA by Health Outcome ................. 3-4  
3.2 Data Extraction Results .................................................................................................. 3-5  
3.3 Toxicokinetic Synthesis .................................................................................................. 3-5  
3.3.1 ADME ....................................................................................................................... 3-5  
3.3.2 Pharmacokinetic Models ............................................................................................ 3-17  
3.4 Non-Cancer Health Effects Evidence Synthesis and Integration .................................. 3-25
3.4.1 Hepatic ................................................................. 3-25
3.4.2 Immune .............................................................. 3-93
3.4.3 Cardiovascular ..................................................... 3-143
3.4.4 Developmental ..................................................... 3-190
3.4.5 Evidence for Other Health Outcomes ..................... 3-261
3.5 Cancer Evidence Study Quality Evaluation, Synthesis, Mode of Action Analysis and Weight of Evidence ................................................. 3-261
3.5.1 Human Evidence Study Quality Evaluation and Synthesis ................................................. 3-261
3.5.2 Animal Evidence Study Quality Evaluation and Synthesis ............................................... 3-268
3.5.3 Mechanistic Evidence ........................................... 3-272
3.5.4 Weight Of Evidence for Carcinogenicity .................. 3-289
3.5.5 Cancer Classification ............................................. 3-306

4 Dose-Response Assessment ........................................................................ 4-1
4.1 Non-Cancer ........................................................................................................ 4-1
4.1.1 Study and Endpoint Selection .............................................................................. 4-1
4.1.2 Estimation or Selection of Points of Departure (PODs) for RfD Derivation ......................... 4-14
4.1.3 Pharmacokinetic Modeling Approaches to Convert Administered Dose to Internal Dose in Animals and Humans .......................................... 4-18
4.1.4 Application of Pharmacokinetic Modeling for Animal-Human Extrapolation of PFOA Toxicological Endpoints and Dosimetric Interpretation of Epidemiological Endpoints .......................................... 4-28
4.1.5 Derivation of Candidate Chronic Oral Reference Doses (RfDs) ............................. 4-41
4.1.6 RfD Selection ......................................................................................................... 4-49
4.2 Cancer .................................................................................................................. 4-54
4.2.1 Animal Toxicological Studies ............................................................................... 4-54
4.2.2 Epidemiological Studies ....................................................................................... 4-56
4.2.3 CSF Selection ........................................................................................................ 4-59
4.2.4 Application of Age-Dependent Adjustment Factors ............................................. 4-59

5 MCLG Derivation ................................................................................................. 5-1

6 Effects Characterization ..................................................................................... 6-1
6.1 Addressing Uncertainties in the Use of Epidemiological Studies for Quantitative Dose-Response Analyses ................................................................................. 6-1
6.2 Comparisons Between Toxicity Values Derived from Animal Toxicological Studies and Epidemiological studies ................................................................. 6-4
6.3 Updated Approach to Animal Toxicological RfD Derivation Compared to the 2016 PFOA HESD ....................................................................................... 6-5
6.4 Consideration of Alternative Conclusions Regarding the Weight of Evidence of PFOA Carcinogenicity ................................................................. 6-7
6.5 Health Outcomes with Evidence Integration Judgments of Evidence Suggests Bordering on Evidence Indicates ........................................................ 6-10
6.6 Challenges and Uncertainty in Modeling .......................................................... 6-12
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.6.1</td>
<td>Modeling of Animal Internal Dosimetry</td>
<td>6-12</td>
</tr>
<tr>
<td>6.6.2</td>
<td>Modeling of Human Dosimetry</td>
<td>6-13</td>
</tr>
<tr>
<td>6.6.3</td>
<td>Approach of Estimating a Benchmark Dose from a Regression Coefficient</td>
<td>6-15</td>
</tr>
<tr>
<td>6.7</td>
<td>Human Dosimetry Models: Consideration of Alternate Modeling Approaches</td>
<td>6-16</td>
</tr>
<tr>
<td>6.8</td>
<td>Sensitive Populations</td>
<td>6-19</td>
</tr>
<tr>
<td>6.8.1</td>
<td>Fetuses, Infants, Children</td>
<td>6-20</td>
</tr>
<tr>
<td>6.8.2</td>
<td>Sex Differences</td>
<td>6-20</td>
</tr>
<tr>
<td>6.8.3</td>
<td>Other Susceptible Populations</td>
<td>6-21</td>
</tr>
<tr>
<td>7</td>
<td>References</td>
<td>7-1</td>
</tr>
</tbody>
</table>
Figures

Figure 1-1. Distribution of PFOA Concentrations in Surface Waters by State/Waterbody (excluding Great Lakes) in the U.S. ................................................................. 1-8

Figure 3-1. Summary of Literature Search and Screening Process for PFOA ........................ 3-3

Figure 3-2. Summary of Epidemiology Studies of PFOA Exposure by Health System and Study Designa ................................................................. 3-4

Figure 3-3. Summary of Animal Toxicological Studies of PFOA Exposure by Health System, Study Design, and Speciesab ................................................................. 3-5

Figure 3-4. Schematic for a Physiologically Motivated Renal Resorption PK Model for PFOA .................................................................................................................. 3-22

Figure 3-5. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA Exposure and Hepatic Effects Published Before 2016 (References in the 2016 HESD) .................................................................................................................. 3-26

Figure 3-6. Overall ALT Levels from Pre-2016 HESD Epidemiology Studies Following Exposure to PFOA .................................................................................................. 3-27

Figure 3-7. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA Exposure and Hepatic Effectsa ................................................................. 3-30

Figure 3-8. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA Exposure and Hepatic Effects (Continued)a ................................................................. 3-31

Figure 3-9. Odds of Elevated ALT Levels from Epidemiology Studies Following Exposure to PFOA ............................................................................................................. 3-33

Figure 3-10. ALT Levels from Medium Confidence Epidemiology Studies Following Exposure to PFOA ...................................................................................................... 3-34

Figure 3-11. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA Exposure and Hepatic Effects ................................................................. 3-36

Figure 3-12. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA Exposure and Hepatic Effects (Continued) ................................................................. 3-37

Figure 3-13. Relative Liver Weight in Rodents Following Exposure to PFOA (logarithmic scale) ............................................................................................................. 3-40

Figure 3-14. Percent Change in Serum Enzyme Levels Relative to Controls in Male Mice Following Exposure to PFOAab .................................................................................. 3-42

Figure 3-15. Percent Change in Enzyme Levels Relative to Controls in Male Rats Following Exposure to PFOAa .................................................................................. 3-43

Figure 3-16. Percent Change in Enzyme Levels Relative to Controls in Female Rodents Following Exposure to PFOAa .................................................................................. 3-45
Figure 3-17. Summary of Mechanistic Studies of PFOA and Hepatic Effects .......................... 3-51
Figure 3-18. Summary of Study Quality Evaluation Results Epidemiology Studies of PFOA and Immune Effects Published Before 2016 (References in 2016 HESD) .................. 3-94
Figure 3-19. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Immunosuppression Effects .................................................................................. 3-96
Figure 3-20. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Immunosuppression Effects (Continued) .................................................. 3-97
Figure 3-21. Overall Tetanus Antibody Levels in Children from Epidemiology Studies Following Exposure to PFOA ........................................................................................................ 3-99
Figure 3-22. Overall Tetanus Antibody Levels in Children from Epidemiology Studies Following Exposure to PFOA (Continued) .................................................................................. 3-100
Figure 3-23. Overall Diphtheria Antibody Levels in Children from Epidemiology Studies Following Exposure to PFOA ........................................................................................................ 3-101
Figure 3-24. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Immune Hypersensitivity Effects ........................................................................ 3-109
Figure 3-25. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Autoimmune Effects .......................................................................................... 3-114
Figure 3-26. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA and Immune Effects .......................................................................................... 3-116
Figure 3-27. Globulin Levels in Rodents Following Exposure to PFOA (logarithmic scale). 3-122
Figure 3-28. Summary of Mechanistic Studies of PFOA and Immune Effects.......................... 3-122
Figure 3-29. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cardiovascular Effects Published Before 2016 (References from 2016 HESD) ........................................................................................................ 3-144
Figure 3-30. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cardiovascular Effects .................................................................................. 3-147
Figure 3-31. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cardiovascular Effects (Continued) ............................................................ 3-148
Figure 3-32. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cardiovascular Effects (Continued) ............................................................ 3-149
Figure 3-33. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Serum Lipids Published Before 2016 (References from 2016 PFOA HESD) ........................................................................................................ 3-156
Figure 3-34. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Serum Lipids ........................................................................................................ 3-159
Figure 3-35. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Serum Lipids (Continued) .................................................................................. 3-160

Figure 3-36. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Serum Lipids (Continued) .................................................................................. 3-161

Figure 3-37. Odds of High Total Cholesterol in Adults from Epidemiology Studies Following Exposure to PFOA ........................................................................................................ 3-167

Figure 3-38. Overall Levels of Total Cholesterol in Adults from Epidemiology Studies Following Exposure to PFOA ........................................................................................................ 3-168

Figure 3-39. Overall Levels of Total Cholesterol in Adults from Epidemiology Studies Following Exposure to PFOA (Continued) .................................................................................. 3-169

Figure 3-40. Overall Levels of Total Cholesterol in Adults from Epidemiology Studies Following Exposure to PFOA (Continued) .................................................................................. 3-170

Figure 3-41. Overall Levels of Total Cholesterol in Adults from Epidemiology Studies Following Exposure to PFOA (Continued) .................................................................................. 3-171

Figure 3-42. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA and Cardiovascular Effects ........................................................................ 3-175

Figure 3-43. Serum Lipid Levels in Rodents Following Exposure to PFOA (logarithmic scale) ........................................................................................................................................ 3-178

Figure 3-44. Summary of Mechanistic Studies of PFOA and Cardiovascular Effects .......... 3-179

Figure 3-45. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Developmental Effects Published before 2016 (References from 2016 PFOA HESD) ........................................................................................................ 3-191

Figure 3-46. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Weight Effects .................................................................................. 3-198

Figure 3-47. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Weight Effects (Continued) .................................................................................. 3-199

Figure 3-48. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Weight Effects (Continued) .................................................................................. 3-200

Figure 3-49. Overall Mean Birth Weight from Epidemiology Studies Following Exposure to PFOA ........................................................................................................ 3-202

Figure 3-50. Overall Mean Birth Weight from Epidemiology Studies Following Exposure to PFOA (Continued) ........................................................................................................ 3-203

Figure 3-51. Overall Mean Birth Weight from Epidemiology Studies Following Exposure to PFOA (Continued) ........................................................................................................ 3-204

Figure 3-52. Overall Mean Birth Weight from Epidemiology Studies Following Exposure to PFOA (Continued) ........................................................................................................ 3-205
Figure 3-53. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Small for Gestational Age and Low Birth Weight Effectsa .................. 3-208
Figure 3-54. Odds of Small-for-gestational-age in Children from High Confidence Epidemiology Studies Following Exposure to PFOA ........................................... 3-209
Figure 3-55. Odds of Small-for-gestational-age in Children from High Confidence Epidemiology Studies Following Exposure to PFOA (Continued) ....................... 3-210
Figure 3-56. Odds of Small-for-gestational-age in Children from Medium Confidence Epidemiology Studies Following Exposure to PFOA ........................................ 3-211
Figure 3-57. Odds of Low Birthweight in Children from Epidemiology Studies Following Exposure to PFOA ................................................................................. 3-212
Figure 3-58. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Length Effects ...................................................................... 3-214
Figure 3-59. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Length Effects (Continued) .................................................. 3-215
Figure 3-60. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Head Circumference Effects .................................................. 3-218
Figure 3-61. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Postnatal Growth ....................................................................... 3-224
Figure 3-62. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Preterm Birth Effects ................................................................. 3-228
Figure 3-63. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Fetal Loss .................................................................................. 3-231
Figure 3-64. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Defects ............................................................................... 3-232
Figure 3-65. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA and Developmental Effects ........................................................ 3-233
Figure 3-66. Maternal Body Weight in Rodents Following Exposure to PFOA (logarithmic scale) ................................................................................................................. 3-236
Figure 3-67. Placental Weights in Mice Following Exposure to PFOA ......................................................................................................................... 3-237
Figure 3-68. Offspring Mortality in Rodents Following Exposure to PFOAa ........................................... 3-240
Figure 3-69. Offspring Body Weight in Rodents Following Exposure to PFOA (logarithmic scale)a ................................................................. 3-243
Figure 3-70. Summary of Mechanistic Studies of PFOA and Developmental Effects ........ 3-247
Figure 3-71. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cancer Effects Published Before 2016 (References from 2016 PFOA HESD) ........................................................................................................ 3-263
Figure 3-72. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cancer Effects .......................................................... 3-265

Figure 3-73. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA and Cancer Effects .................................................. 3-269

Figure 3-74. Summary of Mechanistic Studies of PFOA and Cancer Effects .................. 3-272

Figure 4-1. Model Structure for Life Stage Modeling ..................................................... 4-21

Figure 4-2. Gestation/Lactation Predictions of PFOA in the Rat .................................. 4-23

Figure 4-3. Gestation/Lactation Predictions of PFOA in the Mouse in a Cross-Fostering Study .................................................................................. 4-24

Figure 4-4. Comparison of Candidate RfDs Resulting from the Application of Uncertainty Factors to POD\textsubscript{HEDS} Derived from Epidemiological and Animal Toxicological Studies ........................................................................... 4-50

Figure 4-5. Schematic depicting selection of the overall RfD for PFOA .......................... 4-53
Tables

Table 1-1. Chemical and Physical Properties of PFOA.......................................................... 1-6
Table 3-1. Database Literature Search Results ......................................................................... 3-1
Table 3-2. Associations Between PFOA Exposure and Cell Death or Necrosis in Rodents..... 3-48
Table 3-3. Evidence Profile Table for PFOA Hepatic Effects................................................... 3-87
Table 3-4. Associations between PFOA Exposure and Vaccine Response in Faroe Islands Studies................................................................................................................................................... 3-102
Table 3-5. Effects of PFOA Exposure on Cytokines Impacting Adaptive Immune Responses.............................................................................................................................................. 3-128
Table 3-6. Effects of PFOA Exposure on Pro-Inflammatory Cytokines and Markers of Inflammation........................................................................................................................................... 3-132
Table 3-7. Evidence Profile Table for PFOA Immune Effects..................................................... 3-136
Table 3-8. Evidence Profile Table for PFOA Cardiovascular Effects........................................ 3-184
Table 3-9. Study Design for Perinatal and Postweaning Exposure Levels for F1 Male and Female Rats for the NTP (2020, 7330145) Study............................................................................................................. 3-235
Table 3-10. Evidence Profile Table for PFOA Developmental Effects...................................... 3-255
Table 3-11. Incidences of Liver Adenomas in Male Sprague-Dawley Rats as Reported by NTP (2020, 7330145)................................................................................................................................................. 3-270
Table 3-12. Incidences of Pancreatic Acinar Cell Adenomas in Male Sprague-Dawley Rats as Reported by NTP (2020, 7330145)................................................................................................................................................. 3-271
Table 3-13. Incidences of Uterine Adenocarcinomas in Female Sprague-Dawley Rats from the Standard and Extended Evaluations (Combined) as Reported by NTP (2020, 7330145) ................................................................................................................................................. 3-272
Table 3-14. Mutagenicity Data from In Vitro Studies .................................................................. 3-276
Table 3-15. DNA Damage Data from In Vivo Studies ................................................................. 3-276
Table 3-16. DNA Damage Data from In Vitro Studies ................................................................. 3-277
Table 3-17. Comparison of the PFOA Carcinogenicity Database with the Likely Cancer Descriptor as Described in the Guidelines for Carcinogen Risk Assessment {U.S. EPA, 2005, 6324329} ................................................................................................. 3-307
Table 4-1. Summary of Endpoints and Studies Considered for Dose-Response Modeling and Derivation of Points of Departure for All Effects in Humans and Rodents..... 4-10
Table 4-2. Benchmark Response Levels Selected for BMD Modeling of Health Outcomes.... 4-16
Table 4-3. PK Parameters from Wambaugh et al. (2013, 2850932) Meta-Analysis of Literature Data for PFOA ................................................................. 4-19
Table 4-4. Model Predicted and Literature PK Parameter Comparisons for PFOA ................. 4-20
Table 4-5. Additional PK Parameters for Gestation/Lactation for PFOA ................................. 4-22
Table 4-6. Updated and Original Chemical-Specific Parameters for PFOA in Humans .......... 4-26
Table 4-7. Summary of Studies Reporting the Ratio of PFOA Levels in Breastmilk and Maternal Serum or Plasma ............................................................ 4-28
Table 4-8. PODHEDS Considered for the Derivation of Candidate RfD Values ....................... 4-31
Table 4-9. Uncertainty Factors for the Development of the Candidate Chronic RfD Values from Epidemiological Studies {U.S. EPA, 2002, 88824} .................. 4-43
Table 4-10. Uncertainty Factors for the Development of the Candidate Chronic RfD Values from Animal Toxicological Studies {U.S. EPA, 2002, 88824} ....................... 4-45
Table 4-11. Candidate Reference Doses (RfDs) ..................................................................... 4-47
Table 4-12. Cancer Slope Factors based on Animal Toxicological Data ......................... 4-56
Table 4-13. Cancer Slope Factors based on Epidemiological Data ...................................... 4-58
Table 6-1. Comparison of Candidate RfDs Derived from Animal Toxicological Studies for Priority Health Outcomes a ......................................................... 6-7
Table 6-2. Comparison of the PFOA Carcinogenicity Database with Cancer Descriptors as Described in the Guidelines for Carcinogen Risk Assessment {U.S. EPA, 2005, 6324329} ........................................................................................................ 6-9
# Acronyms and Abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>3D</td>
<td>Three-dimensional</td>
<td>BBB</td>
<td>Blood brain barrier</td>
</tr>
<tr>
<td>8-NO2Gua</td>
<td>8-nitroguanine</td>
<td>Bcl-2</td>
<td>B-cell lymphoma 2</td>
</tr>
<tr>
<td>8-OHdG</td>
<td>8-hydroxydeoxyguanosine</td>
<td>BCRP</td>
<td>Breast cancer resistance protein</td>
</tr>
<tr>
<td>AASLD</td>
<td>American Association for the Study of Liver Diseases</td>
<td>BK</td>
<td>Bradykinin</td>
</tr>
<tr>
<td>ABC</td>
<td>ATP Binding Cassette</td>
<td>BMD</td>
<td>Benchmark dose</td>
</tr>
<tr>
<td>ACG</td>
<td>American College of Gastroenterology</td>
<td>BMDL</td>
<td>Benchmark dose lower limit</td>
</tr>
<tr>
<td>AChE</td>
<td>Acetylcholinesterase</td>
<td>BMDL(_{10})</td>
<td>Dose level corresponding to the 95% lower confidence limit of a 10% change in response</td>
</tr>
<tr>
<td>Acot</td>
<td>Acyl-CoA thioesterase</td>
<td>BMDS</td>
<td>Benchmark Dose Software</td>
</tr>
<tr>
<td>ACOX</td>
<td>Acyl-CoA oxidase</td>
<td>C3a</td>
<td>Complement 3</td>
</tr>
<tr>
<td>Acsl1</td>
<td>Acyl-CoA synthetase</td>
<td>C(_{\text{last7}})</td>
<td>Average concentration over final week of study</td>
</tr>
<tr>
<td>ADME</td>
<td>Absorption, distribution, metabolism, excretion</td>
<td>CAD</td>
<td>Coronary artery disease</td>
</tr>
<tr>
<td>AFFF</td>
<td>Aqueous film forming foam</td>
<td>C(_{\text{avg}})</td>
<td>Average blood concentration</td>
</tr>
<tr>
<td>AL</td>
<td>Human-hamster hybrid cells</td>
<td>C(_{\text{avg,pup,gest}})</td>
<td>Area under the curve normalized per day during gestation</td>
</tr>
<tr>
<td>ALP</td>
<td>Alkaline phosphatase</td>
<td>C(_{\text{avg,pup,gest,lact}})</td>
<td>Area under the curve normalized dose per day during gestation/lactation</td>
</tr>
<tr>
<td>ALSPAC</td>
<td>Avon Longitudinal Study of Parents and Children</td>
<td>CASRN</td>
<td>Chemical Abstracts Service Registry Number</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
<td>CAT</td>
<td>Catalase</td>
</tr>
<tr>
<td>Ap1s1</td>
<td>Adaptor related protein complex 1 subunit sigma 1</td>
<td>C(_{\text{avg}})</td>
<td>Average blood concentration</td>
</tr>
<tr>
<td>APC</td>
<td>Antigen presenting cell</td>
<td>CAR</td>
<td>Constitutive androstane receptor</td>
</tr>
<tr>
<td>APFO</td>
<td>Ammonium perfluoroctanoate</td>
<td>CATRN</td>
<td>Constitutive androstane receptor</td>
</tr>
<tr>
<td>APOA4</td>
<td>Apolipoprotein A4</td>
<td>C(_{\text{avg}})</td>
<td>Average blood concentration</td>
</tr>
<tr>
<td>apoB</td>
<td>Apolipoprotein B</td>
<td>CAT</td>
<td>Catalase</td>
</tr>
<tr>
<td>ApoC-III</td>
<td>Apolipoprotein C-III</td>
<td>C(_{\text{avg,pup,gest}})</td>
<td>Area under the curve normalized per day during gestation</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
<td>C(_{\text{avg,pup,gest,lact}})</td>
<td>Area under the curve normalized dose per day during gestation/lactation</td>
</tr>
<tr>
<td>ATSDR</td>
<td>Agency for Toxic Substances and Disease Registry</td>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>BAFF</td>
<td>B cell activating factor</td>
<td>BAFF</td>
<td>B cell activating factor</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C\textsubscript{avg,pup,lact}</td>
<td>area under the curve normalized per day during lactation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C\textsubscript{avg,pup,total}</td>
<td>area under the curve in gestation/lactation added to the area under the curve from diet (post-weaning) divided by two years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCL</td>
<td>Contaminant Candidate List</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCK</td>
<td>Cholecystokinin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCK-8</td>
<td>Cell Counting Kit-8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD</td>
<td>Circular dichronism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cDNA</td>
<td>complementary DNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ces</td>
<td>Carboxylesterases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CETP</td>
<td>Cholesteryl ester transfer protein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-F</td>
<td>Carbon-fluorine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c-fos</td>
<td>Transcription factor complex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD</td>
<td>Coronary heart disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive heart failure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHO</td>
<td>Chinese hamster ovary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHOP</td>
<td>C/EBP homologous protein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CIMT</td>
<td>Carotid intima-media thickness test</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLR\textsubscript{R}</td>
<td>Renal clearance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C\textsubscript{max}</td>
<td>Maximum blood concentration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C\textsubscript{max_pup_gest}</td>
<td>Maximum fetal concentration during gestation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C\textsubscript{max_pup_lact}</td>
<td>Maximum fetal concentration during lactation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cpt1a</td>
<td>Carnitine palmitoyltransferase 1a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS</td>
<td>cancer slope factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>cancer slope factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSM</td>
<td>Cholestyramine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVD</td>
<td>Cardiovascular disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic blood pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCF</td>
<td>2′,7′-dichlorofluorescein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCF-DA</td>
<td>Dichlorodihydrofluorescein diacetate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DDE</td>
<td>Dichlorodiphenyl dichloethane</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMP</td>
<td>3,5-dimethyl pyrazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNBC</td>
<td>Danish National Birth Cohort</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNMT</td>
<td>Deoxyribonucleic acid methyltransferases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNP</td>
<td>Dinitrophenyl</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dpf</td>
<td>Days post fertilization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPP</td>
<td>Diabetes Prevention Program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPPOS</td>
<td>Diabetes Prevention Program and Outcomes Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DWI-BW</td>
<td>Body weight-based drinking water intake</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2</td>
<td>Estradiol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eGFR</td>
<td>Estimated glomerular filtration rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPA</td>
<td>Environmental Protection Agency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETC</td>
<td>Electron transport chain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F\textsubscript{1}</td>
<td>First generation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F\textsubscript{2}</td>
<td>Second generation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fabp</td>
<td>Fatty acid binding protein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescence activated cell sorting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FeNO</td>
<td>Fractional exhaled nitric oxide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FFA</td>
<td>Free fatty acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FT4</td>
<td>Free thyroxine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FXR</td>
<td>Farnesoid X receptor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Term</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------</td>
<td>--------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>GBCA</td>
<td>Genetic and Biomarker Study for Childhood Asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCL</td>
<td>Glutamate-cysteine ligase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GD</td>
<td>Gestation day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular filtration rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GGT</td>
<td>$\gamma$-glutamyltransferase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GM</td>
<td>Geometric mean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GO</td>
<td>Gene Ontology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSH</td>
<td>Glutathione</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSPE</td>
<td>Grape seed proanthocyanidin extract</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSSG</td>
<td>Glutathione disulfide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GST</td>
<td>Glutathione S-transferases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAT</td>
<td>Histone acetylase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAWC</td>
<td>Health Assessment Workplace Collaborative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDAC</td>
<td>Histone deacetylase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL</td>
<td>High-density-lipoprotein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HED</td>
<td>Human equivalent dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEK-293</td>
<td>Human embryonic kidney</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HERO</td>
<td>Health and Environmental Research Online</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HESD</td>
<td>Health Effects Support Document</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFC</td>
<td>7-hydroxytrifluoromethylcoumarin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFD</td>
<td>High-fat diet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFMD</td>
<td>Hand, foot, and mouth disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFPO</td>
<td>Hexafluoropropylene oxide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>Haemophilus influenza type b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HK</td>
<td>High-molecular-weight kininogen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hL-FABP</td>
<td>Human liver fatty acid binding protein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HMOX</td>
<td>Heme oxygenase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HNF</td>
<td>Hepatocyte nuclear factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOME</td>
<td>Health Outcomes and Measures of the Environment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPA</td>
<td>Hypothalamic-pituitary-adrenal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR</td>
<td>Hazard ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRL</td>
<td>Health reference level</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HSA</td>
<td>Human serum albumin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IARC</td>
<td>International Agency for Research on Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDL</td>
<td>Intermediate-density lipoprotein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN</td>
<td>Interferon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ig</td>
<td>Immunoglobulin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGF-1</td>
<td>Insulin-like growth factor 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IHIC</td>
<td>Hepatic immune cell</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL</td>
<td>Inflammatory cytokine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INMA</td>
<td>Spanish Environment and Childhood (Infancia y Medio Ambiente)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IQR</td>
<td>Interquartile range</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRIS</td>
<td>Integrated Risk Information System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IP</td>
<td>Intraperitoneal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPCS</td>
<td>International Programme on Chemical Safety</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>k_{12}</td>
<td>Intercompartment transfer rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>k_{a}</td>
<td>Absorption rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K_{d}</td>
<td>Disassociation constant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K_{H}</td>
<td>Henry’s Law Constant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KK</td>
<td>Kallikrein-kinn system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KLH</td>
<td>Keyhole limpet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K_{mem/w}</td>
<td>Membrane/water partition coefficients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K_{oc}</td>
<td>Organic carbon-water partitioning coefficient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K_{ow}</td>
<td>Octanol-water partition coefficient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LBW</td>
<td>Low birth weight</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCM</td>
<td>Liver capsular macrophage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCT</td>
<td>Leydig cell tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD</td>
<td>Lactation day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL</td>
<td>Low-density lipoprotein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L-FABP</td>
<td>Liver fatty acid binding protein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LH</td>
<td>Luteinizing hormone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOAEL</td>
<td>Lowest-observed-adverse-effect level</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOD</td>
<td>Limit of detection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lpl</td>
<td>Lipoprotein lipase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTRI</td>
<td>Lower respiratory tract infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LXR</td>
<td>Liver X receptor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LYZ</td>
<td>Lysozyme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M/P</td>
<td>Milk/plasma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAIT</td>
<td>Mucosal associated invariant T</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCLG</td>
<td>Maximum Contaminant Level Goal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Me-PFOSAA-AcOH</td>
<td>2-(N-Methyl-perfluorooctane sulphonamido) acetic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>or MeFOSAA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOD</td>
<td>Nucleotide-binding and oligomerization domain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOS</td>
<td>Nitric oxide synthase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nrf2</td>
<td>Nuclear factor erythroid 2–related factor 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NTCP</td>
<td>Sodium-taurocholate cotransporting polypeptide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAFLD</td>
<td>Non-alcoholic fatty liver disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NF-κB</td>
<td>Nuclear factor kappa B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NO</td>
<td>Nitric oxide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>No-observed-adverse-effect level</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOD</td>
<td>Nucleotide-binding and oligomerization domain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOS</td>
<td>Nitric oxide synthase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPDWR</td>
<td>National Primary Drinking Water Regulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Me-101</td>
<td>NTP National Toxicology Program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDA</td>
<td>Malondialdehyde</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MFC</td>
<td>7-methoxy-4-trifluoromethylcoumarin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>miRNA or miRs</td>
<td>Microribonucleic acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMP</td>
<td>Mitochondrial membrane potential</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td>Measles, mumps, and rubella</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MOA</td>
<td>Mode of action</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MOBA</td>
<td>Norwegian Mother, Father, and Child Cohort Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRL</td>
<td>Minimum reporting level</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger ribonucleic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRP</td>
<td>Multidrug resistance-associated proteins</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MS</td>
<td>Multiple sclerosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MyD</td>
<td>Myeloid differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Me-PFOSAA-AcOH</td>
<td>2-(N-Methyl-perfluorooctane sulphonamido) acetic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OATPs</td>
<td>Organic anion transporting polypeptides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OATs</td>
<td>Organic anion transporters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCM</td>
<td>Organotypic culture models</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OECD</td>
<td>Organisation for Economic Co-operation and Development</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td>Odds Ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORD</td>
<td>Office of Research and Development</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OST</td>
<td>Office of Science and Technology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P0</td>
<td>Parental generation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p0AL</td>
<td>Mitochondrial deficient cell line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PACT</td>
<td>Pancreatic acinar cell tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAD</td>
<td>Peripheral artery disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PanIN</td>
<td>Pancreatic intraepithelial neoplasia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBMC</td>
<td>Peripheral blood mononuclear cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBPK</td>
<td>Physiologically-based pharmacokinetic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC</td>
<td>Partition coefficient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDCD</td>
<td>Programmed cell death protein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PECO</td>
<td>Populations, Exposures, Comparator, and Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PERK</td>
<td>Protein kinase-like endoplasmic reticulum kinase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFAA</td>
<td>Perfluoroalkyl acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFAS</td>
<td>Per- and polyfluoroalkyl Substances</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFBA</td>
<td>Perfluorobutanoic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFCAs</td>
<td>Perfluoroalkyl carboxylic acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFDA</td>
<td>Perfluorodecanoic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFDoDA</td>
<td>Perfluorododecanoic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFHpA</td>
<td>Perfluoroheptanoic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFHxA</td>
<td>Perfluorohexanoic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFHxS</td>
<td>Perfluorohexane-sulfonate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFNA</td>
<td>Perfluorononanoic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFOA</td>
<td>Perfluorooctanoic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFOS</td>
<td>Perfluoroctane sulfonic acid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PG</td>
<td>Prostaglandin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$P_{ion}$</td>
<td>Passive anionic permeability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PK</td>
<td>Pharmacokinetic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pKa</td>
<td>Negative base-10 logarithm of acid dissociation constant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PLCO</td>
<td>Prostate, Lung, Colorectal, and Ovarian Screening Trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$P_{milk}$</td>
<td>Maternal milk: blood partition coefficient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PND</td>
<td>Postnatal day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PNW</td>
<td>Postnatal week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POD</td>
<td>Point of departure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$POD_{HED}$</td>
<td>Point of departure human equivalent dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POUNDs-Lost</td>
<td>Prevention of Obesity Using Novel Dietary Strategies-Lost</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PP2A</td>
<td>Protein phosphatase 2A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPAR</td>
<td>Peroxisome proliferator activated receptor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPK</td>
<td>Plasma prekallikrein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ppm</td>
<td>Parts per million</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR-</td>
<td>Progesterone receptor negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSA</td>
<td>Prostate-specific antigen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTB</td>
<td>Preterm birth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PWS</td>
<td>Public water system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PXR</td>
<td>Pregnane X receptor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q1</td>
<td>Quartile one</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q2</td>
<td>Quartile two</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q3</td>
<td>Quartile three</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q4</td>
<td>Quartile four</td>
<td></td>
<td></td>
</tr>
<tr>
<td>QA</td>
<td>Quality assurance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$R_0$</td>
<td>Baseline risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$r_0^{milk}$</td>
<td>Starting milk consumption rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$r_1^{milk}$</td>
<td>Week 1 milk consumption rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$r_2^{milk}$</td>
<td>Week 2 milk consumption rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$r_3^{milk}$</td>
<td>Week 3 milk consumption rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RARα</td>
<td>Retinoic acid receptor α</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RASA3</td>
<td>RAS P21 protein Activator 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCC</td>
<td>Renal cell carcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RD</td>
<td>Regular diet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RfD</td>
<td>Reference dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$R_{fan}$</td>
<td>Fetus:mother concentration ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$r_i^{milk}$</td>
<td>Milk consumption rate for the $i^{th}$ week of lactation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
<td>TSCATS</td>
<td>Toxic Substance Control Act Test Submissions</td>
</tr>
<tr>
<td>RNS</td>
<td>Reaction nitrogen species</td>
<td>TTEs</td>
<td>Transplacental efficiencies</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
<td>TTR</td>
<td>Transthyretin</td>
</tr>
<tr>
<td>RR</td>
<td>Rate ratio</td>
<td>TXB</td>
<td>Thromboxane</td>
</tr>
<tr>
<td>RRBS</td>
<td>Reduced representation bisulfite sequencing</td>
<td>UCMR3</td>
<td>Third Unregulated Contaminant Monitoring Rule</td>
</tr>
<tr>
<td>RSC</td>
<td>Relative source contribution</td>
<td>UF</td>
<td>Uncertainty factors</td>
</tr>
<tr>
<td>SAB</td>
<td>Science Advisory Board</td>
<td>UF$_A$</td>
<td>Interspecies UF</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
<td>UF$_D$</td>
<td>Database UF</td>
</tr>
<tr>
<td>SDWA</td>
<td>Safe Drinking Water Act</td>
<td>UF$_H$</td>
<td>Intraspecies UF</td>
</tr>
<tr>
<td>SES</td>
<td>Socioeconomic status</td>
<td>UF$_L$</td>
<td>LOAEL-to-NOAEL extrapolation UF</td>
</tr>
<tr>
<td>SGA</td>
<td>Small for gestational age</td>
<td>UF$_S$</td>
<td>UF for extrapolation from a subchronic to a chronic exposure duration</td>
</tr>
<tr>
<td>SIRT</td>
<td>Sirtuin</td>
<td>µM</td>
<td>Micromolar</td>
</tr>
<tr>
<td>slco1d</td>
<td>Solute carrier organic anion transporter</td>
<td>UPR</td>
<td>Unfolded protein response</td>
</tr>
<tr>
<td>SMR</td>
<td>Standardized mortality ratios</td>
<td>UF$_C$</td>
<td>Composite uncertainty factor</td>
</tr>
<tr>
<td>SOD</td>
<td>Superoxide dismutase</td>
<td>UV-vis</td>
<td>Ultraviolet-visible</td>
</tr>
<tr>
<td>SRBC</td>
<td>Sheep red blood cells</td>
<td>V$_d$</td>
<td>Volume of distribution</td>
</tr>
<tr>
<td>SREBP</td>
<td>Sterol regulatory element-binding protein</td>
<td>vtg1</td>
<td>Vitellogenin 1</td>
</tr>
<tr>
<td>T1D</td>
<td>Type 1 diabetes</td>
<td>VLDL</td>
<td>Very low-density lipoproteins</td>
</tr>
<tr>
<td>T4</td>
<td>Thyroxine</td>
<td>Vldlr</td>
<td>Very low-density lipoproteins receptor</td>
</tr>
<tr>
<td>TC</td>
<td>Total cholesterol</td>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>TET</td>
<td>Methylcytosine dioxygenases</td>
<td>WoS</td>
<td>Web of Science</td>
</tr>
<tr>
<td>tfc</td>
<td>Transcription factor</td>
<td>WTC</td>
<td>World Trade Center</td>
</tr>
<tr>
<td>tgf</td>
<td>Transforming growth factor</td>
<td>XBP1</td>
<td>Spliced X box-binding protein 1</td>
</tr>
<tr>
<td>TLDA</td>
<td>Taqman low density arrays</td>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>TLR</td>
<td>Toll-like receptor</td>
<td>WoS</td>
<td>Web of Science</td>
</tr>
<tr>
<td>T$_{max}$</td>
<td>Time to C$_{max}$</td>
<td>WTC</td>
<td>World Trade Center</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
<td>XBP1</td>
<td>Spliced X box-binding protein 1</td>
</tr>
<tr>
<td>TNP</td>
<td>Trinitrophenyl</td>
<td>ZFL</td>
<td>Zebrafish liver cell line</td>
</tr>
<tr>
<td>TReg</td>
<td>Regulatory T cell</td>
<td>ZFL</td>
<td>Zebrafish liver cell line</td>
</tr>
</tbody>
</table>
1 Background

1.1 National Primary Drinking Water Regulation for Per- and Polyfluoroalkyl Substances under the Safe Drinking Water Act

The U.S. Environmental Protection Agency (EPA) has initiated the process to develop a Maximum Contaminant Level Goal (MCLG) and National Primary Drinking Water Regulation (NPDWR) for per- and polyfluoroalkyl substances (PFAS), including perfluorooctanoic acid (PFOA), under the Safe Drinking Water Act (SDWA). As part of the proposed rulemaking, EPA prepared *Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) (CASRN 335-67-1) in Drinking Water* that described the derivation of candidate oral cancer toxicity values and noncancer toxicity values, a relative source contribution (RSC), and cancer classification, which could be subsequently used to derive an MCLG for PFOA. The agency sought peer review from the EPA Science Advisory Board (SAB) on key scientific issues related to the development of the MCLG, including the systematic review approach, oral toxicity values, RSC, and cancer classification. The SAB provided draft recommendations on June 3, 2022 and final recommendations on August 23, 2022 {U.S. EPA, 2022, 10476098}, and EPA addressed those recommendations in the development of this updated assessment, *Toxicity Assessment and Proposed Maximum Contaminant Level Goal (MCLG) for Perfluorooctanoic Acid (PFOA) in Drinking Water*, which derives toxicity values and an MCLG for PFOA. To be responsive to the SAB recommendations, EPA has, for example:

- updated and expanded the scope of the studies included in the assessment;
- expanded the systematic review steps beyond study quality evaluation to include evidence integration to ensure consistent hazard decisions;
- separated hazard identification and dose-response assessment;
- added protocols for all steps of the systematic review and more transparently described the protocols;
- evaluated alternative pharmacokinetic models and further validated the selected model;
- conducted additional dose-response analyses using additional studies and endpoints;
- evaluated and integrated mechanistic information;
- strengthened the weight of evidence for cancer and rationale for the cancer classification;
- strengthened the rationales for selection of points of departure for the noncancer health outcomes; and
- clarified language related to the relative source contribution determination including the relevance of drinking water exposures and the relationship between the reference dose (RfD) and the relative source contribution.

1.2 Background on PFAS

PFAS are a large group of anthropogenic chemicals that share a common structure of a chain of linked carbon and fluorine atoms. The PFAS group includes PFOA, perfluorooctane sulfonic acid (PFOS), and thousands of other chemicals. While the number of PFAS used globally in commercial products in 2021 was approximately 250 substances {Buck, 2021, 9640864}, the
universe of PFAS, including parent chemicals, metabolites, and degradants, is greater than 12,000 compounds (https://comptox.epa.gov/dashboard/chemical-lists/PFASMASTER). The 2018 Organisation for Economic Co-operation and Development (OECD) New Comprehensive Global Database of Per- and Polyfluoroalkyl Substances (PFAS) includes over 4,700 PFAS {OECD, 2018, 5099062}.

PFAS have been manufactured and used in a wide variety of industries around the world, including in the United States, since the 1950s. PFAS have strong, stable carbon-fluorine (C-F) bonds, making them resistant to hydrolysis, photolysis, microbial degradation, and metabolism {Ahrens, 2011, 2657780; Beach, 2006, 1290843; Buck, 2011, 4771046}. The chemical structures of PFAS enable them repel water and oil, remain chemically and thermally stable, and exhibit surfactant properties. These properties make PFAS useful for commercial and industrial applications and make many PFAS extremely persistent in the human body and the environment {Calafat, 2007, 1290899; Calafat, 2019, 5381304; Kwiatkowski, 2020, 7404231}. Due to their widespread use, physicochemical properties, persistence, and bioaccumulation potential, many different PFAS co-occur in environmental media (e.g., air, water, ice, sediment) and in tissues and blood of aquatic and terrestrial organisms, including humans.

Based on structure, there are many families or classes of PFAS, each containing many individual structural homologues that can exist as either branched-chain or straight-chain isomers {Buck, 2011, 4771046}. These PFAS families can be divided into two primary categories: non-polymers and polymers. The non-polymer PFAS include perfluoroalkyl acids (PFAAs), fluorotelomer-based substances, and per- and polyfluoroalkyl ethers. PFOA and PFOS belong to the PFAA family of the non-polymer PFAS category and are among the most researched PFAS in terms of human health toxicity and biomonitoring studies (for review, see Podder et al. (2021, 9640865)).

### 1.3 Evaluation of PFOA Under SDWA

SDWA, as amended in 1996, requires EPA to publish a list every 5 years of unregulated contaminants that are not subject to any current proposed or promulgated NPDWRs, are known or anticipated to occur in public water systems (PWSs), and might require regulation under SDWA. This list is known as the Contaminant Candidate List (CCL). PFOA is included on the third CCL (CCL 3) {U.S. EPA, 2009, 1508321} and on the fourth CCL (CCL 4) {U.S. EPA, 2016, 6115068}.

After PFOA and PFOS were listed on the CCL 3 in 2009, EPA initiated development of health effects support documents (HESDs) for PFOA and PFOS that provided information to federal, state, tribal, and local officials and managers of drinking water systems charged with protecting public health when these chemicals are present in drinking water {U.S. EPA, 2016, 3603365; U.S. EPA, 2016, 3603279}. The two HESDs were peer-reviewed in 2014 and revised based on consideration of peer reviewers’ comments, public comments, and additional studies published through December 2015. The resulting 2016 Health Effects Support Document for Perfluorooctanoic Acid (PFOA) {U.S. EPA, 2016, 3603279} described the assessment of cancer and noncancer health effects and the derivation of a noncancer RfD that served as the basis for the non-regulatory 2016 Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA) {U.S. EPA, 2016, 3982042}.
SDWA requires EPA to make regulatory determinations for at least five CCL contaminants every 5 years. EPA must begin developing an NPDWR when the agency makes a determination to regulate based on a finding that a contaminant meets all three of the following criteria:

- The contaminant may have an adverse effect on the health of persons.
- The contaminant is known to occur or there is substantial likelihood the contaminant will occur in PWSs with a frequency and at levels of public health concern.
- In the sole judgment of the Administrator, regulating the contaminant presents a meaningful opportunity for health risk reductions.

To make these determinations, the agency considers a range of information, including data to analyze occurrence of these compounds in finished drinking water and data on health effects that represent the latest science.

In the Final Regulatory Determinations for Contaminants on the Fourth Drinking Water Contaminant Candidate List {U.S. EPA, 2021, 9640861}, the agency made a determination to regulate PFOA and PFOS with an NPDWR. The agency concluded that all three criteria were met—PFOA and PFOS may have adverse health effects; they occur in PWSs with a frequency and at levels of public health concern; and, in the sole judgment of the Administrator, regulation of PFOA and PFOS presents a meaningful opportunity for health risk reduction for persons served by PWSs {U.S. EPA, 2021, 7487276}. As noted above in Section 1.1, EPA prepared Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) (CASRN 335-67-1) in Drinking Water as part of this rulemaking.

In June 2022, EPA published an interim Drinking Water Health Advisory for PFOA {U.S. EPA, 2022, 10671184} to supersede the 2016 Drinking Water Health Advisory based on analyses of more recent data described in the Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) (CASRN 335-67-1) in Drinking Water, which showed that PFOA can impact human health at exposure levels much lower than reflected by the 2016 Drinking Water Health Advisory {U.S. EPA, 2016, 3982042; U.S. EPA, 2022, 10671184}.

1.4 Purpose of this Document

Consistent with SDWA Section 1412(b)(3)(A) and (B), the primary purpose of this draft document is to obtain public comment on EPA’s toxicity assessment and proposed MCLG for PFOA by describing the best available science on health effects in order to derive an MCLG. To derive an MCLG, the latest science is identified, described, and evaluated, and then a cancer classification, toxicity values (i.e., a noncancer RfD and cancer slope factor (CSF)), and RSC are developed (Section 2.3). The draft cancer and noncancer toxicity values, cancer classification, and RSC derived in this assessment build upon the work described in the Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) (CASRN 335-67-1) in Drinking Water, the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}, and the previous 2016 PFOA Drinking Water Health Advisory {U.S. EPA, 2016, 3982042}. 
In addition to documenting EPA’s basis for the proposed MCLG, this document serves the following purposes:

- Transparently describe and document the literature searches conducted and systematic review methods used to identify health effects information (epidemiological and animal toxicological studies and physiologically-based pharmacokinetic (PBPK) models) in the literature.
- Describe and document literature screening methods, including use of the Populations, Exposures, Comparators, and Outcomes (PECO) criteria and the process for tracking studies throughout the literature screening.
- Identify epidemiological and animal toxicological literature that report health effects after exposure to PFOA (and its associated salts) as outlined in the PECO criteria.
- Evaluate and document the available mechanistic information (including toxicokinetic understanding) associated with PFOA exposure to inform interpretation of findings related to potential health effects in studies of humans and animals, with focus on five main health outcomes (developmental, hepatic, immune, and cardiovascular effects, and cancer).
- Describe and document the study quality evaluations conducted on epidemiological and animal toxicological studies considered potentially useful for point-of-departure (POD) derivation.
- Describe and document the data from high and medium confidence epidemiological and animal toxicological studies (as determined by study quality evaluations) that were considered for POD derivation; in cases of health effects with few available studies, data may be extracted from low confidence studies and used in the evidence syntheses. For dose-response assessment, only high and medium confidence studies were used to quantify health effects.
- Synthesize and document the adverse health effects evidence across studies, assessing health outcomes using a narrative approach. The assessment focuses on synthesizing the available evidence for five main health outcomes—developmental, hepatic, immune, and cardiovascular effects, and cancer—but also provides secondary syntheses of evidence for dermal, endocrine, gastrointestinal, hematologic, metabolic, musculoskeletal, nervous, ocular, renal, and respiratory effects; reproductive effects in males or females; and general toxicity.
- Develop and document strength of evidence judgments across studies (or subsets of studies) separately for epidemiological and for animal toxicological lines of evidence and integrate mechanistic analyses into judgments for the five main health outcomes.
- Develop and document integrated expert judgments across lines of evidence (i.e., epidemiological and animal toxicological lines of evidence) as to whether and to what extent the evidence supports that exposure to PFOA has the potential to be hazardous to humans. The judgments will be directly informed by the evidence syntheses and based on structured review of an adapted set of considerations for causality first introduced by Austin Bradford Hill {Hill, 1965, 71664}. 
- Describe and document the dose-response analyses conducted on the studies identified for POD derivation.
- Derive candidate RfDs and/or CSFs and select the RfD and/or CSF for PFOA and describe the rationale.
- Determine PFOA’s cancer classification using a weight of evidence approach.
- Characterize hazards (e.g., uncertainties, data gaps).

### 1.5 Chemical Identity

PFOA is a perfluorinated aliphatic carboxylic acid. It is a fully fluorinated organic synthetic acid that was used in the United States primarily as an aqueous dispersion agent and emulsifier in the manufacture of fluoropolymers and in a variety of water-, oil-, and stain-repellent products (e.g., adhesives, cosmetics, fire-fighting foams, greases and lubricants, paints, polishes) {NLM, 2022, 10369700}. It can exist in linear- or branched-chain isomeric form. PFOA is a strong acid that is generally present in solution as the perfluorooctanoate anion. Therefore, this assessment applies to all isomers of PFOA, as well as nonmetal salts of PFOA that would be expected to dissociate in aqueous solutions of pH ranging from 4 to 9 (e.g., in the human body).

PFOA is water soluble and mobile in water, with an estimated log organic carbon-water partition coefficient (log $K_{oc}$) of 2.06 {Zareitalabad, 2013, 5080561}. PFOA is stable in environmental media because it is resistant to environmental degradation processes, such as biodegradation, photolysis, and hydrolysis. In water, no natural degradation has been demonstrated, and it dissipates by advection, dispersion, and sorption to particulate matter. PFOA has low volatility in its ionized form but can adsorb to particles and be deposited on the ground and into water bodies. Because of its persistence, it can be transported long distances in air or water, as evidenced by detections of PFOA in arctic media and biota, including polar bears, ocean-going birds, and fish found in remote areas {Lindstrom, 2011, 1290802; Smithwick, 2006, 1424802}.

Physical and chemical properties and other reference information for PFOA are provided in Table 1-1. There is uncertainty in the estimation, measurement, and/or applicability of certain physical/chemical properties of PFOA in drinking water, including the $K_{oc}$ {Li, 2018, 4238331; Nguyen, 2020, 7014622}, octanol-water partition coefficient ($K_{ow}$), and Henry’s Law Constant ($K_H$) {ATSDR, 2021, 9642134; NCBI, 2022, 10411459}. For example, for $K_{ow}$, the Agency for Toxic Substances and Disease Registry (ATSDR) (2021, 9642134) and Lange et al. (2006, 10411376) reported that a value could not be measured because PFOA is expected to form multiple layers in octanol-water mixtures.

Table 1-1. Chemical and Physical Properties of PFOA

<table>
<thead>
<tr>
<th>Property</th>
<th>Perfluorooctanoic Acid; Experimental Average</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Abstracts Service Registry Number (CASRN)(a)</td>
<td>335-67-1</td>
<td>NLM, 2022, 10369702</td>
</tr>
<tr>
<td>Chemical Abstracts Index Name</td>
<td>2,2,3,3,4,4,5,5,6,7,7,8,8,8-pentadecafluorooctanoic acid</td>
<td>EPA CompTox Chemicals Dashboard</td>
</tr>
<tr>
<td>Synonyms</td>
<td>PFOA; pentadecafluoro-1-octanoic acid; pentadecafluoro-n-octanoic acid; octanoic acid, pentadecafluoro-; perfluorocaprylic acid; pentadecafluorooctanoic acid; perfluoroheptanecarboxylic acid</td>
<td>EPA CompTox Chemicals Dashboard</td>
</tr>
<tr>
<td>Chemical Formula</td>
<td>C(<em>8)HF(</em>{15})O(_2)</td>
<td>NLM, 2022, 10369702</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>414.069 g/mol</td>
<td>NLM, 2022, 10369700</td>
</tr>
<tr>
<td>Color/Physical State</td>
<td>White to off-white powder (ammonium salt)</td>
<td>NLM, 2022, 10369700</td>
</tr>
<tr>
<td>Boiling Point</td>
<td>192°C</td>
<td>NLM, 2022, 10369700</td>
</tr>
<tr>
<td>Melting Point</td>
<td>54.3°C</td>
<td>NLM, 2022, 10369700</td>
</tr>
<tr>
<td>Vapor Pressure</td>
<td>0.0316 mm Hg at 19°C; 0.017 mm Hg at 20°C</td>
<td>ATSDR, 2021, 9642134 (extrapolated)</td>
</tr>
<tr>
<td>Henry's Law Constant (K(_H))</td>
<td>0.362 Pa-m(^{-1})mol (converts to 3.57E-06 atm-m(^{-3})mol)</td>
<td>ATSDR, 2021, 9642134</td>
</tr>
<tr>
<td>pK(_a)</td>
<td>1.30, 2.80, –0.5–4.2, 0.5, 0.5</td>
<td>NLM, 2022, 10369700; ATSDR, 2021, 9642134</td>
</tr>
<tr>
<td>K(_oc)</td>
<td>631 ± 7.9 L/kg (mean ± 1 standard deviation of selected values)</td>
<td>Zareitalabad et al., 2013, 5080561 (converted from log K(_oc) to K(_oc))</td>
</tr>
<tr>
<td>Solubility in Water</td>
<td>2,290 mg/L at 24°C (estimated); 3,300 mg/L at 25°C; 4,340 mg/L at 24.1°C; 9,500 mg/L at 25°C; 3,300 mg/L at 25°C</td>
<td>NLM, 2022, 10369700; ATSDR, 2021, 9642134</td>
</tr>
</tbody>
</table>

Notes: K\(_oc\) = organic carbon-water partitioning coefficient; K\(_ow\) = octanol-water partition coefficient; pK\(_a\): negative base-10 logarithm of acid dissociation constant.
(a) The CASRN given is for linear PFOA, but the toxicity studies are based on both linear and branched, thus, this assessment applies to all isomers of PFOA.

1.6 Occurrence Summary

1.6.1 Biomonitoring

The U.S. Centers for Disease Control and Prevention (CDC) National Health and Nutrition Examination Survey (NHANES) has measured blood serum concentrations of several PFAS in the general U.S. population since 1999. PFOA and PFOS have been detected in up to 98% of serum samples taken in biomonitoring studies that are representative of the U.S. general population. Blood levels of PFOA and PFOS dropped 60% to 80% between 1999 and 2014, presumably due to restrictions on their commercial usage in the United States [CDC, 2017, 4296146]. In 2006, EPA secured a commitment from the eight major companies in the PFAS industry to reduce PFOA from facility emissions and product content by 95% no later than 2010,
and to work toward eliminating PFOA from emissions and product content by 2015 (https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/fact-sheet-20102015-pfoa-stewardship-program) (U.S. EPA 2006, 3005012). Manufacturers have since shifted to alternative short-chain PFAS, such as hexafluoropropylene oxide (HFPO) dimer acid and its ammonium salt (two “GenX chemicals”). Additionally, other PFAS were found in human blood samples from recent (2011–2016) NHANES surveys (e.g., perfluorodecanoic acid (PFDA), perfluorododecanoic acid (PFDoDA), perfluorooctanoic acid (PFHpA), perfluorohexanesulfonate (PFHxS), perfluorononanoic acid (PFNA), 2-(N-methylperfluorooctane sulfonamido) acetic acid (Me-PFOSA-AcOH or MeFOSAA)). There is less publicly available information on the occurrence and health effects of these replacement PFAS than for PFOA, PFOS, and other members of the carboxylic acid and sulfonate PFAS categories.

1.6.2 Ambient Water

Among the PFAS with established analytical methods for detection, PFOA (along with PFOS) is one of the dominant PFAS compounds detected in ambient water both in the U.S. and worldwide (Ahrens, 2011, 2657780; Benskin, 2012, 1274133; Dinglasan-Panlilio, 2014, 2545254; Nakayama, 2007, 2901973; Remucal, 2019, 5413103; Zareitalabad, 2013, 5080561). Most of the current, published PFOA occurrence studies have focused on a handful of broad geographic regions in the U.S., often targeting sites with known manufacturing or industrial uses of PFAS such as the Great Lakes, the Cape Fear River, and waterbodies near Decatur, Alabama (Boulanger, 2004, 1289983; Cochran, 2015, 9416545; Hansen, 2002, 1424808; Konwick, 2008, 1291088; Nakayama, 2007, 2901973; 3M Company, 2000, 9419083). PFOA concentrations in global surface waters range over seven orders of magnitude, generally in pg/L to ng/L concentrations, but sometimes reaching µg/L levels (Jarvis, 2021, 9416544; Zareitalabad, 2013, 5080561). Figure 1-1 (adapted from Jarvis, 2021, 9416544) shows the distribution of PFOA concentrations (ng/L) measured in surface waters for each U.S. state or waterbody (excluding the Great Lakes) with reported data in the publicly available literature.
PFOA concentrations in surface water tend to increase with increasing levels of urbanization. Across the Great Lakes region, PFOA was higher in the downstream lakes (Lake Erie and Lake Ontario), which are more heavily impacted by urbanization, and lower in the upstream lakes (Lakes Superior, Michigan, and Huron), which are located in a relatively rural and forested area {Remucal, 2019, 5413103}. Similarly, Zhang et al. (2016, 3470830) found measured surface water PFOA concentrations in urban areas (urban average PFOA concentration = 10.17 ng/L; n = 20) to be more than three times greater than concentrations in rural areas (rural average PFOA concentration = 2.95 ng/L; n = 17) within New Jersey, New York, and Rhode Island. Seasonal variations in PFOA levels in U.S. surface waters remain largely unknown due to a lack of data.

1.6.3 Drinking Water

Ingestion of drinking water is a potentially significant source of exposure to PFOA. Serum PFOA concentrations are known to be elevated among individuals living in communities with drinking water contaminated from environmental discharges.

Data from the third Unregulated Contaminant Monitoring Rule (UCMR 3) are currently the best available nationally representative finished water occurrence information for PFOA {U.S. EPA, 2017, 9419085; U.S. EPA, 2021, 7487276; U.S. EPA, 2023, 10692764}. UCMR 3 monitoring occurred recently (between 2013 and 2015) and analyzed 36,972 samples from 4,920 PWSs for PFOA. The minimum reporting level (MRL)\(^1\) for PFOA was 0.02 µg/L. A total of 379 samples

\(^1\) The minimum reporting level is the threshold at or above which a contaminant’s presence or concentration is officially quantitated. In the case of many of EPA’s nation-wide drinking water studies, the selected reporting level is known officially as the MRL. The MRL for each contaminant in each study is set at a level that EPA believes can be achieved with specified confidence by a broad spectrum of capable laboratories across the nation {U.S. EPA, 2021, 9640861}. 
from 117 PWSs had detections of PFOA (i.e., greater than or equal to the MRL). PFOA concentrations for these detections ranged from 0.02 µg/L (the MRL) to 0.349 µg/L (median concentration of 0.03 µg/L; 90th percentile concentration of 0.07 µg/L).

Because PFOS and PFOA cause similar types of adverse health effects and their 2016 lifetime Health Advisory values were the same, EPA recommended an additive approach when PFOA and PFOS co-occur at the same time and location in drinking water sources {U.S. EPA, 2016, 3603365; U.S. EPA, 2016, 3603279}. This approach was used in the analysis for Regulatory Determination for Contaminants on the Fourth Drinking Water Contaminant Candidate List {U.S. EPA, 2021, 7487276; U.S. EPA, 2021, 9640861} and the reported maximum summed concentration of PFOA and PFOS was 7.22 µg/L and the median summed value was 0.05 µg/L. Summed PFOA and PFOS concentrations reported in UCMR 3 exceeded one-half the health reference level (HRL) (0.035 µg/L) at a minimum of 2.4% of PWSs (115 PWSs) and exceeded the HRL (0.07 µg/L) at a minimum of 1.3% of PWSs (63 PWSs). Since the time of UCMR 3 monitoring, some sites where elevated levels of PFOA and PFOS were previously detected may have installed treatment for PFOA and PFOS, may have chosen to blend water from multiple sources, or may have otherwise remediated known sources of contamination. However, the extent of these changes is unknown. The identified 63 PWSs serve a total population of approximately 5.6 million people and are located across 25 states, tribes, or U.S. territories {U.S. EPA, 2017, 9419085}.

Data from more recent state monitoring efforts demonstrate occurrence in multiple geographic locations consistent with UCMR 3 monitoring {U.S. EPA, 2021, 7487276}. In 2021, at the time of publication of the final regulatory determinations for PFOA and PFOS, the finished water data available from fifteen states collected since UCMR 3 identified at least 29 PWSs where the summed concentrations of PFOA and PFOS exceeded the EPA HRL {U.S. EPA, 2021, 7487276}. The agency notes that some of these data are from targeted sampling efforts and thus may not be representative of levels found in all PWSs within the state or represent occurrence in other states. The state data demonstrate occurrence in multiple geographic locations and support EPA’s finding that PFOA and PFOS occur with a frequency and at levels of public health concern in drinking water systems across the United States.

Likewise, Glassmeyer et al. (2017, 3454569) sampled source and treated drinking water from 29 drinking water treatment plants for a suite of emerging chemical and microbial contaminants, including 11 PFAS. In this study, PFOA was reported in source water at 76% of systems, at a median concentration of 6.32 ng/L and maximum concentration of 112 ng/L. Similarly, in treated drinking water, PFOA was detected in 76% of systems, with a median concentration of 4.15 ng/L and maximum concentration of 104 ng/L.

---

2 Sum of PFOA + PFOS results rounded to 2 decimal places in those cases where a laboratory reported more digits.

3 An HRL is a health-based concentration against which the agency evaluates occurrence data when making decisions about regulatory determinations. The HRL for PFOA that was used to evaluate UCMR 3 results was 0.070 µg/L (equal to the 2016 Drinking Water Health Advisory value).
2 Summary of Assessment Methods

This section summarizes the methods used for the systematic review of the health literature for all isomers of PFOA and PFOS, as well as nonmetal salts of PFOA and PFOS that would be expected to dissociate in aqueous solutions of pH ranging from 4 to 9 (e.g., in the human body). The purposes of the systematic review were to identify the best available and most relevant health effects literature, to evaluate studies for quality, and to subsequently identify and consider studies that can be used for dose-response assessment. A detailed description of these methods is provided as a protocol in the Appendix (see PFOA Appendix).

The information that was gathered in the systematic review was used to update EPA’s 2016 HESD for PFOA {U.S. EPA, 2016, 3603279} and to derive an MCLG to support a National Primary Drinking Water Regulation under the Safe Drinking Water Act.

2.1 Introduction to the Systematic Review Assessment Methods

The methods used to conduct the systematic review for PFOA are consistent with the methods described in the draft and final EPA ORD Staff Handbook for Developing IRIS Assessments {U.S. EPA, 2020, 7006986; U.S. EPA, 2022, 10367891} (hereafter referred to as the Integrated Risk Information System (IRIS) Handbook) and a companion publication {Thayer, 2022, 10259560}. EPA’s IRIS Handbook has incorporated feedback from the National Academy of Sciences (NAS) at workshops held in 2018 and 2019 and was well regarded by the NAS review panel for reflecting “significant improvements made by EPA to the IRIS assessment process, including systematic review methods for identifying chemical hazards” {NAS, 2021, 9959764}. Furthermore, EPA’s IRIS program has used the IRIS Handbook to develop toxicological reviews for numerous chemicals, including some PFAS. Though the IRIS Handbook was finalized concurrently with this assessment, the alterations in the final IRIS Handbook compared to the draft version did not conflict with the methods used in this assessment. In fact, many of the NAS recommendations incorporated into the final IRIS handbook (e.g., updated methods for evidence synthesis and integration) were similarly incorporated into this assessment protocol {NAS, 2021, 9959764}. However, some of the study evaluation refinements recommended by NAS {2021, 9959764}, including clarifications to the procedure for evaluating studies for sensitivity and standardizing the procedure for evaluating reporting quality between human and animal studies, were not included in this assessment protocol, consistent with a 2011 NASEM recommendation not to delay releasing assessments until systematic review methods are finalized {NRC, 2011, 710724}. The assessment team concluded that implementing these minor changes in study quality evaluation would not change the assessment conclusions. Therefore, EPA considers the methods described herein to be consistent with the final IRIS Handbook and cites this version accordingly.

For this updated toxicity assessment, systematic review methods used were comparable to those in the IRIS Handbook for the steps of literature search, screening, study quality evaluation, data extraction, and the display of study quality evaluation results for all health outcomes through the 2020 literature searches {U.S. EPA, 2022, 10476098}. EPA then focused the subsequent steps of the systematic review process (synthesis of human, experimental animal, and mechanistic data; evidence integration; derivation of toxicity values) on health effects outcomes with the strongest
weight of evidence (developmental, hepatic, immune, cardiovascular, and cancer) based on the conclusions presented in EPA’s preliminary analysis, Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluoroctanoic Acid (PFOA) (CASRN 335-67-1) in Drinking Water, and consistent with the recommendations of the SAB {U.S. EPA, 2022, 10476098}.

This section provides a summary of methods used to search and screen the literature identified, evaluate the studies and characterize study quality, extract data, and identify studies that can be used for dose-response analysis. Extracted data are available in interactive visual formats (see Section 3) and can be downloaded in open access formats.

The systematic review protocol (see PFOA Appendix) provides a detailed description of the systematic review methods that were used. The particular focus of the protocol is the description of the problem formulation and key science issues guiding this assessment.

2.1.1 Literature Search

EPA assembled an inventory of epidemiological, animal toxicological, mechanistic, and toxicokinetic studies for this updated toxicity assessment based on three data streams: 1) literature published from 2014 through 2019 and then updated in the course of this review (i.e., through February 3, 2022) identified via literature searches of a variety of publicly available scientific literature databases, 2) literature identified via other sources (e.g., searches of the gray literature and studies shared with EPA by the SAB), and 3) literature identified in EPA’s 2016 HESDs for PFOA and PFOS {U.S. EPA, 2016, 3603279; U.S. EPA, 2016, 3603365}.

The search strings for the new searches for this updated assessment focused on the chemical name (PFOA, PFOS, and their related salts) with no limitations on lines of evidence (i.e., human/epidemiological, animal, in vitro, in silico) or health outcomes. EPA conducted an updated literature search in 2019 (covering January 2013 through April 11, 2019), which was subsequently updated by a search covering April 2019 through September 3, 2020 (2020 literature search) and another covering September 2020 through February 3, 2022 (2022 literature search) using the same search strings used in 2019.

The publicly available databases listed below were searched for literature containing the chemical search terms outlined in the PFOA Appendix:

- Web of Science™ (WoS) (Thomson Reuters),
- PubMed® (National Library of Medicine),
- ToxLine (incorporated into PubMed post 2019), and
- TSCATS (Toxic Substances Control Act Test Submissions).

In addition to the databases above, other review efforts and searches of publicly available sources were used to identify relevant studies, as listed below:

- studies cited in assessments published by other U.S. federal, international, and/or U.S. state agencies (this included assessments by ATSDR and California Environmental Protection Agency (CalEPA)),
• studies identified during mechanistic or toxicokinetic synthesis (i.e., during manual review of reference lists of relevant mechanistic and toxicokinetic studies deemed relevant after screening against mechanistic- and ADME-specific PECO criteria), and
• studies identified by the SAB in their final report dated August 23, 2022 {U.S. EPA, 2022, 10476098}.

The details of the studies included from the 2016 PFOA HESD as well as the search strings and literature sources searched are described in the Appendix (see PFOA Appendix).

EPA relied on epidemiological and animal toxicological literature identified in the 2016 PFOA HESD to identify studies for this updated assessment on five major health outcomes, as recommended by SAB and consistent with EPA’s preliminary analysis in the Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) (CASRN 335-67-1) in Drinking Water. The 2016 HESD for PFOA contained a summary of all relevant literature identified in searches conducted through 2013. EPA’s 2016 HESD relied on animal toxicological studies for quantitative analyses whereas epidemiology studies were considered qualitatively, as a supporting line of evidence. This updated assessment includes the study quality evaluation of epidemiological studies that were identified and included in the 2016 HESD for the five main health outcomes that had the strongest evidence. It also includes “key” animal toxicological studies from the HESD, which includes studies that were selected in 2016 for dose-response modeling. More details are provided in the Appendix (see PFOA Appendix).

All studies identified in the literature searches as well as those brought forward from the 2016 PFOA HESD were uploaded into the Health and Environmental Research Online (HERO) database (https://hero.epa.gov/hero/index.cfm/project/page/project_id/2608) and are publicly available.

EPA has continued to monitor the literature published since February 2022 for other potentially relevant studies published after the 2022 literature search update. Potentially relevant studies identified after February 2022 that were not recommended by the SAB in their final report are not included as part of the evidence base for this updated assessment but are provided in a repository detailing the results and potential impacts of new literature on the assessment (see PFOA Appendix A.3).

### 2.1.2 Literature Screening

This section summarizes the methods used to screen the identified health effects, mechanistic, and absorption, distribution, metabolism, excretion (ADME) literature. Briefly, PECO statements were established and detail the criteria used to screen all of the literature identified from literature searches in this assessment, prioritize the dose-response literature for dose-response assessment, and identify studies containing potentially important supplemental information that may inform key science questions described in the protocol. The PECO criteria used for screening the literature are provided in the Appendix (see PFOA Appendix).

Consistent with protocols outlined in the IRIS Handbook {U.S. EPA, 2022, 10476098}, studies identified in the literature searches and stored in HERO were imported into the Swift-Review software platform and the software was used to identify those studies most likely to be relevant.
to human health risk assessment. Studies captured then underwent title and abstract screening by at least two reviewers using DistillerSR or SWIFT ActiveScreener software, and studies that passed this screening underwent full-text review. Dose-response studies that met PECO inclusion criteria following both title and abstract screening and full-text review underwent study quality evaluation as described below. Studies tagged as supplemental and containing potentially relevant mechanistic or ADME (or toxicokinetic) data following title and abstract and full-text level screening underwent further screening using mechanistic- or ADME-specific PECO criteria, and those deemed relevant underwent light data extraction of key study elements (e.g., extraction of information about the tested species or population, mechanistic or ADME endpoints evaluated, dose levels tested; see PFOA Appendix). Supplemental studies that were identified as mechanistic or ADME via screening did not undergo study quality evaluation.

### 2.1.3 Study Quality Evaluation for Epidemiological Studies and Animal Toxicological Studies

For study quality evaluation of the PECO-relevant human epidemiological and animal toxicological studies identified in the three literature searches (all health outcomes for the 2019 and 2020 searches; the five priority health outcomes for the 2022 search), epidemiological studies from the 2016 HESD that reported results on one or more of the five priority health outcomes, and key animal toxicological studies from the 2016 HESD, two or more quality assurance (QA) reviewers, working independently, assigned ratings about the reliability of study results (good, adequate, deficient (or “not reported”), or critically deficient) for different evaluation domains. These study quality evaluation domains are listed below and details about the domains, including prompting questions and suggested considerations, are described in the PFOA Appendix.

- **Epidemiological study quality evaluation domains**: participant selection; exposure measurement criteria; outcome ascertainment; potential confounding; analysis; selective reporting; and study sensitivity.
- **Animal toxicological study quality evaluation domains**: reporting; allocation; observational bias/blinding; confounding/variable control; reporting and attrition bias; chemical administration and characterization; exposure timing, frequency, and duration; endpoint sensitivity and specificity; and results presentation.

The independent reviewers performed study quality evaluations using a structured platform housed within EPA’s Health Assessment Workplace Collaboration (HAWC; [https://hawcproject.org/](https://hawcproject.org/)). Once the individual domains were rated, reviewers independently evaluated the identified strengths and limitations of each study to reach an overall classification on study confidence of high, medium, low, or uninformative for each PECO-relevant endpoint evaluated in the study. A study can be given an overall mixed confidence classification if different PECO-relevant endpoints within the study receive different confidence ratings (e.g., medium and low confidence classifications).

### 2.1.4 Data Extraction

Data extraction was conducted for all relevant human epidemiological and animal toxicological studies determined to be of medium and high confidence after study quality evaluation. Data
were also extracted from low confidence epidemiological studies when data were limited for a health outcome or when there was a notable effect, consistent with the IRIS Handbook [U.S. EPA, 2022, 10476098]. Studies evaluated as being uninformative were not considered further and therefore did not undergo data extraction. All health endpoints were considered for extraction, regardless of the magnitude of effect or statistical significance of the response relative to the control group. The level of detail in data extractions for different endpoints within a study could differ based on how the data were presented for each outcome (i.e., ranging from a narrative to a full extraction of dose-response effect size information).

Extractions were conducted using DistillerSR for epidemiological studies and HAWC for animal toxicological studies. An initial reviewer conducted the extraction, followed by an independent QA review by a second reviewer who confirmed accuracy and edited/corrected the extraction as needed. Discrepancies in data extraction were resolved by discussion and confirmation within the extraction team.

Data extracted from epidemiology studies included population, study design, year of data collection, exposure measurement, and quantitative data from statistical models. Data extracted from statistical models reported in the studies included the health effect category, endpoint measured, sample size, description of effect estimate, covariates, and model comments. Data extracted from animal toxicological studies included information on the experimental design and exposure duration, species and number of animals tested, dosing regime, and endpoints measured. Further information about data extraction can be found in the PFOA Appendix.

### 2.1.5 Evidence Synthesis and Integration

For the purposes of this assessment, evidence synthesis and integration are considered distinct but related processes. Evidence synthesis refers to the process of analyzing the results of the available studies (including their strengths and weaknesses) for consistency and coherence, often by evidence stream (e.g., human or animal) and health effect outcome. In evidence integration, the evidence across streams is considered together and integrated to develop judgments (for each health outcome) about whether the chemical in question poses a hazard to human health.

The evidence syntheses are summary discussions of the body of evidence for each evidence stream (i.e., human and animal) for each health outcome analyzed. The available human and animal health effects evidence were synthesized separately, with each synthesis resulting in a summary discussion of the available evidence. For the animal toxicological evidence stream, evidence synthesis included consideration of studies rated high and medium confidence. For the epidemiological evidence stream, evidence synthesis was based primarily on studies of high and medium confidence, including discussion of study quality considerations, according to the recommendations of the SAB [U.S. EPA, 2022, 10476098]. Inferences drawn from studies described in the 2016 PFOA HESD were considered when drawing health effects conclusions. Epidemiological studies were excluded from the evidence synthesis narrative if they included data that were reported in multiple studies (e.g., overlapping NHANES studies). Studies reporting results from the same cohort and the same health outcome as another study were considered overlapping evidence, and these additional studies were not discussed in the evidence synthesis narrative to avoid duplication or overrepresentation of results from the same group of participants. In cases of overlapping studies, the study with the largest number of participants and/or the most accurate outcome measures was given preference. Consistent with the IRIS
Handbook {U.S. EPA, 2022, 10476098}, low confidence epidemiological studies and results were used only in a supporting role and given less weight during evidence synthesis and integration compared to high or medium confidence studies. Low confidence epidemiological studies were included in evidence syntheses in order to capture all of the available data for PFOA in the weight of evidence analyses.

For evidence integration, integrated judgments that took into account mechanistic considerations for the five priority health outcomes (i.e., cancer, hepatic, immune, cardiovascular, and developmental) were drawn for each health outcome across human and animal lines of evidence. The evidence integration provides a summary of the causal interpretations between PFOA exposure and health effects based on results of the available epidemiological and animal toxicological studies, in addition to the available mechanistic evidence. Considerations when evaluating the available studies included risk of bias, sensitivity, consistency, strength (effect magnitude) and precision, biological gradient/dose-response, coherence, and mechanistic evidence related to biological plausibility.

The evidence integration was conducted according to guidance outlined in the IRIS Handbook and the Systematic Review Protocol for the PFBA, PFHxA, PFHxS, PFNA, and PFDA (Anionic and Acid Forms) IRIS Assessments {U.S. EPA, 2020, 8642427}. The evidence integration included evidence stream evaluation, in which the qualitative summaries on the strength of evidence from studies in animals and humans were evaluated, and subsequent inference across all evidence streams. Human relevance of animal models as well as mechanistic evidence to inform mode of action were considered. Evidence integration produced an overall judgment about whether sufficient or insufficient evidence of an association with PFOA exposure exists for each human health outcome, as well as the rationale for each judgment. The potential evidence integration judgments for characterizing human health effects are evidence demonstrates, evidence indicates (likely), evidence suggests, evidence inadequate, and strong evidence supports no effect.

Details about evidence synthesis and integration are summarized in the Appendix (see PFOA Appendix).

2.2 Dose-Response Assessment

Evidence synthesis and integration enabled identification of the health outcomes with the strongest weight of evidence supporting causal relationships between PFOA exposure and adverse health effects, as well as the most sensitive cancer and noncancer endpoints. Studies were evaluated for use in POD derivation on the basis of study design, study quality evaluation, and data availability. For human evidence, all high or medium confidence studies were considered; for animal evidence, only animal toxicological studies with at least two PFOA exposure groups and also of high or medium confidence were considered.

2.2.1 Approach to POD and RfD Derivation for Non-Cancer Health Outcomes

The current, recommended EPA human health risk assessment approach described in EPA’s A Review of the Reference Dose and Reference Concentration Processes, which is a multistep approach to dose-response assessment, includes analysis of dose and response within the range
of observation, followed by extrapolation to lower exposure levels {U.S. EPA, 2002, 88824}. For non-cancer health outcomes, EPA performed dose-response assessments to define points of departure (PODs) and extrapolated from the PODs to RfDs.

For PFOA, EPA performed benchmark dose (BMD) modeling of all animal toxicological studies considered for dose-response to refine the POD in deriving the RfD. The BMD modeling approach involves dose-response modeling to obtain BMDs (i.e., dose levels corresponding to specific response levels near the low end of the observable range of the data) and identifies the lower limits of the BMDs (BMDLs) which serve as potential PODs for deriving quantitative estimates below the range of observation {U.S. EPA, 2012, 1239433}. EPA used the publicly available Benchmark Dose Software (BMDS) program developed and maintained by EPA (https://www.epa.gov/bmds). BMDS fits mathematical models to the data and determines the dose (benchmark dose or BMD) that corresponds to a pre-determined level of response (benchmark response or BMR). For dichotomous data, the BMR is typically set at either 5 or 10% above the background or the response of the control group. For continuous data, a BMR of one half or one standard deviation from the control mean is typically used when there are no outcome-specific data to indicate what level of response is biologically significant {U.S. EPA, 2012, 1239433}. For dose-response data for which BMD modeling did not produce an adequate model fit, a no-observed-adverse-effect level (NOAEL) or lowest-observed-adverse-effect level (LOAEL) was used as the POD.

For the epidemiological studies considered for dose-response assessment, EPA used multiple modeling approaches to determine PODs, depending upon the health outcome and the data provided in the studies. For the developmental, hepatic, and serum lipid dose-response studies, EPA used a hybrid modeling approach that involves estimating the incidence of individuals above or below a level considered to be adverse and determining the probability of responses at specified exposure levels above the control {U.S. EPA, 2012, 1239433} for cases in which EPA was able to define a level considered clinically adverse for these outcomes (see PFOA Appendix for details). EPA also performed BMD modeling and provided study LOAELs/NOAELs for the hepatic and serum lipid dose-response studies as sensitivity analyses of the hybrid approach. For the immune studies, where a clinically defined adverse level is not well defined, EPA used multivariate models provided in the studies and determined a BMR according to EPA guidance to calculate BMDs and BMDLs {U.S. EPA, 2012, 1239433}.

See the PFOA Appendix for additional details on the study-specific modeling.

The general steps for deriving an RfD for PFOA are summarized below.

**Step 1: Evaluate the data to identify and characterize endpoints affected by exposure to PFOA.** This step involves selecting the relevant studies and adverse effects to be considered for BMD modeling. Once the appropriate data are collected, evaluated for study quality, and characterized for adverse health outcomes, the risk assessor selects health endpoints/outcomes judged to be relevant to human health and among the most sensitive, defined as effects observed in the lower exposure range. Considerations that might influence selection of endpoints include whether data have dose-response information, percent change from controls, adversity of effect, and consistency across studies.
Step 1a (for dose-response data from a study in an animal model): Convert administered dose to an internal dose. A pharmacokinetic model is used to predict the internal dose (in the animals used in the toxicity studies or in humans) that would correspond to the administered dose used in the study (see 4.1.3 for additional detail). A number of dose-metrics across life stages are selected for simulation in a mouse, rat, monkey, or human. Concentrations of PFOA in blood are considered for all the internal dose-metrics.

Step 2: Conduct dose-response modeling. See above and the PFOA Appendix for study-specific details.

Step 3: Convert the POD to a human equivalent dose (HED) or point of departure human equivalent dose (POD_HED). The POD (a BMDL, NOAEL, or LOAEL) is converted to an HED following the method described in Section 4.1.3. Briefly, a pharmacokinetic model for human dosimetry is used to simulate the HED from the animal PODs from Step 2. Pharmacokinetic modeling is also used to simulate selected epidemiological studies to obtain a chronic dose that would result in the internal POD obtained from dose-response modeling (Section 4.1.3). Based on the available data, a serum PFOA concentration was identified as a suitable internal dosimetry target for the human and animal endpoints of interest.

Step 4: Select appropriate uncertainty factors (UFs) and provide rationale for UF selection. UFs are applied in accordance with EPA guidelines considering variations in sensitivity among humans, differences between animals and humans (if applicable), the duration of exposure in the critical study compared to the lifetime of the species studied, and the completeness of the epidemiological or animal toxicological database.

Step 5: Calculate the chronic RfD. The RfD is calculated by dividing POD_HED by the composite (total) UF.

$$RfD = \left( \frac{POD_{HED}}{UF_C} \right)$$

where:

POD_HED = calculated from the BMDL, NOAEL, or LOAEL using the human pharmacokinetic (PK) model presented in Section 4.1.3.2.

UF_C = Composite (total) UF calculated by multiplying the selected individual UFs for variations in sensitivity among humans, differences between animals and humans, duration of exposure in the critical study compared to the lifetime of the species studied, and completeness of the toxicology database, in accordance with EPA guidelines (U.S. EPA, 2002, 88824).

2.2.2 Cancer Assessment

2.2.2.1 Approach for Cancer Classification

In accordance with EPA’s 2005 Guidelines for Carcinogen Risk Assessment, a descriptive weight of evidence expert judgment is made, based on all available animal, human, and mechanistic data, as to the likelihood that a contaminant is a human carcinogen and the conditions under which the carcinogenic effects may be expressed (U.S. EPA, 2005, 6324329). A narrative is developed to provide a complete description of the weight of evidence and
conditions of carcinogenicity. The potential carcinogenicity descriptors (presented in the 2005 guidelines) are:

- Carcinogenic to humans
- Likely to be carcinogenic to humans
- Suggestive evidence of carcinogenic potential
- Inadequate information to assess carcinogenic potential
- Not likely to be carcinogenic to humans

More than one carcinogenicity descriptor can be applied if a chemical’s effects differ by dose, exposure route, or mode of action (MOA). For example, a chemical may be carcinogenic to humans above but not below a specific dose level if a key event in tumor formation does not occur below that dose. MOA information informs both the qualitative and quantitative aspects of the assessment, including the human relevance of tumors observed in animals. MOA must be considered separately for each target organ.

### 2.2.2.2 Derivation of a Cancer Slope Factor

EPA’s 2005 *Guidelines for Carcinogen Risk Assessment* recommends a two-step process for the quantitation of cancer risk. First, a model is used to fit a dose-response curve to the data, based on the doses and associated tumors observed. For animal toxicological studies, EPA used the publicly available Benchmark Dose Software (BMDS) program developed and maintained by EPA (https://www.epa.gov/bmds). For cancer data, BMDS fits multistage models and the model is used to identify a POD for extrapolation to the low-dose region based on the BMD associated with a significant increase in tumor incidence above the control. According to the 2005 guidelines, the POD is the lowest dose that is adequately supported by the data. The BMD$_{10}$ (the dose corresponding to a 10% increase in tumors) and the BMDL$_{10}$ (the 95% lower confidence limit on that dose) are also reported and are often used as the POD.

In the second step of quantitation, the POD is extrapolated to the low-dose region of interest for environmental exposures. The approach for extrapolation depends on the MOA for carcinogenesis (i.e., linear or nonlinear). When evidence indicates that a chemical causes cancer through a mutagenic MOA (i.e., mutation of deoxyribonucleic acid (DNA)) or the MOA for carcinogenicity is not known, the linear approach is used and the extrapolation is performed by drawing a line (on a graph of dose vs. response) from the POD to the origin (zero dose, zero tumors). The slope of the line ($\Delta$response/$\Delta$dose) gives rise to the CSF, which can be interpreted as the risk per mg/kg/day. In addition, according to EPA’s *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* {U.S. EPA, 2005, 88823}, affirmative determination of a mutagenic MOA (as opposed to defaulting to a mutagenic MOA based on insufficient data or limited data indicating potential mutagenicity) indicates the potential for higher cancer risks from a given exposure occurring early in life compared with exposure during adulthood, and so requires that the application of age-dependent adjustment factors (ADAFs) be considered in the quantification of risk to account for additional sensitivity of children. The ADAFs are 10- and 3-fold adjustments that are combined with age specific exposure estimates.

---

MOA is defined as a sequence of key events and processes, starting with interaction of an agent with a cell, proceeding through operational and anatomical changes, and resulting in cancer formation. It is contrasted with “mechanism of action,” which implies a more detailed understanding and description of events.
when estimating cancer risks from early life (<16 years of age) exposure to a mutagenic chemical.

In cases for which a chemical is shown to cause cancer via an MOA that is not linear at low doses, and the chemical does not demonstrate mutagenic or other activity consistent with linearity at low doses, a nonlinear extrapolation is conducted. EPA’s 2005 Guidelines for Carcinogen Risk Assessment state that “where tumors arise through a nonlinear MOA, an oral RfD or inhalation reference concentration, or both, should be developed in accordance with EPA’s established practice of developing such values, taking into consideration the factors summarized in the characterization of the POD.” In these cases, an RfD-like value is calculated based on the key event\(^5\) for carcinogenesis or the tumor response.

Once a POD is determined, a PK model is used to calculate the HED for animal oral exposures (POD\(_{\text{hed}}\)). The CSF is then calculated by dividing the selected BMR by the POD\(_{\text{hed}}\).

For epidemiological data, EPA used linear regression between PFOA exposure and cancer relative risk to estimate dose-response as well as the generalized least-squares for trend (glst) modeling {Greenland, 1992, 5069} using STATA v17.0 (StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC). The CSF was then calculated as the excess cancer risk associated with each ng/mL increase in serum PFOA. The internal serum CSF was converted to an external dose CSF, which describes the increase in cancer risk per 1 ng/kg-day increase in dose. EPA also considered evaluating the dose-response data using the BMDS; however, categorical data from case-control studies cannot be used with the BMDS since these models are based on cancer risk, and the data needed to calculate risks (i.e., the denominators) were not available.

See the PFOA Appendix for additional details on the study-specific modeling.

### 2.3 MCLG Derivation

As provided in SDWA Section 1412(b)(4)(A), EPA establishes the MCLG at the level at which no known or anticipated adverse effects on the health of persons occur and which allows an adequate margin of safety. EPA assesses the available science examining cancer and noncancer health effects associated with oral exposure to the contaminant. Consistent with the statutory definition of MCLG, EPA establishes MCLGs of zero for carcinogens classified as Carcinogenic to Humans or Likely to be Carcinogenic to Humans\(^6\) for which there is insufficient information

---

\(^5\)The key event is defined as an empirically observed precursor step that is itself a necessary element of the MOA or is a biologically based marker for such an element.

\(^6\)The MCLG is derived depending on the available noncancer and cancer evidence for a particular chemical. Establishing the MCLG for a chemical has typically been accomplished in one of three ways depending upon a three-category classification approach [U.S. EPA, 1985, 9207; U.S. EPA, 1991, 5499]. The categories are based on the available evidence of carcinogenicity after exposure via ingestion. The starting point in categorizing a chemical is through assigning a cancer descriptor using EPA’s current Guidelines for Carcinogen Risk Assessment [U.S. EPA, 2005, 6324329]. The descriptors in the 2005 Guidelines replaced the prior alphanumeric groupings, although the basis for the classifications is similar. In prior rulemakings, the agency typically placed Group A, B1, and B2 contaminants into Category I, Group C into Category II, and Group D and E into Category III based on the agency’s previous cancer classification guidelines (i.e., Guidelines for Carcinogen Risk Assessment, published in 51 FR 33992, September 24, 1986 [U.S. EPA, 1986, 199530] and the 1999 interim final guidelines [U.S. EPA, 1999, 41631; U.S. EPA, 2001, 10442464]):

to determine that a carcinogen has a threshold below which there are no carcinogenic effects {U.S. EPA, 1998, 10442462; U.S. EPA, 2000, 10442463; U.S. EPA, 2001, 10442464}.

For nonlinear carcinogenic contaminants, contaminants that are suggestive carcinogens, and non-carcinogenic contaminants, EPA establishes the MCLG based on a toxicity value, typically an RfD, but a similar toxicity value (e.g., ATSDR Minimal Risk Level) may also be used when it represents the best available science. A noncancer MCLG is designed to be protective of noncancer effects over a lifetime of exposure with an adequate margin of safety, including for sensitive populations and life stages consistent with SDWA 1412(b)(3)(C)(i)(V) and 1412(b)(4)(A). The calculation of a noncancer MCLG includes an oral toxicity reference value such as an RfD, body weight-based drinking water intake (DWI-BW), and RSC as presented in the equation below:

\[ MCLG = \left( \frac{\text{Oral } RfD}{\text{DWI-BW}} \right) \ast RSC \]

Where:

RfD = chronic reference dose—an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure of the human population to a substance that is likely to be without an appreciable risk of deleterious effects during a lifetime. The RfD is equal to a POD\(_{\text{HED}}\) divided by a composite uncertainty factor.

DWI-BW = An exposure factor in the form of the 90th percentile body weight-adjusted drinking water intake value for the identified population or life stage, in units of liters of water consumed per kilogram body weight per day (L/kg bw-day). The DWI-BW considers both direct and indirect consumption of drinking water (indirect water consumption encompasses water added in the preparation of foods or beverages, such as tea or coffee). Chapter 3 of EPA’s *Exposure Factors Handbook* {U.S. EPA, 2019, 7267482} provides DWI-BWs for various populations or life stages within the general population for which there are publicly available, peer-reviewed data such as NHANES data.

RSC = relative source contribution—the percentage of the total exposure attributed to drinking water sources {U.S. EPA, 2000, 19428}, with the remainder of the exposure allocated to all other routes or sources. The purpose of the RSC is to ensure that the level of a contaminant (e.g., MCLG value), when combined with other identified sources of exposure common to the population of concern, will not result in exposures that exceed the RfD. The RSC is derived by applying the Exposure Decision Tree approach published in EPA’s *Methodology for Deriving are: “Carcinogenic to Humans” or “ Likely to be Carcinogenic to Humans” {U.S. EPA, 2005, 6324329}. EPA’s policy under SDWA is to set MCLGs for Category I chemicals at zero, based on the principle that any exposure to known or likely human carcinogens might represent some finite level of risk. In cases when there is sufficient evidence to determine a nonlinear cancer mode of action, the MCLG is based on the RfD approach described below.

Ambient Water Quality Criteria for the Protection of Human Health {U.S. EPA, 2000, 19428}. Further description of the RSC for PFOA can be found in the Appendix (see PFOA Appendix).
3 Results of the Health Effects Systematic Review and Toxicokinetics Methods

3.1 Literature Search and Screening Results

Studies referenced in this assessment are cited as “Author Last Name, Publication Year, HERO ID” and are available in EPA HERO: A Database of Scientific Studies and References. The HERO ID is a unique identifier for studies available in HERO. Additional study metadata are publicly available and can be obtained by searching for the HERO ID on the public facing webpage available here: https://hero.epa.gov/.

The three database searches yielded 6,007 unique records prior to running SWIFT Review. Table 3-1 shows the results from database searches conducted in April 2019, September 2020, and February 2022.

Table 3-1. Database Literature Search Results

<table>
<thead>
<tr>
<th>Database</th>
<th>Date Run: Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>WoS</td>
<td>4/10/2019: 3,081 results</td>
</tr>
<tr>
<td></td>
<td>9/3/2020: 1,286 results</td>
</tr>
<tr>
<td></td>
<td>2/2/2022: 1,021 results</td>
</tr>
<tr>
<td>PubMed</td>
<td>4/10/2019: 2,191 results</td>
</tr>
<tr>
<td></td>
<td>9/3/2020: 811 results</td>
</tr>
<tr>
<td></td>
<td>2/2/2022: 1,728 results</td>
</tr>
<tr>
<td>TOXLINE</td>
<td>4/10/2019: 60 results</td>
</tr>
<tr>
<td>TSCATS</td>
<td>4/11/2019: 0 results</td>
</tr>
<tr>
<td>Total number of references from all databases for all searches(^a)</td>
<td>4/2019: 3,382 results</td>
</tr>
<tr>
<td></td>
<td>9/2020: 1,153 results</td>
</tr>
<tr>
<td></td>
<td>2/2022: 1,858 results</td>
</tr>
<tr>
<td>Total number of references after running SWIFT Review(^b)</td>
<td>4/2019: 1,977 results</td>
</tr>
<tr>
<td></td>
<td>9/2020: 867 results</td>
</tr>
<tr>
<td></td>
<td>2/2022: 1,370 results</td>
</tr>
<tr>
<td>Total number of unique studies moved to screening(^b)</td>
<td>3,921</td>
</tr>
</tbody>
</table>
\(^a\) The number of studies includes duplicate references across search dates due to overlap between search years.  
\(^b\) Duplicates across search dates removed.

The additional sources of literature outlined in Section 2.1.1 (i.e., assessments published by other agencies, studies identified during mechanistic or toxicokinetic syntheses, and studies identified by the SAB) yielded 200 unique records.

The 3,921 studies captured with the SWIFT Review evidence streams filters and the 200 records identified from additional sources yielded a total of 4,121 unique studies. These 4,121 studies were moved to the next stage of screening—title and abstract screening (using either DistillerSR or SWIFT ActiveScreener). Of the 4,121 unique studies, 918 moved on to full-text level review, 1,589 were excluded during title and abstract screening, and 1,614 were tagged as containing potentially relevant supplemental material. Of the 918 screened at the full-text level, 618 were considered to meet PECO eligibility criteria (see PFOA Appendix) and included relevant information on PFOA. The 618 studies that were determined to meet PECO criteria after full-text...
level screening included 443 epidemiological (human) studies, 37 animal toxicological studies, 9 PBPK studies (2 of which were also relevant epidemiological studies), and 131 studies that were not extracted (e.g., low confidence studies, meta-analyses, studies that did not evaluate effects on one of the priority health outcomes). An additional 20 PBPK studies were identified during the toxicokinetic screening for a total of 29 PBPK studies. Details of the literature search and screening process are shown in Figure 3-1.

The 443 epidemiological studies and 37 animal toxicological studies underwent study quality evaluation and were subsequently considered for data extraction as outlined in Sections 2.1.3 and 2.1.4 (see PFOA Appendix for more details). The results of the health outcome-specific study quality evaluations and data extractions are described in Sections 3.4 and 3.5.

Additionally, the 29 studies tagged as containing relevant PBPK models were reviewed by PK subject matter experts for inclusion consideration. The included studies are summarized in Section 3.3.2 and parameters described in these studies were considered for incorporation into the animal and human PK models, which are summarized in Section 4.1.3.

Finally, the 113 toxicokinetic and 270 mechanistic studies identified as relevant for PFOA moved on to a limited data extraction as described in the Appendix (see PFOA Appendix). The toxicokinetic studies pertaining to ADME are synthesized in Section 3.3.1. The mechanistic studies relevant to the 5 prioritized health outcomes are synthesized in Sections 3.4 and 3.5 and were considered as part of the evidence integration.
Figure 3-1. Summary of Literature Search and Screening Process for PFOA

Interactive figure and additional study details available on Tableau.

Interactive figure based on work by Magnuson et al. (2022, 10442900).

“Other sources” include assessments published by other agencies, studies identified during mechanistic or toxicokinetic syntheses, and studies identified by the SAB.

a Includes number of unique references after deduplication of studies captured with the SWIFT Review evidence streams filters and records identified from additional sources.

b Includes number of unique references considered to meet PECO eligibility criteria at the full text level and include relevant information on PFOA.

c Includes number of unique references identified during title/abstract screening, full text screening, and data extraction assessed for toxicokinetic and/or mechanistic eligibility.

d Only includes studies with relevant information on PFOA.

e Includes 9 PBPK studies (2 of which were also relevant epidemiological studies) determined to meet PECO criteria plus an additional 20 PBPK studies identified during the toxicokinetic screening.
3.1.1 Results for Epidemiology Studies of PFOA by Health Outcome

Of the 443 epidemiological studies that met the inclusion criteria, 189 had a cohort study design, 175 had a cross-sectional design, 40 had a case-control design, and 39 had other study designs (e.g., nested case-control). Epidemiological studies were categorized into 18 health outcomes. Most studies reported on the cardiovascular (n = 93), developmental (n = 92), metabolic (n = 78), or immune systems (n = 64). Studies that reported outcomes spanning multiple health outcomes were not counted more than once in the grand totals shown in Figure 3-2.

<table>
<thead>
<tr>
<th>Health System</th>
<th>Case-control</th>
<th>Cohort</th>
<th>Study Design</th>
<th>Other</th>
<th>Grand Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
<td>6</td>
<td>6</td>
<td>3</td>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>5</td>
<td>21</td>
<td>60</td>
<td>7</td>
<td>93</td>
</tr>
<tr>
<td>Dermal</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Developmental</td>
<td>4</td>
<td>61</td>
<td>20</td>
<td>7</td>
<td>92</td>
</tr>
<tr>
<td>Endocrine</td>
<td>1</td>
<td>8</td>
<td>18</td>
<td>8</td>
<td>35</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>1</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Hematologic</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Hepatic</td>
<td>1</td>
<td>6</td>
<td>20</td>
<td>4</td>
<td>31</td>
</tr>
<tr>
<td>Immune</td>
<td>5</td>
<td>33</td>
<td>17</td>
<td>9</td>
<td>64</td>
</tr>
<tr>
<td>Metabolic</td>
<td>7</td>
<td>38</td>
<td>30</td>
<td>5</td>
<td>78</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>0</td>
<td>1</td>
<td>6</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>Nervous</td>
<td>3</td>
<td>26</td>
<td>5</td>
<td>3</td>
<td>37</td>
</tr>
<tr>
<td>Ocular</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Renal</td>
<td>0</td>
<td>6</td>
<td>18</td>
<td>2</td>
<td>26</td>
</tr>
<tr>
<td>Reproductive, Male</td>
<td>0</td>
<td>7</td>
<td>14</td>
<td>1</td>
<td>22</td>
</tr>
<tr>
<td>Reproductive, Female</td>
<td>9</td>
<td>24</td>
<td>22</td>
<td>4</td>
<td>59</td>
</tr>
<tr>
<td>Respiratory</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Grand Total</td>
<td>40</td>
<td>169</td>
<td>175</td>
<td>39</td>
<td>443</td>
</tr>
</tbody>
</table>

Figure 3-2. Summary of Epidemiology Studies of PFOA Exposure by Health System and Study Design

Interactive figure and additional study details available on Tableau.

A study can report on more than one health system. Column grand totals represent the number of unique studies and are not a sum of health system tags.

3.1.2 Results for Animal Toxicological Studies of PFOA by Health Outcome

Of the 37 animal toxicological studies that met the inclusion criteria, most studies had either short-term (n = 16) or developmental (n = 13) study designs and most were conducted in mice (n = 30). The mouse studies had short-term (n = 15), developmental (n = 13), and subchronic (n = 2) study designs. The remaining studies reported results for rats (n = 7) using chronic (n = 3), short-term (n = 2), subchronic (n = 1), or reproductive (n = 1) study designs, or monkeys (n = 1) using a chronic study design. Animal toxicological studies were categorized into 15
health outcomes. Most studies reported results for the hepatic (n = 27), whole body (n = 23; i.e., systemic effects such as bodyweight), reproductive (n = 18), or developmental (n = 14) systems. Studies that reported outcomes spanning multiple health outcomes, study designs, or species were not counted more than once in the grand totals shown in Figure 3-3.

<table>
<thead>
<tr>
<th>Health System</th>
<th>Study Design &amp; Species</th>
<th>Grand Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Short-term</td>
<td>Subchronic</td>
</tr>
<tr>
<td>Cancer</td>
<td>M</td>
<td>0</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>M</td>
<td>2</td>
</tr>
<tr>
<td>Developmental</td>
<td>M</td>
<td>0</td>
</tr>
<tr>
<td>Endocrine</td>
<td>M</td>
<td>3</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>M</td>
<td>0</td>
</tr>
<tr>
<td>Hematologic</td>
<td>M</td>
<td>1</td>
</tr>
<tr>
<td>Hepatic</td>
<td>M</td>
<td>11</td>
</tr>
<tr>
<td>Immune</td>
<td>M</td>
<td>5</td>
</tr>
<tr>
<td>Metabolic</td>
<td>M</td>
<td>0</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>M</td>
<td>1</td>
</tr>
<tr>
<td>Nervous</td>
<td>M</td>
<td>2</td>
</tr>
<tr>
<td>Renal</td>
<td>M</td>
<td>1</td>
</tr>
<tr>
<td>Reproductive</td>
<td>M</td>
<td>3</td>
</tr>
<tr>
<td>Respiratory</td>
<td>M</td>
<td>0</td>
</tr>
<tr>
<td>Whole Body</td>
<td>M</td>
<td>10</td>
</tr>
<tr>
<td>Grand Total</td>
<td>M</td>
<td>15</td>
</tr>
</tbody>
</table>

**Figure 3-3. Summary of Animal Toxicological Studies of PFOA Exposure by Health System, Study Design, and Species**

Interactive figure and additional study details available on Tableau.

<table>
<thead>
<tr>
<th>Study Design &amp; Species</th>
<th>Grand Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term</td>
<td></td>
</tr>
<tr>
<td>Subchronic</td>
<td></td>
</tr>
<tr>
<td>Chronic</td>
<td></td>
</tr>
<tr>
<td>Developmental</td>
<td></td>
</tr>
<tr>
<td>Reproductive</td>
<td></td>
</tr>
</tbody>
</table>

a A study can report on more than one study design and species. Row grand totals represent the number of unique studies and are not a sum of study design and species tags.

b A study can report on more than one health system. Column grand totals represent the number of unique studies and are not a sum of health system tags.

### 3.2 Data Extraction Results

Data extracted from the 443 epidemiological studies are available via [Tableau Public](#) and data extracted from the 37 animal toxicological studies are available in the public HAWC site, displayed as exposure-response arrays, forest plots, and trees. See Sections 3.4 and 3.5 for health outcome-specific data extracted for synthesis development. Additionally, the limited data extractions from the ADME and mechanistic studies can be found via Tableau Public [here](#) and [here](#), respectively.

### 3.3 Toxicokinetic Synthesis

As described in Section 3.1, EPA identified 113 and 29 studies containing information relevant to the toxicokinetics and PBPK modeling of PFOA, respectively. The results of these studies are described in the subsections below and additional information related to toxicokinetic characteristics of PFOA can be found in Appendix B.

#### 3.3.1 ADME

PFOA is resistant to metabolic and environmental degradation due to its strong carbon-fluorine bonds. It also is resistant to metabolic biotransformation. Thus, the toxicity and pharmacodynamics of the parent compound (the anion when dissociated in water or the body) are the concern. Because of its impacts on cellular receptors and proteins, PFOA can influence the biotransformation of dietary constituents, intermediate metabolites, and other xenobiotic chemicals by altering enzyme activities and transport kinetics. PFOA is known to activate
peroxisome proliferator activated receptor (PPAR) pathways by increasing transcription of mitochondrial and peroxisomal lipid metabolism, sterol, and bile acid biosynthesis and retinol metabolism genes. Findings of transcriptional activation of many genes in peroxisome proliferator activated receptor alpha (PPARα)-null mice after PFOA exposure, however, indicate that the effects of PFOA are mediated by other MOAs in addition to PPAR activation and consequent peroxisome proliferation {Wen; 2019, 5080582; Oshida, 2015, 2850125; Oshida, 2015, 5386121; Rosen, 2017, 3859803; U.S. EPA, 2016, 3603279}. The available data indicate that PFOA exposure can also activate the constitutive androstane receptor (CAR), farnesoid X receptor (FXR), and pregnane X receptor (PXR), and can affect metabolic activities linked to these nuclear receptors {Oshida, 2015, 2850125; Oshida, 2015, 5386121; Rosen, 2017, 3859803; U.S. EPA, 2016, 3603279}. Activation of these receptors resulting from PFOA exposure could in turn impact the toxicokinetics of PFOA itself {Andersen, 2008, 3749214}.

PFOA is not readily eliminated from humans and other primates. Toxicokinetic profiles and the underlying mechanism for half-life differences between species and sexes are not completely understood, although many of the differences appear to be related to elimination kinetics and factors that control membrane transport. Thus far, three transport families appear to play a role in PFOA absorption, distribution, and excretion: organic anion transporters (OATs), organic anion transporting polypeptides (OATPs), and multidrug resistance-associated proteins (MRPs) {Klaassen, 2010, 9641804; Launay-Vacher, 2006, 9641802}. These transporters are critical for gastrointestinal absorption, uptake by the tissues, and excretion via bile and the kidney. These transport systems are located at the membrane surfaces of the kidney tubules, intestines, liver, lungs, heart, blood brain barrier (BBB), blood placental barrier, blood testes barrier (BTB), and mammary glands where they function to protect the organs, tissues, and fetus through active removal of foreign compounds {Ito, 2003, 9641803; Klaassen, 2010, 9641804, Zaïr, 2008, 9641805}. However, luminal transporters in the kidney may cause reuptake of PFOA from the proximal tubule resulting in decreased excretion from the body {Weaver, 2009, 2010072}. This reuptake would lead to PFOA persisting in the body over time. Transporters involved in enterohepatic circulation have also been identified that may facilitate uptake and reuptake of PFOA from the gut {Ruggiero, 2021, 9641806}.

There are differences in transporters across species, sexes, and individuals. In addition, more PFOA-specific information is available for the OAT and OATP families than for the MRPs. These data limitations have hindered the development of PK models for use in predicting effects in humans based on the data from animal toxicological studies.

### 3.3.1.1 Absorption

PFOA absorption data are available in laboratory animals for oral, inhalation, and dermal exposures, and extensive data are available from humans demonstrating the presence of PFOA in serum (descriptions of available studies are provided in the PFOA Appendix). In vitro absorption data indicate that uptake is influenced by pH, temperature, and concentration as well as OATP activity (see PFOA Appendix).

#### 3.3.1.1.1 Cellular Uptake

The available information indicates that the absorption process requires transport from the external environment across the interface of the gut, lung, or skin. Uptake in cells cultured in vitro is fast and saturable, consistent with a role of transporters. Cellular transfection of cells
with vectors coding for organic ion transporters have confirmed their role in uptake of PFOA {Kimura, 2017, 3981330; Nakagawa, 2007, 2919370; Nakamura, 2009, 2919342; Yang, 2009, 2919328; Yang, 2010, 2919288}. Several studies suggest involvement of OATs, OATPs, and MRPs in enterocytes in the uptake of PFOA {Klaassen, 2010, 9641804; Zaïr, 2008, 9641805}. Few studies have been conducted on the intestinal transporters for PFOA in humans or laboratory animals, although one study supports a role for OATPs in PFOA uptake by immortalized intestinal cells {Kimura, 2017, 3981330}. Most of the research has focused on transporters in the kidney that are relevant to excretion and were carried out using cultured cells transfected with the transporter proteins.

In addition to facilitated transport, there is evidence supporting passive diffusion in cells cultured in vitro {Yang, 2009, 2919328} and in placenta in vivo {Zhang, 2013, 3859792}. Since PFOA is moderately soluble in aqueous solutions and oleophobic (i.e., minimally soluble in body lipids), movement across interface membranes was thought to be dominated by transporters or mechanisms other than simple diffusion across the lipid bilayer. Recent mechanistic studies, however, support transporter-independent uptake through passive diffusion processes. Ebert et al. (2020, 6505873) determined membrane/water partition coefficients (K_{mem/w}) for PFOA and examined possible permeation into cells by measuring the passive anionic permeability (P_{ion}) through planar lipid bilayers. In this system, the partition coefficients (PCs) were considered high enough to explain observed cellular uptake by passive diffusion in the absence of active uptake processes.

Uptake by cells may be influenced by interactions with lipids and serum proteins. PFOA exhibited lower levels of binding to lipids and phospholipids relative to PFOS, which correlated with uptake into lung epithelial cells {Sanchez Garcia, 2018, 4234856}. Phospholipophilicity correlated to cellular accumulation better than other lipophilicity measures. The extent to which PFOA phospholipophilicity influences absorption through the gastrointestinal tract, lungs, or skin is unknown.

### 3.3.1.1.2 Absorption and Bioavailability in Humans and Animals

*In vivo*, PFOA is well-absorbed following oral exposure, as evidenced by the presence of PFOA in serum of humans following exposure to contaminated drinking water {Xu, 2020, 6781357; Worley, 2017, 3859800}. Studies on male rats administered PFOA by gavage using a single or multiple dose regimen estimated dose absorption of at least 92.3% {Gibson, 1979, 9641813; Cui, 2010, 2919335}. In rats, the time to reach the maximum PFOA plasma concentration (T_{max}) following oral exposure is very fast and varies by sex {Kim, 2016, 3749289; Dzierlenga, 2019, 5916078}. For example, the study by Kim and colleagues estimated T_{max} after a single oral dose of 1 mg/kg to be 1.44 hours in female rats vs. 2.07 days in males.

Recent studies confirm that bioavailability of PFOA after oral exposure is very high in rats. Serum concentrations after oral dosing ranged from 82–140% of levels measured after intravenous (IV) dosing, which may reflect increased reabsorption by intestinal transporters by the oral route relative to the IV route of exposure {Kim, 2016, 3749289; Dzierlenga, 2019, 5916078}. Bioavailability of PFOA appears to be modified by diet. Using *in vitro* and *in vivo* (BALB/c mice) systems, Li et al. (2015, 2851033) found that PFOA bioavailability is strongly influenced by diet, with high fat diets associated with reduced absorption. The authors suggest...
that colloidal stability in intestinal solutions may be an important factor influencing PFOA bioaccessibility.

The available data, although limited, also support PFOA absorption through both inhalation {Hinderliter, 2006, 135732} and dermal routes {Fasano, 2005, 3749187; O’Malley, 1981, 4471529; Kennedy, 1985, 3797585}.

3.3.1.2 Distribution

3.3.1.2.1 PFOA Binding to Blood Fractions and Serum Proteins

Detailed study descriptions of literature regarding the distribution of PFOA in humans and animals are provided in the Appendix (see PFOA Appendix). Distribution of absorbed material requires vascular transport from the portal of entry to receiving tissues. Distribution of PFAS to plasma has been reported to be chain length-dependent {Jin, 2016, 3859825}. Increasing chain length (from C6 to C11) correlated with an increased mass fraction in human plasma. Within the blood cell constituents, PFOA preferentially accumulates in platelets over red blood cells and leukocytes {De Toni, 2020, 6316907}. Among different kinds of human blood samples, PFOA accumulates to highest levels in plasma, followed by whole blood and serum {Forsthuber, 2020, 6311640; Jin, 2016, 3859825; Poothong, 2017, 4239163}. Poothong et al. (2017, 4239163) found that median PFOA concentrations in plasma, serum, and whole blood were 1.90, 1.60, and 0.93 ng/mL, respectively. These findings suggest that the common practice of multiplying by a factor of 2 to convert the concentrations in whole blood to serum {Ehresman, 2007, 1429928} will not provide accurate estimates for PFOA.

PFOA is distributed within the body by noncovalently binding to plasma proteins. Many studies have investigated PFOA interactions with human serum albumin (HSA) {Wu, 2009, 536376; MacManus-Spencer, 2010, 2850334; Qin, 2010, 3858631; Salvalaglio, 2010, 2919252; Weiss, 2009, 534503; Luebker, 2002, 1291067; Zhang, 2013, 5081488; Cheng, 2018, 5024207; Gao, 2019, 5387135; Yue, 2016, 3479514}. In vitro analyses found that plasma proteins can bind 97%–100% of the PFOA in plasma from humans, cynomolgus monkeys, and rats {Kerstner-Wood, 2003, 4771364}.

HSA is the primary PFOA binding protein in plasma {Han, 2003, 5081471} and intermolecular interactions are mediated through van der Waals forces and hydrogen bonds {MacManus-Spencer, 2010, 2850334; Chen, 2020, 6324256}. Beesoon and Martin (2015, 2850292) determined that linear PFOA molecules bound more strongly to calf serum albumin than the branched chain isomers in the order of 4m < 3m < 5m < 6m (iso) < linear. PFOA-mediated conformational changes may interfere with albumin’s ability to transport its natural ligands and pharmaceuticals {Wu, 2009, 536376} such as fatty acids, thyroxine (T4), warfarin, indole, and benzodiazepine.

Binding to albumin and other serum proteins may affect transfer of PFOA from maternal blood to the fetus {Gao, 2019, 5387135}. Since there is effectively a competition between PFOA binding in maternal serum vs. cord blood, lower cord blood albumin levels compared to maternal blood albumin levels are likely to reduce transfer from maternal serum across the placenta. Consistent with this hypothesis, Pan et al. (2017, 3981900) found that high concentration of cord serum albumin was associated with higher PFOA transfer efficiencies, whereas high maternal serum albumin concentration was associated with reduced transfer efficiency.
Other plasma proteins that bind PFOA, albeit with lower affinity than HSA, include low-density lipoproteins (LDLs), alpha-globulins (alpha-2-macroglobulin), gamma-globulins, transferrin, and fibrinogen {Kerstner-Wood, 2003, 4771364}. PFOA also binds the serum thyroid hormone transport protein, transthyretin (TTR), causing up to a 50% inhibition of T4 binding to TTR {Weiss, 2009, 534503}. In contrast to serum proteins, little is known regarding PFOA binding to proteins in the gut. One study found that PFOA can bind to and cause a conformational change in pepsin {Yue, 2016, 3479514}, though it is unclear whether PFOA-pepsin interactions impact absorption from the gut or distribution to other compartments in the body.

### 3.3.1.2.2 PFOA Binding to Subcellular Fractions, Intracellular Proteins, and Transporters

Han et al. (2005, 5081570) observed a sex-dependent subcellular distribution of PFOA in the liver and kidney of male and female adult rats necropsied 2 hours after oral gavage dosing. The proportion of PFOA in the liver cytosol of female rats was almost twice that of the male rats. They hypothesized that females might have a greater amount than males of an unknown liver cytosolic binding protein with an affinity for perfluorinated acids. In the kidney, the subcellular distribution did not show a sex difference comparable to the one seen for liver; however, the protein-bound fraction in males (42%) was about twice that of females (17%), which differs from the sex differences found for the liver.

In a study of human cells {Zhang, 2020, 6316915}, PFOA preferentially distributed to cytosol followed by nuclei and mitochondria in human colorectal cancer cells, human lung epithelial cells, and human normal liver cells. In liver cells, PFOA binds to the liver fatty acid binding protein (L-FABP) through polar and hydrophobic interactions {Luebker, 2002, 1291067; Zhang, 2013, 5081488; Yang, 2020, 6356370}. L-FABP is an intracellular lipid carrier protein that reversibly binds long-chain fatty acids, phospholipids, and an assortment of peroxisome proliferators {Erol, 2004, 5212239} and constitutes 2%–5% of the cytosolic protein in hepatocytes.

PFOA interactions with various protein transporters play a role in the tissue uptake of orally ingested PFOA. The transporters are located at the interface between serum and a variety of tissues (e.g., liver, kidneys, lungs, heart, brain, testes, ovaries, placenta, uterus) {Klaassen, 2010, 9641804}. The liver is an important uptake site for PFOA. OATPs and MRPs, at least one OAT, and the sodium-taurocholate cotransporting polypeptide (NTCP)—a hepatic bile uptake transporter—have been identified at the boundary of the liver at the portal blood and/or the canalicular membranes within the liver {Kim, 2003, 9641809; Kusuhara, 2009, 9641810; Zaïr, 2008, 9641805}. Transporters responsible for PFOA transport across the placenta are not well understood, though preliminary studies examining transporter expression identified OAT4 as a candidate receptor {Kummu, 2015, 3789332}. The expression of 9 transporter genes was found to vary at different stages of gestation {Li, 2020, 6505874}, though direct experimental evidence for these transporters in mediating transfer of PFOA to the fetus is lacking.

### 3.3.1.2.3 Tissue Distribution in Humans and Animals

Evidence from human autopsy and surgical tissues demonstrates that PFOA distributes to a wide range of tissues, organs, and matrices throughout the body. Although blood and liver are major sites of PFOA accumulation {Olsen, 2001, 9641811}, recent findings confirm PFOA accumulation in other tissues and fluids including brain and cerebral spinal fluid {Fujii, 2015,
manner 2850230 PFOA for levels similar to those observed in epididymal fat and in intestin and lungs. Also i although a relatively small amount of administered PFOA was measured in the brains (0.1%). Also in mice, Burkemper et al. (2017, 3858622) observed the highest PFOA levels in bone, liver, and lungs. Bogdanska et al. (2020, 6315801) also observed PFOA in testes of C57BL/6 mice at levels similar to those observed in epididymal fat and in intestines. In BALB/c mice exposed to PFOA for 28 days, PFOA levels in the testes increased with increasing dose {Zhang, 2014, 2850230}, and PFOA accumulated in the epididymis of BALB/c mice in a dose-dependent manner {Lu, 2016, 3981459}.

Liver PFOA levels are regulated in part by PPARα. In human and rodent hepatocytes, PPARα activation induces expression of genes involved in lipid metabolism and cholesterol homeostasis. PFOS and PFOA structurally resemble fatty acids and are well-established ligands of PPARα in the rat and mouse liver. As PPARα agonists, PFOS and PFOA can induce β-oxidation of fatty acids, induce fatty acid transport across the mitochondrial membrane, decrease hepatic very low-density lipoprotein (VLDL)-triglyceride and apolipoprotein B (apoB) production, and promote lipolysis of triglyceride-rich plasma lipoproteins {Fragki, 2020, 8442211}. The liver can transport PFOA from hepatocytes to bile ducts, which is mediated at least partly by PPARα {Minata, 2010, 1937251}. PFOA levels were significantly lower in PPARα-null mice than in wild-type mice exposed to doses of 25 and 50 µmol/kg, supporting a role for PPARα in PFOA clearance in the liver {Minata, 2010, 1937251} but not excluding other factors regulating PFOA levels. It is unclear what role PPARα plays in PFOA clearance in the liver of humans.

Studies administering radiolabeled PFOA to whole animals demonstrate the range of tissue distribution in rats {Kemper, 2003, 6302380} and mice {Burkemper, 2017, 3858622; Bogdanska, 2020, 6315801} that includes the central nervous system (CNS), cardiovascular, gastrointestinal, renal, immune, reproductive, endocrine, and musculoskeletal systems. PFOA crossed the BBB in males an order of magnitude more efficiently than in females {Ylinen, 1990, 5085631}. Fujii and colleagues (2015, 2816710) found that PFOA can cross the BBB in mice, although a relatively small amount of administered PFOA was measured in the brains (0.1%). Also in mice, Burkemper et al. (2017, 3858622) observed the highest PFOA levels in bone, liver, and lungs. Bogdanska et al. (2020, 6315801) also observed PFOA in testes of C57BL/6 mice at levels similar to those observed in epididymal fat and in intestines. In BALB/c mice exposed to PFOA for 28 days, PFOA levels in the testes increased with increasing dose {Zhang, 2014, 2850230}, and PFOA accumulated in the epididymis of BALB/c mice in a dose-dependent manner {Lu, 2016, 3981459}.
Fujii and colleagues (2015, 2816710) observed that perfluoroalkyl carboxylic acids (PFCAs) (C6 and C7) were excreted rapidly through urine in mice, whereas longer-chained PFCAs (≥ C8) accumulated in the liver. Moreover, PFAS with longer chain lengths were found to exhibit increasing affinity for serum and L-FABPs. The authors suggest that differential lipophilicity driven by chain length may account for the distribution patterns of PFAS, which is consistent with the findings of high levels of PFOA accumulation in serum and liver. These large sequestration volumes of PFOA observed in the liver seem to be attributable to the liver’s large binding capacity in mice.

3.3.1.2.4 Distribution During Reproduction and Development

Several studies have confirmed PFOA distribution from rat and mouse dams to fetuses and pups, as well as variable PFOA levels across many fetal tissues {Han, 2003, 5081471; Hinderliter 2006, 3749132; Butenhoff, 2004, 1291063; Mylchreest, 2003, 9642031; Fenton, 2009, 194799; Macon, 2011, 1276151; White, 2011, 1276150; Blake, 2020, 6305864}. Interestingly, Fujii et al. (2020, 6512379) found that the milk/plasma (M/P) concentration ratio for PFOA also exhibited a U-shaped curve with increasing chain length but it did not correlate to lipophilicity of PFAS in FVB/NJcl mice. These findings suggest that the amount transferred from mother to pup during lactation may also relate to chain length-dependent clearance.

Many recent human studies have quantified the distribution of PFOA from pregnant mothers to their fetuses and from mothers to their infants. Distribution from pregnant mother to fetus has been confirmed by measuring PFOA levels in placenta, cord blood, and amniotic fluid during gestation and at birth. The ratio of PFOA in placenta relative to maternal serum during pregnancy (RPM) ranged from 0.326 to 0.460 {Zhang, 2013, 3859792; Chen, 2017, 3859806}. Gestational age and PFOA branching characteristics influence transport across the placenta. PFOA concentrations within the placenta increase during gestation from the first to third trimester {Mamsen, 2019, 5080595}. Linear PFOA is detected at a higher frequency and at higher concentrations in maternal serum than branched PFOA isomers. However, branched PFOA is more efficiently transported into the placenta than linear PFOA {Cai, 2020, 6318671; Chen, 2017, 3859806}.

Several studies reported a strong positive correlation between maternal and cord serum PFOA levels in humans {Kato, 2014, 2851230; Porpora, 2013, 2150057}. The ratio of PFOA in cord serum relative to maternal serum ranged from 0.55 to 1.33 (see PFOA Appendix) and generally increased with gestational age {Li, 2020, 6505874}. Factors such as exposure sources, parity, and other maternal demographics are postulated to influence variations in maternal serum PFAS concentrations and cord:maternal serum ratios {Kato, 2014, 2851230; Brochot, 2019, 5381552}. Cord:maternal serum ratios represent transplacental efficiencies (TTEs), which exhibit a U-shaped curve with PFAS chain length {Zhang, 2013, 3859792} and generally increase as the PFAS branching point moves closer to the carboxyl or sulfonate moiety {Zhao, 2017, 5085130}.

Lower levels of PFOA were measured in amniotic fluid compared to the placenta and cord blood (all collected at delivery) {Zhang, 2013, 3859792}. The mean concentration ratio between amniotic fluid and maternal blood (collected no more than one hour before delivery) was higher for PFOA (0.13) than for PFOS (0.0014). The mean concentration ratio between amniotic fluid and cord blood was higher for PFOA (0.023) than for PFOS (0.0065). Authors attributed the
differences in ratios between the two compartments to the solubilities of PFOS and PFOA and their respective protein binding capacities in the two matrices.

PFOA also distributes widely in human fetal tissues. Mamsen et al. (2017, 3858487) measured the concentrations of five PFAS in fetuses, placentas, and maternal plasma from a cohort of 39 pregnant women in Denmark. PFOA was detected in placenta and fetal liver, extremities, heart, intestines, lungs, connective tissues, spinal cord, and ribs, and concentrations were highest in the placenta and lung. Different patterns of PFOA distribution were observed in fetal tissues depending on fetal age [Mamsen, 2019, 5080595]. Fetal tissue:maternal serum ratios of PFAS were calculated by dividing the fetal tissue concentration by the maternal serum concentration. In general, fetal tissue:maternal serum ratios of PFOA increased from the first trimester to the third trimester, except for the liver and heart, which showed the highest fetal tissue:maternal serum ratios in the second trimester compared with the third trimester.

New studies in humans also confirm that the distribution of PFOA from nursing mothers to their infants via breastmilk correlates with duration of breastfeeding [Mondal, 2014, 2850916; Cariou, 2015, 3859840, Mogensen, 2015, 3859839, Gyllenhammar, 2018, 4778766]. Distribution is influenced by the chemical properties of PFAS including length, lipophilicity, and branching. In the Mondal study [Mondal, 2014, 2850916], the mean maternal serum PFOA concentrations were lower in breastfeeding mothers vs. non-breastfeeding mothers. Conversely, breastfed infants had higher mean serum PFOA than infants who were never breastfed. Maternal serum concentrations decreased with each month of breastfeeding [Mondal, 2014, 2850916; Mogensen, 2015, 3859839]. Cariou et al. (2015, 3859840) reported that PFOA levels in breastmilk were approximately 30-fold lower relative to maternal serum and the ratio between breastmilk and maternal serum PFOA was 0.038 ± 0.013. The authors noted that the transfer rates of PFAS from serum to breastmilk were lower compared to other lipophilic persistent organic pollutants such as polychlorinated biphenyls.

3.3.1.2.5 Volume of Distribution in Humans and Animals
In humans, the volume of distribution (V_d) for PFOA has been assigned values between 170 and 200 mL/kg (see PFOA Appendix). V_d values may be influenced by differences in distribution between males and females, between pregnant and non-pregnant females, and across serum, plasma, and whole blood.

V_d estimates derived in mice and rats vary by species, age, sex, and dosing regimen. For example, Dzierlenga et al. (2019, 5916078) calculated the apparent volume of central and peripheral distribution in male and female adult rats after oral dosing. A one-compartment model for males and a two-compartment model for females was used to characterize PFOA levels. Peripheral V_d values were dramatically lower than central V_d values at all doses after oral administration and, interestingly, also after IV administration. While peak tissue levels were reached readily in both males and females, tissue levels in males were steady over the course of several days whereas tissue levels in females dropped quickly, in the span of hours. Further discussion on the V_d for PFOA can be found in Section 6.6.2.
3.3.1.3 Metabolism

Consistent with other peer-reviewed, published reports and reviews {U.S. EPA, 2016, 3603279; ATSDR, 2021, 9642134; Pizzurro, 2019, 5387175}, the available evidence demonstrates that PFOA is not metabolized in humans, primates, or rodents.

3.3.1.4 Excretion

Excretion data are available for oral exposure in humans and laboratory animals. Most studies have investigated the elimination of PFOA in humans, cynomolgus monkeys, and rats. Fewer studies measured elimination in mice, hamsters, and rabbits. Available evidence supports urine as the primary route of excretion in most species, though fecal elimination is prominent in rats. In rats, hair is another route of elimination in both males and females. In female humans and animals, elimination pathways include menstruation, pregnancy (cord blood, placenta, amniotic fluid, and fetal tissues) and lactation (breast milk) (see PFOA Appendix). Results of elimination half-life determination studies in mammals suggest that PFOA elimination time is longest in humans (years), intermediate in monkeys (days to weeks), and shortest in rodents (hours to days).

3.3.1.4.1 Urinary and Fecal Excretion

Studies in laboratory animals provide evidence that urine is typically the primary route of excretion but that sex impacts excretion by both routes, and these sex differences appear to be species-specific. Limited evidence supports excretion via the fecal route in laboratory animals and humans and via hair in animals. Most studies in all species indicate that excretion by the fecal route is substantially lower than that observed by the urinary route. Excretion through the fecal route appears to be more prominent in males compared to females and in rodents compared to humans. Nevertheless, a comprehensive set of principles governing resorption by renal, hepatic, and enteric routes and how these impact excretion and retention of PFOA has not been established in either humans or animals.

Human studies examined PFOA excretion after oral exposure, primarily through the urinary route. The urinary excretion of PFOA in humans is impacted by the isomeric composition of the mixture present in blood and the sex and age of the individual. The half-lives of the branched-chain PFOA isomers are shorter than those for the linear molecule, indicating that renal resorption is less prevalent for the branched-chain isomers {Zhang, 2014, 2851103; Fu, 2016, 3859819}.

Fujii et al. (2015, 2816710) measured PFOA clearance in mice and humans. Male and female FVB/NJcl mice were administered PFOA by IV (0.31 µmol/kg) or gavage (3.13 µmol/kg) and serum concentration data were analyzed using a two-compartment model. Mouse urinary clearance was analyzed by dividing the total amount excreted in the urine during a 24-hour period with the area under the curve (AUC) of the serum concentration. Human data were analyzed from paired (bile-serum) archived samples from patients undergoing nasobiliary drainage, percutaneous transhepatic biliary drainage, or percutaneous transhepatic gallbladder drainage for 24 hours. Urine-serum pairs were collected from healthy donors. Urinary and biliary clearance was determined by dividing the cumulative urine or bile excretion in a 24-h period with the serum concentration. Fecal clearance was calculated using the estimated biliary resorption rate.
The authors estimated that the total human clearance for PFOA was 0.096 mL/kg/day; PFOA clearance rates via urinary, biliary, and fecal routes were estimated to be 0.044, 2.62, and 0.052 mL/kg/day, respectively. The reabsorption rate of bile excreting PFOA was estimated to be 0.98 (derived by assigning a $V_d$ of 200 mL/kg, a serum half-life of 3.8 years, and the presumption that PFOA could only be excreted into the urine and feces via the bile). The authors also noted that estimated total human clearance was 50–100 times lower than the estimated PFOA clearances in mice after oral gavage dosing.

In rats, urine PFOA concentrations differed with age, dose, and sex {Hinderliter, 2006, 3749132}. For all rats dosed between 3 and 8 weeks of age, urinary excretion of PFOA was substantially higher in females than in males, and this difference increased with age. Several additional studies in rats found that females excreted much higher levels in urine compared to males and compared to feces {Kim, 2016, 3749289; Benskin, 2009, 1617974; Cui, 2010, 2919335}.

### 3.3.1.4.2 Renal and Enterohepatic Resorption

Several studies have been conducted to elucidate the cause of the sex difference in the elimination of PFOA by rats {Kudo, 2002, 2990271; Cheng, 2006, 6551310; Hinderliter, 2006, 3749132}. Many of the studies have focused on the role of transporters in the kidney tubules, especially the OATs and OATPs located in the proximal portion of the descending tubule {Nakagawa, 2007, 2919370; Nakagawa, 2009, 2919342; Yang, 2009, 2919328; Yang, 2010, 2919288}.

The results of *in vitro* studies were consistent with an *in vivo* analysis of OATPs gene and protein expression in rat kidneys {Yang, 2009, 2919328}. Organic anion transporters polypeptide 1a1 (OATP1a1) is located on the apical side of proximal tubule cells and is a potential mechanism for renal reabsorption of PFOA in rats. The level of messenger ribonucleic acid (mRNA) of OATP1a1 in male rat kidney is 5–20-fold higher than in female rat kidney and is regulated by sex hormones. Thus, higher expression of OATP1a1 in male rats would favor resorption of PFOA in the glomerular filtrate which is consistent with reduced excretion in males.

Fewer studies have investigated enterohepatic resorption of PFOA. Gastrointestinal elimination of PFOA was reported in a case report of a single human male with high serum levels of perfluorinated chemicals who was treated with a bile acid sequestrant (cholestyramine (CSM)) {Genuis, 2010, 2583643}. Before treatment, PFOA was detected in urine (3.72 ng/mL) but not in stool (LOD = 0.5 ng/g) or sweat samples. After treatment with CSM for 1 week, the serum PFOA concentration decreased from 5.9 ng/g to 4.1 ng/g, and stool PFOA levels increased to 0.96 ng/g. This observation suggests that PFOA is excreted in bile and that enterohepatic resorption via intestinal transporters limits the loss of PFOA via feces.

Studies in mice {Maher, 2008, 2919367; Cheng, 2008, 758807} suggest that increased expression of MRP3 and MRP4, coupled with decreased OATP levels, leads to increased biliary excretion of bile acids, bilirubin, and potentially toxic exogenous substances, including PFOA. Based on the greater observed downregulation of OATP-encoding genes in wild-type mice exposed to PFDA compared to PPARα-null mice exposed to PFDA, the authors concluded that the changes in receptor proteins were primarily linked to activation of PPARα {Cheng, 2008, 758807}.
Zhao et al. (2017, 3856461) demonstrated that PFOA was a substrate for human OATP1B1, OATP1B3, and OATP2B1 transporters expressed in liver using in vitro studies of Chinese hamster ovary (CHO) and human embryonic kidney (HEK-293) cells transfected with transporter complementary DNA (cDNA). Under these conditions, the three OATPs expressed in human hepatocytes can transport the longer chain PFOA (C8) and perfluorononanoate (C9), but not the shorter chain perfluoroheptanoate (C7). Preliminary evidence suggests that enterohepatic resorption could limit elimination of PFOA by the fecal route, including the recent observation that PFOA binds to NTCP, a transporter that mediates the uptake of conjugated bile acids {Ruggiero, 2021, 9641806}. The extent to which this pathway operates in vivo and whether enterohepatic resorption plays a substantial role in the retention of PFOA in humans and animals is still unknown.

3.3.1.4.3 Maternal Elimination through Lactation and Fetal Partitioning

In humans, PFOA can readily pass from mothers to their fetuses during gestation and through breast milk during lactation. In conjunction with elimination through menstruation, discussed in Section 3.3.1.4.4, human females clearly eliminate PFOA through routes not available to males. The total daily elimination of PFOA in pregnant human females was estimated to be 11.4 ng/day, lower than the 30.1 ng/day estimated for PFOS {Zhang, 2014, 2850251}. Mamsen et al. (2019, 5080595) estimated a placenta PFOA accumulation rate of 0.11% increase per day during gestation and observed that the magnitude of elimination may be influenced by the sex of the fetus. A human study by Zhang et al. (2013, 3859792) observed that the mean levels in the cord blood, placenta, and amniotic fluid were 58%, 47%, and 1.3%, respectively, of those in the mother’s blood, demonstrating that cord blood, placenta, and amniotic fluid are additional routes of elimination in pregnant females. Blood loss during childbirth could be another source of excretion. Underscoring the importance of pregnancy as a life-stage when excretion is altered, Zhang et al. (2015, 2851103) observed that the partitioning ratio of PFOA concentrations between urine and whole blood in pregnant women (0.0011) was lower than the ratios found in non-pregnant women (0.0028). The rate and extent of elimination through these routes are affected by parity {Lee, 2017, 3983576; Jusko, 2016, 3981718} and may be affected by the increase in blood volume during pregnancy {Pritchard, 1965, 9641812}.

Women can also eliminate PFOA via lactation {Tao, 2008, 1290895; Thomsen, 2010, 759807; Kang, 2016, 3859603}. Cariou et al. (2015, 3859840) measured PFOA in maternal serum, cord serum, and breast milk from females with planned Cesarean births. The observed mean ratio of cord serum to maternal serum PFOA was 0.78 in this study. However, the mean ratio between breast milk and maternal serum was 0.038, suggesting transfer from maternal blood to breast milk is lower than transfer from maternal blood to cord blood.

Studies in laboratory animals support elimination through pregnancy and lactation similar to what has been observed in humans. Fujii et al. (2020, 6512379) used the M/P concentration ratio as a measure of chemical transferability in FVB/NJcl mice. Maternal plasma PFOA concentrations were significantly higher than in milk (M/P ratio was 0.32). The M/P ratios were similar for C8, C9, C12, and C13, arguing against a direct relationship with lipophilicity. Potential roles for binding proteins in breast milk or transporters in breast tissue have not been investigated.
In summary, partitioning to the placenta, amniotic fluid, fetus, and breast milk represent important routes of elimination in humans, and may account for some of the sex differences observed for blood and urinary levels of PFOA by sex and life stage.

### 3.3.1.4.4 Other Routes of Elimination

Menstruation may be an important factor in the sex-specific differences observed in PFOA elimination. Zhang et al. (2013, 3859849) estimated a menstrual serum PFOA clearance rate of 0.029 mL/day/kg. The link between menstruation and PFOA elimination is based on several observations. First, postmenopausal females and adult males have longer PFOA elimination half-lives than premenopausal adult females {Zhang, 2013, 3859849}. Challenging the assumption that this is due to menstruation, Singer et al. (2018, 5079732) failed to find evidence of associations between menstrual cycle length and PFAS concentrations. Second, several studies reported on an association between increased serum concentrations of PFOA and PFOS and early menopause {Knox, 2011, 1402395; Taylor, 2014, 2850915}. However, a reanalysis of these data {Ruark, 2017, 3981395} suggested that the association between increased serum PFAS and early menopause could be explained by reversed causality, and more specifically, that pharmacokinetic bias could account for the observed association with epidemiological data. Ruark et al. (2017, 3981395) thus highlight the importance of considering menstrual blood loss as a PFAS elimination pathway. Additional studies may be needed to clarify the significance of the menstruation in PFOA elimination.

One study, Gao et al. (2015, 2851191), found that hair is a potential route of PFAS elimination in rats. A dose-dependent increase in hair PFOA concentration was observed in all exposed animals. Interestingly, hair PFOA concentrations for all treatment doses were significantly higher in males than in females. The sexually dimorphic difference in hair concentrations may be attributed to the sex differences observed in PFOA elimination rate and the transfer from serum to hair.

### 3.3.1.4.5 Half-Life Data

Because there is no evidence that PFOA is metabolized in mammals, half-life determinations are governed by excretion. There have been several studies of half-lives in humans all supporting a long residence time for serum PFOA with estimates measured in years rather than months or weeks (see PFOA Appendix). The calculated PFOA half-lives reported in the literature vary considerably, which poses challenges in predicting both the routes and rates of excretion. Half-life estimates vary considerably by species, being most rapid in rodents (measured in hours to days), followed by primates (measured in days to weeks) and humans (measured in years). Half-life estimates were shorter in human and rodent females relative to males. In the single primate study discussed below, half-lives were shorter in males compared to females.

PFOA half-life values in humans ranged from 0.53 years for a branched PFOA in young adult females {Zhang, 2013, 3859849} to 22 years in a study of primiparous women in Sweden {Glynn, 2012, 1578498} and varied by geographical region {Gomis, 2017, 3981280} (see PFOA Appendix). Age, lifestage, and sex differences in PFOA half-lives have not been rigorously evaluated, though estimates in males are generally longer than those in females {Fu, 2016, 3859819; Gomis, 2017, 3981280; Li, 2017, 4238434} and exhibit an age-related increase in adults {Genuis, 2014, 2851045, Zhang, 2013, 3859849}. While most studies were conducted in adults and/or adolescents, one study in newborns {Spliethoff, 2008, 2919368} calculated a half-
life for PFOA of 4.4 years. Linear isomers exhibit longer half-lives than branched isomers \{Zhang, 2013, 3859849\}.

Half-life estimates in humans rely on measured serum and/or urine concentrations. However, relatively few studies calculated PFOA half-lives along with measured intake and serum and urine PFOA concentrations \{Xu, 2020, 6781357; Worley, 2017, 3859800; Fu, 2016, 3859819; Zhang, 2013, 2639569\} (see PFOA Appendix). PFOA half-life values among these 4 studies varied from 1.7 years in Xu et al. (2020, 6781357) to 4.7 years in Fu et al. (2016, 3859819). These comparisons support principles suggested by the broader literature. First, sex related differences with males exhibiting somewhat longer half-lives compared to females (especially females of reproductive age) may relate, at least in part, to menstruation as a route of elimination \{Zhang, 2013, 3859849\}. Second, blood and urine concentrations varied by several orders of magnitude across these four studies. While blood and urine PFOA concentrations varied by two orders of magnitude across these studies, half-life estimates were similar, ranging from 1.77 to 4.70 years. This variability in serum and urine concentrations may reflect the role of non-urinary routes of PFOA excretion; the variability in concentrations may also reflect the difficulty in measuring renal resorption. Finally, only two studies estimated PFOA intake in subjects \{Xu, 2020, 6781357; Worley, 2017, 3859800\}. Altogether, there is insufficient data to correlate PFOA intake measurements to serum/plasma and urine concentrations. These factors, as well as age and health status of subjects, likely contribute to the reported variability in PFOA half-life estimates in humans.

In experimental animals, half-life values are reported in days rather than in years. Values in cynomolgus monkeys ranged from 13.6 to 41.7 days \{Butenhoff, 2004, 3749227\} and were generally longer than those observed in rodents, but much shorter than values observed in humans. Depending on the experimental conditions, half-lives in rats ranged from 0.03 days in females exposed to a high dose of 40 mg/kg \{Dzierlenga, 2019, 5916078\} to 13.4 days in males exposed to a relatively low dose of 0.4 mg/kg \{Benskin, 2009, 1617974\}. Rats exposed by the IV route exhibited shorter half-lives than rats administered the same dose by the oral gavage route \{Kim, 2016, 3749289; Dzierlenga, 2019, 5916078\}. Similar to humans and mice, half-life estimates were shorter in adult female rats compared to male rats. In contrast, female half-life values exceeded male values in cynomolgus monkeys, suggesting that species-specific factors impact elimination across sexes. Similar to findings in humans, PFOA branched isomers exhibited shorter half-lives compared to linear forms.

### 3.3.2 Pharmacokinetic Models

Pharmacokinetic (PK) models are tools for quantifying the relationship between external measures of exposure and internal measures of dose. For this assessment, PK models were evaluated for their ability to allow for 1) cross-species PK extrapolation of animal studies of both cancer and noncancer effects and 2) the estimation of the external dose associated with an internal dose metric that represents the POD calculated from either animal toxicological or epidemiological studies. The following sections first describe and evaluate published PK modeling efforts and then present conclusions from analyses that assessed the utility of the models to predict internal doses for use in dose-response assessment.

Numerous PK models for PFOA have been developed and published over the years to characterize the unique ADME described in Section 3.3.1. These approaches can be classified
into three categories: classical compartmental models, modified compartmental models, and PBPK models. With classical compartmental modeling, the body is defined as either a one- or two-compartment system with volumes and intercompartmental transfer explicitly fit to the available PFAS PK dataset. Modified compartmental models are more physiologically based in that they attempt to characterize unique aspects of in vivo ADME through protein binding, cardiac output, and known renal elimination from the published literature. However, these models still rely on explicit fitting of data to the non-physiological parameters. Finally, PBPK models describe the tissues and organs of the body as discrete, physiologically-based compartments with transport between compartments informed by the available data on physiologically relevant quantifications of blood flow and tissue perfusion. Determining additional, non-physiological parameters typically requires explicitly fitting the PBPK model to time-course concentration data. However, the number of parameters estimated through data fitting is generally fewer than for classical PK or modified compartmental models. A review of the available PK models regarding their ability to predict PFOA ADME is provided below.

3.3.2.1 Classical Compartmental Analysis

The most common approach for the prediction of serum levels of PFOA is to apply a relatively simple one-compartment model. This type of model describes the toxicokinetics of the substance with a single differential equation that describes the rate of change in the amount or concentration of the substance over time as a function of the exposure rate and the clearance rate. This type of model describes the relationship between exposure, serum concentration, and clearance and can be used to predict one of these values when the other two values are set. Additionally, because the model can produce predictions of changes in exposure and serum concentration over time, these models can be applied to fill the temporal gaps around or between measured serum concentrations or exposures.

The most common use for these models in human populations is to predict serum concentrations from estimated exposures. Some examples of this include the work by Shin et al. (2011, 2572313) who evaluated the exposure predictions from an environmental fate and transport model by comparing the predicted serum PFOA concentrations to observed values and by Avanasi et al. (2016, 3981510) who extended the work of Shin et al. (2011, 5082426) by applying a population model to investigate how variability and uncertainty in model parameters affect the prediction of serum concentrations.

Some examples of one-compartment models used to predict human exposure from serum concentrations include the work of Dassuncao et al. (2018, 4563862) who used a model to describe historical changes in exposure in seafood and consumer products, Hu et al. (2019, 5381562) who used paired tap water and serum concentration to estimate the proportion of total exposure that originates from drinking water, and Balk et al. (2019, 5918617) who used measured concentrations in drinking water, dust and air samples, and serum concentrations in developing children (measured at several time points) to assess the relative proportion of exposure that originates from dietary exposure. Zhang et al. (2019, 5080526) performed a similar study using community tap water measurements and serum concentrations to estimate the proportion of PFOA exposure in humans that originates from drinking water.

Other applications are used to better understand the toxicokinetics of PFOA in humans by combining estimated exposure values and serum values to estimate clearance and half-life in a
population of interest. One example of this type of model application was presented by Gomis et al. (2016, 3749264) who used measurements of serum and exposure, in the form of air concentrations during occupational exposure, to estimate an elimination half-life for PFOA. Those authors were also able to identify the relative contributions of direct occupational exposure to PFOA, indirect occupational exposure to PFOA precursors, and background, non-occupational PFOA exposure. Another example was presented by Worley et al. (2017, 3859800) who estimated the half-life of PFOA using exposure predicted from drinking water PFAS concentration in a community with contaminated drinking water. Fu et al. (2016, 3859819) used paired serum and urine samples from an occupational cohort to estimate the half-life separately from renal clearance (\(CL_R\)) (in urine) and in the whole body (in serum). One challenge in the estimation of half-life is the problem of estimating exposure to PFOA. Russell et al. (2015, 2851185) addressed this problem by estimating the amount of bias in elimination half-life that is introduced when the ongoing background exposure is not taken into account, with application to PFOA as an example.

One common modification of the one-compartment model is to perform a “steady-state approximation” (i.e., to assume that the rate of change of the serum concentration is zero). This scenario occurs when an individual experiences constant exposure, constant body habitus, and constant clearance over a timespan of several half-lives. Due to the long half-life of PFOA, steady state is a reasonable assumption for adults starting from the age of 25 and above. However, the steady state approximation cannot be applied for ages younger than 21 years of age (EPA defines childhood as < 21 years of age; {U.S. EPA, 2021, 9641727}) due to ongoing development during childhood and adolescence. This growth dilutes the concentration of the chemical in the body and results in lower levels than would be seen in its absence. Even though pubertal development including skeletal growth typically ends several years prior to the age of 25, there is a period after growth ceases during which PFOA levels increase until the adult steady-state level is reached. The general acceptability of the steady-state assumption in adults has the caveat that pregnancy or breastfeeding will result in changes in serum concentration and will not be accounted for in the steady-state approximation.

When adopting a steady-state assumption, the rate of change in serum levels over time is zero. It follows that the ratio between exposure to the substance and clearance determines the serum concentration. This is the approach used in the 2016 PFOA HESD to determine the constant exposure associated with a serum concentration {U.S. EPA, 2016, 3603279}. A similar approach was used in the recent risk assessment performed by CalEPA {CalEPA, 2021, 9416932}. Publications reporting applications of similar models include the work of Zhang et al. (2015, 2851103) who used paired human urine and serum data to estimate the total intake of PFOA and compared it to the rate of urinary elimination, and Lorber et al. (2015, 2851157) who examined the effects of regular blood loss due to phlebotomy on PFOA levels and extrapolated that finding to clearance via menstruation.

In animals, three classical PK models for PFOA have been published since the 2016 HESD for PFOA. In Dzierlenga et al. (2020, 5916078), male Sprague-Dawley rats were dosed with PFOA via oral gavage at 6, 12, and 48 mg/kg, or intravenously at 6 mg/kg. Female Sprague-Dawley rats were dosed with PFOA via oral gavage at 40, 80, 320 mg/kg or intravenously at 40 mg/kg. Following the administration of PFOA, rats were sacrificed from five minutes to 50 days post-dosing for males and from five minutes to 12 days post-dosing in females. Differences in length
of study for each sex represent the sex-dependent difference in half-lives for which adult female rats eliminate PFOA more rapidly than adult males. For both sexes, measured plasma concentrations characterized the biphasic PK curve. From these exposure scenarios, Dzierlenga et al. (2020, 5916078) developed a two-compartment model to characterize PK parameters of interest such as the alpha- and beta-phase half-life, central and peripheral compartment volumes, and total PFOA clearance. For each dosing scenario, a single set of PK parameters were fit, making extrapolation to other dosing scenarios difficult. However, the authors demonstrate a significant difference between males and females in beta-phase half-life and overall clearance. This difference in half-life is critical when considering internal dosimetry for a pregnant dam during developmental PK studies.

Fujii et al. (2015, 2816710) conducted a PK analysis in mice by dosing male and female mice either intravenously with 0.313 μmol/kg or through oval gavage with 3.13 μmol/kg. Following administration of PFOA, blood concentrations were collected through tail veins beginning immediately following dosing up to 24 hours post-dosing. Fujii et al. (2015, 2816710) used these data to develop a two-compartment model to describe sex-dependent PK in mice. Unfortunately, the follow-up time of 24 hours post-dosing is not long enough to accurately characterize the beta-phase elimination of PFOA, which the authors predicted was 627 days. The small amount of change in PFOA levels within a 24-hour timespan will make the estimated terminal half-life from a two-compartment model unreliable because PFOA will still be in the distribution phase. In addition, the functional form fit for the oral gavage data in Fujii et al. (2015, 2816710) reflects a one-compartment model with gavage dosing making it not possible to compare the predicted half-lives between the two routes of exposure. While the reported data could be used for characterizing absorption and distribution of PFOA, it cannot be used for characterizing the elimination phase. Additionally, a study with a much longer follow-up time of 80 days post-dosing reported a half-life of 15.6 – 21.7 days {Lou, 2009, 2919359}.

Finally, Gomis et al. (2016, 3749264) utilized the functional form of a two-compartment model with oral gavage to predict internal dosimetry of PFOA in rats using PK data from Perkins et al. (2004, 1291118). However, because the scope of the Gomis et al. (2017, 3981280) study involved predicting internal dose points-of-departure, PK parameters are not presented.

3.3.2.2 Modified Compartmental Models

In addition to the common one-compartment models described above, several models for humans have been developed to extend the simple one-compartment model to describe the PK during pregnancy and lactation. The key factors that must be introduced into the model are the changes in body habitus that occur during pregnancy (e.g., increases in blood plasma volume and body weight), the distribution and transfer of the substance between the maternal and fetal tissues, the transfer from the mother to the infant during nursing, and postnatal development, including growth of the infant during the early period of life. The mathematical formulation of this type of model requires two differential equations, one describing the rate of change in amount or concentration in the mother and one describing the rate of change in infants. One such developmental model with a lactational component was used to predict the maternal serum concentrations and exposure from measurements of PFOA concentrations in breast milk {Abdallah, 2020, 6316215}. Verner et al. (2016, 3299692) presented another developmental model to predict PFOA serum concentrations in the mother and child and predict previous exposure using mother/child paired serum measurements at different times. This model included
all the key aspects previously mentioned for developmental PK models. Another developmental model was developed by Goeden et al. (2019, 5080506) to evaluate the relationship between drinking water concentrations and infant serum levels during breastfeeding resulting from gestational and lactational transfer of PFOA that had accumulated within the mother. A distinguishing feature of the Goeden et al. (2019, 5080506) model is that it incorporates an adjustment for the increased intracellular water in infants and young children compared to adults, under the assumption that PFAS distribution into tissues, quantified by the V_d, will increase proportionally to intracellular water content. This life stage difference in intracellular water content may explain why the ratio of PFOA in cord blood vs. maternal blood at childbirth tends to be less than one. Monroy et al. (2008, 2349575) reported median cord blood PFOA concentration to be 87% of maternal serum, while the median ratio of fetal tissue to placenta PFOA concentration was found to be generally greater than one [Mamsen, 2019, 5080595]. One oversight of this model is that the rate equations take concentration into account, but they do not account for decreases in concentration due to increasing body weight (growth dilution). This is a significant factor for infants who grow quickly.

Other unique analyses that extended the one-compartment framework were publications by Shan et al. (2016, 3360127), who estimated the exposure to specific isomers of PFOA using measurements in food, tap water, and dust to estimate the isomeric profiles of the substances in human serum, and Convertino et al. (2018, 5080342) who used a two-compartment PK-pharmacodynamic model to describe changes in serum concentration during a dose-escalation, phase one clinical trial with PFOA and describe how those serum changes are correlated with changes in serum total cholesterol (TC) and free thyroxine (FT4).

Some other models have added features to accommodate longer half-life values and allow for dose-dependent changes in excretion rate compared to the classic 1- or 2- compartment approaches {Andersen, 2006, 818501; Wambough, 2013, 2850932; Loccisano, 2011, 787186; Loccisano, 2012, 1289830; Loccisano, 2013, 1326665}. The underlying assumption for all the models is saturable resorption from the kidney filtrate, which consistently returns a portion of the excreted dose to the systemic circulation and prolongs both clearance from the body (e.g., extends half-life) and the time needed to reach steady state. These more complex models have been developed for humans, monkeys, mice, and rats.

One of the earliest PK models {Andersen, 2006, 818501} was created using the post-dosing plasma data from the Butenhoﬀ et al. (2004, 3749227) study in cynomolgus monkeys. In this study, groups of six monkeys (three per sex per group) were dosed for 26 weeks with 0, 3, 10, or 20 mg/kg PFOA (and also a high dose of 30 mg/kg PFOA for only the first 12 days) and followed for more than 160 days after dosing. Metabolism cages were used for overnight urine collection. Since urine specimens could only account for overnight PFOA excretion, total volume and total PFOA were extrapolated to 24-hour values based on the excretion rate (volume per hour) for the volume collected and the hours of collection.

The Andersen et al. (2006, 818501) model was based on the hypothesis that saturable resorption capacity in the kidney would possibly account for the unique half-life properties of PFOA across species and sexes. The model structure was derived from a published model for glucose resorption from the glomerular filtrate via transporters on the apical surface of renal tubule epithelial cells {Andersen, 2006, 818501}. 
The renal-resorption model includes a central compartment that receives the chemical from the oral dose and a filtrate compartment for the glomerular filtrate from which resorption with transfer to the central compartment can occur. Transfer from the filtrate compartment to the central compartment decreases the rate of excretion. The resorption in the model was saturable, meaning that there was proportionally less resorption and greater excretion at high serum PFOA concentrations than at low concentrations. In addition to decreased renal excretion due to the renal resorption, excretion is also reduced in the model by implementing a constant proportion of PFOA that is bound to protein in plasma and is not available for renal filtration.

The model was parameterized using the body weight and urine output of cynomolgus monkeys (Butenhoff, 2004, 3749227) and a cardiac output of 15 L/h·kg from the literature (Corley, 1990, 10123). A 20% blood flow rate to the kidney was assumed based on data from humans and dogs. Other parameters were optimized to fit the data for plasma and urine at lower concentrations and then applied for the 20 mg/kg/day dose, which was assumed to represent a concentration at which renal resorption was saturated. Based on the data for the dose of 20 mg/kg/day, the model was able to predict the decline in plasma levels after the cessation of dosing. The predictions were adequate for one of the three modeled monkeys; for the other two monkeys, the model predicted higher serum concentrations than were observed. That discrepancy between model prediction and observations could have occurred because the model did not allow for efflux of PFOA into the glomerular filtrate through transporters on the basolateral surface of the tubular cells. The authors also observed that three of the monkeys had faster CL\textsubscript{R} of PFOA than the other three monkeys, indicating interindividual variability in clearance.

Building on the work of other researchers, Wambaugh et al. (2013, 2850932) developed and published a PK model to support the development of an EPA RfD for PFOA (U.S. EPA, 2016, 3603279). The model was applied to data from studies conducted in monkeys, rats, or mice that demonstrated an assortment of systemic, developmental, reproductive, and immunological effects. A saturable renal resorption term was used. This concept has played a fundamental role.
in the design of all of the published PFOA models summarized in this section. The model structure is depicted in Figure 3-4 (adapted from Wambaugh et al. (2013, 2850392)).

Wambaugh et al. (2013, 2850932) placed bounds on the estimated values for some parameters of the Andersen et al. (2006, 818501) model to support the assumption that serum carries a significant portion of the total PFOA body load. The Andersen et al. (2006, 818501) model is a modified two-compartment model in which a primary compartment describes the serum and a secondary deep tissue compartment acts as a specified tissue reservoir. Wambaugh et al. (2013, 2850932) constrained the total $V_d$ such that the amount in the tissue compartment was not greater than 100 times that in the serum. As a result, the ratio of the two volumes (serum vs. total) was estimated in place of establishing a rate of transfer from the tissue to serum, but the rate of transfer from serum to tissue was also estimated from the data. A nonhierarchical model for parameter values was also assumed. Under this assumption, a single numeric value represents all individuals of the same species, sex, and strain. This sex assumption was applied to male and female rats to determine sex-specific parameters because of established sex-specific toxicokinetic differences. Conversely, monkeys and mice were only grouped by species and strain with only female parameters available for mice and male/female monkey data pooled together for a single set of parameters. Body weight, the number of doses, and magnitude of the doses were the only parameters varied for different studies. Measurement errors were assumed to be log-normally distributed.

Table 4-3 in Section 4.1.3.1.1 provides the estimated and assumed PK parameters applied in the Wambaugh et al. (2013, 2850932) model for each of the species evaluated.

The PK data that supported the Wambaugh et al. (2013, 2850932) analysis were derived from two in vivo PFOA PK studies. The monkey PK data were derived from Butenhoff et al. (2004, 3749227), and the data for the rats (M/F) were from Kemper et al. (2003, 6302380). Two strains of female mice were analyzed separately, with CD1 information derived from Lou et al. (2009, 2919359) and C57BL/6 information derived from DeWitt et al. (2008, 1290826). The data were analyzed within a Bayesian framework using Markov Chain Monte Carlo sampler implemented as an R package developed by EPA to allow predictions across species, strains, and sexes and to identify serum levels associated with the NOAEL and LOAEL external doses. Prior distributions for the parameters were chosen to be broad, log-normal distributions, allowing the fitted parameters to be positive and for the posterior distribution to be primarily informed by the data likelihood rather than by the priors.

### 3.3.2.3 PBPK Models

An alternative approach to the use of a classical or modified compartmental model is a PBPK model, which describes the changes in substance amount or concentration in a number of discrete tissues. One of the main advantages of a PBPK model is the ability to define many parameters based on physiological data, rather than having to estimate them from chemical-specific data. Such physiological parameters include, for example, organ volumes and the blood flow to different organs; they can be measured relatively easily and are chemical independent. Another advantage is that amount and concentration of the substance can be predicted in specific tissues, in addition to blood. This can be valuable for certain endpoints where it is expected that a tissue concentration would better reflect the relevant dosimetry compared to blood concentration.
The first PBPK model developed for this chemical was reported in a series of publications by Loccisano et al. which together describe the PK of PFOA in rats, monkeys, and humans, in both adult and developmental (for rat and human) scenarios {Loccisano, 2011, 787186; Loccisano, 2012, 1289830; Loccisano, 2012, 1289833; Loccisano, 2013, 1326665}. These models were developed based on an earlier “biologically motivated” model that served as a bridge between a one-compartment model and PBPK by implementing a tissue compartment (similar to a 2-compartment model), an absorption compartment, and a renal filtrate compartment with saturable renal resorption {Tan, 2008, 2919374}. The work of Tan et al. (2008, 2919374) was a development of the earlier work of Andersen et al. (2006, 818501) previously discussed. The PBPK model of Loccisano and coauthors then extended this “biologically motivated” model by the addition of discrete tissue compartments, rather than a single compartment representing all tissues.

A series of follow-up studies applied the Loccisano and coauthors’ model structure, with extensions, to address how PK variation in human populations could bias the result of the study. This consisted of the work of Wu et al. (2015, 3223290) who developed a detailed model of adolescent female development during puberty and menstrual clearance of PFOA to investigate the interaction between chemical levels and the timing of menarche, Ruark et al. (2017, 3981395) who added a detailed description of menopause to evaluate how that affects serum levels and the epidemiological association between early menopause and PFOA levels, Ngueta et al. (2017, 3860773) who implemented a reduction in menstrual clearance in individuals using oral contraceptives and the interaction between oral contraceptive use, endometriosis, and serum PFOA levels, and Dzierlenga et al. (2020, 6315786; 2020, 6833691) who applied a model of thyroid disease {Dzierlenga, 2019, 7947729} to describe changes in PFOA and PFOS urinary clearance due to disease state.

In addition to this set of studies, Fabrega et al. (2014, 2850904) updated the model of Loccisano et al. (2013, 1326665) for humans by modeling a human population using regional food and drinking water measurements and human tissue data collected from cadavers in a region of Spain. The use of human tissue data is relatively rare due to the challenges in sourcing human tissue but may prove preferable to the assumption that human distribution is similar to distribution in an animal model. However, Fabrega et al. (2014, 2850904) estimated their tissue to blood partition coefficients from the ratio of tissue concentrations in the cadavers to the average serum concentrations in live volunteers who lived in the same region but were sampled several years earlier {Ericson, 2007, 3858652} and they provided no details on how their renal resorption parameters were estimated from the human blood concentrations. This model was further applied to a population in Norway and extended to other PFAS {Fabrega, 2015, 3223669}.

Brochot et al. (2019, 5381552) presented the application of a PBPK model for PFOA with gestation and lactation life stages to describe development and predicted maternal, infant, and breastmilk concentrations over a variety of scenarios including the prediction of maternal levels across multiple pregnancies.

One of the major challenges in the parameterization of PBPK models for PFOA is the estimation of the chemical-dependent parameters such as those involved in protein binding and renal clearance. One way to investigate this issue is to perform in vitro experiments to help inform the parameters. Worley et al. (2015, 3981311) used in vitro measurements of renal transporter
activity to describe in detail the various steps involved in the renal filtration, resorption, and excretion of PFOA. Cheng et al. (2017, 3981104) went farther in their use of in vitro data and used measurements of PFOA interactions with binding proteins, as well the measured rates of several transporters, to parameterize a rat PBPK model.

No new animal PBPK models for PFOA have been published since the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}. See the 2016 HESD {U.S. EPA, 2016, 3603279} for a more in-depth review of PFOA PBPK models.

3.4 Non-Cancer Health Effects Evidence Synthesis and Integration

3.4.1 Hepatic

EPA identified 32 epidemiological studies (reported in 38 publications)\(^7\),\(^8\) and 28 animal toxicological studies that investigated the association between PFOA and hepatic effects. Of the epidemiological studies, 21 were classified as medium confidence, 8 as low confidence, 1 as mixed (medium/low) confidence, and 8 were considered uninformative (Section 3.4.1.1). Of the 28 animal toxicological studies, 5 were classified as high confidence, 19 as medium confidence, 2 as low confidence, and 2 were considered mixed (medium/uninformative and medium/low/uninformative) (Section 3.4.1.2). Studies have mixed confidence ratings if different endpoints evaluated within the study were assigned different confidence ratings. Though low confidence epidemiology and animal toxicological studies are considered qualitatively in this section (e.g., to inform the weight of the evidence for hazard assessment), they were not considered quantitatively for the dose-response assessment (Section 4).

3.4.1.1 Human Evidence Study Quality Evaluation and Synthesis

3.4.1.1.1 Introduction and Summary of Evidence from the 2016 PFOA HESD

Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are considered reliable markers of hepatocellular function/injury, with ALT considered more specific and sensitive {Boone, 2005, 782862}. Bilirubin and γ-glutamyltransferase (GGT) are also routinely used to evaluate potential hepatobiliary toxicity {Boone, 2005, 782862; EMEA, 2008, 3056793; Hall, 2012, 2718645}. Elevated liver serum biomarkers are frequently an indication of liver injury, though not as specific as structural or functional analyses such as histology findings and liver disease.

There are 12 epidemiological studies (13 publications)\(^8\) from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA exposure and hepatic effects, and study quality evaluations are shown in Figure 3-5.\(^\text{Error! Reference source not found.}\) Emmett et al. (2006, 1290905) was rated as uninformative and will not be further discussed. Nine out of the twelve remaining studies were rated as medium quality and all investigated changes in serum liver enzymes.

---

\(^7\) Multiple publications of the same data: Jain and Ducatman (2019, 5381566); Jain and Ducatman (2019, 5080621); Jain (2019, 5381541); Jain (2020, 6833623); Onoike et al. (2020, 6988477); Liu et al. (2018, 4238514); Gleason et al. (2015, 2966740) all used NHANES data from overlapping years.

\(^8\) Olsen (2003, 1290020) is the peer-review paper of Olsen (2001, 10228462); however, data for PFOA and hepatic outcomes is reported in Olsen (2001, 10228462).
Lin et al. (2010, 1291111) is a medium confidence study that examined 2,216 adults in the NHANES study (1999–2000, and 2003–2004) and observed that higher serum concentrations of PFOA were associated with abnormal liver enzymes increases in the U.S. general population. For each increase in log-PFOA, the serum ALT and GGT concentrations (U/L) increased by 1.86 units (95% CI: 1.24, 2.48), and 0.08 units (95% CI: 0.05, 0.11), respectively {Lin, 2010, 1291111}. Importantly, when PFOS, PFHxS, and PFNA were simultaneously added in the fully adjusted regression models, the associations remained and were slightly larger; one unit increase in serum log-PFOA concentration was associated with a 2.19 unit (95% CI: 1.4, 2.98) increase in serum ALT concentration (U/L), and a 0.15 unit (95% CI: 0.11, 0.19) increase in serum log-GGT concentration (U/L). Another medium confidence cross-sectional study {Yamaguchi, 2013, 2850970} conducted in Japan reported a positive correlation between PFOA and ALT.

A medium confidence study in a highly exposed community provides further support for the positive association between PFOA exposure and ALT findings in the U.S. general population. One of the largest studies of PFOA exposure and ALT in adults, Gallo et al. (2012, 1276142), evaluated 47,092 adults from the C8 Health Project living in communities in Ohio and West Virginia impacted by a manufacturing-related PFOA-contaminated drinking water supply. Natural log transformed serum PFOA concentrations were associated with ln-ALT in linear

---

**Figure 3-5. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA Exposure and Hepatic Effects Published Before 2016 (References in the 2016 HESD)**

Interactive figure and additional study details available on HAWC.
regression models (regression coefficient: 0.022; 95% CI: 0.018, 0.025) and with elevated ALT in logistic regression models across deciles of PFOA (OR = 1.10; 95% CI: 1.07, 1.13). The evidence of an association between PFOA and GGT or bilirubin was less consistent. The level of bilirubin increased with increasing PFOA at low PFOA concentrations and decreased with increasing PFOA levels at higher PFOA concentrations, producing an inverse roughly U-shaped curve of the relationship between PFOA and bilirubin.

Several medium confidence cross-sectional occupational studies reported that higher concentrations of PFOA were associated with higher liver enzyme levels, such as ALT, AST, GGT, and total bilirubin {Sakr, 2007, 1291103; Sakr, 2007, 1430761; Costa, 2009, 1429922}. However, other medium confidence cross-sectional occupational studies in PFOA production workers reported mostly null findings, with some positive associations with ALT in specific locations or specific years {Olsen, 2000, 1424954; Olsen, 2001, 10228462; Olsen, 2003, 1290020; Olsen, 2007, 1290836}.

Figure 3-6. Overall ALT Levels from Pre-2016 HESD Epidemiology Studies Following Exposure to PFOA

Interactive figure and additional study details available on Tableau.

The associations with ALT indicate the potential for PFOA to affect liver function; however, studies of functional hepatic endpoints were limited to two studies in an occupational cohort. The first study was a low confidence study that observed no association between PFOA and hepatitis
or fatty liver disease; however, there was a positive association with non-hepatitis liver disease with a 10-year lag time [Steenland, 2015, 2851015]. A medium confidence cohort mortality study of workers exposed to PFOA at a DuPont chemical plant in West Virginia observed no association between PFOA exposure levels and non-malignant chronic liver disease deaths [Steenland and Woskie, 2012, 2919168].

In conclusion, the majority of the medium confidence studies support an association between PFOA exposure and increases in serum ALT in multiple populations, including occupational and highly exposed communities as well as the general population (see Figure 3-6). Multiple studies demonstrated statistically significant increases in ALT [Gallo, 2012, 1276142; Lin, 2010, 1291111; Yamaguchi, 2013, 2850970; Olsen, 2000, 1424954 for 1997 data] or elevated ALT [Gallo, 2012, 1276142] after PFOA exposure. Increases were also observed for AST and GGT, though less consistently across the available studies.

3.4.1.1.2 Study Quality Evaluation Results for the Relevant Epidemiology Studies Identified from the Updated Literature Review

There are 20 epidemiological studies (25 publications)9 that were identified from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD [U.S. EPA, 2016, 3603279] that investigated the association between PFOA and hepatic effects. Study quality evaluations for these 25 publications are shown in Figure 3-7 and Figure 3-8. Of these 25 publications, 12 were classified as medium confidence, 6 as low confidence, and 7 were considered uninformative.

The following informative studies examined liver enzymes in adults: two cross-sectional studies {Wang, 2012, 2919184; Nian, 2019, 5080307}; multiple publications of data from NHANES {Jain, 2019, 5381541; Liu, 2018, 4238514; Omoike, 2020, 6988477; Jain, 2019, 5080621; Jain, 2019, 5381566; Gleason, 2015, 2966740}; one cohort with retrospective exposure assessment {Darrow, 2016, 3749173}; one prospective cohort {Salihovic, 2018, 5083555}; one open-label controlled trial {Convertino, 2018, 5080342}; and one occupational cohort {Olsen, 2012, 2919185}. Most of these studies were in general population adults, but some assessed specific populations such as the elderly {Salihovic, 2018, 5083555} and fluorochemical plant workers {Wang, 2012, 2919184; Olsen, 2012, 2919185}. In addition, one occupational cohort {Girardi, 2019, 6315730} and three cross-sectional studies {Darrow, 2016, 3749173; Rantakokko, 2015, 3351439; Liu, 2018, 4238396} examined functional liver endpoints in adults (histology, liver disease, hepatic fat mass). In children and adolescents, four studies were available, including one cohort {Mora, 2018, 4239224} and three cross-sectional studies {Khalil, 2018, 4238547; Jin, 2020, 6315720; Attanasio, 2019, 5412069}, with one examining histology endpoints {Jin, 2020, 6315720}.

All of the studies of adults and children in the general population, except for Darrow et al. (2016, 3749173), and one of the two occupational cohorts {Olsen, 2012, 2919185} measured exposure to PFOA using biomarkers in blood. Darrow et al. (2016, 3749173) modeled exposure based on residential history, drinking water sources, and water consumption rates. The other occupational cohort study estimated PFOA exposure based on job duties {Girardi, 2019, 6315730}. The

---

9 Multiple publications of the same data: Jain and Ducatman (2019, 5381566); Jain and Ducatman (2019, 5080621); Jain (2019, 5381541); Jain (2020, 6833623); Omoike et al. (2020, 6988477); Liu et al. (2018, 4238514); and Gleason et al. (2015, 2966740) all used NHANES data from overlapping years.
uninformative studies were excluded due to potential confounding {Jiang, 2014, 2850910; Predieri, 2015, 3889874; Abraham, 2020, 6506041; Sinisalu, 2021, 7211554}, lack of information on participant selection {Sinisalu, 2020, 9959547}, or use of PFAS as the dependent variable (in a publication with a more suitable analysis {Jain, 2020, 6833623}, or in cases where the independent variable is a genetic variant and thus not affected by PFAS exposure {Fan, 2014, 2967086}).

High and medium confidence studies were the focus of the evidence synthesis for endpoints with numerous studies, though low confidence studies were still considered for consistency in the direction of association (and details are provided in PFOA Appendix). For endpoints with fewer studies (e.g., AST serum levels and functional assays), the evidence synthesis below included details on any low confidence studies available. Studies considered uninformative were not considered further in the evidence synthesis.
Figure 3-7. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA Exposure and Hepatic Effects

Interactive figure and additional study details available on [HAWC](#).

* Multiple publications of the same data: Jain and Ducatman (2019, 5381566); Jain and Ducatman (2019, 5080621); Jain (2019, 5381541); Jain (2020, 6833623); Omoike et al. (2020, 6988477); Liu et al. (2018, 4238514); Gleason et al. (2015, 2966740) all use NHANES data from overlapping years.
### Figure 3-8. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA Exposure and Hepatic Effects (Continued)\(^a\)

Interactive figure and additional study details available on [HAWC](https://www.hawcproject.org).

\(^a\) Multiple publications of the same data: Jain and Ducatman (2019, 5381566); Jain and Ducatman (2019, 5080621); Jain (2019, 5381541); Jain (2020, 6833623); Omoike et al. (2020, 6988477); Liu et al. (2018, 4238514); Gleason et al. (2015, 2966740) all use NHANES data from overlapping years.
3.4.1.1.3 Synthesis of Hepatic Injury from the Updated Literature Review

Results for the studies that examined ALT are presented in the Appendix (see PFOA Appendix). As shown in Figure 3-9 and Figure 3-10, of the available informative studies that measured ALT in adults, statistically significant positive associations between ALT and PFOA (i.e., increased ALT as a continuous measure with higher PFOA exposure levels) were observed in all of the medium confidence studies, which consisted of one cross-sectional study {Nian, 2019, 5080307}, two cohort studies {Darrow, 2016, 3749173; Salihovic, 2018, 5083555}, and two NHANES publications {Gleason, 2015, 2966740; Jain, 2019, 5381541}.

In addition, an exposure-response gradient was observed in the single study that examined quintiles of exposure {Darrow, 2016, 3749173}. This study additionally examined elevated ALT as a dichotomous outcome and reported an OR of 1.16 (95% CI 1.02, 1.33) in the highest vs. lowest quintiles of exposure (Figure 3-9). The positive associations in Jain (2019, 5381541) were observed only in certain sub-groups (e.g., by renal function (i.e., glomerular filtration stage), obesity status) and according to no clear pattern across sub-groups (NHANES 2003-2014), but in Gleason et al. (2015, 2966740), the positive association was observed in the entire study population (NHANES 2007-2010). Results of the low confidence studies of ALT in adults are further described in the PFOA Appendix and not described further in this section because there are numerous medium confidence studies describing ALT measures in adults that were included in the 2016 PFOA HESD (see Section 1.13.1.1.1) or identified in the updated literature search.
Figure 3-9. Odds of Elevated ALT Levels from Epidemiology Studies Following Exposure to PFOA

Interactive figure and additional study details available on [Tableau](#).
In children and adolescents, positive associations were observed in girls (with exposure-response gradient across quartiles) in the medium confidence study by Attanasio et al. (2019, 5412069) and in the low confidence study of obese children {Khalil, 2018, 4238547}. However, inverse associations were observed in boys in Attanasio et al. (2019, 5412069) and Mora et al. (2018, 4239224), which may indicate that the associations in children are less consistent than in adults or that there are sex differences in children. Insufficient data were available to assess the potential for effect modification by sex.

The studies that examined AST are presented in the Appendix (see PFOA Appendix). In adults in the general population, positive associations were observed in the two medium confidence studies {Jain, 2019, 5381541; Nian, 2019, 5080307}. In the two low confidence studies of fluorochemical plant workers {Olsen, 2012, 2919185; Wang, 2012, 2919184}, no associations were observed. In children including adolescents, the medium confidence study {Attanasio, 2019, 5412069} reported a positive association in girls but an inverse association in boys. In the low confidence study {Khalil, 2018, 4238547}, the direction of association was inverse, but the result was extremely imprecise. For the other liver enzymes (bilirubin, GGT), results were generally consistent with those of ALT and AST, with the exception that inverse associations for bilirubin were observed in some studies {Salihovic, 2018, 5083555; Darrow, 2016, 3749173}. 

Figure 3-10. ALT Levels from Medium Confidence Epidemiology Studies Following Exposure to PFOA

Interactive figure and additional study details available on Tableau.
For functional measures of liver injury, two medium confidence studies (one in adults and one in children including adolescents) examined histology endpoints. Both studies examined lobular inflammation. Rantakokko et al. (2015, 3351439) reported that higher PFOA exposure levels were associated with extremely reduced odds of lobular inflammation (OR = 0.02, p < 0.05), whereas Jin et al. (2020, 6315720) reported the opposite direction of association, though the results in the latter study were non-monotonic and not statistically significant. Jin et al. (2020, 6315720) additionally reported lower odds of ballooning and portal inflammation, but higher odds of steatosis (association non-monotonic) and nonalcoholic steatohepatitis. Three additional studies examined some form of liver disease. In a medium confidence study, Darrow et al. (2016, 3749173) reported no increases in any liver disease or specifically enlarged liver, fatty liver, or cirrhosis. In contrast, in a low confidence study, Girardi and Merler (2019, 6315730) reported that workers at a PFAS production plant had higher mortality from liver cancer or cirrhosis when compared to regional mortality statistics and a control group of non-chemical workers (p < 0.05 for some comparisons). Lastly, a second low confidence study by Liu et al. (2018, 4238396) examined hepatic fat mass and found no correlation with PFOA exposure.

3.4.1.2 Animal Evidence Study Quality Evaluation and Synthesis

There are 9 animal toxicological studies from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} and 19 studies identified from recent systematic literature searches and review efforts conducted after publication of the 2016 PFOA HESD that investigated the association between PFOA and hepatic effects. Study quality evaluations for these 28 studies are shown in Figure 3-11 and Figure 3-12.
Figure 3-11. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA Exposure and Hepatic Effects

Interactive figure and additional study details available on HAWC.
Figure 3-12. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA Exposure and Hepatic Effects (Continued)

Interactive figure and additional study details available on HAWC.
Hepatic effects (e.g., increased absolute and relative liver weight, altered clinical parameters indicating potential liver injury, and histopathological alterations of liver tissue) were observed in male and female mice, rats, and monkeys after oral PFOA doses of different durations. Data from numerous studies provide evidence confirming that the liver is a target of PFOA toxicity.

### 3.4.1.2.1 Liver Weight

Generally, increases in absolute and/or relative liver weight were observed in all available PFOA animal toxicological studies, regardless of species, sex, life stage, and exposure paradigm (Figure 3-13). Significant increases in absolute and relative liver weight were reported at doses as low as 0.05 mg/kg/day and 0.31 mg/kg/day, respectively \{Li, 2017, 4238518; Yan, 2014, 2850901\}, and were often observed at the lowest dose administered in each study. In male mice, significant increases in absolute and/or relative liver weights were observed at doses ranging from 0.31–30 mg/kg/day after 4–5 weeks of exposure \{Loveless, 2008, 988599; Minata, 2010, 1937251; Yan, 2014, 2850901; Yu, 2016, 3981487; Li, 2017, 4238518; Crebelli, 2019, 5381564; Guo, 2019, 5080372; Guo, 2021, 9963377; Shi, 2020, 7161650\}. Similarly, significant increases in absolute and relative liver weights were reported in male rat short-term/subchronic studies at doses of 0.625–30 mg/kg/day \{Perkins, 2004, 1291118; Loveless, 2008, 988599; Cui, 2009, 757868; NTP, 2019, 5400977\}. Two subchronic dietary studies in adult male rats with exposures lasting 13–16 weeks significantly increased absolute and relative liver weights at doses as low as 1 mg/kg/day \{Perkins, 2004, 1291118; NTP, 2020, 7330145\}. In one chronic study in male Crl:CD BR (CD) rats, relative liver weight was significantly increased after 15 months of exposure to 13.6 mg/kg/day via the diet \{Biegel, 2001, 673581\}. Similar results were observed at the 1-year interim sacrifice of a 2-year dietary study in male Sprague-Dawley rats exposed to 14.2 mg/kg/day PFOA, but the effect was not statistically significant at the 2-year timepoint \{Butenhoff, 2012, 2919192\}. Male cynomolgus monkeys orally administered PFOA capsules daily for 26 weeks also had significantly increased absolute liver weights at doses ≥3 mg/kg/day, though the increase in relative liver weight was only statistically significant in the highest dose group (30/20 mg/kg/day) \{Butenhoff, 2002, 1276161\}.

Several systemic toxicity studies evaluating liver weight in female mice and rats after short-term, subchronic, or chronic PFOA exposures are also available \{Butenhoff, 2012, 2919192; De Guise, 2021, 9959746; Li, 2017, 4238518; NTP, 2019, 5400977; NTP, 2020, 7330145; Zhang, 2020, 6505878\}. Two 28-day studies in female mice reported significant increases in absolute liver weight at doses ranging from 0.05–5 mg/kg/day (relative liver weight not reported) \{Li, 2017, 4238518; Zhang, 2020, 6505878\}. A third 28-day study in female B6C3F1 mice reported significant increases in absolute and relative liver weights at both doses tested (1.88 and 7.5 mg/kg/day) \{De Guise, 2021, 9959746\}. NTP (2019, 5400977) conducted a 28-day gavage study in female Sprague-Dawley rats and reported significant increases in both absolute and relative liver weights at doses ≥25 mg/kg/day. In a chronic feeding study (see study design details in Section 3.4.4.2.1.2), NTP (2020, 7330145) reported significant increases in absolute and relative liver weight in female Sprague-Dawley rats after 16 weeks of exposure to 63.4 but not 18.2 mg/kg/day PFOA. A 2-year feeding study in female Sprague-Dawley rats similarly found no significant difference in absolute or relative liver weight at doses of 1.6 or 16.1 mg/kg/day PFOA \{Butenhoff, 2012, 2919192\}.

There are also multiple reproductive and developmental toxicity studies that report maternal and/or offspring liver weight in rodents after gestational PFOA exposures. Blake et al. (2020,
6305864) reported significant increases in absolute and relative liver weights in CD-1 mouse dams exposed to PFOA at doses of 1 or 5 mg/kg/day from GD 1.5–11.5 or GD 1.5–17.5. Yahia et al. (2010, 1332451) similarly reported significant increases in maternal ICR mouse absolute liver weights at doses ≥ 5 mg/kg/day and relative liver weights at doses ≥ 1 mg/kg/day. In a 2-generation reproductive toxicity study in Sprague-Dawley rats {Butenholz, 2004, 1291063}, P₀ dams dosed with 1, 3, 10, or 30 mg/kg/day PFOA at least 70 days prior to mating through lactation did not show consistent alterations in absolute or relative liver weights at the time of sacrifice on PND 22. However, significantly increased absolute and relative liver weights were observed in P₀ males and male F₁ offspring starting at the lowest dose of 1 mg/kg/day, whereas no statistically significant differences in absolute or relative liver weights were reported for female F₁ offspring.

Several other developmental toxicity studies reported significantly increased maternal, fetal, and/or pup liver weights associated with gestational PFOA exposure, but the authors did not further examine tissue or serum samples for hepatic effects {Lau, 2006, 1276159; Wolf, 2007, 1332672; Abbott, 2007, 1335452; White, 2009, 194811; Macon, 2011, 1276151; White, 2011, 1276150; Tucker, 2015, 2851046; Li, 2018, 5084746; Cope, 2021, 10176465}. For example, White et al. (2011, 1276150) orally dosed pregnant CD-1 mice with 0, 1, or 5 mg/kg/day PFOA from GD 1 to GD 17. F₁ offspring liver-to-body weight ratios were significantly increased at 1 mg/kg/day on PND 22 and at 5 mg/kg/day on PND 22 and PND 42. Macon et al. (2011, 1276151) exposed pregnant CD-1 mice to PFOA from GD 1 to GD 17 (full gestation) or GD 10 to GD 17 (late gestation). At PND 7, significantly increased absolute and relative liver weights in offspring were observed as low as 0.3 mg/kg/day after full-gestation exposure; significantly increased absolute and relative liver weights were also observed at the high dose of 1 mg/kg/day PFOA after late-gestation exposure (PND 4 and PND 7; relative liver weights were also significantly increased at PND 14). Wolf et al. (2007, 1332672) reported that offspring of pregnant CD-1 mice orally dosed with 0 and 5 mg/kg/day on GD 7–GD 17, GD 10–GD 17, GD 13–GD 17, and GD 15–GD 17 or with 20 mg/kg/day on GD 15–GD 17 had significantly increased liver-to-body weight ratios at PND 22. White et al. (2009, 194811) reported that offspring of CD-1 mice exposed to 5 mg/kg/day PFOA during gestation or during gestation plus lactation had significantly increased liver-to-body weight ratios on PND 1. Inconsistent results were observed on PND 22 and PND 128 in male and female CD-1 mice gestationally exposed to 0.1 and 1 mg/kg/day PFOA from GD 1.5–17.5 and then given either a high- or low-fat diet starting on PND 22 {Cope, 2021, 10176465}. Specifically, increased relative liver weights were observed at PND 22 for both males and females exposed to 1 mg/kg/day (statistically significant in males only), but not at PND 128 {Cope, 2021, 10176465}. One study reported no significant change in relative liver weights, which were only measured on PND 48 in the female offspring of C57BL/6N mouse dams exposed to 0.5 or 1 mg/kg/day PFOA in drinking water from GD 6–17 {Hu, 2010, 1332421}. 

3-39
Figure 3-13. Relative Liver Weight in Rodents Following Exposure to PFOA (logarithmic scale)
PFOA concentration is presented in logarithmic scale to optimize the spatial presentation of data. Interactive figure and additional study details available on HAWC.

GD = gestation day; PND = postnatal day; PNW = postnatal week; LD = lactational day; P₀ = parental generation; F₁ = first generation; d = day; wk = week; y = year.

3.4.1.2.2 Clinical Chemistry Measures

Albumin, a blood protein that plays a major role in PFOA toxicokinetics (Section 3.3), is synthesized by the liver. Increases in serum albumin were reported in several short-term and chronic studies in male rodents, with increases observed at doses as low as 0.4 and 1.3 mg/kg/day in mice and rats, respectively {Buthenhoff, 2012, 2919192; Yan, 2014, 2850901; Guo, 2019, 5080372; NTP, 2020, 7330145}. Females appeared to be less sensitive, with increased albumin at doses ≥ 25 mg/kg/day in rats after short-term or chronic exposures and no significant differences or inconsistent decreases in pregnant mice after gestational exposures {Yahia, 2010, 1332451; Buthenhoff, 2012, 2919192; NTP, 2019, 5400977; Blake, 2020, 6305864; NTP, 2020, 7330145}. The albumin/globulin ratio was significantly increased in both adult males and females after PFOA exposure for 28 days or 16 weeks {Guo, 2019, 5080372; NTP, 2019, 5400977; NTP, 2020, 7330145}.

Similar to albumin, inconsistent results were observed for total protein, with statistically significant decreases observed in some studies in male rats {NTP, 2019, 5400977; NTP, 2020, 7330145} and pregnant female mice in one study {Blake, 2020, 6305864}, and increases or no significant changes observed in several other studies in adult male rats or mice {Guo, 2019, 5080372; Buthenhoff, 2012, 2919192} and in female rats {Buthenhoff, 2012, 2919192; NTP, 2019, 5400977; NTP, 2020, 7330145}.

Increases in enzymes including ALT, ALP, and AST following PFOA exposures were observed across multiple species, sexes, and exposure paradigms (Figure 3-14 (male mice), Figure 3-15 (male rats), Figure 3-16 (female rodents)). These enzymes are often useful indicators of hepatic enzyme induction, hepatocellular damage, or hepatobiliary damage as increased serum levels are thought to be due to hepatocyte damage resulting in release into the blood {EPA, 2002, 625713}. Alterations in serum enzymes are generally considered to reach biological significance and indicate potential adversity at levels ≥ 2-fold compared to controls (i.e., ≥ 100% change relative to controls) {U.S. EPA, 2002, 625713; Hall, 2012, 2718645}.

In adult male mice dosed with PFOA for 4–5 weeks, statistically significant increases in ALT and/or AST were observed at PFOA exposure levels ranging from 2–21.6 mg/kg/day {Minata, 2010, 1937251; Yan, 2014, 2850901; Crebelli, 2019, 5381564; Guo, 2019, 5080372}. Increases in ALT were ≥ 100% above control values at doses as low as 1.25 mg/kg/day {Yan, 2014, 2850901}. Biologically significant increases in AST were only observed in two of these studies at doses ≥ 20 mg/kg/day {Minata, 2010, 1937251; Yan, 2014, 2850901}. In the only short-term study examining ALP in male mice, ALP was significantly increased at concentrations of 5 and 20 mg/kg/day after 28-day exposure {Yan, 2014, 2850901}; serum ALP levels were ≥ 100% change at doses of 1.25 mg/kg/day and higher.

In male CD-1 mice gestationally exposed to 0.1 and 1 mg/kg/day from GD 1.5–17.5 and then fed either a high- or low-fat diet starting on PND 22, no significant changes were observed in ALT, AST, or ALP on PND 128 {Cope, 2021, 10176465}.
Figure 3-14. Percent Change in Serum Enzyme Levels Relative to Controls in Male Mice Following Exposure to PFOA\textsuperscript{a,b}

Interactive figure and additional study details available on HAWC and Tableau.

ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; d = day; wk = week; CI = confidence interval.
\textsuperscript{a} The red dashed lines indicate a 100\% increase or 100\% decrease from the control response.
\textsuperscript{b} Results for Yan et al. (2014, 2850901) are presented for 6 doses (0, 0.08, 0.31, 1.25, 5, and 20 mg/kg/day), and a statistically significant response of 7,000\% occurred at the highest dose for the ALT endpoint. The axis has been truncated at 3,000\% to allow results at lower doses for other studies and endpoints to be legible.

NTP (2019, 5400977; 2020, 7330145) reported significantly increased ALT and ALP at all doses tested in the 28-day and 16-week exposures of male Sprague-Dawley rats to PFOA (dose range of 0.625–32.1 mg/kg/day). However, increases in ALT did not exceed 100\% change in either study. Similarly, increases in ALP did not exceed 100\% change in the 28-day gavage study {NTP, 2019, 5400977} and only exceeded 100\% change with doses \geq 15.6 mg/kg/day at the 16-week interim time point of the chronic dietary study {NTP, 2020, 7330145}. In another chronic dietary study, Butenhoff et al. (2012, 2919192) generally observed increased ALT and ALP in male Sprague-Dawley rats dosed with 1.3 and 14.2 mg/kg/day PFOA at time points ranging from...
3 months to 2 years of administration. Increases in ALT were above or approximately 100% change in both dose groups at 6, 12, and 18 months of exposure. ALP levels were elevated at all time points with 14.2 mg/kg/day PFOA but were only above 100% change at the 18-month time point. AST was also less sensitive than ALT or ALP in male rats. NTP (2019, 5400977) observed statistically significant but not biologically significant increases in AST at doses of 2.5 mg/kg/day and higher (up to 10 mg/kg/day) after 4 weeks. Butenhoff et al. (2012, 2919192) did not observe biologically significant increases in AST at any time of assessment during the 2-year feeding study.

Figure 3-15. Percent Change in Enzyme Levels Relative to Controls in Male Rats Following Exposure to PFOA

Interactive figure and additional study details available on HAWC and Tableau.
ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; GD = gestation day; PND = postnatal day; PNW = postnatal week; F1 = first generation; d = day; wk = week; CI = confidence interval.
*A The red dashed line indicates a 100% increase from the control response.

In addition to the findings in rodents, no consistent responses of serum enzymes were observed in the one available study in male cynomolgus monkeys dosed with PFOA for 26 weeks {Butenhoff, 2002, 1276161}.

The only available studies measuring ALT, AST, or ALP in female mice were after gestational PFOA exposures. Blake et al. (2020, 6305864) reported no statistically significant effects on ALT or ALP levels in CD-1 dams after gestational PFOA exposure, and significantly increased AST (113% increase over control) only after exposure to the high dose of 5 mg/kg/day from GD 1.5–17.5. In contrast, Yahia et al. (2010, 1332451) reported biologically significant increases in ALT and AST in dams after gestational exposure to 5 or 10 mg/kg/day PFOA (150% and 372% increase from control ALT levels, respectively; 312% and 813% increase from control AST levels, respectively). Biologically significant increases in ALT, ALP, and AST were only observed at the highest dose of 10 mg/kg/day. In a study in which female CD-1 mice were gestationally exposed to 0.1 or 1 mg/kg/day from GD 1.5–17.5 and then given a low-fat diet starting on PND 22, no significant changes were observed in ALT, AST, or ALP on PND 128 {Cope, 2021, 10176465}. However, in the group of females exposed to 1 mg/kg/day and then given a high-fat diet, statistically significant increases were observed in ALT (130% control), AST (23% control), and ALP (43% control).

Short-term and chronic studies reported statistically but not biologically significant increases in ALT in female rats after 4- or 16-week PFOA exposures between 50–100 mg/kg/day {NTP, 2019, 5400977; NTP, 2020, 7330145}. The 4- and 16-week studies also reported no biologically significant changes in ALP with any PFOA dose, though PFOA exposures resulted in statistically significant ALP increases at gavage doses as low as 6.25 mg/kg/day after 4 weeks {NTP, 2019, 5400977; NTP, 2020, 7330145}. NTP (2019, 5400977) and found no statistically or biologically significant differences in AST in adult female Sprague-Dawley rats following 4-week PFOA gavage dosing. Butenhoff et al. (2012, 2919192) also did not observe statistically significant changes in ALT, AST, or ALP in adult female Sprague-Dawley rats exposed to 1.6 or 16.1 mg/kg/day PFOA for up to 2 years.
Figure 3-16. Percent Change in Enzyme Levels Relative to Controls in Female Rodents Following Exposure to PFOA

Interactive figure and additional study details available on HAWC and Tableau.

ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; GD = gestation day; PND = postnatal day; PNW = postnatal week; P0 = parental generation; F1 = first generation; d = day; wk = week; CI = confidence interval.

a The red dashed lines indicate a 100% increase or 100% decrease from the control response.
3.4.1.2.3 Histopathology

The available animal toxicology literature provides evidence of alterations in liver histopathology were observed after PFOA exposure. Increased cell proliferation/division, bile duct hyperplasia, and hepatocellular hypertrophy were common responses across multiple studies. Loveless et al. (2008, 988599) reported increased incidence and severity of hepatocellular hypertrophy with increasing doses of PFOA (0.3–30 mg/kg/day) in male CD-1 mice dosed for 29 days (incidences of 0/19, 20/20, 20/20, 20/20, and 19/19 (all severity grades combined) in the 0, 0.3, 1, 10, and 30 mg/kg/day groups, respectively). Several other 28-day studies in adult male mice provided qualitative descriptions and images as evidence of increased hypertrophy, though results were not quantitatively reported {Minata, 2010, 1937251; Yan, 2017, 3981501; Li, 2017, 4238518; Guo, 2019, 5080372}.

Doses as low as 0.3 mg/kg/day PFOA resulted in increased incidence and severity of hypertrophy in male rats dosed for 28 or 29 days {Perkins, 2004, 1291118; Loveless, 2008, 988599; NTP, 2019, 5400977}; female rats dosed for 28 days showed slight increases at 50 mg/kg/day (20%) and a 100% hypertrophy incidence rate at 100 mg/kg/day compared to 0% incidence at all lower doses (6.25, 12.5, or 25 mg/kg/day) and in controls (n = 10) {NTP, 2019, 5400977}. Butenhoff et al. (2012, 2919192) reported significant increases in the incidence of hypertrophy in male and female adult Sprague-Dawley rats administered PFOA for 1 or 2 years at the highest dose tested for each sex (14.2 and 16.1 mg/kg/day for males and females, respectively). NTP (2020, 7330145) also reported increased incidence of hepatocellular hypertrophy in male and female adult rats dosed with PFOA for 16 or 107 weeks (see study design details in Section 3.4.4.2.1.2). At the 16-week interim necropsy, males had significantly increased incidences of hypertrophy at all doses tested (1–32.1 mg/kg/day); significantly increased incidences of hypertrophy were only observed in females at the highest doses tested (63.4/63.5 mg/kg/day) at 16 weeks. At 107-weeks, significantly increased incidences of hypertrophy were observed in males and females at doses ≥ 1.1 mg/kg/day and ≥ 18.2 mg/kg/day, respectively.

In a developmental toxicity study, Blake et al. (2020, 6305864) observed 100% incidence of hepatocellular hypertrophy with decreased glycogen and intensely eosinophilic granular cytoplasm at both the GD 11.5 and GD 17.5 time points with doses of 1 and 5 mg/kg/day compared to 0% incidence in controls (all n = 5–6); however, control CD-1 mouse dams at the GD 17.5 time point also exhibited what the authors characterized as hepatocellular hypertrophy consistent with pregnancy at that stage of gestation. Quist et al. (2015, 6570066) similarly reported increased severity of hepatocellular hypertrophy with increasing PFOA doses (0.01–1 mg/kg/day) in PND 91 female CD-1 mouse offspring exposed from GD 1–17. In a standard 2-generation reproductive toxicity study, significant increases in the incidence of diffuse hepatocellular hypertrophy were reported for male F1 Sprague-Dawley rat offspring at doses of 3 mg/kg/day and higher {Butenhoff, 2004, 1291063}.

In addition to hepatocellular hypertrophy, significantly increased incidences of mitotic figures and bile duct hyperplasia were observed in adult male CD-1 mice exposed to 10 or 30 mg/kg/day PFOA for 29 days {Loveless, 2008, 988599}. NTP (2020, 7330145) reported significantly increased incidences of mitoses and bile duct hyperplasia in female Sprague-Dawley rats dosed with 63.5 mg/kg/day PFOA for 2 years, but not in males. In contrast, Filgo et al. (2015, 2851085) reported the incidence and severity of bile duct hyperplasia in two strains of 18-month-
old wild-type female mice exposed to PFOA during gestation and found no alterations in CD-1 mice and a significant decrease in the severity of bile duct hyperplasia in 129/Sv mice. However, increased mitoses were observed (data not provided) in ICR mouse dams exposed to 1–10 mg/kg/day PFOA during gestation {Yahia, 2010, 1332451}.

Several studies reported cytoplasmic alterations including cytoplasmic vacuolization resulting from PFOA exposures. Male mice dosed with PFOA for 28 days were reported to have increased vacuolation at doses between 5.4–21.6 mg/kg/day (incidence data not provided) and significantly decreased numbers of nuclei per unit area with 28-day exposures to ≥ 0.4 mg/kg/day {Minata, 2010, 1937251; Guo, 2019, 5080372}. Male rats were particularly susceptible to cytoplasmic alterations; NTP (2019, 5400977; 2020, 7330145) reported incidences of 90–100% in animals receiving doses ≥ 1 mg/kg/day for 4 or 16 weeks compared to 0% incidences in controls (all n = 10). In the 2-year study, males receiving ≥ 2.1 mg/kg/day showed a 58% or greater incidence rate compared to 0% incidence rates in controls (all n = 50) {NTP, 2020, 7330145}.

Female rats receiving doses ≥ 25 mg/kg/day for 4, 16, or 107 weeks had 98%–100% incidence rates of cytoplasmic alterations compared to 0% incidence rates in controls {NTP, 2019, 5400977; NTP, 2020, 7330145}. In CD-1 mouse dams, 100% incidence rates of cytoplasmic vacuolization were observed only at the highest dose of 5 mg/kg/day but at both gestational time points (GD 11.5 and GD 17.5) compared to 0% incidence rates in controls (n = 5–6) {Blake, 2020, 6305864}. In this study, the vacuoles frequently contained remnant membrane material as myelin figures.

Cell and tissue death and degeneration was the final category of hepatic histological effects observed across multiple studies, species, and sexes (Table 3-2). Incidence rates of individual cell necrosis in male CD-1 mice dosed with PFOA for 29 days were above 50% at doses ≥ 1 mg/kg/day {Loveless, 2008, 988599}. There was similarly a significantly increased percentage of necrotic liver cells, analyzed by flow cytometry, in male C57BL/6 mice administered 5 mg/kg/day PFOA in drinking water for 5 weeks {Crebelli, 2019, 5381564}. Significantly increased incidences of single cell death were observed in male Sprague-Dawley rats after 16 weeks of exposure to doses as low as 1 mg/kg/day but were not increased in females at this time point {NTP, 2020, 7330145}. Incidence rates of single cell death in male and female rats after 2-year exposures as reported in NTP (2020, 7330145) are provided in Table 3-2 (see further study design details in Section 3.4.4.2.1.2). Apoptosis and single-cell necrosis were also observed in livers of pregnant CD-1 mice after gestational exposures of 1 and 5 mg/kg/day, with increasing length of exposure resulting in increased incidence rates {Blake, 2020, 6305864}. In male and female CD-1 mice gestationally exposed to 0.1 and 1 mg/kg/day from GD 1.5–17.5 and then given a low-fat diet on PND 22, incidences of single cell necrosis were higher in the exposed groups but not significantly increased at PNW 18 (Table 3-2) {Cope, 2021, 10176465}. However, in females exposed to 1 mg/kg/day and then to a high-fat diet, incidences of single cell necrosis were significantly increased at PNW 18.

In male CD-1 mice exposed to PFOA for 29 days, the incidence of hepatic focal necrosis increased with increasing PFOA doses between 1–30 mg/kg/day {Loveless, 2008, 988599}. In

---

10 In this document, EPA used the cell death nomenclature as reported in the individual studies to describe the observed effects. Cell “necrosis” is a type of cell death, the term for which is generally used when a specific method to distinguish necrotic cells from other dying cells (e.g., apoptotic cells) has been employed {Elmore, 2016, 10671182}. EPA did not evaluate the methods of individual studies to ensure that the nomenclature used by the authors accurately reflected the type of cell death reported.
the same study, increased incidences of necrosis were reported in male Sprague-Dawley rats only with the highest dose tested (30 mg/kg/day) {Loveless, 2008, 988599}. Inconsistent incidences of hepatic necrosis were observed in male and female Sprague-Dawley rats administered PFOA in feed for 16 weeks, though there were increases reported after 2 years {NTP, 2020, 7330145}. Table 3-2 depicts the 2-year data for males and females. In a separate 2-year study, there were no significant differences in the incidences of hepatic necrosis in male or female Sprague-Dawley rats {Butenhoff, 2012, 2919192}. Blake et al. (2020, 6305864) did not observe consistent increases in the incidence of focal necrosis in mouse CD-1 dams dosed with PFOA during gestation. However, Butenhoff et al. (2004, 1291063) reported significant increases in focal and multifocal necrosis in F1 generation male Sprague-Dawley rats in a 2-generation reproductive toxicity study (data not provided).

Table 3-2. Associations Between PFOA Exposure and Cell Death or Necrosis in Rodents

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study Design</th>
<th>Endpoint Name</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTP (2019, 5400977)</td>
<td>28-day Sprague Dawley rat oral gavage dosing; 0, 0.625, 1.25, 2.5, 5, 10 mg/kg/day</td>
<td>Focal Hepatocellular Necrosis</td>
<td>0/10, 0/10, 0/10, 0/10, 1/10, 0/10</td>
</tr>
<tr>
<td>Loveless (2008, 988599)</td>
<td>29-day Crl:CD(SD)IGS BR rat oral gavage dosing; 0, 0.3, 1, 10, 30 mg/kg/day</td>
<td>Focal Necrosis</td>
<td>0/10, 0/10, 0/10, 1/10, 4/10</td>
</tr>
<tr>
<td>Perkins (2004, 1291118)</td>
<td>4-week Crl:CD®BR rat feeding study; 0, 0.06, 0.64, 1.94, 6.5 mg/kg/day</td>
<td>Coagulative Necrosis</td>
<td>0/15, 0/15, 0/15, 1/15, 2/14</td>
</tr>
<tr>
<td>Butenhoff (2012, 2919192)</td>
<td>2-year Crl:COBS® CD(SD)BR rat feeding study; 0, 1, 1.3, 14.2 mg/kg/day</td>
<td>Focal Hepatocellular Necrosis</td>
<td>3/50, 5/50, 5/50</td>
</tr>
<tr>
<td>Cope (2021, 10176465)</td>
<td>Gestational CD-1 mouse gavage dosing from GD 1.5–GD 17.5 (offspring); 0, 0.1, 1 mg/kg/day</td>
<td>Hepatocyte Single Cell Necrosis</td>
<td>2/8, 5/9, 6/9</td>
</tr>
<tr>
<td>NTP (2020, 7330145)</td>
<td>16-week Hsd:Sprague Dawley SD rat feeding study, with and without perinatal exposure; 0/0, 0/150, 0/300, 150/150, and 300/300 ppm</td>
<td>Hepatocellular Single Cell Death Necrosis</td>
<td>0/10, 10/10, 10/10, 9/10, 10/10</td>
</tr>
<tr>
<td>Reference</td>
<td>Study Design</td>
<td>Endpoint Name</td>
<td>Incidence</td>
</tr>
<tr>
<td>----------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>NTP (2019, 5400977)</td>
<td>16-week Hsd:Sprague Dawley SD rat feeding study, with and without perinatal exposure; 0/0, 0/20, 0/40, 0/80, 300/0, 300/20, 300/40, 300/80 ppm</td>
<td>Hepatocellular Single Cell Death</td>
<td>0/10, 7/10, 9/10, 10/10, 0/10, 5/10, 8/10, 10/10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Necrosis</td>
<td>1/10, 1/10, 6/10, 4/10, 0/10, 2/10, 3/10, 1/10</td>
</tr>
<tr>
<td>Butenhoff (2012, 2919192)</td>
<td>2-year Hsd:Sprague Dawley SD rat feeding study, with and without perinatal exposure; 0/0, 0/20, 0/40, 0/80, 300/0, 300/20, 300/40, 300/80 ppm</td>
<td>Hepatocellular Single Cell Death</td>
<td>1/50, 1/50, 11/50, 24/50, 1/50, 3/50, 5/50, 29/50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Necrosis</td>
<td>2/50, 17/50, 23/50, 20/50, 1/50, 11/50, 14/50, 21/50</td>
</tr>
<tr>
<td>Blake (2020, 6305864)</td>
<td>28-day Hsd:Sprague Dawley SD rat oral gavage dosing; 0, 6.25, 12.5, 25, 50, 100 mg/kg/day</td>
<td>Hepatocellular Single Cell Death</td>
<td>0/10, 0/10, 0/10, 0/10, 0/10, 0/10, 0/10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Necrosis</td>
<td>0/10, 0/10, 0/10, 0/10, 0/10, 0/10, 0/10</td>
</tr>
<tr>
<td>Butenhoff (2012, 2919192)</td>
<td>2-year Crl:COBS@CD(SD)BR rat feeding study; 0, 1.6, 16.1 mg/kg/day</td>
<td>Focal Hepatocellular Necrosis</td>
<td>5/50, 6/50, 2/50</td>
</tr>
<tr>
<td>Blake (2020, 6305864)</td>
<td>Gestational CD-1 mouse gavage dosing from GD 1.5–11.5 (dams); 0, 1, 5 mg/kg/day</td>
<td>Focal Necrosis</td>
<td>1/5, 0/5, 2/5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cell Death (including apoptosis and single-cell necrosis of individual hepatocytes)</td>
<td>0/5, 1/5, 3/5</td>
</tr>
<tr>
<td>Cope (2021, 10176465)</td>
<td>Gestational CD-1 mouse gavage dosing from GD 1.5–17.5 (dams); 0, 1, 5 mg/kg/day</td>
<td>Focal Necrosis</td>
<td>0/5, 0/5, 0/6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cell Death (including apoptosis and single-cell necrosis of individual hepatocytes)</td>
<td>0/5, 5/5, 6/6</td>
</tr>
<tr>
<td>NTP (2020, 7330145)</td>
<td>16-week Hsd:Sprague Dawley SD rat feeding study, with and without perinatal exposure; 0/0, 0/300, 0/1,000, 150/300, and 300/1,000 ppm</td>
<td>Hepatocellular Single Cell Death</td>
<td>0/10, 0/10, 0/10, 0/10, 0/10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Necrosis</td>
<td>0/10, 0/10, 2/10, 0/10, 0/10, 0/10</td>
</tr>
<tr>
<td></td>
<td>2-year Hsd:Sprague Dawley SD rat feeding study, with and without perinatal exposure; 0/0, 0/300, 0/1,000, 150/300, and 300/1,000 ppm</td>
<td>Hepatocellular Single Cell Death</td>
<td>0/50, 4/50, 29/50, 5/50, 32/50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Necrosis</td>
<td>0/50, 1/50, 8/50, 4/50, 5/50</td>
</tr>
</tbody>
</table>

**Notes:**

GD = gestation day.

*Incidence data as reported by Perkins et al. (2004, 1291118) were split into severity categories within the original study. For the purposes of this table, all non-grade 0 severities were considered an incidence (results for severity grades 1–3 were combined). Data are summarized for low-fat diet only from Cope et al. (2021, 10176465).

*Incidence data not explicitly reported by NTP (2019, 5400977).
Cystic degeneration was also observed across two chronic feeding studies in male rats. Butenhoff et al. (2012, 2919192) reported incidences of cystic degeneration characterized as areas of multilocular microcysts in the liver parenchyma in 4/50 (8%), 7/50 (14%), and 28/50 (56%) male rats dosed for 2 years with 0, 1.3, or 14.2 mg/kg/day, respectively. NTP (2020, 7330145) similarly reported increases in the incidence of cystic degeneration in the liver of male rats administered 4.6 mg/kg/day PFOA for 107 weeks.

### 3.4.1.2.4 Additional Hepatic Endpoints

A suite of other liver effects was observed but were either not included as endpoints of interest across multiple studies or had inconsistent results between studies, sexes, and/or species. These included serum measures of gamma-glutamyl transpeptidase (only measured in one short-term study of male BALB/C mice that showed increases at 2 and 10 mg/kg/day exposures) {Guo, 2021, 9963377}, bile acids (study results generally showed no response or increases at high doses) {Butenhoff, 2002, 1276161; Yan, 2014, 2850901; NTP, 2019, 5400977; Blake, 2020, 6305864; NTP, 2020, 7330145; Guo, 2021, 7542749}, bilirubin (study results showed no change or minimal increases at high doses) {Butenhoff, 2002, 1276161; Butenhoff, 2012, 2919192; Yahia, 2010, 1332451; NTP, 2019, 5400977; Guo, 2021, 7542749}, and histopathological findings such as hepatic inflammation (study results showed increased incidence/severity, decreased incidence, or no response) {Filgo, 2015, 2851085; Quist, 2015, 6570066; NTP, 2020, 7330145}, increased incidence of cellular infiltration {Cope, 2021, 10176465; Butenhoff, 2012, 2919192}, and increased incidence of hepatocytomegaly {Zhang, 2020, 6505878}. NTP (2020, 7330145) also reported a variety of other histopathological outcomes including eosinophilic or mixed-cell foci (significant increases in male Sprague-Dawley rats) and pigmentation (significant increases in males and females). Butenhoff et al. (2004, 1291063) similarly reported increased discoloration of the liver in male F1 Sprague-Dawley rats analyzed during a standard 2-generation reproductive toxicity study.

### 3.4.1.3 Mechanistic Evidence

Mechanistic evidence linking PFOA exposure to adverse hepatic outcomes is discussed in Sections 3.2.1, 3.2.2, 3.2.3, 3.2.7, 3.2.8, 3.2.9, 3.3.2, 3.3.3, 3.3.4, 3.4.1, 3.4.2, 3.4.3, 3.4.4, and 4.2 of the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}. There are 81 studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD that investigated the mechanisms of action of PFOA that lead to hepatic effects. A summary of these studies is shown in Figure 3-17.
Figure 3-17. Summary of Mechanistic Studies of PFOA and Hepatic Effects

Interactive figure and additional study details available on Tableau.

3.4.1.3.1 Nuclear Receptor Activation

3.4.1.3.1.1 Introduction

The ability of PFOA to mediate hepatotoxicity via nuclear receptor activation has been investigated for several receptor-signaling pathways, including that of the peroxisome proliferator-activated receptors (PPARα, PPARδ, PPARγ), the pregnane X receptor (PXR), and the constitutive androstane receptor (CAR). PPARα is a major target for PFOA. A primary mechanism of hepatic injury associated with PFOA-mediated activation of PPARα relates to impacts on hepatic lipid metabolism caused by altered expression of genes and proteins within the PPARα signaling pathway {U.S. EPA, 2016, 3603279; Das, 2017, 3859817; Hui, 2017, 3981345; Li, 2019, 5387402; Pouwer, 2019, 5080587; Rebbolz, 2016, 3981499; van Esterik, 2015, 2850288; Wang, 2013, 2850952; Wen, 2019, 5080582; Yan, 2015, 2851199; Yang, 2014, 2850321}. Activation of PPARα has been cited as a mechanism of action for PFAS, including PFOA {U.S. EPA, 2016, 3603279}, because of the association between hepatic lesions and/or increased liver weight and peroxisome proliferation downstream of PPARα activation in rats. However, increased hepatic lipid content in the absence of a strong PPARα response (i.e., activation of downstream target genes) is a characteristic of exposure to PFOA. Additionally, many of the genes activated by PFOA are regulated by transcription factors other than PPARα, including CAR, PPARγ, PXR, Erα, and HNF4α {U.S. EPA, 2016, 3603279}. PPARs, CAR, and PXR are nuclear receptors that can form heterodimers with one another to induce transcription of linked genes. Other factors impacting nuclear receptor activation in hepatocytes include dose and duration of PFOA exposure and the genetic background, diet, and sex of exposed animals. Sex-specific hepatic effects varied by strain, and long-term PFOA oral exposure in mice with pre-existing steatosis had protective effects against hepatic injury {NTP, 2019, 5400977; Li, 2017, 4238518; Li, 2019, 5080362}. Thus, the underlying mechanism(s) of PFOA-induced hepatotoxicity may involve multiple nuclear receptors. Additionally, hepatic effects observed
with PFAS exposure, including inflammation and necrosis, cannot be fully explained by PPARα activation (Section 3.4.1.2.3). This updated assessment includes a summary of studies that have examined PPARs, CAR, PXR, Erα, and HNF4α activation as potential mechanisms underlying the health effects induced by PFOA.

### 3.4.1.3.1.2 PPARα Receptor Binding and Activation

Receptor binding and activation assays have been performed to examine the association between activation of PPARs, CAR, and/or PXR, and PFOA-mediated hepatotoxicity. PPARs modulate gene expression in response to exogenous or endogenous ligands and play essential roles in lipid metabolism, energy homeostasis, development, and cell differentiation {U.S. EPA, 2016, 3603279}.

Several studies used luciferase reporter assays to examine the activation of PPARα by PFOA in vitro using human and animal cell lines transfected with mouse and human PPARα {Wolf, 2014, 2850908; Rosenmai, 2018, 4220319; Behr, 2020, 6305866; Buhrke, 2013, 2325346}. In African green monkey kidney COS-1 cells transfected with mouse PPARα, PFOA was the most potent activator of PPARα among the 5 PFAS tested, with PPARα activation observed at less than 1 μM after a 24 h exposure {Wolf, 2014, 2850908}. A study in human HEK293T cells found that human PPARα was activated at a concentration of 50 μM PFOA after a 24 h exposure {Behr, 2020, 6305866}. Whether PFOA activates other nuclear receptors is less clear from studies conducted in HEK293 cells and may be cell type- and dose-dependent. PFOA had no activity in HEK293 cells transfected with constructs encoding other nuclear receptors, including PPARδ, CAR, PXR, the farnesoid X receptor (FXR), the liver X receptor α (LXRα), the retinoid X receptor α (RXRα) and retinoic acid receptor α (RARα), at concentrations up to 100 μM for 24 hours {Behr, 2020, 6305866}. In a second study using a human PPARα construct in HEK293 cells, PFOA induced PPARα activation at concentrations of 25 μM and higher, whereas PFOA concentrations of at least 100 μM were necessary to activate PPARγ and PPARδ {Buhrke, 2013, 2325346}. Results from the single study conducted in a human hepatic cell line (HepG2) were consistent with results in other cell lines {Rosenmai, 2018, 4220319}. Of the 14 PFAS substances tested, PFOA was the most potent PPARα activator, showing significant elevation of luciferase activity after a 24 hour exposure to 30 and 100 μM PFOA. While luciferase levels were elevated at 10 μM of PFOA, the increase did not reach significance. These in vitro studies support PPARα activation by PFOA.

Another study measured the expression of hepatic carboxylesterases (Ces) that function in the metabolism of drugs, chemical toxicants, and endogenous lipids {Wen, 2019, 5080582}. PFOA upregulated expression of the PPARα target gene, Cyp4a14, in the livers of male C57BL/6 NCrl mice after exposure to 3 mg/kg/day by gavage for 7 days. PFOA exposure also led to alterations to the expression of Ces genes: Ces1d, 1e, 1f, 1 g, 2c, and 2e mRNA levels were increased between 1.5- and 2.5-fold, while Ces1c and 2b transcripts were decreased. In a second study within Wen et al. (2019, 5080582), Ces genes were measured in the livers of C57BL/6NTac mice and PPARα-null mice also exposed to 3 mg/kg/day PFOA by gavage for 7 days. Ces1e and If mRNA and protein levels were PPARα dependent, whereas Ces1c, 1d, 1 g, 2a, 2b, and 2e mRNA and CES2 protein levels were induced by PFOA in PPARα-null mice, implicating a CAR-mediated pathway for differential expression of these genes.
The mechanism by which PFOA activates PPARα is likely dependent on interactions with liver fatty acid binding protein (L-FABP). L-FABP facilitates the nucleo-cytoplasmic shuttling of activator ligands, such as fatty acids, for nuclear receptors, including PPAR activators, PXR, and LXRs. PFOA is structurally similar to fatty acids, and both exhibit a strong binding affinity with L-FABP (Section 3.3.1.2). Thus, L-FABP is responsible for delivering PFOA to the nuclei of hepatic cells for access to nuclear receptors. Sheng et al. (2018, 4199441) used circular dichroism (CD) spectroscopy, fluorescence displacement assays, and molecular docking approaches to evaluate the binding mode and capacity of PFOA as well as PFOS and PFAS replacement chemicals to purified human L-FABP (hL-FABP). The purified recombinant hL-FABP was calculated to consist of 15.7% α-helix and 54.4% β-sheet. In the presence of PFOA, α-helix content of the protein increased slightly, whereas the β-sheet content decreased. The dissociation constant (Kd) of PFOA to hL-FABP was 8.03 ± 2.10 μM, which was higher than PFOS and lower than some (but not all) replacement PFAS substances. By molecular docking, PFOA bonded with hL-FABP in a “head-out” mode, such that the carboxyl head of PFOA will interacted with R122 amino acid residue through hydrogen bonding and N111 amino acids residue through hydrophobic interactions. Introduction of oxygen molecules into the backbone could flip the binding prediction to a “head-in” mode characterized by interactions with amino acid residue N61. By comparing PFOA to PFOS and replacement PFAS chemicals, the authors demonstrated that these three parameters correlated both with cytotoxicity in human liver HL7702 cells and binding affinity for hL-FABP. Notably, expression of select PPARα-regulated genes showed no significant change across the chemicals tested, with one exception, the Cd36 gene. Expression of other genes, including cell cycle genes, did correlate with these binding parameters. These findings suggest that binding of PFAS to hL-FABP can mediate toxicity in a manner that is not exclusively dependent on PPARα-mediated changes in gene expression in liver cells, but possibly through effects on other FABP-related events such as binding to the CD36 protein or effects on cell proliferation.

3.4.1.3.1.3 Receptor Binding and Activation of Other Nuclear Receptors
PFOA can activate PPARα in the liver of rodents and humans. However, the extent by which activation of PPARα mediates hepatotoxicity may be species-specific, and activation of other receptors may also contribute to toxicity {U.S. EPA, 2016, 3603279}. Indeed, studies in mice and rats indicate that PFOA may activate PPARα, CAR, and PXR in the liver {NTP, 2019, 5400977; Wen, 2019, 5080582; Li, 2019, 5080362; Rose, 2016, 9959775}. Several studies observed perturbations in lipid transport, fatty acid metabolism, triglyceride synthesis, and cholesterol synthesis in PFOA-exposed mice {Das, 2017, 3859817; Rosen, 2017, 3859803; Li, 2019, 5387402}. A few of these studies, Das et al. (2017, 3859817), Rosen et al. (2008, 1290832), and Rosen et al. (2017, 3859803), investigated the effects of PFOA on lipid metabolism and homeostasis in the absence of PPARα by using knockout mouse models. After exposure to 10 mg/kg/day PFOA for 7 days, Das et al. (2017, 3859817) observed that a smaller subset of genes related to lipid homeostasis was activated in PPARα null mice compared to wild-type (WT) mice. Increased expression of genes regulating fatty acid and triglyceride synthesis and transport into hepatocytes was attenuated but not entirely abolished in PFOA-exposed PPARα null mice compared to WT mice. Gene expression changes in PPARα null mice implicate a role for PPARβ/δ and/or PPARγ in the absence of PPARα {Rosen, 2008, 1290832}. Mechanistically, these changes correlated with the development of steatosis in PFOA-exposed WT mice consistent with increased triglyceride accumulation. In contrast, elevated triglyceride
levels and steatosis develop in PPARα null mice even in the absence of PFOA exposure. The authors propose that PFOA exposure alters lipid metabolism to favor biosynthesis and accumulation over β-oxidation, leading to hepatic steatosis. PFOA increased the expression of genes related to fatty acid β-oxidation, lipid catabolism, lipid synthesis, and lipid transport in both strains; however, gene induction was lower in PPARα null mice {Rosen, 2008, 1290832; Rosen, 2017, 3859803}. In fact, the authors suggest that the transcriptome of the mice resembled that of mice treated with PPARγ agonists, thus indicating a role for other PPAR isoforms in the dysregulation of lipid synthesis {Rosen, 2017, 3859803}. Furthermore, Rosen and colleagues {2017, 3859803} demonstrated that PFOA significantly downregulated the Signal Transducer and Activator of Transcription 5B gene (STAT5B), a transcription factor and member of the STAT family, in a PPARα-dependent manner. STAT5B has been demonstrated in regulation of sexually-dimorphic gene expression in the liver between males and females, raising the possibility that that PFOA exposure may promote feminization of the liver in male mice {Oshida, 2016, 6781228; Rosen, 2017, 3859803}.

Increasing evidence links CAR activation as a mechanism of PFOA-induced liver toxicity {NTP, 2019, 5400977; Wen, 2019, 5080582; Li, 2019, 5080362}. The use of genetically modified mice and gene expression analyses has demonstrated that PFOA exposure activates both PPARα and CAR receptors {NTP, 2019, 5400977; Abe, 2017, 3981405; Li, 2019, 5080362; Rosen, 2017, 3859803; Wen, 2019, 5080582; Li, 2019, 5080362; Oshida, 2015, 2850125; Oshida, 2015, 5386121}.

Five recent studies also examined PFOA activation of CAR-specific genes {Abe, 2017, 3981405; NTP, 2019, 5400977; Wen, 2019, 5080582; Rosen, 2017, 3859803; Rose, 2016, 9959775}. Additionally, one study used both a cell-based reporter assay and in silico approaches to examine PFOA activation of PXR {Zhang, 2020, 6324307}, and one study examined other PFOA effects on other nuclear receptors in vitro {Buhrke, 2015, 2850235}. In support of PFOA as a CAR receptor activator, PFOA induced expression of the CAR target genes CYP2B6 in a human hepatocyte cell line in vitro (HepaRG), and Cyp2b10 in wild type mice but not CAR-null mice in vivo {Abe, 2017, 3981405}. Evidence of CAR-specific gene expression was also noted in male and female rats administered PFOA. Exposed animals exhibited significant increases in expression of PPARα-stimulated genes (Acox1, Cyp4a1) and CAR-specific genes (Cyp2b1, Cyp2b2) in livers compared to controls, suggesting increases in PPARα and CAR activity {NTP, 2019, 5400977}. Males were exposed to a range of doses between 0 and 10 mg/kg/day and females to between 0 and 100 mg/kg/day PFOA for 28 days. Gene expression in liver tissue was analyzed using qRT-PCR. Female rats displayed the greatest fold increase for the CAR-related genes Cyp2b1 whereas males exhibited the greatest fold increase for Cyp4a1 and Cyp2b1 compared to controls.

Rosen et al. (2008, 1290832) postulated that gene expression changes in the liver should overlap between PFOA and phenobarbital, a known CAR activator. To test this, differentially expressed genes in wild-type or CAR-null mice treated with PFOA by gavage (3 mg/kg/day) for 7 days were compared to differentially expressed genes in the livers of mice exposed to 100 mg/kg/day phenobarbital for three days {Rosen, 2017, 3859803}. Similarity in differentially expressed genes between the two studies (i.e., overlap) was analyzed using a Running Fisher Test for pairwise comparisons. As expected, there was significant similarity between the lists of differentially expressed genes for PFOA and phenobarbital in WT mice, but not in CAR-null
mice. In fact, close to 15% of genes differentially expressed upon PFOA exposure in liver were considered PPARα-independent. Two gene expression compendium studies further analyzed these data using gene expression biomarker signatures built using microarray profiles from livers of WT mice, CAR-null mice {Oshida, 2015, 2850125}, and PPARα-null mice {Oshida, 2015, 5386121}. These analyses found that both CAR and PPARα were activated by PFOA, and that CAR activation was generally more significant in PPARα-null mice. The authors concluded that CAR likely plays a subordinate role to PPARα in mediating the adverse hepatic effects of PFOA {Oshida, 2015, 2850125}.

Activation of CAR may occur via direct activation or indirect activation. Indirect activation of CAR by phenobarbital involves blockade of the downstream phosphorylation pathway of EGFR protein phosphatase 2A (PP2A), which dephosphorylates CAR to enable nuclear translocation. Using a COS-1 fibroblast cell-based reporter gene assay that is capable of detecting CAR ligands but not indirect activators, Abe et al. (2017, 3981405) observed that PFOA failed to activate reporter gene expression. In a second study using primary mouse hepatocytes, PFOA exposure led to CAR-mediated expression of Cyp2b10 even in the presence of okadaic acid, a PP2A drug inhibitor. Together these findings suggest the mechanism of PFOA-mediated CAR activation indirect and distinct from that of phenobarbital. Moreover, an analysis of historical and new data of gene expression in PPARα- and CAR-null mice indicate the pathway of PFOA-mediated CAR activation is PPARα-independent {Rosen, 2017, 3859803}. Thus, the precise mechanism of CAR activation by PFOA remains to be determined.

Several studies evaluated PFOA activation of other nuclear receptors. Rosen et al. {2017, 3859803} noted that PFOA activated PPARγ and ERα in trans-activation assays from the ToxCast screening program. Zhang et al. {2020, 6324307} used a cell-based reporter assay and an in silico approach to estimate PFOA-mediated activation of the PXR receptor. The PFOA log EC50 was 5.04 M in the luciferase-based PXR reporter assay, a higher concentration (i.e., less potent) than observed for PPARα. These authors also developed classical QSAR and 3D-QSAR models that predicted very similar values of log EC50 of 4.92 M and 4.94 M, respectively. Both models suggested that molecular structural factors including molecular polarizability, charge, and atomic mass are key parameters dictating hPXR agonistic activity of PFOA and other perfluoroalkyl chemicals.

In addition to the key role of PPARα and other nuclear receptors discussed above, other transcription factors and epigenetic mechanisms influence PFOA-mediated changes in lipid metabolism and storage. Beggs et al. (2016, 3981474) observed a decrease in hepatocyte nuclear factor alpha (HNF4α) protein, a master regulator of hepatic differentiation, in the livers of ten-week-old CD-1 mice exposed to 3 mg/kg/day PFOA once daily by oral gavage for 7 days. HNF4α regulates liver development (hepatocyte quiescence and differentiation), transcriptional regulation of liver-specific genes, and regulation of lipid metabolism. In this study, PFOA exposure correlated with downregulation of HNF4α target genes involved in differentiation (Cyp7a1) and induced pro-mitogenic genes including CCND1. Other genes altered by PFOA exposure mapped to pathways involved in lipid metabolism, liver cholestasis, and hepatic steatosis. PFOA also led to diminished accumulation of HNFα protein. This decrease in HNF4α was not accompanied by a change in expression of the gene, suggesting that the decrease in HNF4α occurs post-translationally. The decreased HNFα correlated with upregulation of genes that are negative targets of HNF4α. HNF4α is considered an orphan receptor, with various fatty
acids as its endogenous ligands. These fatty acids maintain the structure of the receptor homodimer. PFOA and PFOS are analogous in structure to fatty acids and may also provide stabilization of the homodimer. The authors investigated the role of PFOA and PFOS interaction with this protein via in silico docking models, which showed a displacement of fatty acids by PFOA/PFOS, possibly tagging HNF4α for degradation. The authors hypothesize that steatosis, hepatomegaly, and carcinoma in rodents may be a consequence of the loss of this protein and also presents a mechanism for PFOA-induced hepatic effects in humans.

In primary human hepatocytes exposed to 1, 25, or 100 μM PFOA for 24 hours, the number of differentially regulated genes was 43, 109, and 215, respectively, as measured using a human genome gene chip {Buhrke, 2015, 2850235}. Based on known activators of the differentially expressed genes, the authors suggest that in addition to PPARα, PPARγ and HNF4α may contribute to changes in expression of genes involved in carnitine metabolism. PFOA-mediated induction of ERα signaling was also predicted based on pathway analysis.

3.4.1.3.1.4 Host Factors Impacting PPARα Signaling

The effects of PFOA on PPARα activation depend on diet and pre-existing conditions {Li, 2019, 5080362}. Mice were subjected to control diet or high-fat diet (HFD) for 16 weeks to induce non-alcoholic fatty liver disease (NAFLD), after which they were exposed to vehicle or 1 mg/kg/day PFOA by oral gavage for 2, 8, or 16 weeks; control diet and HFD were continued throughout this exposure period. Preexisting NAFLD in mice fed a HFD enhanced the induction of PPARα activation by PFOA early in the exposure but reduced the severity of macrovesicular steatosis and sinusoidal fibrosis induced by a HFD, and reversed HFD-induced increase in body weight and serum alanine aminotransferase (ALT). The authors hypothesized that PFOA exposure in animals with a lipid burden in the liver leads to PFOA-mediated inhibition of fatty acid biosynthesis pathways by the metabolic end-product feedback effect. The authors also observed reduced Tgf-β gene expression in PFOA-treated HFD-fed mice compared to vehicle-treated HFD-fed mice, which could account for the diminished level of hepatic stellate cell activation and collagen production associated with fibrosis. Furthermore, the duration of PFOA exposure impacted gene expression and hepatic injury. For example, PFOA induced Srebfl and Srebfl genes in the fatty acid biosynthesis pathway following 2 weeks of treatment, but this effect was not seen following 8 or 16 weeks of PFOA treatment. Notably, this increase in Srebfl expression following 2 weeks of PFOA exposure was only observed with the co-treatment of PFOA and HFD; the Srebfl effect was not observed in the PFOA-treated mice fed the control diet.

PFOA-driven changes in PPARα-mediated gene expression may also be modified by age, strain, or species. Pregnant Kunming mice were exposed to PFOA at doses of 1, 2.5, 5 and 10 mg/kg/day from gestational days 1-17, and female offspring were analyzed on postnatal day 21 {Li, 2019, 5387402}. Genes involved in fatty acid β-oxidation including acyl-CoA synthetase (Acs1l1), carnitine palmitoyl transferase I, Palmitoyl-CoA oxidase (Acox1), acyl-CoA thioesterase 1 (Aco1), and carnitine palmityltransferase 1a (Cpt1a) were significantly downregulated at the two highest doses, as was the PPARα gene. In this strain of mouse, perinatal PFOA disrupts the gene expression of enzymes involved in fatty acid oxidation induced by PPARα, possibly through an epigenetic mechanism. In contrast, several studies have shown PFOA to upregulate expression of PPAR signaling pathway genes, including Acox in rats and mice {Li, 2019, 5080362; NTP, 2019, 5400977; Cavallini, 2017, 3981367}. One such study
proposed that the PFOA-mediated gene expression changes are due to changes in the activity of histone acetyltransferase (HAT) and HDAC (histone deacetylase) \cite{Li, 2019, 5387402}. In female offspring of pregnant Kunming mice treated with PFOA by oral gavage at doses between 0 and 10 mg/kg/day on GD 1-17, the overall levels of histone H3 and H4 acetylation were decreased in a dose-dependent manner in liver tissues in the pups at post-natal day 21. Histone acetylase (HAT) activity was reduced in pups at all doses except for the highest dose (10 mg/kg/day), in which there was no significant difference in HAT activity compared to controls. HDAC activity was increased in all dose groups. The changes in HAT and HDAC activity did not follow a dose-responsive pattern. Notably, gene-specific alterations in histone acetylation activity were not measured; thus, follow-up studies are needed to clarify the relationship between the global histone modifications and the gene expression changes.

Additional support for species-specificity derives from studies demonstrating that PFOA-mediated gene expression changes were distinctly different in primary human hepatocytes compared to primary mouse hepatocytes \cite{Rosen, 2013, 2919147}. Custom Taqman PCR arrays were generated to include transcripts regulated by PPARα as well as transcripts regulated independently of this nuclear receptor. Mouse and human hepatocytes were exposed to PFOA at doses ranging from 0–100 and 0–200 μM, respectively, or the PPARα activator Wy14,643. In mouse cells, many fewer genes were altered by PFOA treatment compared to whole livers from mice exposed in vivo. Also, genes typically regulated by PPARα agonists were not altered by PFOA in mouse cells, including Acox1, Me1, Acaa1a, Hmgcs1, and Slc27a1. The CAR target gene Cyp2b10 was also unchanged in cultured mouse hepatocytes. In contrast, a larger group of genes were differentially expressed in primary human hepatocytes, including PPARα-independent genes (CYP2B6, CYP3A4, and PPARγ). These findings underscore some of the difficulty in extrapolating in vitro results from rodents to humans after PFOA exposure and suggest PPARα may elicit species-specific changes in gene expression.

3.4.1.3.1.5 Conclusions
Although activation of PPARα is a widely cited mechanism of liver toxicity induced by PFAS exposure, PFOA has been shown to activate a number of other nuclear receptors, including PPARγ, CAR/PXR, Erα, and HNF4α. Many of these nuclear receptors, including CAR and PPARγ, are also known to play an important role in liver homeostasis and have been implicated in liver dysfunction, including steatosis \cite{Armstrong, 2019, 6956799}. Therefore, there is accumulating evidence that PFOA exposure may lead to liver toxicity through the activation of multiple nuclear receptors in both rodents and humans. However, the contribution of gene expression changes induced and associated toxicity by these other receptors is not clear. Also, it is possible that other receptors may play compensatory roles in PPARα null mice. In addition, PFOA-mediated changes in hepatic gene expression and toxicity exhibit strain, sex, and species specificity. Thus, the interplay between nuclear receptor activation and host factors may dictate the nature and severity of liver toxicity in response to PFOA exposure.

3.4.1.3.2 Lipid Metabolism, Transport, and Storage
3.4.1.3.2.1 Introduction
The liver is the prime driver of lipid metabolism, transport, and storage within an organism. It is responsible for the absorption, packaging, and secretion of lipids and lipoproteins. Lipids are absorbed from digestion through biliary synthesis and secretion, where they are converted to
fatty acids \cite{Trefts2017,10284972}. These fatty acids are then transported into hepatocytes, cells that make up roughly 80\% of the liver mass, via a variety of transport proteins such as CD36, FATP2, and FATP5 \cite{Lehner2016,10284974}. Fatty acids can be converted to triglycerides, which can be packaged with high or very-low-density lipoproteins (HDL or VLDL) for secretion. Lipid handling for the liver is important for energy metabolism \cite[e.g., fatty acid β-oxidation]{} in other organs and for the absorption of lipid-soluble vitamins \cite{Huang2011,10284973}. De novo cholesterol synthesis is another vital function of the liver. Cholesterol is important for the assembly and maintenance of plasma membranes. Dysregulation of any of these functions of the liver can have implications for metabolic and homeostatic processes within the liver itself and other organs, and can contribute to the development of diseases such as non-alcoholic fatty liver disease, steatosis, hepatomegaly, and obesity.

PFOA accumulates in liver tissue, and as such, not only influences lipid levels but can also alter gene expression for a variety of pathways involved in biological processes \cite{US-EPA2016,3603279}. PFAS have been shown to induce steatosis and increase hepatic triglyceride levels in rodents via inducing changes in genes directly involved with fatty acid and triglyceride synthesis that may have variable effects on serum triglyceride levels depending on species, sex, and exposure conditions \cite{Das2017,3859817;Rosen2013,2919147;Rosen2017,3859803;Li2019,5387402;Beggs2016,3981474;Liang2019,5412467}. These include genes such as fatty acid binding protein 1 (Fabp1), sterol regulatory element binding protein 1 (Srebp1), VLDL receptor (Vldlr), and lipoprotein lipase (Lpl1) \cite{Armstrong2019,6956799}. Various studies have also shown that PFOA alters expression of genes directly involved in cholesterol biosynthesis \cite{Pouwer2019,5080587;Das2017,3859817;Rosen2017,3859803;Li2019,5387402} and in β-oxidation of fatty acids \cite[e.g., Acox1 and/or carnitine palmitoyltransferase 1A (Cpt1a)]{Lee2020,6323794;NTP2019,5400977;Cavallini2017,3981367;Li2019,5387402;Rosen2013,2919147;Schlezinger2020,6833593}. Genes involved in lipid metabolism and homeostasis can be altered through PPARα, PPARγ, CAR, and HNF4α induction pathways and are dose-, life stage-, species-, and sometimes sex-dependent.

3.4.1.3.2.2 \textit{In Vivo Models}

3.4.1.3.2.2.1 Rats

Two studies conducted in Sprague Dawley rats reported marked effects on lipid metabolism, including sex-dependent effects, of PFOA on hepatic outcomes \cite{NTP2019,5400977;Cavallini2017,3981367}.

The study conducted by NTP in 2019 \cite{NTP2019,5400977} used an oral dosing paradigm of 0, 0.625, 1.25, 2.5, 5, or 10 mg/kg (males) or 0, 6.25, 12.5, 25, 50, or 100 mg/kg/day (females) for 28 days. Males exhibited higher plasma levels of PFOA despite receiving a 10-fold lower dose across the dose groups.

Serum cholesterol levels were decreased in PFOA exposed males and females, whereas serum triglyceride levels were decreased in males but increased in females. In liver, PPARα- and CAR-induced genes including Acox1, Cyp4a1, Cyp2b1, and Cyp2b2 were upregulated in both males and females compared to controls. In females, the CAR-induced Cyp2b1 and Cyp2b2 exhibited a greater increase than that of Acox1 and Cyp4a1, whereas Cyp4a1 and Cyp2b1 exhibited the greatest fold increase in males. Acox1 was more strongly upregulated in males than females. This gene expression profile indicates a stronger PPARα signal in males relative to females, and
stronger CAR activation signal in females. Bile acid concentrations were increased at the two highest dose groups (5 and 10 mg/kg/day) in males, but were not measured in females.

PFOA is known to activate PPAR receptors and proliferation of peroxisomes, and increase expression of Acyl-CoA oxidase (ACOX) activity, the first enzyme in the fatty acid beta oxidation pathway. In one study, a single dose of PFOA (150 mg/kg) in male Sprague-Dawley 2-month-old rats caused increased liver weight associated with an eight-fold and a fifteen-fold increase in ACOX after 2 and 4 days, respectively {Cavallini, 2017, 3981367}. PFOA exposure was associated with generation of new, ACOX rich peroxisomes. Autophagy was induced in fasted rats by an injection of an antilipolytic agent (3,5-dimethyl pyrazole (DMP)). In PFOA-treated rats, DMP-induced autophagy delayed the decrease in ACOX activity relative to controls. The authors hypothesized that autophagy may preferentially target older peroxisomes for degradation. However, another possibility not considered by the authors is that PFOA could disrupt drug-induced autophagy, which may represent an interesting area for further research.

3.4.1.3.2.2.2 Mice
Several studies were conducted to investigate the effects of PFOA on lipid accumulation in hepatocytes by histopathological and metabolomic methods using mice of different genetic backgrounds and life stages, and mice genetically modified to mimic human lipid metabolism {Wang, 2013, 2850952; Pouwer, 2019, 5080587; Hui, 2017, 3981345; Rebholz, 2016, 3981499; van Esterik, 2015, 2850288}. Other studies focused on the transcription and translation of genes involved in lipid metabolism and biliary pathways. The focus of these studies was to identify key genes, gene products, and transcriptional regulators affected by PFOA exposure and to examine how PFOA alters metabolism of lipids {Zhang, 2020, 6833704; Das, 2017, 3859817; Rosen, 2017, 3859803; Li, 2019 5387402; Beggs, 2016, 3981474; Yan, 2015, 2851199; Yu, 2016, 3981487; Song, 2016, 9959776; Wu, 2018, 4238318}.

3.4.1.3.2.2.1 Changes in hepatic lipid homeostasis
Many biochemical changes occurred with lipids and bile within the liver as well as lipid transport out of the liver (serum/plasma values). In several mouse studies, PFOA increased hepatic lipid levels including triglycerides, total cholesterol, and LDL, which correlated with histopathological changes that are often consistent with steatosis.

In Das et al. (2017, 3859817), WT male SV129 mice administered 10 mg/kg/day PFOA for 7 days had increased lipid accumulation in liver, as seen by Oil Red O staining, as well as increased liver triglyceride levels. These effects were mainly attributed to activation of PPARα, as they were attenuated in PFOA-exposed PPARα null mice (Section 3.4.1.2). In contrast, in male BALB/c mice administered 0.08, 0.31, 1.25, 5, or 20 mg/kg/day PFOA for 28 days, liver cholesterol was significantly decreased at 0.31 mg/kg/day and above, while triglycerides were significantly decreased at 0.08 and 20 mg/kg/day and significantly increased at 1.25 mg/kg/day (no changes were seen at other concentrations) {Yan, 2015, 2851199}. An increase in the transcriptional activity of PPARα and sterol regulatory element-binding proteins (SREBPs) was also observed. The authors hypothesize that altered lipid metabolism is induced by PPARα activation, with increased SREBP activity as a mediator in this pathway.

One study evaluated PFOA effects on storage in hepatic lipid droplets (LDs) in BALB/c mice {Wang, 2013, 2850952}. LDs are storage structures for neutral lipids that form in the
endoplasmic reticulum and release into the cytoplasm. In addition to lipid storage, they influence lipid metabolism, signal transduction, intracellular lipid trafficking, and protein degradation. Four-week-old BALB/c mice fed either regular or HFD were dosed with 5, 10, or 20 mg/kg/day PFOA by gavage for 14 days. Cytoplasmic LDs were apparent in both regular- and HFD-fed mice, though more were observed in HFD-fed mice. However, in PFOA-exposed mice, LDs transferred from the cytoplasm to the nucleus, forming hepatocyte intranuclear inclusions in a dose-dependent manner. The authors suggest that this translocation of LDs to the nucleus is a critical factor in PFOA-mediated liver toxicity. As discussed below (Section 3.4.1.3.2.2.2.2), at least two genes involved in lipid droplet formation, PLIN2 and PLIN4, were increased in PFOA-exposed HepaRG cells in vitro, supporting a role for PFOA in altering lipid droplets in hepatocytes {Louisse, 2020, 6833626}.

A targeted metabolomics approach was used to directly identify alterations in 278 metabolites in livers of BALB/c mice exposed to either 0.5 or 2.5 mg/kg/day PFOA for 28 days by gavage {Yu, 2016, 3981487}. A total of 274 of these metabolites were identified in liver and were mapped to KEGG metabolic pathways including amino acid, lipid, carbohydrate, and energy metabolism. In liver, nine metabolites mapped to lipid metabolism as evidenced by alterations in the relative concentrations of acylcarnitines, sphingomyelins, phosphatidylcholines, and oxidized polyunsaturated fatty acids. Among the 18 liver metabolites that were significantly different between exposed and control mice were six acylcarnitines, one phosphatidylcholine, and two polyunsaturated fatty acids, which could serve as potential biomarkers of PFOA exposure. The altered lipid profiles are consistent with the finding that PFOA upregulates hepatic nuclear receptors and their target genes directly involved in lipid metabolism and the β-oxidation of fatty acids {Lee, 2020, 6323794}. The profile of both phosphatidylcholine and fatty acid metabolites indicated a PFOA-mediated shift to phosphatidylcholines with more carbons and more double bonds. Because a change to fatty acids with more carbon atoms and double bonds is due to biosynthesis reactions of saturated and unsaturated fatty acids, these findings suggest PFOA exposure may stimulate fatty acid biosynthesis, which may account for the altered profile of both phosphatidylcholines and fatty acids in liver. Thus, PFOA may regulate both catabolic and anabolic lipid metabolism in liver.

3.4.1.3.2.2.2.2 Gene expression and metabolite accumulation impacting lipid homeostasis
Several studies probed the genes and pathways by which PFOA alters hepatic lipid homeostasis. Hui et al. {2017, 3981345} demonstrated that the expression of genes and proteins associated with lipid storage in was altered in the liver of PFOA-exposed BALB/c mice. Male mice were exposed to 1 or 5 mg/kg/day for 7 days and the expression of lipid metabolism genes was analyzed. Triglyceride and free fatty acid contents in serum were reduced, while hepatic triglyceride levels were increased in the PFOA-exposed mice compared to controls. In liver, transcript levels of hepatic lipoprotein lipase (Lpl) and fatty acid translocase (Cd36) were elevated, while apolipoprotein-B100 (ApoB) expression was diminished. LPL and CD36 regulate lipid intake through lipid hydrolysis and transport of lipids from blood to liver, whereas APOB is required for lipid export from liver. Protein levels aligned with the changes in transcript levels for these genes. The authors suggest that dysregulation of lipid metabolism and, specifically, fatty acid trafficking, leads to decreased body weights and lipid malnutrition and deposition of lipids in liver. These findings are consistent with observations in male Kunming mice exposed to 5 mg/kg/day PFOA for 21 days {Wu, 2018, 4238318}. In these mice, PFOA exposure led to reduced APOB and elevated CD36 protein levels as measured.
immunohistochemically and correlated to increased liver triglyceride levels. In addition to genes directly involved in regulating lipid metabolism and storage, Eldasher et al. (2013, 2850979) demonstrated that Bcrp mRNA and protein are increased in the livers, but not the kidneys of male C57BL/6 mice exposed to 1 or 3 mg/kg/day PFOA by gavage for 7 days. BCRP is an ATP-binding cassette efflux transporter protein involved in active transport of various nutrients and drugs and implicated in transport of xenobiotics. In addition, BCRP can function sterol transport and its ATPase activity can be stimulated with cholesterol [Neumann, 2017, 10365731]. Further studies are needed to elucidate the role of BCRP or other transport proteins in PFOA-mediated disruption of lipid metabolism.

MicroRNAs (miRNAs or miRs) are also altered after exposure to PFOA in mice in a dose-dependent manner. In serum of male BALB/c mice, 24 and 73 circulating miRNAs were altered in mice exposed to 1.25 and 5 mg/kg/day PFOA, respectively, for 28 days [Yan, 2014, 2850901]. Changes in expression of six miRNAs (miR-28-5p, miR-32-5p, miR-34a-5p, miR-200c-3p, miR-122-5p, miR-192-5p) were confirmed in liver, including two (miR-122-5p and miR-192-5p) considered to be biomarkers for drug-induced liver injury. MiRNAs may play a specific role in regulating expression of genes involved in lipid metabolism and storage.

Cui et al. (2019, 5080384) observed that PFOA exposure (5 mg/kg/day PFOA for 28 d) led to a significant increase of miR-34a, but not miR-34b or miR-34c, in the livers of male BALB/c mice, consistent with the findings of Yan et al. [Yan, 2014, 2850901]. Liver toxicity was evaluated by Cui et al. (2019, 5080384) by measuring liver weight, elevated liver enzymes, and hepatic cell swelling manifested in both WT mice and in miR-34a-null mice generated on a C57BL/6J background. RNASeq analysis of hepatic tissue showed that expression of lipid metabolism genes was significantly altered in both WT mice and in miR-34a-null mice after PFOA exposure; however, fewer genes were altered in livers of miR-34a-null mice. Metabolism genes dominated those changed by miR-34a, including Fabp3, Cyp7a1, and Apoa4. Based on the transcriptome analysis, the authors found that miR-34a mainly exerts a metabolic regulation role, rather than the pro-apoptosis and cell cycle arrest role reported previously in vitro.

In addition to perturbed expression of genes as a consequence of activating PPARα and other nuclear receptors, PFOA may directly target enzymes involved in fatty acid metabolism. Shao et al. (2018, 5079651) postulated that based on the electrophilic properties of PFOA, it may preferentially bind to proteins harboring reactive cysteine residues. To test this hypothesis, proteomic and metabolomic approaches were applied. Two cysteine-targeting probes were used to enrich putative target proteins in mouse liver extracts in the absence or presence of PFOA, resulting in the identification of ACACA and ACACB as novel target proteins of PFOA. Parallel reaction monitoring (PRM)-based targeted proteomics combined with thermal shift assay-based chemical proteomics was used to verify ACACA and ACACB as PFOA binding targets. Next, the authors used a metabolomic approach to analyze liver extracts from female C57BL/6 mice four hours after IP injection with a very high dose (300 mg/kg) of PFOA to confirm abnormal fatty acid metabolism, including significantly elevated levels of carnitine and acyl-carnitines. ACACA and ACACB are acetyl-CoA carboxylases that can regulate fatty acid biosynthesis. The authors suggest PFOA interactions with these carboxylases leads to a downregulation of malonyl-CoA, required for the rate-limiting step of fatty acid biosynthesis and an inhibitor of carnitine palmitoyl transferase 1 (Cpt1). Despite the correlation to altered fatty acid profiles,
additional studies are required to confirm PFOA binding to these lipid enzyme targets and changes in hepatic fatty acid metabolism.

3.4.1.3.2.2.2.3 Host factors influencing lipid metabolism and storage
Rebholz et al. (2016, 3981499) underscored the relevance of genetic background, sex, and diet in PFOA-mediated alterations of hepatic gene expression and highlighted the role of genes involved in sterol metabolism and bile acid production. Young, sexually immature male and female C57BL/6 and BALB/c mice were placed on diets to target a dose of approximately 0.56 mg/kg/day of PFOA and supplemented with 0.25% cholesterol and 32% fat. Hypercholesterolemia developed in male and female C57BL/6 mice exposed to PFOA. Hypercholesterolemia was also observed in male BALB/c mice but to a lesser degree than C57BL/6, and did not manifest in female BALB/c mice. The PFOA-induced hypercholesterolemia appeared to be the result of increased liver masses and altered expression of genes associated with hepatic sterol output, specifically bile acid production. These data support genetic background and dietary levels of fat and cholesterol as important variables influencing PFOA-mediated changes in cholesterol. However, an important caveat in this study is that female mice in the control groups for both strains had higher than expected blood PFOA levels.

PFOA-mediated changes in lipid levels may be programmed during early life exposure. C57BL/6JxFVB hybrid mice were exposed during gestation and lactation via maternal feed {van Esterik, 2015, 2850288} to seven doses of PFOA targeting 0.003–3 mg/kg/day. The dose range was chosen to be at or below the NOAEL used for current risk assessment. Liver morphology and serum lipids were analyzed at in the pups at 26 weeks (males) and 28 weeks (females) of age. Histopathological changes, including microvesicular steatosis and nuclear dysmorphology, were more frequent in PFOA-exposed mice compared to controls, though the incidence did not reach statistical significance over the dose range. However, perinatal exposure induced a sex-dependent change in lipid levels. In females only, serum cholesterol and triglycerides showed a dose-dependent decrease with a maximum change of -20% for cholesterol and -27% for triglycerides (BMDLs of 0.402 and 0.0062 mg/kg/day, respectively). The authors suggest that perinatal exposure to PFOA in mice alters metabolic programming in adulthood. Based on the sexually dimorphic lipid levels, as well as extrahepatic changes, females appear more sensitive to PFOA-mediated alterations in metabolic programming.

The potential developmental effects of PFOA in liver are also of interest considering recent findings that PFOA regulates expression of homeobox genes involved in both development and carcinogenesis {Zhang, 2020, 6833704}. Adult male C57BL/6 mice, PPARα-null mice, or CAR-null mice were given a single IP administration of 41.4 mg/kg and livers were collected on Day 5. PFOA induced mRNA expression of Hoxa5, b7, c5, d10, Pdx1 and Zeb2 in wild-type mice in a manner dependent on PPARα and CAR. Whether exposure to PFOA alters homeobox genes during perinatal exposure, and the potential for homeobox proteins to alter PFOA susceptibility in different life stages remains to be determined.

One difference between human and rodent lipid metabolism relates to transfer of cholesterol ester from HDL to the APOB-containing lipoproteins in exchange for triglycerides. Mice lack cholesteryl ester transfer protein (CETP) and rapidly clear APOB-containing lipoproteins. In contrast, a higher proportion of HDL relative to LDL is observed in humans and primates due to the function of CETP. APOE*3-Leiden.CETP transgenic mice, a strain that expresses human
CETP, exhibit a more human-like lipoprotein metabolism with transfer of cholesterol ester from HDL to the APOB-containing lipoproteins in exchange for triglycerides resulting in delayed APOB clearance. Pouwer et al. (2019, 5080587) utilized these transgenic mice to evaluate the effect of PFOA on plasma cholesterol and the mechanism for the hypolipidemic responses observed with PFOA exposures. APOE*3-Leiden.CETP mice were fed a Western-type diet (0.25% cholesterol (wt/wt), 1% corn oil (wt/wt), and 14% bovine fat (wt/wt)) with PFOA (0.01, 0.3, or 30 mg/kg/day) for 4–6 weeks. The doses were chosen to parallel environmental and occupational exposures in humans. PFOA exposure did not alter plasma lipids at lower doses, but did decrease plasma triglycerides, total cholesterol, and non-HDL levels, and increased HDL levels. Overall, these findings mirrored a clinical trial in humans demonstrating PFOA-induced decreases in cholesterol levels. This lipid profile could be attributed to decreased very low-density lipoprotein (VLDL) production and increased VLDL clearance by the liver through increased lipoprotein lipase activity. The concomitant increase in HDL was attributed to decreased CETP activity subsequent to PPARα activation and the downregulation of hepatic genes involved in lipid metabolism, including Apoa1, Scarb1, and Lipc (genes involved in HDL formation, HDL clearance, and HDL remodeling, respectively). Based on the lipid profiles, gene expression analysis, and pathway analysis, the authors propose a mechanistic model in which high PFOA exposure increases VLDL clearance by the liver through increased LPL-mediated lipolytic activity. These changes lead to lower VLDL serum levels consistent with reduced VLDL particle formation and secretion from the liver due to reduced ApoB transcript levels and de novo synthesis.

To further explore mechanistic differences in PFOA-induced changes in lipid metabolism between humans and mice, Schlezinger et al. (2020, 6833593) investigated PFOA-mediated lipid dysregulation in mice expressing human PPARα (hPPARα) and compared results to PPARα-null mice. Male and female mice were fed an American style diet (51.8% carbohydrate, 33.5% fat, and 14.7% protein, based on an analysis of what 2–to-19-year-old children and adolescents eat using NHANES data) and exposed to PFOA (8 μM) in drinking water for 6 weeks that led to serum PFOA levels of 48 μg/mL. Both hPPARα-null and PPARα-null mice developed hepatosteatosis after PFOA exposure. Changes in gene expression and increased serum cholesterol that was more pronounced in males than females correlated with changes in expression of genes that regulate cholesterol homeostasis. PFOA decreased expression of Hmgcr in a PPARα-dependent manner. Ldlr and Cyp7a1 were also decreased but in a PPARα-independent manner. Apob expression was not changed. While many of the target genes analyzed were similarly regulated in both sexes, some sex-specific changes were observed. PFOA induced PPARα target genes in livers of both sexes including Acox1 (involved in fatty acid β-oxidation), Adrp (involved in coating lipid droplets), and Mogat1 (involved in diacylglycerol biosynthesis). PPARγ target genes were also upregulated in both sexes and included Fabp4 and Cd36 that contribute to lipid storage and transport as was the CAR target gene Cyp2b10. PFOA exposure decreased expression of Cyp7a1 required for conversion of cholesterol to bile acids and efflux, but more so in females than in males.

Sex-specific changes in hepatic gene expression in response to PFOA exposure was also observed in zebrafish (Hagenaars, 2013, 2850980). Adult zebrafish were exposed to 0.1, 0.5, or 1 mg/L PFOA for 28 days. Livers were harvested and subjected to transcriptomic analysis. Similar to observations in mice, expression of genes regulating fatty acid metabolism and cholesterol metabolism and transport were generally upregulated in males and suppressed in
females. Thus, sex-specific effects of PFOA on fatty acid and cholesterol metabolism is observed across different vertebrate species, but also exhibits species specificity. For example, genes in the cytochrome P450 family involved in cholesterol metabolism and transport were suppressed in female zebrafish but upregulated in male zebrafish {Hagenaars, 2013, 2850980}. However, Cyp2b genes downstream of CAR (e.g., Cyp2b1 and Cyb2b10) were more strongly upregulated in females compared to males in both rats and mice {Schlezinger, 2020, 6833593; NTP, 2019, 5400977}. Differences in expression of Cyp450 genes may in part relate to species-specific activity of nuclear receptors, and the fact that no CAR orthologues have been identified in zebrafish nor any other fish species {Schaaf, 2017, 10365760}.

3.4.1.3.2.2.3  In Vitro Studies

In vitro studies reported genetic profiles and pathway analyses in mouse and human hepatocytes to determine the effect of PFOA treatment on lipid homeostasis and bile synthesis. Six studies investigated the effect of PFOA on lipid homeostasis using primary hepatocytes and human cell lines such as HepG2, HepaRG, and HL-7702 cells. Various endpoints were also investigated in these cell lines such as mRNA expression through microarray and qRT-PCR assays; lipid, triglyceride, cholesterol, and choline content; and protein levels via ELISA or western blot. In addition, two studies evaluated PFOA-mediated changes to lipids using metabolomic approaches.

Franco et al. (2020, 6507465) exposed HepaRG cells to PFOA and PFOS and evaluated metabolomics at a dose range of 100 pM to 1 µM. The highest PFOA exposure levels (10–100 µM) were associated with significant increases in total lipid concentrations, especially at the three highest concentrations tested (10, 100, and 1,000 nM). Interestingly, hepatocyte lipids were decreased in response to increasing PFOS exposure in this system. The affected classes of lipids also diverged, with PFOA associated with increased diglycerides, triglycerides, and phosphatidylcholines, whereas PFOS was associated with decreased diglycerides, ceramides, and lysophosphatidylcholines. Staining of neutral lipids was also prominent in PFOA-treated hepatocytes, suggesting an obesogenic role PFOA that may directly impact hepatic steatosis. The authors further hypothesized that the concentration-dependent decrease in lipid accumulation associated with PFOS may be related to differential ability of these compounds to interact with PPARs, including PPARγ.

Peng et al. (2013, 2850948) evaluated disturbances of lipids in the human liver cell line L-02 using metabolomic and transcriptomic approaches. Specifically, PFOA exposure was associated with altered mitochondrial metabolism of carnitine to acylcarnitines. The effect was dose-dependent and correlated with altered expression levels of key genes involved in this pathway. Downstream of this pathway, cholesterol biosynthesis was upregulated as measured by both increased cholesterol content and elevated expression levels of key genes. The profile of PFOA-associated disturbance in lipid metabolism was consistent with initial changes in fatty acid catabolism in cytosol that altered mitochondrial carnitine metabolism, ultimately impacting cholesterol biosynthesis.

In contrast to the findings of Peng et al. (2013, 2850948) in L-02 cells, Das et al. (2017, 3859817) reported that PFOA did not inhibit palmitate-supported respiration (mitochondrial metabolism) in HepaRG cells. There was no effect on oxidation or translocation of palmitoylcarnitine, an ester involved the in metabolism of fatty acids, as part of the tricarboxylic
acid (TCA) cycle in the mitochondrial fraction. This may indicate less of a perturbation to fatty acid metabolism in this cell line. This suggests that intermediary steps in fatty acid activation, transport, and/or oxidation are affected. The authors suggest that PFOA effects on mitochondrial synthesis of fatty acid and other lipids are secondary and possibly compensatory to any mitochondrial-induced toxicity, rather than as the result of activation of peroxisomes, which are mediated by PPARs.

Rosen et al. (2013, 2919147) exposed mouse and human primary hepatocytes to 0-100 or 0-200 µM PFOA, respectively. Gene expression was evaluated using microarrays and qRT-PCR. For PFOA-exposed murine hepatocytes, a much smaller group of genes was found to be altered compared to the whole liver. These genes included those associated with β-oxidation and fatty acid synthesis such as Ehhadh and Fabp1, which are upregulated by PFOA. In contrast to the transcriptome of primary mouse hepatocytes, a large group of genes related to lipid metabolism was differentially expressed in primary human hepatocytes including perilipin 2 (PLIN2) and CYPTA1, which were upregulated at 100 µM PFOA. The authors attribute some of these differences between mouse and human hepatocytes to a less robust activation of PPARα in humans. Further, many of the genes investigated were chosen to explore effects of PFOS exposure that are independent of PPARα activation but may include other nuclear receptors such as CAR, LXR, PXR, and AhR (Section 3.4.1.3.1). Beggs et al. (2016, 3981474) exposed human primary hepatocytes to 0.01-10 µM PFOA for 48 or 96 hours to determine pathways affected by PFOA exposure. PFOA treatment altered 40 genes (20 upregulated and 20 downregulated). Upregulated genes were primarily associated with lipid metabolism, hepatic steatosis and cholestasis, and liver hyperplasia. Among the top 10 upregulated genes were PLIN2, CYP4A22, and apolipoprotein A4 (APOA4).

Differential regulation of lipid metabolism and storage genes was also observed in HepG2 cells exposed to PFOA (dose range of 20-200 µM) for 48 hours (Wen, 2020, 6302274). Some specific metabolic pathway genes were not altered, including genes encoding the acyl-CoA dehydrogenase enzyme, FABP1, which encodes for a key protein responsible for fatty acid uptake, transport, and metabolism, exhibited decreased expression. Acyl-CoA oxidase 2 (ACOX2), which is involved in the peroxisome-mediated degradation of fatty acids, was also decreased. In contrast, a number of genes involved in fatty acid anabolism were upregulated. The authors linked PFOA-mediated gene expression changes to diminished global methylation, implicating epigenetic factors in PFOA-mediated changes in gene expression.

In human hepatic cell lines such as HepaRG, PFOA treatment led to downregulation of genes involved in cholesterol homeostasis. Louisse et al. (2020, 6833626) noted a concentration-dependent increase in triglycerides, a decrease of cholesterol at a high dose, and a downregulation of cholesterogenic genes especially after 24 hours of exposure to the high dose of 200 µM PFOA in HepaRG cells. Cellular cholesterol biosynthesis genes are regulated by SREBPs, which were also downregulated with PFOA exposure. In contrast, PPARα-responsive genes were upregulated with PFOA exposure, particularly at higher doses. Behr et al. (2020, 6505973) also exposed HepaRG cells to 0-500 µM PFOA for 24 or 48 hours. Similar to the results from Louisse et al. (2020, 6833626), at 24 hours, genes related to cholesterol synthesis and transport were downregulated at the highest dose except for several genes that were upregulated, including bile and cholesterol efflux transporters (SLC51B and ABCG1), and genes involved in bile acid and bilirubin detoxification (CYP3A4, UGT1A1). The gene profiles after
48 hours of exposure were similar, except at the high dose, at which there was an attenuation of the response in cholesterol synthesis and transport. Cholesterol content was significantly higher in the supernatant at the highest dose of 500 µM but there was no significant difference after 48 hours between treated cells and controls, which aligns with the attenuation of gene expression changes. Both studies also observed a PFOA-associated decrease in CYP7A1, a key enzyme involved in the initial step of cholesterol catabolism and bile acid synthesis.

3.4.1.3.2.2.4 Conclusions

Despite some inconsistencies in the literature, an emerging picture of PFOA-related dyslipidemia is largely initiated by activation of nuclear receptors targeted by PFOA, primarily PPARα, PPARγ, and CAR. A primary consequence of this interaction is altered expression of genes regulating hepatic lipid homeostasis. Gene expression profiles of lipid metabolism genes were observed both in vivo and in vitro, and in a diverse set of study designs. While changes in gene expression were consistently observed, the magnitude of the changes varied according to dose, dose duration, and model system. PPARα appears to be the primary driver regulating gene expression. However, studies in PPARα-null mice and analysis of nuclear receptor-specific genes implicate PPARγ, CAR, and possibly PPARδ as important contributors to the changes in PFOA-mediated gene expression. It should be noted, however, that a thorough analysis of potential compensatory changes in gene knock-out mice was not discussed in the literature reviewed here.

Two of the primary pathways targeted by PFOA-induced changes in gene expression include metabolism of fatty acids leading to triglyceride synthesis and metabolism of cholesterol and bile acids. In both mice and rats, gene expression changes generally correlated with increased triglyceride levels in liver, and decreased levels of circulating serum triglycerides. For cholesterol, in vitro studies were conflicting but suggest hepatic cholesterol content generally increases in PFOA-exposed animals. However, serum cholesterol levels were reduced in rats but were generally elevated in mice. Hepatic changes in lipid-regulating gene expression appear to influence circulating levels of lipids in serum in a manner that varies by sex, species, and life stage. For example, adult male rats exhibited decreases in serum triglycerides, whereas adult female rats exhibited increases {NTP, 2019, 5400977}. However, in mice exposed perinatally and then examined in adulthood, females, but not males, exhibited decreased serum levels of triglycerides, a treatment effect that was not observed in males {van Esterik, 2015, 2850288}. Male Kunming mice also exhibited a dose-dependent decrease in serum triglycerides and an increase in liver triglycerides {Wu, 2018, 4238318}. For cholesterol, serum levels were decreased in PFOA-exposed male rats and increased in female rats {NTP, 2019, 5400977}. In contrast, young male and female C57BL/6 mice exhibited hypercholesterolemia after PFOA exposure, though this was less striking male among BALB/c mice and did not manifest in female BALB/c mice {Rebholz, 2016, 3981499}. Elevated serum cholesterol was also more pronounced in males than females in mice expressing human PPARα {Schlezinger, 2020, 6833593}.

Importantly, changes in gene expression and lipid content in liver ultimately manifest in altered hepatocyte morphology. Most strikingly and consistently, steatosis manifests in PFOA-exposed animals. Other pathogenetic changes associated with PFOA included hepatomegaly, cholestasis, hyperplasia, and carcinoma. The finding of steatosis is interesting in light of observation that PFOA exposure downregulates expression of HNF4α in liver with concomitant changes in
HNF4α target genes because HNF4α-deficient mice develop steatosis in the absence of exposure to toxicants.

While the precise events that lead to steatosis have yet to be elucidated, the current studies conducted in animals and in vitro studies support the following key molecular and cellular events related to PFOA-mediated hepatotoxicity specific to changes in lipid metabolism: (1) PFOA accumulation in liver activates nuclear receptors; (2) nuclear receptors, including PPARα, then alter expression of genes involved in lipid homeostasis and metabolism; (3) the products of the genes altered by activated nuclear receptors modify the lipid content of liver to favor triglyceride accumulation, and possibly also cholesterol accumulation; (4) altered lipid content in liver leads to accumulation of lipid droplets promoting development of steatosis and other changes leading to liver dysfunction; and (5) alterations in lipid metabolism leads to alterations in serum levels of triglycerides and cholesterol. An intriguing possibility that may be concurrent to these events is direct binding of PFOA to ACACA and ACACB enzymes in a manner that interferes with fatty acid biosynthesis. Although this series of events is plausible, significant gaps remain in understanding this process, including how these events interface with other cellular processes such as cell growth and survival, oxidative stress, and others in understanding the mechanisms of PFOA-mediated hepatotoxicity.

There are challenges in the extrapolation of results from research related to PFOA-mediated changes to lipid metabolism in animals to humans. As presented in the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}, serum lipid levels were variably altered in humans exposed to PFOA in their environments. In occupationally exposed humans and humans exposed to high levels of PFOA, there was a general association with increased serum total cholesterol and LDL, but not HDL. At least one obstacle to extrapolating from rodent to humans is that the cholesteryl ester transfer protein encoded by the CETP gene in humans is absent in rodents. Mice lack CETP and rapidly clear apoB-containing lipoproteins. In contrast, a higher proportion of HDL relative to LDL is observed in humans and primates due to the function of CETP. New models designed to develop mice that are “humanized” for lipid metabolism, including APOE*3-Leiden.CETP {Pouwer, 2019, 5080587}, and mice expressing human nuclear receptors {Schlezinger, 2020, 6833593}, are likely to accelerate the extrapolation of mechanistic information from animals to humans.

3.4.1.3.3 Hormone Function and Response

While much of the literature relevant to hormone function and response is focused on reproductive or endocrine outcomes (see PFOA Appendix), recent literature has also shown a relationship between hepatic hormonal effects and PFOA exposure. PFOA has been found to affect thyroid mechanisms in hepatic cells. Huang et al. (2013, 2850934) studied the effect of 5, 10, 25, or 50 mg/L PFOA in a human non-tumor hepatic cell line (L-02 cells) and found that PFOA exposure downregulated thyroid hormone binding protein precursor.

While there are a small number of studies regarding hormone function and response specifically within the liver, there is evidence that PFOA has the potential to perturb hormonal balance in hepatic cells, particularly in regard to thyroid function. This could have implications for hormone function and responses in other organ systems and may also be important for MOA considerations for hepatotoxicity.
3.4.1.3.4 Xenobiotic Metabolism

Xenobiotic metabolism is the detoxification and elimination of endogenous and exogenous chemicals via enzymes (i.e., cytochrome P450 (CYP) enzymes) and transporters (i.e., organic anion transporting peptides [OATPs]) \{Lee, 2011, 3114850\}. As described in Section 3.3.1.3, the available evidence demonstrates that PFOA is not metabolized in humans or other species. However, several studies have investigated how PFOA could alter xenobiotic metabolism in the liver by downregulating or upregulating the gene expression of enzymes and transporters.

Li et al. (2017, 3981403) summarized the literature on molecular mechanisms of PFOA-induced toxicity in animals and humans. The authors noted how Elcombe et al. (2007, 5085376) and Guruge et al. (2006, 1937270) reported PFOA activation of PXR/CAR and subsequent manipulation of the expression of genes responsible for xenobiotic metabolism \{Li, 2017, 3981403\}. For instance, Cheng and Klaassen (2008, 2850410) concluded that PFOA induced the gene expression of CYP2B10 in mice.

Overall, results from both in vivo and in vitro model systems suggest that genes responsible for xenobiotic metabolism are upregulated as a result of PFOA exposure.

3.4.1.3.4.1 In Vivo Models

Three studies investigated xenobiotic metabolism endpoints in in vivo models with two using mice \{Li, 2019, 5080362; Wen, 2019, 5080582\} and one using zebrafish \{Jantzen, 2016, 3860109\}.

Li et al. (2019, 5080362) examined 5–6-week-old male C57BL/6 mice administered PFOA (1 mg/kg/day) via oral gavage for 2, 8, or 16 weeks. CYP2B and CYP3A activity were assessed via PROD and BQ assays as an indicator of CAR/PXR activity in the liver. As discussed in Section 3.4.1.3.1, the authors reported upregulation of Cyp2b and Cyp3a gene expression with downstream effects to CAR/PXR activation and xenobiotic metabolism. Similarly, Wen et al. (2019, 5080582) investigated CYP gene expression (including Cyp1a1, Cyp2b10, and Cyp3a11) with a focus on the activation of the nuclear receptor PPARα and downstream alteration of metabolism and excretion of xenobiotics. Adult, male wild-type C57BL/6NTac and PPARα-null mice were administered PFOA (3 mg/kg/day) for 7 days \{Wen, 2019, 5080582\}. Expression of a targeted list of genes, including Cyp1a1, Cyp2b10, and Cyp3a11, was quantified by qRT-PCR. In PFOA-treated wild-type mice, gene expression of Cyp1a1 and Cyp3a11 were not significantly changed. Conversely, in PFOA-treated PPARα-null mice, gene expression of Cyp2b10 and Cyp3a11 were significantly altered compared to the wild-type mice (11-fold increase for Cyp2b10 and 1.7-fold increase for Cyp3a11). Authors noted the differences between wild-type and PPARα mice were consistent with a previous study \{Corton, 2014, 2215399\}.

One study examined the expression of four genes related to xenobiotic metabolism in zebrafish \{Jantzen, 2016, 3860109\}. Zebrafish embryos (AB strain) were exposed to 2.0 µM PFOA dissolved in water from 3 to 120 hours post-fertilization (hpf) and evaluated 180 days post-fertilization (dpf) at adult life stage for gene expression. Females and males both had significant reductions in slco1d1 expression; however, only males had significant reductions in slco2b1 expression \{Jantzen, 2016, 3860109\}. Jantzen et al. (2016, 3860109) noted that in their previous study \{Jantzen, 2016, 3860114\}, PFOA exposure from 5 to 14 dpf resulted in significantly increased slco2b1 expression. Given the fluctuation in gene expression from short-term to long-
term, further studies with additional timepoints are needed to elucidate the effect of PFOA exposure on OATPs expression.

3.4.1.3.4.2 In Vitro Models

CYP2B6 is expressed in the liver and is predominately responsible for xenobiotic metabolism; similar to previous studies, Behr et al. (2020, 6305866) investigated activation of nuclear receptors by PFAS. Authors exposed HEK293T cells and HepG2 cells to varying concentrations of PFOA (0, 50, 100, or 250 µM) for 24 hours. As discussed further in Section 3.4.1.3.1, the authors reported the downstream effects of PFOA-mediated PPARα activation. At the highest concentration of 250 µM, Behr et al. (2020, 6305866) reported that PFOA significantly induced gene expression of CYP2B6 by 11.2-fold. CYP2B6 gene expression was assessed in an additional study that used primary human and mouse hepatocytes {Rosen, 2013, 2919147}. In primary human hepatocytes, PFOA concentrations ranged between 0 and 200 µM; in mouse hepatocytes, concentrations ranged between 0 and 100 µM. Results varied between human and mouse hepatocytes, with CYP2B6 upregulated in human hepatocytes but not in mouse hepatocytes. The authors noted that the differences between gene expression of the human and mouse hepatocytes were unclear; however, cell density, collection methods, and time in culture were possible factors.

Franco et al. (2020, 6315712) assessed the expression of genes encoding several phase I and II biotransformation enzymes following exposure to PFOA concentrations (10-10, 10-9, 10-8, 10-7, 10-6 M) for 24 or 48 hours. Gene expression of phase I enzymes (CYP1A2, CYP2C19, and CYP3A4) varied across concentrations and between the 24- and 48-hour exposures. For CYP1A2, after 24 hours, expression was significantly upregulated at concentrations ≥10-9 M; however, after 48 hours, expression was significantly downregulated at concentrations ≥10-8 M. CYP2C19 was downregulated across all concentrations after both 24- and 48-hour exposures; downregulation was significant for concentrations after both 24- and 48-hour exposures with the exception of 10-8 M after 24-hours. The authors concluded that PFOA exposure can significantly reduce expression of phase I biotransformation enzymes.

Evidence varied across studies for the effect of PFOA on the expression of CYP3A4, a phase I enzyme involved in bile acid metabolism and detoxification by hydroxylation and xenobiotic metabolism, depending on the model and duration of exposure, as well as whether gene expression or enzyme activity was assessed {Behr, 2020, 6505973; Franco, 2020, 6315712; Louisse, 2020, 6833626; Rosen, 2013, 2919147; Shan, 2013, 2850950}. Franco et al. (2020, 6315712) reported that after 24-hours, there were not significant changes in CYP3A4 expression. However, after 48 hours, there was a five-fold reduction in the expression. Conversely, Behr et al. (2020, 6505973) and Louisse et al. (2020, 6833626) reported upregulation of CYP3A4 enzyme activity following 24- or 48-hour PFOA exposure in HepaRG cells; specifically, Behr et al. (2020, 6505973) reported significant upregulation at 50 and 100 µM after both 24- and 48-hour PFOA exposure.

Rosen et al. (2013, 2919147) also reported upregulation of CYP3A4 expression following PFOA exposure (0–100 µM) in human hepatocytes; however, significant changes were not reported for mouse hepatocytes. Lastly, Shan et al. (2013, 2850950) reported no significant changes in CYP3A4 enzyme activity following PFOA exposure (0, 100, 200, 300, or 400 µM) in HepG2 cells.
Franco et al. (2020, 6315712) also assessed gene expression of phase II enzymes, glutathione-s-transferase mu1 (GST-M1) and UDP glucuronosyltransferase-1A1 (UGT-1A1), which were not significantly affected by exposure to PFOA after 24 or 48 hours. The authors noted that it was unclear where and how PFOA alters gene expression of phase I enzymes and not phase II enzymes. Further research is needed to determine whether altered gene expression occurs by interference with cytoplasm receptors, inhibition of nuclear translocation, and/or inhibition of the interaction of nuclear translocator complexes with DNA sequences (Franco, 2020, 6315712).

Orbach et al. (2018, 5079788) focused on the gene expression of the CYP2E1 enzyme. PFOA was added to primary human hepatocytes and primary rat hepatocytes at either $\frac{1}{2}$ LC50 or LC50 (500 µM for both humans and rats) for 24 hours. CYP2E1 enzymatic activity was estimated by the conversion of 7-methoxy-4-trifluoromethylcoumarin (MFC) to 7-hydroxytrifluoromethylcoumarin (HFC). However, in both human and rat hepatocytes, there were no significant changes in CYP2E1 activity.

Song et al. (2016, 9959776) analyzed the expression of over 1,000 genes by expression microarray analysis following exposure of HepG2 cells with increasing concentrations (0–1,000 µM) of PFOA for 48h. As a result, 1,973 genes expressed ≥1.5-fold changes in the exposed groups compared to the control group, including 20 genes responsible for metabolism of xenobiotics by cytochrome P450.

3.4.1.3.4.3 Conclusions

Several studies are available that assessed xenobiotic metabolism endpoints as a response to PFOA exposure, including studies in mice {Li, 2019, 5080362; Wen, 2019, 5080582}, zebrafish {Jantzen, 2016, 3860109}, primary hepatocytes {Orbach, 2018, 5079788; Rosen, 2013, 2919147}, or hepatic cell lines {Behr, 2020, 6305866; Franco, 2020, 6315712; Louisse, 2020, 6833626; Shan, 2013, 2850950; Song, 2016, 9959776}. Jantzen et al. (2016, 3860109) reported significant reductions in the expression of OATPs (slco1d1 and slco2b1). While the majority of studies reported altered gene expression of CYP enzymes, the direction and magnitude of change varied across doses and exposure durations. Jantzen et al. (2016, 3860109) and Franco et al. (2020, 6315712) both noted the need for further research to elucidate any potential relationships between PFOA exposure and xenobiotic metabolism.

3.4.1.3.5 Cell Viability, Growth and Fate

3.4.1.3.5.1 Cytotoxicity

Several in vitro studies have examined the cytotoxic effect of PFOA on cell viability assays in both primary hepatic cell cultures {Beggs, 2016, 3981474; Xu, 2019, 5381556} and in hepatic cell lines {Wen, 2020, 6302274; Hu, 2014, 2325340; Rosenmai, 2018, 4220319; Shan, 2013, 2850950; Lv, 2019, 5080368; Yan, 2015, 2851199; Zhang, 2020, 6316915; Sheng, 2018, 4199441; Wielsoe, 2015, 2533367; Florentin, 2011, 2919235; Franco, 2020, 6315712; Ojo, 2020, 6333436; Franco, 2020, 6507465; Huang, 2014, 2851292; Cui, 2015, 3981517; Behr, 2020, 6505973; Song, 2016, 9959776}, with varying results depending on the exposure concentration and duration, cell line, and culturing methods.

In mouse primary hepatocytes, cell viability as determined by cell counting Kit-8 (CCK-8) assay did not significantly change at concentrations of PFOA in the range of 10-500 µM; however, a 41% decrease in viability was observed after 24 hours of exposure to 1000 µM PFOA {Xu,
In primary rat hepatocytes exposed to PFOA for 24 hours showed no changes in cell viability at concentrations ≤25 µM, but cell viability was increased by approximately 16% in the 100 µM concentration \{Liu, 2017, 3981337\}.

PFOA exposure duration and concentration affect cytotoxicity. In HepG2 cells, 100 µM PFOA did not affect cell viability after 1-3 hours of exposure \{Florentin, 2011, 2919235; Shan, 2013, 2850950\}. However, after 72 hours, cell viability as determined by neutral red assay was reduced by nearly 80% in the same cell line \{Buhrke, 2013, 2325346\}, suggesting that PFOA cytotoxicity is increased with long-term exposure. Additionally, in human HEPG2 cells treated at different concentrations of PFOA for 24 hours, viability as determined by MTT assay did not change with 100 µM PFOA, but was significantly reduced by 14% at 200 µM, 22% at 400 µM, 47% at 600 µM, and 69% at 800 µM, suggesting a concentration-dependent reduction in cell viability \{Florentin, 2011, 6333436\}. In contrast, cell viability dropped below 80% in HepaRG cells exposed to 100 µM PFOA at 24 hours \{Franco 2020, 6315712\}. Another study in HepaRG cells \{Louisse, 2020, 6833626\} showed no effect on cell viability up to concentrations of 400 µM for 24 hours. Although some results are conflicting, overall, these studies suggest that exposure duration and concentration, type of cell lines, species, and viability assessment methods are determinants of PFOA-induced cytotoxicity.

IC50 values in hepatic cell lines ranged from approximately 42 µM PFOA after 72 hours \{Buhrke et al., 2013, 2325346\}, 102-145 µM after 24 hours \{Ojo, 2020, 6333436; Franco, 2020, 6315712\}, to 305 µM after 48 hours of exposure in HepG2 cells \{Song, 2016, 9959776\}. In a fetal liver cell line (HL-7702), IC50 values were 647 µM after 24 hours exposure and 777 µM after 48 hours exposure \{Hu, 2014, 2325340; Sheng, 2018, 4199441\}. One study in zebrafish liver cells reported IC50 values of 84.76 µg/mL after 48 hours exposure \{Cui, 2015, 3981517\}.

### 3.4.1.3.5.2 Apoptosis

To determine the mechanism underlying PFOA-induced cytotoxicity, several studies have interrogated the apoptosis pathway as a potential mechanism \{Li, 2017, 4238518; Buhrke, 2013, 2325346; Cui, 2015, 3981517\}. Apoptosis is characterized by biochemical and morphological changes in cells. Flow cytometry has been used to quantify the percentage of apoptotic cells and their phase in cells exposed to PFOA. The percentage of apoptotic cells in the early and late phases of apoptosis nearly doubled in isolated C57BL/6J mice hepatocytes exposed to 500 µM and 1,000 µM PFOA for 24 hours \{Xu, 2019, 5381556\}. In zebrafish liver cells exposed to the IC50 (84.76 µg/mL) and IC80 (150.97 µg/mL) for 48 hours, the percentage of dead cells in the late phase of apoptosis did not change in cells exposed to the IC50 compared to control, while a significant increase in the percentage of apoptotic cells in the late phase of apoptosis was observed in the cells exposed to the IC80 \{Cui, 2015, 3981517\}.

Activation of cysteine aspartic acid-specific protease (caspase) family is essential for initiation and execution of apoptosis. PFOA-induced apoptosis via caspase activities have been examined in primary mouse hepatocytes, mouse cell lines, and human cell lines after exposure to various PFOA concentrations \{Sun, 2019, 5024252; Cui, 2015, 3981517; Buhrke, 2013, 2325346; Huang, 2013, 2850934; Li, 2017, 4238518; Xu, 2020, 6316207\}. In mouse hepatocytes, PFOA induced caspase activity in a dose-dependent manner \{Li, 2017, 4238518\}. In male C57BL/6J mouse hepatocytes treated with PFOA for 24 hours, caspase 3 activity did not change at doses below 1,000 µM but increased by more than 1,000% at 1,000 µM \{Xu, 2020, 6316207\}. In a
spheroid model of mouse liver cells (AML12), increased activity of caspase 3/7 was detected from 14 to 28 days of ≥100 µM PFOA exposure {Sun, 2019, 5024252}. In contrast, 100 µM PFOA did not change caspase 3/7 activity in HepG2 cells exposed for 48 hours {Buhrke, 2013, 2325346}.

Another key feature of cells undergoing apoptosis is the release of lactate dehydrogenase (LDH). Many studies have reported intracellular release of LDH in hepatocytes treated with PFOA {Yan 2015, 3981567; Shan, 2013, 2850950; Wielsøe, 2015, 2533367; Sun, 2019, 5024252}. In male C57BL/6J mouse primary hepatocytes treated with PFOA for 24 hours, 35% increase in LDH was observed at the 10 mM dose compared to control. However, for all concentrations below 10 mM, the difference was not significant {Xu, 2020, 6316207}.

Changes in mRNA and protein expression of apoptotic genes is a hallmark of apoptosis. Increased expression of p53, Bcl-2, Bcl-2 associated X-protein (Bax), caspase-3, nuclear factor kappa B (NF-κB) mRNA and protein was observed in zebrafish liver {Cui, 2015, 3981517}. In human hepatoma SMM-721 cells treated with 10 or 100 µg/mL PFOA for 3 hours, BAX mRNA was significantly increased while B-cell lymphoma 2 (Bcl-2) decreased compared to control {Lv, 2019, 5080368}. Proteomic analysis of 28 proteins differentially expressed in PFOA-exposed human non-tumor hepatic cells (L-02) led the authors to conclude that PFOA induces apoptosis by activating the p53 mitochondria pathway {Huang, 2013, 2850934}. This result is consistent with several studies showing that PFOA-induced liver apoptosis is in part mediated through p53 activation {Li, 2017, 4238518; Sun, 2019, 5024252}. In a third study that examined miRNA expression in the mouse liver, an increase in the expression of miR-34a-5p, which has been shown to be involved in p53-mediated apoptosis, was observed {Yan, 2014, 2850901}.

PFOA has been shown to induce apoptosis through morphological changes to the mitochondrial membrane {Xu, 2020, 6316207; Li, 2017, 4238518}. One study in Balb/c male mice gavaged with PFOA (0.08-20 mg/kg/day) for 28 days suggested that hepatocyte apoptosis following exposure to PFOA may be caused by endoplasmic reticulum stress, mediated by the induction of ER stress markers including phosphorylated eukaryotic initiation factor 2α (p-elf2α), spliced X box-binding protein 1 (XBP1), and C/EBP homologous protein (CHOP) {Yan, 2015, 3981567}.

An RNA-sequencing study in primary human hepatocytes found that PFOA exposure was associated with changes in gene expression that aligned with cell death and hepatic system disease, including necrosis, cholestasis, liver failure, and cancer {Beggs, 2016, 3981474}. Another RNA-sequencing study showed that PFOA induced intracellular oxidative stress in Sprague Dawley rats leading to apoptosis {Liu, 2017, 3981337}. Other mechanisms underlying PFOA-induced apoptosis include DNA damage {Wielsøe, 2015, 2533367}, autophagosome accumulation {Yan, 2015, 3981567; Yan, 2017, 3981501}, induction of ER stress biomarkers and oxidative stress {Li, 2017, 4238518; Huang, 2013, 2850934; Panaretakis, 2001, 5081525; Wielsøe, 2015, 2533367}, and reduction of mitochondrial ATP {Mashayekhi, 2015, 2851019; Sun, 2019, 5024252}. Although many studies have reported oxidative stress as a potential mechanism underlying PFOA-induced apoptosis, Florentin et al. (2011, 2919235) did not observe an increase in DNA damage or ROS at doses that proved cytotoxic to HEPG2 cells, leading the authors to conclude that PFOA-induced apoptosis is not related to DNA damage nor oxidative stress.
PFOA-induced apoptosis has been shown to differ between males and females. In male and female Balb/c mice gavaged with PFOA at doses ranging from 0.01-2.5 mg/kg/day for 28 days, caspase-9 activity and dissipation of the mitochondrial membrane potential were higher in females than males. Specifically, mitochondrial membrane dissipation was 25% in males and 39% in females for mice in the 2.5 mg/kg/day groups. In the 0.05 mg/kg/day group, caspase-9 activity was elevated by 72% in females compared to 40% in males. The sexual dimorphic changes in caspase-9 and mitochondrial membrane dissipation were accompanied by morphological changes in the mitochondria characterized by increased mitochondrial vesicle formation and swelling in female than male hepatocytes, suggesting that female livers are more susceptible to PFOA-induced apoptosis than males {Li, 2017, 4238518}.

3.4.1.3.5.3 Cell Cycle and Proliferation
Alterations in cell proliferation and cell cycle were also seen in many in vivo and in vitro studies {Zhang, 2020, 6316915; Zhang, 2016, 3748826; Beggs, 2016, 3981474; Buhrke, 2013, 2325346; Buhrke, 2015, 2850235; Lv, 2019, 5080368; Wen, 2020, 6302274}. In mice exposed to 3 mg/kg/day PFOA for 7 days by oral gavage, proliferation in the liver, as seen through proliferation cell nuclear antigen (PCNA) staining, was increased relative to control {Beggs, 2016, 3981474}. HL-7702 cells were treated with PFOA at concentrations of 50-400 µM for 48 or 96 hours {Zhang, 2016, 3748826}. All except the highest dose (400 µM) group showed an increase in cell proliferation compared to control at 48 hours. Other studies have reported a similar pattern where proliferation is significantly increased at low doses and decreased at high doses of PFOA in human primary hepatocytes {Buhrke, 2015, 2850235}, HepG2 {Buhrke, 2013, 2325346}, and HepaRG cells {Behr, 2020, 6505973}. Together these studies suggest that higher concentration of PFOA may interfere with cell cycle progression by reducing cell proliferation rather than severely inducing apoptosis.

In contrast, a study in primary hepatocytes of Sprague Dawley rats found increased proliferation at the highest dose and no proliferative effect at low doses. Approximately 16% increase in proliferation was observed with PFOA exposures of 100 µM for 24 hours compared to controls {Liu, 2017, 3981337}. However, no changes in cell number as measured by MTT assay was observed at the PFOA concentration range of 0.4-25 µM at the same duration, adding to the evidence that PFOA-induced proliferation is dose-dependent and may vary by cell type.

PFOA has also been shown to disrupt cell cycle progression. Using flow cytometry, Zhang et al. 2016, 3748826) found that in HL-7702 cells, the proportion of cells in the G0/G1 phase (non-dividing) significantly decreased while cells in the S phase increased after 48 hours of exposure to 50 and 100 µM PFOA. However, at the 200 µM and 400 µM exposure for 48 hours, percentage of cells in the G0/G1 phase increased while cells in the G2/M phase (interphase growth/mitosis) decreased significantly compared to control. Interestingly, the same trend was observed in cells incubated at the same dose for 96 hours {Zhang, 2016, 3748826}. A second study in immortalized non tumor cells derived from human normal liver tissue (L-02 cells) also used flow cytometry to examine changes in the cell cycle after 72 hours at 25 and 50 mg/L and found that PFOA increased the percentage of cells in G2/M phases but decreased the number of cells in G0/G1 and S phases {Huang, 2013, 2850934}. Additionally, the percentage of cells in apoptotic sub-G1 (G1-) phase increased significantly from 19% to 33% compared to 10% of cells in the G1-phase in the control group, leading the authors to conclude that PFOA treatment disrupt cell cycle in L-02 cells by arresting cells in G2/M phase while inducing apoptosis. A
third study in a zebrafish liver cell line also used flow cytometry to identify changes in the cell cycle after 85 and 151 µg/mL PFOA exposure for 48 hours. In corroboration with the study in L-02 cells, PFOA concentration of 151 µg/mL showed an increase in the percentage of cells in the G2/M/S stage and a decrease in the percentage of cells in the G1/G0 phase {Cui, 2015, 3981517}. Together, these studies suggest that PFOA interferes with the balance between apoptosis and proliferation by disrupting cell cycle progression.

PFOA-induced changes in cell proliferation and cell cycle progression are often accompanied with changes in mRNA and protein expression of genes implicated in cell cycle progression. Pathway analysis of protein expression in human HL-7702 normal liver cells exposed to 50 µM PFOA for 48 and 96 hours identified 68 differentially expressed proteins that are related to cell proliferation and apoptosis {Zhang, 2016, 3748826}. Western blot analysis from the same study showed differential protein expression of positive cell cycle-regulators, including cyclins and cyclin-dependent kinases (Cyclin/CDKs) that are known to control G1/G2/S/M cell cycle progression, as well as negative regulators (p53, p21, MYT1, and WEE1). Interestingly, expression of cell cycle regulations was dose-dependent. Significant induction of cyclin D1, CDK6, cyclin E2, cyclin A2, CDK2, p-CDK1, p53, p21, p-WEE1 and myelin transcription factor 1 (MYT1) was observed at low dose (50 or 100 µM). However, cyclin A2, cyclin B1 and p21 proteins were significantly inhibited at high dose (400 µM) at the same duration (48 hours) {Zhang, 2016, 3748826}. In primary human hepatocytes treated with 10 µM PFOA, CCND1 and Aldo-keto reductase family 1 member B10 (AKR1B10) mRNA were significantly induced after 96 hours {Beggs, 2016, 3981474}. AKR1B10 is a promitogenic gene that has been associated with the progression of hepatocellular carcinoma {Matkowski, 2014, 10365736}. In addition, two microarray studies in hepatic cell lines found that PFOA exposures ranging from 100-305 µM for up to 48 hours were associated with pathways involved in the regulation of cellular proliferation or the cell cycle {Song, 2016, 9959776; Louisse, 2020, 6833626}.

PFOA has been shown to decrease the expression of hepatocyte nuclear factor 4-alpha (HNF4α), a regulator of hepatic differentiation and quiescence, in multiple studies and is thought to mediate steatosis following PFOA exposure {Behr, 2020, 6505973; Beggs, 2016, 3981474}. One study suggested that PFOA-induced proliferation may be mediated by the degradation of HNF4α {Beggs, 2016, 3981474}. This study, using wild type CD-1 and HNF4α knockout mice, reported that 11 out of 40 genes altered by PFOA exposure were regulated by HNF4α. PFOA exposure decreased the expression of HNF4α in both male mice and primary human hepatocytes and increased the expression of Nanog, a stem cell marker, suggesting that PFOA may be de-differentiating hepatocytes. Increased relative liver weight in PFOA-exposed mice was observed in this study and the authors concluded that hepatomegaly, along with other liver effects such as steatosis, may be mediated by PFOA-induced dysregulation of HNF4α.

**3.4.1.3.5.4 Conclusions**

Hepatotoxicity is widely cited as a type of toxicity induced by PFOA exposure. PFOA has been shown to trigger apoptosis at high doses and induce cell proliferation at low doses. PFOA-induced apoptosis is activated through a cascade of mechanisms including activation of caspase activity, intracellular release of LDH, induction of apoptotic genes, morphological changes to the mitochondria membrane, and activation of p53 mitochondria pathway. Additionally, PFOA induced hepatocyte proliferation both in vivo and in vitro by disrupting cell cycle progression.
leading to liver dysfunction, including steatosis and hepatomegaly. Therefore, PFOA exposure may lead to liver cytotoxicity through a myriad of intracellular events.

### 3.4.1.3.6 Inflammation and Immune Response

The liver is an important buffer between the digestive system and systemic circulation and is thus exposed to compounds that are potentially immunogenic, resulting in protective immune and inflammatory responses. Kupffer cells constitute the majority of the liver-resident macrophages and make up one third of the non-parenchymal cells in the liver. Kupffer cells phagocytose particles, dead erythrocytes, and other cells from the liver sinusoids and play a key role in preventing immunoreactive substances from portal circulation from entering systemic circulation \cite{Dixon, 2013}. While Kupffer cells can be protective in drug- and toxin-induced liver toxicity, dysregulation of Kupffer cell-mediated inflammatory responses is associated with a range of liver diseases, including steatosis. Other liver-resident immune cells include natural killer (NK) cells, invariant NKT cells, mucosal associated invariant T (MAIT) cells, γδT cells, and memory CD8+ T cells \cite{Wang et al., 2019}. The non-immune cells of the liver, liver sinusoidal endothelial cells (LSECs), hepatocytes, and stellate cells, also participate in immunity. They can express pattern recognition receptors and present antigens to T cells \cite{Robinson, 2016}. However, the impact of PFOA on the immune function of these cell types has not been thoroughly investigated.

#### 3.4.1.3.6.1 In Vivo Studies

Investigations into the liver immune response have been conducted in a single human study in the C8 Health Project cohort \cite{Bassler, 2019}, and in several rodent studies \cite{Botelho, 2015, Li, 2019, Liu, 2016, Yu, 2016, Hui, 2017, Wu, 2018}. Bassler et al. \cite{Bassler, 2019} collected 200 serum samples from participants of the C8 Health Project to analyze mechanistic biomarkers of non-alcoholic fatty liver disease (NAFLD) and test the hypothesis that PFAS exposures are associated with increased hepatocyte apoptosis and decreased proinflammatory cytokines. PFOA levels were significantly correlated with decreases in serum levels of the proinflammatory cytokine tumor necrosis factor α (TNFα). In contrast, both interferon γ (IFNγ) and cleaved complement 3 (C3a) were positively associated with PFOA levels. The authors state that these results are consistent with other findings that PFAS are immunotoxic and downregulate some aspects of the immune responses, but paradoxically result in increased apoptosis, which may subsequently result in progression of liver diseases (including NAFLD).

A study in mice acutely exposed to PFOA also linked hepatic injury to activation of the complement system. In contrast to the human study \cite{Bassler, 2019}, a decrease in serum C3a was observed in mice \cite{Botelho 2015}. C57BL/6 mice exposed to a 10-day dietary treatment with PFOA (0.002–0.02%, w/w) exhibited hepatomegaly, elevated serum triglycerides, elevated alanine aminotransferase (ALAT), hepatocyte hypertrophy, and hepatocellular necrosis at all doses. At the highest dose only, PFOA-induced hepatic injury coincided with deposition of the complement factor C3a fragment in the hepatic parenchyma. The findings support activation of the classical, but not alternative complement cascade in liver, and correlated with diminished C3 levels in serum. In serum, commercial hemolytic assays indicated attenuation of both the classical and alternative complement pathways. These authors proposed that that PFOA-mediated induction of hepatic parenchymal necrosis is the initiation event that leads to activation of the complement cascade and pro-inflammatory responses.
In another study in mice, the effects of PFOA exposure on inflammatory changes in liver varied depending on the presence of pre-existing NAFLD (Li, 2019, 5080362). Mice were subjected to control diet or HFD for 16 weeks to induce NAFLD, after which they were exposed to vehicle or 1 mg/kg/day PFOA by oral gavage for 2, 8, or 16 weeks; the control diet and HFD were continued throughout the exposure period until necropsy. In mice on the control diet, inflammatory changes were not observed in the first 8 weeks of PFOA treatment. However, after 16 weeks of PFOA treatment, mild hepatic lobular inflammation was observed in 3 of 5 animals, suggesting that chronic exposure to PFOA induces inflammatory changes in liver. In HFD-fed mice, focal inflammation was seen as early as 2 weeks after initiating PFOA treatment and inflammatory foci were observed in 2 of 5 mice after 16 weeks of PFOA exposure. Gene expression of Tnfα measured by qRT-PCR was elevated in the HFD group exposed to PFOA for all three treatment durations (2, 8, or 16 weeks of PFOA). Similarly, Liu et al. (2016, 3981762) observed an induction of TNFα in liver homogenates, measured by ELISA, in male Kunming mice fed a regular diet (Liu, 2016, 3981762) and exposed to a higher dose of PFOA (10 mg/kg/day for 2 weeks). This study observed significantly elevated levels of both TNFα and IL-6 in liver homogenates.

Li et al. (2019, 5080362) also confirmed increased expression of inflammatory genes using an RNA-Seq transcriptomic approach. Compared to mice on the control diet, the HFD group exposed to PFOA resulted into 537 differentially expressed genes. The inflammatory response was among the top enriched Gene Ontology (GO) terms for the gene set specific to the PFOA-exposed HFD. Analysis using Ingenuity Pathway Analysis showed significant upregulation of chemokines and chemokine-related genes and toll-like receptor (TLR) related genes in the PFOA-exposed HFD group compared to mice fed the control diet. Taken together with the histopathological findings, these gene expression changes suggest that that preexisting fatty liver may enhance PFOA-mediated inflammatory changes in liver.

Another potential nexus between changes in hepatic lipid metabolism and inflammation comes from a high-throughput metabolomics study in male BALB/c mice (Yu, 2016, 3981487). After a 28-day exposure to 0, 2.5 or 5 mg/kg/day PFOA, livers were subjected to metabolomic analysis. Metabolite analysis indicated PFOA altered polyunsaturated fatty acid metabolism including the arachidonic acid pathway. Arachidonic acid is a precursor in production of inflammatory mediators including prostaglandins, thrombaxanes, and leukotrienes. Prostaglandins (PGD2, PGE2, and PGF2α) were slightly elevated but increases did not reach statistical significance. However, the ratio of the thromboxane A2 (TXBA2) metabolite thromboxane X2 (TXB2) to prostaglandin I2 (PGI2) was significantly decreased in PFOA-exposed mice. Given the prothrombotic role of TXBA2 and the vasodilatory role of PGI2, the authors suggest these changes are consistent with ischemic liver injury that is characterized by vasodilation of microvasculature, lessened adherent leukocytes, and improved flow velocity in liver. Two leukotrienes, LTD4 and LTB4 were significantly lower in the high dose group. Both leukotrienes can also regulate vascular permeability and the authors suggest these changes are consistent with PFOA-induced inflammation in liver. PFOA also upregulates CD36 gene expression in hepatocytes (Hui, 2017, 3981345; Wu, 2018, 4238318), which is a negative regulator of angiogenesis (Silverstein, 2009, 10365842). Together with the PFOA-mediated changes in abundance of prostaglandins and thrombaxanes, these findings raise the possibility that PFOA-mediated alterations of the hepatic microvasculature are key events in the development or persistence of liver inflammation.
3.4.1.3.6.2 In Vitro Studies
In a study investigating the hepatic effects of PFOA in vitro, Song et al. (2016, 9959776) evaluated gene expression changes in human liver hepatocellular carcinoma HepG2 cells using a whole genome expression microarray. After exposing these cells to 306 µM PFOA (the IC20 dose for cell viability inhibition) for 48 hours, gene expression changes were evaluated. PFOA exposure led to differential regulation of 1,973 genes. Through KEGG pathway analyses, the authors reported that genes related to immune response were among the most differentially expressed biological process out of the 189 processes with altered genetic profiles. The authors identified 17 immune-associated genes that were differentially expressed. These genes mapped to the TNF signaling pathway, nucleotide-binding and oligomerization domain (NOD)-like receptor signaling, cytokine-cytokine receptor interactions, and the complement and coagulation cascade system. These findings support a role for PFOA in dysregulating innate immune mechanisms.

Alterations in cytokines associated with regulation of adaptive immunity were also observed using multi-cellular hepatic organotypic culture models composed of primary human or rat cells (Orbach, 2018, 5079788). This system involved seeding primary liver sinusoidal epithelial cells and Kupffer cells encapsulated in extracellular matrix proteins above the hepatocytes. This culture system forms a stratified three-dimensional (3D) structure designed to more accurately mimic liver tissue. Organotypic cultures were exposed to 500 µM PFOA for 24 hours (the LC50 in human cultures). PFOA exposure led to a 62% decrease in IL-10 levels. In addition to being a key cytokine in development of T helper lymphocytes, IL-10 has anti-inflammatory properties. Thus, the decrease in IL-10 observed in organotypic culture is consistent with the proinflammatory changes in liver associated with PFOA exposure. Using a proteomic approach, another cytokine, IL-22, has also been shown to be downregulated in PFOA-exposed human hepatic L-02 cells (Huang, 2013, 2850934). IL-22, a member of the IL-10 cytokine family, exerts protective effects in liver during acute inflammation and alcoholic liver injury (Ki, 2010, 10365730; Zenewicz, 2007, 10365732). T helper (Th22) cells are a T-cell subset responsive to IL-22. Th22 cells function in maintaining the integrity of the epithelial barriers (Hossein-Khannazar, 2021, 10365738). As such, diminished levels of IL-22 in the liver suggest that PFOA could interfere with the protective effects of IL-22 and Th22 cells.

3.4.1.3.6.3 Conclusions
The limited number of studies reviewed support a role PFOA in inducing hepatic inflammation through dysregulation of innate immune responses. This includes elevated levels of TNFα as well as changes in prostaglandin and thromboxane levels. Gene expression studies also suggest a role for chemokines in elaborating inflammation in liver. Expression of genes coding for products involved in innate immune defense systems were altered, including TLRs, molecules involved in NOD signaling, and C3a, a key indicator of complement cascade activation. Far less is known regarding PFOA effects on adaptive immunity in liver. PFOA exposure caused a reduction in IL-10 levels in organotypic culture of liver. IL-10 has anti-inflammatory properties in addition to promoting differentiation of Th2 CD4+ T cells. Intriguingly, IL-22 levels were diminished in PFOA-exposed hepatic cells. This cytokine may impact the function of Th22 T lymphocytes and impact the epithelial barriers in liver. Moreover, IL-22 reduction may reduce the protective effects of this cytokine during inflammation. Altogether, induction of inflammation appears to be an important mechanism that impacts liver pathogenesis in response to PFOA exposure, though the contribution of specific populations of resident or infiltrating liver
immune cells and the series of events that produce inflammation have yet to be elucidated. Adaptive immune responses are disrupted in PFOA-exposed animals (Section 3.4.2.2). However, whether alterations in adaptive immunity impact pathogenetic mechanisms in liver remain unknown.

3.4.1.3.7 Oxidative Stress and Antioxidant Activity

3.4.1.3.7.1 Introduction

Oxidative stress, caused by an imbalance of reactive oxygen species (ROS) production and detoxification processes, is a key part of several pathways, including inflammation, apoptosis, mitochondrial function, and other cellular functions and responses. In the liver, oxidative stress contributes to the progression and damage associated with chronic diseases, such as alcoholic liver disease, non-alcoholic fatty liver disease, hepatic encephalopathy, and Hepatitis C viral infection {Cichoz-Lach, 2014, 2996796}. Indicators of oxidative stress include but are not limited to increased oxidative damage (e.g., malondialdehyde (MDA) formation); increased reactive oxygen species (ROS) production (e.g., hydrogen peroxide and superoxide anion); altered antioxidant enzyme levels or activity (e.g., superoxide dismutase (SOD) and catalase (CAT) activity); changes in total antioxidant capacity (T-AOC); changes in antioxidant levels (e.g., glutathione (GSH) and glutathione disulfide (GSSG) ratios); and changes in gene or protein expression (e.g., nuclear factor-erythroid factor 2-related factor 2 (Nrf2) protein levels). PFOA has been implicated as a chemical that can induce these indicators of oxidative stress, inflammation, and cell damage.

3.4.1.3.7.2 In Vivo Models

3.4.1.3.7.2.1 Mouse

Yan et al. (2015, 3981567) examined livers from male Balb/c mouse following PFOA exposure of 0.08, 0.31, 1.25, 5, or 20 mg/kg/day for evidence of oxidative stress, including changes in expression of oxidative stress-related genes. While no change was observed in Cat expression levels, increases in Sesn1, Sod1, and Sod2 were observed in livers from mice exposed to 1.25, 5, and 20 mg/kg/day PFOA, respectively. PFOA exposure led to increased CAT activity and decreased SOD activity in mouse livers. MDA contents were decreased at all dose levels, and levels of the antioxidant GSH increased at 5 and 20 mg/kg/day PFOA. Authors concluded that the changes in SOD, CAT, GSH, and MDA reflect PFOA-induced disruptions to the antioxidant defense system in the livers of exposed mice. However, no significant oxidative damage was observed.

Li et al. (2017, 4238518) explored the role of ROS accumulation in apoptosis in male and female Balb/c mice dosed with 0.05, 0.5, or 2.5 mg/kg/day PFOA for 28 days. The authors explored how activation of PPARα and suppression of the electron transport chain (ETC) sub-unit Complex I influenced ROS generation. Excluding the lowest male dose group, PFOA exposure significantly increased 8-OHdG levels in the liver, a key indicator of oxidative DNA damage. 8-OHdG levels were higher among dosed females compared to males, which authors suggest signals stronger genotoxicity in females. Authors explored the connection between the oxidative stress and apoptosis through the p53 signal pathway. Increases in p53 levels occurred in the same dose groups with elevated 8-OHdG, which authors suggest indirectly links oxidative stress to apoptosis. Authors posited that ROS hypergeneration led to increased 8-OHdG levels, and DNA damage then leads to increases in programmed cell death protein 5 (PDCD5), which activates
p53 to induce apoptosis. At 0.5 and 2.5 mg/kg/day, PFOA exposure decreased expression of electron transport chain (ETC) proteins, which corresponds to an increase in ROS generation and accumulation. For two ETC subunits, ACP and NDUV2, expression was increased, which also indicates an accumulation of ROS and an increase in antioxidant activity to counter ROS generation. At 0.05 mg/kg/day, female mice showed more oxidative stress than males. In these females, Complex I suppression drove ultimate apoptosis, while PPARα activation drove apoptosis among males.

Two studies examined changes in oxidative stress endpoints in male Kunming mice exposed to PFOA {Yang, 2014, 2850321; Liu, 2016, 3981762}, and an additional two studies evaluated oxidative stress endpoints in pregnant female Kunming mice and their pups {Li, 2019, 537402; Song, 2019, 5079965}. In the livers of male Kunming mice exposed to 2.5, 5, or 10 mg/kg/day PFOA for 14 days, MDA at all doses and H2O2 at 5 and 10 mg/kg/day levels were significantly increased compared to controls {Yang, 2014, 2850321}. Liu et al. (2016, 3981762) explored grape seed proanthocyanidn extract (GSPE) as a protective agent against PFOA damage in the liver. The authors reported significantly increased MDA and H2O2, significantly decreased Nrf2 protein levels, and significantly decreased SOD and CAT activity in the liver following PFOA exposure. Additionally, expression of SOD and CAT, measured via qRT-PCR, were significantly decreased in the livers of exposed mice. Li et al. (2019, 5387402) found that serum levels of SOD and 8-OHdG were significantly increased in pups of females dosed at 2.5, 5, and 10 mg/kg/day PFOA. Serum levels of CAT were increased at 5 and 10 mg/kg/day PFOA. PFOA-induced changes in SOD, CAT, and 8-OHdG reflect increased antioxidant activity in response to increased oxidative stress and increased DNA damage. In their study examining the protective effects of lycopene against PFOA-induced damage, Song et al. (2019, 5079965) exposed pregnant mice to 20 mg/kg/day PFOA via oral gavage from gestational days (GD) 1-7. After sacrifice on GD 9, levels of MDA were significantly increased in livers of pregnant mice treated with 20 mg/kg/day PFOA, while SOD and GSH-Ps levels were significantly decreased compared to controls, providing evidence of oxidative damage in the liver following PFOA exposure.

Three studies dosed C57Bl/6 mice with PFOA to study impacts on oxidative stress endpoints {Wen, 2019, 5080582; Crebelli, 2019, 5381564; Kamendulis, 2014, 5080475}. In male C57Bl/6 mice dosed with 28 mg/L PFOA, Crebelli et al. (2019, 5381564) found slightly decreased T-AOC, but the results were not statistically significant. MDA levels were below detection limits in all collected samples. Additionally, there was no statistically significant change in the levels of liver TBARS that would indication lipid peroxidation. Kamendulis et al. (2014, 5080475) exposed male C57Bl/6 mice to 5 mg/kg/day and found that PFOA exposure led to a 1.5-fold increase in 8-iso-PGF2α levels, a measure of lipid peroxidation that indicates oxidative damage. Additionally, PFOA led to a nearly 2-fold increase in mRNA levels of Sod1 in liver cells extracted from mice dosed at 2.5 and 5 mg/kg/day PFOA. mRNA levels of Sod2 and Cat were increased 3-fold and 1.3-fold, respectively. The same doses of PFOA also led to a nearly 2-fold increase in Nqo1 mRNA levels. The induction of genes for detoxifying enzymes following PFOA exposure suggests PFOA causes increased oxidative stress activity. In a different study {Wen, 2019, 5080582}, 1 and 3 mg/kg/day PFOA exposure in wild-type C57BL/6 NCr1 male mice increased gene expression of Nrf2 and Nqo1, measured via qRT-PCR assays, by 50-300%.

One gene expression compendium study aimed to examine the relationship between activation of xenobiotic receptors, Nrf2, and oxidative stress by comparing the microarray profiles in mouse
livers (strain and species not specified) {Rooney, 2019, 6988236}. The study authors compiled gene expression data from 163 chemical exposures found within Illumina’s BaseSpace Correlation Engine. Gene expression data for PFOA exposure was obtained from a previously published paper by Rosen et al. (2008, 1290832). In WT (129S1/SvlmJ) and Pparα-null male mice, Nrf2 activation was observed (as seen by increases in gene expression biomarkers) after a 7-day exposure to 3 mg/kg/day PFOA via gavage. Similar to Nrf2, CAR was also activated in both mouse strains after PFOA exposure. The authors proposed that CAR activation by chemical exposure (PFOA or otherwise) leads to Nrf2 activation, and that oxidative stress may be a mediator.

3.4.1.3.7.3 In Vitro Models
Rosen et al. (2013, 2919147) assessed oxidative stress-related gene expression changes using Taqman low density arrays (TLDA) in both mouse and human primary hepatocytes exposed to levels of PFOA ranging from 0-200 µM. PFOA exposure led to a decrease in the expression of the heme oxygenase 1 (Hmox1) gene in human primary hepatocytes. There were no changes observed in the nitric oxide synthase 2 (Nos2) gene nor in either gene in primary mouse hepatocytes.

Orbach et al. (2018, 5079788) examined the impacts of 500 µM PFOA exposure in multi-cellular organotypic culture models (OCM) of primary human and rat hepatocytes and in collagen sandwich (CS) models via high-throughput screening. In exposed rat and human cells, PFOA decreased GSH levels by <10%. The authors suggest that PFOA did not bind to or oxidize GSH. In human OCMs, mitochondrial integrity decreased 37% following PFOA exposure. In human CS models, the decrease was 39%. In rat OCMs, exposure decreased mitochondrial integrity by 47%, and by 45% in rat CS models.

In primary rat hepatocytes incubated with 100 µM PFOA for 24-hours, Liu et al. (2017, 3981337) found that intracellular oxidant intensity increased to more than 120% of control levels as measured by mean fluorescence intensity of 2’,7’-dichlorofluorescein (DCF). In addition, cells incubated with 6.25, 25, or 100 µM PFOA displayed significantly increased levels of mitochondrial superoxide, measured by MitoSOX fluorescence. In cells exposed to 100 µM PFOA, mitochondrial superoxide levels were elevated to 130% of those of controls. Authors suggest that these results indicate that mitochondrial superoxide is a more sensitive marker of oxidative stress than intracellular ROS levels.

Two studies examined oxidative stress endpoints following PFOA exposure in mitochondria isolated from Sprague Dawley rats {Mashayekhi, 2015, 2851019; Das, 2017, 3859817}. Mashayekhi et al. (2015, 2851019) examined oxidative damage in the mitochondria, an important organelle in the oxidative stress pathway, associated with PFOA exposure. In mitochondria isolated from the livers of male Sprague Dawley rats, significant increases in the percent ROS formation were observed following exposure to 0.75, 1, or 1.5 mM PFOA for up to 20 minutes. At 30 minutes and longer, significant increases were observed at the two highest concentrations only. Mashayekhi et al. (2015, 2851019) also observed significantly increased levels of ROS formation in complexes I and III of the mitochondrial respiratory chain, key sources of ROS production. Disruption to the chain can lead to accumulation of ROS and, ultimately, oxidative stress. In complex II, activity levels were significantly decreased at 0.75 and 1.5 mM PFOA exposure. There was no significant difference in MDA of GSH content in
liver mitochondria following PFOA exposure. PFOA exposure from 0.5-1.5 mM significantly decreased mitochondrial membrane potential and ATP levels and significantly increased mitochondrial swelling, suggesting a decrease in mitochondrial function following exposure to PFOA.

Xu et al. (2019, 5381556) exposed mouse hepatic primary cells from C57Bl/6J male mice to 0.01, 0.1, 0.5, or 1 mM PFOA for 24 hours. ROS levels, measured by a CM-H2DCFDA fluorescent probe, were significantly increased in cells exposed to 0.5 and 1 mM PFOA. Interestingly, SOD activity was significantly increased in cells exposed to 0.5 and 1 mM PFOA, up to 123% with 1 mM, while CAT activity was reduced to 7.7% in cells at the highest concentration. Increasing PFOA exposure also led to alterations in the structure of SOD, resulting in a significantly decreased percentage of α-helix structures (20%) and an increased percentage of β-sheet structures (29%), providing evidence of polypeptide chain unfolding and decreased helical stability. These structural changes suggest that PFOA interacts directly with SOD, resulting in polypeptide chain extension and, ultimately, diminished antioxidant capacity. Additionally, GSH content was increased by 177% and 405% in cells exposed to 0.5 mM and 1 mM PFOA, respectively. The authors suggest that increases in GSH may reflect cellular adaptations to oxidative stress and can lead to detoxification of oxidized GSSG to GSH.

Xu et al. (2020, 6316207) exposed cultured primary mouse hepatocytes to 0.01, 0.1, 0.5, or 1 mM of PFOA for 24 hours to examine oxidative stress-related apoptosis. The authors examined the impact of PFOA exposure on endogenous levels of lysozyme (LYZ), an enzyme that inhibits oxidative stress-induced damage, and demonstrated that PFOA exposure impacted LYZ molecular structure, subsequently decreasing activity levels, leading to oxidative stress-induced apoptosis. Decreases in peak intensity at 206 nm during ultraviolet-visible (UV-vis) absorption spectrometry represented an unfolding of the LYZ molecule following exposure to PFOA, which inhibited enzyme activity. At concentrations of 100 µM and above, LYZ enzyme activity decreased to 91% of control levels. Such an impact on LYZ activity was deemed to be related to the high affinity of PFOA for key central binding sites on the LYZ molecule.

In human HL-7702 liver cells, 24 hours of PFOA exposure at 1, 2.5, or 7.5 µg/mL led to a dose-dependent increase in 8-OHdG levels in cells exposed to the two highest concentrations {Li, 2017, 4238518}. The authors noted that DNA damage, which frequently accompanies increases in 8-OHdG, was observed in their in vivo models following PFOA exposure, suggesting increased oxidative stress following exposure. In human non-tumor hepatic cells (L-02) exposed to 25 or 50 mg/L PFOA for 72 hours, Huang et al. (2013, 2850934) observed concentration-dependent increases in ROS levels measured via DCFH-DA fluorescent probe, evidence of the role of PFOA in inducing oxidative stress.

Six additional studies examined oxidative stress endpoints following PFOA exposure in HepG2 cell lines {Wan, 2016, 3981504; Wielsøe, 2015, 2533367; Shan, 2013, 2850950; Florentin, 2011, 2919235; Panaretakis, 2001, 5081525; Yan, 2015, 3981567}. Four studies reported increases in ROS levels following PFOA exposure {Wan, 2016, 3981504; Wielsøe, 2015, 2533367; Panaretakis, 2001, 5081525; Yan, 2015, 3981567}, while two studies did not observe statistical differences in ROS levels following 1- or 24-hour PFOA exposures up to 400 µM {Florentin, 2011, 2919235} or following 3-hour PFOA exposures up to 400 µM {Shan, 2013, 2850950}.
Wielsøe et al. (2015, 2533367) incubated HepG2 cells with up to 2 x 10^-4 M PFOA to detect changes in ROS, T-AOC, and DNA damage. PFOA exposure significantly increased ROS production, as measured with the carboxy-H2DCFDA, and significantly decreased T-AOC at all concentrations by 0.70–0.82-fold compared to controls. Additionally, PFOA induced DNA damage, specifically, increased mean percent tail intensity, an indicator of strand breaks, measured via comet assay. In cells exposed up to 400 µM PFOA for up to 24 hours, Panaretakis et al. (2001, 5081525) observed increased ROS levels, measured via DCFH-DA and dihydroethidium fluorescent probes, following 3 hours PFOA exposure. H2O2 levels were detectable in 91% and 98% of the cell population at 200 and 400 µM PFOA, respectively. Additionally, superoxide anion levels were detectable in 43% and 71% of cells exposed to 200 and 400 µM PFOA, respectively. Authors reported evidence of depolarized mitochondrial membranes in cells exposed up to 24 hours. Yan et al. (2015, 3981567) observed significantly increased ROS levels in cells incubated with 100 and 200 µM PFOA for 24 hours, but no changes were observed in superoxide anion levels. After 72 hours of exposure, however, ROS levels decreased at those concentrations, with statistically significant results observed at 200 µM PFOA. Activity levels of SOD and CAT were not altered in exposed cells compared to controls, nor were MDA or GSH contents. Similarly, in HepG2 cells treated with PFOA for 24 hours, Yan et al. (2015, 3981567) found ROS levels significantly increased, but no significant changes were observed in SOD and CAT activity or MDA and GSH levels. Yarahalli Jayaram et al. (2018, 5080662) examined the impacts of PFOA exposure on oxidative stress endpoints and small ubiquitin-like modifiers (SUMO), which play a key role in posttranslational protein modifications. SUMOylation of a protein has been identified as a key part of the oxidative stress pathway. In cells incubated with 250 µM PFOA, ROS levels were significantly increased. Cells incubated with PFOA also showed increased levels of nitric oxide (NO). Additionally, expression levels of genes related to SUMOylation were measured. PFOA treatment significantly increased levels of SUMO2 in HepG2 cells, but did not impact SUMO1, SUMO3, or UBC9 mRNA levels.

In cells exposed to 10 and 200 µM PFOA for 24 hours, Florentin et al. (2011, 2919235) observed significant increases in the percentage of DNA tails, an indicator of DNA damage measured via comet assay. However, no such changes were observed at the 1-hour time point or at other concentrations (5, 50, 100, or 400 µM) after 24 hours. Additionally, no significant changes in ROS generation were observed. Shan et al. (2013, 2850950) exposed HepG2 cells to 100 µM PFOA for 3 hours and found an increase in ROS generation, though the effect was not statistically significant. Additionally, no changes were observed in the GSH/GSSG ratio.

In two cell lines derived from Hepa1c-1c7 mouse cells, CR17 and HepaV cells, Melnikov et al. (2018, 5031105) found that Hmox1 gene expression was significantly decreased in cells exposed to PFOA for 24 hours compared to controls. Additionally, exposed HepaV cells showed significantly decreased expression of Gclc and Gclm. There were no significant changes in GSH levels after exposure to 100 µM PFOA for 24 hours. CR17 cells have increased glutamate-cysteine ligase (GCL) activity, leading to increased GSH content. Authors anticipated that the elevated GSH levels in the CR17 cell line would better resist PFOA toxicity. They concluded that the observed changes in gene expression in PFOA exposed HepaV cell lines, but not in CR17 cell lines, supported this hypothesis.
Sun et al. (2019, 5024252) examined the impacts of PFOA exposure on both a monolayer and a scaffold-free three-dimensional spheroid model of mouse liver cells (AML12). Monolayer cells were exposed to 6.25-2,000 µM PFOA for 24 and 72 hours. The spheroid cell model was exposed to 50, 100, and 200 µM PFOA for up to 28 days. In monolayer cells exposed to 200 µM PFOA for 72 hours, ROS levels, measured via an ROS-Glo assay kit, increased 1.6-fold compared to controls. In the spheroid cell models, however, ROS levels decreased in cells exposed to 100 and 200 µM PFOA for 24 and 72 hours, which authors report suggests that monolayer cells demonstrate higher PFOA toxicity due to the absence of an endogenous extracellular matrix with the potential to inhibit PFOA diffusion. After 14 days of exposure, ROS levels in spheroid cells significantly increased at all concentrations. Gene expression of glutathione S-transferases alpha 2 (Gsta2), Nqo1, and Ho-1 increased with increasing PFOA concentration and duration of exposure, which provides additional evidence of PFOA’s effect on oxidative stress.

3.4.1.3.7.4 Conclusions

Results from new studies published since the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} further support the 2016 conclusions that PFOA can cause oxidative stress and related cellular damage. Evidence of increased oxidative stress in the liver, including increased ROS levels, changes in GSH and GSSG levels, and decreases in T-AOC, was observed following both in vivo and in vitro exposures to PFOA. PFOA exposure was also associated with increased levels of markers of oxidative damage and decreased activity or levels of protective antioxidants that play a role in the reduction of oxidative damage. There was also evidence that PFOA can disrupt the structure and subsequent function of crucial enzymes that mitigate ROS production and oxidative damage, SOD and LYZ. While further research is needed to understand the underlying mechanisms of PFOA-induced oxidative stress responses, it is clear that PFOA induces oxidative stress in hepatic tissues.

3.4.1.4 Evidence Integration

There is moderate evidence for an association between PFOA exposure and hepatic effects in humans based on associations with liver biomarkers, especially ALT, in several medium confidence studies. Across the studies in the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} and this updated systematic review, there is consistent evidence of a positive association between exposure to PFOA and ALT in adults. An exposure-response gradient observed in one medium quality study that examined categorical exposure in adults {Darrow, 2016, 3749173} increases certainty in the association. These associations were observed in studies of the general population, in communities with high exposure in water due to contamination events, and in occupational studies. Consistency in the direction of association across these different population sources increases certainty in the results and reduces the likelihood that they can be explained by confounding across PFAS. For example, studies in communities with high exposure in water and occupational participants are less susceptible to potential confounding from other PFAS due to PFOA exposure predominating over other PFAS. In addition, the single general population that performed multi-pollutant modeling {Lin, 2010, 1291111} found no attenuation of the association, further increasing confidence in the association between PFOA exposure and increased ALT. The positive associations with ALT are also supported by the recent meta-analysis of 25 studies in adolescents and adults {Costello, 2022, 10285082}. Associations for
other hepatic outcomes were less consistent, including for functional outcomes such as liver disease. This may be due to a relative lack of high confidence studies of these outcomes.

The animal evidence for an association between PFOA exposure and hepatic toxicity is robust based on 25 high or medium confidence animal toxicological studies. However, it is important to distinguish between alterations that may be non-adverse (e.g., hepatocellular hypertrophy alone) and those that indicate functional impairment or lesions (U.S. EPA, 2002, 625713; FDA, 2009, 6987952; EMEA, 2010, 3056796; Hall, 2012, 2718645). EPA considers responses such as increased relative liver weight and hepatocellular hypertrophy adverse when accompanied by hepatotoxic effects such as necrosis, inflammation, or biologically significant increases in enzymes indicative of liver toxicity (U.S. EPA, 2002, 625713). Many of the studies discussed in this section reported dose-dependent increases in liver weight and hepatocellular hypertrophy in rodents of both sexes. However, a limited number of these studies additionally examined functional or histopathological hepatic impairment to provide evidence that the enlargement of hepatic tissue was an adverse, and not adaptive, response {Minata, 2010, 1937251; Yan, 2014, 2850901; Crebelli, 2019, 5381564; Guo, 2019, 5080372; Blake, 2020, 6305864; Loveless, 2008, 7330145; NTP, 2020, 7330145}.

EPA identified the following studies as providing the most comprehensive evidence of dose-dependent hepatotoxicity resulting from oral PFOA exposure: a chronic dietary study in male and female Sprague Dawley rats {NTP, 2020, 7330145} (see study design details in Section 3.4.4.2.1.2); a developmental study in male and female CD-1 mice {Cope, 2021, 10176465}; and a 29-day oral gavage study in male rats and mice {Loveless, 2008, 988599}. NTP (2020, 7330145) conducted histopathological examinations of liver tissue in male and female rats and reported dose-dependent increases in the incidence of hepatocellular hypertrophy and hepatocellular cytoplasmic vacuolation, as well as increases in the incidence of hepatocellular single cell death and hepatocellular necrosis at the same dose levels. Cope et al. (2021, 10176465) also provides evidence of hepatic lesions in adult male and female CD-1 mice offspring exposed gestationally from GD 1.5–17.5. When the offspring were weaned, they were placed on a low- or high-fat diet. At 18 weeks there were increases in the incidence and severity of hepatocellular single cell death in females on either the low- or high-fat diets and males on the low-fat diet. Loveless et al. (2008, 988599) similarly provides concurrent evidence of liver enlargement and hepatic lesions in male mice gavaged with PFOA for 29 days. Increases in the incidence and severity of hepatocellular hypertrophy and individual cell or focal cell necrosis were dose-dependent. Similar to the NTP (2020, 7330145) study, Loveless et al. (2008, 988599) provides a comprehensive report of hepatotoxicity, with a low dose range resulting in dose-dependent increases in histopathological outcomes indicating adversity.

An important element of understanding the underlying mechanism(s) of toxicity is species-specificity and relevance of data collected from laboratory models in relation to observed human effects as well as in consideration of human hazard. There are several studies that have proposed potential underlying mechanisms of the hepatotoxicity observed in rodents exposed to PFOA, such as induction of hepatocytic proliferation leading to hypertrophy or nuclear receptor activation leading to lipid droplet accumulation and steatosis. Generally, mechanistic evidence supports the ability of PFOA to induce hepatotoxicity which may explain elevated serum ALT levels in humans (and animals). However, mechanistic studies did not specifically relate (or, “anchor”) mechanistic data with serum ALT levels in animals, and challenges exist in the
extrapolation of evidence for PFOA-mediated changes in rodents to humans. For example, there is substantial evidence that PFOA-induced liver toxicity, specifically alterations to lipid metabolism and accumulation, occurs via the activation of multiple nuclear receptors, including PPARα. Activation of PPARα by PFOA has been demonstrated in multiple studies across various model systems, both in vivo and in vitro. Several studies examined the activation of PPARα in vitro in both human and animal cell lines transfected with mouse and human PPARα using luciferase reporter assays, the results of which demonstrate that PFOA can activate human PPARα in vitro. In addition to PPARα, evidence also exists indicating that PFOA can activate CAR, PXR, PPARγ, ERα, and HNFα, as evidenced by receptor activation assays as well as changes in target genes of these receptors. PFOA showed the highest potency for PPARα in comparison to PPARγ and PPARδ, although PFOA did activate these receptors at concentrations of 100 μM (compared to 25 μM for PPARα). Like PPARα, PPARγ and CAR are known to play important roles in liver homeostasis, and dysregulation of these nuclear receptors can lead to steatosis and liver dysfunction, potentially presenting an important mechanism for the liver effects observed in rodent studies. Beyond receptor activation assays, individual target genes that represent reliable markers of CAR and PPARα activation (e.g., Cyp2b1 and Cyp4a1, respectively) have been clearly demonstrated to be altered by PFOA, and changes to these nuclear receptors have important implications in regard to hepatotoxicity, specifically steatosis. PPARα has vastly different expression in rodents compared to humans, and this species difference is known to play a major role in differences in liver effects between the two species. PPARα is the most demonstrated nuclear receptor to be activated by PFOA, and it should be noted that using PPARα-null mice to study PPARα-independent effects of PFOA may lead to compensatory mechanisms involving other nuclear receptors.

Another example of species-specificity for an effect of PFOA is the presence or absence of a transfer protein that is important in cholesterol accumulation, CETP, which is expressed in humans but not in rodents. Transgenic mice that express human CETP exhibit a more human-like lipoprotein metabolism. Laboratory models that are designed to better predict human-relevant mechanisms, such as mice expressing human CETP or PPARα, will continue to aid in accuracy of the extrapolation of mechanistic findings in rodents to humans. Despite these challenges, the evidence that PFOA leads to hepatotoxicity via activation of hepatic nuclear receptors and dysregulation of lipid metabolism and accumulation is clear.

When considering the evidence from both in vivo and in vitro studies, PFOA-mediated hepatotoxicity specific to changes in lipid metabolism leading to steatosis, the most commonly reported hepatocytic morphological alteration in PFOA-exposed animals, likely occurs through the following molecular and cellular events: (1) PFOA accumulation in liver activates nuclear receptors, including PPARα; (2) expression of genes involved in lipid homeostasis and metabolism is altered by nuclear receptor activation; (3) gene products (translated proteins) modify the lipid content of liver to favor triglyceride accumulation and potentially cholesterol accumulation; (4) altered lipid content in the liver leads to accumulation of lipid droplets, which can lead to the development of steatosis and liver dysfunction; and (5) alterations in lipid metabolism lead to alterations in serum levels of triglycerides and cholesterol. Although individual studies have not demonstrated every step of this proposed process, each event has been demonstrated for PFOA, including steatosis in PFOA-exposed animals. It has also been suggested that PFOA could interfere with fatty acid biosynthesis by binding to the Acetyl-CoA carboxylase 1 and Acetyl-CoA carboxylase 2 enzymes; however, only a single study has
demonstrated such a binding event and further research is needed to understand the plausibility of this binding occurring across species and exposure scenarios.

In addition (and potentially related) to the abundance of evidence related to hepatic nuclear receptors, PFOA also alters apoptosis and cell proliferation in the liver. Specifically, PFOA exposure at high doses causes apoptosis through a cascade of mechanisms including activation of caspase activity, intracellular release of LDH, induction of apoptotic genes, morphological changes to the mitochondria membrane, autophagy, and activation of the p53 mitochondria pathway. PFOA has been shown to induce hepatocytic proliferation at low doses by disrupting cell cycle progression, leading to steatosis, hepatomegaly, and liver dysfunction in general.

There are other mechanisms that may be involved in PFOA-induced hepatotoxicity, but the evidence for such is limited and the relevance to liver outcomes is less clear. These include hormone perturbation, inflammatory response, and oxidative stress. There are very limited data demonstrating the potential of PFOA to perturb hormone balance, particularly related to thyroid function. There are also a limited number of studies that reported inflammation in the liver, including changes in cytokine levels and the expression of genes involved in innate immunity. PFOA can cause oxidative stress in the liver, as demonstrated by standard indicators of oxidative stress including increased ROS levels, changes in GSH and GSSG levels, and decreased total antioxidant capacity in both *in vivo* and *in vitro* exposures to PFOA. The direct relevance of oxidative stress to liver pathology induced by PFOA requires further study, but it is clear that PFOA can cause oxidative stress. These other mechanisms that have a limited evidence base may also occur in relation to the more well-characterized mechanisms of PFOA-induced hepatotoxicity. For example, while the role of alterations in adaptive immunity in PFOA-induced liver pathology is not clear, it is plausible that the inflammatory response is related to fatty liver and associated liver dysfunction, such as the liver outcomes observed in humans and rodents, that can occur via nuclear receptor-mediated pathways.

3.4.1.4.1 Evidence Integration Judgment

Overall, considering the available evidence from human, animal, and mechanistic studies, the evidence indicates that PFOA exposure is likely to cause hepatotoxicity in humans under relevant exposure circumstances (Table 3-3). This conclusion is based primarily on coherent liver effects in animal models following exposure to doses as low as 0.3 mg/kg/day PFOA. In human studies, there is consistent evidence of a positive association with ALT in adults, at median PFOA levels as low as 1.3 ng/mL. The available mechanistic information provides support for the biological plausibility of the phenotypic effects observed in exposed animals as well as the activation of relevant molecular and cellular pathways across human and animal models in support of the human relevance of the animal findings.
### Table 3-3. Evidence Profile Table for PFOA Hepatic Effects

<table>
<thead>
<tr>
<th>Evidence Stream Summary and Interpretation</th>
<th>Evidence from Studies of Exposed Humans (Section 3.4.1.1)</th>
<th>Evidence Integration Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Studies and Interpretation</strong></td>
<td></td>
<td>⚫⚫⚫ Evidence Indicates (likely)</td>
</tr>
<tr>
<td><strong>Summary and Key Findings</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Factors that Increase Certainty</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Factors that Decrease Certainty</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Evidence Stream Judgment</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Serum biomarkers of hepatic injury**

9 *Medium* confidence studies

4 *Low* confidence studies

Studies in adults consistently reported significant increases in ALT (5/7). Findings for AST and GGT in adults were generally positive (3/6). Some studies reported conflicting or non-significant associations, however, these were mostly of low confidence. Findings for liver enzymes in children were mixed and different by sex at times.

- **Medium confidence studies**
- **Consistent direction of effect for ALT in both the 2016 epidemiological studies and the updated literature**
- **Coherence of findings between liver enzyme increases**

- **Low confidence studies**
- **Inconsistent direction of effect in children**

Evidence for hepatic effects is based on increases in ALT in adults. Supporting evidence includes increases in other liver enzymes such as AST and GGT and increased incidence of liver disease mortality in occupational settings. Minor uncertainties remain regarding mixed liver enzyme findings in children and coherence of liver enzyme and albumin findings.

**Liver disease or injury**

4 *Medium* confidence studies

2 *Low* confidence studies

A limited number of studies examined liver disease or injury in general population adults. One study reported increased risk of liver disease (1/2) but was of low confidence, whereas the only medium confidence study reported no significant association. The only occupational study reported significantly higher mortality from liver cancer or cirrhosis compared to the general population. Other measures of

- **No factors noted**
- **Association only observed in Low confidence studies**
- **Incoherence of findings among measures of liver inflammation**

Evidence for hepatic injury is based on consistent evidence of hepatoxicity as noted by increased serum biomarkers of hepatic injury (primarily ALT) with coherent results for increased incidence of hepatic nonneoplastic lesions, increased liver weight, and elevated serum biomarkers of hepatic injury in animal models. Although a few associations between other serum biomarkers of hepatic injury and PFOA exposure were identified in medium confidence epidemiological studies, there is considerable uncertainty in the results due to inconsistency across studies.

*Human relevance and other inferences:*
## Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Serum protein</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medium confidence studies</td>
<td>Significant increases in albumin were consistently observed in adults (4/5).</td>
<td>• Medium confidence studies</td>
<td>• Low confidence studies</td>
<td></td>
</tr>
<tr>
<td>Low confidence studies</td>
<td>Findings for total serum protein and fibrinogen were mixed or imprecise.</td>
<td>• Consistent direction of effect for albumin</td>
<td>• Imprecision of findings</td>
<td></td>
</tr>
<tr>
<td><strong>Serum iron</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medium confidence study</td>
<td>Only one large cross-sectional study examined serum iron concentrations and reported a significant positive association.</td>
<td>• Medium confidence study</td>
<td>• Limited number of studies examining outcome</td>
<td></td>
</tr>
</tbody>
</table>

*The available mechanistic information overall provide support for the biological plausibility of the phenotypic effects observed in exposed animals as well as the activation of relevant molecular and cellular pathways across human and animal models in support of the human relevance of the animal findings.*
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histopathology</strong></td>
<td></td>
<td></td>
<td></td>
<td>☀️☀️☀️ Robust</td>
</tr>
<tr>
<td>3 High confidence studies</td>
<td>Histopathological alterations in liver were observed in male and female rodents exposed to PFOA for various durations (12/12). Increased hepatocellular hypertrophy (8/12) and necrosis (5/12) were the most common lesions. Other lesions included inflammation or cellular infiltration (4/12), cytoplasmic alteration or vacuolation (3/12), mitosis or mitotic figures (3/12), bile duct hyperplasia (2/12), cystic/cystoid degeneration (2/12), fatty change (2/12), and/or pigment (1/12).</td>
<td>• High and medium confidence studies</td>
<td>• No factors noted</td>
<td>Evidence is based on 26 high or medium confidence animal toxicological studies indicating increased incidence of hepatic nonneoplastic lesions, increased liver weight, and elevated serum biomarkers of hepatic injury. However, it is important to distinguish between alterations that may be non-adverse (e.g., hepatocellular hypertrophy alone) and those that indicate functional impairment or lesions. EPA considers responses such as increased relative liver weight and hepatocellular hypertrophy adverse when accompanied by hepatotoxic effects such as necrosis, inflammation, or biologically significant (i.e., greater than 100% change) increases in enzymes indicative of hepatobiliary damage. Many of the studies</td>
</tr>
<tr>
<td>9 Medium confidence studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Liver weight</strong></td>
<td>Absolute (17/19) and relative (17/20) liver weights were increased in male and female rodents exposed to PFOA for various durations. Several</td>
<td>• High and medium confidence studies</td>
<td>• Confounding variables such as decreases in body weights</td>
<td></td>
</tr>
<tr>
<td>5 High confidence studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19 Medium confidence studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studies that included both males and females suggested that males may be more sensitive than females (4/7).</td>
<td></td>
<td>design, sex, and species</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Dose-dependent response
- Coherence of effects with other responses indicating increased liver size (e.g., hepatocellular hypertrophy)

- High and medium confidence studies
- Consistent direction of effects across study design, sex, and species
- Dose-dependent response
- Coherence of findings with other responses indicating hepatobiliary damage (i.e., histopathological lesions)
- Large magnitude of effect, with evidence of biologically significant increases (i.e., ≥100% control responses) in serum liver enzymes indicating adversity

#### Serum biomarkers of hepatic injury

| 3 High confidence studies | Increases were observed in ALT (6/9), AST (6/7), ALP in (4/6), and GGT (1/1). Biologically significant changes (≥100%) in an enzyme level were observed in 6/9 studies. Albumin (5/6) and albumin/globulin ratio (3/3) were increased. Bile acids were increased in males (4/4) and unchanged in females (3/3). Inconsistent changes in bilirubin were observed with direct bilirubin increased in males (2/2) or females (0/1), increased indirect bilirubin in males (1/1), and mixed effects on total bilirubin in males (2) and transient effects in females (1). Total protein was decreased in males (3/5) and females (1/4). | Limited number of studies examining specific outcomes | discussed in this section reported dose-dependent increases in liver weight and hepatocellular hypertrophy in rodents of both sexes. Although a limited number of these studies additionally examined functional or histopathological hepatic impairment, several provide evidence of adverse hepatic responses. |
### Mechanical Evidence and Supplemental Information (Section 3.4.1.3)

<table>
<thead>
<tr>
<th>Biological Events or Pathways</th>
<th>Summary of Key Findings, Interpretation, and Limitations</th>
<th>Evidence Stream Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular initiating events - PPARα</td>
<td>Key findings and interpretation:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Activation of human PPARα in vitro.</td>
<td>Overall, studies in rodent and human in vitro and in vivo models suggest that PFOA induces hepatic effects, at least in part, through PPARα. The evidence also suggests a role for PPARα-independent pathways in the MOA for noncancer liver effects of PFOA.</td>
</tr>
<tr>
<td></td>
<td>• Increased expression of PPARα-target genes in vitro in rat and human hepatocytes, and cells transfected with rat or human PPARα.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Altered expression of genes involved in lipid metabolism and lipid homeostasis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Limitations:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Increased hepatic lipid content has also been reported for PFOA in the absence of a strong PPARα response.</td>
<td></td>
</tr>
<tr>
<td>Molecular or cellular initiating events – other pathways</td>
<td>Key findings and interpretation:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Increased apoptosis is a high dose effect demonstrated in vivo, as well as in vitro, occurring through a cascade of mechanisms:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>o activation of caspase activity, intracellular release of LDH, induction of apoptotic genes, morphological changes to the mitochondria membrane, autophagy, and activation of p53 mitochondria pathway.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Inflammation of the liver (e.g., changes in cytokine levels and the expression of genes involved in innate immunity) has been reported in a limited number of studies.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Induction of oxidative stress in vivo and in vitro, including increased ROS levels, changes in GSH and GSSG levels, and decreased total antioxidant capacity.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Indirect evidence of activation of alternative pathways, including activation of other nuclear receptors, primarily CAR and PPARγ, following observations in knockout or humanized PPARα mice.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Limitations:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The direct relevance of oxidative stress to liver pathology induced by PFOA requires further study.</td>
<td></td>
</tr>
<tr>
<td>Studies and Interpretation</td>
<td>Summary and Key Findings</td>
<td>Factors that Increase Certainty</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

_Notes: ALP = alkaline phosphatase; ALT = alanine transaminase; AST = aspartate transaminase; CAR = constitutive androstane receptor; EPA = Environmental Protection Agency; GGT = gamma-glutamyl transferase; GSH = glutathione; GSSG = glutathione disulfide; LDH = lactate dehydrogenase; MOA = mode of action; PPARγ = peroxisome proliferator-activated receptor gamma; PPARα = peroxisome proliferator-activated receptor alpha; ROS = reactive oxygen species._
3.4.2 Immune

EPA identified 49 epidemiological and 13 animal toxicological studies that investigated the association between PFOA and immune effects. Of the epidemiological studies, 1 was classified as high confidence, 28 as medium confidence, 12 as low confidence, 6 as mixed (6 medium/low) confidence, and 2 were considered uninformative (Section 3.4.2.1). Of the animal toxicological studies, 3 were classified as high confidence, 9 as medium confidence, and 1 was considered mixed (medium/low) confidence (Section 3.4.2.2). Studies have mixed confidence ratings if different endpoints evaluated within the study were assigned different confidence ratings. Though low confidence studies are considered qualitatively in this section, they were not considered quantitatively for the dose-response assessment (Section 4).

3.4.2.1 Human Evidence Study Quality Evaluation and Synthesis

3.4.2.1.1 Immunosuppression

Immune function—specifically immune system suppression—can affect numerous health outcomes, including risk of common infectious diseases (e.g., colds, influenza, otitis media) and some types of cancer. The WHO guidelines for immunotoxicity risk assessment recommend measures of vaccine response as a measure of immune effects, with potentially important public health implications {WHO, 2012, 9522548}.

There are 11 epidemiological studies from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA and immune effects. Study quality evaluations for these 11 studies are shown in Figure 3-18.
Three studies reported decreases in response to one or more vaccines in relation to higher PFOA exposure in children {Grandjean, 2012, 1248827; Granum, 2013, 1937228} and adults {Looker, 2014, 2850913}. Antibody responses for diphtheria and tetanus in children (n = 587) were examined at multiple timepoints in a study on a Faroese birth cohort {Grandjean, 2012, 1248827}. Prenatal and age five serum PFOA concentrations were inversely associated with...
childhood anti-diphtheria antibody response at all measured timepoints, and the association was significant for anti-diphtheria antibody response at age seven in separate models for prenatal and age five serum PFOA concentrations. The association was less pronounced when examining anti-tetanus antibody responses in relation to prenatal PFOA measurements, but the anti-tetanus antibody response (age seven) was significantly decreased in relation to PFOA measured in child serum at five years of age. Prenatal PFOA exposure was associated with diminished vaccine response in a different birth cohort study {Granum, 2013, 1937228}. Decreases in the anti-rubella antibody response (age seven) was significantly decreased in relation to PFOA measured in child serum at five years of age. Prenatal PFOA exposure was associated with diminished vaccine response in a different birth cohort study {Grandjean, 2013, 1248827}. Decreases in the anti-rubella antibody response were significantly associated with elevated prenatal PFOA concentrations among three-year-old children. A C8 Health Project study examining influenza vaccine responses in highly exposed adults {Looker, 2014, 2850913} observed that pre-vaccination PFOA concentrations were inversely associated with GM A/H3N2 antibody titer rise, but no association was found with antibody titers for A/H1N1 and influenza type B. In the studies of children, there was concern that the associations were also seen with other correlated PFAS, but this was not considered a limitation in the study in adults, which was conducted in a population with known high PFOA exposure (the C8 Health Project study).

Associations between prenatal PFOA exposure and risk of infectious diseases (as a marker of immune suppression) were not seen in one study, although there was some indication of effect modification by gender (i.e., associations seen in females but not in males). Fei et al. (2010, 1290805) examined hospitalizations for infectious diseases in early childhood in a Danish birth cohort with mean maternal PFOA concentration of 0.0056 μg/mL. A slightly higher risk for hospitalizations was observed in females whose mothers had higher PFOA concentrations (incidence rate ratio [IRR] = −1.20, 1.63, 1.74 for quartile 2 [Q2], quartile 3 [Q3], and quartile 4 [Q4], respectively compared with quartile 1 [Q1]; see PFOA Appendix), and the risk for males was below 1.0 for each quartile. Overall, there was no association between hospitalizations due to infectious diseases and maternal PFOA exposure.

Overall, the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} found consistent evidence of an association between PFOA exposure and immunosuppression.

3.4.2.1.2 Immunosuppression Study Quality Evaluation and Synthesis from the Updated Literature Review

There are 26 epidemiological studies identified from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated associations between prenatal, childhood, or adult PFOA exposure and immunosuppression since publication of the 2016 PFOA HESD. Study quality evaluations for these 26 studies are shown in Figure 3-19 and Figure 3-20.

One study from the 2016 assessment {Grandjean, 2012, 1248827} was updated during this period, and the update was included in the systematic review {Grandjean, 2017, 3858518}. 
Figure 3-19. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Immunosuppression Effects

Interactive figure and additional study details available on HAWC.
High and medium confidence studies were the focus of the evidence synthesis for endpoints with numerous studies, though low confidence studies were still considered for consistency in the direction of association (and details are provided in PFOA Appendix). For endpoints with fewer studies, the evidence synthesis below included details on any low confidence studies available. Studies considered uninformative were not considered further in the evidence synthesis.
3.4.2.1.2.1 Vaccine Response

Nine studies (ten publications)\(^{11}\) studied the relationship between antibody response to vaccination and PFOA exposure. Five of these studies (six publications) investigated antibody response to vaccination in children {Timmermann, 2020, 6833710; Abraham, 2020, 6506041; Grandjean, 2017, 3858518; Mogensen, 2015, 3981889; Grandjean, 2017, 4239492; Timmermann, 2021, 9416315}. In adults, two studies investigated antibody response to diphtheria and tetanus {Kielsen, 2016, 4241223; Shih, 2021, 9959487}, one study investigated hepatitis vaccine response {Shih, 2021, 9959487}, one study investigated adult flu vaccine response {Stein, 2016, 3860111}, and one study measured antibody response to measles vaccination in children at birth, 18 months, age 5 years (pre-and post-booster), and at age 7 years, with some being statistically significant. These studies measured PFOA exposure levels in maternal blood during the perinatal period and at later time periods from children (at ages 5, 7, and 13 years). There are a few results in the opposite direction for sub-analyses of the Faroe Island cohorts {Grandjean, 2017, 3858518; Grandjean, 2017, 4239492}, such as maternal PFOA exposure and anti-tetanus antibodies at 7 years (Table 3-4 and the Appendix).

Of the studies that measured antibody response to vaccination in children, four studies were cohorts {Timmermann, 2020, 6833710; Grandjean, 2017, 3858518; Grandjean, 2017; 4239492; Mogensen, 2015, 3981889}, and two were cross-sectional {Abraham, 2020, 6506041; Timmermann, 2021, 9416315} (maternal serum was also available for a subset of participants in Timmermann et al. (2021, 9416315)). These included multiple prospective birth cohorts in the Faroe Islands, one with enrollment in 1997–2000 and subsequent follow-up to age 13 {Grandjean, 2017, 3858518} and one with enrollment in 2007–2009 and follow-up to age five {Grandjean, 2017, 4239492}. One additional cohort in the Faroe Islands examined outcomes in adults with enrollment in 1986–1987 and follow-up to age 28 {Shih, 2021, 9959487}. Five of these studies measured antibody response to tetanus vaccination {Abraham, 2020, 6506041; Grandjean, 2017, 3858518; Grandjean, 2017; 4239492; Mogensen, 2015, 3981889; Timmermann, 2021, 9416315}; the same studies also measured antibody response to diphtheria vaccination; one study measured antibody response to measles vaccination {Timmermann, 2020, 6833710}, and one study to Haemophilus influenza type b (Hib) antibodies {Abraham, 2020, 6506041}.

The results for this set of studies in children are shown in Table 3-4 and the Appendix (see PFOA Appendix). The Faroe Islands studies {Grandjean, 2017, 3858518; Grandjean, 2017; 4239492; Mogensen, 2015, 3981889} observed associations between higher levels of PFOA and lower antibody levels against tetanus and diphtheria in children at birth, 18 months, age 5 years (pre-and post-booster), and at age 7 years, with some being statistically significant. These studies measured PFOA exposure levels in maternal blood during the perinatal period and at later time periods from children (at ages 5, 7, and 13 years). There are a few results in the opposite direction for sub-analyses of the Faroe Island cohorts {Grandjean, 2017, 3858518; Grandjean, 2017, 4239492}, such as maternal PFOA exposure and anti-tetanus antibodies at 7 years (Table 3-4 and the Appendix).

---

\(^{11}\) Multiple publications of the same study: the study populations are the same in Grandjean et al. (2017, 3858518) and Mogensen et al. (2015, 3981889).
3-4). No biological rationale has been identified as to whether one particular time period or duration of exposure or outcome measurement is more sensitive to an overall immune response to PFOA exposure.

It is plausible that the observed associations between decreased antibody concentration and PFOA exposure observed in the Faroe Islands cohort could be partially explained by confounding across the PFAS (e.g., exposure levels to PFOS were higher than PFOA (PFOS 17 ng/mL, PFOA 4 ng/mL); there was a moderately high correlation between PFOA and PFOS, PFHxS, and PFNA (0.50, 0.53, 0.54, respectively) \{Grandjean, 2017, 3858518; Grandjean, 2017, 4239492\}). To investigate this, the authors assessed the possibility of confounding in a follow-up paper {Budtz-Jorgensen, 2018, 5083631}. In these analyses, estimates were adjusted for PFOS and there was no notable attenuation of the observed effects. The other available studies did not perform multipollutant modeling, so it is difficult to determine the potential for highly correlated PFAS to confound the effect estimates. However, as described above, one study \{Looker, 2014, 2850913\} observed an association with PFOA in a population where PFOA exposure predominated (the C8 Health Project population), and this is not likely to be confounded by other PFAS. Overall, the available evidence suggests that confounding is unlikely to explain the observed effects.

![Figure 3-21. Overall Tetanus Antibody Levels in Children from Epidemiology Studies Following Exposure to PFOA](image-url)

Interactive figure and additional study details available on Tableau.
Figure 3-22. Overall Tetanus Antibody Levels in Children from Epidemiology Studies Following Exposure to PFOA (Continued)

Interactive figure and additional study details available on Tableau.

Grandjean et al., 2012 was reviewed as a part of the 2016 HESD
Figure 3-23. Overall Diphtheria Antibody Levels in Children from Epidemiology Studies Following Exposure to PFOA

Interactive figure and additional study details available on Tableau.
Grandjean et al., 2012 was reviewed as a part of the 2016 HESD
Table 3-4. Associations between PFOA Exposure and Vaccine Response in Faroe Islands Studies

<table>
<thead>
<tr>
<th>Exposure measurement timing, PFOA levels (ng/mL)</th>
<th>Diphtheria Antibody Associations with PFOA by Age at Assessment</th>
<th>Tetanus Antibody Associations with PFOA by Age at Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 years (Pre-Booster) (C3 and/or C5)</td>
<td>7 years (C3 only)</td>
<td>13 years (C3 only)</td>
</tr>
<tr>
<td>Maternal C3: GM: 3.20 (2.56–4.01)</td>
<td>↓ (C3; age, sex)</td>
<td>↓ (C3; age, sex)</td>
</tr>
<tr>
<td></td>
<td>BMD/BMDL (C3 &amp; 5; sex, birth cohort, log-PFOA)</td>
<td>BMD/BMDL (C3&amp;5; sex, birth cohort, log-PFOA)</td>
</tr>
<tr>
<td>Birth (modeled)</td>
<td>↓ (C3; age, sex)</td>
<td>↓ (C3; age, sex)</td>
</tr>
<tr>
<td></td>
<td>↓↓ (C3 &amp; 5; age, sex)</td>
<td>↓↓ (C3 &amp; 5; age, sex)</td>
</tr>
<tr>
<td></td>
<td>↓↓ (C5; age, sex)</td>
<td>↓↓ (C5; age, sex)</td>
</tr>
<tr>
<td>18 months</td>
<td>↑ (C3; age, sex)</td>
<td>↓ (C3; age, sex)</td>
</tr>
<tr>
<td>C3: NR</td>
<td>↑ (C3 &amp; 5; age, sex)</td>
<td>↓↓ (C3 &amp; 5; age, sex)</td>
</tr>
<tr>
<td>C5: 2.8 (2.0–4.5)</td>
<td>↑ (C5; age, sex)</td>
<td>↓↓ (C5; age, sex)</td>
</tr>
<tr>
<td>5 years</td>
<td>↓ (C3; age, sex)</td>
<td>↓↓ (C3; age, sex)</td>
</tr>
<tr>
<td>C3: GM: 4.06 (3.33–4.96)</td>
<td>↓ (C3; age, sex)</td>
<td>↓↓ (C3; age, sex)</td>
</tr>
<tr>
<td>C5: 2.2 (1.8–2.8)</td>
<td>↓ (C3 &amp; 5; age, sex)</td>
<td>↓↓ (C3; age, sex)</td>
</tr>
<tr>
<td></td>
<td>↑ (C3; age, sex)</td>
<td>↓↓ (C3; age, sex)</td>
</tr>
<tr>
<td></td>
<td>→ (C3; age, sex)</td>
<td>↓↓ (C3; age, sex)</td>
</tr>
<tr>
<td></td>
<td>↓↓ (C5; age, sex)</td>
<td>↓↓ (C5; age, sex)</td>
</tr>
<tr>
<td></td>
<td>↓↓ (C3; age, sex)</td>
<td>↓↓ (C3; age, sex)</td>
</tr>
<tr>
<td></td>
<td>↓↓ (C3 &amp; 5; age, sex)</td>
<td>↓↓ (C3 &amp; 5; age, sex)</td>
</tr>
<tr>
<td></td>
<td>↓↓ (C5; age, sex)</td>
<td>↓↓ (C5; age, sex)</td>
</tr>
<tr>
<td>Exposure measurement</td>
<td>5 years (Pre-Booster)</td>
<td>7 years (C3 only)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>7 years</td>
<td></td>
<td>↓↓ (C3; age, sex, booster type)(^f)</td>
</tr>
<tr>
<td>C3: 4.4 (3.5–5.7)</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>13 years</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>C3: 2.0 (1.6–2.5)</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>

**Notes:** C3 = cohort 3, born 1997–2000; C5 = cohort 5, born 2007–2009; GM = geometric mean; NR = not reported.

Arrows indicate direction of association with PFOA levels; double arrows indicate statistical significance (p < 0.05) where reported. Arrows are followed by parenthetical information denoting the cohort(s) studied and confounders (factors the models presented adjusted for).

- \(^a\) Exposed levels reported from serum as median (25th–75th percentile) unless otherwise noted.
- \(^b\) Grandjean et al. (2012, 1248827); medium confidence
- \(^c\) Budtz-Jørgensen and Grandjean (2018, 5083631); medium confidence
- \(^d\) Grandjean et al. (2017, 4239492); medium confidence
- \(^e\) Grandjean and Budtz-Jørgensen (2013, 1937222); medium confidence
- \(^f\) Mogensen et al. (2015, 3981889); medium confidence
- \(^g\) Grandjean et al. (2017, 3858518); high confidence
A cross-sectional study of these antibody levels in Greenlandic children {Timmermann, 2021, 9416315} reported results that differed in direction of association based on the covariate set selected. The exposure measurement in these analyses may not have represented an etiologically relevant window; cross-sectional analyses in the Faroe Islands studies at similar ages also found weaker associations than analyses for some other exposure windows. A subset of the study population did have maternal samples available and those results were also inconsistent by vaccine. However, this study was the only one to examine the OR for not being protected against diphtheria (antibody concentrations, which has clear clinical significance, and they reported elevated odds of not being protected (based on antibody concentrations < 0.1 IU/mL, OR (95% CI) per unit increase in exposure: 1.41 (0.91, 2.19)).

In children from Guinea-Bissau, West Africa, Timmermann et al. (2020, 6833710) observed non-significant associations between elevated levels of PFOA and decreased adjusted anti-measles antibody levels across time in the group with no measles vaccination at age 9 months. This association was not seen in the group with one measles vaccination. The same pattern was observed at the 2-year follow-up.

Lastly, the low confidence cross-sectional study of one-year-old children in Germany, Abraham et al. (2020, 6506041), reported statistically significant correlations between PFOA concentrations and adjusted levels of antibodies against tetanus, Hib, and diphtheria.

Of the three studies that measured vaccine response in adults or adolescents, two were cohorts {Stein, 2016, 3860111; Shih, 2021, 9959487} and one was a cross-sectional analysis {Pilkerton, 2018, 5080265}. The medium confidence study by Shih et al. (2021, 9959487) measured PFOA in cord blood and at multiple points through childhood to early adulthood in people in the Faroe Islands, with outcome measurement at age 28 years. The study by Stein et al. (2016, 3860111) was rated low confidence because it utilized convenience sampling to recruit participants, had low seroconversion rates, and was at high risk of residual confounding. The study of the adult population in Pilkerton et al. (2018, 5080265) suffered from potential exposure misclassification due to concurrent exposure and outcome measurements and was also rated low confidence, but this was less of a concern for the adolescent participants, so the study of this sub-population was rated as medium confidence.

In adults and adolescents, results were less consistent than in children. Shih et al. (2021, 9959487) reported inverse associations for all exposure windows in the total cohort (not statistically significant) for hepatitis B antibodies but for other vaccines (diphtheria, tetanus, and hepatitis A), the direction of association was inconsistent across exposure windows. Results also differed by sex for all vaccines, but without a consistent direction (i.e., stronger associations were sometimes observed in women and sometimes in men). Similar to the results in 13-year-old children in the other Faroe Islands cohorts, this may indicate that by age 28, the effect of developmental exposure is less relevant. Pilkerton et al. (2018, 5080265) observed statistically significant associations between high-quartile PFOA levels and decreased rubella IgA levels compared with low-quartile PFOA levels in adult men but found no association between PFOA exposure and anti-rubella antibody levels in adolescents. Stein et al. (2016, 3860111) reported no immunosuppression based on seroconversion following FluMist vaccination.

Despite the imprecision (i.e., wide CIs) of some of the exposure-outcome analysis pairs, the findings are generally consistent with respect to an association between PFOA exposure and
immunosuppression in children. Changes in antibody levels of 10%–20% per doubling of exposure were observed in the Faroe Islands cohorts (Grandjean, 2017, 3858518; Grandjean, 2017, 4239492). The variability in some of the results could be related to differences in etiological relevance of exposure measurement timing, vaccine type, and timing of the boosters, as well as differences in timing of antibody measurements in relation to the last booster. However, these factors cannot be explored further with currently available evidence. Overall, the evidence indicates an association between increased serum PFOA levels and decreased antibody production following routine vaccinations, particularly in children.

In addition to these studies of antibody response to vaccination, there are two studies that examined antibody response to HFMD (Zeng, 2019, 5081554) and hepatitis B infection (Zeng, 2020, 6315718). This birth cohort study in China (Zeng, 2019, 5081554) measured antibody levels in infants at birth and age 3 months, which represent passive immunity from maternal antibodies. This study (Zeng, 2019, 5081554) was rated low confidence because the clinical significance of the outcome is difficult to interpret in infants and there are concerns for confounding by timing of HFMD infection as well as other limitations. Statistically significant increased odds of HFMD antibody concentration below clinically protective levels per doubling of PFOA were observed. This is coherent with the vaccine antibody results, but there is uncertainty due to study deficiencies. Zeng et al. (2020, 6315718) observed negative associations (p > 0.05) between serum PFOA concentration and hepatitis B surface antibody; however, there are study limitations due to concurrent measurement of exposure and outcome and potential for reverse causality, and this study was rated low confidence.

In a C8 Health Project study, Lopez-Espinoza et al. (2021, 7751049) measured serum PFAS and white blood cell types in 42,782 adults in 2005–2006 and 526 adults in 2010 from an area with PFOA drinking water contamination in the Mid-Ohio Valley (USA). Generally positive monotonic associations between total lymphocytes and PFOA were found in both surveys (difference range: 1.12%–5.50% for count and 0.36–1.24 for percentage, per PFOA IQR increment). Findings were inconsistent for lymphocyte subtypes. However, the magnitude of the differences was small.

### 3.4.2.1.2.2 Infectious Disease

Overall, ten studies (eleven publications) measured associations between PFOA exposure and infectious diseases (or disease symptoms) in children with follow-ups between 1 and 16 years. Infectious diseases measured included common cold, respiratory tract infections, respiratory syncytial virus, otitis media, pneumonia, chickenpox (varicella), bronchitis, bronchiolitis, ear infections, gastric flu, urinary tract infections, and streptococcus. Of the studies measuring associations between infectious disease and PFOA exposure, eight (nine publications) were cohorts {Ait Bamai, 2020, 6833636; Dalsager, 2016, 3858505; Dalsager, 2021, 7405343; Kvalem, 2020, 6316210; Manzano-Salgado, 2019, 5412076; Gourdzi, 2017, 3859808; Impinen, 2019, 5080609; Wang, 2022, 10176501; Huang, 2020, 6988475}, one was a case control study nested in a cohort {Impinen, 2018, 4238440}, and one was a cross-sectional study {Abraham, 2020, 6506041}. Six studies measured PFOA concentrations from mothers during pregnancy {Ait Bamai, 2020, 6833636; Dalsager, 2016, 3858505; Manzano-Salgado, 2019, 5412076;}

---

12 Multiple publications of the same study: both Dalsager et al. (2016, 3858505) and Dalsager et al. (2021, 7405343) use data from the Odense cohort in Denmark and thus have overlapping, though not identical populations. They received different ratings due to outcome ascertainment methods.
Gourdazi, 2017, 3859808; Impinen, 2019, 5080609; Wang, 2022, 10176501}. Two studies {Impinen, 2018, 4238440; Huang, 2020, 6988475} measured PFOA concentrations from cord blood at delivery. Two studies measured PFOA concentrations in children’s serum at age one year {Abraham, 2020, 6506041} and at age 10 years {Kvalem, 2020, 6316210}.

Several of the studies measured infectious disease incidences as parental self-report, which may have led to outcome misclassification {Kvalem, 2020, 6316210; Abraham, 2020, 6506041; Impinen, 2018, 4238440; Impinen, 2019, 5080609}. Four studies measured infections as the doctor-diagnosed incidence of disease over a particular period {Gourdazi, 2017, 3859808; Manzano-Salgado, 2019, 5412076; Ait Bamai, 2020, 6833636; Huang, 2020, 6988475}, and Wang et al. (2022, 10176501) used a combination of parental report and medical records. One study used hospitalizations as an outcome, with events identified based on medical records {Dalsager, 2021, 7405343}. Overall, six studies were medium confidence {Ait Bamai, 2020, 6833636; Goudarzi, 2017, 3859808; Manzano-Salgado, 2019, 5412076; Dalsager, 2021, 7405343; Wang, 2022, 10176501; Huang, 2020, 6988475} and five were low confidence {Abraham, 2020, 6506041; Dalsager, 2016, 3858505; Impinen, 2018, 4238440; Impinen, 2019, 5080609; Kvalem, 2020, 6316210}.

Increased incidence of some infectious diseases in relation to PFOA exposure was observed, although results were not consistent across studies (see PFOA Appendix). The most commonly examined types of infections were respiratory, including pneumonia/bronchitis, upper and lower respiratory tract, throat infections, and common colds. Dalsager et al. (2021, 7405343) reported higher rates of hospitalization for upper and lower respiratory tract infections with higher PFOA exposure (statistically significant only for lower respiratory tract). Among studies that examined incidence, two studies (one medium and one low confidence) examining pneumonia/bronchitis observed statistically significant associations between elevated PFOA concentrations and increased risk of developing pneumonia in 0- to 3-year-old children {Impinen, 2019, 5080609} and 7-year-old children {Ait Bamai, 2020, 6833636}; one other low and one other medium confidence study did not report an increase in infections {Abraham, 2020, 6506041; Wang, 2022, 10176501}. Huang et al. (2020, 6988475), a medium confidence study, examined recurrent respiratory infections and found no association. Two low confidence studies and one medium confidence study found positive associations with lower respiratory tract infection {Kvalem, 2020, 6316210; Impinen, 2018, 4238440; Dalsager, 2021, 7405343}, while another medium confidence study reported no association {Manzano-Salgado, 2019, 5412076}. In addition, non-statistically significant positive associations were reported with upper respiratory tract infection {Dalsager, 2021, 7405343} and throat infection {Impinen, 2019, 5080609}. There were also statistically significant associations seen for PFOA in relation to respiratory syncytial virus, rhinitis, throat infection, and pseudocroup {Ait Bamai, 2020, 6833636; Kvalem, 2020, 6316210; Impinen, 2019, 5080609}, but findings were inconsistent across studies. No positive associations were reported with common cold {Impinen, 2019, 5080609; Kvalem, 2020, 6316210}. Outside of respiratory tract infections, two medium confidence studies examined total infectious diseases. Dalsager et al. (2021, 7405343) reported higher rates of hospitalization for any infections with higher PFOA exposure (not statistically significant), while Goudarzi et al. (2017, 3859808) reported higher odds of total infectious disease incidence in girls (p > 0.05) but not boys. Results for other infection types, including gastrointestinal, generally did not indicate a positive association. Lastly, one study {Dalsager, 2016, 3858505} measured common infectious disease symptoms in children aged 1 to 4 years and found a positive association with fever and nasal
discharge, but not cough, diarrhea, or vomiting. Overall, the observed associations provide some coherence with the associations observed with vaccine response, but inconsistency across studies reduces confidence in the evidence.

In addition to the studies in children, three studies examined infectious disease in adults, {Ji, 2021, 7491706; Grandjean, 2020, 7403067; Bulka, 2021, 7410156} (see PFOA Appendix). All three studies were medium confidence. Ji et al. (2021, 7491706) was a case-control study of COVID-19 infection. They reported higher odds of infection with higher PFOA exposure (OR (95% CI) per log-2 SD increase in PFOA: 2.73 (1.71, 4.55)). In contrast, a cross-sectional study examining severity of COVID-19 illness in Denmark using biobank samples and national registry data {Grandjean, 2020, 7403067} reported no association between PFOA exposure and increased COVID-19 severity. Bulka et al. (2021, 7410156) used NHANES data from 1999–2016 in adolescents and adults and examined immunoglobulin G (IgG) antibody levels to several persistent infections, including cytomegalovirus, Epstein Barr virus, hepatitis C and E, herpes simplex 1 and 2, HIV, Toxoplasma gondii and Toxocara species. High levels of these antibodies were interpreted as presence of a persistent infection. They found higher prevalence of herpes simplex viruses 1 and 2 and total pathogen burden with higher PFOA exposure in adults but no association with other individual pathogens.

**3.4.2.1.3 Immune Hypersensitivity Study Quality Evaluation and Synthesis from the Updated Literature Review**

Another major category of immune response is the evaluation of sensitization-related or allergic responses resulting from exaggerated immune reactions (e.g., allergies or allergic asthma) to foreign agents {IPCS, 2012, 1249755}. A chemical may be either a direct sensitizer (i.e., promote a specific immunoglobulin E (IgE)-mediated immune response to the chemical itself) or may promote or exacerbate a hypersensitivity-related outcome without evoking a direct response. For example, chemical exposure could promote a physiological response resulting in a propensity for sensitization to other allergens (e.g., pet fur, dust, pollen). Hypersensitivity responses occur in two phases. The first phase, sensitization, is without symptoms, and it is during this step that a specific interaction is developed with the sensitizing agent so that the immune system is prepared to react to the next exposure. Once an individual or animal has been sensitized, contact with that same or in some cases, a similar agent leads to the second phase, elicitation, and symptoms of allergic disease. While these responses are mediated by circulating factors such as T cells, IgE, and inflammatory cytokines, there are many health effects associated with hypersensitivity and allergic response. Functional measures of sensitivity and allergic response consist of health effects such as allergies or asthma and skin prick tests.

In the 2016 HESD for PFOA, two epidemiological studies reported higher odds of asthma with higher PFOA exposure in children {Dong, 2013, 1937230; Humblet, 2014, 2851240}. A case-control study {Dong, 2013, 1937230} of children in Taiwan reported increased odds of asthma with increasing childhood PFOA exposure. The magnitude of association was particularly large comparing each of the highest quartiles of exposure to the lowest. In cross-sectional analyses of asthmatic children, the study authors reported monotonic increases for IgE in serum, absolute eosinophil counts, eosinophilic cationic protein, and asthma severity score. A study on NHANES (1999–2000, 2003–2008) adolescents also reported significantly increased odds of ‘ever asthma’ per doubling of concurrent PFOA measurements, where ‘ever asthma’ was defined as ever having received an asthma diagnosis from a healthcare professional {Humblet, 2014 2851240}. 
Results were less consistent for measures of hypersensitivity (e.g., food allergy, eczema); however, among female infants, decreased cord blood IgE (Okada, 2012, 1332477) was significantly associated with prenatal PFOA exposure.

There are 24 epidemiological studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD (U.S. EPA, 2016, 3603279) that investigated the association between PFOA and hypersensitivity (i.e., asthma, allergy, and eczema) effects. Study quality evaluations for these 24 studies are shown in Figure 3-24. High and medium confidence studies were the focus of the evidence synthesis for endpoints with numerous studies, though low confidence studies were still considered for consistency in the direction of association (and details are provided in PFOA Appendix). For endpoints with fewer studies, the evidence synthesis below included details on any low confidence studies available. Studies considered uninformative were not considered further in the evidence synthesis.
Figure 3-24. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Immune Hypersensitivity Effects

Interactive figure and additional study details available on HAWC.
Thirteen studies (fifteen publications)\textsuperscript{13} examined asthma (or asthma symptoms) and PFOA exposure. Nine of these studies were cohorts \cite{Averina2019, Beck2019, Zhou2017, Manzano-Salgado2019, Zeng2019, Impinen2019, Smit2015, Timmermann2017, Workman2019}; three studies (five publications) were case-control investigations \cite{Zhou2017, Zhou2017, Zhou2016}. Seven studies measured the prevalence of “current” asthma for at least one time point \cite{Averina2019, Zhou2017, Beck2019, Manzano-Salgado2019, Zeng2019, Impinen2019, Smit2015, Timmermann2017, Workman2019}. Nine studies measured ‘ever asthma’ for at least one time point \cite{Averina2019, Zhou2017, Beck2019, Manzano-Salgado2019, Zeng2019, Impinen2019, Smit2015, Timmermann2017, Workman2019}. For asthma, ten publications were rated medium confidence and five publications were rated low confidence (Figure 3-24). Timmermann et al. \cite{Averina2019, Timmermann2017} was low confidence for asthma because the questionnaire used to ascertain status was not validated. Averina et al. \cite{Averina2019, Zhou2017} was considered low confidence because results were not provided quantitatively. Two studies from the Genetic and Biomarker Study for Childhood Asthma (GBCA) \cite{Zhou2017, Zhou2016} were considered low confidence based on participant selection. Cases and controls were recruited from different catchment areas, and the resulting differences between cases and controls indicated potential for residual confounding by age. Additionally, the timing of exposure assessment in relation to outcome assessment was unclear, and it was not reported whether outcome status was confirmed in controls.

Results across these studies were inconsistent (see PFOA Appendix), and few statistically significant results were observed. Several studies observed positive associations with ORs greater than 1.2 between PFOA concentration levels and increased “current” or “ever” asthma \cite{Beck2019, Timmermann2017, Jackson-Browne2020, Zeng2019, Kvale2020}. but often only within population subgroups. Averina et al. \cite{Averina2019, Zhou2017} observed statistically significant increased odds of self-reported doctor diagnosed asthma among adolescents in their first year of high school. Beck et al. \cite{Zhou2017} observed statistically significant increased odds of self-reported asthma per PFOA increase in boys, but this was not observed in girls. For doctor diagnosed asthma in the same study, an inverse association \cite{Beck2019} was observed in boys and a positive association \cite{Beck2019} was observed in girls. Kvale et al. \cite{Kvale2020} reported increased odds of asthma in girls at age 10 \cite{Kvale2020} and between 10–16 years of age, but null associations at 16 years, while the opposite was true for boys. Zeng et al. \cite{Zeng2019} observed a positive association in girls and an inverse association in boys \cite{Zeng2019}. Jackson-Browne et al. \cite{Jackson-Browne2020} also observed statistically significant increased odds of “ever” asthma from increased PFOA concentrations in children aged 3–5. However, these associations were null in other age groups and in sex and race categories. Gaylord et al. \cite{Gaylord2019} reported non-significant positive associations in youths of 13–22 years in age.

\textsuperscript{13} Three publications \cite{Zhou2017, Zhou2017, Zhou2016} reported on the same cohort (Genetic and Biomarker study for Childhood Asthma) and outcome and are considered one study.
confidence study by Timmermann et al. (2017, 3858497) observed positive associations (p < 0.05) between increased asthma odds and elevated PFOA concentrations in a small subset of children aged 5 and 13 who did not receive their measles, mumps, and rubella (MMR) vaccination before age 5. However, in children of the same ages who had received their MMR vaccination before age 5, an inverse association was observed (p > 0.05). Low confidence studies from the GBCA study [Zhou, 2017, 3858488; Zhu, 2016, 3360105] observed elevated PFOA levels (p < 0.001) in children with asthma compared to those without [Zhou, 2017, 3981296], and the odds of current asthma were also found to be elevated among boys and girls with increasing PFOA exposure [Zhu, 2016, 3360105]. Two other studies [Impinen, 2018, 4238440; Impinen, 2019, 5080609] observed small positive associations (OR: 1.1); in Impinen et al. (2019, 5080609), this was only observed for current asthma in boys. Two studies reported non-significant inverse associations with asthma [Manzano-Salgado, 2019, 5412076; Smit, 2015, 2823268], and one low confidence study did not observe a significant effect for recurrent wheeze [Workman, 2019, 5387046].

In addition to the studies of asthma in children, one medium confidence study using data from NHANES examined fractional exhaled nitric oxide (FeNO), a measure of airway inflammation, in adults ([Xu, 2020, 6988472]; see PFOA Appendix). Among participants without current asthma, this study found higher FeNO levels with higher PFOA exposure, indicating greater inflammation (percent change (95% CI) for tertiles vs. T1, T2: 5.29 (1.88, 8.81); T3: 6.34 (2.81, 10.01)).

Overall, there is some evidence of an association between PFOA exposure and asthma, but there is considerable uncertainty due to inconsistency across studies and sub-populations. Sex-specific differences were reported in multiple studies, but there was inconsistency in the direction of association within each sex. There is not an obvious pattern of results by analysis of “ever” vs. “current” asthma, and no studies beyond the Dong et al. (2013, 1937230) study described in the 2016 PFOA HESD examined asthma incidence.

Seven studies observed associations between PFOA exposure and allergies, specifically allergic rhinitis or rhinoconjunctivitis, skin prick test, and food or inhaled allergies. Five of these studies were cohorts [Goudarzi, 2016, 3859523; Ait Bamai, 2020, 6833636; Kvalem, 2020, 6316210; Impinen, 2019, 5080609; Timmermann, 2017, 3858497], one study was a case-control analysis [Impinen, 2018, 4238440], and one study was a cross-sectional study using data from NHANES 2005–2010 [Buser, 2016, 3859834]. One study was considered high confidence [Goudarzi, 2016, 3859523] and the rest were considered medium confidence for allergy outcomes. PFOA concentrations were measured at a variety of time points: three studies measured PFOA during pregnancy [Goudarzi, 2016, 3859523; Ait Bamai, 2020, 6833636; Impinen, 2019, 5080609]; three studies measured PFOA concentrations in children at age 5 years [Timmermann, 2017, 3858497], age 10 years [Kvalem, 2020, 6316210], age 13 years [Timmermann, 2017, 3858497] and ages 12–19 years [Buser, 2016, 3859834]; and one study measured PFOA in cord blood at delivery [Impinen, 2018, 4238440] (see PFOA Appendix).

Results were generally inconsistent across studies. Three studies conducted skin prick tests on participants to determine allergy sensitization at age 10 years [Kvalem, 2020, 6316210; Impinen, 2018, 4238440], at age 13 years [Timmermann, 2017, 3858497], and at age 16 years [Kvalem, 2020, 6316210]. Skin prick tests were conducted to test sensitization to dust mites, pets, grass, trees and mugwort pollens and molds, cow’s milk, wheat, peanuts, and cod. Kvalem et al. (2020,
6316210) reported a statistically significant but small association (OR: 1.1) with a positive skin prick test at ages 10 and 16 years. Timmermann et al. (2017, 3858497) also reported a positive association (p > 0.05) in children who had received an MMR before age 5 years (but an inverse association in those who had not received an MMR) and results in Impinen et al. (2018, 4238440) were null. Five studies measured symptoms of “current” or “ever” allergic rhinitis or rhinoconjunctivitis {Goudarzi, 2016, 3859523; Ait Bamai, 2020, 6833636; Impinen, 2018, 4238440; Kvalem, 2020, 6316210; Timmermann, 2017, 3858497}. Rhinitis was defined as at least one symptom of runny or blocked nose or sneezing. Rhinoconjunctivitis was defined as having symptoms of rhinitis, in addition to itchy and watery eyes. Rhinitis was increased with exposure at age 16 years (p < 0.05) but decreased at age 10 years in Kvalem et al. (2020, 6316210). Non-significant increases in rhinitis were also reported in Impinen et al. (2018, 4238440) and Timmermann et al. (2017, 3858497), but results were null in Ait Bamai et al. (2020, 6833636) and Goudarzi et al. (2016, 3859523) for rhinoconjunctivitis. Impinen et al. (2019, 5080609) measured parent-reported, doctor-diagnosed “current” or “ever” allergy symptoms at age 7 years in addition to known food and inhaled allergies and reported higher odds of current food allergies and ever inhaled allergies (both p > 0.05), but not ever food allergies or current inhaled allergies. Buser et al. (2016, 3859834) measured food sensitization (defined as having at least one food-specific serum IgE ≥ 0.35 kU/L) and self-reported food allergies and reported statistically significant positive associations with self-reported food allergies in NHANES 2007–2010 but not in in NHANES 2005–2006.

Seven studies measured the association between PFOA concentration and eczema (described by some authors as atopic dermatitis). Six of these studies were cohorts {Goudarzi, 2016, 3859523; Wen, 2019, 5387152; Wen, 2019, 5081172; Manzano-Salgado, 2019, 5412076; Chen, 2018, 4238372; Timmermann, 2017, 3858497}, and one was a case-control analysis {Impinen, 2018, 4238440}. Four studies measured PFOA concentrations in cord blood at delivery {Wen, 2019, 5387152; Wen, 2019, 5081172; Chen, 2018, 4238372; Impinen, 2018, 4238440}, three studies measured maternal PFOA concentrations during pregnancy {Goudarzi, 2016, 3859523; Manzano-Salgado, 2019, 5412076; Timmermann, 2017, 3858497}, and one study measured PFOA concentrations in children at age 5 and 13 years {Timmermann, 2017, 3858497}. All of the studies were considered medium confidence for eczema (see PFOA Appendix).

Two studies (three publications) observed statistically significant associations between increased odds of eczema within the highest quantiles of PFOA exposure {Wen, 2019, 5387152; Wen, 2019, 5081172; Chen, 2018, 4238372}; however, the associations were non-monotonic across categories of exposure. Impinen et al. (2018, 4238440) also observed a non-significant association between higher PFOA concentrations and “ever” eczema at age 2 years; however, results were null for “current” eczema at age 10 years. Results from Goudarzi et al. (2016, 3859523), Manzano-Salgado et al. (2019, 5412076) and Timmermann et al. (2017, 3858497) were null.

One medium confidence nested case-control study examined chronic spontaneous urticaria {Shen, 2022, 10176753}. They found no association between PFOA exposure and case status.
3.4.2.1.4 Autoimmune Disease Study Quality Evaluation and Synthesis from the Updated Literature Review

Autoimmunity and autoimmune disease arise from immune responses against endogenously produced molecules. The mechanisms of autoimmune response rely on the same innate and adaptive immune functions that respond to foreign antigens: inflammatory mediators, activation of T lymphocytes, or the production of antibodies for self-antigens {IPCS, 2012, 1249755}. Chemical exposures that induce immune response or immunosuppression may initiate or exacerbate autoimmune conditions through the same functions. Autoimmune conditions can affect specific systems in the body, such as the nervous system (e.g., multiple sclerosis (MS)), or the effects can be diffuse, resulting in inflammatory responses throughout the body (e.g., lupus).

The 2016 HESD for PFOA {U.S. EPA, 2016, 3603279} identified one occupational study in workers highly exposed to PFOA (part of the C8 Health Project) {Steenland, 2015, 2851015} that reported significant positive trends for rheumatoid arthritis and ulcerative colitis with increasing cumulative PFOA exposure. The C8 Science Panel concluded there was a probable link between PFOA and ulcerative colitis {C8 Science Panel, 2012, 1430770}.

There are 6 epidemiological studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA and autoimmune disease. Study quality evaluations for these 6 studies are shown in Figure 3-25. High and medium confidence studies were the focus of the evidence synthesis for endpoints with numerous studies, though low confidence studies were still considered for consistency in the direction of association (and details are provided in PFOA Appendix). For endpoints with fewer studies, the evidence synthesis below included details on any low confidence studies available. Studies considered uninformative were not considered further in the evidence synthesis.
One study examined the association between PFOA exposure and multiple autoimmune conditions (rheumatoid arthritis, lupus, MS, ulcerative colitis, and Crohn’s disease) in the combined C8 Health Project occupational and community cohort [Steenland, 2013, 1937218]. Two case-control studies examined MS [Ammitzbøll, 2019, 5080379] and ulcerative colitis [Steenland, 2018, 5079806] in adults, and two case-control studies examined celiac disease in children and young adults [Gaylord, 2020, 6833754; Sinisalu, 2020, 7211554]. One study was a cohort study that examined ulcerative colitis in children and adults from a high-exposure community in Sweden (Ronneby cohort) [Xu, 2020, 6315709]. The combined occupational and community study used modeled PFOA exposure based on serum concentrations and historical data on residences and drinking water quality [Steenland, 2013, 1937218], and the case-control studies measured PFOA in serum or plasma only [Ammitzbøll, 2019, 5080379; Gaylord, 2020, 6833754; Sinisalu, 2020, 7211554; Steenland, 2018, 5079806]. Two studies were without notable deficiencies and considered medium confidence [Gaylord, 2020, 6833754; Steenland, 2013, 1937218]. Four studies were considered low confidence [Steenland, 2018, 5079806; Ammitzbøll, 2019, 5080379; Sinisalu, 2020, 7211554; Xu, 2020, 6315709]. Steenland et al. (2018, 5079806) examined exposure concentrations one to two years after diagnosis of celiac
disease, resulting in some concern for reverse causation. Additionally, there was potential for residual confounding by SES which was not considered in the analysis. These factors together contributed to a low confidence rating. Information on participant selection, particularly control selection, was not reported in Ammitzbøl (2019, 5080379). Additionally, PFOA was evaluated as a dependent rather than independent variable, making no informative determinations about associations between PFOA exposure and risk of MS.

In a C8 Health Project study {Steenland, 2013, 1937218}, associations for rheumatoid arthritis were generally consistent and positive across unlagged and 10-year lagged PFOA quartiles. The risk of rheumatoid arthritis was significantly elevated comparing those in the third quartile of 10-year lagged exposure to participants in the first quartile, but this was the only significant association. The risk of MS was non-significantly elevated in unlagged and 10-year lagged models {Steenland, 2013, 1937218}. Significantly increased risk of ulcerative colitis among adults across increasing quartiles of PFOA exposure was also observed (p-trend < 0.0001). Associations with lupus and Crohn’s disease were non-significant and inconsistent in the direction of effect {Steenland, 2013, 1937218}.

Evidence from a case-control study suggested lower PFOA concentrations among healthy controls compared to those with MS {Ammitzbøl, 2019, 5080379}. Serum PFOA concentrations were 12% lower (95% CI: −24%, 2%; p = 0.099) in healthy controls compared to cases of relapsing remitting MS and clinically isolated MS. Restricting the analysis to men, serum PFOA levels were 28% lower (95% CI: −42%, −9%; p = 0.006) in healthy controls compared to cases, but this effect was not seen in women. Steenland et al. (2018, 5079806) detected significantly increased levels of PFOA in ulcerative colitis cases vs. those with Crohn’s disease or controls and observed statistically significantly increased odds of ulcerative colitis with increased PFOA exposure among combined children and adults; however, the trend was not consistent across increasing quintiles of PFOA exposure, with a peak in the third quintile. Xu et al. (2020, 6315709) observed significant decreases in risk of Crohn’s disease in an early exposure period, but not in later exposure periods, or for UC in children and adults from a high-exposure community in Sweden (Ronneby cohort).

The risk of celiac disease was elevated among children and young adults (≤ 21 years old) in a case-control study {Gaylord, 2020, 6833754}, particularly in females (p < 0.05), but the association did not reach significance among the whole population.

In the prospective observational Finnish Diabetes Prediction and Prevention (DIPP) study in which children genetically at risk to develop type 1 diabetes (T1D) and celiac disease were followed from birth, with blood samples taken at birth and 3 months of age {Sinisalu, 2020, 7211554}, there was no significant difference in the levels of PFOA exposure in those children that later developed celiac disease, which may be due to the small sample size, but age at diagnosis of celiac disease was strongly associated with the PFOA exposure.

### 3.4.2.2 Animal Evidence Study Quality Evaluation and Synthesis

There are 4 studies from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} and 9 studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD that investigated the association between PFOA and immune effects in animal models. Study quality evaluations for these 13 studies are shown in Figure 3-26.
The data available on immunological responses of animals following oral exposure to PFOA are extensive, especially as they apply to mice. A number of studies reported effects on spleen and

---

**Figure 3-26. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA and Immune Effects**

Interactive figure and additional study details available on [HAWC](#).
thymus weights, immune system cellular composition, and the ability to generate an immune response following PFOA doses ranging from approximately 1–40 mg/kg/day.

### 3.4.2.2.1 Organ Weight/Histopathology

Short-term exposure studies by Yang et al. (2000, 699394), Yang et al. (2001, 1014748), Qazi et al. (2009, 1937259), and Yang et al. (2002, 1332453) using male C57BL/6 mice, by DeWitt et al. (2008, 1290826) using female C57BL/6 mice, and by DeWitt et al. (2016, 2851016) using female C57BL/6Tac mice were conducted using relatively high PFOA doses (up to approximately 40 mg/kg/day). In each study, the PFOA-treated C57BL/6 mice exhibited significant reductions in spleen and thymus weights after 5–16 days of exposure. Yang et al. (2000, 699394) and DeWitt et al. (2008, 1290826) observed up to an approximately 80% reduction in absolute and relative thymus weight and up to a 30%–48% reduction in absolute and relative spleen weight. Similar reductions in absolute thymus and spleen weights were observed in Yang et al. (2002, 1332453); relative weights were not reported. In DeWitt et al. (2016, 2851016), relative spleen weights were significantly reduced by 30% after exposure to 30 mg/kg/day, and relative thymus weights were significantly reduced by 55.4% after exposure to 7.5 mg/kg/day (but not after exposure to 30 mg/kg/day). Absolute weights were not reported in this study. In male CD-1 mice exposed for 29 days via gavage to 1, 10, or 30 mg/kg/day PFOA, absolute and relative spleen weights were reduced to approximately 90%, 60%, and 50% of controls, respectively (Loveless, 2008, 988599). Absolute and relative thymus weights were decreased to approximately 50% of controls in the 10 and 30 mg/kg/day groups. Spleen and thymus weights were only reduced by up to 9% (not statistically significant) in male ICR mice administered 47.21 mg/kg/day PFOA in drinking water for 21 days (Son, 2009, 1290821). In male BALB/c mice dosed with 0.4, 2, or 10 mg/kg/day PFOA via gavage for 28 days, absolute spleen weights were significantly reduced by 88% and 50% of the control in the 2 and 10 mg/kg/day groups, respectively (Guo, 2021, 7542749). Relative spleen weights in these groups were similarly reduced to 84% and 56% of the control. In the same study, however, no significant changes in spleen or thymus weights were observed in male Sprague Dawley rats. In a separate 28-day study, male Sprague Dawley rats administered 2.5–10 mg/kg/day displayed significantly lower absolute spleen weights that reached 76% of control at the highest dose (NTP, 2019, 5400977). Absolute thymus weight was decreased to 74% of control in males administered 10 mg/kg/day compared to those of the vehicle group. Female spleen and thymus weights were not altered.

In one developmental study, pregnant C57BL/6N mice were exposed to 0.5 or 1 mg/kg/day PFOA from GD 6–17; the relative spleen and thymus weights of the female offspring were unchanged at PND 48 (Hu, 2010, 1332421). The male offspring were not assessed in this study. However, a reduction in spleen and thymus weights has been reported in male rats following developmental PFOA exposure. NTP (2020, 7330145) exposed pregnant rats to PFOA beginning on GD 6, and exposure was continued in offspring postweaning for a total of 107 weeks. Dose groups for this report are referred to as “[perinatal exposure level (ppm)]/[postweaning exposure level (ppm)]” (see further study design details in Section 3.4.4.2.1.2). Following perinatal and postweaning PFOA exposure (150/150 and 300/300 ppm), significant reductions in absolute and relative spleen weight and absolute thymus weight were observed at 16 weeks in male rats. Reduced absolute and relative spleen weights were also observed in rats following 300/20, 300/40, and 300/80 ppm PFOA exposure. Postweaning exposure alone (0/20, 0/40, 0/150, and 0/300 ppm) significantly reduced absolute and relative spleen weights. Absolute thymus weight
was reduced following 0/150 and 0/300 ppm {NTP, 2020, 7330145}. No changes in spleen or thymus weights were reported in females.

Two studies describing effects of subchronic PFOA exposure in adult male mice {Crebelli, 2019, 5381564; Shi, 2020, 7161650} and one chronic study in adult male rats {Butenhoff, 2012, 2919192} did not report reduced spleen weight, and thymus weights were not examined. No changes to spleen weights were observed in C57BL/6 male mice administered ≤5 mg/kg/day for 5 weeks {Crebelli, 2019, 5381564; Shi, 2020, 7161650}. Although the changes were not statistically significant, Shi et al. (2020, 7161650) observed 21%, 32%, and 32% reductions in relative spleen weight (compared to controls) in mice exposed to 0.5, 1, or 3 mg/kg/day, respectively. Body weight gain was also significantly reduced in these groups, and absolute spleen weight was not reported. Similarly, spleen weight was not affected in male Sprague-Dawley rats chronically exposed to 30 or 300 ppm (1.3 or 14.2 mg/kg/day) for 1 or 2 years {Butenhoff, 2012, 2919192}. An increase in absolute and relative spleen weight (40% and 30% increase, respectively) was observed only in female rats exposed to 30 ppm (1.6 mg/kg/day) for 2 years.

### 3.4.2.2.2 Histopathology

Several studies reported on histological evaluations of the spleen and thymus from rodents orally administered PFOA at varying doses and durations. In male Crl:CD-1 (ICR)BR mice administered PFOA for 29 days, decreased spleen weights at 10 and 30 mg/kg/day correlated with the gross observation of small spleens {Loveless, 2008, 988599}. An increased incidence of spleen atrophy was also observed in the 30 mg/kg/day group. The decreased thymus weights at these doses correlated with the microscopic finding of lymphoid depletion and with the gross observation of small thymuses {Loveless, 2008, 988599}. Loveless et al. (2008, 988599) also reported increased incidences of granulocytic hyperplasia of the bone marrow in mice in the 10 and 30 mg/kg/day groups.

Other microscopic findings were reported in Son et al. (2009, 1290821) in the histological evaluation of male ICR mice administered PFOA (0.49–47.21 mg/kg/day) for 21 days. The thymus of mice exposed to 47.21 mg/kg/day PFOA revealed atrophy with decreased thickness of the cortex and medulla compared to control, but increased cellular density of lymphoid cells in the cortex was observed {Son, 2009; 1290821}. The authors also reported an enlargement of the spleen with marked hyperplasia of the white pulp in the 47.21 mg/kg/day PFOA-treated group, and an increased area of the lymphoid follicles in the spleen with increased cellular density {Son, 2009, 1290821}. In contrast, in a study in male BALB/c mice administered 0.4–10 mg/kg/day PFOA via gavage, the authors noted decreased white pulp content, with the white pulp content in the highest dose group being reduced to nearly in half of that of the control group (quantitative results were not provided) {Guo, 2021, 7542749}.

After 5–6 days of recovery, Loveless et al. (2008, 988599) observed increased extramedullary hematopoiesis in the spleens of male Crl:CD(SD)IGS BR rats and Crl:CD-1 (ICR)BR mice exposed to 30 mg/kg/day PFOA for 23–24 days. However, these changes were not observed in rats and mice after a continuous 29-day exposure {Loveless, 2008, 988599}. Likewise, splenic hematopoiesis was not affected in male or female Sprague-Dawley rats administered 0.625–10 or 6.25–50 mg/kg/day PFOA, respectively {NTP, 2019, 5400977}.
Two studies in male Sprague-Dawley rats exposed to up to 30 mg/kg/day PFOA for 28–29 days reported no histopathological changes in the spleen, thymus, and/or lymph nodes \{Loveless, 2008, 988599; NTP, 2019, 5400977\}. However, a significant increase in bone marrow hypocellularity of minimal severity was reported in male rats exposed to 10 mg/kg/day (6/10 compared to 1/10 in controls) but not in female rats \{NTP, 2019, 5400977\}.

Histological evaluation of the spleen following chronic PFOA exposure was only reported in one study, which administered 30 or 300 ppm PFOA to male and female Sprague-Dawley rats for 2 years. Hemosiderin, an iron-rich pigment, was found in greater amounts in the spleens of males dosed with 300 ppm (approximately 15 mg/kg/day), though this change was not significant, but was significantly reduced in the 30 ppm groups (approximately 1.5 mg/kg/day) and in the 300 ppm females \{Butenhoff, 2012, 2919192\}. However, no histopathological changes in the thymus, spleen, bone marrow, or lymph nodes were reported in a study that exposed Sprague-Dawley rats to up to 300 ppm PFOA for 16 weeks (males and females) or up to 80 ppm PFOA (males) or 300 ppm (females) for 2 years \{NTP, 2020, 7330145\}.

Histological evaluation of the spleen and thymus following reproductive PFOA exposure was only reported in one study \{Butenhoff, 2004, 1291063\}. P0 males and females were administered 1–30 mg/kg/day PFOA from premating until the end of lactation and the F1 generation was exposed throughout their life. The authors note that no histopathological changes were reported, though qualitative results were not provided.

### 3.4.2.2.3 Immune Cellularity

#### 3.4.2.2.3.1 White Blood Cells and Differentials

Evidence supporting an effect of PFOA exposure on immune system-associated cellularity has been reported. A decrease in total serum white blood cells to 28% of control was observed in male C57BL/6 (H-2b) mice fed 40 mg/kg/day for 10 days \{Qazi, 2009, 1937259\}. Total number of circulating neutrophils and lymphocytes (T and B cells) were decreased to 50% and 27% of control, respectively. The numbers of circulating monocytes, eosinophils, and basophils were too small to be determined reliably, according to the study \{Qazi, 2009, 1937259\}.

In a similar study, male Crl:CD-1(ICR)BR mice were exposed to PFOA (10 or 30 mg/kg/day) by oral gavage for 29 days. At both doses tested, increases in total serum neutrophils and monocytes (reaching 296% and 254% of control, respectively, at the highest dose), and a decrease in total number of eosinophils (approximately 60% of control, data not statistically significant) were observed \{Loveless, 2008, 988599\}. Loveless et al. (2008, 988599) also reported a decrease in lymphocytes in male mice dosed with 30 mg/kg/day, but these data were not provided in the study. In a second short-term study, white blood cell count was significantly decreased to 71% and 36% of the control in male BALB/c mice exposed to 2 and 10 mg/kg/day PFOA, respectively, for 28 days \{Guo, 2021, 7542749\}. White blood cell differentials were not measured in this study.

In a short-term study in male and female Sprague-Dawley exposed to 0.625–10 or 6.25–100 mg/kg/day PFOA, respectively, no changes in white blood cell counts or differentials were reported \{NTP, 2019, 5400977\}. 

3-119
DRAFT FOR PUBLIC COMMENT

March 2023

In male and female Sprague-Dawley rats chronically exposed to 30 or 300 ppm PFOA
(approximately 1.5 or 15 mg/kg/day) for 2 years, PFOA did not affect total white blood cell
count, blood lymphocytes, or neutrophils {Butenhoff, 2012, 2919192}. However, white blood
cell counts were increased in males through the first year of the study. The authors suggest that
these changes were due to increases in absolute counts of lymphocytes at 3 and 6 months and in
neutrophils at 12 months {Butenhoff, 2012, 2919192}.

3.4.2.2.3.2

Spleen, Thymus, Lymph Nodes, and Bone Marrow Cellularity

Short-term PFOA exposure (10–40 mg/kg/day) significantly decreased splenocyte and
thymocyte cell populations by up to approximately 30% and 15% of control, respectively, in
male Crl:CD-1 (ICR)BR mice {Loveless, 2008, 988599} and male C57BL/6 mice {Yang, 2001,
1014748}. Similarly, in male C57BL/6 mice administered 40 mg/kg/day PFOA for 7 days, the
number of thymocytes was decreased to 14% of control; immature thymocyte populations
(CD4+CD8+) were the most affected {Yang, 2000, 699394}. In the spleen, both B and T cells
were significantly reduced in these mice, and the number of total splenocytes was decreased to
20% of control {Yang, 2000, 699394}. Reduced splenocyte and thymocyte CD4+CD8+ cells
were also observed in male ICR mice administered PFOA (0, 0.49, 2.64, 17.63, and
47.21 mg/kg/day) in drinking water for 21 days, reflecting an impairment in cell maturation
{Son, 2009, 1290821}.
No changes in splenocyte and thymocyte cell populations were observed in one study of male
Sprague-Dawley rats exposed to 0.3–30 mg/kg/day PFOA for 29 days {Loveless, 2008,
988599}.
Developmental PFOA exposure may also impact cellularity of the spleen. In one study by Hu et
al. (2012, 1937235), an approximate 22% reduction in splenic regulatory T cells
(CD4+CD25+Foxp3+) was observed in PND 42 male and female offspring from C57BL/6N dams
exposed to 2 mg/kg/day PFOA from gestation through lactation. Thymic cellularity was not
examined in this study {Hu, 2012, 1937235}.

3.4.2.2.4

Ability to Generate an Immune Response

The ability to generate an immune response following PFOA has been investigated in rodent
models. Male Crl:CD-1 (ICR)BR mice were exposed to PFOA (0, 0.3, 1, 10, or 30 mg/kg/day)
by oral gavage for 29 days and received an injection of serum sheep red blood cells (SRBC) on
day 24 {Loveless, 2008; 988599}. The induced immunoglobulin M (IgM) response was
significantly reduced to 80% and 72% of controls in mice exposed to 10 and 30 mg/kg/day,
respectively. The same study found no changes in IgM in rats. After an injection with keyhole
limpet hemocyanin (KLH), a similar reduction in anti-KLH IgM response was observed in
female B6C3F1 mice administered 1.88 and 7.5 mg/kg/day PFOA in drinking water for 28 days
{De Guise, 2021, 9959746}. The IgM response in the mice exposed to 1.88 or 7.5 mg/kg/day
was significantly reduced to 29% and 8% of the control’s response, respectively. The ability to
respond to an immunological challenge was also reduced in female C57BL/6N mice exposed to
3.75 to 30 mg/kg/day PFOA in drinking water for 15 days {DeWitt, 2008, 1290826}. The mice
showed a dose-dependent reduction in IgM levels (between 11% and 30% decrease) after
injection with SRBC to induce an immune response. The IgG response to SRBC significantly
increased by approximately 15% following 3.75 and 7.5 mg/kg/day PFOA exposure, but no
change was observed at higher doses {DeWitt, 2008, 1290826}. In a separate study, female

3-120


C57BL/6Tac mice were exposed to 0, 7.5, or 30 mg/kg/day PFOA in drinking water for 15 days and injected with SRBC on day 11 {DeWitt, 2016; 2851016}. Exposure to 30 mg/kg/day PFOA reduced SRBC-specific IgM antibody responses by 16%. Similarly, male C57BL/6 mice were fed approximately 40 mg/kg/day PFOA for 10 days and then evaluated for their immune response to horse red blood cells {Yang, 2002, 1332454}. PFOA-exposed mice were unable to produce an increase in plaque-forming cells in response to the immune challenge, compared to control mice, suggesting a suppression of the humoral immune response.

One developmental study assessed the ability to generate an immune response following gestational exposure to PFOA {Hu, 2010, 1332421}. In this study, pregnant C57BL/6N mice were exposed to 0.5 or 1 mg/kg/day PFOA from GD 6–17. The adult female offspring were immunized with SRBC on PND 44. No change in the immune response was observed, as measured through IgM titers (PND 48) and IgG titers 2 weeks later (PND 63) following an SRBC booster.

Alterations in the serum levels of globulin can be associated with decreases in antibody production {FDA, 2002, 88170}. PFOA exposure at 12.5 mg/kg/day and up to 100 mg/kg/day for 28 days decreased globulin concentrations in female Sprague-Dawley rats by up to 79% of control. In males, a decrease in globulin concentrations was observed at 0.625 mg/kg/day (74% of control) and up to 10 mg/kg/day (61% of control), highlighting greater PFOA tolerance in females compared to males (Figure 3-27) {NTP, 2019, 5400977}. In contrast, an increase in globulin concentrations, by approximately 7%, was observed in male BALB/c mice exposed to 0.4 or 2 mg/kg/day PFOA (but not 10 mg/kg/day) for 4 weeks (Figure 3-27) {Guo, 2019, 5080372}. In a similar study by the same group, immunoglobulins were measured, and IgA concentrations were found to be significantly increased by 12%, 16%, and 33% in male BALB/c mice exposed to 0.4, 2, or 10 mg/kg/day, respectively, PFOA for 4 weeks {Guo, 2021, 7542749}. IgM was increased by 3% and 6% in mice exposed to 2 or 10 mg/kg/day, respectively, and IgG was increased by 6% in mice exposed to 10 mg/kg/day.

Globulin levels were also decreased in pregnant ICR dams on GD 18 following 5 or 10 mg/kg/day PFOA from GD 0–18 {Yahia, 2010, 1332451}. Globulin levels were decreased to 78 and 68% of control, respectively. Globulin levels in offspring were not measured. In a developmental study conducted by NTP (2020, 7330145), Sprague-Dawley rats were exposed perinatally and/or postweaning for a total of 107 weeks to varying doses of PFOA ((perinatal exposure level (ppm))/((postweaning exposure level (ppm))); see further study design details in Section 3.4.4.2.1.2). In male Sprague-Dawley rats at the 16-week interim timepoint, perinatal exposure to 300 ppm (300/0) and/or postweaning exposure to doses ranging from 20–300 ppm (0/150, 0/300, 150/150, 300/300, 0/20, 0/40, 0/80, 300/20, 300/40, or 300/80 ppm) significantly decreased globulin levels. Female rats displayed decreased globulin levels following exposure to 0/300, 0/1,000, 150/300, or 300/1,000 ppm PFOA {NTP, 2020, 7330145} (Figure 3-27).
### 3.4.2.3 Mechanistic Evidence

Mechanistic evidence linking PFOA exposure to adverse immune outcomes is discussed in Sections 3.3.2 and 3.4.1 of the 2016 PFOA HESD [U.S. EPA, 2016, 3603279]. There are 22 studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD that investigated the mechanisms of action of PFOA that lead to immune effects. A summary of these studies is shown in Figure 3-28.

#### Figure 3-28. Summary of Mechanistic Studies of PFOA and Immune Effects

Interactive figure and additional study details available on Tableau.

A consistent pattern of findings from human (Section 3.4.2.1) and animal (Section 3.4.2.2) studies support that higher serum concentrations of PFOA are associated with immunosuppression. Additional findings included reduced spleen and thymus weights, reduced cellularity of white blood cells and differentials in circulation, reduced immune cellularity in primary and secondary lymphoid organs, and altered globulin levels. Mechanistic data available from *in vitro*, *in vivo*, and epidemiological studies were used to evaluate the mode of action of PFOA-associated immunosuppression and other effects on the immune system.
3.4.2.3.1 Mechanistic Evidence for PFOA-mediated Effects on Immune System Development and Physiology

Reductions in lymphocyte numbers have been consistently reported in animal toxicological studies (Section 3.4.2.2), with parallel observations of reduced antibody responses in human studies (Section 3.4.2.1). PFOA can alter the number of various B and T cell subsets in primary and secondary lymphoid organs, which may reflect effects on immune system development including effects on proliferation, differentiation, and/or apoptosis of immune cells.

Two in vivo studies were identified that evaluated PFOA-mediated effects on immune system development, reflected in numbers of B and T cell populations. In female BALB/c mice dermally exposed to PFOA for 14 days, the total numbers of splenic CD4+ T cells were reduced, as were the total numbers and percent of CD4+ T cells in the lymph nodes. The percent of splenic CD4+ T cells was increased \cite{Shane, 2020, 6316911}. The authors also observed that the absolute number and percent of splenic B cells were reduced, an observation which could be explained by increased apoptosis of B cells in the spleen or diminished proliferation in the bone marrow, where B cells develop. Effects on B cell differentiation may also reflect reduced cellularity of bone marrow, thymus, and spleen. Qazi et al. (2012, 1937236) reported reduced percentages of the relatively undifferentiated pro/pre-B cells (CD19+/CD138+/IgM-) in the bone marrow of male C57BL/6 mice fed diets containing 0.02% PFOA for 10 days. Morphological assessment of the bone marrow was consistent with the reduced cell populations; mice treated with 0.02% PFOA displayed hypocellularity in the bone marrow. The authors note that food consumption of the mice exposed to 0.02% PFOA can be reduced up to 35%. Moreover, although experimentally restricting food consumption by 35% in the absence of PFOA exposure affects pro/pre-B cell populations in a similar manner to PFOA, the effect is not identical, which may support that PFOA exposure is associated with decreased pro/pre-B cells in the bone marrow independent of reduced food consumption. The study also demonstrated that the number of myeloid cells (Gr1+/CD11b+) is reduced by 0.02% PFOA but to a lesser magnitude than that of B lymphoid cells (CD19+), suggesting that the B-lymphoid cell lineage is more sensitive than the myeloid cell lineage.

Several in vitro studies have reported reductions in immune cell viability or increases in cytotoxicity following exposure to PFOA \cite{Sørli, 2020, 5918817; Rainieri, 2017, 3860104}, which could also contribute to reduced lymphocyte cellularity or reduced immune organ weight observed in the animal literature (Section 3.4.2.2).

Reductions in immune cellularity of B and T cell populations in the thymus and spleen (Section 3.4.2.2) as well as the bone marrow may reflect perturbations in cellular and/or molecular events including cell proliferation, apoptosis, and oxidative stress. An in vitro study by Rainieri et al. (2017, 3860104) evaluated the effects of PFOA on cell proliferation by quantifying the distribution of cells in different stages of the cell cycle in a human macrophage cell line (TLT cells). Significantly more cells were in G2/M phase of mitosis following exposure to PFOA in parallel with a lower proportion of cells in the G0/G1 phase, suggesting increased cell proliferation. However, increased cell proliferation is inconsistent with the immune organ atrophy reported in animal toxicological studies (Section 3.4.2.2) and findings of other mechanistic studies in immune organs. Yang et al. (2002, 1332453) reported significant reductions in the proportion of thymocytes in the S and G2/M phases and significant increases in the G0/G1 phases of mice treated with PFOA, which were attenuated in PPARα-null mice. These
results imply that reductions in cell numbers in the S and G2/M phases of the cell cycle are partially mediated by PPARα.

Two studies \{Wang, 2014, 3860153; Rainieri, 2017, 3860104\} have reported increased apoptosis in immune cells following PFOA exposure \textit{in vivo} and \textit{in vitro}. Increased apoptosis may contribute to the reductions in immune organ weight observed in the animal literature and/or reduced populations of immune cells (Section 3.4.2.2). Wang et al. (2014, 3860153) exposed BALB/c mice to 0, 5, 10, or 20 mg/kg/day PFOA via gavage for 14 days and reported that the percent of apoptotic cells increased in the spleen at 10 and 20 mg/kg/day and increased in the thymus at 20 mg/kg/day. Increased apoptosis was associated with atrophy of these immune system organs, suggesting that PFOA-induced apoptosis may contribute to organ atrophy. In parallel, the authors explored the association between lipid metabolism and immunotoxicity of PFOA by including a high-fat diet (HFD) group in addition to the regular diet (RD) group; there was a higher percentage of apoptosis in the HFD vehicle control group than the RD vehicle control group, indicating that HFD could cause or exacerbate apoptosis. Based on these diet-related results along with gene expression data showing that PPARα and PPARγ were also up-regulated in the thymus and the spleen, the authors concluded that immunomodulation by PFOA occurs via the PPAR pathway and the induction of mitochondrial damage and lymphocyte apoptosis pathway. Rainieri et al. (2017, 3860104) evaluated apoptosis in TLT cells exposed to 0, 50, 250, or 500 mg/L PFOA for 12 hours. The percentage of apoptotic cells was significantly elevated only at the highest concentration.

Generation of oxidative stress is a potential underlying mechanism linking PFOA to the aforementioned effects on proliferation, differentiation, and/or apoptosis of immune cells. Oxidative stress has been implicated in PFOA immunotoxicity by one in vivo study and several in vitro studies \{Wang, 2014, 3860153; Yahia, 2014, 2851192; Rainieri, 2017, 3860104\}. Wang et al. (2014, 3860153) observed that the spleens of mice treated with PFOA had mitochondrial swelling and cavitation as well as swollen and ruptured cristae, which suggests impaired oxidative processes. However, there were no significant changes in H$_2$O$_2$ concentrations or superoxide dismutase (SOD) activity in spleens of mice exposed to PFOA versus controls. There were no differences in mitochondrial ultrastructure between the HFD group and the RD group, implying that although PFOA-related mitochondrial damage may contribute to apoptosis in lymphocytes, the mechanism may not involve perturbed lipid metabolism. Rainieri et al. (2017, 3860104) reported increased lipid peroxidation in zebrafish embryos that coincided with a dose-dependent increase in gene expression of glutathione S-transferase pi 1.2 (gstp1) and heat shock cognate 70-kd protein, like (hsp70l), which is typically observed in response to oxidative stress. However, it is important to note that lipid peroxidation and gene expression analyses were evaluated in whole zebrafish embryos and therefore may not necessarily be specific to effects in immune organs. Oxidative DNA damage was reported by Yahia et al. (2014, 2851192) in a human lymphoblast cell line (TK6 cells) exposed to PFOA at concentrations of 0, 125, 250, and 500 ppm, including a dose-dependent increase in 8-OHdG levels that coincided with increases in tail moment, Olive Tail moment, and tail length in the comet assay at 250 and 500 ppm, which is indicative of DNA damage. Altogether, the evidence suggests that PFOA can induce oxidative stress in immune cells, including oxidation of lipids and DNA, potentially leading to DNA damage.
3.4.2.3.2 Mechanistic Evidence for PFOA-mediated Effects on Adaptive Immune Responses

3.4.2.3.2.1 Mechanistic data informing suppression of immune responses to vaccines and infectious diseases

PFOA-associated immunosuppressive effects are described in Section 3.4.2.2.1. Adaptive immune responses include B and T cell-mediated responses to infection and vaccination, as well as allergic responses related to allergens or autoimmune responses. Mechanistic studies suggest that chemicals, such as PFOA, can perturb the function of mature B or T lymphocytes by acting at several stages of leukocyte function, including antigen recognition, antigen signaling through the antigen receptor, activation, proliferation, and differentiation {Klaassen, 2013, 2993368}. In mice, PFOA has been shown to diminish the immune response to sheep red blood cells (SRBC), a T cell-dependent antibody response (Section 3.4.2.2), indicating that B and/or T cells can be impacted by PFOA. A review of antigen-specific IgM antibody responses by NTP (2016, 4613766) indicated that both T cell-independent responses (e.g., immunized with dinitrophenyl (DNP) or trinitrophenyl (TNP)) and T cell-dependent responses were reduced by PFOA.

One study provided evidence that antibody glycosylation patterns could be perturbed by PFOA: Liu et al. (2020, 6833599) reported that children with higher levels of serum PFOA had altered levels of N-glycosylation of IgG antibodies, which could perturb normal cell-cell interactions through protein receptors involved in antigen recognition and presentation.

Activation of T cells can be demonstrated by transcriptional changes in the genes that encode cytokines (e.g., IL-2) and cell surface proteins (e.g., IL-2 receptor); however, none of the transcriptomic studies reported significant associations with IL-2 levels and PFOA. Although not significant, one study by Zhu et al. (2016, 3360105) reported trending reductions in the levels of IL-2 and increased serum PFOA concentrations in male and female asthmatic children.

The effect of PFOA on immunoglobulin classes was evaluated in a study by Zhang et al. (2014, 2851150), in which zebrafish were exposed to 0, 0.05, 0.1, 0.5, or 1 mg/L PFOA and immunoglobulin gene expression was quantified in spleens. In contrast to mammals, which have five different classes of immunoglobulin (i.e., IgM, IgA, IgD, IgE, and IgG), zebrafish have three (IgM, IgD, and IgZ). The authors reported a dose-dependent reduction in IgM and non-monotonic dose responses in IgD and IgZ, where the greatest increases in expression were observed at the middle doses. Another zebrafish study by Zhong et al. (2020, 6315790) reported a similar inverse U-shaped dose-response curve for IgD after 7 or 14 days of exposure to 0, 0.05, 0.1, 0.5, or 1 mg/L PFOA, but reported that IgZ and IgM were elevated in groups exposed to 0.1 or 0.5 mg/L PFOA. Additionally, the effect of PFOA on gene expression of B cell activating factor (baff) paralleled that of IgD, suggesting that PFOA disrupts immunoglobulin levels by interfering with baff mRNA expression.

Differentiation of B and T cells into mature effector cells can also be affected by PFOA exposure. The cytokine milieu surrounding the T cell and antigen presenting cell (APC) influences the fate of the T cell. In addition to the cytokines mentioned above, fluctuations have been reported in IL-10, IL-5, and IL-4 levels. Associations between PFOA exposure and IL-4 or IL-5 are discussed in relation to allergic and asthmatic responses below. The data on IL-10 is limited to a single developmental study by Hu et al. (2012, 1937235), which exposed pregnant
C57BL/6N mice to 0, 0.02, 0.2, or 2 mg/kg PFOA via gavage and examined cytokine levels in the spleens of male and female PND 21 offspring. In males, IL-10 was reduced by approximately 70% relative to IL-10 released from control animals at every exposure level. In contrast, IL-10 was unaffected in females at every exposure level except for an elevation at 0.02%. IL-10 is released by regulatory T (TReg) cells and function to inhibit macrophage responses, therefore the aforementioned impacts of PFOA on macrophages may be downstream of an effect on TRegs.

The impacts of PFOA on the adaptive immune system may reflect dysregulation of cell-signaling pathways involved in adaptive immune responses. The predominant cell-signaling pathways implicated in PFOA-mediated immunotoxicity include the PPAR and NF-κB signaling pathways, which are both involved in the generation of adaptive immune responses. PPARγ activation is involved in the differentiation and development of TH1, TH2, and NK cells, and inhibits the production of inflammatory cytokines in monocytes {Liang, 2021, 9959458}.

Multiple in vitro and in vivo studies have investigated the involvement of the PPAR pathway in PFOA-immunotoxicity {Wang, 2014, 3860153; Yang, 2002, 1332453; Dewitt, 2016, 2851016}. Wang et al. evaluated the effects of PFOA in thymocytes of mice exposed to PFOA (0, 5, 10, or 20 mg/kg/day) via gavage and fed RD or HFD. PFOA upregulated gene expression of PPARα and PPARγ in the thymus of RD animals at the highest dose and elicited a dose-dependent elevation in PPARγ in the thymus for HFD animals that reached significance at 10 mg/kg group. An additional study using PPARα knock-out mice suggested the immunosuppressive effects of PFOA are independent of PPARα {DeWitt, 2016, 2851016}. In this study, female C57BL/6Tac PPARα knock-out mice and C57BL/6Tac wild-type mice were exposed to 0, 7.5, or 30 mg/kg/day PFOA in drinking water for 14 days and then injected with SRBC on day 11 {DeWitt, 2016; 2851016}. Exposure to 30 mg/kg/day PFOA for 15 days reduced SRBC-specific IgM antibody responses in both wild-type and PPARα knock-out mice by 16% and 14%, respectively. There was no significant difference between genotypes, suggesting that PPARα may not be responsible for the suppression of the immune system induced by PFOA exposure. Interestingly, this study also reported reductions in relative spleen weights (30% reduction after exposure to 30 mg/kg/day PFOA) and thymus weights (55.4% after exposure to 7.5 mg/kg/day PFOA) in the wild-type mice, but not in the knockout mice. Similarly, absolute spleen weights of male Sv/129 PPARα-null mice fed approximately 40 mg/kg/day for 7 days were unaffected by PFOA exposure, whereas in male C57BL/6 wild-type mice, absolute spleen weights were significantly reduced by 39% {Yang, 2002, 1332453}. A significant decrease in absolute thymus weight was observed in PFOA-exposed PPARα-null mice, to a lesser degree compared to the reduction observed in PFOA-exposed wild-type mice (39% reduction in PPARα-null mice and 79% reduction in wild-type mice).

One transcriptomics study in humans reported significant associations between maternal blood levels of PFAS (including PFOA), enrichment of genes in neonatal cord blood samples, and episodes of the common cold and antibody titers against the rubella vaccine in children {Pennings, 2016, 3352001}. Enrichment of PPARD in neonatal cord blood samples was correlated with maternal PFAS exposure and later common cold episodes in the children. The NF-κB pathway was proposed to be involved in this phenomenon; a comparison of the transcriptomics to the number of common cold episodes revealed that several genes in the NF-κB pathway were altered.
The NF-κB signaling pathway is essential for many parts and functions of the immune system, including a pro-survival role during lymphopoiesis and regulation of T cell differentiation. Wang et al. (2014, 3860153) provided indirect evidence that NF-κB pathway stimulation may be involved in PFOA immunotoxicity. Gene expression of the glucocorticoid receptor (GR), which stimulates the NF-κB pathway, was increased in the thymus of PFOA-treated animals at the highest exposure level (20 mg/kg), suggesting mechanisms involving NF-κB pathway stimulation may be involved in PFOA immunotoxicity. Additionally, the authors observed that IL-1B gene expression was elevated in the thymus, suggesting that the NF-κB pathway is not suppressed.

3.4.2.3.2.2 Mechanistic data informing allergic or asthmatic responses

Several studies evaluated potential associations between PFOA exposure and allergic responses or asthma. An epidemiological study by Zhu et al. (2016, 3360105) explored the associations between PFOA exposure and TH1/TH2 polarization in asthmatic children. Male asthmatic children with higher serum levels of PFOA tended to have higher serum IL-4 and IL-5, evident of a TH2 skew. This association was not observed in females, suggesting that the exacerbation of asthma by PFOA involving TH2 cytokines may be male-specific (Table 3-5).

More detailed mechanistic evidence on the relationship between PFOA and allergic responses is available from animal toxicological studies. A dermal exposure study by Shane et al. (2020, 6316911) applied 0.5–2 % (w/v; equivalent to 12.5–50 mg/kg) PFOA to the skin of BALB/C mice and evaluated allergic sensitization and IgM response. PFOA did not elicit an irritancy response, suggesting that PFOA is not an allergic sensitizer or dermal irritant. However, the splenic IgM response to SRBC was suppressed after 4 days of exposure to 2% PFOA, implying that T cell-dependent immune responses to dermal allergens may be affected by PFOA. Moreover, mice exposed to PFOA had increased expression of Tslp, which is associated with a polarization towards a TH2 response {Shane, 2020, 6316911}. In adult zebrafish, the effect of PFOA exposure on mRNA expression of IL-4 was mixed: it was elevated at most doses tested, but reduced at the highest dose {Zhang, 2014, 2851150}. More data from mammalian models on the associations between IL-4 or IL-10 and PFOA are needed to better understand the potential impacts of PFOA on adaptive immune responses involving T cell subsets.

An in vitro study conducted by Lee et al. (2017, 3981419) demonstrated that PFOA increased IL-1β gene and protein expression in a dose-related manner in IgE-stimulated RBL-2H3 cells (a rat basophil cell line). Elevated IL-1β was also observed in a study of human bronchial epithelial cells (HBEC3-KT cells) stimulated with a pro-inflammatory agent, Poly I:C, and then treated with 0.13, 0.4, 1.1, 3.3, or 10 μM PFOA {Sørli, 2020, 5918817}.

Several studies have evaluated molecular signaling pathways to better understand the mechanistic underpinnings of allergic or asthmatic responses related to exposure to PFOA. At least four mechanistic studies have evaluated the involvement of the NF-κB signaling pathway, which plays an important role in the regulation of inflammation and immune responses, including expression of pro-inflammatory cytokines {Lee, 2017, 3981419; Shane, 2020, 6316911; Zhong, 2020, 6315790; Zhang, 2014, 2851150}. Histamine release and mast cell degradation were increased in parallel with increased nuclear localization of NF-κB and concomitant reduction in IκB in IgE-stimulated mast cells, suggesting that allergic immune responses and inflammation are exacerbated by PFOA through a mechanism involving the NF-κB pathway.
κB pathway \{Lee, 2017, 3981419\}. Zhang et al. (2014, 2851150) reported that PFOA exposure for 21 days can disrupt the NF-κB pathway to mediate inflammatory cytokines in zebrafish. The authors reported a non-monotonic dose-response in gene expression of the p65 transcription factor in RNA isolated from zebrafish splenocytes. In a more recent study, zebrafish were exposed to PFOA for a shorter period (7 or 14 days) and the authors reported that splenic gene expression was increased in all exposed groups \{Zhong, 2020, 6315790\}. Shane et al. (2020, 6316911) showed that gene expression of NF-κB (Nfkb1) was reduced in the skin of female BALB/c mice dermally exposed to 1 or 2% PFOA after 14 days. However, the study design did not quantify nuclear NF-κB, so it is difficult to discern whether the NF-κB pathway was activated. The authors also reported that gene expression of PPARα was reduced by more than 50% in female mice dermally exposed to 1% or 2% PFOA for 14 days. Mechanistically, PPARα is known to block the NF-κB pathway and thereby modulate immune responses. These data suggest that the NF-κB pathway activity can be reduced independent of action by PPARα in PFOA-mediated immunotoxicity with respect to allergic responses in the skin.

**Table 3-5. Effects of PFOA Exposure on Cytokines Impacting Adaptive Immune Responses**

<table>
<thead>
<tr>
<th>Study</th>
<th>Species or Cell Type</th>
<th>Study Type</th>
<th>Cytokine</th>
<th>Measurement</th>
<th>Significant Change in Cytokine</th>
<th>Relevant Immune response</th>
</tr>
</thead>
<tbody>
<tr>
<td>{Zhu, 2016, 3360105}</td>
<td>Human males and females, GBCA study</td>
<td>Epi</td>
<td>IL-2</td>
<td>serum protein (ELISA)</td>
<td>None</td>
<td>Allergy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IL-4</td>
<td>serum protein (ELISA)</td>
<td>↑*</td>
<td>Allergy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IL-5</td>
<td>serum protein (ELISA)</td>
<td>↑*</td>
<td>Allergy</td>
</tr>
<tr>
<td></td>
<td>C57BL/6N mice</td>
<td>Ex vivo</td>
<td>IL-10</td>
<td>IL-10 production assay in CD4+CD25+ T cells</td>
<td>T_{reg} responses</td>
<td></td>
</tr>
</tbody>
</table>

Notes: ELISA = enzyme-linked immunosorbent assay; GBCA = Genetic and Biomarkers study for Childhood Asthma; IL-2 = Interleukin 2; IL-4 = Interleukin 4; IL-5 = Interleukin 5; IL-10 = Interleukin 10; T_{reg} = regulatory T cells.

*a Males only

*b Purity of CD4+CD25+ T cells derived by cell estimate to be 84–95% based on manufacturer specification for the cell isolation kit.

**3.4.2.3.2.3 Mechanistic data informing autoimmune diseases**

Select data on PFOA and autoimmune diseases in humans have been summarized by NTP (2016, 4613766). NTP’s conclusion that PFOA was presumed to be an immune hazard to humans was partially based on the positive associations that exist between PFOA exposure and rheumatoid arthritis, ulcerative colitis, and auto-antibodies specific to neural and non-neural antigens. However, the association was considered low confidence by the NTP. No animal or in vitro studies have been identified to inform the potential associations between PFOA and autoimmunity.
3.4.2.3.3 Mechanistic Evidence for PFOA-mediated Effects on Innate Immune Responses

Neutrophils are important cells of the innate immune system that contribute to inflammation and are the first cells to arrive at the site of injury or infection. Reductions in neutrophil migration to the site of injury have been noted in zebrafish exposed to PFOA {Pecquet, 2020, 6833701}, suggesting diminished innate immune responses.

Neutrophil migration occurs in response to inflammation and in response to effector cytokines such as IL-8 released from macrophages, which may also be sensitive to PFOA. Qazi et al. (2010, 1276154) evaluated liver homogenates from male C57BL/6 mice and found that ex vivo production of TNF-α was significantly decreased in animals treated with 0.002% or 0.005% PFOA. Because macrophages are the major producers of TNF-α, the authors propose that PFOA may directly or indirectly affect specialized hepatic macrophages (e.g., Kupffer cells). The decrease in TNF-α release from macrophages could also be related to PFOA effects on the adaptive immune system, given that macrophage responses are inhibited by IL-10 released by TReg cells. Indeed, Hu et al. (2012, 1937235) demonstrated that ex vivo release of IL-10 from splenocytes was reduced in male mice. Furthermore, cells of the monocyte/macrophage lineage express PPARα and PPARγ {Zhu, 2016, 3360105; Braissant, 1998, 729555}, which supports a mechanism for immunosuppression involving macrophages and PPAR pathways.

Rainieri et al. (2017, 3860104) also conducted an in vitro assessment using TLT cells and found that PFOA led to an increase in relative reactive oxygen species (ROS) production measured via the dichlorodihydrofluorescein diacetate (DCF-DA) assay, indicating that PFOA can induce ROS in macrophages.

Although the innate immune system also includes natural killer (NK) cells, no mechanistic studies were identified that evaluated associations with PFOA. One study by Qazi et al. (2010, 1276154) reported that there were no significant differences in number or percent of NK cells in isolated hepatic immune cells (IHICs) of mice exposed to 0.002% (w/w) PFOA in the diet for 10 days.

3.4.2.3.4 Mechanistic Evidence for PFOA-mediated Effects on Intrinsic Cellular Defense Pathways

Zhang et al. (2014, 2851150) exposed zebrafish to PFOA (0.05, 0.1, 0.5, and 1 mg/L) for 21 days. After exposure, spleens were analyzed for expression patterns of myeloid differentiation 88 (MyD88) and toll-like receptor 2 (TLR2) as well as several cytokines. In addition to the above-mentioned effects on gene expression of IL-4, PFOA exerted dose-dependent effects on IL-1β and IL-21 that were stimulated at a low exposure concentration (0.05 mg/L) and inhibited at higher exposure concentrations (≥0.1 mg/L). The Myd88/NF-κB pathway was found to mediate inflammatory cytokine (IL-1 and IL-21) gene expression in zebrafish spleen. Interestingly, exposure of zebrafish to 1 mg/L PFOA reduced TLR2 mRNA expression in spleen by 56% compared to controls. These findings suggest that exposure to PFOA in zebrafish can activate the NF-κB pathway and interfere with TLR2 expression in a dose-dependent manner to enhance pro-inflammatory cytokine gene expression.
3.4.2.3.4.1 Mechanistic Evidence for PFOA-mediated Effects on Inflammation

The observed increases in circulating leukocytes (neutrophils and monocytes) of experimental animals (Section 3.4.2.2) are consistent with an inflammatory response. Inflammation is a physiological response to tissue damage or infection that can induce components of the innate and adaptive immune system {Klaassen, 2013, 2993368}. Processes that contribute to inflammation and are affected by PFOA include the complement cascade, release and/or upregulation of pro-inflammatory cytokines, and neutrophil migration.

3.4.2.3.4.1.1 Pro-inflammatory Responses Including Cytokines

The available mechanistic data support that pro-inflammatory cytokines such as IL-1β, TNF-α, and possibly IL-6 are elevated by PFOA exposure (Table 3-6). However, the effect of PFOA (or lack thereof) for some cytokines varies between model organisms and exposure levels. Altered production and/or release of these cytokines may represent an underlying mechanism of the reductions in innate and/or adaptive immune function that has been reported in the human (Section 3.4.2.1) and animal (Section 3.4.2.2) literature.

Elevation of IL-1β is consistent across study designs in mammalian models in vivo and in vitro. Wang et al. (2014, 3860153) exposed 4–5-week-old male BALB/C mice to 0, 5, 10, or 20 mg/kg/day PFOA via gavage for 14 days in combination with HFD or RD and measured gene expression of cytokines in the thymus and spleen. In the thymus, IL-1β was elevated in mice exposed to 20 mg/kg/day and fed RD. There were no significant effects in the spleen for mice fed RD at any PFOA concentration. In HFD-fed mice, there was an increase in IL-1β in the spleen for the 10 mg/kg/day PFOA group, but no significant changes at any exposure level in the thymus. Likewise, Lee et al. (2017, 3981419) and Sørlø et al. (2020, 5918817) have demonstrated that PFOA elevates IL-1β gene and/or protein expression in various cell lines. In contrast to the consistent increases in IL-1β reported in mammalian models, one study in adult zebrafish reported decreased IL-1β mRNA in the spleen following exposure to 0.1, 0.5, or 1 mg/L PFOA for 21 days {Zhang, 2014, 2851150}. More research is needed to determine whether interspecies differences exist in immunomodulation by PFOA. Elevated production of IL-1β is triggered by activation of the inflammasome, which is an innate immune response known to be activated by xenobiotics, and this mechanism may deserve further investigation {Mills, 2013, 2556647}.

Several studies have reported elevated levels of TNF-α during immune responses following exposure to PFOA. Qazi et al. (2010, 1276154) reported decreased levels of TNF-α in liver homogenates of male C57BL/6 mice orally exposed to 0.002% PFOA for 10 days. Lee et al. (2017, 3981419) quantified TNF-α levels in blood from male ICR mice following an active systemic anaphylaxis experiment. Mice were sensitized to ovalbumin on day 0 and day 7 via intraperitoneal (i.p.) injection, and PFOA was orally administered on day 9, 11, and 13. Following ovalbumin challenge (i.p.) on day 14, a dose-dependent increase in TNF-α levels in blood was observed, suggesting PFOA aggravates allergic inflammation. In the same study, in vitro experiments using three independent methods (Western blot, RT-PCR, and ELISA) demonstrated a dose-dependent elevation in TNF-α in RBL-2H3 cells sensitized with anti-DNP IgE, then treated with PFOA for 24 hours. Likewise, an in vitro study by Brieger et al. (2011, 1937244) observed a slight increase in TNF-α released from peripheral blood mononuclear cells (PBMCs) obtained from the blood of 11 human donors. Not all studies reported positive associations of PFOA and TNF-α. Although Bassler et al. (2019, 5080624) reported positive
associations between serum PFOA levels and IFN-γ, the authors found inverse associations with TNF-α.

A few of the studies that observed increases in IL-1β and TNF-α also evaluated other pro-inflammatory cytokines such as IL-8 and IL-6. The in vitro studies by Lee et al. (2017, 3981419) did not find significant effects of PFOA on IL-8 expression. This finding was consistent with those of Sørli et al. (2020, 5918817) and Bassler et al. (2019, 5080624). IL-6 gene and protein expression were elevated in the study by Lee et al. (2017, 3981419), which was consistent with results of Brieger et al. (2011, 1937244) in human PBMCs stimulated with LPS. Most other studies reported either no effect or inverse associations with IL-6 {Mitro, 2020, 6833625; Shane, 2020, 6316911}. Giménez-Bastida et al. (2015, 3981569) reported that PFOA attenuated the elevation in IL-6 levels that normally follows IL-1β-induction in a human colon cell line (CCD-18Co).

IFN-γ is released from activated T cells and NK cells and induces macrophages to produce a variety of inflammatory mediators and reactive oxygen and nitrogen intermediates that contribute to inflammation {Klaassen, 2013, 2993368}. In general, studies did not find associations between PFOA and changes in IFN-γ. The sole exception by Zhong et al. (2020, 6315790) reported elevations in IFN gene expression in splenocytes of adult zebrafish exposed to 0.05, 0.1, 0.5, or 1 mg/L PFOA for 7 days. Zhu et al. (2016, 3360105) reported that children with asthma generally had higher serum PFOA concentrations and lower levels of IFN-γ than non-asthmatic children, but there was not a significant association between IFN-γ and PFOA. Qazi et al. (2010, 1276154) measured IFN-γ levels secreted from IHICs of 6-8-week-old male C57BL/6 (H-2b) mice that were exposed to 0 or 0.002% (w/w) PFOA in feed for ten days. A subgroup of IHIC were stimulated with Concanavalin A, which activates T cells to produce IFN-γ. No PFOA-related differences in IFN-γ production were observed in any group in IHICs. The authors also reported a 37% reduction in hepatic levels of IFN-γ, in parallel with reductions in hepatic levels of IL-4 and TNF-α.

Inflammatory responses can be accompanied by increased levels of the activated pro-inflammatory transcription factor, NF-κB. Sirtuins (SIRTs) have been shown to deacetyllate NF-κB, which suppresses its transcriptional activation, thereby inhibiting the production of pro-inflammatory cytokines. Park et al. (2019, 5412425) exposed a macrophage cell line (RAW 264.7 cells) to 0, 0.5, 5 or 50 μM PFOA and observed significant increases in expression for SIRT3 and SIRT6 at 5 μM exposure, which is inconsistent with a model where PFOA induces inflammation. Interestingly, SIRT4 and SIRT7 expression was more sensitive to PFOA and exhibited non-linear dose-response curves; SIRT4 was significantly reduced at 0.5 μM and significantly elevated at 5 μM, whereas SIRT7 was significantly elevated at 0.5 μM and significantly reduced at 5 and 50 μM. Altogether, the results support that a pro-inflammatory response of PFOA may not follow a linear dose-response.

3.4.2.3.4.1.2 Complement Pathways

PFOA can affect both the innate and adaptive immune system to perturb activation of one of the three main pathways of the complement cascade. A study conducted in the C8 Health Project cohort found that serum biomarkers of PFOA were positively associated with serum C3a levels in men, but negatively associated in women, supporting sex-specific perturbations in immune function {Bassler, 2019, 5080624}. Also using data from the C8 Health Project, another group of
researchers, Genser et al. (2015, 3271854) found evidence that PFOA blood levels were negatively associated with blood levels of C-reactive Protein (CRP), which is essential for the classical pathway of complement activation [Klaassen, 2013, 2993368]. However, another human study, that measured CRP as one among several blood biomarkers of cardiometabolic disruption reported that serum PFOA was “generally weakly” (i.e., not significantly) associated with CRP and other biomarkers in women 3 years postpartum [Mitro, 2020, 6833625]. In contrast to the human evidence, serum C3 levels were reduced in male C57BL/6 (H-2b) mice exposed to 0.02% w/w PFOA in feed for 10 consecutive days [Botelho, 2015, 2851194]. Female mice were not studied. Reduced activities of the classical and alternative complement pathways (reflected by CH50 and AH50 response, respectively) were also reported, supporting that PFOA can disrupt the classical (IgM/IgG dependent) and alternative pathways of complement activation, which both require C3.

Table 3-6. Effects of PFOA Exposure on Pro-Inflammatory Cytokines and Markers of Inflammation

<table>
<thead>
<tr>
<th>Study</th>
<th>Species or Cell Type</th>
<th>Study Type</th>
<th>Cytokine or Inflammatory Marker</th>
<th>Measurement</th>
<th>Direction of Change Following PFOA Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitro et al. (2020, 6833625)</td>
<td>Human females, 3 years postpartum</td>
<td>In vivo</td>
<td>IL-6</td>
<td>blood protein (ELISA)</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CRP</td>
<td>blood protein (immunoturbidimetric high-sensitivity assay)</td>
<td>↓</td>
</tr>
<tr>
<td>Bassler et al. (2019, 5080624)</td>
<td>Human males and females, C8 Health Project</td>
<td>In vivo</td>
<td>IL-6</td>
<td>serum protein (Multispot Immunoassay)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TNF-α</td>
<td>serum protein (Multispot Immunoassay)</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IL-8</td>
<td>serum protein (Multispot Immunoassay)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IFNγ</td>
<td>serum protein (Multispot Immunoassay)</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C3a</td>
<td>serum protein (ELISA)</td>
<td>None</td>
</tr>
<tr>
<td>Sørli et al. (2020, 5918817)</td>
<td>Human bronchial epithelial cell line</td>
<td>In vitro</td>
<td>IL-6</td>
<td>culture supernatant protein (ELISA)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IL-1α</td>
<td>culture supernatant protein (ELISA)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IL-1β</td>
<td>culture supernatant protein (ELISA)</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CXCL8</td>
<td>culture supernatant protein (ELISA)</td>
<td>None</td>
</tr>
<tr>
<td>Wang et al. (2014, 3860153)</td>
<td>BALB/c mice</td>
<td>In vivo</td>
<td>IL-1β</td>
<td>Gene expression</td>
<td>↑</td>
</tr>
<tr>
<td>Shane et al. (2020, 6316911)</td>
<td>BALB/c mice</td>
<td>In vivo</td>
<td>IL-1β</td>
<td>Gene expression</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IL-6</td>
<td>Gene expression</td>
<td>None</td>
</tr>
<tr>
<td>Study</td>
<td>Species or Cell Type</td>
<td>Study Type</td>
<td>Cytokine or Inflammatory Marker</td>
<td>Measurement</td>
<td>Direction of Change Following PFOA Exposure</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------</td>
<td>------------</td>
<td>---------------------------------</td>
<td>-------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Qazi et al. (2010, 1276154)</td>
<td>C57BL/6 mice</td>
<td>Ex vivo</td>
<td>IFN-γ</td>
<td>culture supernatant protein (ELISA)</td>
<td>None</td>
</tr>
</tbody>
</table>

Notes: IL-6 = Interleukin 6; CRP = C-Reactive Protein; TNF-α = Tumor Necrosis Factor α; IL-8 = Interleukin 8; IFNγ = Interferon γ; C3a = cleavage product of Complement 3

3.4.2.3.5 Conclusions

Overall, the available evidence supports that PFOA affects the innate and adaptive immune system as well as immune organ physiology at multiple levels including immune system development, survival, proliferation, and differentiation of B and T cells, inflammatory responses, neutrophil migration, and complement activation. One study provided evidence that antibody glycosylation patterns could be perturbed. Mechanistic data available from \textit{in vitro}, \textit{in vivo}, and epidemiological studies were used to evaluate the etiology and mode of action of PFOA-associated immunosuppression and other effects on the immune system. The pleotropic immunomodulatory effects of PFOA, including impaired vaccine responses, may reflect perturbed function of B and/or T cells. At the molecular level, dysregulation of the NF-κB pathway may contribute to the immunosuppressive effects of PFOA. The NF-κB pathway facilitates initial T cell responses by supporting proliferation and regulating apoptosis, participates in the regulation of CD4+ T cell differentiation, and is involved in mediating inflammatory responses. Dysregulation of the NF-κB pathway by PFOA, potentially consequent to the induction of oxidative stress, may be a key component of the mechanism underlying PFOA-mediated immunosuppression. Reduced NF-κB activation and consequent elevation of apoptosis is consistent with increased apoptosis in multiple cell types, the reduction of pre/pro-B cell numbers, and dysregulation of pro-inflammatory cytokines and mediators of inflammation.

NF-κB activation also facilitates the induction of apoptosis during negative selection of T cells in the thymus, which is essential for the deletion of T cells that recognize self. In contrast, NF-κB acts as a pro-survival factor during the negative selection of B cells. In human studies, PFOA exposure has been associated with autoimmune diseases including ulcerative colitis. Further mechanistic evidence is needed to determine the directionality of the effect of PFOA on NF-κB, which will inform the cell types that predominantly contribute to the etiology of autoimmune diseases associated with PFOA exposure.

3.4.2.4 Evidence Integration

There is moderate evidence for an association between PFOA exposure and immunosuppressive effects in human studies based on largely consistent decreases in antibody response following vaccinations (against two different infectious agents: tetanus and diphtheria) in multiple medium confidence studies in children. Reduced antibody response is an indication of immunosuppression and may result in increased susceptibility to infectious disease. The antibody response results present a consistent pattern of findings that higher prenatal, childhood, and adult serum concentrations of PFOA were associated with suppression of at least one measure of the anti-vaccine antibody response to common vaccines in two well-conducted (though overlapping) birth cohorts in the Faroe Islands, supported by a low confidence study in adults.
The results in human epidemiological studies measuring PFOA concentrations and hypersensitivity were mixed. Significant associations between PFOA exposure and “ever” or “current” asthma were seen primarily in sex- or age-specific subgroups but were null or insignificant in whole study analyses. For allergy and eczema outcomes, results were inconsistent across studies.

The associations between PFOA exposure and human autoimmune disease were also mixed. Two studies {Steenland, 2013, 1937218; Steenland, 2018, 5079806} found significant associations indicating increased risk of autoimmune disease. Also, PFOA levels were found to be lower in healthy controls compared to cases with MS {Ammitzbøll, 2019, 5080379}. Results were most consistent for ulcerative colitis, with significant associations indicating increased risk with increasing PFOA exposure in one medium confidence study {Steenland, 2013, 1937218} and one low confidence study {Steenland, 2018, 5079806}.

The animal evidence for an association between PFOA exposure and immunosuppressive responses is moderate based on 13 high or medium confidence animal toxicological studies. Short-term and developmental PFOA exposure in rodents resulted in reduced spleen and thymus weights, altered immune cell populations, and decreased splenic and thymic cellularity. In functional assessment of the immune response, PFOA exposure was associated with reduced globulin and immunoglobulin levels {Dewitt, 2008, 1290826; Loveless, 2008, 988599}. Suppression of the immunoglobulin response in these animals is consistent with decreased antibody response seen in human subpopulations.

Mechanistic data related to the human immunomodulatory effects were similarly inconsistent compared to the human epidemiological data. The available mechanistic data indicate that pro-inflammatory cytokines such as IL-1β, TNF-α, and possibly IL-6 are elevated by PFOA exposure. However, the specific effects vary across model organisms and exposure levels. Altered production and/or release of these cytokines may reflect reductions in innate and/or adaptive immune function that has been reported in the human and animal literature.

While evidence exists for reduced antibody response, such as diminished immune response to sheep red blood cells in mice treated with PFOA (a T cell-dependent antibody response), data are limited. Both T cell-dependent and T cell-independent responses are reduced by PFOA, according to a systematic review conducted by the NTP {NTP, 2016, 4613766}. Alterations to these responses could explain the decreased antibody response in humans. Although the evidence is not consistent across studies or between sexes and/or model systems, several studies have reported that PFOA appears to exacerbate allergic immune and inflammatory response, likely through disruption to the NF-κB pathway, increased TNFα, and/or TH2 response.

One proposed mechanism of immunotoxicity involves apoptosis of immune cells, which appears to be a high-dose phenomenon, as evidenced by in vivo and in vitro studies in which the effects were only seen at ≥ 10 mg/kg/day in mice or 500 mg/L in the human macrophage TLT cell line. Relatedly, NF-κB activation also facilitates the induction of apoptosis during negative selection of T cells in the thymus, which is essential for the deletion of T cells that recognize host cells (i.e., “self”). In contrast, NF-κB acts as a pro-survival factor during the negative selection of B cells. PFOA has been shown to disrupt the NF-κB pathway. At the molecular level, dysregulation of the NF-κB pathway may contribute to the immunosuppressive effects of PFOA. The NF-κB pathway facilitates initial T cell responses by supporting proliferation and regulating
apoptosis, participating in the regulation of CD4+ T cell differentiation, and participating in mediating inflammatory responses. Dysregulation of the NF-κB pathway by PFOA, potentially consequent to the induction of oxidative stress, may be a key component of the mechanism underlying PFOA-mediated immunosuppression. Reduced NF-κB activation and consequent elevation of apoptosis is consistent with increased apoptosis in multiple cell types, the reduction of pre/pro B cell numbers, and dysregulation of pro-inflammatory cytokines and mediators of inflammation.

There is conflicting evidence regarding the involvement of PPAR signaling in immunotoxic effects of PFOA: there is evidence of PPAR-independent alterations to adaptive immunity, while suppressive effects of innate immunity appear to involve macrophages and PPAR signaling.

3.4.2.4.1 Evidence Integration Judgment

Overall, considering the available evidence from human, animal, and mechanistic studies, the evidence indicates that PFOA exposure is likely to cause adverse immune effects, specifically immunosuppression, in humans under relevant exposure circumstances (Table 3-7). The hazard judgment is driven primarily by consistent evidence of reduced antibody response from epidemiological studies at median levels as low as 1.1 ng/mL PFOA. The evidence in animals showed coherent immunomodulatory responses at doses as low as 1 mg/kg/day PFOA that are consistent with potential immunosuppression and supportive of the human studies, although issues with overt organ/systemic toxicity raise concerns about the biological significance of some of these effects. While there is some evidence that PFOA exposure might also have the potential to affect sensitization and allergic responses in humans given relevant exposure circumstances, the human evidence underlying this possibility is uncertain and with limited support from animal or mechanistic studies. Based on the antibody response data in humans, children and young individuals exposed during critical developmental windows may represent a potential susceptible population for the immunosuppressive effects of PFOA. The absence of additional epidemiological studies or any long-term/chronic exposure studies in animals examining alterations in immune function or immune-related disease outcomes during different developmental life stages represents a source of uncertainty in the immunotoxicity database of PFOA.
Table 3-7. Evidence Profile Table for PFOA Immune Effects

<table>
<thead>
<tr>
<th>Evidence Stream Summary and Interpretation</th>
<th>Evidence Integration Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence from Studies of Exposed Humans (Section 3.4.2.1)</td>
<td>⊕⊕⊙ Evidence Indicates (likely)</td>
</tr>
<tr>
<td>Immunosuppression</td>
<td>Primary basis and cross-stream coherence: Human data indicated consistent evidence of reduced antibody response. Evidence in animals showed coherent immunomodulatory responses that are consistent with potential immunosuppression and supportive of the human studies, although issues with overt organ/systemic toxicity raise concerns about the biological significance of some of these effects. While there is some evidence that PFOA exposure might also have the potential to affect sensitization and allergic responses in humans given relevant exposure circumstances, the human evidence underlying this possibility is uncertain and has only limited support from animal or mechanistic studies.</td>
</tr>
<tr>
<td>1 High confidence study</td>
<td>Moderate</td>
</tr>
<tr>
<td>15 Medium confidence studies</td>
<td></td>
</tr>
<tr>
<td>8 Low confidence studies</td>
<td></td>
</tr>
<tr>
<td>1 Mixed confidence study</td>
<td></td>
</tr>
</tbody>
</table>

Studies conducted in the Faroe Islands examined antibody levels among children at various timepoints compared to exposure measured prenatally and throughout childhood. Lower antibody levels against tetanus and diphtheria were observed in children at birth, 18 months, age 5 years (pre- and post-booster), and at age 7 years, with some being statistically significant. Findings in the three studies examining adults and adolescents were less consistent than in children. One study reported an inverse association for hepatitis B antibodies, but other antibody responses were inconsistent across all exposure windows. Infectious disease was examined in 11 studies of children. Studies examining infections of the respiratory system observed some positive • High and medium confidence studies • Consistent direction of effect • Coherence of findings between antibody response and increased infectious disease • Low confidence studies • Imprecision of findings
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune hypersensitivity</td>
<td>Examination of immune hypersensitivity includes outcomes such as asthma, allergies, and eczema. Increased odds of asthma were reported in most medium confidence studies (6/9), although associations were often inconsistent by subgroups. Low confidence studies supported the findings of increased odds of asthma or higher exposure levels among asthmatics, although results were not always consistent or precise. Seven studies examined allergies, rhinitis, or rhinoconjunctivitis. Some positive associations (3/7) were observed, although this varied by outcome timing and were at times inconsistent. Significantly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 High confidence study</td>
<td></td>
<td>• High and medium confidence studies</td>
<td>• Low confidence studies</td>
<td></td>
</tr>
<tr>
<td>16 Medium confidence studies</td>
<td></td>
<td>• Consistent direction of effect for asthma across medium confidence studies</td>
<td>• Inconsistent direction of effect between subpopulations</td>
<td></td>
</tr>
<tr>
<td>5 Low confidence studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Mixed confidence studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Human relevance and other inferences:**
Based on the antibody response data in humans, children and young individuals exposed during critical developmental windows may represent a potential susceptible population for the immunosuppressive effects of PFOA. The absence of additional epidemiological studies or any long-term/chronic exposure studies in animals examining alterations in immune function or immune-related disease outcomes during different developmental life stages represents a source of uncertainty in the immunotoxicity database of PFOA.
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autoimmune disease</strong></td>
<td>Increased risk of autoimmune disease was reported in several studies (4/6). One study reported a significantly increased risk of rheumatoid arthritis, and two studies reported a significantly increased risk of ulcerative colitis. Two studies reported positive associations for multiple sclerosis, with one reaching significance. One study observed increased risk of celiac disease among children and young adults. Findings for Crohn’s disease and type 1 diabetes were less consistent.</td>
<td>• Medium confidence studies</td>
<td>• Low confidence studies</td>
<td>• Limited number of studies examining outcome</td>
</tr>
</tbody>
</table>

### Evidence from In Vivo Animal Toxicological Studies (Section 3.4.2.2)

<table>
<thead>
<tr>
<th>Organ weights</th>
<th>Decreases in absolute (6/8) and relative (4/8) spleen weights and in absolute (5/5) and relative (3/5) thymus weights were observed across studies regardless of study design. Overall, decreases in</th>
<th>• High and medium confidence studies</th>
<th>• Inconsistent direction of effects across sex</th>
<th>Moderate</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 High confidence studies</td>
<td></td>
<td>• Dose-response relationship seen within multiple studies</td>
<td>• Confounding variables such as decreases in body weights</td>
<td></td>
</tr>
</tbody>
</table>
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune cellularity</td>
<td>spleen and thymus weights were more frequently observed in males than females and tended to coincide with reductions in body weight.</td>
<td>immunological endpoints</td>
<td></td>
<td>developmental PFOA exposure in rodents resulted in reduced spleen and thymus weights, altered immune cell populations, and decreased splenic and thymic cellularity. In functional assessments of the immune response, PFOA exposure was associated with reduced globulin and immunoglobulin levels. Suppression of the immunoglobulin response in these animals is consistent with decreased antibody response seen in human subpopulations.</td>
</tr>
</tbody>
</table>
| 1 High confidence study   | Of the studies that measured circulating WBCs and differentials, one short-term study in male mice found decreases in WBC counts, while a chronic rat study observed transient increases in males that were attributed to increased counts of lymphocytes and neutrophils. One short-term study in male rats and mice reported increased neutrophils and monocytes, decreased eosinophils, as well as reduced splenocytes and thymocytes in mice but no changes in rats. One developmental study in mice observed decreases in splenic regulatory T cells in males and females. | • High and medium confidence studies  
• Dose-response relationship seen within multiple studies  
• Coherence of findings | • Inconsistent direction of effects across species, sex, and study design  
• Limited number of studies examining specific outcomes | |
| 4 Medium confidence studies | Mixed results were reported for concentrations of globulins and immunoglobulins. Decreased globulin levels | | | |
| Globulins and immunoglobulins | | • High and medium confidence studies  
• Dose-response relationship | • Inconsistent direction of effects between species | |
## Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Medium confidence studies</td>
<td>(2/3) were observed in male and female rats, in a dose-dependent manner (1/3), following short-term and chronic exposure to PFOA. One short-term study reported increased globulins (1/3) in male mice. Additional findings, including increases in IgA, IgG, and IgM, were found in male mice.</td>
<td>• Limited number of studies examining specific outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune response 4 Medium confidence studies</td>
<td>Dose-dependent decreases in IgM following a SRBC or KLH challenge was seen in three short-term studies in mice (3/4). No changes in IgM were observed in chronically exposed male rats nor developmentally exposed female mice (2/4). In a short-term study that assessed female mice, increased IgG levels were observed after a SRBC challenge (1/2), but a developmental study in female mice found no changes in IgG levels (1/2).</td>
<td>• Limited number of studies examining specific outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histopathology 3 High confidence studies</td>
<td>A short-term study in male mice and rats reported increased incidence of granulocytic hyperplasia</td>
<td>• High and medium confidence studies</td>
<td>• Limited number of studies examining specific outcomes</td>
<td></td>
</tr>
</tbody>
</table>

### Immune response
- Medium confidence studies
  - Dose-response relationship seen within multiple studies

### Histopathology
- High confidence studies
Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Medium confidence studies</td>
<td>of the bone marrow and increased incidence of splenic and thymic atrophy in mice but not rats. One high confidence short-term study in male and female rats observed no changes in the spleen, thymus, or lymph nodes but found increased bone marrow hypocellularity in male rats. One chronic study found decreased incidence of splenic hemosiderosis in male and female rats. One chronic and one developmental study observed histopathological changes in the spleen, thymus, bone marrow, and/or lymph nodes of male and female rats.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mechanistic Evidence and Supplemental Information (Section 3.4.2.3.4)

Summary of Key Findings, Interpretation, and Limitations

<table>
<thead>
<tr>
<th>Key findings and interpretation:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Apoptosis of immune cells is a high dose immunotoxic phenomenon that has been observed in both <em>in vivo</em> and <em>in vitro</em> studies of PFOA.</td>
</tr>
<tr>
<td>• Disruption of the NF-κB signaling pathway, which is involved in T-cell responses, regulation of apoptosis, and inflammatory response, has been demonstrated both directly and indirectly in <em>in vivo</em> human and animal data, as well as <em>in vitro</em>.</td>
</tr>
<tr>
<td>• Inconsistent evidence of exacerbation of allergic immune and inflammatory responses via NF-κB pathway, increased TNFα, and/or T_2_ response.</td>
</tr>
</tbody>
</table>

Evidence Stream Judgement

Findings support plausibility that PFOA exposure can lead to dysregulation of signaling pathways related to immune response; however, data have inconsistencies.
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgment</th>
<th>Evidence Integration Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Limitations:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Inconsistent findings between sexes, model systems, and studies regarding allergic immune response.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Limited database for immune response data.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• While PPARα is mechanistically linked to immune signaling (blocking the NF-κB pathway), it is not clear if PFOA-induced alterations to PPARα are involved in immunomodulatory effects: some PPARα-knockout mouse studies have suggested that immunomodulation occurs independent of PPARα.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** COVID-19 = coronavirus disease 2019; WBC = white blood cells; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; SRBC = sheep red blood cells; KLH = keyhole limpet hemocyanin; NF-κB = nuclear factor kappa B; TNFα = tumor necrosis factor alpha; T_{H}2 = T helper 2; PPARα = peroxisome proliferator activated receptor alpha.

*Studies may be of mixed confidence due to differences in how individual outcomes within the same study were assessed (e.g., clinical test vs self-reported data).*
3.4.3 Cardiovascular

EPA identified 112 epidemiological and 9 animal toxicological studies that investigated the association between PFOA and cardiovascular effects. Of the 54 epidemiological studies addressing cardiovascular endpoints, 3 were classified as high confidence, 28 as medium confidence, 14 as low confidence, 5 as mixed (1 high/medium and 4 medium/low) confidence, and 4 were considered uninformative (Section 3.4.3.1). Of the 87 epidemiological studies addressing serum lipid endpoints, 1 was classified as high confidence, 29 as medium confidence, 32 as low confidence, 19 as mixed (1 high/medium and 18 medium/low) confidence, and 8 were considered uninformative (Section 3.4.3.1). Of the animal toxicological studies, 3 were classified as high confidence, 4 as medium confidence, and 2 were considered low confidence (Section 3.4.3.2). Studies have mixed confidence ratings if different endpoints evaluated within the study were assigned different confidence ratings. Though low confidence studies are considered qualitatively in this section, they were not considered quantitatively for the dose-response assessment (Section 4).

3.4.3.1 Human Evidence Study Quality Evaluation and Synthesis

3.4.3.1.1 Cardiovascular Endpoints

3.4.3.1.1.1 Introduction

Cardiovascular disease (CVD) is the primary cause of death in the United States with approximately 12% of adults reporting a diagnosis of heart disease (Schiller, 2012, 1798736). Studied health effects include ischemic heart diseases (IHD), coronary artery disease (CAD), coronary heart disease (CHD), hypertension, cerebrovascular disease, atherosclerosis (plaque build-up inside arteries and hardening and narrowing of their walls), microvascular disease, markers of inflammation (e.g., C-reactive protein), and mortality. These health outcomes are interrelated—IHD is caused by decreased blood flow through coronary arteries due to atherosclerosis resulting in myocardial ischemia.

There are 6 epidemiological studies from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA and cardiovascular effects. Study quality evaluations for these 6 studies are shown in Figure 3-29.

The 2016 PFOA Health Advisory {U.S. EPA, 2016, 3982042} and HESD {U.S. EPA, 2016, 3603279} did not identify strong evidence for an association between CVD and PFOA, based on five occupational studies. Several occupational studies examined cardiovascular-related cause of death among PFOA-exposed workers at the West Virginia Washington Works plant {Leonard, 2008, 1291100; Sakr, 2009, 2593135; Steenland, 2012, 2919168} and the 3M Cottage Grove plant in Minnesota {Lundin, 2009, 1291108; Gilliland, 1993, 1290858; Raleigh, 2014, 2850270}. This type of mortality is of interest because of the relation between lipid profiles (e.g., LDL) and the risk of CVD. A study in West Virginia did not find an association between cumulative PFOA levels and IHD mortality across four quartiles of cumulative exposure {Steenland, 2012, 2919168}. Based on these data from the worker cohorts (part of the C8 Health Project), the C8 Science Panel (2012, 1430770) concluded that there is no probable link between PFOA and stroke and CAD. The analysis of the workers at the Minnesota plant also did not observe an association between cumulative PFOA exposure and IHD risk, but an increased risk of cerebrovascular disease mortality was seen in the highest exposure category {Lundin, 2009,
DRAFT FOR PUBLIC COMMENT

March 2023

1291108]. These studies are limited by the reliance on mortality (rather than incidence) data, which can result in a substantial degree of under ascertainment and misclassification. Evidence was limited in studies on the general population, with only one high-exposure community study and two NHANES studies examining the association between PFOA and hypertension risk. Increased risk of hypertension was observed in a C8 community study [Winquist, 2014, 2851142]; however, the association was imprecise for estimates comparing the highest two quintiles to the lowest quintile of exposure. One NHANES study identified in the 2021 ATSDR Toxicological Profile for Perfluoroalkyls [ATSDR, 2021, 9642134] observed a large increased risk of hypertension for adults not using hypertensive medication in the highest exposure quartile {Min, 2012, 2919181}. The other NHANES study reported a decreased risk of hypertension in children {Geiger, 2014, 2851286}.

Figure 3-29. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cardiovascular Effects Published Before 2016 (References from 2016 HESD)

Interactive figure and additional study details available on HAWC.

Since publication of the 2016 PFOA HESD [U.S. EPA, 2016, 3603279], 49 new epidemiological studies report on the association between PFOA and CVD, including outcomes such as hypertension, CAD, congestive heart failure (CHF), microvascular diseases, and mortality. Of these, 21 examined blood pressure or hypertension in adults. Pregnancy-related hypertension is discussed in the Appendix (See PFOA Appendix). Two of the publications
measuring levels in maternal serum studies measured PFOA in European countries Pitter, 2020, Vargas, 2019, 5080588; Lind, 2017, 3858504; Mattsson, 2015, 3859607; 4238509; 2013, 2850967; Lin, 2016, 3981457 2919176; Mi, 2020, 6833736; 2022, 10176386; 2019, 5080551; 5080398; in the United States The studies were conducted in different study populations with the majority of studies conducted cardiovascular risk purposes.

weight loss in Outcomes Study (DPPOS) intervention 6988486 2020, 6988476 7021479; 6833623; 2017, 4238478; Jain, 2020, 6311650; Huang, 2018, 5024212; Hutcheson, 2020, 6320195; Jain, 2020, 6311650; Jain, 2020, 6833623; Jain, 2020, 6988488; Zare Jeddi, 2021, 7021479; Koshy, 2017, 4238478; Koskela, 2022, 10176386; Leary, 2020, 7240043; Lin, 2020, 6988476; Liao, 2020, 6356903; Lin, 2013, 2850967; Lin, 2016, 3981457; Lind, 2017, 3858504; Liu, 2018, 4238514; Ma, 2019, 5413104; Mi, 2020, 6833736; Mobacke, 2018, 4354163; Pitter, 2020, 6988479; Shankar, 2012, 2919176; Yang, 2018, 4238462; Yu, 2021, 8453076; Ye, 2021, 6988486. The three controlled trial studies [Cardenas, 2019, 5381549; Liu, 2018, 4238396; Osorio-Yáñez, 2021, 7542684] were not controlled trials of PFAS exposures, but rather health interventions: prevention of type 2 diabetes in the Diabetes Prevention Program (DPP) and Outcomes Study (DPPOS) [Cardenas, 2019, 5381549; Osorio-Yáñez, 2021, 7542684] and weight loss in Prevention of Obesity Using Novel Dietary Strategies Lost (POUNDS-Lost) Study [Liu, 2018, 4238396]. Thus, these studies can be interpreted as cohort studies for evaluating cardiovascular risk purposes.

The studies were conducted in different study populations with the majority of studies conducted in the United States [Cardenas, 2019, 5381549; Christensen, 2016, 3858533; Christensen, 2019, 5080398; Fry, 2017, 4181820; Graber, 2019, 5080653; He, 2018, 4238388; Honda-Kohmo, 2019, 5080551; Huang, 2018, 5024212; Hutcheson, 2020, 6320195; Jain, 2020, 6311650; Jain, 2020, 6833623; Jain, 2020, 6988488; Zare Jeddi, 2021, 7021479; Khalil, 2018, 4238547; Khalil, 2020, 7021479; Koshy, 2017, 4238478; Koskela, 2022, 10176386; Leary, 2020, 7240043; Lin, 2020, 6988476; Liao, 2020, 6356903; Lin, 2013, 2850967; Lin, 2016, 3981457; Lind, 2017, 3858504; Liu, 2018, 4238514; Ma, 2019, 5413104; Mi, 2020, 6833736; Mobacke, 2018, 4354163; Pitter, 2020, 6988479; Shankar, 2012, 2919176; Yang, 2018, 4238462; Yu, 2021, 8453076; Ye, 2021, 6988486]. The remaining studies were conducted in China [Bao, 2017, 3860099; Yang, 2018, 4238462; Yu, 2021, 8453076; Ye, 2021, 6988486], Taiwan [Lin, 2013, 2850967; Lin, 2016, 3981457; Lin, 2020, 6988476], Spain [Manzano-Salgado, 2017, 4238509; Matilla-Santander, 2017, 4238432], Croatia [Chen, 2019, 5387400], Sweden [Donat-Vargas, 2019, 5080588; Lind, 2017, 3858504; Mattsson, 2015, 3859607; Mobacke, 2018, 4354163], Italy [Canova, 2021, 10176518; Girardi, 2019, 6315730; Zare Jeddi, 2021, 7404065; Pitter, 2020, 6988479], Norway [Averina, 2021, 7410155], and two studies conducted in several European countries [Papadopoulou, 2021, 9960593; Warembourg, 2019, 5881345]. All the studies measured PFOA in blood components (i.e., serum or plasma) with three studies measuring levels in maternal serum [Papadopoulou, 2021, 9960593; Li, 2021, 7404102;
Warembourg, 2019, 5881345}, and four studies measuring levels in maternal plasma {Papadopoulou, 2021, 9960593; Warembourg, 2019, 5881345; Manzano-Salgado, 2017, 4238509; Mitro, 2020, 6833625}.

3.4.3.1.1.2 Study Quality
There are 48 epidemiological studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA and cardiovascular effects. Study quality evaluations for these 48 studies are shown in Figure 3-30, Figure 3-31, and Figure 3-32.

Of the 48 studies identified since the 2016 assessment, 3 studies were high confidence, 26 were medium confidence, 12 were considered low confidence, 3 were considered mixed confidence, and 4 studies were considered uninformative {Jain, 2020, 6833623; Jain, 2020, 6311650; Leary, 2020, 7240043; Seo, 2018, 4238334}. The main concerns with the low confidence studies included the possibility of outcome misclassification (e.g., reliance on self-reporting) in addition to potential for residual confounding or selection bias (e.g., unequal recruitment and participation among subjects with outcome of interest, lack of consideration and potential exclusion due to medication usage). Residual confounding was possible due to SES, which can be associated with both exposure and the cardiovascular outcome. Although PFOA has a long half-life in the blood, concurrent measurements may not be appropriate for cardiovascular effects with long latencies. Further, temporality of PFOA exposure could not be established for several low confidence studies due to their cross-sectional design. Several of the low confidence studies also had sensitivity issues due to limited sample sizes {Christensen, 2016, 3858533; Girardi, 2019, 6315730; Graber, 2019, 5080653; Khalil, 2018, 4238547}. Two studies were rated adequate for all domains, indicating lower risk-of-bias; however, both studies treated PFOA as the dependent variable, resulting in both studies being considered uninformative {Jain, 2020, 6833623; Jain, 2020, 6311650}. Analyses treating PFOA as a dependent variable support inferences for characteristics (e.g., kidney function, disease status, race/ethnicity) that affect PFOA levels in the body, but it does not inform the association between exposure to PFOA and incidence of cardiovascular disease. Small sample size (n = 45) and missing details on exposure measurements were the primary concerns about the remaining uninformative study {Leary, 2020, 7240043}.

High and medium confidence studies were the focus of the evidence synthesis for endpoints with numerous studies, though low confidence studies were still considered for consistency in the direction of association (and details are provided in PFOA Appendix). For endpoints with fewer studies, the evidence synthesis below included details on any low confidence studies available. Studies considered uninformative were not considered further in the evidence synthesis.
Figure 3-30. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cardiovascular Effects

Interactive figure and additional study details available on HAWC.
Figure 3-31. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cardiovascular Effects (Continued)

Interactive figure and additional study details available on HAWC.
Figure 3-32. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cardiovascular Effects (Continued)

Interactive figure and additional study details available on HAWC.
### 3.4.3.1.1.3 Findings from Children and Adolescents

One high confidence study (Li, 2021, 7404102) and six medium confidence studies (Averina, 2021, 7410155; Canova, 2021, 10176518; Ma, 2019, 5413104; Manzano-Salgado, 2017, 4238509; Papadopoulou, 2021, 9960593; Warembourg, 2019, 5881345) examined blood pressure in children and adolescents and reported no associations (see PFOA Appendix). No association was observed in a high confidence study in infants from the Health Outcomes and Measures of the Environment (HOME) Study (Li, 2021, 7404102) between PFOA in maternal serum and child blood pressure measured at 12 years of age. In a cross-sectional analysis, Ma et al. (2019, 5413104) did not observe an association between serum PFOA and blood pressure among 2,251 NHANES (2003–2012) participants (mean age 15.5 years). Similarly, Manzano-Salgado et al. (2017, 4238509) did not observe an association between maternal PFOA and child blood pressure in combined or in gender-stratified analyses at age 4 and 7 years.

In a cohort of 1,277 children (age 6–11 years), PFOA measured both in maternal blood during the pre-natal period and in plasma during the postnatal period were not associated with blood pressure in single-pollutant models (Warembourg, 2019, 5881345). However, the association was significantly positive for systolic blood pressure (SBP) after co-adjustment for organochlorine compounds (i.e., dichlorodiphenyldichloroethane (DDE) and hexachlorobenzene (0.9; 95% CI: 0.1, 1.6; p = 0.021)). An overlapping study (Papadopoulou, 2021, 9960593) examined the association for z-scores of blood pressure in children in a model mutually adjusted for other PFAS and did not find an association. In a cross-sectional study of children and adolescents in a high-exposure community (Canova, 2021, 10176518), blood pressure was lower among adolescents with increasing serum PFOA, but none of the associations reached significance. An increased risk of hypertension (SBP ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg) was observed in a medium confidence cross-sectional study (Averina, 2021, 7410155) on Norwegian adolescents taking part in the Fit Futures. The magnitude of the association was larger among increasing quartiles of PFOA exposure, reaching significance for those in the fourth quartile of exposure (OR: 2.08; 95% CI: 1.17, 3.69, p = 0.013). Two low confidence studies did not observe associations between serum PFOA and blood pressure (Khalil, 2018, 4238547; Lin, 2013, 2850967).

Other cardiovascular conditions reported in children and adolescents include carotid intima-media thickness test (CIMT) and brachial artery distensibility. Two medium confidence studies that examined CIMT among adolescents and young adults from the Young Taiwanese Cohort Study (Lin, 2013, 2850967; Lin, 2016, 3981457) reported no associations. A low confidence study of children and adolescents from the World Trade Center (WTC) Health Registry reported PFOA was significantly associated with increased brachial artery distensibility (0.45; 95% CI: 0.04, 0.87; p = 0.03), but was not associated with pulse wave velocity (Koshy, 2017, 4238478). However, concerns for residual confounding by age and SES contributed to the low confidence.

### 3.4.3.1.1.4 Findings from the General Adult Population

Most of the studies identified since the last assessment were conducted among general population adults (see PFOA Appendix). A total of 15 studies examined PFOA in association with SBP, diastolic blood pressure (DBP), hypertension, and elevated blood pressure (Bao, 2017, 3860099; Chen, 2019, 5387400; Christensen, 2016, 3858533; Christensen, 2019, 5080398; Donat-Vargas, 2019, 5080588; He, 2018, 4238388; Zare Jeddi, 2021, 7404065; Mitro, 2020,
Of the ten studies that examined blood pressure as a continuous measure, six reported statistically significant positive associations. However, the results were not always consistent between SBP and DBP.

A high confidence study in 6,967 NHANES (2003–2012) participants 20 years and older reported a statistically significant positive association with SBP (per 10-fold change in PFOA: 1.83; 95% CI: 0.40, 3.25) in the fully adjusted model. No association was observed for DBP.

A high confidence study conducted among 761 women that examined associations between PFOA concentrations measured during pregnancy and blood pressure assessed at 3 years post-partum reported a positive but non-significant association with SBP (beta per doubling of PFOA: 0.8; 95% CI: −0.3, 1.8). No association was observed with DBP.

Two medium confidence cross-sectional studies with overlapping data from the “Isomers of C8 Health Project,” a highly-exposed population of Shenyang, China, also reported positive associations for blood pressure. In 1,612 participants with elevated PFOA levels (median 6.19 ng/mL), Bao et al. (2017, 3860099) reported large increases in DBP (2.18; 95% CI: 1.38, 2.98) and SBP (1.69; 95% CI: 0.25, 3.13). After stratification by sex, a positive association was observed in men only for DBP (1.48; 95% CI: 0.58, 2.37) and in women only for SBP (6.65; 95% CI: 4.32, 8.99). In participants with high PFOA levels (median 4.8 ng/mL), Mi et al. (2020, 6833736) observed statistically significant increases in DBP (1.49; 95% CI: 0.34, 2.64). No association was observed for SBP.

Similar findings were observed in another medium confidence study in a high-exposure community in Italy. Adults (20–39 years old) included in a regional surveillance program were included in a cross-sectional analysis of blood pressure and PFOA exposure. Significant positive associations were reported for DBP (0.34; 95% CI: 0.21, 0.47) and SBP (0.37; 95% CI: 0.19, 0.54) in the overall (n = 15,380) population. Results were generally consistent after stratification by sex. Minor sex differences were observed, such as slightly larger increases in SBP among men (0.46; 95% CI: 0.19, 0.73) and larger increases in DBP among women (0.39; 95% CI: 0.21, 0.57). Monotonic trends were observed in all quartile analyses, although significance was not reported.

Lin et al. (2020, 6311641), a medium confidence study using data from the Diabetes Prevention Program, a randomized controlled health intervention trial, reported that an increase in baseline PFOA concentration was significantly associated with higher SBP (1.49; 95% CI: 0.29, 2.70); no association was observed with DBP or pulse pressure. In a medium confidence weight loss-controlled trial population (the POUNDS Lost Study), Liu et al. (2018, 4238396) observed that baseline PFOA was positively correlated with DBP (p < 0.05), but at 6- and 24-month follow-up assessments, no associations were observed with SBP or DBP.

The findings from three low confidence studies of PFOA and blood pressure were mixed. Yang et al. (2018, 4238462)
reported a statistically significant positive increased risk of high SBP (≥ 140 mmHg) for n-PFOA (linear isomers), but no association for SBP as a continuous measure. Two additional studies reported no associations for SBP {Chen, 2019, 5387400; He, 2018, 4238388}, and three studies reported no associations for DBP {Chen, 2019, 5387400; He, 2018, 4238388; Yang, 2018, 4238462].

Of the eleven studies that examined risk of elevated blood pressure (hypertension), six reported statistically significant associations {Liao, 2020, 6356903; Mi, 2020, 6833736; Bao, 2017, 3860099; Lin, 2020, 6311641; Pitter, 2020, 6988479; Ye, 2021, 6988486}. Hypertension was defined as average SBP > 140 mmHg and average DBP > 90 mmHg, or self-reported use of prescribed anti-hypertensive medication. Using a generalized additive model and restricted cubic splines, Liao et al. (2020, 6356903) reported a non-linear (J-shaped) relationship with hypertension, with the inflection point of PFOA at 1.80 ng/mL. Each 10-fold increase in PFOA was associated with a 44% decrease (OR: 0.56; 95% CI: 0.32, 0.99) in the risk of hypertension on the left side of the inflection point, and an 85% increase (OR: 1.85; 95% CI: 1.34, 2.54) on the right side of the inflection point. A significant association with hypertension was observed for the highest (> 4.4 ng/mL) vs. lowest (≤ 2.5 ng/mL) tertile (OR: 1.32; 95% CI: 1.13, 1.54), and the test for trend was significant (p < 0.001). Additionally, positive associations were observed among women (OR: 1.42; 95% CI: 1.12, 1.79) and in participants 60 years and older (OR: 1.32; 95% CI: 1.03, 1.68). The studies {Mi, 2020, 6833736; Bao, 2017, 3860099; Ye, 2021, 6988486} with overlapping data on highly-exposed Isomers of C8 Health Project participants reported significant associations. An overlapping low confidence study {Ye, 2021, 6988486} on metabolic syndrome observed a moderate increase (OR: 1.31; 95% CI: 1.11, 1.56) in the risk of elevated blood pressure (SBP ≥ 130 and/or DBP ≥ 85; or medication use). Mi et al. (2020, 6833736) reported higher risk of hypertension overall (OR: 1.72; 95% CI: 1.27, 2.31) and among women (OR: 2.32; 95% CI: 1.38, 3.91), but not in men. Bao et al. (2017, 3860099) did not observe an association between total-PFOA and hypertension. However, in isomer-specific analysis, a natural-log unit (ng/mL) increase of 6-m-PFOA was significantly associated with higher risk of hypertension among all participants (OR: 1.24; 95% CI: 1.05, 1.47) and among women (OR: 1.86; 95% CI: 1.25, 2.78). These results suggest branched PFOA isomers have a stronger association with increased risk of hypertension compared to linear isomers (n-PFOA).

Increased risk of hypertension was observed in a pair of overlapping studies on another high exposure community located in Italy {Zare Jeddi, 2021, 7404065; Pitter, 2020, 6988479}. Pitter et al. (2020, 6988479), a medium confidence study, observed a significant association (OR: 1.06; 95% CI: 1.01, 1.12) between PFOA exposure and hypertension in a large cross-sectional sample of adults (n = 15,786). The association remained significant in men (OR: 1.08; 95% CI: 1.02, 1.15), but was not significant in women (OR: 1.06; 95% CI: 0.97, 1.15). A similar increased risk of hypertension was observed among all participants in the overlapping study {Zare Jeddi, 2021, 7404065}.

A medium confidence study, Lin et al. (2020, 6311641), reported in a cross-sectional analysis that the association with hypertension was not statistically significant but was modified by sex. Among males, a doubling of baseline plasma PFOA was associated with a significantly higher risk of hypertension (RR: 1.27; 95% CI: 1.06, 1.53); no association with hypertension was observed among females. In a prospective analysis, among participants who did not have hypertension at baseline, there was no association with hypertension at the approximately
15 years of follow-up {Lin, 2020, 6311641}. In addition, three medium confidence studies {Donat-Vargas, 2019, 5080588; Christensen, 2019, 5080398; Liu, 2018, 4238514} and a low confidence study {Christensen, 2016, 3858533} did not observe associations with hypertension.

Ten studies examined other CVD-related outcomes including CHD, stroke, carotid artery atherosclerosis, angina pectoris, C-reactive protein, CHF, peripheral artery disease (PAD), microvascular disease, CIMT, and mortality.

Among the four studies that examined CHD, the findings were mixed. A high confidence study {Mattsson, 2015, 3859607}, a medium confidence study of 10,850 NHANES participants from 1999–2014 {Huang, 2018, 5024212}, and a low confidence study {Christensen, 2016, 3858533} all reported no associations with CHD. A low confidence study from the C8 Health Project {Honda-Kohmo, 2019, 5080551} reported a significant inverse association between PFOA and CHD among adults with and without diabetes. However, study limitations that may have influenced these findings include the reliance on self-reporting of a clinician-based diagnosis for CHD outcome classification and residual confounding by SES.

Among the two NHANES-based studies that examined CVD {Shankar, 2012, 2919176; Huang, 2018, 5024212}, the findings were mixed. Using data from NHANES 1999–2000 and 2003–2004 cycles, Shankar et al. {2012, 2919176} reported significant associations with CVD. The analysis by PFOA quartiles reported significantly higher odds for the presence of CVD in the third (OR: 1.77; 95% CI: 1.04, 3.02) and the highest (OR: 2.01; 95% CI: 1.12, 3.60) quartiles compared to the lowest quartile, with a significant trend (p = 0.01). In contrast, using a larger dataset from NHANES 1999–2014 cycles, Huang et al. {2018, 5024212} did not observe an association with total CVD by quartiles of exposure, nor a positive trend.

Shankar et al. {2012, 2919176} also observed a significant association with PAD. The analysis by PFOA quartiles reported significantly higher odds for the presence of PAD (OR: 1.78; 95% CI: 1.03, 3.08) in the highest compared to the lowest quartile, with a significant trend (p = 0.04).

Among the two studies that examined stroke, the findings also were mixed. A borderline positive association (p = 0.045) was observed by Huang et al. {2018, 5024212}. In contrast, Hutcheson et al. {2020, 6320195} observed a significant inverse association with history of stroke in adults with and without diabetes participating in the C8 Health Project (OR: 0.90; 95% CI: 0.82, 0.98, p = 0.02). However, a borderline-significant inverse association was observed among non-diabetics (OR: 0.94; 95% CI: 0.88, 1.00; p = 0.04) but not among those with diabetes, although the interaction was not significant.

In addition, a low confidence study of adults and children did not observe an association between serum PFOA and self-reported cardiovascular conditions, including high blood pressure, CAD, and stroke {Graber, 2019, 5080653}. However, potential selection bias is a major concern for this study owing to the recruitment of volunteers who already knew their PFAS exposure levels and were motivated to participate in a lawsuit.

Huang et al. {2018, 5024212} also reported significantly higher odds of heart attack for the third quartile (OR: 1.62; 95% CI: 1.04, 2.53) and second quartile (OR: 1.57; 95% CI: 1.06, 2.34), compared to the first quartile. No associations were observed with CHF and angina pectoris.
No associations with microvascular diseases (defined as the presence of nephropathy, retinopathy, or neuropathy) were observed \{Cardenas, 2019, 5381549\}.

One medium confidence study \{Osorio-Yáñez, 2021, 7542684\} examined changes in atherosclerotic plaque in a sample of participants enrolled in the Diabetes Prevention Program. A non-significant positive association (OR: 1.17; 95% CI: 0.91, 1.50) was observed for the odds of having a mild to moderate coronary artery calcium Agatston score (11–400). Two studies examined changes in heart structure \{Mobacke, 2018, 4354163\} and carotid atherosclerosis \{Lind, 2017, 3858504\} in participants 70 years and older. Mobacke et al. (2018, 4354163) examined alterations of left ventricular geometry, a risk factor for CVD, and reported that serum PFOA was significantly associated with a decrease in relative wall thickness (−0.12; 95% CI: −0.22, −0.001; p = 0.03), but PFOA was not observed to be associated with left ventricular mass or left ventricular end diastolic diameter. Lind et al. (2017, 3858504) examined markers of carotid artery atherosclerosis including atherosclerotic plaque, the intima-media complex, and the CIMT (a measure used to diagnose the extent of carotid atherosclerotic vascular disease) and observed no associations.

The association between exposure to PFOA and apolipoprotein B, a protein associated with LDL and increased risk of artherosclerosis, was examined in a medium confidence study \{Jain, 2020, 6311650\} on NHAMES participants (2007–2014). Serum apolipoprotein B was significantly increased (beta per log10-unit increase PFOA: 0.03878; p < 0.01) with increasing PFOA exposure in non-diabetic participants who did not take lipid-lowering medication. No significant associations were observed among lipid-lowering medication users and participants with diabetes. No association between PFOA and C-reactive protein levels (a risk factor for CVD) were observed in two studies, one in women from Project Viva \{Mitro, 2020, 6833625\} and the other in pregnant women from the Spanish Environment and Childhood (Infancia y Medio Ambiente, INMA) study \{Matilla-Santander, 2017, 4238432\}. One medium confidence study examined mortality due to heart/cerebrovascular diseases in 1,043 NHAMES (2003–2006) participants 60 years and older and observed no associations \{Fry, 2017, 4181820\}.

Overall, the findings from one high confidence study and several medium confidence studies conducted among the general population did not provide consistent evidence for an association between PFOA and SBP and DBP. The evidence for an association between PFOA and increased risk of hypertension/elevated blood pressure, overall and in gender-stratified analyses was inconsistent. Evidence for other CVD-related outcomes was more limited, and similarly inconsistent.

### 3.4.3.1.1.5 Findings from Occupational Studies

Two low confidence studies examined occupational PFOA exposure and cardiovascular effects (see PFOA Appendix). Steenland et al. (2015, 2851015) examined 1,881 workers with high serum PFOA levels (median 113 ng/mL) from a subset of two prior studies conducted by the C8 Science Panel. No trend was observed in the exposure-response gradient for stroke, CHD, and hypertension and. In analysis of PFOA levels by quartiles, a significantly higher risk of stroke (no lag) was observed for the 2nd quartile vs. the 1st quartile (Rate Ratio (RR): 2.63; 95% CI: 1.06, 6.56). No association was observed with 10-year lag stroke, CHD, and hypertension, respectively. For the assessment of stroke, this study had low confidence because of concerns for selection bias, specifically survival bias. For other chronic diseases examined, this study is of
low confidence due to concerns about outcome misclassification, particularly for hypertension due to lack of medical record validation. In another occupational study of 120 male workers with very high PFOA serum levels (GM: 4,048 ng/mL), Girardi et al. (2019, 6315730) reported no association with increased risk of mortality due to cardiovascular causes, including hypertensive disease, ischemic heart disease, stroke, and circulatory diseases. However, the potential for selection bias, outcome misclassification, and limited control for confounding may have influenced the reported results.

Overall, the limited evidence available from occupational studies was inconsistent for an association with risk of stroke and indicated PFOA is not associated with an increased risk of CHD, hypertension, and mortality due to cardiovascular causes. However, the findings based on two low confidence studies should be interpreted with caution due to potential biases arising from the selection of participants and outcome misclassification.

3.4.3.1.2 Serum Lipids
3.4.3.1.2.1 Introduction
Serum cholesterol and triglycerides are well-established risk factors for CVDs. Major cholesterol species in serum include LDL and HDL. Elevated levels of TC, LDL, and triglycerides are associated with increased cardiovascular risks, while higher levels of HDL are associated with reduced risks. There are 21 epidemiological studies (22 publications)\textsuperscript{14} from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA and serum lipid effects. Study quality evaluations for these 22 studies are shown in Figure 3-33.

In the 2016 Health Assessment {U.S. EPA, 2016, 3603279} for PFOA, there was relatively consistent and robust evidence of positive associations between PFOA and TC and LDL in occupational {Sakr, 2007, 1291103; Sakr, 2007, 1430761; Olsen, 2003, 1290020; Costa, 2009, 1429922} and high-exposure community settings {Frisbee, 2010, 1430763; Steenland, 2009, 1291109; Fitz-Simon, 2013, 2859062; Winquist, 2014, 2851142}. Two of the studies were cross-sectional, however, Fitz-Simon (2013, 2859062) reported positive associations for LDL and TC in a longitudinal analysis of the change in lipids seen in relation to a change in serum PFOA. General population studies {Lin, 2009, 1290820; Geiger, 2014, 2850925; Nelson, 2010, 1291110} in children and adults using NHANES reported positive associations for TC and increased risk of elevated TC. Other general population studies were generally consistent, reporting positive associations for TC in adults {Fisher, 2013, 2919156; Eriksen, 2013, 2919150} and pregnant women {Starling, 2014, 2850928}. Positive associations between PFOA and HDL were also observed in most studies in the general population {Lin, 2009, 1290820; Frisbee, 2010, 1430763; Steenland, 2009, 1291109; Fisher, 2013, 2919156}. Positive associations were observed for triglycerides and LDL in high-exposure community studies {Frisbee, 2010, 1430763; Steenland, 2009, 1291109}, but associations for triglycerides and LDL were less consistent in other general population studies {Fisher, 2013, 2919156; Lin, 2009, 1290820; Geiger, 2014, 2850925}.

\textsuperscript{14} Olsen (2003, 1290020) is the peer-review paper of Olsen (2001, 10228462).
Figure 3-33. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Serum Lipids Published Before 2016 (References from 2016 PFOA HESD)

Interactive figure and additional study details available on HAWC.
3.4.3.1.2.2 Study Quality

All studies were evaluated for risk of bias, selective reporting, and sensitivity following the EPA IRIS protocol. Three considerations were specific to evaluating the quality of studies on serum lipids. First, because lipid-lowering medications strongly affect serum lipid levels, unless the prevalence of medication use is assumed to be low in the study population (e.g., children), studies that did not account for the use of lipid-lowering medications by restriction, stratification, or adjustment were rated as deficient in the participant selection domain. Second, because triglyceride levels are sensitive to recent food intake [Mora, 2016, 9564968], outcome measurement error is likely substantial when triglyceride is measured without fasting. Thus, studies that did not measure triglycerides in fasting blood samples were rated deficient in the outcome measures domain for triglycerides. The outcome measures domain for LDL was also rated deficient if LDL was calculated based on triglycerides. Fasting status did not affect the outcome measures rating for TC, directly measured LDL, and HDL because the serum levels of these lipids change minimally after a meal {Mora, 2016, 9564968}. Third, measuring PFOA and serum lipids concurrently was considered adequate in terms of exposure assessment timing. Given the long half-life of PFOA (median half-life = 2.7 years) {Li, 2018, 4238434}, current blood concentrations are expected to correlate well with past exposures. Furthermore, although reverse causation due to hypothyroidism {Dzierlenga, 2020, 6833691} or enterohepatic cycling of bile acids {Fragki, 2021, 8442211} has been suggested, there is not yet clear evidence to support these reverse causal pathways.

Since publication of the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}, 66 new epidemiological studies (65 publications)\(^\text{15}\) report on the association between PFOA exposure and serum lipids. Except for ten studies {Olsen, 2012, 2919185; Domazet, 2016, 3981435; Lin, 2019, 5187597; Liu, 2020, 6318644; Donat-Vargas, 2019, 5080588; Liu, 2018, 4238396; Blomberg, 2021, 8442228; Sinisalu, 2020, 7211554; Li, 2021, 7404102; Tian, 2020, 7026251}, all studies were cross-sectional. Some cohort studies provided additional cross-sectional analyses {Blomberg, 2021, 8442228; Sinisalu, 2020, 7211554; Li, 2021, 7404102}. Most studies assessed exposure to PFOA using biomarkers in blood, and measured serum lipids with standard clinical biochemistry methods. Serum lipids were frequently analyzed as continuous outcomes, but a few studies examined the prevalence or incidence of hypercholesterolemia, hypertriglyceridemia, and low HDL based on clinical cut-points, medication use, doctor’s diagnosis, or criteria for metabolic syndrome. Study quality evaluations for these 65 studies are shown in Figure 3-34, Figure 3-35, and Figure 3-36.

Based on the considerations mentioned, one study was classified as high confidence, one study was classified as high confidence for prospective analyses and medium confidence for cross-sectional analyses, 21 studies were classified medium confidence for all lipid outcomes, nine studies were rated medium confidence for TC or HDL, but low confidence for triglycerides or LDL, 26 studies were rated low confidence for all lipid outcomes, and 7 studies were rated uninformative for all lipid outcomes {Seo, 2018, 4238334; Abraham, 2020, 6506041; Predieri, 2015, 3889874; Huang, 2018, 5024212; Leary, 2020, 7240043; Sinisalu et al., 2020, 7211554; Sinisalu, 2021, 9959547}. Notably, ten studies {Zeng, 2015, 2851005; Manzano-Salgado, 2017, 4238509; Canova, 2020, 7021512; Matilla-Santander, 2017, 4238432; Lin, 2020, 6988476; Blomberg, 2021, 8442228; Tian, 2020, 7026251; Yang, 2020, 7021246; Canova, 2021,

\(^{15}\) Dong 2019, 5080195 counted as two studies, one in adolescents and one in adults.
10176518; Dalla Zuanna, 2021, 7277682} were rated low confidence specifically for triglycerides and/or LDL because these studies measured triglycerides in non-fasting blood samples. The low confidence studies had deficiencies in participant selection {Wang, 2012, 2919184; Khalil, 2018, 4238547; Lin, 2013, 2850967; Lin, 2020, 6315756; Fassler, 2019, 6315820; Chen, 2019, 5387400; Li, 2020, 6315681; He, 2018, 4238388; Yang, 2018, 4238462; Christensen, 2016, 3858533; Graber, 2019, 5080653; Sun, 2018, 4241053; Rotander, 2015, 3859842; Liu, 2018, 4238396; Cong, 2021, 8442223; Khalil, 2020, 7021479; Kobayashi, 2021, 8442188; Liu, 2021, 10176563; Ye, 2021, 6988486; Yu, 2021, 8453076}, outcome measures {Koshy, 2017, 4238478; Yang, 2018, 4238462; Christensen, 2016, 3858533; Kishi, 2015, 2850268; Graber, 2019, 5080653; Rotander, 2015, 3859842; Kobayashi, 2021, 8442188}, confounding {Wang, 2012, 2919184; Convertino, 2018, 5080342; Khalil, 2018, 4238547; Koshy, 2017, 4238478; Olsen, 2012, 2919185; Lin, 2013, 2850967; Lin, 2020, 6315756; Fassler, 2019, 6315820; Li, 2020, 6315681; Yang, 2018, 4238462; Christensen, 2016, 3858533; Graber, 2019, 5080653; Khalil, 2020, 7021479; Liu, 2021, 10176563; Sinisalu, 2020, 7211554}, analysis {He, 2018, 4238388; Sun, 2018, 4241053; Liu, 2018, 4238396}, sensitivity {Wang, 2012, 2919184; Khalil, 2018, 4238547; Olsen, 2012, 2919185; Christensen, 2016, 3858533; Graber, 2019, 5080653; Rotander, 2015, 3859842}, highly unequal recruitment efforts in sampling frames with potentially different joint distributions of PFOA and lipids {Lin, 2013, 2850967}, and missing key information on the recruitment process {Khalil, 2018, 4238547; Fassler, 2019, 6315820; Yang, 2018, 4238462; Khalil, 2020, 7021479}. Another common reason for low confidence was a serious risk for residual confounding by SES {Wang, 2012, 2919184; Khalil, 2018, 4238547; Koshy, 2017, 4238478; Olsen, 2012, 2919185; Lin, 2013, 2850967; Lin, 2020, 6315756; Fassler, 2019, 6315820; Li, 2020, 6315681; Yang, 2018, 4238462; Christensen, 2016, 3858533; Graber, 2019, 5080653; Sinisalu, 2020, 7211554}. Frequently, deficiencies in multiple domains contributed to an overall low confidence rating. The uninformative studies had critical deficiencies in at least one domain or were deficient in several domains. These critical deficiencies include a lack of control for confounding {Seo, 2018, 4238334; Huang, 2018, 5024212; Abraham, 2020, 6506041}, convenience sampling {Sinisalu, 2021, 9959547}, and treating PFOA as an outcome of all lipids instead of an exposure, which limits the ability to make causal inference for the purpose of hazard determination {Predieri, 2015, 3889874}. Small sample size (n = 45) and missing details on exposure measurements were the primary concerns of the remaining uninformative study {Leary, 2020, 7240043}.

High and medium confidence studies were the focus of the evidence synthesis for endpoints with numerous studies, though low confidence studies were still considered for consistency in the direction of association (and details are provided in PFOA Appendix). For endpoints with fewer studies, the evidence synthesis below included details on any low confidence studies available. Studies considered uninformative were not considered further in the evidence synthesis.
**Figure 3-34. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Serum Lipids**

Interactive figure and additional study details available on [HAWC](#).
Figure 3-35. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Serum Lipids (Continued)

Interactive figure and additional study details available on HAWC.
Figure 3-36. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Serum Lipids (Continued)

Interactive figure and additional study details available on HAWC.
3.4.3.1.2.3  Findings from Children

Results for the studies that examined TC in children are presented in the Appendix (see PFOA Appendix). Eleven medium confidence and four low confidence studies examined the association between PFOA and TC in children. Of these, five studies examined the association between prenatal PFOA exposure and TC in childhood [Spratlen, 2020, 5915332; Jensen, 2020, 6833719; Manzano-Salgado, 2017, 4238509; Mora, 2018, 4239224; Tian, 2020, 7026251; Averina, 2021, 7410155] and ten examined the association between childhood PFOA exposure and concurrent TC {Mora, 2018, 4239224; Jain, 2018, 5079656; Zeng, 2015, 2851005; Kang, 2018, 4937567; Khalil, 2018, 4238547; Koshy, 2017, 4238478; Fassler, 2019, 6315820; Dong, 2019, 5080195; Canova, 2021, 10176518; Blomberg, 2021, 8442228]. Positive associations between PFOA and TC were reported in seven medium confidence studies [Zeng, 2015, 2851005; Spratlen, 2020, 5915332; Jensen, 2020, 6833719; Manzano-Salgado, 2017, 4238509; Mora, 2018, 4239224; Canova, 2021, 10176518; Blomberg, 2021, 8442228], but the direction of association sometimes differed by age and sex {Jensen, 2020, 6833719; Manzano-Salgado, 2017, 4238509; Blomberg, 2021, 8442228}. Of all the positive associations observed in medium confidence studies, only three were significant, including: all children (age 12–15 years) in Zeng (2015, 2851005), among girls in mid-childhood in Mora (2017, 4239224), and children and adolescents in the highest quartile of exposure from Canova (2021, 10176518).

In three out of four low confidence studies, PFOA was positively associated with TC {Khalil, 2018, 4238547; Koshy, 2017, 4238478; Fassler, 2019, 6315820}. However, residual confounding by SES may have positively biased these findings. Taken together, these studies suggest a positive association between PFOA and TC in children. However, the true association between PFOA and TC remains uncertain given the heterogeneity by age and sex and the imprecise findings in most medium confidence studies.

Seven medium confidence and five low confidence studies examined the association between PFOA and LDL in children. Of these, five examined prenatal exposure [Jensen, 2020, 6833719; Manzano-Salgado, 2017, 4238509; Mora, 2018, 4239224; Tian, 2020, 7026251; Papadopoulou, 2021, 9960593; Mora, 2018, 4239224] and eight examined childhood exposure [Mora, 2018, 4239224; Zeng, 2015, 2851005; Kang, 2018, 4937567; Khalil, 2018, 4238547; Koshy, 2017, 4238478; Canova, 2021, 10176518; Averina, 2021, 7410155; Dong, 2019, 5080195, adolescent portion]. The medium studies generally reported small, positive associations between PFOA and LDL, but most of the associations were not statistically significant (see PFOA Appendix) [Jensen, 2020, 6833719; Mora, 2018, 4239224; Kang, 2018, 4937567]. In one medium study, the association was inverse among 3-month old infants and 18-month old boys [Jensen, 2020, 6833719].

One low confidence study [Canova, 2021, 10176518] on children and adolescents in a high-exposure community located in Italy observed significantly increased LDL among adolescents (beta per ln-unit increase in PFOA: 1.03; 95% CI: 0.39, 1.66). Most low confidence studies reported a positive association between PFOA and LDL {Khalil, 2018, 4238547; Koshy, 2017, 4238478; Zeng, 2015, 2851005; Manzano-Salgado, 2017, 4238509; Canova, 2021, 10176518}, but residual confounding by SES {Khalil, 2018, 4238547; Koshy, 2017, 4238478} and the use of non-fasting samples {Zeng, 2015, 2851005; Manzano-Salgado, 2017, 4238509; Canova, 2021, 10176518} were concerns in these studies. Overall, increases in LDL with increasing PFOA were observed in children, though less consistently.
One high confidence, nine medium confidence and four low confidence studies examined the association between PFOA and HDL in children. Of these, six examined prenatal exposure \{Jensen, 2020, 6833719; Manzano-Salgado, 2017, 4238509; Mora, 2018, 4239224; Papadopoulou, 2021, 9960593; Blomberg, 2021, 8442228; Li, 2021, 7404102\} and 12 examined childhood exposure \{Mora, 2018, 4239224; Jain, 2018, 5079656; Zeng, 2015, 2851005; Khalil, 2018, 4238547; Koshy, 2017, 4238478; Fassler, 2019, 6315820; Papadopoulou, 2021, 9960593; Blomberg, 2021, 8442228; Li, 2021, 7404102; Canova, 2021, 10176518; Averina, 2021, 7410155; Dong, 2019, 5080195, adolescent portion\}. Prenatal PFOA exposure was inversely associated with HDL, but most associations were not statistically significant \{Jensen, 2020, 6833719; Manzano-Salgado, 2017, 4238509; Mora, 2018, 4239224; Papadopoulou, 2021, 9960593; Blomberg, 2021, 8442228; Li, 2021, 7404102\} (see PFOA Appendix). Sex-stratified analyses showed that the inverse association occurred mainly in boys \{Manzano-Salgado, 2017, 4238509; Mora, 2018, 4239224\}. Results on childhood exposure were less consistent (see PFOA Appendix). One medium study reported a statistically significant, positive association between PFOA and HDL in mid-childhood \{Mora, 2018, 4239224\}, but another medium study reported an inverse, though statistically non-significant association \{Zeng, 2015, 2851005\}. One medium confidence study \{Canova, 2021, 10176518\} in a high-exposure community observed a significant increase in HDL in children, but results were less consistent in adolescents. Most low confidence studies reported a positive association between childhood PFOA exposure and HDL \{Khalil, 2018, 4238547; Koshy, 2017, 4238478; Fassler, 2019, 6315820\}. In summary, PFOA was not consistently associated with lower HDL in children. Effect modification by exposure window may explain this inconsistency.

One high confidence, nine medium confidence and five low confidence studies examined the association between PFOA and triglycerides in children. Of these, seven examined prenatal exposure \{Spratlen, 2020, 5915332; Jensen, 2020, 6833719; Manzano-Salgado, 2017, 4238509; Mora, 2018, 4239224; Papadopoulou, 2021, 9960593; Li, 2021, 7404102; Tian, 2020, 7026251\} and 11 examined childhood exposure \{Domazet, 2016, 3981435; Mora, 2018, 4239224; Zeng, 2015, 2851005; Kang, 2018, 4937567; Khalil, 2018, 4238547; Koshy, 2017, 4238478; Fassler, 2019, 6315820; Papadopoulou, 2021, 9960593; Li, 2021, 7404102; Canova, 2021, 10176518; Averina, 2021, 7410155\}. No association was observed in the only high confidence study \{Li, 2021, 7404102\}. PFOA was significantly associated with increased triglycerides in newborns in one medium study \{Spratlen, 2020, 5915332\} (see PFOA Appendix). Some medium studies also reported positive associations, but they were not statistically significant \{Jensen, 2020, 6833719; Mora, 2018, 4239224; Kang, 2018, 4937567\}. Results from other medium confidence studies were imprecise \{Papadopoulou, 2021, 9960593; Li, 2021, 7404102\}. In one medium study that examined the association between PFOA and triglycerides longitudinally, PFOA at age 9 years was associated with lower triglycerides at age 15 years and 21 years, while PFOA at age 15 years was associated with higher triglycerides at age 21 years \{Domazet, 2016, 3981435\}. None of the associations were statistically significant. In most low confidence studies, PFOA was positively associated with triglycerides \{Manzano-Salgado, 2017, 4238509; Zeng, 2015, 2851005; Khalil, 2018, 4238547; Koshy, 2017, 4238478\}, but the use of non-fasting samples and residual confounding by SES may have biased these results upwards. Overall, increased triglycerides with increasing PFOA were observed in children, but results were less consistent and not always statistically significant.
In summary, the association between PFOA and serum lipids in children remains inconclusive. For TC, LDL, and triglycerides, positive associations were generally observed, but few were statistically significant. Differences in the direction of association by age or sex further contributed to inconsistency in findings; it is difficult to determine if the differences were due to effect modification or random error. For HDL, prenatal exposure appeared to be associated with lower HDL, especially in boys, although childhood exposure was associated with higher HDL. Few findings were statistically significant, however, suggesting caution in interpreting these results.

3.4.3.1.2.4 Findings from Pregnant Women

Four medium confidence studies examined the association between PFOA and TC in pregnant women {Matilla-Santander, 2017, 4238432; Skuladottir, 2015, 3749113; Dalla Zuanna, 2021, 7277682; Yang, 2020, 7021246} and two reported significantly positive associations between PFOA and TC (see PFOA Appendix) {Matilla-Santander, 2017, 4238432; Skuladottir, 2015, 3749113}. One medium confidence study in a high-exposure community {Dalla Zuanna, 2021, 7277682} considered PFOA exposure concentrations across trimesters using a generalized additive model (GAM). Authors reported significantly decreased TC with an increasingly inverse trend across all sampled trimesters. Results were consistent for second and third trimester samples in sensitivity analyses, but the direction of effect was positive for first trimester samples (see PFOA Appendix). No association between PFOA and TC was observed in a Chinese study of pregnant women {Yang, 2020, 7021246}. No association was found in the single low confidence study {Varshavsky, 2021, 7410195} on total serum lipids after adjustment for race/ethnicity, insurance type, and parity. These findings suggest a consistently positive association between PFOA and TC in pregnant women.

Two studies examined PFOA and LDL in pregnant women {Dalla Zuanna, 2021, 7277682; Yang, 2020, 7021246} and were considered low confidence due to lack of fasting blood samples for LDL measurement. In a high-exposure community {Dalla Zuanna, 2021, 7277682}, a decrease in LDL was reported with increasing PFOA concentrations when considering exposure concentrations sampled across trimesters. In individual trimester sensitivity analyses, results were consistently inverse for second and third trimester samples, including a significant finding for the third trimester. However, non-significant positive associations were observed for first trimester samples. No associations were observed for LDL in the other low confidence study, but a significant decrease was reported for the LDL:HDL ratio (see PFOA Appendix). Two medium confidence studies examined PFOA and HDL and reported statistically significant positive associations between PFOA and HDL (see PFOA Appendix) {Starling, 2017, 3858473; Dalla Zuanna, 2021, 7277682}. Dalla Zuanna (2021, 7277682) observed significant positive associations when considering blood samples across all trimesters of pregnancy (GAM model). The association was consistent, but no longer significant, when trimesters were modeled individually. Another medium confidence study {Yang, 2020, 7021246} reported no association.

One medium confidence and three low confidence studies examined the association between PFOA and triglycerides in pregnant women. The medium confidence study reported an inverse association between PFOA and triglycerides, but the association was small and not statistically significant {Starling, 2017, 3858473}. The low confidence studies each reported inverse {Matilla-Santander, 2017, 4238432; Yang, 2020, 7021246} or positive associations {Kishi, 2015, 2850268} that were not statistically significant. Each study was limited by their use of
non-fasting blood samples. Kishi et al. (2015, 2850268) additionally examined the association between PFOA and select fatty acids in serum. PFOA was not significantly associated with any fatty acids, but the associations were generally positive except for arachidonic acid, docosahexaenoic acid, and omega 3. Together, these studies suggest PFOA was not associated with triglycerides or fatty acids in pregnancy.

In summary, the available evidence supports a positive association between PFOA and HDL in pregnancy. The available evidence does not support a consistent, positive association between PFOA and TC or triglycerides. Finally, the available evidence is too limited to determine the association between PFOA and LDL in pregnant women.

3.4.3.1.2.5 Findings from the General Adult Population

Ten medium confidence and 13 low confidence studies examined PFOA and TC or hypercholesterolemia in adults (Figure 3-34, Figure 3-35, Figure 3-36). All studies examined cross-sectional associations {Dong, 2019, 5080195; Jain, 2019, 5080642; Liu, 2018, 4238514; Liu, 2020, 6318644; Lin, 2019, 5187597; Donat-Vargas, 2019, 5080588; Wang, 2012, 2919184; Convertino, 2018, 5080342; Chen, 2019, 5387400; Li, 2020, 6315681; He, 2018, 4238388; Christensen, 2016, 3858533; Graber, 2019, 5080653; Sun, 2018, 4241053; Canova, 2020, 7021512; Fan, 2020, 7102734; Liu, 2018, 4238396; Lin, 2020, 6988476; Han, 2021, 7762348; Cong, 2021, 8442223; Bjorke-Monsen, 2020, 7643487; Khalil, 2020, 7021479; Liu, 2021, 10176563} and two studies additionally examined the association between baseline PFOA and changes in TC or incident hypercholesterolemia {Liu, 2020, 6318644; Lin, 2019, 5187597}.

Of the ten medium confidence studies, eight reported positive associations. In a population of young adults aged 20 to 39 years in Veneto region, Italy, an area with water contamination by PFAS, Canova et al. (2020, 7021512) reported statistically significant, positive associations with TC. Canova et al. (2020, 7021512) also reported a concentration-response curve when PFOA was categorized in quartiles or deciles, with a higher slope at higher PFOA concentrations, which tended to flatten above around 20–30 ng/mL. Results from another medium confidence study {Lin, 2020, 6988476} on older adults in a high-exposure community in Taiwan also reported positive associations for TC, which was consistent across quartiles of PFOA exposure.

Four of the medium confidence studies used overlapping data from NHANES 2003–2014. All four studies reported significant positive associations between PFOA and TC in adults {Dong, 2019, 5080195; Jain, 2019, 5080642; Liu, 2018, 4238514; Fan, 2020, 7102734} (see PFOA Appendix). Stratified analyses in Jain et al. (2019, 5080642) suggested that the positive association occurred mainly in obese men. A significantly positive association between PFOA and TC also was observed at baseline in the DPPOS {Lin, 2019, 5187597}. This study reported positive associations between PFOA and prevalent, as well as incident, hypercholesterolemia. However, the HR for incident hypercholesterolemia was relatively small and not statistically significant (HR = 1.06, 95% CI: 0.94, 1.19). In contrast to these findings, Liu et al. (2020, 6318644) reported no association between PFOA and TC. Further, Donat-Vargas et al. (2019, 5080588) reported generally inverse associations between PFOA and TC, regardless of whether PFOA was measured concurrently or averaged between baseline and follow-up. It is noteworthy that all participants in Lin et al. (2019 5187597) were prediabetic, all participants in Liu et al. (2020, 6318644) were obese and enrolled in a weight loss trial, and all participants in Donat-
Vargas et al. (2019, 5080588) were free of diabetes for at least 10 years of follow-up. It is unclear if differences in participants’ health status explained the studies’ conflicting findings.

In low confidence studies, positive associations between PFOA and TC or hypercholesterolemia were reported in nine of thirteen studies {Chen, 2019, 5387400; Cong, 2021, 8442223; Khalil, 2020, 7021479; Li, 2020, 6315681; He, 2018, 4238388; Christensen, 2016, 3858533; Graber, 2019, 5080653; Sun, 2018, 4241053; Liu, 2018, 4238396}. However, oversampling of persons with potentially high PFOA exposure and health problems was a concern in three of these studies {Li, 2020, 6315681; Christensen, 2016, 3858533; Graber, 2019, 5080653}. Selection bias concerns, including lack of consideration of lipid-lowering medication and convenience sampling, were issues in two of the studies {Cong, 2021, 8442223; Khalil, 2020, 7021479}. Further, He et al. (2018, 4238388) used similar data as the four medium NHANES studies and thus added little information.

Contrary to these findings, in one low confidence study, participants treated with extremely high levels of ammonium perfluorooctanoate (APFO) in an open-label, nonrandomized, phase 1 trial, were found to have reduced levels of TC with increasing plasma PFOA concentrations {Convertino, 2018, 5080342}. This study differed from the other studies in several ways. First, all participants were solid-tumor cancer patients who failed standard therapy and may have distinct metabolic profiles compared to the general population. Second, participants ingested high dose levels of APFO rather than being exposed to PFOA. Third, participants’ plasma PFOA concentrations were several orders of magnitude higher than those reported in the general population. Participant serum concentrations were of similar magnitude as serum concentrations resulting in decreased TC serum in rodent studies (see Section 3.4.3.2). It is unclear if these factors explained the inverse association between PFOA and TC.

Considering medium and low confidence studies together, increased TC with increasing PFOA was observed in adults. Some inconsistencies in the direction of association across studies were found. Further studies are needed to determine if these inconsistencies reflect effect modification by subject characteristics or PFOA dose levels.
Figure 3-37. Odds of High Total Cholesterol in Adults from Epidemiology Studies Following Exposure to PFOA

Interactive figure and additional study details available on Tableau.
Figure 3-38. Overall Levels of Total Cholesterol in Adults from Epidemiology Studies Following Exposure to PFOA

Interactive figure and additional study details available on Tableau.
Figure 3-39. Overall Levels of Total Cholesterol in Adults from Epidemiology Studies Following Exposure to PFOA (Continued)

Interactive figure and additional study details available on Tableau.
Figure 3-40. Overall Levels of Total Cholesterol in Adults from Epidemiology Studies Following Exposure to PFOA (Continued)

Interactive figure and additional study details available on [Tableau](#).
Six *medium* confidence studies examined PFOA and LDL in adults, and all reported positive associations (Figure 3-34, Figure 3-35, Figure 3-36). Higher PFOA was significantly associated with higher LDL at baseline in the DPPOS {Lin, 2019, 5187597} (see PFOA Appendix). This study also reported statistically significant, positive associations between PFOA and cholesterol in non-HDL and VLDL, which are lipoprotein fractions related to LDL and associated with increased cardiovascular risks {Lin, 2019, 5187597}. A positive association was observed in a cross-sectional analysis of cases and controls in a study on type 2 diabetes {Han, 2021, 7762348}. Positive associations between PFOA and LDL were also reported in the four NHANES studies {Dong, 2019, 5080195; Jain, 2019, 5080642; Liu, 2018, 4238514; Fan, 2020, 7102734}, but statistical significance was observed in obese men only {Jain, 2019, 5080642} and in participants from NHANES cycle 2011–2012 {Dong, 2019, 5080195; Fan, 2020, 7102734}. Liu et al. (2020, 6318644) reported that PFOA was positively associated with cholesterol and apolipoprotein C-III (ApoC-III) in combined fractions of intermediate-density (IDL) and LDL that contained ApoC-III; the association with ApoC-III was statistically significant. IDL and LDL containing ApoC-III and ApoC-III itself are strongly associated with increased cardiovascular risks. Thus, the positive associations with cholesterol and ApoC-III in ApoC-III-containing fractions of IDL and LDL were consistent with the positive associations reported for LDL.
Consistent with these findings, nine of the thirteen low confidence studies report positive associations between PFOA and LDL \{Lin, 2020, 6315756; Chen, 2019, 5387400; Li, 2020, 6315681; He, 2018, 4238388; Canova, 2020, 7021512; Liu, 2018, 4238396; Cong, 2021, 8442223; Khalil, 2020, 7021479; Lin, 2020, 6988476; Liu, 2021, 10176563 \}. Altogether, the available evidence supports a relatively consistent positive association between PFOA and LDL in adults, especially those who are obese or prediabetic. Associations with other lipoprotein cholesterol known to increase cardiovascular risks were also positive, which increased confidence in the findings for LDL.

Eleven medium confidence and thirteen low confidence studies examined PFOA and HDL or clinically defined low HDL in adults (Figure 3-34, Figure 3-35, Figure 3-36). All studies examined cross-sectional associations \{Dong, 2019, 5080195; Jain, 2019, 5080642; Christensen, 2019, 5080398; Fan, 2020, 7102734; Liu, 2018, 4238514; Liu, 2020, 6318644; Lin, 2019, 5187597; Wang, 2012, 2919184; Convertino, 2018, 5080342; Lin, 2020, 6315756; Chen, 2019, 5387400; Li, 2020, 6315681; He, 2018, 4238388; Yang, 2018, 4238462; Canova, 2020, 7021512; Liu, 2018, 4238396; Lin, 2020, 6988476; Han, 2021, 7762348; Jeddi, 2021, 7404065; Cong, 2021, 8442223; Khalil, 2020, 7021479; Liu, 2021, 10176563; Bjorke-Monsen, 2020, 7643487; Yu, 2021, 8453076 \}. Two studies also examined the association between baseline PFOA and changes in HDL \{Liu, 2020, 6318644; Liu, 2018, 4238396 \}. In a population of young adults aged 20 to 39 years in the Veneto region, Italy, an area with water contamination by PFAS, Canova et al. (2020, 7021512) reported statistically significant, positive associations with HDL. Canova et al. (2020, 7021512) also reported a concentration-response curve when PFOA was categorized in deciles. PFOA was inversely associated with HDL at baseline in the DPPOS, but the association was not statistically significant \{Lin, 2019, 5187597 \} (see PFOA Appendix). Four studies used overlapping data from NHANES 2003–2014 and reported associations with HDL that were sometimes positive \{Liu, 2018, 4238514; Christensen, 2019, 5080398; Fan, 2020, 7102734 \} and sometimes inverse \{Dong, 2019, 5080195 \}. The direction of association differed by survey cycles. Few associations in this set of NHANES analyses were statistically significant. In an additional medium confidence study, PFOA was not associated with HDL at baseline or changes in HDL over two years \{Liu, 2020, 6318644 \}. Similarly, low confidence studies also reported a mix of positive \{Lin, 2020, 6315756; Li, 2020, 6315681; He, 2018, 4238388; Yang, 2018, 4238462; Liu, 2018, 4238396 \} associations with changes in HDL in the 6–24 months of the study), inverse \{Chen 2019, 5387400; Liu 2018, 4238396 \} associations with concurrent HDL or changes in HDL in the first 6 months of the study \{Ye, 2020, 6988486, positive finding for reduced HDL\}, or essentially null \{Wang, 2012, 2919184; Convertino, 2018, 5080342; Liu, 2021, 10176563; Khalil, 2020, 7021479; Cong, 2021, 8442223; Bjorke-Monsen, 2020, 7643487 \} associations, with few being statistically significant. Given the inconsistent findings in both medium and low confidence studies, the available evidence suggests PFOA is not associated with HDL in adults.

Nine medium confidence and sixteen low confidence studies examined the association between PFOA and triglycerides or hypertriglyceridemia. All studies examined the cross-sectional association \{Jain, 2019, 5080642; Christensen, 2019, 5080398; Liu, 2018, 4238514; Liu, 2020, 6318644; Lin, 2019, 5187597; Donat-Vargas, 2019, 5080588; Wang, 2012, 2919184; Convertino, 2018, 5080342; Lin, 2013, 2850967; Lin, 2020, 6315756; Chen, 2019, 5387400; Li, 2020, 6315681; He, 2018, 4238388; Yang, 2018, 4238462; Sun, 2018, 4241053; Canova, 2020, 7021512; Fan, 2020, 7102734; Liu, 2018, 4238396; Lin, 2020, 6988476; Han, 2021, 7762348;
three studies additionally examined the association between baseline PFOA and changes in triglycerides or incident hypertriglyceridemia \{Liu, 2020, 6318644; Lin, 2019, 5187597; Liu, 2018, 4238396\}. Higher PFOA was significantly associated with higher levels of triglycerides in the DPPOS \{Lin, 2019, 5187597\} (see PFOA Appendix). This study also reported that PFOA was significantly associated with higher odds of hypertriglyceridemia at baseline and higher incidence of hypertriglyceridemia prospectively \{Lin, 2019, 5187597\}. Similarly, PFOA was associated with slightly higher levels of triglycerides in Liu et al. (2020, 6318644). The association was stronger and statistically significant for triglycerides in the apoC-III-containing combined fractions of IDL and LDL and apoC-III-negative HDL \{Liu, 2020, 6318644\}. In contrast, the four medium studies using overlapping data from NHANES 2005–2014 reported positive \{Jain, 2019, 5080642; Christensen, 2019, 5080398\} or inverse associations \{Jain, 2019, 5080642; Liu, 2018, 4238514; Fan, 2020, 7102734\} between PFOA and triglycerides/hypertriglyceridemia. The direction of association appeared to differ by survey cycle, sex, and obesity status. No associations in these NHANES analyses were statistically significant. In an additional medium confidence study, PFOA was inversely associated with triglycerides, regardless of whether PFOA was measured concurrently or averaged between baseline and follow-up \{Donat-Vargas, 2019, 5080588\}. All participants in this study were free of diabetes for over 10 years, as opposed to the obese or prediabetic adults in Liu et al. (2020, 6318644) and Lin et al. (2019, 5187597). It is unclear if participants’ different health status explained differences in the findings across medium studies.

In low confidence studies, a mix of positive \{Khalil, 2020, 7021479; Liu, 2021, 10176563; Ye, 2021, 6988486; Lin, 2020, 6315756; Chen, 2019, 5387400; He, 2018, 4238388; Yang, 2018, 4238462; Sun, 2018, 4241053; Canova, 2020, 7021512; Lin, 2020, 6988476, in women; Liu, 2018, 4238396, association with concurrent triglycerides or changes in triglycerides in the first 6 months of the study\}, inverse \{Lin, 2013, 2850967; Li, 2020, 6315681; Lin, 2020, 6988476, in men; Liu, 2018, 4238396, association with changes in triglycerides in the 6–24 months of the study\}, and essentially null \{Wang, 2012, 2919184; Convertino, 2018, 5080342; Cong, 2021, 8442223\} associations with triglycerides or hypertriglyceridemia were reported. Some associations were statistically significant. Overall, the available evidence suggests that PFOA was associated with elevated triglycerides in some adults. Whether PFOA increases triglycerides in all adults is unclear given inconsistency in reported associations.

In summary, in the general adult population, a relatively consistent, positive association was observed between PFOA and LDL or TC. Increased triglycerides with increasing PFOA exposure were also observed, but less consistently. HDL was not associated with PFOA.

3.4.3.1.2.6 Findings from Occupational Studies

Workers are usually exposed to higher levels of PFOA, in a more regular manner (sometimes daily), and potentially for a longer duration than adults in the general population. At the same time, according to the “healthy worker effect,” workers tend to be healthier than non-workers, which may lead to reduced susceptibility to toxic agents \{Shah, 2009, 9570930\}. Because of these potential differences in exposure characteristics and host susceptibility, occupational studies are summarized separately from studies among adults in the general population.
Three low confidence studies examined the association between PFOA and TC or hypercholesterolemia in workers. Two of these studies examined the cross-sectional association between PFOA and TC in fluorochemical plant workers or firefighters exposed to aqueous film forming foam (AFFF) \{Wang, 2012, 2919184; Rotander, 2015, 3859842\}. One investigated the association between baseline PFOA and changes in TC over the course of a fluorochemical plant demolition project \{Olsen, 2012, 2919185\}. The cross-sectional studies reported positive \{Wang, 2012, 2919184\} or inverse \{Rotander, 2015, 3859842\} associations between PFOA and TC; neither association was statistically significant. Olsen et al. (2012, 2919185) reported that over the course of the demolition project, changes in PFOA were inversely associated with changes in TC; this association was not statistically significant \{Olsen, 2012, 2919185\}. Taken together, these studies suggest no association between PFOA and TC in workers.

Two studies examined PFOA and LDL in workers. One study examined PFOA and non-HDL, of which LDL is a major component. All studies were considered low confidence. The two studies on LDL reported positive \{Wang, 2012, 2919184\} or inverse \{Rotander, 2015, 3859842\} association between PFOA and concurrent LDL; neither association was statistically significant. The study examining non-HDL reported that changes in PFOA during the fluorochemical plant demolition project were inversely associated with changes in non-HDL, but the association was not statistically significant \{Olsen, 2012, 2919185\}. Overall, these studies suggest no association between PFOA and LDL in workers.

The studies that examined LDL or non-HDL also examined the association between PFOA and HDL \{Wang, 2012, 2919184; Rotander, 2015, 3859842; Olsen, 2012, 2919185\}. The two cross-sectional studies in this set of studies reported inverse association between PFOA and HDL, including a statistically significant finding in Wang (2012, 2919184) \{Wang, 2012, 2919184; Rotander, 2015, 3859842\}. Contrary to these findings, Olsen et al. (2012, 2919185) reported that changes in PFOA over the demolition project were positively associated with changes in HDL \{Olsen, 2012, 2919185\}. This association was not statistically significant. When changes in TC to HDL ratio were examined as an outcome, however, a statistically significant, inverse association was observed. This suggests that increasing PFOA exposure was associated with decreases in TC/HDL over time, potentially partly due to a positive association between changes in PFOA and changes in HDL. Together, the occupational studies reported a consistently inverse association between PFOA and concurrent HDL, but this cross-sectional association was not coherent with longitudinal findings.

Two low confidence cross-sectional studies examined PFOA and triglycerides in workers and reported inverse associations between PFOA and triglycerides \{Wang, 2012, 2919184; Rotander, 2015, 3859842\}. Neither association was statistically significant.

In summary, among workers, the available evidence suggests no association between PFOA and TC or LDL. Inverse, cross-sectional associations between PFOA and HDL and triglycerides were found, but these associations were small, often not statistically significant, and were not coherent with longitudinal findings. Overall, the associations between PFOA and serum lipids among workers are different than those in the general adult population. It is unclear if well-known biases in occupational studies such as “healthy worker effect” may have attenuated the association between PFOA and an unfavorable serum lipid profile. More higher quality occupational studies are needed to improve hazard identification among workers.
3.4.3.2 Animal Evidence Study Quality Evaluation and Synthesis

There are 2 studies from the 2016 PFOA HESD [U.S. EPA, 2016, 3603279] and 7 studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD that investigated the association between PFOA and cardiovascular effects in animal models. Study quality evaluations for these 9 studies are shown in Figure 3-42.

![Figure 3-42. Summary of Study Quality Evaluation Results for Animal Toxicological Studies of PFOA and Cardiovascular Effects](image)

Cardiovascular effects following exposure to PFOA were minimal according to two chronic studies with doses between 1.1 – 14.2 mg/kg/day {Butenhoff, 2012, 2919192; NTP, 2020, 7330145} and one short-term 28-day study with doses between 0.312 – 5 mg/kg/day {NTP, 2019, 5400977}. No toxicologically-relevant changes were observed for heart weight {Butenhoff, 2012, 2919192; NTP, 2019, 5400977; NTP, 2020, 7330145}, minimal changes were observed for heart histopathology {Butenhoff, 2012, 2919192; NTP, 2019, 5400977; NTP, 2020,
and no changes were observed for aorta histopathology {Butenhoff, 2012, 2919192; NTP, 2019, 5400977} following exposure to PFOA in male and female Sprague-Dawley rats.

PFOA has been observed to cause perturbations in lipid homeostasis, which may have effects on the cardiovascular system. Alterations in serum lipid levels have been observed in mice and rats in subchronic, chronic, and developmental studies of oral exposure to PFOA (Figure 3-43). Overall, studies have generally reported consistent decreases in serum lipids including TC, triglycerides, LDL cholesterol, HDL cholesterol, and/or non-HDL cholesterol in rats {Martin, 2007, 758419; Loveless, 2008, 988599; Elcombe, 2010, 2850034; NTP, 2019, 5400977; NTP, 2020, 7330145} and mice {Loveless, 2008, 988599; De Witt, 2009, 1937261; Minata, 2010, 1937251; Yahia, 2010, 1332451; Yan, 2014, 2850901; Quist, 2015, 6570066; Blake, 2020, 6305864; Cope, 2021, 10176465}.

In a developmental study of female CD-1 P₀ mice exposed to PFOA (0, 1, and 5 mg/kg/day) by oral gavage from either GD 1.5–11.5 or GD 1.5–17.5, authors reported maximum decreases in serum triglyceride levels of 58% and 66%, respectively, at the highest dose of 5 mg/kg/day. No changes were observed for serum TC, HDL cholesterol, or LDL cholesterol {Blake, 2020, 6305864}. In a secondary developmental study of gestational PFOA exposure (0.1 and 1.0 mg/kg/day), female CD-1 P₀ mice were exposed via gavage from GD 1.5 – 17.5 {Cope, 2021, 10176465}. Male and female F₁ offspring were fed either a low-fat diet (LFD) or high fat diet (HFD) at PND 22 and serum cholesterol markers were evaluated at PND 22 and at postnatal week (PNW) 18. At PND 22, there was a significant reduction in serum triglycerides in males and females and a significant reduction in LDL in males only but no effects in TC or HDL. At PNW 18, LFD female mice exhibited non-significant decreases in TC, HDL, LDL, and triglycerides. However, animals that were given a HFD no longer exhibited decreased levels of TC, HDL, or triglycerides and developed significantly higher levels of LDL (1.0 mg/kg/day) when compared to HFD control. Males fed the LFD exhibited non-significant increases in TC, HDL, LDL, and triglycerides; however, this trend was lost when animals were fed the HFD.

Male BALB/c mice exposed to PFOA by gavage for 28 days had significant decreases in serum TC and HDL levels at concentrations as low as 1.25 mg/kg/day {Yan, 2014, 2850901}. For serum triglyceride levels, significant increases were observed at lower exposure concentrations of PFOA (0.31 and 1.25 mg/kg/day) while significant decreases were seen following exposure to higher PFOA concentrations (5 and 10 mg/kg/day); no changes were observed in serum LDL cholesterol levels. In a study conducted by NTP, sex differences were observed in Sprague-Dawley rats exposed to PFOA by gavage for 28 days {NTP, 2019, 5400977}. Males had significantly decreased serum TC and triglyceride levels at exposure concentrations as low as 0.625 mg/kg/day. Female rats in the same study were exposed to 10-fold higher doses than their male counterparts due to sex differences in PFOA excretion (see PFOA Appendix). Females had significant increases in both serum TC and triglyceride levels at the two highest doses (50 and 100 mg/kg/day). In the available chronic study {NTP, 2020, 7330145}, F₁ male and female Sprague-Dawley rats were exposed during gestation and lactation (perinatal exposure with postweaning exposure) or postweaning exposure only until animals were 19 weeks of age (e.g., 16-week interim time point; see further study design details in Section 3.4.4.2.1.2). Serum TC levels were significantly decreased only in males exposed during both the perinatal and postweaning phases (at postweaning doses of approximately 1 and 4.6 mg/kg/day); serum triglyceride levels were decreased in all exposure groups. Serum TC levels were significantly
decreased only in the mid-dose F₁ females exposed during both perinatal and postweaning phases; TG levels were not altered in F₁ females.

Conclusions from these studies are met with limitations as the difference in serum lipid composition between humans and commonly used rodent models may impact the relevance to human exposures {Getz, 2012, 1065480; Oppi, 2019, 5926372}. It should noted that human-population based PFOA exposure studies have consistently found that as PFOA exposure increases both serum cholesterol and serum triglycerides also increase. Some rodent studies {Yan, 2014, 2850901} exhibit a biphasic dose response where low exposure concentrations lead to increased serum lipid levels while high exposure concentrations lead to decreased serum lipid levels. This has called in the validity of using rodent models to predict human lipid outcomes. The relatively high exposure and PFOA serum concentrations that produce these inverse effects are generally beyond the scope of human relevance, though there is some evidence in humans that similarly high serum PFOA serum concentrations result in decreased serum total cholesterol (e.g., Convertino et al. (2018, 5080342)). This suggests that rodent models may be utilized accurately if the tested doses are within human health relevant exposure scenarios. Additionally, food consumption and food type may confound these results {Cope, 2021, 10176465; Schlezinger, 2020, 6833593; Fragki, 2021, 8442211}, as diet is a major source of lipids, yet studies do not consistently report a fasting period before serum collection and laboratory diets contain a lower fat content compared to typical Westernized human diets. More research is needed to understand the influence of diet on the response of serum cholesterol levels in rodents treated with PFOA.
3.4.3.3 Mechanistic Evidence

Mechanistic evidence linking PFOA exposure to adverse cardiovascular outcomes is discussed in Sections 3.1.1.1 and 3.4.1 of the 2016 PFOA HESD [U.S. EPA, 2016, 3603279]. There are 8 studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD that investigated the mechanisms of action of PFOA that lead to cardiovascular effects. A summary of these studies is shown in Figure 3-44.
Figure 3-44. Summary of Mechanistic Studies of PFOA and Cardiovascular Effects

Interactive figure and additional study details available on Tableau.

3.4.3.3.1 Lipid transport and metabolism

Blood lipid levels are associated with risk factors for cardiovascular disease. Pouwer et al. (2019, 5080587) investigated how PFOA influences plasma cholesterol and triglyceride metabolism using a transgenic mouse model of human-like lipoprotein metabolism (APOE*3-Leiden.CETP mice, which express the human CETP gene), human plasma samples, and in silico predictions. In the animal toxicological study, mice were fed a semisynthetic Western-type diet (0.25% cholesterol (wt/wt), 1% corn oil (wt/wt), and 14% bovine fat (wt/wt)) with varying levels of PFOA added (10, 300, or 30,000 ng/g/d). At the end of 4 or 6 weeks, mice were sacrificed and levels of triglycerides, TC, free fatty acids (FFA), ALT, glycerol, VLDL, HDL, and CETP were measured. The authors found that administration of PFOA at the 30,000 ng/g/d levels “reduced plasma TG and TC levels by affecting VLDL-TG production through decreased apoB synthesis and by increasing VLDL clearance.” The authors also observed that PFOA at the highest dose decreased hepatic VLDL production rate, increased plasma VLDL clearance through enhanced LPL activity and affected gene expression of TG and cholesterol metabolism markers. Upon further analysis, PPARα was determined to be the major transcription factor affecting gene expression and fatty acid oxidation that regulates triglyceride and TC levels.

One study summarized in the 2016 PFOA HESD (U.S. EPA, 2016, 3603279) evaluated a subset of 290 individuals in the C8 Health Project for evidence that PFOA exposure can influence the transcript expression of genes involved in cholesterol metabolism, mobilization, or transport [Fletcher, 2013, 2850968]. Inverse associations were found between PFOA levels and expression of genes involved in cholesterol transport including Nuclear Receptor Subfamily 1 Group H Member 2 (NR1H2), Niemann-Pick disease type C (NPC1), and ATP Binding Cassette Subfamily G Member 1 (ABCG1). When males and females were analyzed separately, PFOA serum concentrations were negatively associated with expression of genes involved in cholesterol transport in both males and females, although the genes themselves differed between
sexes (males: NPC1, ABCG1, PPARα; females: Nuclear Receptor Subfamily 1, Group H, Member 1 (NCEH1)). For additional information on the disruption of lipid metabolism, transport, and storage in the liver following PFOA exposure, please see Section 3.4.1.3.2.

### 3.4.3.3.2 Apoptosis and cell cycle regulation

To elucidate the mechanisms involved in PFOA-induced vascular tissue apoptosis and CIMT, the levels of endothelial microparticles (CD62E, CD31+/CD42a−) and platelet microparticles (CD62P, CD31+/CD42a+) were measured in the serum of adolescents and young adults in another epidemiological study {Lin, 2016, 3981457}. The results showed that there was no association between PFOA serum levels and markers of apoptosis, endothelial activation, or platelet activation. This study also measured the relationship between oxidative stress and PFOA by measuring levels of 8-hydroxydeoxyguanosine (8-OHdG) in the urine. Similar to the markers of apoptosis, no association was found between PFOA and 8-OHdG. Another study by the same researchers also found that there was no association between PFOA and oxidative/nitrative stress markers 8-OHdG and 8-nitroguanine (8-NO2Gua) in Taiwanese adults {Lin, 2020, 6315756}.

One study evaluated the potential for PFOA to affect cell-cycle regulation in the heart and other tissues {Cui, 2019, 5080384}. Male mice were orally dosed with 5 mg/kg/day PFOA for 28 days, and microRNA-34 (miR-34), a marker of tissue damage, was measured in the heart at the end of the exposure period. To further study the role of cardiovascular miR-34a under PFOA treatment, the authors also dosed miR-34a-knockout and wild-type mice for 28 days. In the wild-type mice, the expression of miR-34a in the heart was not significantly different in the treatment group compared to the control group. There were also no detectible levels miR-34b or miR-34c in the heart for either the treatment group or the control group.

### 3.4.3.3.3 Mechanisms of atherogenesis and clot formation

Four groups of researchers published studies on the mechanism of atherogenesis and clot formation. The first two studies investigated how the structure of PFOA and other PFAS leads to activation of the plasma kallikrein-kinin system (KKS) using in vitro and ex vivo activation assays and in silico molecular docking analysis. KKS is a key component of plasma that plays a role in regulation of inflammation, blood pressure, coagulation, and vascular permeability. Activation of the plasma KKS can release the inflammatory peptide bradykinin (BK), which can lead to dysfunction of vascular permeability. The cascade activation of KKS includes the autoactivation of Hageman factor XII (FXII), cleavage of plasma prekallikrein (PPK), and activation of high-molecular-weight kininogen (HK) {Liu, 2018, 4238499}. Results from the ex vivo mouse plasma study by Liu et al. (2017, 4238579) revealed that the addition of PFOA (5 mM) at the highest dose binds with FXII in a structure dependent manner and triggers the cascade to the rest of the system. Liu et al. (2018, 4238499) observed no activation of the KKS cascade when mouse plasma was incubated with up to 500 μM PFOA.

Bassler et al. (2019, 5080624) focused on several disease biomarkers, including plasminogen activator inhibitor-1 (PAI-1), an indicator of clot formation and that may lead to atherosclerosis. Human serum was collected from 200 patients as part of the larger C8 Health Project and analyzed for PFOA content. The authors found that there was no statistically significant difference in PAI-1 concentration in association with high exposure to PFOA concentrations.
The final study among the four groups of researchers, conducted by De Toni et al. (2020, 6316907), investigated the effect of PFOA on platelet function, a key factor in atherosclerosis. Whole blood and peripheral blood samples were taken from healthy males that lived in low exposure areas and incubated with 400 ng/mL of PFOA. After isolating erythrocytes, leukocytes, and platelets and quantifying the amount of PFOA present, platelets were found to be the cell target of PFOA accumulation. The authors then used the platelets in an in vitro system and inoculated them with 400 ng/mL of PFOA and found that substantially more PFOA accumulated in the membrane of platelets vs. the cytoplasm. Using molecular docking analysis, they were able to target the specific binding sites of PFOA to phosphatidylcholine, a major platelet phospholipid, suggesting that the accumulation of PFOA in the platelet may alter the activation process of platelets by impairing membrane stability.

3.4.3.4 Evidence Integration

There is moderate evidence for an association between PFOA exposure and cardiovascular effects in humans based on consistent positive associations with serum lipids, particularly LDL, TC, and triglycerides. Additional evidence of positive associations with blood pressure and hypertension in adult populations supported this classification. The lack of evidence of consistent or precise effects for CVD or atherosclerotic changes raise uncertainty related to cardiovascular health effects following PFOA exposure. The available data for CVD and atherosclerotic changes was limited and addressed a wider range of outcomes, resulting in some residual uncertainty for the association between PFOA exposure and these outcomes.

Based on this systematic review of 43 epidemiologic studies, the available evidence revealed positive associations between PFOA exposure and TC, LDL, and triglycerides effects in some human populations. For TC, the association was consistently positive in adults from the general population, positive but less consistently so in children and pregnant women, and generally null in workers. For LDL, the association was generally positive among adults, positive but less consistently so in children, and generally null in workers. Data were not available for PFOA and LDL in pregnant women. For triglycerides, positive, often non-significant associations were observed in some adults and children, but not pregnant women and workers. Except for workers, these results are consistent with findings from the 2016 HESD. Differences in findings from occupational studies between the 2016 HESD and this review may be attributable to limitations of occupational studies in this review. Similar to the 2016 HESD, the available evidence in this review does not support an inverse association between PFOA and HDL in any populations. The positive associations with TC are also supported by the recent meta-analysis restricted to 14 general population studies in adults {U.S. EPA, 2022, 10369698}. Similarly, a recent meta-analysis including data from 11 studies reported consistent associations between serum PFOA or a combination of several PFCs including PFOA and PFOS, and increased serum TC, LDL, triglyceride levels in children and adults {Abdullah Soheimi, 2021, 9959584}.

The epidemiological studies identified since the 2016 assessments do not provide additional clarity on the association between PFOA and CVD. Most of the CVD evidence identified in this review focused on blood pressure in the general adult population (13 studies). The findings from a single high confidence study and five medium confidence studies conducted in the general adult population did not provide consistent evidence for an association between PFOA and blood pressure. The evidence for an association between PFOA and increased risk of hypertension overall and in gender-stratified analysis was inconsistent. Evidence in children and adolescents
also is less consistent. Five studies in children and adolescents, and one study in pregnant women suggest no associations with elevated blood pressure in these populations. Evidence for other CVD-related outcomes across all study populations was more limited, and similarly inconsistent. Consequently, the evidence for these CVD outcomes is broadly consistent with the conclusions of the C8 Science Panel and in the 2016 PFOA assessment, which found no probable link between PFOA exposure and multiple other conditions, including high blood pressure and CAD. It is challenging to compare findings on CVD related mortality in the current assessment to the prior assessment due to differences in how this outcome was defined. Findings from the prior assessment were mixed, with one study reporting an increased risk of cerebrovascular disease mortality observed in the highest PFOA exposure category among occupationally exposed subjects. However, no association was reported with IHD mortality. The current evidence from a single study indicated PFOA was not associated with an increased risk of mortality due to cardiovascular causes, including hypertensive disease, IHD, stroke, and circulatory diseases. Future analyses of cause-specific CVD mortality could help elucidate whether there is a consistent association between PFOA and cerebrovascular disease mortality. No studies or endpoints were considered for the derivation of PODs since findings for an association between PFOA and CVD outcomes are mixed.

The animal evidence for an association between PFOA exposure and cardiovascular toxicity is moderate based on effects on serum lipids observed in animal models in six high or medium confidence studies. The most consistent results are for TC and triglycerides, although direction of effect can vary by dose. The biological significance of the decrease in various serum lipid levels observed in these animal models regardless of species, sex, or exposure paradigm is unclear; however, these effects do indicate a disruption in lipid metabolism. No effects or minimal alterations were noted for heart weight and histopathology in the heart and aorta.

The underlying mechanisms for the observed cardiovascular effects related to PFOA exposure are likely related to changes in lipid metabolism, as described in detail in Section 3.4.1.3. Specifically, alterations in lipid metabolism lead to alterations in serum levels of triglycerides and cholesterol, as evidenced by in vivo in animal models. The events that precede and result in the alterations in serum levels have been proposed as the following, based on experimental evidence: (1) PFOA accumulation in liver activates nuclear receptors, including PPARα; (2) expression of genes involved in lipid homeostasis and metabolism is altered by nuclear receptor activation; (3) gene products (translated proteins) modify the lipid content of liver to favor triglyceride accumulation and potentially cholesterol accumulation; (4) altered lipid content in the liver leads to accumulation of lipid droplets, which can lead to the development of steatosis and liver dysfunction. It should be noted that the results for PFOA-induced changes to serum lipid levels contrast between rodents (generally decreased) and humans (generally increased). Evidence is ultimately limited regarding a clear mechanism of alterations to serum lipid homeostasis caused by PFOA exposure. In humans, as discussed in the 2016 PFOA HESD [U.S. EPA, 2016, 3603279] data from the C8 Health Project indicated that PFOA exposure can influence expression of genes involved in cholesterol metabolism, mobilization, or transport. Specifically, an inverse association was found between PFOA levels and expression of genes involved in cholesterol transport, with sex-specificity for some of the individual gene expression changes. The authors of the study suggested that exposure to PFOA may promote a hypercholesterolaemic environment. Results were inconsistent regarding effects of PFOA on indicators or mechanisms related to atherosclerosis, including a lack of effect on an indicator of
clot formation in human serum samples, and dose-dependent effects on the plasma kallikrein-kinin system in mouse plasma. A single study found that PFOA accumulates in platelets in human blood samples exposed in vitro, which may alter the activation process of platelets, although it was not directly evaluated. PFOA did not induce apoptosis or oxidative stress in vascular tissue in humans, as evidenced in two studies that evaluated serum levels of endothelial microparticles and platelet microparticles, and urinary 8-hydroxydeoxyguanosine (8-OHdG) in relation to PFOA levels.

3.4.3.4.1 Evidence Integration Judgment
Overall, considering the available evidence from human, animal, and mechanistic studies, the evidence indicates that PFOA exposure is likely to cause adverse cardiovascular effects, specifically serum lipid effects, in humans under relevant exposure circumstances (Table 3-8). The hazard judgment is driven primarily by consistent evidence of serum lipid responses from epidemiological studies at median PFOA exposure levels representative of the NHANES population (median = 3.7 ng/mL). The evidence in animals showed coherent results for perturbations in lipid homeostasis in rodent models in developmental, subchronic, and chronic studies following exposure to doses as low as 0.3 mg/kg/day PFOA. While there is some evidence that PFOA exposure might also have the potential to affect blood pressure and other cardiovascular responses in humans given relevant exposure circumstances, the human evidence underlying this possibility is uncertain and without support from animal or mechanistic studies.
### Table 3-8. Evidence Profile Table for PFOA Cardiovascular Effects

#### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgment</th>
</tr>
</thead>
</table>
| Serum lipids              | Examination of serum lipids included measures of TC, LDL, HDL, and TG. In studies of adults from the general population (23), there is evidence of positive associations with TC (17/23), but there was some inconsistency by sex or health status. Positive associations were also observed for LDL (15/23), and mostly positive, but slightly mixed, associations with TG. Evidence from studies of children (15) was mixed, and observed associations often failed to reach significance. Findings were mostly positive for TC (8/15). Among studies of pregnant women (6), evidence indicated positive associations with HDL (2/6) but not other serum lipid measures. Evidence of inverse associations with HDL and TG was observed in occupational populations. | • High and medium confidence studies  
• Consistent findings of positive associations with serum lipid measures in adults from the general population  
• Coherence of observed associations in adults from the general population with previous evidence of serum lipid effects | • Low confidence studies  
• Inconsistent findings of effect in children, likely due to variations in measured exposure window, and occupational populations | ⊕⊕⊙ Moderate |

#### Evidence from Studies of Exposed Humans (Section 3.4.3.1)

Evidence for cardiovascular effects is based on numerous medium confidence studies reporting positive associations with serum lipids, such as TC, LDL, and TG, in adults from the general population. Results from some studies of children and pregnant women also observed positive effects for TC and TG. Results from occupational studies were inconsistent with those from other populations, though this may be due to deficiencies in the occupational study designs. High and medium confidence studies of adults reported positive associations with blood pressure and risk of hypertension, though other medium and low confidence studies.

Primary basis and cross-stream coherence: Human evidence indicated consistent evidence of serum lipids response and animal evidence showed coherent results for perturbations in lipid homeostasis in rodent models in developmental, subchronic, and chronic studies following exposure to PFOA. While there is some evidence that PFOA exposure might also have the potential to affect blood pressure and other cardiovascular responses in humans given relevant exposure circumstances, the human evidence underlying this possibility is uncertain and without support from animal or mechanistic studies.

Human relevance and other inferences: No specific factors are noted.
## Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood pressure and hypertension</strong>&lt;br&gt;3 <em>High</em> confidence studies&lt;br&gt;14 <em>Medium</em> confidence studies&lt;br&gt;6 <em>Low</em> confidence studies</td>
<td>Studies examining changes in blood pressure, including DBP and SBP, and risk for hypertension had mixed results with limited statistical significance. The majority of studies in children (10) did not find an association with blood pressure and/or hypertension (7/10), though one study reported positive associations with risk of hypertension (1/10), one reported evidence of an increase of SBP (1/10), another reported evidence of increased mean of SBP and DBP (1/10). Studies of adults in the general population (16) observed some positive associations with continuous blood pressure (6/16), though results varied between SBP and DBP, and with risk of hypertension</td>
<td>• <em>High</em> and <em>medium</em> confidence studies&lt;br&gt;• <em>Consistent</em> findings of positive effects for blood pressure measures, including hypertension, among adults&lt;br&gt;• <em>Consistent</em> findings of effects observed in studies of children for blood pressure measures and hypertension</td>
<td>• <em>Low</em> confidence studies&lt;br&gt;• Imprecision of findings&lt;br&gt;• Inconsistent findings of effects observed for SBP and DBP across studies in adults</td>
<td>reported non-significant associations. Observed effects were inconsistent for CVD and imprecise for atherosclerotic changes across all study populations.</td>
</tr>
</tbody>
</table>
Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(6/16). Other studies did not report significant associations. Hypertension analyses provided evidence of modification by sex, with males having higher risk in some studies.</td>
<td>Measures of CVD included CHD, PAD, stroke, heart attack, and MVD. Studies in adults from the general population (8) reported mixed results. Positive associations were reported for odds of PAD and CHD (1/8), odds of CVD (1/8), and odds of heart attack (1/8), while other studies reported inverse effects for CHD (1/8) and stroke (1/8). Still, other studies did not observe evidence of CVD associations. One study of a population of workers (1/3) reported significantly increased odds of stroke in one exposure group, but the effect diminished when a 10-year lag was included in analyses. Two additional occupational studies reported imprecise findings.</td>
<td>• High and medium confidence studies</td>
<td>• Low confidence studies</td>
<td>• Inconsistent findings for CVD-related outcomes</td>
</tr>
</tbody>
</table>

Cardiovascular disease
1 High confidence study
5 Medium confidence studies
5 Low confidence studies
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atherosclerotic changes</strong></td>
<td>One study of children reported increased brachial artery distensibility (1/3). No significant associations were observed for CIMT among Taiwanese children (2/3) or pulse wave velocity among American children (1/3). Studies of adults (3) reported mixed results for measures of atherosclerotic changes. Most studies did not report associations that reached significance, however, one study reported decreased left ventricular relative wall thickness (1/3).</td>
<td><strong>High and medium confidence studies</strong></td>
<td><strong>Low confidence studies</strong></td>
<td>Imprecision of findings across children and adult study populations</td>
</tr>
</tbody>
</table>

| **Serum lipids** | Significant decreases in serum TC were observed in 4/6 studies that examined this endpoint, regardless of species, sex, or study design. In two developmental studies, no changes were observed in mice. Similar decreases were observed in serum TG (6/6). In a developmental study, | **High and medium confidence studies** | **Incoherence of findings in other cardiovascular outcomes** | Moderate | Evidence based on six high or medium confidence studies observed that PFOA affects serum lipids in animal models. The most consistent results are for total cholesterol and triglycerides, although |

| **Evidence from In Vivo Animal Toxicological Studies (Section 3.4.3.2)** | | | | |
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>decreased serum TG were observed in mice at PND 22 but not during adulthood. In a short-term exposure study, female rats were given 10-fold higher doses of PFOA than males due to sex differences in excretion, and it was found that serum TC and TG were decreased in males but increased in females. Fewer studies examined HDL and LDL, with decreases found in HDL (2/4). Two studies found no changes in LDL, but one developmental study in mice observed increased LDL in males at PND 22 but no changes during adulthood.</td>
<td>direction of effect can vary by dose. The biological significance of the decrease in various serum lipid levels observed in these animal models regardless of species, sex, or exposure paradigm is unclear; however, these effects indicate a disruption in lipid metabolism. No effects or minimal alterations were noted for heart weight and histopathology in the heart and aorta. However, many of the studies identified may not be adequate in exposure duration to assess potential toxicity to the cardiovascular system.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Histopathology

2 **High confidence** studies

1 **Medium confidence** study

| **Histopathology** | No changes in heart histopathology were reported in two studies. One chronic study reported decreased incidence of chronic myocarditis in female rats in the mid-dose group only. No changes in aorta histopathology were noted in two studies. | **High and medium confidence studies** | **Limited number of studies examining outcome** |
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Organ weight</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgment</th>
</tr>
</thead>
</table>
| 2 High confidence studies, 1 Medium confidence study | No changes in absolute or relative heart weights were found in one short-term study and one chronic study in rats. One chronic study in rats reported decreased absolute heart weights in males and females, but those reductions were found to be related to reduced body weights. | • High and medium confidence studies | • Limited number of studies examining outcome  
• Confounding variables such as decreases in body weights may limit ability to interpret these responses | |

### Mechanistic Evidence and Supplemental Information (Section 3.4.3.3)

<table>
<thead>
<tr>
<th>Key findings and interpretation:</th>
<th>Evidence Stream Judgment</th>
</tr>
</thead>
</table>
| • Alterations in lipid metabolism results in alterations in serum levels of TG and TC via:  
  o PFOA accumulation in liver activates nuclear receptors, including PPARα.  
  o Nuclear receptor activation alters the expression of genes involved in lipid homeostasis and metabolism.  
PPARα is a major transcription factor affecting expression of genes that regulate fatty acid oxidation and triglyceride and total cholesterol levels. | Findings support plausibility that cardiovascular effects, specifically changes to serum TG and TC levels, can occur through changes in lipid metabolism related to PFOA exposure. |

<table>
<thead>
<tr>
<th>Limitations:</th>
<th></th>
</tr>
</thead>
</table>
| • Only a single study demonstrating PFOA accumulation in platelets in vitro.  
• Results are inconsistent and conflicting regarding effects on indicators or mechanisms related to atherosclerosis, primarily related to clot formation. | |

**Notes:** CHD = coronary heart disease; CIMT = carotid intima-media thickness; CVD = cardiovascular disease; DBP = diastolic blood pressure; HDL = high density lipoprotein; LDL = low density lipoprotein; MVD = microvascular disease; PAD = peripheral arterial disease; PPARα = peroxisome proliferator-activated receptor alpha; SBP = systolic blood pressure; TC = total cholesterol; TG = triglyceride.

* Mixed confidence studies had split confidence determinations for different serum lipid measures with some measures rated medium confidence and others rated low confidence.
3.4.4 Developmental

EPA identified 100 epidemiological and 18 animal toxicological studies that investigated the association between PFOA and developmental effects. Of the epidemiological studies, 30 were classified as high confidence, 39 as medium confidence, 19 as low confidence, 5 as mixed (2 high/medium, 1 medium/low, 2 low/uninformative) confidence, and 7 were considered uninformative (Section 3.4.4.1). Of the animal toxicological studies, 2 were classified as high confidence, 11 as medium confidence, and 4 as low confidence, and 1 was considered mixed (medium/low) (Section 3.4.4.2). Studies have mixed confidence ratings if different endpoints evaluated within the study were assigned different confidence ratings. Though low confidence studies are considered qualitatively in this section, they were not considered quantitatively for the dose-response assessment (Section 4).

3.4.4.1 Human Evidence Study Quality Evaluation and Synthesis

3.4.4.1.1 Introduction

This section describes studies of PFOA exposure and potential in utero and perinatal effects or developmental delays, as well as effects attributable to developmental exposure. The latter includes all studies where exposure is limited to gestation and/or early life up to 2 years of age. Developmental endpoints can include gestational age, measures of fetal growth (e.g., birth weight), and miscarriage, as well as infant/child development.

The 2016 PFOA HESD {U.S. EPA, 2016, 3603279} summarized epidemiological studies that examined developmental effects in relation to PFOA exposure. There are 21 studies from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA and developmental effects. Study quality evaluations for these 21 studies are shown in Figure 3-45.

Studies included ones conducted both in the general population as well as in communities known to have experienced high PFOA exposure (e.g., the C8 population in West Virginia and Ohio). Results of 16 high or medium confidence epidemiological studies and five low confidence or uninformative studies (see Section 2.1.3 for information about study quality evaluations) discussed in the 2016 PFOA HESD are summarized below.
Figure 3-45. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Developmental Effects Published before 2016 (References from 2016 PFOA HESD)

Interactive figure and additional study details available on HAWC.
As noted in the 2016 HESD, several available studies measured fetal growth outcomes. Apelberg et al. (2007, 1290833) found that birth weight was inversely associated with umbilical cord PFOA concentration (change in birth weight per log unit increase: −104; 95% confidence interval (CI): −213, −5; g) in a study of 293 infants born in Maryland in 2004–2005 (mean PFOA concentration of 0.0016 μg/mL). Maisonet et al. (2012, 1332465) evaluated fetal growth outcomes in 395 singleton female births of participants in the Avon Longitudinal Study of Parents and Children (ALSPAC) and found that increased maternal PFOA concentration (median concentration of 0.0037 μg/mL) was associated with lower birth weights (change in birth weight per log unit increase: −34.2; 95% CI: −54.8, −13; g). A study of 252 pregnant women in Alberta, Canada found no statistically significant association between birth weight and PFOA concentration measured in maternal blood during the second trimester (mean concentration of 0.0021 μg/mL) {Hamm, 2010, 1290814}. In a prospective cohort study in Japan (2002–2005), Washino et al. (2009, 1291133) found no association between PFOA concentration in maternal blood during pregnancy (mean PFOA concentration of 0.0014 μg/mL) and birth weight. Chen et al. (2012, 1332466) examined 429 mother-infant pairs from the Taiwan Birth Panel Study and found no significant association between umbilical cord blood PFOA concentration (geometric mean (GM) of 0.0018 μg/mL) and birth weight.

Some studies evaluated fetal growth parameters in the prospective Danish National Birth Cohort (DNBC; 1996–2002) {Andersen, 2010, 1429893; Fei et al., 2007, 1005775; Fei, 2008, 2349574}. Maternal blood samples were taken in the first and second trimester. Fei et al. (2007, 1005775) found an inverse association between maternal PFOA concentration (blood samples taken in the first and second trimester) and birth weight (change in birth weight per unit increase: −8.7; 95% CI: −19.5, 2.1). Fei et al. (2008, 2349574) found an inverse association between maternal PFOA levels and birth length and abdominal circumference in the DNBC. Change in birth length per unit increase was 0.069 cm (95% CI: 0.024, 0.113) and change in abdominal circumference per unit increase was 0.059 cm (95% CI: 0.012, 0.106). Andersen et al. (2010, 1429893) examined the association between maternal PFOA concentrations and birth weight, birth length, and infant body mass index (BMI) and body weight at 5 and 12 months of age in DNBC participants. They found a positive association between maternal PFOA concentration and BMI measured at 5 and 12 months in boys, but not girls.

Some studies described in the 2016 PFOA HESD evaluated developmental outcomes in the C8 Health Project study population, which comprises a community known to have been subjected to high PFAS exposure {Darrow, 2013, 2850966; Savitz, 2012, 1276141; Savitz, 2012, 1424946; Stein, 2009, 1290816; Darrow, 2014, 2850274}. The C8 Health Project included pregnancies within 5 years prior to exposure measurement, and many of the women may not have been pregnant at the time of exposure measurement. As noted in the 2016 HESD, none of the studies reported associations between PFOA and either birth weight or the risk of low birth weight. Additionally, two studies {Nolan, 2009, 2349576; Nolan, 2010, 1290813} evaluated birth weight, gestational age of infants, and frequencies of congenital anomalies in this community based on whether participants were supplied with contaminated public drinking water (PFOA concentrations were not measured in participants). The studies found no associations between these developmental effects and water supply status. These two studies were rated low confidence.
3.4.4.1.2 Study Evaluation Considerations

There were multiple developmental outcome-specific considerations that informed domain-specific ratings and overall study confidence. For the Confounding domain, downgrading of studies occurred when key confounders of the fetal growth and PFAS relationship, such as parity, were not considered. Some hemodynamic factors related to physiological changes during pregnancy were also considered in this domain as potential confounders (e.g., GFR and blood volume changes over the course of pregnancy) because these factors may be related to both PFOA levels and the developmental effects examined here. More confidence was placed in the epidemiologic studies that adjusted for GFR in their regression models or if they limited this potential source of confounding by sampling PFAS levels earlier in pregnancy. An additional source of uncertainty was the potential for confounding by other PFAS (and other co-occurring contaminants). Although scientific consensus on how best to address PFAS co-exposures remains elusive, this was considered in the study quality evaluations and as part of the overall weight of evidence determination.

For the Exposure domain, all the available studies analyzed PFAS in serum or plasma using standard methods. Given the estimated long half-life of PFOA in humans noted in Section 3.3.1.4.5, samples collected during all three trimesters, before birth or shortly after birth were considered adequately representative of the most critical in utero exposures for fetal growth and gestational duration measures. The postnatal anthropometric studies were evaluated with consideration of fetal programming mechanisms (i.e., Barker hypothesis) where in utero perturbations, such as poor nutrition, can lead to developmental effects such as fetal growth restriction and ultimately adult-onset metabolic-related disorders and related complications (see more on this topic in {De Boo, 2009, 6937194} and {Perng, 2016, 6814341}. There is some evidence that birth weight (BWT) deficits can be followed by increased weight gain that may occur especially among those with rapid growth catch-up periods during childhood {Perng, 2016, 6814341}. Therefore, the primary critical exposure window for measures of postnatal (and early childhood) weight and height change is assumed to be in utero for study evaluation purposes, and studies of this outcome were downgraded in the exposure domain if exposure data were collected later during childhood or concurrently with outcome assessment (i.e., cross-sectional analyses).

Studies were also downgraded for study sensitivity, for example, if they had limited exposure contrasts and/or small sample sizes, since this can impact the ability of studies to detect statistically significant associations that may be present (e.g., for sex-stratified results). In the Outcome domain, specific considerations address validation and accuracy of specific endpoints and adequacy of case ascertainment for some dichotomous (i.e., binary) outcomes. For example, BWT measures have been shown to be quite accurate and precise, while other fetal and early childhood anthropometric measures may result in more uncertainty. Mismeasurement and incomplete case ascertainment can affect the accuracy of effect estimates by impacting both precision and validity. For example, the spontaneous abortion studies were downgraded for incomplete case ascertainment in the Outcome domain given that some pregnancy losses go unrecognized early in pregnancy (e.g., before implantation). This incomplete ascertainment, referred to as left truncation, can result in decreased study sensitivity and loss of precision. Often, this type of error can result in bias towards the null if ascertainment of fetal loss is not associated with PFOA exposures (i.e., non-differential). In some situations, differential loss is possible and bias away from the null can manifest as an apparent protective effect. Fetal and
childhood growth restriction were examined using several endpoints including low BWT, small for gestational age (SGA), ponderal index (i.e., BWT grams/birth length (cm³) × 100), abdominal and head circumference, as well as upper arm/thigh length, mean height/length, and mean weight either at birth or later during childhood. The developmental effects synthesis is largely focused on the higher quality endpoints (i.e., classified as good in the Outcome domain) that were available in multiple studies to allow for an evaluation of consistency and other considerations across studies. However, even when databases were more limited, such as for spontaneous abortions, the evidence was evaluated for its ability to inform developmental toxicity more broadly, even if available in only one study.

Overall, mean BWT and BWT-related measures are considered very accurate and were collected predominately from medical records; therefore, more confidence was placed in these endpoints in the Outcome domain judgments. Some of the adverse endpoints of interest examined here included fetal growth restriction endpoints based on BWT such as mean BWT (or variations of this endpoint such as standardized BWT z-scores), as well as binary measures such as SGA (e.g., lowest decile of BWT stratified by gestational age and other covariates) and low BWT (i.e., typically < 2500 grams; 5 pounds, 8 ounces) births. Sufficient details on the SGA percentile definitions and stratification factors as well as sources of standardization for z-scores were necessary to be classified as good for these endpoints in this domain. In contrast, other measures of fetal growth that are subject to more measurement error (e.g., head circumference and body length measures such as ponderal index) were given a rating of adequate {Shinwell, 2003, 6937192}. These sources of measurement error are expected to be non-differential with respect to PFOA exposure status and, therefore, would not typically be a major concern for risk of bias but could impact study sensitivity.

Gestational duration measures were presented as either continuous (i.e., per each gestational week) or binary endpoints such as preterm birth (PTB, typically defined as gestational age < 37 weeks). Although changes in mean gestational age may lack some sensitivity (especially given the potential for measurement error), many of the studies were based on ultrasound measures early in pregnancy, which should increase the accuracy of estimated gestational age and the ability to detect associations that may be present. Any sources of error in the classification of these endpoints would also be anticipated to be non-differential with respect to PFOA exposure. While they could impact precision and study sensitivity, they were not considered a major concern for risk of bias.

3.4.4.1.3 Study Inclusion
There are 79 epidemiological studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA and developmental effects. Although every study is included in the endpoint-specific study quality evaluation heat maps for comprehensiveness, six developmental epidemiological studies identified in the literature search were excluded from this synthesis due to study population overlap with other included studies (i.e., were considered duplicative). The Li et al. (2017, 3981358) Guangzhou Birth Cohort Study overlaps with a more recent study by Chu et al. (2020, 6315711). Four other studies {Kishi, 2015, 2850268; Kobayashi, 2017, 3981430; Minatoya, 2017, 3981691; Kobayashi, 2022, 10176408} were also not considered in this synthesis, because they provided overlapping data from the same Hokkaido Study on Environment and Children’s Health birth cohort as Kashino et al. (2020,
For those studies with the same endpoints analyzed across different subsets from the same cohort, such as mean BWT, the analysis with the largest sample size was used in forest plots and tables (e.g., Kashino, 2020, 6311632 for the Hokkaido birth cohort study). Although the Kobayashi et al. (2017, 3981430) study included a unique endpoint called ponderal index, this measure is more prone to measurement error and was not considered in any study given the wealth of other fetal growth restriction data. Similarly, the Costa et al., (2019, 5388081) study that examined a less accurate in utero growth estimate was not considered in lieu of their more accurate birth outcomes measures reported in the same cohort (Manzano-Salgado, 2017, 4238465). One study by Bae et al. (2015, 2850239) was the only study to examine sex ratio and was not further considered here. In general, to best gauge consistency and magnitude of reported associations, EPA largely focused on the most accurate and most prevalent measures within each fetal growth endpoint. Three additional studies with overlapping cohorts were all included in the synthesis, as they provided some unique data for different endpoints. For example, the Woods et al. (2017, 4183148) publication on the Health Outcomes and Measures of the Environment (HOME) cohort overlaps with Shoaff et al. (2018, 4619944) but the authors provided additional mean BWT data. The mean BWT results for singleton and twin births from Bell et al. (2018, 5041287) are included in forest plots here, while the postnatal growth trajectory data in the same UPSTATE KIDS cohort by Yeung et al. (2019, 5080619) are also included as they target different developmental endpoints. The Bjerregaard-Olesen et al. (2019, 5083648) study from the Aarhus birth cohort also overlaps with Bach et al. (2016, 3981534). The main effect results are comparable for head circumference and birth length in both studies despite a smaller sample size in the Aarhus birth cohort subset examined in Bjerregaard-Olesen et al. (2019, 5083648). Given that additional sex-specific data are available in the Bjerregaard-Olesen et al. (2019, 5083648) study, the synthesis for head circumference and birth length are based on this subset alone. Chen et al., (2021, 7263985) reported an implausibly large effect estimate for head circumference. After correspondence with study authors, an error was identified, and the study was not considered for head circumference.

Following exclusion of the seven studies above, 72 developmental epidemiological studies were available for the synthesis. One study by Bae et al. (2015, 2850239) was the only study to examine sex ratio and was not further considered here. Six additional studies (Alkhalawi, 2016, 3859818; Gundacker, 2021, 10176483; Jin, 2020, 6315720; Lee, 2013, 3859850; Lee, 2016, 3981528; Maekawa, 2017, 4238291) were considered uninformative due to critical deficiencies in some risk of bias domains (e.g., confounding) or multiple domain deficiencies and are not further examined here. Thus, 66 studies were included across various developmental endpoints for further examination and synthesis. Forty-six of the 66 studies examined PFOA in relation to fetal growth restriction measured by the following fetal growth restriction endpoints: SGA, low BWT, head circumference, as well as mean and standardized BWT and birth length measures. Twenty studies examined different measures of gestation duration, five examined fetal loss, four examined birth defects, and 13 examined postnatal growth.

High and medium confidence studies were the focus of the evidence synthesis for endpoints with numerous studies, though low confidence studies were still considered for consistency in the direction of association (and details are provided in PFOA Appendix). For endpoints with fewer studies, the evidence synthesis below included details on any low confidence studies available. Studies considered uninformative were not considered further in the evidence synthesis.
3.4.4.1.4 Growth Restriction: Fetal Growth

3.4.4.1.4.1 Birth Weight

Of the 43 studies examining different BWT measures in relation to PFOA exposures, 37 examined mean birth weight differences. Fifteen studies examined standardized BWT measures (e.g., z-scores) with nine of these reporting results for mean and standardized BWT {Ashley-Martin, 2017, 3981371; Bach, 2016, 3981534; Eick, 2020, 7102797; Gyllenhammar, 2018, 4238300; Meng, 2018, 4829851; Sagiv, 2018, 4238410; Wang, 2019, 5080598; Wikström, 2020, 6311677; Workman, 2019, 5387046}. Twenty-six of the 37 mean BWT were prospective birth cohort studies, and the remaining eleven were cross-sectional analyses defined here as if biomarker samples were collected at birth or post-partum {Bell, 2018, 5041287; Callan, 2016, 3858524; de Cock, 2016, 3045435; Gao, 2019, 5387135; Gyllenhammar, 2018, 4238300; Kwon, 2016, 3858531; Shi, 2017, 3827535; Wang, 2019, 5080598; Wu, 2012, 2919186; Xu, 2019, 5381338; Yao, 2021, 9960202}.

Eight of the 37 studies with data on the overall population relied on umbilical cord measures {Cao, 2018, 5080197; de Cock, 2016, 3045435; Govarts, 2016, 3230364; Kwon, 2016, 3858531; Shi, 2017, 3827535; Wang, 2019, 5080598; Workman, 2019, 5387046; Xu, 2019, 5381338}, and one collected blood samples in infants 3 weeks following delivery {Gyllenhammar, 2018, 4238300}. Results from the Bell et al. (2018, 5041287) study were based on infant whole blood taken from a heel stick and captured onto filter paper cards at 24 hours or more following delivery, and one study used both maternal serum samples collected 1–2 days before delivery and cord blood samples collected immediately after delivery {Gao, 2019, 5387135}. One of the prospective birth cohort studies examined pre-conception maternal serum samples {Robledo, 2015, 2851197}. Twenty-four studies had maternal exposure measures that were sampled during trimesters one {Ashley-Martin, 2017, 3981371; Bach, 2016, 3981534; Lind, 2017, 3858512; Manzano-Salgado, 2017, 4238465; Sagiv, 2018, 4238410}, two {Buck Louis, 2018, 5016992; Lauritzen, 2017, 3981410}, three {Callan, 2016, 3858524; Chu, 2020, 6315711; Kashino, 2020, 6311632; Luo, 2021, 9959610; Valvi, 2017, 3983872; Wang, 2016, 3858502; Wu, 2012, 2919186; Yao, 2021, 9960202}, or across multiple trimesters {Chang, 2022, 9959688; Chen, 2021, 7263985; de Cock, 2016, 3045435; Eick, 2020, 7102797; Hjermitstlev, 2020, 5880849; Lenters, 2016, 5617416; Marks, 2019, 5081319; Starling, 2017, 3858473; Wikström, 2020, 6311677; Woods, 2017, 4183148}. The study by Meng et al. (2018, 4829851) pooled exposure data from two study populations, one which measured PFOA in umbilical cord blood and one which measured PFOA in maternal blood samples collected in trimesters 1 and 2. For comparability with other studies of mean BWT, only one biomarker measure was used (e.g., preferably maternal samples when collected in conjunction with umbilical cord samples or maternal only when more than the parent provided samples). In addition, other related publications (e.g., Gyllenhammar et al. (2017, 7323676)) or additional information or data provided by study authors were used.

Sixteen of the 37 studies reporting mean BWT changes in relation to PFOA in the overall population were rated high in overall study confidence {Ashley-Martin, 2017, 3981371; Bach, 2016, 3981534; Bell, 2018, 5041287; Buck Louis, 2018, 5016992; Chu, 2020, 6315711; Eick, 2020, 7102797; Govarts, 2016, 3230364; Lauritzen, 2017, 3981410; Lind, 2017, 3858512; Luo, 2021, 9959610; Manzano-Salgado, 2017, 4238465; Sagiv, 2018, 4238410; Starling, 2017, 3858473; Valvi, 2017, 3983872; Wang, 2016, 3858502; Wikström, 2020, 6311677}, while 13 were rated medium {Chang, 2022, 9959688; Chen, 2021, 7263985; de Cock, 2016, 3045435;
Gyllenhammar, 2018, 4238300; Hjermitslev, 2020, 5880849; Kashino, 2020, 6311632; Kwon, 2016, 3858531; Lenters, 2016, 5617416; Meng, 2018, 4829851; Robledo, 2015, 2851197; Wang, 2019, 5080598; Woods et al., 2017, 4183148; Yao, 2021, 9960202}, and eight were classified as low \{Callan, 2016, 3858524; Cao, 2018, 5080197; Gao, 2019, 5387135; Marks, 2019, 5081319; Shi, 2017, 3827535; Workman, 2019, 5387046; Wu, 2012, 2919186; Xu, 2019, 5381338\} as shown in Figure 3-46, Figure 3-47, and Figure 3-48.

Of the 29 high or medium confidence studies highlighted in this synthesis, two had deficient study sensitivity \{Bell, 2018, 5041287; de Cock, 2016, 3045435\}. Nine studies \{Chen, 2021, 7263985; Lauritzen, 2017, 3981410; Lenters, 2016, 5617416; Robledo, 2015, 2851197; Starling, 2017, 3858473; Wang, 2016, 3858502; Wikström, 2020, 6311677; Woods, 2017, 4183148; Yao, 2021, 9960202\} were considered to have good study sensitivity, and eighteen studies \{Ashley-Martin, 2017, 3981371; Bach, 2016, 3981534; Buck Louis, 2018, 5016992; Chang, 2022, 9959688; Chu, 2020, 6315711; Eick, 2020, 7102797; Govarts, 2016, 3230364; Gyllenhammar, 2018, 4238300; Hjermitslev, 2020, 5880849; Kashino, 2020, 6311632; Kwon, 2016, 3858531; Lind, 2017, 3858512; Luo, 2021, 9959610; Manzano-Salgado, 2017, 4238465; Meng, 2018, 4829851; Sagiv, 2018, 4238410; Valvi, 2017, 3983872; Wang, 2019, 5080598\} were considered adequate. The median exposure values across all studies ranged from 0.86 ng/mL \{Callan, 2016, 3858524\} to 42.8 ng/mL \{Yao, 2021, 9960202\}.
Figure 3-46. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Weight Effects

Interactive figure and additional study details available on HAWC.
### Figure 3-47. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Weight Effects (Continued)

Interactive figure and additional study details available on [HAWC](https://www.hawcproject.org).

<table>
<thead>
<tr>
<th>Study Reference</th>
<th>Participant selection</th>
<th>Exposure measurement</th>
<th>Outcome</th>
<th>Confounding</th>
<th>Analysis</th>
<th>Selective</th>
<th>Study sensitivity</th>
<th>Overall confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gundacker et al., 2021, 10176483</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gyllenhammar et al., 2018, 42383009</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Hjermitslev et al., 2020, 5880649</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Jin et al., 2020, 03160202</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kashino et al., 2020, 0311632</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Kishi et al., 2015, 2850268</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Kobayashi et al., 2017, 3981430</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Kobayashi et al., 2022, 10176408</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Kwon et al., 2016, 3858531</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Lauritzen et al., 2017, 39814110</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Lee et al., 2013, 3859850</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lee et al., 2016, 3981528</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Lonters et al., 2016, 5617416</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Lind et al., 2017, 3858512</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Luo et al., 2021, 9959610</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Maekawa et al., 2017, 4238291</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manzano-Salgado et al., 2017, 4238465</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Marks et al., 2019, 5081319</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
### Figure 3-48. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Weight Effects (Continued)

Interactive figure and additional study details available on HAWC.
Mean Birth Weight Study Results: Overall Population Studies

Thirty-two of the 37 included studies with mean BWT data that examined data in the overall population {Bach, 2016, 3981534; Bell, 2018, 5041287; Buck Louis, 2018, 5016992; Callan, 2016, 3858524; Cao, 2018, 5080197; Chang, 2022, 9959688; Chen, 2021, 7263985; Chu, 2020, 6315711; de Cock, 2016, 3045435; Eick, 2020, 7102797; Gao, 2019, 5387135; Gyllenhammar, 2018, 3230364; Hjermitslev, 2020, 5880849; Kashino, 2020, 6311632; Kwon, 2016, 3858531; Lauritzen, 2017, 3981410; Lenters, 2016, 5617416; Luo, 2021, 9959610; Manzano-Salgado, 2017, 4238465; Marks, 2019, 5081319; Meng, 2018, 4829851; Robledo, 2015, 2851197; Shi, 2017, 3827535; Starling, 2017, 3858473; Valvi, 2017, 3983872; Wang, 2016, 3858502; Woods, 2017, 4183148; Wu, 2012, 2919186; Xu, 2019, 5381338; Yao, 2021, 9960202}, while five reported sex-specific data only {Ashley-Martin, 2017, 3981371; Lind, 2017, 3858512; Marks, 2019, 5081319; Robledo, 2015, 2851197; Wang, 2016, 3858502}. Twenty-one of the 32 PFOA studies reported some mean BWT deficits in the overall population, albeit these were not always statistically significant (See PFOA Appendix). Five of these mean BWT studies in the overall population reported null associations {Bach, 2016, 3981534; Bell, 2018, 5041287; Buck Louis, 2018, 5016992; Valvi, 2017, 3983872; Woods et al., 2017, 4183148}, while six reported increased mean BWT deficits with increasing PFOA exposures {Chen, 2021, 7263985; de Cock, 2016, 3045435; Eick, 2020, 7102797; Gao, 2019, 5387135; Shi, 2017, 3827535; Xu, 2019, 5381338}. Seventeen of the 25 medium and high confidence studies reported some BWT deficits in relation to PFOA exposures. Among the ten studies presenting results based on categorical data, two studies {Meng, 2018, 4829851; Starling, 2017, 3858473} showed inverse monotonic exposure-response relationships (Figure 3-49, Figure 3-50, Figure 3-51, Figure 3-52).

Among the 21 studies showing some adverse associations in the overall population, there was a wide distribution of deficits ranging from −14 to −267 grams across both categorical and continuous exposure estimates with results based on a per unit (continuous measure) when studies presented both. Among those with continuous PFOA results in the overall population, 14 of 20 studies reported deficits from −27 to −82 grams with increasing PFOA exposures. There were no clear patterns were observed by confidence level, but there was a preponderance of inverse associations based on studies with later biomarker sampling timing (i.e., trimester two onward) including 15 of the overall 21 studies and 6 of the 9 high confidence studies only. The two largest associations (one medium and one low confidence study) expressed per each PFOA change were detected in studies with later pregnancy samples, while three of the four smallest associations were based on earlier biomarker samples. Thus, some of these reported results may be related to pregnancy hemodynamic influences on the PFOA biomarkers during pregnancy. For example, 11 of the 12 largest mean BWT deficits (−48 grams or larger per unit change) in the overall population were detected among studies with either later pregnancy samples (i.e., maternal samples during trimesters 2, 3, or post-partum or umbilical cord samples).
Figure 3-49. Overall Mean Birth Weight from Epidemiology Studies Following Exposure to PFOA

Interactive figure and additional study details available on Tableau.
Figure 3-50. Overall Mean Birth Weight from Epidemiology Studies Following Exposure to PFOA (Continued)

Interactive figure and additional study details available on Tableau.
Figure 3-51. Overall Mean Birth Weight from Epidemiology Studies Following Exposure to PFOA (Continued)

Interactive figure and additional study details available on Tableau.
Wikstrom (2019) has a manuscript error in the regression coefficient for Q4 vs Q1.
Interactive figure and addition al study details available on Tableau.

3.4.4.1.4.1.2 Mean BWT-Overall Population Summary

Overall, 21 of the 32 PFOA studies reported some mean BWT deficits in the overall population with limited evidence of exposure-response relationships. Seventeen of the 21 studies were medium or high confidence, but the majority of studies that showed inverse associations were based on later biomarker sampling timing (i.e., trimester two onward). While some of the changes were relatively large in magnitude (most were from –27 to –82 grams per each unit PFOA change), there was also a pattern of stronger associations detected amongst studies with later pregnancy biomarker samples. These patterns may be indicative of pregnancy hemodynamic influences on the PFOA biomarkers during pregnancy.

3.4.4.1.4.1.3 Mean Birth Weight Study Results: Sex Specific Studies

Mean BWT findings were reported for 18 and 19 studies in female and male neonates, respectively. Eleven of 18 epidemiological studies examining sex-specific results in female neonates showed some BWT deficits including 10 of 16 medium and high confidence studies. Twelve of 19 epidemiological studies examining sex-specific results in male neonates showed some BWT deficits. The remaining 7 studies {Bach, 2016, 3981534; de Cock, 2016, 3045435; Hjermitslev, 2020, 5880849; Lind, 2017, 3858512; Robledo, 2015, 2851197; Shi, 2017,
3827535; Wang, 2019, 5080598) in male neonates were either null or showed larger birth weights with increasing PFOA exposures. The low confidence study by Marks et al. (2019, 5081319) of boys only reported large deficits in the upper two PFOA tertiles (−53 and −46 grams, respectively) with no exposure-response relationship. None of the 5 studies with categorical data in either girls or boys showed evidence of monotonic exposure-response relationships.

Nine of the 18 studies examining mean BWT associations in both boys and girls detected some deficits in both sexes with one of these reporting comparable BWT deficits {Lenters, 2016, 5617416}. Five of the 9 studies showed larger deficits in girls {Ashley-Martin, 2017, 3981371; Cao, 2018, 5080197; Hjermitslev, 2020, 5880849; Wang, 2019, 5080598; Wikström, 2020, 6311677} and 3 showed larger deficits among boys {Chu, 2020, 6315711; Lauritzen, 2017, 3981410; Meng, 2018, 4829851}. One study showed comparable results irrespective of sex {Lenters, 2016, 5617416}. Three additional studies each reported mean BWT deficits either only in boys {Kashino, 2020, 6311632; Manzano-Salgado, 2017, 4238465; Valvi, 2017, 3983872} or girls {Hjermitslev, 2020, 5880849; Robledo, 2015, 2851197; Wang, 2016, 3858502}.

Overall, no consistent patterns in magnitude of deficits were observed with the sex-specific studies by sample timing and other study characteristics; however, the three largest deficits in male studies were later pregnancy sampled studies. Although other studies based on different exposure measures were more variable, some consistency in the magnitude of deficits (range: −80 to −90 g) was observed amongst 4 studies in girls {Ashley-Martin, 2017, 3981371; Wang, 2016, 3858502; Wang, 2019, 5080598; Wikström, 2020, 6311677} including three high confidence studies based on continuous (i.e., per each ln or log10 PFOA exposures increase). The magnitude of deficits in boys across 7 studies {Ashley-Martin, 2017, 3981371; Kashino, 2020, 6311632; Lenters, 2016, 5617416; Manzano-Salgado, 2017, 4238465; Meng, 2018, 4829851; Wang, 2019, 5080598; Wikström, 2020, 6311677} was fairly consistent per each continuous unit PFOA change (range: −21 to −49 g), although 3 studies {Chu, 2020, 6315711; Lauritzen, 2017, 3981410; Valvi, 2017, 3983872} reported larger deficits in excess of −71 grams.

3.4.4.1.4.1.4 Standardized Birth Weight Measures

Fifteen studies examined standardized BWT measures including 14 studies reporting a change in BWT z-scores on a continuous scale per each PFOA comparison. Eight of the 15 were high confidence studies {Ashley-Martin, 2017, 3981371; Bach, 2016, 3981534; Eick, 2020, 7102797; Gardener, 2021, 7021199; Sagiv, 2018, 4238410; Shoaff, 2018, 4619944; Wikström, 2020, 6311677; Xiao, 2019, 5918609}, 4 were medium {Chen, 2017, 3981292; Gyllenhammar, 2018, 438300; Meng, 2018, 4829851; Wang, 2019, 5080598} and 3 were low confidence {Espindola-Santos, 2021, 8442216; Gross, 2020, 7014743; Workman, 2019, 5387046}.

Nine out of 15 studies with standardized BWT scores in the overall population showed some inverse associations and 5 of these were high confidence. The high confidence study by Gardener et al. (2021, 7021199) reported that participants in PFOA quartiles 2 (OR=0.84; 95% CI: 0.40–1.80) and 3 (OR=0.91; 95% CI: 0.41–2.02) had a lower odds of being in the lowest standardized birth weight category (vs. the top 3 birth weight z-score quartiles). They also reported that there were no statistically significant interactions for their BWT-z measures by sex.
Among the 14 studies examining continuous BWT z-score measures in the overall population, 8 showed some inverse associations of at least −0.1. The ranges of deficits were −0.1 {Ashley-Martín, 2017, 3981371; Sagiv, 2018, 4238410; Wang, 2019, 5080598}, −0.2 {Chen, 2017, 3981292; Shoaff, 2018, 4619944; Wikström, 2020, 6311677}, and −0.3 {Gross, 2020, 7014743; Xiao, 2019, 5918609}. More associations were detected among the high confidence studies (6/8), compared to 2 of the 4 medium, and 1 of the 3 low confidence studies. None of the 5 studies {Bach, 2016, 3981534; Eick, 2020, 7102797; Sagiv, 2018, 4238410; Shoaff, 2018, 4619944; Wikström, 2020, 6311677} showed any evidence of exposure-response relationships. Overall, 4 out of 6 studies in boys and 3 of 6 in girls showed lower BWT z-scores with increasing PFOA exposures. For example, the low confidence study by Gross et al. (2020, 7014743) reported BWT z-score deficits for both males (−0.17; SE = 0.29; p-value = 0.57) and females (−0.38; SE = 0.26; p-value = 0.16) for PFOA levels greater than the mean level. Gardener et al. (2021, 7021199) only reported that there were no statistically significant interactions for BWT-z measures by sex in their analysis.

3.4.4.1.4.1.5 BWT z-score summary
Nine out of 15 studies with standardized BWT scores in the overall population showed some inverse associations with PFOA exposures. Six of these 9 studies were either medium or high confidence studies, and most of these had moderate or large exposure contrasts. Although some studies may have been underpowered to detect associations small in magnitude relative to PFOA exposure, there was consistent lower BWT z-scores reported across all confidence levels. There was no apparent pattern related to magnitude of deficits across study confidence, but more associations were evident across high confidence levels in general. Twice as many studies showing adverse associations were based on later (6 of 9) versus early (i.e., at least some trimester one maternal samples) pregnancy sampling (3 of 9); this might be reflective of some impact of pregnancy hemodynamics on biomarker concentrations over time. There was no evidence of exposure-response relationships in the 5 studies reporting categorical data. There were also few evident patterns and minimal differences seen across sexes. Overall, 9 out of 15 overall studies in the overall population showed some suggestion of inverse associations with the same studies showing associations in 3 out of 4 studies of male neonates and 3 of 4 studies in females.

3.4.4.1.4.2 Small for Gestational Age/Low Birth Weight
Eleven informative and non-overlapping epidemiological studies examined associations between PFOA exposure and different dichotomous fetal growth restriction endpoints, such as SGA (or related intrauterine growth retardation endpoints), low birth weight (LBW), or both (i.e., {Manzano-Salgado, 2017, 4238465}). Five studies were high confidence {Chu, 2020, 6315711; Lauritzen, 2017, 3981410; Manzano-Salgado, 2017, 4238465; Wang, 2016, 3858502; Wikström, 2020, 6311677}, three were medium confidence {Govarts, 2018, 4567442; Hjermitslev, 2020, 5880849; Meng, 2018, 4829851}, three were low confidence studies {Chang, 2022, 9959688; Souza, 2020, 6833697; Xu, 2019, 5381338} and one as uninformative {Arbuckle, 2013, 2152344}. Four of these studies had good study sensitivity {Lauritzen, 2017, 3981410; Manzano-Salgado, 2017, 4238465; Meng, 2018, 4829851; Wang et al. 2016, 3858502}, while five were considered adequate {Arbuckle, 2013, 2152344; Chang, 2022, 9959688; Chu, 2020, 6315711; Hjermitslev, 2020, 5880849; Wikström, 2020, 6311677} and three were deficient {Govarts, 2018, 4567442; Souza, 2020, 6833697; Xu, 2019, 5381338}.  

3-207
Six of eight SGA studies [Chang, 2022, 9959688; Govarts, 2018, 4567442; Lauritzen, 2017, 3981410; Souza, 2020, 6833697; Wang, 2016, 3858502; Wikström, 2020, 6311677] showed some adverse associations, while two studies were entirely null [Manzano-Salgado, 2017, 4238465; Xu, 2019, 5381338]. Although they were not always statistically significant, the
relative risks reported in the five studies examining the overall population based on either categorical or continuous exposures (per each unit increase) were fairly consistent in magnitude (odds ratio (OR) range: 1.21 to 2.81). The *medium* confidence study by Govarts et al. (2018, 4567442) reported an increased risk (OR = 1.64; 95% CI: 0.97, 2.76) per each PFOA IQR increase. The *high* confidence study by Lauritzen et al. (2017, 3981410) showed a slight increased risk in the overall population (OR = 1.21; 95% CI: 0.69, 2.11 per each ln-unit PFOA increase), but this was driven by associations only in participants from Sweden (OR = 5.25; 95% CI: 1.68, 16.4) including large risks detected for both girls and boys. One (Souza, 2020, 6833697) of the three studies examining exposure quartiles detected an exposure-response relationship in the overall population (OR range: 1.26–2.81). The *medium* confidence study by Chang et al. (2022, 9959688) reported non-monotonic but consistent statistically significant ORs across the upper three quartiles (range: 2.22–2.44) in their study of African American pregnant women. The *high* confidence study by Wikström et al. (2020, 6311677) reported comparable ORs for the 4th quartiles (OR=1.44; 95% CI: 0.86, 2.40) as well as per each per ln-unit increase (OR=1.43; 95%CI: 1.03, 1.99). Among females only, they reported a two-fold increased risk per each ln-unit increase risk (OR = 1.96; 95% CI: 1.18, 3.28) and non-monotonic increased risks in the upper two quartiles (OR range: 1.64–2.33). The *high* confidence study by Wang et al. (2016, 3858502) only reported sex-specific results but also showed an increased risk (OR = 1.48; 95% CI: 0.63, 3.48 per each ln-unit increase) for SGA among girls only.

![Figure 3-54. Odds of Small-for-gestational-age in Children from High Confidence Epidemiology Studies Following Exposure to PFOA](image-url)
Interactive figure and additional study details available on Tableau.
Small-for-gestational-age defined as birthweight below the 10th percentile for the reference population.

Figure 3-55. Odds of Small-for-gestational-age in Children from High Confidence Epidemiology Studies Following Exposure to PFOA (Continued)

Interactive figure and additional study details available on Tableau.
Small-for-gestational-age defined as birthweight below the 10th percentile for the reference population.
Odds of Small-for-gestational-age in Children from Medium Confidence Epidemiology Studies Following Exposure to PFOA

Five studies examined LBW in relation to PFOA including one uninformative \{Arbuckle et al., 2013, 2152344\} and two each that were high \{Chu, 2020, 6315711; Manzano-Salgado, 2017, 4238465\} or medium confidence \{Hjemritslev et al. 2019, 5880849; Meng, 2018, 4829851\} confidence. Two of five LBW studies \{Manzano-Salgado, 2017, 4238465; Meng, 2018, 4829851\} showed some associations within the overall population, and/or in boys or girls. The medium confidence study by Meng et al. (2018, 4829851) reported non-significant increased ORs (range: 1.2–1.5) across all quartiles but saw no evidence of an exposure-response relationship. The high confidence Manzano-Salgado \{2017, 4238465\} study showed some suggestion of an increased risk (OR = 1.67; 95% CI: 0.72, 3.86) for term LBW but was detected among boys only.
Overall, nine of the eleven informative studies reporting main effects for either SGA or LBW or both showed some increased risks with increasing PFOA exposures. The magnitude of the associations was typically from 1.2 to 2.8 with limited evidence of exposure-response relationships among the studies with categorical data. Although the number of studies was fairly small, few discernible patterns across study characteristics or confidence ratings were evident across the SGA or LBW findings. For example, four of the nine studies showing increased odds of either SGA or LBW were based on early sampling biomarkers. Collectively, the majority of SGA and LBW studies were supportive of an increased risk with increasing PFOA exposures.

### 3.4.4.1.4.3 Birth Length

As shown in Figure 3-58 and Figure 3-59, 34 birth length studies were considered as part of the study evaluation. Four studies were considered uninformative (Alkhalawi, 2016; Gundacker, 2021; Jin, 2020; Lee, 2013) and four more studies noted above (Bach, 2016; Kishi, 2015; Kobayashi, 2022) were not further considered for multiple publications from the same cohort studies. Among the twenty-six non-overlapping informative studies examined birth length in relation to PFOA, including five studies with standardized birth length measures.
{Chen, 2017, 3981292; Espindola-Santos, 2021, 8442216; Gyllenhammar, 2018, 4238300; Shoaff, 2018, 4619944; Xiao, 2019, 5918609}, and one study evaluated standardized and mean birth length changes {Workman, 2019, 5387046}. Eighteen studies examined mean birth length differences in the overall study population. Thirteen studies examined sex-specific data with three studies {Marks, 2019, 5081319; Robledo, 2015, 2851197; Wang, 2016, 3858502} reporting only sex-specific results.

Nine of the 26 studies were high confidence {Bell, 2018, 5041287; Bjerregaard-Olesen, 2019, 5083648; Buck Louis, 2018, 5016992; Lauritzen, 2017, 3981410; Manzano-Salgado, 2017, 4238465; Shoaff, 2018, 4619944; Valvi, 2017, 3983872; Wang, 2016, 3858502; Xiao, 2019, 5918609}, eight were medium {Chen, 2017, 3981292; Chen, 2021, 7263985; Gyllenhammar, 2018, 4238300; Hjermitslev, 2020, 5880849; Kashino, 2020, 6311632; Luo, 2021, 9959610; Robledo, 2015, 2851197; Wang, 2019, 5080598} and nine were low confidence {Callan, 2016, 3858524; Cao, 2018, 5080197; Espindola-Santos, 2021, 8442216; Gao, 2019, 5387135; Marks, 2019, 5081319; Shi, 2017, 3827535; Workman, 2019, 5387046; Wu, 2012, 2919186; Xu, 2019, 5381338}. Eight PFOA studies had good study sensitivity {Bjerregaard-Olesen, 2019, 5083648; Chen, 2021, 7263985; Lauritzen, 2017, 3981410; Manzano-Salgado, 2017, 4238465; Robledo, 2015, 2851197; Shoaff, 2018, 4619944; Wang, 2016, 3858502; Wu, 2012, 2919186}, 14 had adequate {Buck Louis, 2018, 5016992; Callan, 2016, 3858524; Cao, 2018, 5080197; Chen, 2017, 3981292; Gao, 2019, 5387135; Gyllenhammar, 2018, 4238300; Hjermitslev, 2020, 5880849; Kashino, 2020, 6311632; Luo, 2021, 9959610; Marks, 2019, 5081319; Shi, 2017, 3827535; Valvi, 2017, 3983872; Wang, 2019, 5080598; Xiao, 2019, 5918609} sensitivity and four {Bell, 2018, 5041287; Espindola-Santos, 2021, 8442216; Workman, 2019, 5387046; Xu, 2019, 5381338} considered deficient.
### Figure 3-58. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Length Effects

Interactive figure and additional study details available on [HAWC](https://www.hawcproject.org).

<table>
<thead>
<tr>
<th>Study Reference</th>
<th>Participant selection</th>
<th>Exposure measurement</th>
<th>Outcome</th>
<th>Confounding Analysis</th>
<th>Selective</th>
<th>Study sensitivity</th>
<th>Overall confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkhalawi et al., 2016, 3895818</td>
<td></td>
<td></td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>++</td>
</tr>
<tr>
<td>Bach et al., 2016, 3891534</td>
<td></td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Bell et al., 2018, 5041287</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>-</td>
<td>++</td>
</tr>
<tr>
<td>Bjørregaard-Olesen et al., 2019, 5083648</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Buck Louis et al., 2018, 5016992</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Callan et al., 2016, 3858524</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Cao et al., 2018, 5080197</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chen et al., 2017, 3981292</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chen et al., 2021, 7263985</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Espindola Santos et al., 2021, 8442216</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gao et al., 2019, 5387135</td>
<td>+</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Gundacker et al., 2021, 10176483</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gyllenhammar et al., 2018, 4238300</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Hjermitslev et al., 2020, 5880849</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Jin et al., 2020, 6316202</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>Kashino et al., 2020, 6311632</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Kishi et al., 2015, 2850268</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

**Legend**
- **++**: Good (metric) or High confidence (overall)
- **+**: Adequate (metric) or Medium confidence (overall)
- **-**: Deficient (metric) or Low confidence (overall)
- **-**: Critically deficient (metric) or Uninformative (overall)
- **#**: Multiple judgments exist
Figure 3-59. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Length Effects (Continued)

Interactive figure and additional study details available on HAWC.
Amongst the 26 birth length studies (examining mean differences or changes in standardized scores), nine of them reported some inverse associations including three of the six studies that reported standardized birth length data. There was limited evidence of exposure-response relationships in the three studies that examined categorical data. The high confidence study by Xiao et al. (2019, 5918609) reported a reduced birth length z-score (−0.14; 95%CI: −0.40, 0.13) in the overall population per each log2 increase in PFOA that appeared to be driven by male neonates (−0.27; 95% CI: −0.65, 0.10). The low confidence Workman et al. (2019, 5387046) study reported a non-significant deficit similar in magnitude (−0.26; 95% CI: −1.13, 0.61). The other high confidence study by Shoaff et al. (2018, 4619944) of standardized birth length measures showed a deficit only for tertile 3 (−0.32; 95% CI: −0.72, 0.07) compared to tertile 1. In contrast, the low confidence study by Espindola-Santos et al. (2021, 8442216) reported a larger birth length z-score per each log10 PFOA increase (0.26; 95%CI: -0.21, 0.73).

Amongst the 21 studies examining mean birth length differences, eight different studies showed adverse associations. This included six different studies (out of 18) based on the overall population as well two out of three studies {Robledo, 2015, 2851197; Wang, 2016, 3858502} reporting only sex-specific results. The high confidence study by Wang et al. (2016, 3858502) only showed deficits among females for only PFOA quartiles 1 (−0.39 cm; 95% CI: −1.80, 1.02) and 3 (−0.60 cm; 95% CI: −1.98, 0.77). The medium confidence study by Chen et al. (2021, 7263985) reported similar birth length deficits in the overall population (−0.27 cm; 95%CI: −0.61, 0.07), males (−0.21; 95%CI: -0.73, 0.32) and females (−0.21; 95%CI: -0.74, 0.33) per each ln-unit PFOA increase. In the medium confidence study by Robledo et al. (2015, 2851197), smaller deficits in birth length were detected for both male and female neonates per each 1 standard deviation (SD) PFOA increase. The high confidence study by Lauritzen et al. (2017, 3981410) showed a deficit in the overall population (−0.49 cm; 95% CI: −0.99, 0.02), but detected the strongest association when restricted to the Swedish population (−1.2 cm; 95% CI: −2.1, −0.3) and especially Swedish boys (−1.6 cm; 95%CI: −2.9, −0.4). Overall, four sex-specific studies showed deficits for both boys and girls with two studies showing larger deficits among boys. One study showed larger deficits amongst girls and the fourth study showed results equal in magnitude.

In the overall population studies showing adverse associations, the reported magnitude of deficits was quite variable (range: −0.16 to −1.91 cm). For example, the low confidence study by Wu et al. (2012, 2919186) showed the largest deficit (−1.91 cm; 95% CI: −3.31, −0.52 per each log10 increase). The low confidence study by Cao et al. (2018, 5080197) showed consistent results across their overall population (−0.45 cm; 95%CI: −0.79, −0.10 per each ln-unit PFOA increase), male (−0.36 cm; 95% CI: −0.80, 0.09), and female neonates (−0.58 cm; 95% CI: −1.12, −0.04) with evidence of exposure-response relationships in all three of these groups. Overall, 6 of 12 studies in girls and 4 of 13 studies in boys showed some birth length deficits. One of the three studies in either or both boys and girls showed some additional evidence of exposure-response relationships. The same study by Cao et al., (2018, 5080197) was the only study in the overall population to show evidence of exposure-response.

Overall, nine different studies out of 26 studies examining birth length deficits in relation to PFOA exposures. There was no apparent relationship between studies showing inverse associations and study confidence ratings. However, six of these studies sampled PFOA biomarkers characterized as later in pregnancy and may be more prone to potential bias from
pregnancy hemodynamic changes. Among the mean birth length studies, most showed consistent deficits ranging from –0.21 to –0.49 cm per different PFOA comparisons. An unusually large result (-1.91 cm per each log10 PFOA increase) was reported in an earlier study {Wu, 2012, 2919186} that reported the largest exposure range. There was a preponderance of inverse associations amongst females (6 of 12 studies) compared to males (4 of 13); however, amongst the four studies that reported associations in both sexes, more studies reported larger deficits in male neonates.

3.4.4.1.4.4 Head Circumference at Birth

As shown in Figure 3-60, 21 informative studies examined head circumference at birth in relation to PFOA exposures. Six of the 21 studies were low confidence {Callan, 2016, 3858524; Cao, 2018, 5080197; Espindola-Santos, 2021, 8442216; Marks, 2019, 5081319; Workman, 2019, 5387046; Xu, 2019, 5381338}, while studies seven were medium {Chen, 2021, 7263985; Gyllenhammar, 2018, 4238300; Hjermitslev, 2020, 5880849; Kashino, 2020, 6311632; Lind, 2017, 3858512; Robledo, 2015, 2851197; Wang, 2019, 5080598} and eight were high confidence {Bell, 2018, 5041287; Bjerregaard-Olesen, 2019, 5083648; Buck Louis, 2018, 5016992; Lauritzen, 2017, 3981410; Manzano-Salgado, 2017, 4238465; Valvi, 2017, 3983872; Wang, 2016, 3858502; Xiao, 2019, 5918609}. Four studies were deficient in study sensitivity {Bell, 2018, 5041287; Espindola-Santos, 2021, 8442216; Workman, 2019, 5387046; Xu, 2019, 5381338}, while five were good {Chen, 2021, 7263985; Lauritzen, 2017, 3981410; Manzano-Salgado, 2017, 4238465; Robledo, 2015, 2851197; Wang, 2016, 3858502} and twelve had adequate study sensitivity {Bjerregaard-Olesen, 2019, 5083648; Buck Louis, 2018, 5016992; Callan, 2016, 3858524; Cao, 2018, 5080197; Gyllenhammar, 2018, 4238300; Hjermitslev, 2020, 5880849; Kashino, 2020, 6311632; Lind, 2017, 3858512; Marks, 2019, 5081319; Valvi, 2017, 3983872; Wang, 2019, 5080598; Xiao, 2019, 5918609}. 
Eighteen of the 21 included studies reported PFOA in relation to mean head circumference differences including 17 studies that provided results based on the overall population. Including the Xiao et al. (2019, 5918609) z-score data, thirteen of these 21 studies reported sex-specific
head circumference data with four other studies {Lind, 2017, 3858512; Marks, 2019, 5081319; Robledo, 2015, 2851197; Wang, 2016, 3858502} providing sex-specific data only.

Among the 21 studies, ten reported some inverse associations between PFOA exposures and different head circumference measures in the overall population, in either or both male and female neonates, across different racial strata, or different countries in the same study population. For example, the high confidence study by Lauritzen et al. (2017, 3981410) reported a similar deficit only in their Swedish population (−0.4 cm; 95% CI: −1.0, 0.1) per each ln-unit PFOA change; this was largely due to an association seen in male neonates (−0.6 cm; 95% CI: −1.3, 0.1). The high confidence study by Buck Louis et al. (2018, 5016992), reported non-significant head circumference differences (−0.14 cm; 95% CI: −0.29, 0.02) among black neonates but no main effect association in the overall population. Six out of seventeen studies based on the overall population reported some adverse associations between PFOA exposures and either mean head circumference measures or standardized z-scores. The high confidence study by Xiao et al. (2019, 5918609) reported a reduced head circumference z-score (−0.17; 95% CI: −0.48, 0.15) in the overall population per each log2 increase in PFOA that appeared to be driven by female neonates (−0.30; 95% CI: −0.74, 0.13) (data not shown on figures). Although it was not statistically significant, the low confidence study by Espindola-Santos et al. (2021, 8442216) reported a larger head circumference z-score (0.62; 95% CI: −0.06, 1.29 per each log10 PFOA). The medium confidence study by Gyllenhammar et al. (2018, 4238300) was null based on their standardized head circumference measure.

Among the fifteen studies that examined mean head circumference at birth in the overall population, four of them reported adverse associations. Eight studies were largely null, and two studies showed larger mean head circumference in the overall population with increasing PFOA exposures. Of the eleven different studies examining sex-specific results associations including five of ten in female neonates {Bjerregaard-Olesen, 2019, 5083648; Cao, 2018, 5080197; Hjermitslev, 2020, 5880849; Robledo, 2015, 2851197; Wang, 2019, 5080598) and three {Lauritzen, 2017, 3981410; Manzano-Salgado, 2017, 4238465; Wang, 2019, 5080598} of eleven studies in male neonates. The medium confidence study by Wang et al. (2019, 5080598) reported an association in the overall population (−0.37 cm; 95% CI: −7.00, -0.40) with larger deficits noted in female (−0.57 cm; 95% CI: −1.07, −0.08) than in male neonates (−0.35 cm; 95% CI: −0.79, −0.10). The medium confidence study by Hjermitslev et al. (2019, 5880849) showed a non-significant reduction in head circumference for the overall population (−0.14 cm; 95% CI: −0.42, 0.14 per each ng/ml PFOA increase) which seemed to be driven by results in females (−0.25 cm; 95% CI: −0.65, 0.14). The high confidence study by Manzano-Salgado et al. (2017, 4238465) reported a non-significant decrease only in quartile 4 (−0.16 cm; 95% CI: −0.38, 0.06) compared to quartile 1 and a deficit among male neonates only (−0.13 cm; 95% CI: −0.27, 0.0) per each log2 PFOA increase. In the medium confidence study by Robledo et al. (2015, 2851197), opposite results were seen for male (0.18 cm; 95% CI: −0.25, 0.60) and female neonates (−0.18 cm; 95% CI: −0.59, 0.23) per each 1 SD PFOA increase. In their low confidence study, Cao et al. (2018, 5080197) reported an overall null association, while divergent and large changes were seen for male (0.72 cm; 95% CI: −0.51, 1.94) and female neonates (−1.46 cm; 95% CI: −2.96, 0.05) per each ln-unit PFOA increase. The low confidence study by Callan et al.
(2016, 3858524) reported a −0.40 cm (95% CI: −0.96, 0.16) difference per each ln-unit PFOA change.

Among the 21 epidemiological studies examining PFOA and head circumference, nine different studies reported some evidence of adverse associations in the overall population or across sexes. This included four of fifteen studies in the overall population and five of twelve sex-specific studies in either or both sexes. Few patterns across sex were reported as deficits were found in four or fewer studies in both male and female neonates. Apart from the Wang et al. (2019, 5080598) study, no other sex-specific studies reported reduced head circumference in both sexes. Few patterns by study characteristics or overall confidence levels although nearly all of the high and low confidence studies were null. Among the nine different studies reporting associations across various populations examined there was no definitive pattern of results by biomarker sample timing as five studies relied on early sampling periods.

3.4.4.1.4.5 Fetal Growth Restriction Summary

The majority of studies examining fetal growth restriction showed some evidence of associations with PFOA exposures especially those that included BWT data (i.e., SGA, low BWT, as well as mean and standardized BWT measures). The evidence for two fetal growth measures such as head circumference and birth length were less consistent but still reported many associations. For example, 10 (out of 21) different epidemiological studies of PFOA examining head circumference reported some evidence of adverse associations in either the overall population or across the sexes. Nine different studies out of 26 studies reported some birth length deficits in relation to PFOA exposures with limited evidence of exposure-response relationships. Across the fetal growth measures, there was not consistent evidence of sexual dimorphic differences across the fetal growth measures; however, as noted above, many of the individual study results lacked precision and power to detect sex-specific differences. There was minimal evidence of exposure-response relationships reported amongst those examining categorical exposure data, but the categorical data generally supported the linearly expressed associations that were detected.

Among the most accurate fetal growth restriction endpoints examined here, there was generally consistent evidence for BWT deficits across different measures and types of PFOA exposure metrics considered. For example, nearly two-thirds of studies showed BWT deficits based on differences in means or standardized BWT measures. There was limited evidence of exposure-response relationships in either analyses specific to the overall population or different sexes, although the categorical data generally supported the linearly expressed associations that were detected. Associations were also seen for the majority of studies examining small for gestational age and low birth weight measures. The magnitude of some fetal growth measures were at times considered large especially when considering the per unit PFOA increases across the exposure distributions. The range of deficits detected in the overall population across all categorical and continuous exposure estimates ranged from -14 to -267 grams. Among those with continuous PFOA results in the overall population. For example, 14 of the 21 studies reported deficits from -27 to -82 grams in the overall population based on each unit increase in PFOA exposures.

The current database (since the 2016 HESD) is fairly robust given the wealth of studies included here with most of them considered high or medium confidence (e.g., 17 out of 25 mean BWT studies with data in the overall population) and most of them had adequate or good study sensitivity, so the database is fairly robust. As noted earlier, one source of uncertainty is that previous meta-analyses of PFOS by Dzierlenga et al. (2020, 7643488) and PFOA by Steenland et
al. (2018, 5079861) have shown that some measures like mean BWT may be prone to bias from pregnancy hemodynamics especially in studies with sampling later in pregnancy. For many of these endpoints, such as birth weight measures, there was a preponderance of associations amongst studies with later biomarker samples (i.e., either exclusive trimester 2/3 maternal sample or later, such as umbilical cord or post-partum maternal samples). This would seem to comport with the PFOA meta-analysis by Steenland et al. (2018, 5079861) that suggested that results for mean BWT may be impacted by some bias due to pregnancy hemodynamics. Therefore, despite some consistency in evidence across these fetal growth endpoints, some important uncertainties remain mainly around the degree that some of the results examined here may be influenced by sample timing. This source of uncertainty and potential explanation of different results across studies may indicate some bias due to the impact of pregnancy hemodynamics.

3.4.4.1.5 Postnatal Growth

Thirteen studies examined PFOA exposure in relation to postnatal growth measures. The synthesis here is focused on postnatal growth measures including body mass index (BMI)/adiposity measures {Chen, 2017, 3981292; de Cock, 2014, 2713590; Gross, 2020, 7014743; Jensen, 2020, 6833719; Shoaff, 2018, 4619944; Starling, 2019, 5412449; Yeung, 2019, 5080619} and rapid growth during infancy {Manzano-Salgado, 2017, 4238509; Shoaff, 2018, 4619944; Starling, 2019, 5412449; Tanner, 2020, 6322293; Yeung, 2019, 5080619}, as well as mean and standardized weight (all 13 studies except Gross et al. (2020, 7014743), Tanner et al. (2020, 6322293), and Jensen et al. (2020, 6833719) depicted in Figure 3-61), and height {Cao, 2018, 5080197; Chen, 2017, 3981292; de Cock, 2014, 2713590; Gyllenhammar, 2018, 4238300; Lee, 2018, 4238394; Shoaff, 2018, 4619944; Wang, 2016, 3858502; Yeung, 2019, 5080619} measures.

Six postnatal growth studies were high confidence {Jensen, 2020, 6833719; Shoaff, 2018, 4619944; Starling, 2019, 5412449; Tanner, 2020, 6322293; Wang, 2016, 3858502; Yeung, 2019, 5080619}, four were medium confidence {Chen, 2017, 3981292; de Cock, 2014, 2713590; Gyllenhammar, 2018, 4238300; Manzano-Salgado, 2017, 4238509} and three were low confidence {Cao, 2018, 5080197; Gross, 2020, 7014743; Lee, 2018, 4238394}. Five postnatal growth studies had good study sensitivity {Lee, 2018, 4238394; Manzano-Salgado, 2017, 4238509; Shoaff, 2018, 4619944; Tanner, 2020, 6322293; Wang, 2016, 3858502}, six were adequate {Cao, 2018, 5080197; Chen, 2017, 3981292; Gyllenhammar, 2018, 4238300; Jensen, 2020, 6833719; Starling, 2019, 5412449; Yeung, 2019, 5080619} and two were considered deficient {de Cock, 2014, 2713590; Gross, 2020, 7014743}. The synthesis here is focused on postnatal body mass index (BMI)/adiposity measures, head circumference and mean and standardized weight and height measures. Rapid growth during infancy is also included as it was examined in five studies {Manzano-Salgado, 2017, 4238509; Shoaff, 2018, 4619944; Starling et al. 2019, 5412449; Tanner et al. 2020; Yeung, 2019, 5080619}. The medium confidence study by deCock et al. (2014, 2713590) did not report effect estimates for postnatal infant height (p-value=0.045), weight (p-value=0.35), and BMI (p-value=0.81) up to 11 months of age. But their lack of reporting of effect estimates precluded consideration of magnitude and direction of any associations and are not further considered below in the summaries.

The medium confidence study by Manzano-Salgado et al. (2017, 4238509) had null associations for their overall population and female neonates measured at 6 months but reported an increased
weight gain z-score for males (0.13; 95% CI: 0.01, 0.26) per each log2 PFOA increases. The medium confidence study by Chen et al. (2017, 3981292) did not report associations between each per ln unit PFOA exposure increase and height z-score measures up to 24 months of age. The sex-specific data were not always consistent across time. For example, non-significant increases small in magnitude for boys (0.11; 95% CI: −0.04, 0.27) and decreases in greater height per each ln unit PFOA increase in the 12- to 24-month window. The low confidence study by Lee et al. (2018, 4238394) reported statistically significant associations detected for mean height differences at age 2 years (−0.91 cm; 95% CI: −1.36, −0.47 for each PFOA ln unit increase), as well as height change from birth to 2 years (−0.86 cm; 95% CI: −1.52, −0.20). Large differences were seen for mean weight differences at age 2 years (−210 g; 95% CI: −430, 0.20) but not for weight change from birth to 2 years. An exposure-response relationships was detected when examined across PFOA categories with the highest exposure associated with smaller statistically significant height increases at age 2 compared to lower exposures.

In the medium confidence study by Gyllenhammar et al. (2018, 4238300), no associations were detected for infant height deficits among participants followed from 3 months to 60 months of age per each IQR PFOA change. They also did not report statistically significant standardized BWT deficits per each IQR PFOA change, but they did show slight weight deficits (approximately −0.2) at 3 months that gradually decreased over time (to approximately −0.1) at 60 months of age. Compared to the PFOA tertile 1 referent, the low confidence study by Cao et al. (2018, 5080197) reported slight increases (1.37 cm; 95% CI: −0.5, 3.28) in postnatal length (i.e., height) amongst infants (median age of 19.7 months), while large postnatal weight deficits were reported for tertile 2 (−429.2 g; 95% CI: −858.4, −0.12) and tertile 3 (−114.9 g; 95% CI: −562.0, 332.1). These height increases were predominately due to female infants, while the weight deficits were driven by males. Few differences were observed in the overall population for postnatal head circumference with slight non-significant deficits seen amongst females only.

In their high confidence study, Wang et al. (2016, 3858502) reported statistically significant childhood weight (−0.14; 95% CI: −0.39, 0.11) and height (−0.15; 95% CI: −0.38, 0.08) z-scores for female neonates when averaged over the first 11 years and per 1-ln-unit PFOA increase. Results were null for male neonates for childhood average weight (0.03; 95% CI: −0.11, 0.18) and height (0.01; 95% CI: −0.24, 0.25) z-scores. However, when they examined the first 2 years only, statistically significant deficits in both height and weight z-scores were only seen for male neonates. These weight deficits dissipated in males later during childhood, while the height deficits detected at age 2 years continued through age 11. In contrast, the height deficits in female children that were detected at birth were no longer evident in older kids until later ages (i.e., 11 years). The weight deficits in female children detected at birth did not persist.

In their high confidence study, Yeung et al. (2019, 5080619) reported statistically significant negative growth trajectories for weight for length z-scores in relation to each log SD increase in PFOA exposures among singletons followed for three years. In contrast, the authors showed positive infant length (i.e., height) growth trajectory across two different measures. Some sex-specific results were detected with larger associations seen in singleton females for weight for length z-score (−0.13; 95% CI: −0.19, −0.06). An infant weight deficit of −12.6 g (95% CI: −49.5, 24.3 per each 1 log SD PFOA increase) was also observed and appeared to be driven by results in females (−30.2 g; 95% CI: −84.1, 23.6). In their high confidence study of repeated measures at 4 weeks, 1 year and 2 years of age, Shoaff et al. (2018, 4619944) detected
statistically significant deficits for weight-for-age (−0.46; 95% CI: −0.78, −0.14) z-score, and weight-for-length z-score (−0.34; 95% CI: −0.59, −0.08) in PFOA tertile 3 compared to tertile 1 with exposure-response relationships detected for infant weight-for-length z-score. Deficits comparable in magnitude that were not statistically significant were observed in tertile 3 for height measured as length for age z-score (−0.32; 95% CI: −0.72, 0.07). No associations were found in the overall population from the high confidence study by Starling et al. (2019, 5412449) for postnatal measures at 5 months of age, but an exposure-response relationship of increased adiposity was seen among male neonates with increasing PFOA tertiles (2.81; 95% CI: 0.79, 4.84 for tertile 3). Similarly, no associations were found in the overall population for weight-for-age or weight-for-length z-scores and PFOA exposures, but both measures were increased among male neonates.

Overall, seven of nine studies with quantitative estimates (including six high and medium confidence studies) showed some associations between PFOA exposures and different measures of infant weight. Two of four studies with categorical data showed some evidence of inverse monotonic exposure-response relationships. Three (two high and one low confidence) of seven studies with quantitative estimates examining different infant height measures showed some evidence of adverse associations with PFOA. Study quality ratings, including study sensitivity and overall confidence, did not appear to be explanatory factors for heterogeneous results across studies.
Figure 3-61. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Postnatal Growth

Interactive figure and additional study details available on [HAWC](#).
3.4.4.1.5.1 Adiposity/BMI

The medium confidence study by Chen et al. (2017, 3981292) reported lower BMI z-scores (−0.16; 95% CI: −0.37, 0.05) per each ln unit PFOA increase in the birth to 6–months window. In their high confidence study of repeated measures at 4 weeks, 1 year, and 2 years of age, Shoaff et al. (2018, 4619944) detected statistically significant deficits for infant BMI z-score (−0.36; 95% CI: −0.60, −0.12) in PFOA tertile 3 compared to tertile 1 with exposure-response relationships detected for infant BMI z-score. The high confidence study by Yeung et al. (2019, 5080619) reported statistically significant negative growth trajectories for BMI, BMI z-score in relation to each log SD increase in PFOA exposures among singletons followed for three years. Some sex-specific results were detected with larger associations seen in singleton females for BMI (−0.18 kg/m²; 95% CI: −0.27, −0.09) and BMI z-scores (−0.13; 95% CI: −0.19, −0.07). An exposure-response relationship was evident with decreasing BMI z-scores across PFOA quartiles in the overall population and for female neonates. An exposure-response relationship of increased adiposity was seen among male neonates with increasing PFOA tertiles (2.81; 95% CI: 0.79, 4.84 for tertile 3) in the high confidence study by Starling et al. (2019, 5412449). The high confidence study by Jensen et al. (2020, 6833719) reported null associations between adiposity and per each 1-unit increase in PFOA measured at 3 and 18 months. The low confidence study by Gross et al. (2020, 7014743) reported a null association (OR = 0.91; 95% CI: 0.36 to 2.29) of being overweight at 18 months for PFOA levels greater than the mean level. They showed discordant sex-specific results with higher odds of being overweight at 18 months in males (OR = 2.62; p-value = 0.22) and lower odds among females (OR = 0.41; p-value = 0.27).

Overall, there was very limited evidence of adverse associations between PFOA exposures and either increased BMI or adiposity measures. Only one out of seven studies in the overall population showed evidence of increased adiposity or BMI changes in infancy in relation to PFOA. One of these studies did report increased odds of being overweight at 18 months for higher PFOA levels in males only. Only one of two studies showed an inverse monotonic relationship between either BMI or adiposity with increasing PFOA exposures.

3.4.4.1.5.2 Rapid Weight Gain

Five studies {Manzano-Salgado, 2017, 4238509; Shoaff, 2018, 4619944; Starling, 2019, 5412449; Tanner, 2020; Yeung, 2019, 5080619} examined rapid infant growth, with all five considered high confidence. Limited evidence of associations was reported with these studies, as only one {Starling et al., 2019, 5412449} of four studies {Manzano-Salgado, 2017, 4238509; Shoaff, 2018, 4619944; Starling, 2019, 5412449; Yeung, 2019, 5080619} showed increased odds of rapid weight gain with increasing PFOA. For example, Starling et al. (2019, 5412449) reported small increased ORs (range: 1.25 to 1.43) for rapid growth in the overall population based on either weight for age z-or weight for length-based z-scores. The most detailed evaluation by Tanner et al. (2020, 6322293) also showed some adverse associations including higher prenatal PFOA concentrations related to a longer duration of time needed to complete 90% of the infant growth spurt (Δtertile 1: 0.06; 95% CI: 0.01, 0.11). Higher prenatal PFOA concentrations were also significantly related to delayed infant peak growth velocity (δ1: 0.58; 95% CI: 0.17, 0.99) and a higher post-spurt weight plateau (α1: 0.81; 95% CI: 0.21, 1.41).

3.4.4.1.5.3 Postnatal Growth Summary

Seven of the nine studies reporting quantitative results for different infant weight measures showed some evidence of adverse associations with PFOA exposures, with two of these studies
showing adverse results predominately in females and one in males only. Two other studies showed increased weight among males only and lack of reporting of effect estimates in one study precluded further consideration of adversity. Two (Manzano-Salgado, 2017, 4238509; Starling, 2019, 5412449) of three studies did not report adverse associations in either the overall population and females, but did detect increased infant weight measures among males. Three of the seven studies reporting quantitative results showed some evidence of adverse associations between PFOA exposures and infant height. Only one out of seven studies in the overall population showed evidence of increased adiposity or BMI changes in infancy in relation to PFOA. One study showed increased adiposity amongst males only, while four studies each were null or reported some inverse associations (i.e., lower adiposity/BMI with increasing PFOA). Two of the studies showed exposure-response relationships for PFOA and decreased BMI scores, while a third showed the opposite exposure-response for increased adiposity. Although the data across different endpoints was not entirely consistent, the majority of infant weight studies indicated that PFOA may be associated with post-natal growth measures up to two years of age.

3.4.4.1.6 Gestational Duration
Twenty-two different studies examined gestational duration measures (i.e., PTB or gestational age measures) in relation to PFOA exposures. Nine of these studies examined both PTB and gestational age measures, while two studies only examined PTB (Liu, 2020, 6833609; Gardener, 2021, 7021199). Two of these studies were uninformative and not considered further below (Gundacker, 2021, 10176483; Lee, 2013, 3859850).

3.4.4.1.6.1 Gestational Age
Eighteen different informative studies examined the relationship between PFOA and gestational age (in weeks). Seventeen of these examined associations in the overall population and one study reported sex-specific findings only (Lind, 2017, 3858512). Ten of these 18 studies were high confidence (Bach, 2016, 3981534; Bell, 2018, 5041287; Buck Louis, 2018, 5016992; Chu, 2020, 6315711; Eick, 2020, 7102797; Huo, 2020, 6505752; Lauritzen, 2017, 3981410; Lind, 2017, 3858512; Manzano-Salgado, 2017, 4238465; Sagiv, 2018, 4238410), four were medium (Gyllenhammar, 2018, 4238300; Hjermitlsve, 2020, 5880849; Meng, 2018, 4829851; Yang, 2022, 10176806) and four were low confidence (Gao, 2019, 5387135; Workman, 2019, 5387046; Wu, 2012, 2919186; Xu, 2019, 5381338). Six of the studies had good study sensitivity (Huo, 2020, 6505752; Lauritzen, 2017, 3981410; Manzano-Salgado, 2017, 4238465; Meng, 2018, 4829851; Sagiv, 2018, 4238410; Wu, 2012, 2919186), nine were adequate (Bach, 2016, 3981534; Buck Louis, 2018, 5016992; Chu, 2020, 6315711; Eick, 2020, 7102797; Gao, 2019, 5387135; Gyllenhammar, 2018, 4238300; Hjermitlsve, 2020, 5880849; Lind, 2017, 3858512; Yang, 2022, 10176806) and three (Bell, 2018, 5041287; Workman, 2019, 5387046; Xu, 2019, 5381338) were deficient.

Five (3 low confidence and 1 each medium and high confidence) of the 18 studies showed some evidence of increased gestational age (Bach, 2016, 3981534; Gao, 2019, 5387135; Hjermitlsve, 2020, 5880849; Workman, 2019, 5387046; Xu, 2019, 5381338) in relation to PFOA while six others were largely null (Bell, 2018, 5041287; Buck Louis, 2018, 5016992; Gyllenhammar, 2018, 4238300; Huo, 2020, 6505752; Manzano-Salgado, 2017, 4238465; Sagiv, 2018, 4238410). The remaining seven studies showed some evidence of adverse impacts on gestational age either in the overall population or either. The high confidence study by Lind et al. (2017,
DRAFT FOR PUBLIC COMMENT
March 2023

3858512) examined only sex-specific data and reported larger deficits in female (−0.21 cm; 95% CI: −0.61, 0.19 per each ln unit PFOA increase) than male neonates (−0.10 cm; 95% CI: −0.41, 0.21). Among the other six studies with results based on the overall population, three were high confidence, two were medium, and one was low confidence. The low confidence study by Wu et al. (2012, 2919186) study reported an extremely large difference (−2.3 weeks; 95% CI: −4.0, −0.6) in gestational age per each log10 unit PFOA change. The medium confidence study by Yang et al. (2022, 10176806) reported a larger (−1.04 weeks; 95% CI: −3.72, 1.63 per each PFOA IQR increase) difference in gestational age among preterm births than among term births (−0.38 weeks; 95% CI: −1.33, 0.57 per each PFOA IQR increase). The medium confidence study by Meng et al. (2018, 4829851) reported statistically significant gestational age deficits (range: −0.17 to −0.24 weeks) across all quartiles but no evidence of an exposure-response relationship. The high confidence study by Lauritzen et al. (2017, 3981410) reported a slight decrease in the overall population (−0.2 weeks; 95% CI: −0.34, 0.14). They also showed larger deficits in their Swedish population (−0.3 weeks; 95% CI: −0.9, 0.3) which was predominately driven by results among male neonates (−0.4 weeks; 95% CI: −1.2, 0.5). The high confidence study by Chu et al. (2020, 6315711) showed larger deficits in the overall population (−0.21 weeks; 95% CI: −0.44, 0.02) which was driven by female neonates (−0.83 weeks; 95% CI: −0.53, −0.23). The high confidence study by Eick et al. (2020, 7102797) reported decreased gestational age only among tertile 2 only in the overall population (−0.29 weeks; 95% CI: −0.74, 0.17), males (−0.24 weeks; 95% CI: −0.91, 0.43) and females (−0.31 weeks; 95% CI: −0.95, 0.34) relative to tertile 1.

Overall, seven of the 18 studies showed some evidence of adverse impacts on gestational age. Six of the seven studies were either medium or high confidence studies. Few patterns emerged based on study confidence or other study characteristics. For example, three of the null studies were rated as having good sensitivity, along with two studies with adequate and one with deficient ratings. There was a preponderance of associations related to sample timing possibly related to pregnancy hemodynamic influences on the PFOA biomarkers, as five of the seven studies reporting adverse associations were sampled later in pregnancy (i.e., exclusively trimester two or later).

3.4.4.1.6.2 Preterm Birth
As shown in Figure 3-62, eleven studies examined the relationship between PFOA and PTB; all of the studies were either medium {Hjermitslev, 2020, 5880849; Liu, 2020, 6833609; Meng, 2018, 4829851; Yang 2022, 10176806} or high confidence {Bach, 2016, 3981534; Chu, 2020, 6315711; Eick, 2020, 7102797; Gardener, 2021, 7021199; Huo, 2020, 6835452; Manzano-Salgado, 2017, 4238465; Sagiv, 2018, 4238410}. Nine of the eleven studies were prospective birth cohort studies, and the two studies by Liu et al. (2020, 6833609) and Yang et al. (2022, 10176806) were case-control studies nested with prospective birth cohorts. Four studies had maternal exposure measures that were sampled either during trimester one {Bach, 2016, 3981534; Manzano-Salgado, 2017, 4238465; Sagiv, 2018, 4238410} or trimester three {Gardener, 2021, 7021199}. The high confidence study by Chu et al. (2020, 6315711) sampled during the late third trimester or within three days of delivery. Four studies collected samples across multiple trimesters {Eick, 2020, 7102797; Hjermitslev, 2020, 5880849; Huo, 2020, 6835452; Liu, 2020, 6833609}. The medium confidence study by Meng et al. (2018, 4829851) pooled exposure data from two study populations, one which measured PFOA in umbilical cord blood and one which measured PFOA in maternal blood samples collected in trimesters 1 and 2. The medium confidence study by Yang et al. (2022, 10176806) collected umbilical cord blood
samples. Four studies {Huo, 2020, 6835452; Manzano-Salgado, 2017, 4238465; Meng, 2018, 4829851; Sagiv, 2018, 4238410} were considered to have good sensitivity and one was deficient {Liu, 2020, 6833609}. The other six studies were rated adequate in this domain. The median exposure values across all studies ranged from 0.76 ng/mL {Eick, 2020, 7102797} to 11.85 ng/mL {Huo, 2020, 6835452}.

![Figure 3-62. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Preterm Birth Effects](image)

Interactive figure and additional study details available on HAWC.
Adverse associations were reported with five of the eleven studies showing increased risk of PTB with PFOA exposures. Null or inverse associations were reported by Bach et al. (2016, 3981534), Hjermtislev et al. (2019, 5880849), Liu et al. (2020, 6833609), Manzano-Salgado et al. (2017, 4238465) and Yang et al. (2022, 10176806). The medium confidence study by Meng et al. (2018, 4829851) reported consistently elevated non-monotonic ORs for PTB in the upper three PFOA quartiles (OR range: 1.7–3.2), but little evidence was seen when examined per each doubling of PFOA exposures (OR = 1.1; 95% CI: 0.8, 1.5). Although they were not statistically significant, the high confidence study by Chu et al. (2020, 6315711) reported increased ORs of similar magnitude per each ln ng/mL increase (OR = 1.49; 95% CI: 0.94, 2.36) and when quartile 3 (OR = 1.60; 95% CI: 0.60, 4.23) and quartile 4 (OR = 1.84; 95% CI: 0.72, 4.71) exposures were compared to the referent. ORs similar in magnitude were detected in the high confidence study by Eick et al. (2020, 7102797) study albeit in a more monotonic fashion across all quartiles (tertile 2: OR = 1.48; 95% CI: 0.66, 3.31); 95%CI: tertile 3: OR = 1.63; 95% CI: 0.74, 3.59). Associations between PFOA and overall PTB near or just below the null value were consistently detected for either categorical or continuous exposures in the high confidence Huo et al. (2020, 6835452) study. Few patterns emerged across PTB subtypes in that study, although there was an increase in clinically indicated PTBs (OR = 1.71; 95% CI: 0.80, 3.67 per each In-unit PFOA increase) which seemed to be largely driven by results in female neonates (OR = 2.64; 95%CI: 0.83, 8.39). The high confidence study by Sagiv et al. (2018, 4238410) showed increased non-significant risks (OR range: 1.1–1.2) for PTB across all PFOA quartiles. Relative to the referent, the high confidence study by Gardener {2021, 7021199} showed higher odds of PTB in PFOA quartiles 2 and 3 (range: 3.1–3.2) than that found in quartile 4 (OR=1.38; 95% CI: 0.32–5.97). Outside of the aforementioned Eick et al. (2020, 7102797) study, none of the other seven studies with categorical data showed evidence of exposure-response relationships.

Limited adverse associations were reported with only three of the eight studies consistently showing increased risk of PTB with PFOA exposures. The Meng et al. (2018, 4829851) study reported consistently elevated non-monotonic ORs for PTB in the upper three PFOA quartiles (OR range: 1.7–3.2), but little evidence was seen when they were examined per each doubling of PFOA exposure (OR = 1.1; 95% CI: 0.8, 1.5). Although they were not statistically significant, Chu et al. (2020, 6315711) reported increased ORs of similar magnitude per 1 ln ng/mL unit increase (OR = 1.49; 95% CI: 0.94, 2.36) or when quartile 3 (OR = 1.60; 95% CI: 0.60, 4.23) and quartile 4 (OR = 1.84; 95% CI: 0.72, 4.71) exposures were compared to the referent. Associations between PFOA and (overall) PTB near or just below the null value were consistently detected in the Huo et al. (2020, 6835452) study. Few patterns emerged across PTB subtypes, although there was an increase in clinically indicated PTBs per each In-unit increase in PFOA (OR = 1.71; 95% CI: 0.80, 3.67). The high confidence study by Sagiv et al. (2018, 4238410) showed increased non-significant risks (OR range: 1.1–1.2) for PTB across all PFOA quartiles. Null or inverse associations were reported by Bach et al. (2016, 3981534), Hjermtislev et al. (2019, 5880849), Liu et al. (2020, 6833609), and Manzano-Salgado et al. (2017, 4238465). None of the six studies showed strong evidence of exposure-response relationships.

Overall, five of the eleven studies showed increased risk of PTB with PFOA exposures with no evidence of exposure-response relationships. Although small numbers limited the confidence in many of the sub-strata comparisons, there were few apparent patterns by study evaluation ratings or other characteristics that explained the heterogeneous results across studies. However, there were more associations amongst studies with later sample timing data collection, as three of the
five studies with later PFOA biomarker sampling showed some increased odds of preterm birth compared to two of six studies with earlier sampling.

3.4.4.1.6.3 Gestational Duration Summary
Overall, there was mixed evidence of adverse associations between PFOA and both gestational age and preterm birth. Most of the associations for either gestational duration measures were reported in medium or high confidence studies. Few other patterns were evident that explained any between study heterogeneity.

3.4.4.1.7 Fetal Loss
Five (2 high, 2 medium and 1 low confidence) studies examined PFOA exposure and fetal loss with limited evidence as only one study showing increased risks of miscarriage. Two studies had good study sensitivity {Wang, 2021, 10176703; Wikström, 2021, 7413606}, while three had adequate sensitivity {Buck Louis, 2016, 3858527; Jensen, 2015, 2850253; Liew, 2020, 6387285} (Figure 3-63).

The high confidence study by Wikström et al. {2021, 7413606} showed a statistically significant association between PFOA and miscarriages (OR = 1.48; 95% CI: 1.09, 2.01 per doubling of PFOA exposures. The authors also reported a monotonic exposure-response relationship across PFOA quartiles (ORs/95%CIs: Q2: 1.69; 0.8, 3.56; Q3: 2.02; 0.95, 4.29; Q4: 2.66; 1.26, 5.65). The medium confidence study by Liew et al. {2020, 6387285} detected a 40% increased risk of miscarriage (OR = 1.4; 95% CI: 1.0, 1.9) per each PFOA doubling with increased risks detected for quartiles three (OR=1.4; 95% CI: 0.8, 2.6) and four (OR = 2.2; 95% CI: 1.2, 3.9) only. No associations were detected in the high confidence study by Wang et al. {2021, 10176703} for preclinical spontaneous abortion (OR = 0.99; 95% CI: 0.94, 1.05) or in the medium confidence study by Buck Louis et al. {2016, 3858527} (hazard ratio (HR) =0.81; 95% CI: 0.65, 1.00 per each SD PFOA increase). In the low confidence study by Jensen et al. {2015, 2850253}, a decreased risk of miscarriages was reported (OR = 0.64; 95% CI: 0.36, 1.18 per each ln-unit PFOA increase).

Overall, there was positive evidence for fetal loss with increased relative risk estimates in two out of five studies. In those two studies, the magnitude of associations detected ranged from 1.4 to 2.7 with an exposure-response relationship detected in one study. No patterns in the results were detected by study confidence ratings including sensitivity.
3.4.4.1.8 Birth Defects

Four birth defect studies examined PFOA exposure with three of these four having adequate study sensitivity (one was deficient) as shown in Figure 3-64. This included a medium confidence study by Vesterholm Jensen et al. (2014, 2850926) that reported no adverse associations for cryptorchidism (OR = 0.83; 95% CI: 0.44, 1.58 per each ln-unit PFOA increase). A medium confidence study by Ou et al. (2021, 7493134) reported decreased risks for septal defects (OR = 0.54; 95% CI: 0.18, 1.62), conotruncal defects (OR = 0.28; 95% CI: 0.07, 1.10), and total congenital heart defects (OR = 0.64; 95% CI: 0.34, 1.21) among participants with maternal serum levels over >75th PFOA percentile (relative to those <75th percentile). A low confidence study {Cao, 2018, 5080197} of a non-specific all birth defect grouping reported limited evidence of an association (OR = 1.24; 95% CI: 0.57, 2.61), but interpretation of an all-birth defect grouping is challenging given that etiological heterogeneity may occur across individual defects. Compared to the referent group of no Little Hocking Water Association supplied water, no associations (both ORs were 1.1) were reported in a low confidence study from Washington County, Ohio among infants born to women partially or exclusively supplied in part by the Little Hocking Water Association {Nolan, 2010, 1290813}. The study was
considered *uninformative* for examination of individual defects given the lack of consideration of confounding and other limitations in those analyses.

Overall, there was negligible evidence of associations between PFOA and birth defects based on the four available epidemiological studies including two *medium* confidence studies which reported decreased odds of birth defects relative to exposures. As noted previously, there is considerable uncertainty in interpreting results for broad any defect groupings which are anticipated to have decreased sensitivity to detect associations.

![Figure 3-64. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Birth Defects](image)

Interactive figure and additional study details available on [HAWC](https://hawc.wustl.edu).

### 3.4.4.2 Animal Evidence Study Quality Evaluation and Synthesis

There are 5 studies from the 2016 PFOA HESD (U.S. EPA, 2016, 3603279) and 13 studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD that investigated the association between PFOA and developmental effects in animal models. Study quality evaluations for these 18 studies are shown in Figure 3-65.
Evidence suggests that PFOA exposure can adversely affect development. Oral studies in mice and rats report effects in offspring including decreased survival, decreased body weights, structural abnormalities (e.g., reduced skeletal ossification), delayed eye opening, and altered
mammary gland development. Doses that elicited responses were generally lower in mice than in rats. Additionally, three studies of gestational PFOA exposure to mice reported effects on placental weight and histopathological changes in placental tissue, suggesting that the placenta may be a target of PFOA. In some cases, adverse developmental effects of PFOA exposure that relate to other health outcomes may be discussed in the corresponding health outcome section (e.g., neurodevelopmental effects are discussed in the Appendix; see PFOA Appendix).

3.4.4.2.1 Maternal Effects
Exposure to PFOA resulted in significant decreases in maternal body weight and/or weight gain at doses ≥ 10 mg/kg/day in multiple strains of pregnant mice {Li, 2018, 5084746; Lau, 2006, 1276159; Yahia, 2010, 1332451} and at doses ≥ 30 mg/kg/day in pregnant Sprague Dawley rats {Butenhoff, 2004, 1291063; Hinderliter, 2005, 1332671}. The effect followed a dose-related trend in some studies. PFOA exposure was also associated with significantly delayed parturition at doses ≥ 3 mg/kg/day in CD-1 mice {Lau, 2006, 1276159} and at 10 mg/kg/day in ICR mice {Yahia, 2010, 1332451}.

3.4.4.2.1.1 Studies in Mice
Li et al. (2018, 5084746) reported marked, dose-related decreases in maternal body weight gain at ≥ 10 mg/kg/day in pregnant Kunming mice exposed from gestation day 1 to 17 (GD 1 to GD 17; no statistical tests performed). Dose-related decreases in body weight gain were also seen in pregnant CD-1 mice exposed to 10, 20, or 40 mg/kg/day (significant at 20 and 40 mg/kg/day) by Lau et al. (2006, 1276159); significantly delayed time to parturition was also seen at 3, 10, and 20 mg/kg/day in this study (all litters at 40 mg/kg/day were resorbed). Yahia et al. (2010, 1332451) dosed pregnant ICR mice with 0, 1, 5, or 10 mg/kg/day from GD 0 to GD 17 (sacrificed on GD 18) or GD 0 to GD 18 (allowed to give birth), and at 10 mg/kg/day, observed significant decreases in body weight gain from GD 12 onward in dams allowed to give birth as well as significantly decreased terminal body weight in dams sacrificed on GD 18. In the same study, a significant decrease in food intake during early gestation was also reported for the dams allowed to give birth, but data were not shown. Delayed parturition was also observed at 10 mg/kg/day (data not shown). Pregnant CD-1 mice exposed to 25 mg/kg/day from GD 11 to GD 16 exhibited significantly decreased body weight from GD 13 to GD 16 {Suh, 2011, 1402560}. Hu et al. (2010, 1332421) exposed pregnant C57BL/6N mouse dams to 0.5 or 1.0 mg/kg/day PFOA and found no significant differences relative to controls on GD 19. No significant effects on maternal body weight were noted in C57BL/6N mouse dams exposed to 0.02, 0.2, or 2 mg/kg/day PFOA from time of mating through PND 21 (Hu, 2012, 1937235). In contrast to the above-described findings, two studies in pregnant CD-1 mice reported significantly increased maternal body weight gain after exposure to 5 mg/kg/day {Blake, 2020, 6305864} or 3 or 5 mg/kg/day PFOA {Wolf, 2007, 1332672} from GD 1–17. Abbott et al. (2007, 1335452) found no effects of 0.1, 0.3, 0.6, or 1 mg/kg/day PFOA on maternal weight changes in 129S1/SvImJ wild-type mice (exposure to 5, 10, and 20 mg/kg/day PFOA led to increased maternal death) (Figure 3-66).

3.4.4.2.1.2 Studies in Rats
A two-generation oral gavage reproductive toxicity study in Sprague-Dawley rats reported no effect on parental generation (P0) maternal body weight or food consumption, but found significantly decreased body weight in first-generation (F1) parental females at 30 mg/kg/day during pre-cohabitation, gestation (GD 0–GD 14), and lactation day 5 to 15 (LD 5–LD 15).
Decreased absolute food consumption was reported, but data were not shown; relative feed consumption was unaffected {Butenhoff, 2004, 1291063}. In pregnant Sprague-Dawley rats dosed with 30 mg/kg/day from GD 4 to LD 21, body weight gain was decreased during gestation and body weight was 4% lower than controls during lactation (statistical significance not indicated) {Hinderliter, 2005, 1332671}.

In a two-year chronic toxicity/carcinogenicity assay conducted by the NTP (2020, 7330145), female Sprague Dawley (Hsd:Sprague Dawley® SD®) rat dams were exposed to 0, 150, or 300 parts per million (ppm) PFOA in feed during the perinatal period. In study 1, F₁ male rats were administered 0, 150, or 300 ppm PFOA and F₁ female rats were administered 0, 300, or 1,000 ppm PFOA in feed during the postweaning period. For study 2, lower postweaning exposure levels (0, 20, 40, or 80 ppm) were utilized for males due to unexpected toxicity in male offspring using the original exposure regime. Exposure for all F₁ generations in both studies occurred for 107 weeks or until the 16-week interim necropsy. The perinatal and postweaning exposure regimes for females and males for both studies are presented in Table 3-9. Dose groups for this study are referred to as “[perinatal exposure level]/[postweaning exposure level]” (e.g. 300/100).

Table 3-9. Study Design for Perinatal and Postweaning Exposure Levels for F₁ Male and Female Rats for the NTP (2020, 7330145) Study

<table>
<thead>
<tr>
<th>Perinatal Dose</th>
<th>Postweaning Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 ppm</td>
</tr>
<tr>
<td>Study 1 Females</td>
<td></td>
</tr>
<tr>
<td>0 ppm</td>
<td>X</td>
</tr>
<tr>
<td>150 ppm</td>
<td>–</td>
</tr>
<tr>
<td>300 ppm</td>
<td>–</td>
</tr>
<tr>
<td>Study 1 Males</td>
<td></td>
</tr>
<tr>
<td>0 ppm</td>
<td>X</td>
</tr>
<tr>
<td>150 ppm</td>
<td>–</td>
</tr>
<tr>
<td>300 ppm</td>
<td>–</td>
</tr>
<tr>
<td>Study 2 Males</td>
<td></td>
</tr>
<tr>
<td>0 ppm</td>
<td>X</td>
</tr>
<tr>
<td>300 ppm</td>
<td>X</td>
</tr>
</tbody>
</table>

Notes: F₁ = first generation; X = exposure level used.

In pregnant Sprague-Dawley rats exposed to 150 or 300 ppm via diet (equivalent to approximately 11 and 22 mg/kg/day during gestation and 22 and 45 mg/kg/day from LD 1 to LD 14), no consistent effects were observed on body weight or body weight gain during gestation or lactation (Figure 3-66). Food consumption was marginally but significantly decreased (up to 4%) at one or both dose levels at various intervals. In a repeat of this study that tested a single dose level of 300 ppm (approximately 21.8 mg/kg/day during gestation and 48.3 mg/kg/day from LD 1 to LD 14), no effects were observed on maternal body weight or body weight gain during gestation; from LD 1 to LD 14, there was a marginal but significant decrease (2%–3%) in maternal body weight and body weight gain and a significant decrease (5%) in food consumption {NTP, 2020, 7330145}.
DRAFT FOR PUBLIC COMMENT
March 2023

Figure 3-66. Maternal Body Weight in Rodents Following Exposure to PFOA (logarithmic scale)

PFOA concentration is presented in logarithmic scale to optimize the spatial presentation of data. Interactive figure and additional study details available on HAWC.

3.4.4.2.2 Placenta Effects

Two oral gavage studies in CD-1 mice reported significant decreases in embryo to placenta weight ratio at 5 mg/kg/day PFOA {Blake, 2020, 6305864} or doses ≥ 2 mg/kg/day {Suh, 2011, 1402560}, as well as treatment-related histopathological lesions at 5 mg/kg/day {Blake, 2020, 6305864} or doses ≥ 10 mg/kg/day {Suh, 2011, 1402560}. A third study in Kunming mice reported decreased placenta to body weight ratio at PFOA doses ≥ 5 mg/kg/day and histopathological changes in placental tissue at doses ≥ 2.5 mg/kg/day {Jiang, 2020, 6320192} (Figure 3-67).

Blake et al. (2020, 6305864) administered 0, 1, or 5 mg/kg/day to pregnant CD-1 mice from GD 1.5 through sacrifice on GD 11.5 or GD 17.5, Suh et al. (2011, 1402560) administered 0, 2, 10, or 25 mg/kg/day to CD-1 mice from GD 11 through sacrifice on GD 16, and Jiang et al. (2020, 6320192) administered 0, 2.5, 5, or 10 mg/kg/day to Kunming mice from GD 1 through sacrifice on GD 13. The embryo to placental weight ratio was significantly decreased at 5 mg/kg/day in Blake et al. (2020, 6305864) and at doses ≥ 2 mg/kg/day in Suh et al. (2011, 1402560). Blake et al. (2020, 6305864) observed significantly increased placental weight at 5 mg/kg/day at GD 17.5 and no changes in the numbers of viable fetuses or resorptions, whereas Suh et al. (2011, 1402560) observed significantly decreased placental weight and increased numbers of resorptions and dead fetuses at ≥ 2 mg/kg/day. Jiang et al. (2020, 6320192) observed significantly decreased relative placental weight at ≥ 5 mg/kg/day (decreases were also seen at lower dose levels, but they did not reach statistical significance). Histopathological changes in placental tissue were also observed at PFOA doses ≥ 2.5 mg/kg/day (increased area of spongiotrophoblast, decreased blood sinusoidal area in labyrinth), ≥ 5 mg/kg/day (increased...
interstitial edema of spongiotrophoblast), or 10 mg/kg/day (decreased labyrinth area, increased ratio of spongiotrophoblast to labyrinth area). Jiang et al. (2020, 6320192) found no effect on fetus to maternal body weight ratio. Viable fetus weight was significantly decreased in Blake et al. (2020, 6305864) at 5 mg/kg/day and in Suh et al. (2011, 1402560) at ≥ 10 mg/kg/day and corresponded with treatment-related lesions in the placenta. The incidence of GD 17.5 placenta within normal limits was significantly lower in mice exposed to 5 mg/kg/day {Blake, 2020, 6305864}, and the lesions observed in placentas from that group included labyrinth atrophy (3/40 placentas), labyrinth congestion (23/40), and early fibrin clot (1/40). In dams treated with 1 mg/kg/day, labyrinth necrosis was observed in 1/32 placentas and placental nodules were observed in 2/32 placentas. Histopathologic examination by Suh et al. (2011, 1402560) showed norm al placental tissue in 0 and 2 mg/kg/day groups and dose-dependent necrotic changes in placentas from the 10 and 25 mg/kg/day groups (incidences of specific lesions and statistical significance not reported).

3.4.4.2.3 Offspring Mortality

Studies of oral PFOA exposure in mice reported significant increases in resorptions and dead fetuses with PFOA dose levels as low as 2 mg/kg/day in prenatal evaluations {Li, 2018, 5084746; Suh, 2011, 1402560; Lau, 2006, 1276159}. Stillbirths, pup mortality, and total litter loss were observed in several strains of mice at doses ≥ 5 mg/kg/day {Lau, 2006, 1276159; Song, 2018, 5079725; White, 2011, 1276150; Wolf, 2007, 1332672; Yahia, 2010, 1332451}; increased litter loss was seen as low as 0.6 mg/kg/day PFOA in one study in 129S1/SvImJ mice {Abbott, 2007, 1335452}. Comparatively, rat pup mortality (pre- and post-weaning) was reported at a higher dose of 30 mg/kg/day {Butenhoff, 2004, 1291063}. Maternal effects observed in some of these studies were not sufficient to explain effects observed in the offspring, as some studies reported effects on offspring survival at dose levels that did not produce maternal effects.

3.4.4.2.3.1 Mice, Prenatal Evaluations

In two studies of gestational PFOA exposure in pregnant Kunming mice, Li et al. (2018, 5084746) reported significantly decreased GD 18 fetal survival at 10 and 20 mg/kg/day and total fetal resorption at 40 mg/kg/day (fetal survival was also decreased at 5 mg/kg/day, but the effect did not reach statistical significance), and Chen et al. (2017, 3981369) reported a significant increase in the number of resorbed fetuses at GD 13, but not GD 7, after exposure to 10 mg/kg/day PFOA beginning on GD 1 (there were no effects on the number of implantation sites). Suh et al. (2011, 1402560) exposed pregnant CD-1 mice to 0, 2, 10, or 25 mg/kg/day from GD 11 to GD 16 (dams were sacrificed on GD16) and observed significant increases in the
number of resorptions and dead fetuses at all dose levels; post-implantation loss was 3.87%, 8.83%, 30.98%, and 55.41% at 0, 2, 10, and 25 mg/kg/day, respectively. In pregnant CD-1 mice exposed from GD 1 to GD 17, Lau et al. (2006, 1276159) reported significant increases in the number of full-litter resorptions at PFOA doses ≥ 5 mg/kg/day, with complete loss of all pregnancies at the high dose of 40 mg/kg/day (no effect was observed on the number of implantation sites in litters that were fully resorbed). At 20 mg/kg/day, a significant increase in the percentage of prenatal loss per live litter was observed. White et al. (2011, 1276150) reported significantly fewer implants in F1-generation CD-1 mouse dams that had been exposed to 5 mg/kg/day PFOA.

### 3.4.4.2.3.2 Mice, Postnatal Evaluations

Wolf et al. (2007, 1332672) reported a significant increase in total litter loss following oral PFOA exposure of pregnant CD-1 mice to 5 mg/kg/day (no effect on the number of implantation sites). In offspring exposed to 5 mg/kg/day PFOA in utero and throughout lactation, significantly decreased pup survival was observed from postnatal day (PND) 4 to 22; this effect was not seen in cross-fostered offspring exposed during gestation only or during lactation only. In a separate study, these authors exposed pregnant CD-1 mice to 5 mg/kg/day PFOA for different lengths of time (GD 7–GD 17, GD 10–GD 17, GD 13–GD 17, or GD 15–GD 17) and to 20 mg/kg/day from GD 15–17. Control mice received deionized water from GD 7 to GD 17. Although gestational PFOA exposure from GD 1 to GD 6 was not required to elicit adverse developmental responses in pups, the severity of postnatal responses, including decreased pup weight during lactation and delayed eye opening, increased with earlier and longer exposure durations (i.e., GD 7–GD 17 exposure resulted in more severe decreases in pup body weight when compared to pups exposed from GD 15 to GD 17). The authors could not attribute the observed adverse effects to a sensitive window of development as the pups exposed for longer durations had higher serum PFOA levels than pups exposed for shorter durations. Notably, significantly decreased offspring survival was observed in pups exposed to 20 mg/kg/day with the shortest exposure duration from GD 15 to GD 17.

Lau et al. (2006, 1276159) reported significant increases in the incidence of stillbirths and pup mortality at 5, 10, and 20 mg/kg/day PFOA in CD-1 mice exposed from GD 1 to GD 18 and allowed to deliver naturally. Complete loss of all pregnancies was observed at the high dose of 40 mg/kg/day, though there were no effects on the number of implantation sites. At 10 and 20 mg/kg/day, most of the pups died on PND 1. After exposure of pregnant Kunming mice to 1, 2.5, or 5 mg/kg/day from GD 1 to GD 17, Song et al. (2018, 5079725) reported a significant decrease in the number of surviving pups per litter on PND 7, 14, and 21 at 5 mg/kg/day (a dose-related trend was observed, but statistical significance was achieved only at the high dose). Yahia et al. (2010, 1332451) dosed pregnant ICR mice with 0, 1, 5, or 10 mg/kg/day PFOA from GD 0 to GD 18, and the dams were allowed to give birth naturally. Approximately 58% of pups born to high-dose dams were stillborn, and the remaining pups died within 6 hours of birth. Mean PND 4 survival rate was 98%, 100%, 84.4%, and 0% at 0, 1, 5, and 10 mg/kg/day, respectively (with significant decreases at 5 and 10 mg/kg/day). In the same study, some of the pregnant mice were exposed to the same dose levels from GD 0 to GD 17 and sacrificed on GD 18, and the number of live GD 18 fetuses from these dams was not significantly affected at any dose level. White et al. (2011, 1276150) conducted a multi-generational study and dosed pregnant CD-1 mice with 0, 1, 5 mg/kg/day from GD 1 to GD 17. Exposure to 5 mg/kg/day significantly increased prenatal loss, significantly decreased the number of live pups born, and significantly
reduced postnatal survival. In adult female F1 animals, no effects were observed on the prenatal loss or postnatal pup survival of the second generation (F2) offspring.

Abbott et al. (2007, 1335452) exposed pregnant 129S1/SvImJ wild-type and PPARα-null mice from GD 1 to GD 17 to dose levels ranging from 0.1 to 20 mg/kg/day and allowed the mice to deliver naturally. There were no treatment-related effects on the number of implantation sites, but wild-type dams exposed to ≥ 0.6 mg/kg/day PFOA and PPARα-null dams exposed to ≥ 5 mg/kg/day PFOA had significantly increased litter loss compared to their respective controls. At doses ≥ 5 mg/kg/day in wild-type dams and 20 mg/kg/day in PPARα-null dams, 100% litter loss occurred. The percentage of dams with full litter resorptions significantly increased in the 5, 10, and 20 mg/kg/day groups, with 100% full litter resorption in the 20 mg/kg/day group. When excluding dams with full litter resorptions, wild-type dams exposed to 1 mg/kg/day had a significant increase in litter loss. Pup survival from birth to weaning was significantly decreased in wild-type litters exposed to PFOA doses ≥ 0.6 mg/kg/day. No effect was seen in PPARα-null litters. Survival was significantly decreased for wild-type and heterozygous pups born to wild-type dams dosed with 1 mg/kg/day and for heterozygous pups born to PPARα-null dams dosed with 3 mg/kg/day. In the wild-type mice, the number of live and dead pups per litter were not affected by PFOA. Similarly, the number of pups per litter in CD-1 mice exposed to 0.1 or 1 mg/kg/day PFOA from GD 1.5–17.5 did not significantly differ from control groups (Cope, 2021, 10176465).

3.4.4.2.3.3 Rats, Postnatal Evaluations
The NTP two-year carcinogenicity studies in Sprague-Dawley rats found no effects on offspring survival {NTP, 2020, 7330145}, but Butenhoff et al. (2004, 1291063) reported an increase in the total number of dead F1 rat pups during lactation (26/388 deaths at 30 mg/kg/day and 10/397 in the control group; statistically significant only on LD 6–LD 8) and a significant increase in F1 female pup deaths with 30 mg/kg/day on post-weaning days 2–8. F2 generation pup survival was unaffected. In pregnant Sprague-Dawley rats dosed with 0, 3, 10, or 30 mg/kg/day from GD 4 to LD 21, one dam at 3 mg/kg/day and two dams at 30 mg/kg/day delivered small litters (3–6 pups/litter compared to 12–19 pups/litter in the control group); however, statistical significance was not indicated, and given the small sample size (5 dams/group), the biological significance of this finding is unclear {Hinderliter, 2005, 1332671} (Figure 3-68).
Figure 3-68. Offspring Mortality in Rodents Following Exposure to PFOA

Interactive figure and additional study details available on HAWC.

GD = gestation day; PND = postnatal day; P₀ = parental generation; F₁ = first generation; F₂ = second generation; d = day.

a Lau et al. (2006, 1276159) exposed pregnant mice from GD 1–19, but some of the mice were sacrificed and examined on GD 18. Based on data from the pregnant mice sacrificed on GD 18, all litters from dams administered 40 mg/kg/day were resorbed, and therefore no offspring were available for postnatal assessments.

3.4.4.2.4 Offspring Body Weight

Available studies of oral gestational PFOA exposure to mice report significant decreases in offspring body weight in prenatal evaluations at doses ≥ 5 mg/kg/day and postnatal evaluations at dose levels as low as 0.5 mg/kg/day (Abbott, 2007, 1335452; Blake, 2020, 6305864; Hu, 2012, 1937235; Lau, 2006, 1276159; Li, 2018, 5084746; Suh, 2011, 1402560; Tucker, 2015, 2851046; White, 2011, 1276150; Wolf, 2007, 1332672; Yahia, 2010, 1332451; Hu, 2010, 1332421). Offspring weight deficits in pups were observed to extend beyond weaning in three studies in CD-1 mice (at 1, ≥ 3, and 5 mg/kg/day, respectively) (Tucker, 2015, 2851046; Lau, 2006, 1276159; White, 2011, 1276150) and in a multi-generation rat study at doses of 30 mg/kg/day (Butenhoff, 2004, 1291063). In some studies, decreased fetal and/or pup body weight was observed in the absence of maternal body weight effects.
3.4.4.2.4.1 Mice, Prenatal Evaluations
Blake et al. (2020, 6305864) reported significantly decreased GD 17.5 fetal weight with 5 mg/kg/day PFOA following gestational exposure in CD-1 mice, despite significantly increased maternal body weight gain. Lau et al. (2006, 1276159) reported a significant decrease in GD 18 fetal body weights after gestational exposure of CD-1 mice to 20 mg/kg/day PFOA. In pregnant Kunming mice, gestational exposure was associated with significantly decreased GD 18 fetal weights at 5–40 mg/kg/day [Li, 2018, 5084746]. Suh et al. (2011, 1402560) reported a significant decrease in GD 16 fetal weights at doses ≥ 10 mg/kg/day after exposure of pregnant CD-1 mice to 0, 2, 10, or 25 mg/kg/day from GD 11 to GD 16. Body weights of GD 18 ICR mouse fetuses were significantly decreased following gestational exposure to 5 or 10 mg/kg/day PFOA [Yahia, 2010, 1332451].

3.4.4.2.4.2 Mice, Postnatal Evaluations
Wolf et al. (2007, 1332672) reported that CD-1 mouse pup body weights were significantly decreased after gestational exposure to 5 mg/kg/day PFOA from GD 1 to GD 17. The authors also exposed pregnant mice to 20 mg/kg/day from GD 15 to GD 17 and to 5 mg/kg/day for different lengths of time (GD 7–GD 17, GD 10–GD 17, GD 13–GD 17, or GD 15–GD 17). After exposure to 5 mg/kg/day from GD 7 to GD 17 or GD 10 to GD 17 and to 20 mg/kg/day from GD 15 to GD 17, male pup body weights were significantly decreased. Additionally, with 5 mg/kg/day PFOA, male and female pup body weights were significantly decreased throughout lactation in all exposure groups, and the magnitude of the effect increased with increasing number of exposure days. Body weight deficits in male pups that had been exposed from GD 7 to GD 17 or GD 10 to GD 17 persisted for 10–11 weeks.

Hu et al. (2010, 1332421) exposed C57BL/6N pregnant mice with 0.5 or 1.0 mg/kg/day PFOA in drinking water from GD 6 through GD 17. At PND 2, litter weights were significantly reduced in the PFOA treatment groups (7%—12% less than the controls). At PND 7 and 14, the 0.5 mg/kg/day group litter weight was equivalent to the controls, but the 1.0 mg/kg/day group was still significantly less than the controls (14% and 5%, respectively, by time point).

Body weights of live pups born to pregnant ICR mice dosed with 5 or 10 mg/kg/day during gestation were significantly reduced [Yahia, 2010, 1332451]. At ≥ 3 mg/kg/day, a dose-related trend in growth retardation (body weight reductions of 25%–30%) was observed in neonates at weaning; body weights reached control levels by 6 weeks of age for females and by 13 weeks of age for males [Lau, 2006, 1276159]. Exposure of pregnant C57BL/6N mice to 2 mg/kg/day from mating through lactation resulted in significantly decreased pup weights (32.6% lower than controls, on average) from PND 1 to PND 21 (there were no effects on maternal body weights) [Hu, 2012, 1937235]. Song et al. (2018, 5079725) observed significantly increased body weights in PND 21 male offspring after gestational exposure to 2.5 or 5 mg/kg/day PFOA (female data not provided). However, the authors did not report controlling for litter size in this study; the significantly decreased litter size in the 5 mg/kg/day group could potentially result in increased body weight in those pups due to reduced competition for maternal resources.

In a study in which pregnant 129S1/SvImJ wild-type and PPARα-null mice were orally exposed from GD 1 to GD 17 to dose levels ranging from 0.1 to 20 mg/kg/day [Abbott, 2007, 1335452], decreased offspring body weight was seen in wild-type mice at 1 mg/kg/day (highest dose level at which this effect was measured due to extensive litter loss at higher doses) beginning around
PND 6, and this effect achieved statistical significance on PND 9, PND 10, and PND 22 (males) and PND 7–PND 10 and PND 22 (females). No effects were observed on PPARα-null offspring body weights. White et al. (2011, 1276150) exposed pregnant CD-1 mice to 0, 1, or 5 mg/kg/day from GD 1 to GD 17. A separate group of pregnant mice was dosed with either 0 or 1 mg/kg/day from GD 1 to GD 17 and received drinking water containing 5 ppb PFOA beginning on GD 7. F₁ females and F₂ offspring from the second group continued to receive drinking water that contained 5 ppb PFOA until the end of the study, except during F₁ breeding and early gestation, to simulate a chronic low-dose exposure. F₁ offspring body weight at PND 42 was significantly reduced at 5 mg/kg/day; at PND 63, body weight was significantly reduced for offspring from dams given 1 mg/kg/day plus 5 ppb in the drinking water compared to offspring from dams given only 1 mg/kg/day. For the F₂ pups, a significant reduction in body weight was observed in control plus 5 ppb drinking water PFOA offspring on PND 1, but there was no difference by PND 3. F₂ offspring from the 1 mg/kg/day and 1 mg/kg/day plus 5 ppb drinking water PFOA groups had increased body weights compared to controls on PND 14, PND 17, and PND 22. Female CD-1 mice that had been exposed gestationally to 1 mg/kg/day had significantly decreased body weights at PND 21 and PND 35 but not at PND 56 (Tucker, 2015, 2851046). Macon et al. (2011, 1276151) found no effects on offspring body weights following exposure of pregnant CD-1 mice to PFOA from GD 1 to GD 17 with doses up to 1 mg/kg/day or from GD 10 to GD 17 with doses up to 3 mg/kg/day. Similarly, Cope et al. (2021, 10176465) exposed CD-1 dams to 0.1 or 1.0 mg/kg/day PFOA via oral gavage from GD 1.5 to GD 17.5 and did not find treatment-related changes in pup weight at PND 0.5, PND 5, or PND 22.

3.4.4.2.4.3 Rats, Postnatal Evaluations

In two NTP 2-year carcinogenicity studies (NTP, 2020, 7330145), dietary exposure of pregnant Sprague-Dawley rats to 300 ppm PFOA (approximately 22 mg/kg/day during gestation and 45 mg/kg/day from LD 1 to LD 14) resulted in significantly decreased pup weights throughout lactation (3%–8% lower than controls). In both studies, there were minimal to no effects on maternal body weight.

Significantly decreased F₁ pup weight (8%–11% lower than controls) during lactation was observed following exposure of pregnant Sprague-Dawley rats to 30 mg/kg/day, in the absence of effects on maternal body weight; F₂ pup weight was slightly decreased at 30 mg/kg/day, but the effect was not statistically significant (Butenhoff, 2004, 1291063). At 30 mg/kg/day, significant decreases in body weight and body weight gain were seen in F₁ male offspring during the juvenile and peripubertal phases and in F₁ female offspring beginning on day 8 postweaning and continuing through pre-cohabitation, gestation, and lactation (along with decreased food consumption) (Figure 3-69).
Figure 3-69. Offspring Body Weight in Rodents Following Exposure to PFOA (logarithmic scale)a

PFOA concentration is presented in logarithmic scale to optimize the spatial presentation of data. Interactive figure and additional study details available on HAWC.

GD = gestation day; PND = postnatal day; P₀ = parental generation; F₁ = first generation; F₂ = second generation; d = day.

GD = gestation day; PND = postnatal day; P₀ = parental generation; F₁ = first generation; F₂ = second generation; d = day.

a Lau et al. (2006) exposed pregnant mice from GD1–19, but some of the mice were sacrificed and examined on GD18. Based on data from the pregnant mice sacrificed on GD18, all litters from dams administered 40 mg/kg/day were resorbed, and therefore no offspring were available for postnatal assessments.

3.4.4.2.5 Skeletal and Visceral Alterations

Following exposure of pregnant CD-1 mice to 1, 3, 5, 10, 20, or 40 mg/kg/day PFOA during gestation, Lau et al. (2006, 1276159) reported decreases in ossification of the forelimb proximal
phalanges (significant at all dose levels except 5 mg/kg/day), hindlimb proximal phalanges (significant at all dose levels except 3 and 5 mg/kg/day), calvaria (significant at 1, 3, and 20 mg/kg/day), enlarged fontanel (significant at 1, 3, and 20 mg/kg/day), and supraoccipital bone (significant at 10 and 20 mg/kg/day). Significantly reduced ossification of caudal vertebrae, metacarpals, metatarsals, and hyoid was observed at 20 mg/kg/day. Significant increases in minor limb and/or tail defects were observed in fetuses at ≥5 mg/kg/day (no defects were observed at 0, 1, or 3 mg/kg/day) and significantly increased incidence of microcardia was observed at 10 and 20 mg/kg/day (no incidences were observed in any other groups). Yahia et al. (2010, 1332451) dosed pregnant ICR mice with 0, 1, 5, or 10 mg/kg/day from GD 0 to GD 17 (sacrificed on GD 18) and reported a significant increase in the incidence of cleft sternum and ossification delays (phalanges) in GD 18 fetuses at 10 mg/kg/day. In the same study, some dams were dosed from GD 0 to GD 18 and allowed to give birth, and pup lungs and brains were examined at PND 4; no abnormalities were reported.

3.4.4.2.6 Altered Developmental Timing
Reduced postnatal growth leading to developmental delays was observed in both rats and mice. Lau et al. (2006, 1276159) and Wolf et al. (2007, 1332672) reported delayed eye opening in CD-1 mice offspring after gestational exposure to ≥5 mg/kg/day PFOA. Additionally, Wolf et al. (2007, 1332672) observed delayed eye opening following gestational plus lactational exposure to 3 or 5 mg/kg/day. Wolf et al. (2007, 1332672) also observed delayed body hair emergence following gestational exposure to 5 mg/kg/day or gestational plus lactational exposure to 3 or 5 mg/kg/day. In pregnant 129S1/SvImJ wild-type and PPARα-null mice orally exposed from GD 1 to GD 17 to 0.1–20 mg/kg/day PFOA {Abbott, 2007, 1335452}, offspring born to wild-type dams showed a dose-related trend for delayed eye opening compared to controls at 0.6 and 1 mg/kg/day (significant at 1 mg/kg/day; extensive litter loss seen at the higher doses). In PPARα-null offspring, none of the litters from dams exposed to 3 mg/kg/day had eyes open on PND 13, but no significant difference between this group and the control was observed by PND 14. Yahia et al. (2010, 1332451) dosed pregnant ICR mice with 0, 1, 5, or 10 mg/kg/day PFOA from GD 0 to GD 17 (sacrificed on GD 18) and reported a significant decrease in the percentage of GD 18 fetuses with erupted incisors at 10 mg/kg/day.

3.4.4.2.7 Mammary Gland Development
Altered mammary gland development has been shown to result in later-life functional reproductive consequences, such as reduced lactational efficacy and subsequent pup loss, and has been linked to increased incidence of mammary and breast cancers {Fenton, 2006, 470286; Macon, 2013, 3827893; Birnbaum, 2003, 197117}. Studies examining effects of PFOA exposure on mammary gland development in CD-1 mice reported delayed mammary gland development at dose levels as low as 0.01 mg/kg/day {Macon, 2011, 1276151; Tucker, 2015, 2851046}. However, no differences in response to a lactation challenge were seen in PFOA-exposed CD-1 mouse dams with delayed mammary gland development, and no significant effects on body weight gain were seen in pups nursing from dams with less fully developed mammary glands {White, 2011, 1276150}.

Macon et al. (2011, 1276151) exposed pregnant CD-1 mice to PFOA from GD 1 to GD 17 (full gestation) or GD 10 to GD 17 (late gestation) to examine effects of PFOA exposure on mammary gland morphology. Mammary gland whole mounts were scored on a 1 to 4 subjective, age-adjusted, developmental scale. Quantitative measures also were made of longitudinal
growth, lateral growth, and number of terminal end buds. At all PFOA exposure levels in both experiments (≥ 0.3 mg/kg/day in the full gestation study and ≥ 0.01 mg/kg/day in the late-gestation study), significantly stunted mammary epithelial growth was observed in female offspring in the absence of effects on offspring body weight. Additionally, there were significant differences from controls in quantitative measures of longitudinal and lateral growth and numbers of terminal end buds at 1 mg/kg/day in the late-gestation experiment. The delayed development was characterized by reduced epithelial growth and the presence of numerous terminal end buds. Photographs of the mammary gland whole mounts at PND 21 and PND 84 from the full-gestation experiment showed differences in the duct development and branching pattern of offspring from dams given 0.3 and 1 mg/kg/day PFOA (offspring from high-dose dams not pictured). At PND 21, mammary glands from the 1 mg/kg/day late-gestation group had significantly less longitudinal epithelial growth and fewer terminal end buds compared with controls. In the late-gestation experiment, mammary gland development was delayed by exposure to PFOA, especially longitudinal epithelial growth. At PND 21, all treatment groups had significantly lower developmental scores. At the highest dose, poor longitudinal epithelial growth and decreased number of terminal end buds were observed. The quantitative measures were statistically significant only for the high dose compared to the controls, whereas the qualitative scores at all doses were significantly different from controls.

CD-1 mice were dosed with 5 mg/kg/day on GD 7–GD 17, GD 10–GD 17, GD 13–GD 17, or GD 15–GD 17 or with 20 mg/kg/day on GD 15–GD 17 (controls were dosed GD 7–GD 17) and mammary gland effects of this study were published by White et al. (2009, 194811). Mammary gland developmental scores for all offspring of dams exposed to PFOA were significantly lower at PND 29 and PND 32. Delayed ductal elongation and branching and delayed appearance of terminal end buds were characteristic of delayed mammary gland development at PND 32. At 18 months of age, mammary tissues were not scored (due to the lack of a protocol applicable to mature animals) but dark foci (composition unknown) in the mammary tissue were observed at a higher frequency in exposed animals compared to controls. There was no consistent response with respect to dosing interval. Qualitatively, mammary glands from treated dams on LD 1 appeared immature compared with control dams (White, 2009, 194811). The authors also exposed pregnant CD-1 mice to 0, 3, or 5 mg/kg/day from GD 1 to GD 17 and offspring were cross-fostered at birth to create seven treatment groups: control, in utero exposure only (3U and 5U), lactational exposure only (3L and 5L), and in utero + lactational exposure (3U+L and 5U+L). Mammary gland whole mounts from female offspring between PND 22 and PND 63 were scored. With the exception of females of the 3L group, all female offspring of PFOA-exposed dams had reduced mammary gland developmental scores at PND 22. At PND 42, mammary gland scores from females in the 3U+L group were the only ones not statistically different from control scores. This might have been due to inter-individual variance and multiple criteria used to calculate mammary gland development scores. All offspring of dams exposed to PFOA exhibited delayed mammary gland development at PND 63, including those exposed only through lactation (3L and 5L).

White et al. (2011, 1276150) dosed pregnant CD-1 mice with 0, 1, or 5 mg/kg/day from GD 1 to GD 17. A second group of pregnant mice was dosed with either 0 or 1 mg/kg/day from GD 1 to GD 17 and also received drinking water containing 5 ppb PFOA beginning on GD 7. The F1 females and F2 offspring from the second group continued to receive drinking water that contained 5 ppb PFOA until the end of the study, except during F1 breeding and early gestation,
to simulate a chronic low-dose exposure. Only the P₀ dams were given PFOA by gavage. P₀ females were sacrificed on PND 22. F₁ offspring were weaned on PND 22 and bred at 7–8 weeks of age. F₂ litters were maintained through PND 63. Groups of F₁ and F₂ offspring were sacrificed on PND 22, PND 42, and PND 63. A group of F₂ offspring also was sacrificed on PND 10. A lactational challenge experiment was performed on PND 10 with F₁ dams and F₂ offspring to estimate the volume of milk produced during a discrete period of nursing. Mammary glands were evaluated from P₀ dams on PND 22, from F₁ dams on PND 10 and PND 22, and from F₁ and F₂ female offspring on PND 10 (F₂ only), PND 22, PND 42, and PND 63. Mammary gland whole mounts were scored qualitatively. At PND 22, control P₀ dams displayed weaning-induced mammary involution. At PND 22, the mammary glands of all PFOA-exposed P₀ dams, including the dams receiving 5 ppb PFOA via drinking water only, resembled glands of mice at or near the peak of lactation (~PND 10). The F₁ dams examined on PND 10 and PND 22 had significantly lower developmental scores on PND 10, but that was no longer evident at PND 22, except for those exposed in utero to 5 mg/kg/day. In the F₁ female offspring not used for breeding, the mammary glands of all PFOA-exposed mice were significantly delayed in development on PND 22, 42, and 63. For the F₂ female offspring, some differences in mammary gland scores were observed between the groups, but most were not significantly different from controls. No differences in response to a lactational challenge were seen in PFOA-exposed dams with morphologically delayed mammary gland development.

Tucker et al. (2015, 2851046) orally exposed pregnant CD-1 and C57BL/6 mice to 0, 0.01, 0.1, 0.3, or 1 mg/kg/day from GD 1 to GD 17. After parturition, the number of pups was reduced so that there were ultimately four to eight CD-1 litters and three to seven C57BL/6 litters per treatment. Different treatment blocks monitored for different endpoints at different times. There was a dose-related trend towards decreasing mammary gland developmental scores for both strains of mice. In CD-1 mice, scores were significantly reduced at PFOA doses ≥ 0.01 mg/kg/day on PND 35 and ≥ 0.1 mg/kg/day on PND 21. In C57BL/6 mice, scores were significantly reduced at 0.3 and 1.0 mg/kg/day on PND 21. The authors suggest that these differences in responses between strains may be due to increased serum PFOA levels of the CD-1 mice (Tucker, 2015, 2851046). At 5 mg/kg/day, in mammary glands of C57BL/6 mice, there was a significant increase in the number of terminal end buds and stimulated terminal ducts; ductal length was not affected. Mammary gland development was inhibited in C57BL/6 mice dosed with 10 mg/kg/day, with no terminal end buds or stimulated terminal ducts present and very little ductal growth.

In a study of direct peripubertal exposure, Yang et al. (2009, 5085085) orally dosed 21-day-old female BALB/c or C57BL/6 mice with 0, 1, 5, or 10 mg/kg/day PFOA for 5 days/week for 4 weeks. Mammary glands of BALB/c mice treated with 5 or 10 mg/kg/day had reduced ductal length, decreased number of terminal end buds, and decreased stimulated terminal ducts; injection with bromo-2′-deoxyuridine, a marker of cell proliferation, into the mammary gland revealed a significantly lower number of proliferating cells in the ducts and terminal end buds/terminal ducts at 5 mg/kg/day (not examined at 10 mg/kg/day).

### 3.4.4.3 Mechanistic Evidence

Mechanistic evidence linking PFOA exposure to adverse developmental outcomes is discussed in Sections 3.2.6, 3.2.7, 3.3.4, 3.4.1, and 3.4.5 of the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}. There are 19 studies from recent systematic literature search and review efforts.
conducted after publication of the 2016 PFOA HESD that investigated the mechanisms of action of PFOA that lead to developmental effects. A summary of these studies is shown in Figure 3-70.

### Figure 3-70. Summary of Mechanistic Studies of PFOA and Developmental Effects

Interactive figure and additional study details available on Tableau.

Mechanistic data available from *in vitro, in vivo*, and epidemiological studies were evaluated to inform the mode of action of developmental effects of PFOA. Outcomes included early survival, general development, and gross morphology; fetal growth and placental effects; metabolism; hepatic development; cardiac development; and neurological development.

#### 3.4.4.3.1 Early Survival, General Development, Gross Morphology

Mechanisms through which PFOA exposure may alter survival and development were studied in several *in vivo* experimental animal models. In an *in vivo* mouse developmental study, pregnant NMRI dams exposed to PFOA from GD 5—9 via intraperitoneal (IP) injection showed increased fetal death in the offspring at the highest dose (20 mg/kg/day) of PFOA, as well as histopathological abnormalities in the brain, liver, and heart, possibly due to the observed mitochondrial toxicity/dysfunction (e.g., increased mitochondrial swelling, increased mitochondrial membrane potential (MMP) collapse) or oxidative stress (e.g., increased mitochondrial ROS formation) {Salimi, 2019, 5381528}. In another mouse developmental study examining lower doses in the dams, embryo survival was not affected at up to 10 mg/kg/day PFOA exposure in dams exposed from GD 1.5—11.5 or GD 1.5—17.5 via oral gavage {Blake, 2020, 6305864}. However, 5 and 10 mg/kg exposure via oral gavage from GD 1—17 decreased survival rate in 5-day old pups, possibly due to hepatotoxicity; the authors observed significantly
increased liver index in pups and increased reactive oxygen species and changes in liver enzyme function, mediated by the PPARα pathway {Li, 2019, 5387402}.

Several studies using zebrafish as a model organism that were identified in the current assessment were included in a recent review of developmental effects of PFOA {Lee, 2020, 6323794}. In general, PFOA exposure was associated with developmental delays, reductions in measures of embryo survival, and increased malformations in the head and tail that may be related to perturbations in gene expression during critical windows of organism development.

The review by Lee et al. (2020, 6323794) included a zebrafish multigenerational study by Jantzen et al. (2017, 3603831), in which embryos were exposed to PFOA from 3 to 120 hours post-fertilization (hpf). Embryos were allowed to reach adulthood and breed. Although exposure to PFOA did not decrease survival in the first exposed generation (P₀), there were significantly fewer eggs and viable embryos than the controls in the P₀. Further, F₁ embryos had significant developmental delays and delayed hatching. Gene expression analysis of four solute carrier organic anion transporter family members (slco1d1, slco2b1, slco3a1, and slco4a1) and the growth factor transforming growth factor beta 1a (tgfb1a) in the P₀ generation showed that PFOA exposure led to decreased expression in slco2b1, slco3a1, and slco4a1 and increased expression in slco1d1. In the F₁ embryos, there was a significant increase in expression of the protein transporter adaptor related protein complex 1 subunit sigma 1 (ap1s1). The authors concluded that alterations in the expression of these genes during development likely contributed to the delayed development and morphologic and toxic effects observed {Jantzen, 2017, 3603831}. The elevations in ap1s1 were in conflict with a prior publication from the same research group that reported decreased ap1s1 at 120 hpf, which coincided with alterations in morphometric parameters in zebrafish embryos, including increased interocular distance (a metric of cranio-facial development), reduced total body length, and reduced yolk sac area {Jantzen, 2016, 3860114}. Other alterations in gene expression at 120 hpf included elevations in slco2b1 (transport protein) and transcription factor 3a (tfc3a; involved in muscle development), and c-fos (transcription factor complex). Altogether, results suggest that alterations in ap1s1 are unlikely the result of a global upregulation or downregulation of genes and that PFOA may differentially influence genes at certain points in development. However, the current data cannot rule out the possibility that the observed alterations in gene expression are due to a delay or acceleration in development.

In another zebrafish study by Bouwmeester et al. (2016, 3378942), embryos that were exposed to 10–320 μM PFOA were examined for developmental toxicity and morphological effects. PFOA did not induce embryotoxic effects at the exposure levels in the experiment; however, some epigenome modifications were noted. When locus-specific methylation was assessed, PFOA exposure was associated with hypomethylation on the CpG region of vasa, and hypermethylation at CpG1 in vitellogenin 1 (vtg1). Vasa is expressed in the germline and is active during development, and vtg1 is expressed in the liver of egg-laying vertebrates and encodes for the estrogen responsive egg-yolk protein vitellogenin, although, interestingly, PFOA was included in this study to demonstrate a “non-estrogenic PPARy/RXR agonist.” These epigenetic modifications early in life and development may play a role in the development of later life adverse health outcomes {Bouwmeester, 2016, 3378942}.

In humans, epigenetic modification during development of the fetus can be measured via cord blood at birth. Several human studies evaluated cord-blood DNA methylation patterns to
understand the epigenetic effects of PFOA exposure. Miura et al. (2018, 5080353) found that increased PFOA in the cord blood was associated with global hypermethylation in a cohort from Japan; however, two other cord blood studies of global methylation found no associations between PFOA exposure and global methylation changes {Liu, 2018, 4926233; Leung, 2018, 4633577}. Similarly, Kingsley et al. (2017, 3981315) did not observe associations between PFOA exposure in cord blood and epigenome-wide changes in global methylation status. However, for the high PFOA exposure group, the authors found hypomethylation in seven CpG sites located in several genes, including RAS P21 protein Activator 3 (RASA3) and Opioid Receptor Delta 1 (OPRD1). RASA3 methylation changes could result in impaired cell growth and differentiation, contributing to reduced fetal growth and birth weight. OPRD1 is involved in weight and obesity, as well as morphine and heroin dependence, and could potentially be a mechanistic pathway linking PFOA and obesity, an association that has previously been reported {Kingsley, 2017, 3981315}. Cord blood samples from a prospective cohort in China were used by Liu et al. (2018, 4239494) to evaluate potential associations between PFOA exposure and leukocyte telomere lengths (LTLs). There was no association between PFOA exposure and LTLs in this study.

### 3.4.4.3.2 Fetal Growth and Placental Effects

Growth was assessed in four mouse developmental studies. Blake et al. (2020, 6305864) found decreased embryonic weights in CD-1 mice at GD 17.5, with concurrent increases in placental weights and placental lesions consistent with labyrinth congestion (Section 3.4.4.2.4.1). Placentas also had higher thyroxine (T4) levels relative to controls, suggesting a possible endocrine mechanistic pathway of effect. In NMRI mice exposed to 0, 1, 10, or 20 mg/kg/day PFOA from GD 5—9, Salimi et al. (2019, 5381528) observed reduced fetal length and weight, and decreased placental diameter at the highest dose group (20 mg/kg/day). The authors note that toxicity was likely mediated through mitochondrial toxicity in the liver (described below), which appeared to be isolated to the mouse fetus rather than the placenta. Li et al. (2019, 5387402) reported a dose-dependent reduction in growth and weight gain in Kunming mouse pups exposed to PFOA during gestation (GD 0—17). The authors attribute the stunted growth to hepatotoxicity consequent to increased ROS and changes in liver enzyme function mediated by the PPARα pathway {Li, 2019, 5387402}.

Perturbations in growth and corresponding changes in gene expression of key developmental genes have been observed in several studies in zebrafish. In the multigenerational zebrafish study by Jantzen et al. (2017, 3603831), P0 generation fish exposed to PFOA had significantly shorter body length and reduced body weight compared to controls. Offspring of PFOA exposed fish were significantly developmentally delayed and had increased expression in the protein transport gene ap1s1 at 48 hpf, possibly leading to the changes in growth {Jantzen, 2017, 3603831}. In Jantzen et al. (2016, 3860114), several morphometric endpoints were measured in zebrafish embryos exposed to 0.02, 0.2, or 2.0 μM PFOA, including interocular distance, total body length, and yolk sac area. The size of all three parameters was reduced in groups exposed to PFOA, indicating slowed embryonic development at values 5- to 25-fold below previously calculated median lethal concentration (LC50) values. The authors also evaluated gene expression at 120 hpf and 14 days post-fertilization (dpf). At 120 hpf, slco2b1 (transport protein), tcf3a (involved in muscle development), and c-fos (transcription factor complex) were upregulated, while ap1s (involved in protein transport) was downregulated. At 14 dpf, slco2b1 and Tcf3a (involved in muscle development) were upregulated {Jantzen, 2016, 3860114}. 

3-249
Gorrochategui et al. (2014, 2324895) evaluated cytotoxicity and aromatase activity in a placental cell line (JEG-3 cells). PFOA exposure was found to induce cytotoxicity and inhibit aromatase (CYP19) activity {Gorrochategui, 2014, 2324895}. In a rhesus monkey trophoblast cell line, PFOA treatment showed significant differences in gene expression, with possible affected diseases/biological functions including cell movement, epithelial tissue growth, and vasculogenesis. Pathways included cysteine metabolism, interleukin signaling, Toll-like receptor, TGF-β, PDGF, PPAR, NFKB, MAPK, Endothelin 1, TNRF2, tight junctions, cytokines including IFNY and IFNa, and possible FOS signaling {Midic, 2018, 4241048}.

Lastly, a longitudinal study by Ouidir et al. (2020, 6833759) examined global methylation in the placenta at birth in women for whom PFOA levels in the plasma were determined in the first trimester. The authors did not find any associations between PFOA exposure and DNA methylation status of the placenta {Ouidir, 2020, 6833759}.

### 3.4.4.3.3 Metabolism

van Esterik et al. (2015, 2850288) examined metabolic effects of developmental exposure to 3–3000 µg/kg PFOA exposure in C57BL/6JxFVB hybrid mice. The authors found that PFOA exposure during gestation and lactation resulted in reduction in weight that persisted to adulthood. The weight loss was attenuated by a high-fat diet (from 21—25 days) in males, but not females, suggesting that the weight reductions were mediated through metabolic mechanisms that may exhibit a female bias. There were no significant changes in metabolic parameters (i.e., glucose homeostasis, basal glucose, energy expenditure, uncoupling protein 1 (ucp1; also known as thermogenin) expression in brown adipose tissue) in either sex. However, in females, cholesterol and triglycerides showed a dose-dependent decrease. The authors suggest that these changes in lipid metabolism could be mediated by PPARα activation {van Esterik, 2015, 2850288}. Li et al. (2019, 5387402) examined PPARα activation pathways as a mechanism of PFOA-induced liver and metabolic toxicity during development in mice. The authors found that female mice exposed gestationally to PFOA had significantly downregulated gene expression of PPARα in the 2.5 and 5 mg/kg/day groups, but not the highest dose group (i.e., 10 mg/kg/day). PFOA exposure also increased gene expressions of Acot1 and Acox1 (downstream regulatory genes of PPARα), indicating that early PFOA exposure causes lasting changes in the PPARα pathway. PPARα regulates fatty acid oxidative metabolism and energy consumption, through peroxisome and mitochondrial β-oxidation and microsome ω-oxidation {Li, 2019, 5387402}. PFOA has been described as a weak PPARα ligand, but the role of PPARα in mediating the developmental toxicity associated with PFOA exposure is not yet clear {Peraza, 2006, 509877}.

Metabolomic profiles in relation to PFOA exposure were analyzed in a human study. In a cross-sectional study in 8-year-old children in Cincinnati, OH, the authors conducted untargeted, high-resolution metabolomic profiling in relation to serum PFOA concentrations. They found that PFOA exposure was associated with several lipid and amino acid metabolism pathways, including that of arginine, proline, aspartate, asparagine, and butanoate {Kingsley, 2019, 5405904}.

### 3.4.4.3.4 Hepatic Development

Three developmental mouse studies examined the effect of PFOA on liver development and function. van Esterik et al. (2015, 2850288) found that developmental exposure to PFOA resulted in increased liver weights and abnormal liver histopathology, with toxicity possibly
mediated through the PPARα pathway. Salimi et al. (2019, 5381528) exposed pregnant mice to PFOA from GD 5—9 and observed mitochondrial disruption in the fetal liver, including mitochondrial swelling and mitochondrial membrane potential collapse. These effects significantly increased at the highest (20 mg/kg/day) exposure group. Measures of oxidative stress (hydrogen peroxide production) in the liver were also significantly higher in groups exposed to 10 or 20 mg/kg/day PFOA in comparison to control animals. Li et al. (2019, 5387402) hypothesized that PFOA accumulation in pup liver may promote oxidative stress via PPARα activation pathways that contribute to liver and metabolic toxicity in mice. The authors found that female mice exposed gestationally to PFOA had increased liver weight and dose-responsive morphological changes in the liver including swollen hepatocytes, blurred architecture, and vacuolar degeneration. Liver enzymes (AST and ALT) were increased in the serum, and oxidative stress biomarkers (Catalase (CAT), Superoxide dismutase (SOD), and 8-OHdG) were increased. Liver histone acetyltransferase (HAT) activity was reduced, and histone deacetylase (HDAC) activity was increased. Further, histone acetylation in the liver was reduced. These effects suggest that PFOA can alter the epigenetic regulation of liver responses which may contribute to adverse hepatic health outcomes (Section 3.4.1).

### 3.4.4.3.5 Cardiac Development

Data from one study in mice, one study in zebrafish, and one in vitro study provide insight into the mechanism by which PFOA perturbs cardiac development. In a recent review that covered PFOA toxicity in zebrafish, Lee et al. (2020, 6323794) reported that PFOA exposure has been consistently associated with increases in pericardial edema and altered heart rates at various stages of development in embryos. An in vivo mouse developmental study by Salimi et al. (2019, 5381528) also found that PFOA exposure was associated with cardiotoxicity in offspring. In this study, pregnant dams were treated with PFOA, and fetuses were studied for tissue abnormalities. Groups treated with PFOA showed increased histopathological abnormalities in the fetal heart, including hepatomegaly. Mitochondrial swelling in mitochondrial suspension of fetal heart tissue was also observed along with increased mitochondrial membrane potential collapse. Measures of oxidative stress in the fetal heart were also significantly higher in exposed vs. control animals {Salimi, 2019, 5381528}. An in vitro experiment by Zhou et al. (2017, 3981356) examined the ability of mouse embryonic stem cells to differentiate into myocardiocytes following exposure to 2.5, 5, 10, 20, 40, 80, or 160 μg/mL PFOA. Differentiation was determined by the contractility (i.e., contract rate) of the cells, as well as the upregulation of myh6, which is a regulatory gene that is essential for cardiac muscle development. No effects on differentiation or myh6 expression were observed below 20 μg/mL.

### 3.4.4.3.6 Neurological Development

Salimi et al. (2019, 5381528) also reported teratogenic effects in the brain of fetal mice following maternal exposures up to 20 mg/kg/day PFOA via IP injection from GD 5—9. The histopathological abnormalities in the brain included anencephaly, microcephaly, and hydrocephaly, all at the highest (20 mg/kg/day) exposure. Mitochondrial swelling in mitochondrial suspension of fetal brain tissue was also observed along with increased mitochondrial membrane potential collapse. Higher mitochondrial disruption was observed at lower concentrations in the brain tissue than other fetal tissues (i.e., heart and liver), suggesting that the brain was more susceptible to mitochondrial toxicity/dysfunction. Measures of oxidative stress in the brain were also significantly higher in exposed animals in comparison to controls.
The effects of PFOA on neurodevelopment and behavior in zebrafish were examined in two studies. In the aforementioned zebrafish embryo assay by Jantzen et al. (2016, 3860114), embryonic exposure to 0.02, 0.2, or 2.0 micromolar (µM) PFOA during the first five dpf resulted in hyperactive locomotor activity in larvae as evidenced by increased swimming velocity, possibly mediated through altered expression of development-associated genes (c-fos, tfc3a, slco2b1, and ap1s). Stengel et al. (2018, 4238489) developed a neurodevelopmental toxicity test battery using zebrafish embryos. PFOA did not produce any changes in acetylcholinesterase (AChE) inhibition, nor the neuromast assay, olfactory, or retinal toxicity assays {Stengel, 2018, 4238489}.

### 3.4.3.7 Conclusion

In the context of the available mechanistic studies, it appears that several mechanisms may be involved in PFOA-driven developmental toxicity. In general, the observed effects suggest that the developing liver, developing heart, and placenta may be affected by PFOA at the molecular level (e.g., differential methylation of genes, gene expression changes), which may be reflected in developmental health effects described in Section 3.4.4. The effects tend to vary by sex and developmental timepoint of outcome evaluation. More research is needed to strengthen the association between PFOA exposure to any one of the several possible contributing factors, including fluctuations in transporter gene expression, epigenetic changes, oxidative stress, and PPARα pathway activation, particularly in the placenta.

### 3.4.4.4 Evidence Integration

The evidence of an association between PFOA and developmental effects in humans is moderate based on the recent epidemiological literature. As noted in the fetal growth restriction summary, there is evidence that PFOA may impact fetal growth restriction across a variety of BWT-related measures. Comparing the postnatal growth results in infants with birth-related measures is challenging due to complex growth dynamics including rapid growth catch-up periods for those with fetal restriction. Nonetheless, the evidence for postnatal weight deficits was comparable to that seen for BWT. Collectively, the majority of LBW studies were supportive of an increased risk with increasing PFOA exposures. Five medium or high confidence studies on LBW showed increased risks with increased PFOA levels. Several meta-analyses also support evidence of associations between maternal or cord blood serum PFOA and BWT or BWT-related measures {Johnson, 2014, 2851237; Verner, 2015, 3150627; Negri, 2017, 3981320; Steenland, 2018, 5079861} (Table A-41, PFOA Appendix A).

Overall, there was mixed evidence of adverse associations between PFOA and both gestational age (7 of the 18 studies) and preterm birth (6 of 11 studies). Most of the associations for either of these gestational duration measures were reported in medium or high confidence studies. For example, five of six studies were increased odds of PTB were high confidence. Few other patterns were evident that explained any between study heterogeneity. For example, five of the null studies were rated as having adequate sensitivity, and one was rated deficient. There was a preponderance of associations related to sample timing possibly related to pregnancy hemodynamic influences on the PFOA biomarkers, as five of the seven studies reporting adverse associations were sampled later in pregnancy (i.e., trimester two onward).

There was less consistent evidence of PFOA impacts on rapid growth measures, postnatal height and postnatal adiposity measures up to age 2. There was less evidence available for other
endpoints such as fetal loss and no evidence of associations in recent studies of PFOA and birth defects such as cryptorchidism or hypospadias. Similarly, there was less consistent evidence of an impact of PFOA exposure on gestational duration measures (i.e., either preterm birth or gestational age measures) as many of studies did not show adverse associations.

However, as noted previously there is some uncertainty as to what degree the evidence may be impacted by pregnancy hemodynamics and sample timing differences across studies as this may result in either confounding or reverse causality (Steenland, 2018, 5079861). Additional uncertainty exists due to the potential for confounding by other PFAS. Very few of the existing studies performed multipollutant modeling in comparison with single pollutant estimates of PFOA associations. The multipollutant modeling results were often mixed from single pollutant estimates with some estimates increasing and some decreasing. Unlike other PFAS, PFOA was chosen amongst dimension-reducing statistical approaches from models with various PFAS and or other environmental contaminants adjusted for two different studies (Lenters, 2016, 5617416; Starling, 2017, 3858473). Although these results are smaller in magnitude, they appear coherent with single exposure model results. There is some concern that controlling for other highly correlated co-exposures in the same model may amplify the potential confounding bias of another co-exposure rather than removing it (Weisskopf, 2018, 7325521). Given these interpretation difficulties and potential for this co-exposure amplification bias, it remains unclear whether certain mutually adjusted models give a more accurate representation of the independent effect of specific pollutants for complex PFAS mixture scenarios.

The animal evidence of an association between PFOA and developmental toxicity is robust based on 13 high or medium confidence animal toxicological studies, in concordance with the data in humans, supporting that the developing fetus is a target of PFOA toxicity. Specifically, several studies in rodents show decreased fetal and pup weight with gestational PFOA exposure, similar to the evidence of LBW seen in infants. Oral studies in rodents consistently show that gestational PFOA exposure results in pre- and postnatal effects on offspring, as well as maternal effects in dams. Notably, mice appear to be more sensitive to developmental toxicity as a result of gestational exposure compared to rats. In addition, studies in both rats and mice show that effects on offspring (e.g., decreases in body weight, survival) occur at lower dose levels than those that produce maternal body weight effects.

Evidence from mechanistic studies that relates to observed developmental effects of PFOA is limited. Decreased survival in the offspring of pregnant mice exposed to PFOA was potentially related to hepatotoxicity induced by PPARα activation, as discussed in detail in Section 3.4.1.3. In human cord blood samples, evidence of epigenetic alterations within genes that are involved in cell growth and differentiation and obesity was observed; however, these epigenetic alterations were not evaluated in the context of postnatal outcomes and are inconsistent; two other studies found no association between PFOA exposure and changes to the epigenome. In zebrafish studies, the expression of several genes that are related to growth and development (e.g., tfc3a, which is involved in muscle development) was altered by PFOA exposure, with variable magnitude and, in some cases, the direction of change according to the timepoint measured. Oxidative stress was observed in the developing brain and heart of mice exposed to PFOA in utero, suggesting toxicity of PFOA during development. Overall, the data demonstrate that PFOA may alter the expression of genes involved in growth and development, although additional studies in mammals are needed to confirm such. Additionally, evidence exists that
PFOA can alter the epigenome, although the functional effects of the epigenetic effects are not clear.

### 3.4.4.4.1 Evidence Integration Judgment

Overall, considering the available evidence from human, animal, and mechanistic studies, the evidence indicates that PFOA exposure is likely to cause developmental toxicity in humans under relevant exposure circumstances (Table 3-10). This conclusion is based primarily on evidence of decreased birth weight from epidemiologic studies in which PFOA was measured during pregnancy, primarily with median PFOA ranging from 1.1 to 5.2 ng/mL. The conclusion is supported by coherent epidemiological evidence for biologically related effects (e.g., decreased postnatal growth, birth length), as well as consistent findings of dose-dependent decreases in fetal weight and other developmental effects observed in animal models gestationally exposed to PFOA at doses as low as 0.5 mg/kg/day. Although there is available mechanistic information that provides support for the biological plausibility of the phenotypic effects observed in exposed animals, the data are too limited to sufficiently support the human relevance of the animal findings.
Table 3-10. Evidence Profile Table for PFOA Developmental Effects

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Summary and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal growth restriction</td>
<td>Some deficits in mean birth weight were observed in most studies (21/32) in the overall population, but evidence for the exposure-response relationship was limited. The majority of studies on changes in standardized birth weight measures reported inverse associations (9/15), with most (6/9) of these being high and medium confidence. Similarly, most studies (9/12) observed either an increased risk of low birth weight or SGA. Deficits in birth weight were supported by adverse findings for related FGR outcomes such as birth length (9/26) and head circumference (10/21) in the overall population or across sexes.</td>
<td>High and medium confidence studies</td>
<td>Limited evidence of exposure-response relationships based on categorical data</td>
<td>Moderate</td>
</tr>
<tr>
<td>22 High confidence studies</td>
<td>Evidence from Studies of Exposed Humans (Section 3.4.4.1)</td>
<td>Consistent direction of effects for most outcomes</td>
<td>Potential bias due to hemodynamic differences noted in studies using samples from later pregnancy</td>
<td>Evidence Indicates (likely)</td>
</tr>
<tr>
<td>14 Medium confidence studies</td>
<td></td>
<td>Coherence of findings between different measures of FGR</td>
<td></td>
<td>Epidemiological evidence for developmental effects is based on consistent adverse effects for FGR. Consistent deficits in birth weight and standardized birth weight were observed in many high and medium confidence cohort studies. Birth weight findings were supported by adverse results reported for other measures of FGR, including birth length and head circumference, and adverse effects on gestational duration. Some uncertainties remain regarding the shape of the exposure-response relationship, and the potential impact</td>
</tr>
<tr>
<td>10 Low confidence studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Primary basis and cross-stream coherence: Evidence consisted of decreased birth weight from epidemiologic studies in which PFOA was measured during pregnancy. This is supported by coherent epidemiological evidence for biologically related effects (e.g., decreased postnatal growth, birth length) and consistent findings of dose-dependent decreases in fetal weight observed in animal models gestationally exposed to PFOA.

Human relevance and other inferences: Although there is available mechanistic information that provides support for the biological plausibility of the phenotypic effects observed in exposed animals, the data are too limited to sufficiently...
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Evidence Category</th>
<th>Studies</th>
<th>High Confidence</th>
<th>Medium Confidence</th>
<th>Low Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gestational duration</strong></td>
<td>11</td>
<td>1</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Adverse effects on gestational age were observed (7/18), with most (6/7) considered high or medium confidence. Increased risk of preterm birth was also observed in some studies (5/11).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• High and medium confidence studies</td>
<td>• Potential bias due to hemodynamic difference noted in studies using samples from later pregnancy of hemodynamics in later pregnancy due to use of biomonitoring samples from the second and third trimester or post-partum.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fetal Loss</strong></td>
<td>2</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Increased risk of fetal loss was reported in one high (1/2) and one medium (1/2) confidence study. The response in the high confidence study was monotonic across exposure quartiles. One study reported a decreased risk of fetal loss, but the study was considered low confidence.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• High and medium confidence studies</td>
<td>• No factors noted</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Post-natal growth</strong></td>
<td>6</td>
<td>4</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Increased risk of adverse weight changes in infancy was observed in most studies (7/9) examining the outcome. Decreases in infant height were observed in a few studies (3/7). Only one study (1/7) reported increased adiposity, which was in male infants only.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• High and medium confidence studies</td>
<td>• Inconsistent timing of follow-up evaluation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Birth Defects</strong></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Two low confidence studies reported mixed results for total or</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• No factors noted</td>
<td>• Low confidence studies</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Evidence Stream Summary and Interpretation</th>
<th>Evidence Integration Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Low confidence studies combined birth defects. No association with cryptorchidism was reported in one study; one study reported decreased odds of septal defects, conotruncal defects, and total congenital heart defects.</td>
<td>⊕⊕⊕ Robust Evidence based on 13 high or medium confidence animal toxicological studies indicates that the developing fetus is a target of PFOA toxicity. Several studies in rodents show decreased fetal and pup weight with gestational PFOA exposure, similar to the evidence of FGR seen in human infants. Oral studies in rodents consistently show that gestational PFOA exposure results in pre- and postnatal effects on offspring, as well as</td>
</tr>
</tbody>
</table>

### Evidence from In Vivo Animal Toxicological Studies (Section 3.4.4.2)

<table>
<thead>
<tr>
<th>Studies and Interpretation</th>
<th>Summary and Key Findings</th>
<th>Factors that Increase Certainty</th>
<th>Factors that Decrease Certainty</th>
<th>Evidence Stream Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal body weight</td>
<td>Many rodent studies observed a change in maternal body weight or weight gain following PFOA exposure (5/8). The direction of this change was not consistent among studies, with some rodent studies observing a decrease in weight (3/5), and some mouse studies observing an increase (2/5).</td>
<td>• High and medium confidence studies</td>
<td>• Inconsistent direction of effects</td>
<td>⊕⊕⊕ Robust Evidence based on 13 high or medium confidence animal toxicological studies indicates that the developing fetus is a target of PFOA toxicity. Several studies in rodents show decreased fetal and pup weight with gestational PFOA exposure, similar to the evidence of FGR seen in human infants. Oral studies in rodents consistently show that gestational PFOA exposure results in pre- and postnatal effects on offspring, as well as</td>
</tr>
<tr>
<td>Offspring body weight</td>
<td>Many rodent studies observed changes in fetal or pup body weight following PFOA exposure (9/11). Most of these show a decrease in offspring weight (8/9). One study observed an increase in offspring</td>
<td>• High and medium confidence studies</td>
<td>• No factors noted</td>
<td></td>
</tr>
</tbody>
</table>

- • Low confidence studies
- ⊕⊕⊕ Robust
### Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Offspring mortality</th>
<th>Evidence Integration Summary Judgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>body weight, but only in male mice. Two mouse studies showed no change in offspring body weight (2/11). Many rodent studies observed increases in offspring mortality following PFOA exposure (6/9). A rat study observed increased post-weaning mortality in female pups but no pre-weaning mortality or change in stillborn pups. Five mouse studies found increased offspring mortality including increased resorption (4/4), decreased live fetuses or live pups born (2/4), and decreased postnatal survival (2/3). Two studies found no change in offspring mortality or survival (2/8). No change in litter size was observed in any rat or mouse study (3/3).</td>
<td>maternal effects in dams. Notably, mice appear to be more sensitive to developmental toxicity as a result of gestational exposure compared to rats. In addition, studies in both rats and mice show that effects on offspring (e.g., decreases in body weight, survival) occur at lower dose levels than those that produced maternal body weight effects.</td>
</tr>
</tbody>
</table>

**Offspring mortality**
- 2 *High* confidence studies
- 7 *Medium* confidence studies

- **Maternal effects in dams.** Notably, mice appear to be more sensitive to developmental toxicity as a result of gestational exposure compared to rats. In addition, studies in both rats and mice show that effects on offspring (e.g., decreases in body weight, survival) occur at lower dose levels than those that produced maternal body weight effects.

### Placenta effects
- 2 *Medium* confidence studies

- **Maternal effects in dams.** Notably, mice appear to be more sensitive to developmental toxicity as a result of gestational exposure compared to rats. In addition, studies in both rats and mice show that effects on offspring (e.g., decreases in body weight, survival) occur at lower dose levels than those that produced maternal body weight effects.

- **Medium confidence studies**
- **Limited number of studies examining outcomes**

- **No factors noted**
- **Consistent direction of effects**

- **High and medium confidence studies**
## Evidence Stream Summary and Interpretation

<table>
<thead>
<tr>
<th>Evidence Stream</th>
<th>Summary and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>histopathological changes were observed including changes to the labyrinth (e.g., atrophy, decreased area, congestion, necrosis) and early fibrin clot. Fewer placentas were determined to be within normal limits (1/1).</td>
<td></td>
</tr>
<tr>
<td><strong>Offspring liver weight</strong></td>
<td>Increases in offspring relative liver weight were noted in two mouse studies following gestational PFOA exposure (2/2).</td>
</tr>
<tr>
<td>2 Medium confidence studies</td>
<td></td>
</tr>
<tr>
<td><strong>Developmental timing</strong></td>
<td>Delayed eye opening (2/2) and delayed body hair development (1/1) was observed in both sexes of mice.</td>
</tr>
<tr>
<td>2 Medium confidence studies</td>
<td></td>
</tr>
<tr>
<td><strong>Structural abnormalities</strong></td>
<td>One mouse study found structural abnormalities (e.g., reduced skeletal ossification) after developmental exposure to PFOA.</td>
</tr>
<tr>
<td>1 Medium confidence study</td>
<td></td>
</tr>
<tr>
<td><strong>Mammary gland development</strong></td>
<td>One mouse study found abnormal mammary gland development in animals exposed to PFOA during gestation (e.g., decreases in terminal end buds, mammary gland developmental score).</td>
</tr>
<tr>
<td>1 Medium confidence study</td>
<td></td>
</tr>
<tr>
<td>• Medium confidence studies</td>
<td>• Limited number of studies examining outcomes</td>
</tr>
<tr>
<td>• Limited number of studies examining outcomes</td>
<td></td>
</tr>
</tbody>
</table>
**Evidence Stream Summary and Interpretation**

<table>
<thead>
<tr>
<th>Lactation index</th>
<th>Of the two rat studies that evaluated lactation index, one noted a decrease following PFOA (1/2).</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 High confidence studies</td>
<td>• High confidence studies</td>
</tr>
</tbody>
</table>

**Mechanistic Evidence and Supplemental Information (Section 3.4.4.3)**

**Summary of Key Findings, Interpretation, and Limitations**

**Key findings and interpretation:**

- Decreased survival in mice offspring exposed to PFOA in utero related to PPARα-related hepatotoxicity.
- Alterations to the expression of genes related to growth and development in vivo in zebrafish.
- Inconsistent results for PFOA-related alterations to DNA methylation in human cord blood.

**Limitations:**

- Very limited database.
- The role of epigenetic mechanisms in changes at the mRNA level is not clear, nor is the relationship between molecular changes and apical developmental outcomes.

The limited evidence demonstrates that PFOA exposure during development can alter the epigenome and the expression of genes that control regular growth and development; it is possible that such changes are related, although the relationship has not been directly measured.

**Notes:** DNA = deoxyribonucleic acid; FGR = fetal growth restriction; mRNA = messenger ribonucleic acid; PPARα = peroxisome proliferator-activated receptor alpha; SGA = small-for-gestation-age.
3.4.5 Evidence for Other Health Outcomes

Consistent with the SAB’s recommendation, EPA concluded that the non-cancer health outcomes with the strongest evidence are hepatic, immune, cardiovascular, and developmental. For all other health outcomes (e.g., reproductive and endocrine), EPA concluded that the epidemiological and animal toxicological evidence available at this time and from the preliminary scoping considered in the Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) (CASRN 335-67-1) in Drinking Water is either suggestive of associations or inadequate to determine associations between PFOA and the health effects described. Based on this analysis, these outcomes were not prioritized for the MCLG assessment. The evidence synthesis and integration for these outcomes are presented in the PFOA appendix. In addition, Section 6.5 further describes rationale for evidence integration judgments for health outcomes which EPA determined had evidence suggestive of associations between PFOA and related adverse health effects, though the databases for those health outcomes shared some characteristics with the evidence indicates judgment.

3.5 Cancer Evidence Study Quality Evaluation, Synthesis, Mode of Action Analysis and Weight of Evidence

EPA identified 16 epidemiological and 4 animal toxicological studies that investigated the association between PFOA and cancer. Of the epidemiological studies, 8 were classified as medium confidence, 7 as low confidence, and 1 was considered uninformative (Section 3.5.1). Of the animal toxicological studies, 2 were classified as high confidence, 1 as medium confidence, and 1 as low confidence (section 3.5.2). Though low confidence studies are considered qualitatively in this section, they were not considered quantitatively for the dose-response assessment (Section 4).

3.5.1 Human Evidence Study Quality Evaluation and Synthesis

3.5.1.1 Introduction

There are 9 epidemiological studies from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA and cancer effects. Study quality evaluations for these 9 studies are shown in Figure 3-71.

The 2016 HESD for PFOA {U.S. EPA, 2016, 3603279} concluded there was suggestive evidence of carcinogenic effects of PFOA for kidney and testicular cancer, based on two C8 Health Project studies and 2 occupational cohorts (Figure 3-71). Specifically, two studies involving participants in the C8 Health Project showed a positive association between PFOA levels (mean at enrollment 24 ng/mL) and kidney and testicular cancers {Barry, 2013, 2850946; Vieira, 2013, 2919154}. There is some overlap in the cases included in these studies. As part of the C8 Health Project, the C8 Science Panel {C8 Science Panel, 2012, 1430770} concluded that a probable link existed between PFOA exposure and testicular and kidney cancer. Two occupational cohorts in Minnesota and West Virginia {Raleigh, 2014, 2850270; Steenland, 2012, 2919168} also examined cancer mortality. Raleigh et al. (2014, 2850270) reported no evidence of elevated risk for kidney cancer. In the West Virginia occupational cohort, Steenland and
Woskie (2012, 2919168) observed significantly elevated risk of kidney cancer deaths in the highest quartile of modeled PFOA exposure (> 2,384 ng/mL-years). However, each of these studies is limited by a small number of observed cases (six kidney cancer deaths, sixteen incident kidney cancer cases, and five incidence testicular cancer cases in Raleigh et al. (2014, 2850270); twelve kidney cancer deaths and one testicular cancer death in Steenland and Woskie (2012, 2919168)). None of the general population studies reviewed for the 2016 PFOA Health Advisory examined kidney or testicular cancer, and no associations were observed in the general population between exposure to PFOA (mean serum PFOA levels up to 86.6 ng/mL) and colorectal, breast, prostate, bladder, or liver cancer (Bonefeld-Jørgensen, 2014, 2851186; Eriksen, 2009, 2919344; Hardell, 2014, 2968084; Innes, 2014, 2850898). In the C8 Health Project cohort, Barry et al. (2013, 2850946) observed a significant inverse association with breast cancer for both unlagged and 10-year lagged estimated cumulative PFOA serum concentrations. Barry et al. (2013, 2850946) also observed positive and significant associations between PFOA and thyroid cancer in DuPont workers at the Washington, West Virginia plant, but not in community residents. However, Vieira et al. (2013, 2919154) found no association between estimated serum concentrations of PFOA with thyroid cancer risk among residents living near the DuPont Teflon-manufacturing plant in Parkersburg, West Virginia.
Figure 3-71. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cancer Effects Published Before 2016 (References from 2016 PFOA HESD)

Interactive figure and additional study details available on HAWC.

Since publication of the 2016 HESD (U.S. EPA, 2016, 3603279), 17 epidemiological studies have been published that investigated the association between PFOA and cancer (see PFOA Appendix). Two of the publications (Girardi, 2019, 6315730; Steenland, 2015, 2851015) were occupational studies and the remainder were conducted on the general population, with one in a high-exposure community (C8 Health Project). Different study designs were also used including four cohort studies (Fry, 2017, 4181820; Girardi, 2019, 6315730; Steenland, 2015, 2851015; Li, 2022, 9961926), five case-control studies (Wielsoe, 2017, 3858479; Tsai, 2020, 6833693; Lin, 2020, 6835434; Itoh, 2021, 9959632; Liu, 2021, 10176563), five nested case-control studies (Mancini, 2020, 5381529; Ghisari, 2017, 3860243; Shearer, 2021, 7161466; Hurley, 2018, 5080646; Cohn, 2020, 5412451), and three cross-sectional studies (Christensen, 2016, 3858533; Ducatman, 2015, 3859843; Omoike, 2021, 7021502). The studies were conducted in different
study populations including populations from China {Lin, 2020, 6835434; Liu, 2021, 10176563}, Denmark {Ghisari, 2017, 3860243}, France {Mancini, 2020, 5381529}, Greenland {Wielsøe, 2017, 3858479}, Italy {Girardi, 2019, 6315730}, Japan {Itoh, 2021, 9959632}, Sweden {Li, 2022, 9961926}, Taiwan {Tsai, 2020, 6833693}, and the United States {Fry, 2017, 4181820; Christensen, 2016, 3858533; Ducatman, 2015, 3859843; Steenland, 2015, 2851015; Shearer, 2021, 7161466; Hurley, 2018, 5080646; Cohn, 2020, 5412451; Omoike, 2021, 7021502}. All studies measured PFOA in study subjects’ blood components (i.e., serum or plasma) with two exceptions: one study measured PFOA in the maternal serum {Cohn, 2020, 5412451} and one study categorized exposure to any PFAS based on residence near highly contaminated sources of drinking water {Li, 2022, 9961926}. Cancers evaluated included bladder {Steenland, 2015, 2851015; Li, 2022, 9961926}, breast {Cohn, 2020, 5412451; Ghisari, 2017, 3860243; Hurley, 2018, 5080646; Itoh, 2021, 9959632; Li, 2022, 9961926; Mancini, 2020, 5381529; Omoike, 2021, 7021502; Tsai, 2020, 6833693; Wielsøe, 2017, 3858479}, colorectal {Steenland, 2015, 2851015; Li, 2022, 9961926}, germ cell tumors {Lin, 2020, 6835434}, kidney {Shearer, 2021, 7161466; Li, 2022, 9961926}, liver {Girardi, 2019, 6315730; Li, 2022, 9961926}, lung {Girardi, 2019, 6315730; Li, 2022, 9961926}, lymphatic or hematopoietic tissue {Girardi, 2019, 6315730; Li, 2022, 9961926}, melanoma {Steenland, 2015, 2851015; Li, 2022, 9961926}, ovarian {Omoike, 2021, 7021502}, prostate {Steenland, 2015, 2851015; Ducatman, 2015, 3859843; Omoike, 2021, 7021502}, thyroid {Liu, 2021, 10176563} uterine {Omoike, 2021, 7021502}, and any cancer {Christensen, 2016, 3858533; Fry, 2017, 4181820; Girardi, 2019, 6315730; Li, 2022, 9961926}.

3.5.1.2 Study Quality

There are 16 studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} that investigated the association between PFOA and cancer effects. Study quality evaluations for these 16 studies are shown in Figure 3-72. Of the 16 studies identified since the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}, seven were considered medium confidence, and seven were low confidence {Christensen, 2016, 3858533; Girardi, 2019, 6315730; Itoh, 2021, 9959632; Lin, 2020, 6835434; Liu, 2021, 10176563; Omoike, 2021, 7021502; Steenland, 2015, 2851015; Tsai, 2020, 6833693}. One study conducted in the high exposure to PFAS Ronneby Register Cohort in Sweden was uninformative {Li, 2022, 9961926} because of concerns about exposure assessment and lack of data on important covariates. One study conducted in Greenland was uninformative {Wielsøe, 2017, 3858479} because of concerns about selection bias and exposure assessment. As a result, these two studies will not be further considered in this review. Concerns with the low confidence studies included the possibility of outcome misclassification, confounding, or participation selection methods. Residual confounding was also a concern, including lack of considering co-exposures by other PFAS, and lack of appropriately addressing SES and other lifestyle factors, which could be associated with both exposure and cancer diagnosis. The two low confidence occupational studies {Girardi, 2019, 6315730; Steenland, 2015, 2851015} had several potential sources of bias including potential selection bias, outcome measurement limitations which may lead to survival bias, and poor/insufficient study sensitivity due to a small number of deaths. Girardi et al. (2019, 6315730) had the potential for residual confounding because of use of standardized mortality ratios (SMRs), which only account for gender, age, and calendar year.
Confounders specific for cancer outcomes, besides age and gender, including factors such as smoking or socioeconomic factors were not addressed in the study and behavioral risk factors could have differed by outcome. Although PFOA has a long half-life in the blood, concurrent measurements may not be appropriate for cancers with long latencies. Temporality of exposure in terms of cancer development was noted to be an issue in several low confidence studies {Tsai, 2020, 6833693; Itoh, 2021, 9959632; Liu, 2021, 10176563; Omoike, 2021, 7021502}. Many of the low confidence studies also had sensitivity issues due to limited sample sizes.

Figure 3-72. Summary of Study Quality Evaluation Results for Epidemiology Studies of PFOA and Cancer Effects

Interactive figure and additional study details available on [HAWC](https://www.hawcproject.org).

### 3.5.1.3 Findings from Children

One low confidence study examined cancers in children {Lin 2020, 6835434} and reported a statistically significant higher median PFOA concentration in 42 pediatric germ cell tumor cases.
compared to 42 controls in blood samples collected from the children one week after diagnosis. However, the study did not observe an increase in cancer risk when evaluated on a per ng/mL increase in blood PFOA.

3.5.1.4 Findings from the General Adult Population

PFOA was associated with an increased risk of kidney cancer (i.e., renal cell carcinoma (RCC)) [Shearer, 2021, 7161466]. This large medium confidence case-control study nested within the National Cancer Institute’s (NCI) Prostate, Lung, Colorectal, and Ovarian Screening Trial (PLCO) reported a statistically significant increase in risk of RCC with pre-diagnostic serum levels of PFOA (OR = 2.63; 95% CI: 1.33, 5.20 for the highest vs. lowest quartiles; p-trend = 0.007, or per doubling of PFOA: OR: 1.71; 95% CI: 1.23, 2.37) [Shearer, 2021, 7161466]. Even after adjusting for other PFAS the association remained significant in analyses on a per doubling increase in PFOA. The increase in odds remained across the quartiles and the magnitude was similar (i.e., OR = 2.63 without adjusting for other PFAS vs. 2.19 after adjusting for other PFAS in the highest vs. lowest quartiles), although it was no longer statistically significant. Statistically significant increased odds of RCC were observed in participants ages 55–59 years, and in men and in women, separately (See PFOA Appendix).

Seven general population studies published since the 2016 assessment examined breast cancer [Cohn, 2020, 5412451; Ghisari, 2017, 3860243; Hurley, 2018, 5080646; Itoh, 2021, 9959632; Mancini, 2020, 5381529; Omoike, 2021, 7021502; Tsai, 2020, 6833693]. Four were considered medium confidence [Cohn, 2020, 5412451; Ghisari, 2017, 3860243; Hurley, 2018, 5080646; Mancini, 2020, 5381529] and had mixed results. All studies were case-control studies (with some nested designs), except for one cross-sectional NHANES-based study [Omoike, 2021, 7021502]. Two nested case-control studies did not observe an association between breast cancer and PFOA concentrations measured in maternal serum throughout pregnancy and 1–3 days after delivery ([Cohn, 2020, 5412451]; 75th percentile PFOA 0.6 ng/mL) or in in serum after case diagnosis and breast cancer ([Hurley, 2018, 5080646]; max concentration of 39.1 ng/mL). Both studies were conducted in California and most breast cancer cases were obtained from the cancer registry. Two nested case-control studies found associations between PFOA and breast cancer, but only in specific genotype or estrogen receptive groups of participants [Ghisari, 2017, 3860243; Mancini, 2020, 5381529]. Ghisari (2017, 3860243) reported an increased risk for breast cancer identified from the cancer registry with increasing PFOA concentrations only in participants with a CC genotype (n = 36 cases and 47 controls) in the CYP19 gene (cytochrome P450 aromatase). A nested case-control study (194 pairs of breast cancer cases and controls) within the French E3N cohort found an 86% higher risk of breast cancer in the 2nd quartile of PFOA (4.8–6.8 ng/mL) compared to the first quartile (1.3–4.8 ng/mL) (OR = 1.86; 95% CI: 1.03, 3.36) in a partially adjusted model [Mancini, 2020, 5381529]. Mancini et al. (2020, 5381529) also reported that the risk for breast cancer (93% verified as pathologically confirmed from medical records after self-reported cancer diagnosis) varied by type of cancer with a statistically significant increase in estrogen receptor negative (ER−) and progesterone receptor negative (PR−) breast cancers in the second quartile of PFOA only. The sample size was small with 26 participants having ER− breast cancers and 57 having PR− breast cancers. No association was observed between PFOA and receptor-positive breast cancer risk.

Three studies were considered low confidence [Tsai, 2020, 6833693; Itoh, 2021, 9959632; Omoike, 2021, 7021502] because of concerns about temporality of exposure measurements and
breast cancer development, lack of confirmation of control status via examination or medical records \{Tsai, 2020, 6833693\}, and potential for residual confounding due to SES, life-style factors and other PFAS. One low confidence study \{Tsai, 2020, 6833693\} conducted in Taiwan observed a statistically significant increase in risk of breast cancer only in women younger than 50 years (OR = 1.14; 95% CI: 0.66, 1.96). Tsai et al. (2020, 6833693) also reported an increase in risk in ER+ participants aged 50 years or younger and a decrease in risk for ER− breast cancers in participants aged 50 years or younger, but neither achieved statistical significance. Statistically significant increased odds of breast cancer were also observed in a low confidence NHANES study (2005–2012) \{Omoike, 2021, 7021502\} both per ng/mL increase in PFOA (OR = 1.089; 95% CI: 1.089, 1.090) and across quartiles of exposure. One low confidence case-control study conducted in Japanese women \{Itoh, 2021, 9959632\} observed a significant inverse association across serum PFOA quartiles with a significant dose-response trend (p-value < 0.0001) \{see PFOA Appendix\}. Median PFOA levels ranged from 3.2 ng/mL in the lowest quartile to 9.3 ng/mL in the highest quartile. The association was null in pre-menopausal women and remained significantly inverse in postmenopausal women in the highest tertile of exposure, with a significant dose-response trend (p-value for trend = 0.005).

One medium confidence study based on the C8 Health Project \{Ducatman, 2015, 3859843\}. examined prostate-specific antigen (PSA) as a biomarker for prostate cancer in adult males over age 20 years who lived, worked, or went to school in one of the six water districts contaminated by the DuPont Washington Works facility. No association was observed between PSA levels in either younger (i.e., 20–49 year old) or older (i.e., 50–69 year old) men and concurrent mean serum PFOA concentration up to 46 ng/mL. In an NHANES population, Omoike et al. (2021, 7021502) observed a significantly inverse association with prostate cancer (OR = 0.944; 95% CI: 0.943, 0.944).

Omoike et al. (2021, 7021502) also observed statistically significant increased odds of ovarian cancer both per ng/mL increase in PFOA (OR = 1.015; 95% CI: 1.013, 1.017) and for the highest vs. lowest quartiles of exposure (OR = 1.77; 95% CI: 1.75, 1.79), although the association was significantly inverse for the second and third quartiles of exposure \{see PFOA Appendix\}. A significantly inverse association was also observed for uterine cancer (OR = 0.912; 95% CI: 0.910, 0.914 per ng/mL increase in PFOA) \{Omoike, 2021, 7021502\}.

One low confidence study conducted in Shandong Province, in eastern China \{Liu, 2021, 10176563\} observed a statistically significant inverse association with thyroid cancer across quartiles of serum PFOA (p-value for trend < 0.001). The median serum PFOA levels were higher in controls than in cases (10.9 vs. 7.7 ng/mL, p-value < 0.001). However, there is some concern about possible reverse causality. The ability to metabolize PFAS could change when the thyroid becomes cancerous, thereby changing the PFAS concentrations. The abnormality of thyroid hormones may also disturb the PFAS levels.

Two studies examined all cancers together, but collected different information on cancers (i.e., incidence vs. mortality) and obtained the information using different methods. Cancer mortality based on Public-use Linked Mortality Files was observed with PFOA exposure in a medium confidence study among subjects over 60 years of age from NHANES 2003–2006 with median PFOA concentration 23.7 ng/g lipid \{Fry, 2017, 4181820\}. PFOA was associated with an increase in self-reported cancer incidence in a low confidence study on male anglers over 50 years \{Christensen, 2016, 3858533\}. Christensen et al. (2016, 3858533) was considered low
confidence due to the potential of self-selection because subjects were recruited from flyers and other methods and filled out an online survey including self-reported outcomes.

### 3.5.1.5 Findings from Occupational Studies

Two low confidence occupational studies examined cancer incidence {Steenland, 2015, 2851015} and mortality {Girardi, 2019, 6315730}. Issues of population selection, outcome measurement and small number of deaths reducing the sensitivity were noted. In a retrospective occupational cohort study based on the same DuPont cohort from West Virginia reported in the 2016 assessment {Steenland, 2012, 2919168}, Steenland et al. (2015, 2851015) observed no significant associations with incidence of cancers of the bladder, colorectal, prostate, and melanoma when compared to the general population (median serum levels in workers was 113 ng/mL in 2005 compared to 4 ng/mL in the general population). There was modest evidence of a positive non-significant trend for prostate cancer (across quartiles) and a statistically significant negative exposure-response trend for bladder cancers (p-value = 0.04).

Girardi et al. (2019, 6315730) conducted a retrospective cohort study at a factory in Italy where PFOA was produced from 1968–2014 and observed statistically significant increases in liver cancer mortality, malignant neoplasms of the lymphatic and hematopoietic tissue, and in all malignant neoplasms with cumulative serum PFOA exposure of > 16,956 ng/mL-years. There was no association observed with lung cancer in this occupational cohort. Mortality from cancers in this cohort was low and supplemental data provided mortality for other cancers including kidney, but no risk estimates were calculated.

### 3.5.2 Animal Evidence Study Quality Evaluation and Synthesis

There are 2 studies from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} and 2 studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD that investigated the association between PFOA and cancer effects in animal models. Study quality evaluations for these 4 studies are shown in Figure 3-73.
Three *high* or *medium* confidence animal carcinogenicity studies indicate that PFOA exposure can lead to multiple types of neoplastic lesions including liver adenomas {Biegel, 2001, 673581; NTP 2020, 7330145} or carcinomas {NTP, 2020, 7330145}, Leydig cell tumors (LCTs) {Biegel, 2001, 673581; Butenhoff, 2012, 2919192}, and pancreatic acinar cell tumors (PACTs) {Biegel, 2001, 673581; NTP 2020, 7330145} in male Sprague-Dawley rats. Neoplastic lesions were also observed in female Sprague-Dawley rats, but the incidence was not as high as observed in the males and often did not achieve statistical significance {Butenhoff, 2012, 2919192; NTP, 2020, 7330145}. NTP (2020, 7330145) reported increased incidences of neoplastic lesions in female Sprague-Dawley rats, though these changes were not statistically significant, statistics could not be computed (liver neoplasms and PACTs), or there was uncertainty regarding the strength of response compared to controls (uterine adenocarcinomas). Another study {Filgo, 2015, 2851085} assessed hepatic tumor development in three strains of female mice after perinatal exposures to PFOA. This study was not evaluated and is not further discussed here because of an inadequate study design to assess lifetime/chronic carcinogenicity (i.e., the study did not include exposure postweaning) and the results were equivocal (i.e., few significant findings that did not display a dose-response relationship) and difficult to interpret due to small sample sizes (n = 6–10 for some strains).

In the three rat carcinogenicity studies {Biegel, 2001, 673581; Butenhoff, 2012, 2919192; NTP, 2020, 7330145}, rats were fed diets containing similar concentrations of PFOA for approximately 2 years. Butenhoff et al. (2012, 2919192) analyzed a variety of tissues collected...
from male and female Sprague-Dawley rats fed diets containing 0, 30, or 300 ppm PFOA (equivalent to 1.3 and 14.2 mg/kg for males and 1.6 and 16.1 mg/kg for females) for 2 years. Similarly, Biegel et al. (2001, 673581) analyzed tissues collected from male Crl:CD® BR (CD) rats fed diets containing 0 or 300 ppm PFOA (equivalent to 13.6 mg/kg/day) for 24 months. Using a matrix-type exposure paradigm, NTP (2020, 7330145) administered PFOA in feed to pregnant Sprague-Dawley (Hsd:Sprague Dawley® SD®) rats starting on GD 6 and analyzed tissues of male and female offspring also fed postweaning diets containing PFOA for a total of 107 weeks. Dose groups for this report are referred to as “[perinatal exposure level]/[postweaning exposure level]” (e.g. 300/1,000; see further study design details in Section 3.4.4.2.1.2).

Liver adenomas were observed in the Biegel et al. study (2001, 673581) at an incidence of 10/76 (13%) at 13.6 mg/kg/day, compared to 2/80 (3%) in controls. Liver adenomas were also significantly increased in the NTP (2020, 7330145) in the 0/40, 0/80, and 300/80 ppm groups (Table 3-11). Both the 0/0 and 300/0 ppm control groups had no observed liver adenomas. Although no liver adenomas were observed in Butenhoff et al. (2012, 2919192), carcinomas were identified in the male controls, males in the low-dose group (1.3 mg/kg/day), and male and female rats in the high-dose group (14.2 and 16.1 mg/kg/day, respectively). NTP (2020, 7330145) reported increases in the incidence of hepatocellular carcinomas in the 300/80 ppm group. The differences in carcinoma incidences from controls were not statistically significant in either the Butenhoff et al. (2012, 2919192) or NTP (2020, 7330145) studies.

**Table 3-11. Incidences of Liver Adenomas in Male Sprague-Dawley Rats as Reported by NTP (2020, 7330145)**

<table>
<thead>
<tr>
<th>Perinatal Dose</th>
<th>Postweaning Dose</th>
<th>0 ppm</th>
<th>20 ppm</th>
<th>40 ppm</th>
<th>80 ppm</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 ppm</td>
<td></td>
<td>0/50 (0%)****</td>
<td>0/50 (0%)</td>
<td>7/50 (14%)*</td>
<td>11/50 (22%)***</td>
</tr>
<tr>
<td>300 ppm</td>
<td></td>
<td>0/50 (0%)****</td>
<td>1/50 (2%)</td>
<td>5/50 (10%)</td>
<td>10/50 (20%)***</td>
</tr>
</tbody>
</table>

Notes:
*Statistically significant compared to the respective control group (0/0 or 300/0 ppm) at p ≤ 0.05.
**Statistically significant compared to the respective control group (0/0 or 300/0 ppm) at p ≤ 0.01.
***Statistically significant trend of response at p ≤ 0.001.

Accompanying non-neoplastic/proneoplastic liver lesions were identified by Butenhoff et al. (2012, 2919192) in males and females at the 1- and 2-year sacrifices. An increased incidence of diffuse hepatomegalocytosis and hepatocellular necrosis occurred in the high-dose groups. At the 2-year sacrifice, hepatic cystic degeneration (characterized by areas of multilocular microcysts in the liver parenchyma) was observed in males. Hyperplastic nodules in male livers were increased in the 14.2 mg/kg/day group. NTP similarly reported a variety of non-neoplastic and proneoplastic liver lesions in both male and female rats including increased incidences of liver necrosis and mixed-cell foci, hepatocyte hypertrophy, and focal inflammation. These lesions were more pronounced in males than females and were observed at both the 16-week interim and 107-week final necropsies.

Testicular LCTs were identified in both the Butenhoff et al. (2012, 2919192) and Biegel et al. (2001, 673581) studies. The tumor incidence reported by Butenhoff et al. (2012, 2919192) was
0/50 (0%), 2/50 (4%), and 7/50 (14%) for the 0, 1.3, and 14.2 mg/kg/day dose groups, respectively. The Biegel et al. study (2001, 673581) included one dose group (13.6 mg/kg/day); the tumor incidence was 8/76 (11%) compared to 0/80 (0%) in the control group. LCT incidence at similar dose levels was comparable between the two studies (11% and 14%). NTP (2020, 7330145) analyzed testicular tissue for LCTs but did not observe increased incidence due to PFOA treatment. The authors noted that this inconsistency with other carcinogenicity studies could be a result of differences in exposure concentrations or stock of Sprague-Dawley rat (i.e. CD vs. Hsd:Sprague Dawley).

PACTs were observed in both the NTP (2020, 7330145) and Biegel et al. (2001, 673581) studies. NTP (2020, 7330145) reported increased incidences of pancreatic acinar cell adenomas in males in all treatment groups compared to their respective controls (Table 3-12). NTP (2020, 7330145) observed increases in pancreatic acinar cell adenocarcinoma incidence in males in multiple dose groups and slight increases in the incidence of combined acinar cell adenoma or carcinoma in females from the 300/1,000 ppm dose group, though these increases did not reach statistical significance. In male rats, the incidence of PACTs in the Biegel et al. (2001, 673581) study was 8/76 (11%; 7 adenomas, 1 carcinoma) at 13.6 mg/kg/day while none were observed in the control animals. In a peer-reviewed pathological review of male pancreatic tissue collected by Butenhoff et al. (2012, 2919192), Caverly Rae et al. (2014, 5079680) identified 1/47 carcinomas in the 300 ppm group (compared to 0/46 in the control and 30 ppm groups) and no incidence of adenomas with any treatment. Pancreatic acinar hyperplasia was observed in males of the control, 1.3, and 14.2 mg/kg/day groups at incidences of 3/46 (7%), 1/46 (2%), and 10/47 (21%), respectively. Butenhoff et al. (2012, 2919192) also reported increased incidences of acinar atrophy in males (6/46 (13%), 9/46 (20%), and 11/49 (22%) in 0, 1.3, and 14.2 mg/kg/day dose groups, respectively), though this lesion was not discussed in the peer-reviewed pathology report (Caverly Rae, 2014, 5079680). NTP (2020, 7330145) similarly reported increased incidences of acinus hyperplasia in males at incidence rates of 32/50 (64%), 37/50 (74%), 31/50 (62%) in the 0/20, 0/40, 0/80, and 27/50 (54%), 38/50 (76%), and 33/50 (66%) in the 300/20, 300/40, and 300/80 groups. The incidences in controls were 18/50 (36%) and 23/50 (46%) in the 0/0 and 300/0 groups, respectively. There were also low occurrences of acinus hyperplasia in the exposed female groups, though not as frequently observed as in males. However, the authors concluded that the incidence of pancreatic acinar cell neoplasms in males increased confidence that the occurrence in females was due to PFOA exposure.

Table 3-12. Incidences of Pancreatic Acinar Cell Adenomas in Male Sprague-Dawley Rats as Reported by NTP (2020, 7330145)

<table>
<thead>
<tr>
<th>Perinatal Dose</th>
<th>Postweaning Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 ppm</td>
</tr>
<tr>
<td>0 ppm</td>
<td>3/50 (6%)**</td>
</tr>
<tr>
<td>300 ppm</td>
<td>7/50 (14%)**</td>
</tr>
</tbody>
</table>

Notes:
*Statistically significant compared to the respective control group (0/0 or 300/0 ppm) at p ≤ 0.05.
**Statistically significant compared to the respective control group (0/0 or 300/0 ppm) at p ≤ 0.001. Asterisks on the control group denotes a statistically significant trend of response.
NTP (2020, 7330145) observed increased incidences of uterine adenocarcinomas in female Sprague-Dawley rats during the extended evaluation (i.e., uterine tissue which included cervical, vaginal, and uterine tissue remnants). Incidence rates for this lesion are reported in Table 3-13. The accompanying incidences of uterine hyperplasia did not follow a dose-response relationship. Butenhoff et al. (2012, 2919192) identified mammary fibroadenomas and ovarian tubular adenomas in female rats, though there were no statistical differences in incidence rates between PFOA-treated dose groups and controls.

Table 3-13. Incidences of Uterine Adenocarcinomas in Female Sprague-Dawley Rats from the Standard and Extended Evaluations (Combined) as Reported by NTP (2020, 7330145)

<table>
<thead>
<tr>
<th>Perinatal Dose</th>
<th>0 ppm</th>
<th>300 ppm</th>
<th>1,000 ppm</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 ppm</td>
<td>1/50 (2%)</td>
<td>5/49 (10%)</td>
<td>7/48 (15%)*</td>
</tr>
<tr>
<td>150 ppm</td>
<td>–</td>
<td>3/50 (6%)</td>
<td>–</td>
</tr>
<tr>
<td>300 ppm</td>
<td>–</td>
<td>–</td>
<td>5/48 (10%)</td>
</tr>
</tbody>
</table>

Notes:
*Statistically significant compared to the control group (0/0 ppm) at p = 0.050.

NTP concluded that under the exposure conditions presented, there was clear evidence of carcinogenic activity of PFOA in male Sprague Dawley rats based on increased incidences of hepatocellular neoplasms (predominately hepatocellular adenomas) and acinar cell neoplasms (predominately acinar cell adenomas) of the pancreas {NTP, 2020, 7330145}. In females, NTP concluded there was some evidence of carcinogenic activity of PFOA based on increased incidences of pancreatic acinar cell adenoma or adenocarcinoma (combined) neoplasms. The study authors also noted that the higher incidence of hepatocellular carcinomas and adenocarcinomas of the uterus may have been related to exposure.

3.5.3 Mechanistic Evidence
Mechanistic evidence linking PFOA exposure to adverse cancer outcomes is discussed in Sections 3.1.2, 3.2.9, 3.3.1, 3.4.2, 3.4.3, 3.4.4, and 4.2 of the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}. There are 40 studies from recent systematic literature search and review efforts conducted after publication of the 2016 PFOA HESD that investigated the mechanisms of action of PFOA that lead to cancer effects. A summary of these studies is shown in Figure 3-74.

![Figure 3-74. Summary of Mechanistic Studies of PFOA and Cancer Effects](Image)

Interactive figure and additional study details available on [Tableau](#).
(i.e., Group 1 carcinogens as determined by IARC) {Smith, 2016, 3160486}. In contrast to the “Hallmarks of cancer” as presented by Hanahan and Weinberg {Hanahan, 2022, 10164687; Hanahan, 2011, 758924; Hanahan, 2000, 188413}, the key characteristics focus on the properties of human carcinogens that induce cancer, not the phenotypic or genotypic traits of cancers. The ten key characteristics provide a framework to systematically identify, organize, and summarize mechanistic information for cancer hazard evaluations {Smith, 2016, 3160486}.

To aid in the evaluation of the carcinogenic potential of PFOA, the studies containing mechanistic data were organized by the proposed key characteristics of carcinogens for the following section. Evidence related to eight of the ten key characteristics was identified in the literature included in this assessment: ‘Is Genotoxic’, ‘Induces Epigenetic Effects’, ‘Induces Oxidative Stress’, ‘Induces Chronic Inflammation’, ‘Is Immunosuppressive’, ‘Modulates Receptor Mediated Effects’, ‘Alters Cells Proliferation, Cell Death, and Nutrient Supply’, and ‘Causes Immortalization’. No studies from the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} and recent systematic literature search and review efforts were identified for the following key characteristics: ‘Is Electrophilic or Can Be Metabolically Activated to Electrophiles’ and ‘Alters DNA Repair and Causes Genomic Instability’.

3.5.3.1 Key Characteristic #2: Is Genotoxic

Genotoxicity is a well-studied mode of action for carcinogens, defined as alterations to DNA through single or double strand breaks, alterations to DNA synthesis, and DNA adducts, all of which can result in chromosomal aberrations, formation of micronuclei, and mutagenesis if not effectively repaired.

3.5.3.1.1 Mutagenicity

All of the studies investigating the mutagenic potential of PFOA were conducted in in vitro models. Of the available studies, most found that PFOA exposure did not induce mutagenicity (Table 3-14). Studies involving Chinese hamster ovary (CHO) K-1 cell lines presented primarily negative results. Sadhu (2002, 10270882) reported PFOA exposure did not induce gene mutations in CHO K-1 cells when tested with or without metabolic activation. Zhao et al. (2011, 847496) also observed that PFOA did not induce mutagenesis in human-hamster hybrid (A1L) cells, which contain a standard set of CHO-K1 chromosomes and a single copy of human chromosome 11, at sub-cytotoxic concentrations (<200 µM). A subsequent experiment using DMSO to quench oxidative stress found that PFOA was not mutagenic in the presence of DMSO, suggesting that an increase in reactive oxygen species production may be required for PFOA-induced mutagenicity (Section 3.5.3.3).

Of the six publications that tested PFOA mutagenicity in Salmonella typhimurium (S. typhimurium) or Escherichia coli (E. coli) {NTP, 2019, 5400977; Buhnhoff, 2014, 5079860; Buhrke, 2015, 2850235; Fernández Friere, 2008, 2919390; Lawlor, 1995, 10228128; Lawlor, 1996, 10228127}, two reported exposure-associated mutagenicity {NTP, 2019, 5400977; Buhnhoff, 2014, 5079860} (Table 3-14). Mutation was observed in S. typhimurium following exposure to cytotoxic concentrations of PFOA in the presence of S9 metabolic activation {Buhnhoff, 2014, 5079860}. NTP (2019, 5400977) reported PFOA exposure caused a slight increase in mutation in S. typhimurium TA98 cells, and Lawlor (1996, 10228127) reported that one plate of S. typhimurium had a significant amount of mutagenicity in the absence of S9 metabolic activation. However, neither of these results were reproducible.
3.5.3.1.2 DNA Damage

- In Vivo Evidence

3.5.3.1.2.1.1 Human Studies
Two studies have reported on the genotoxic potential of PFOA exposure in humans (Table 3-15). Franken et al. (2017, 3789256) measured blood PFOA concentrations in adolescents (14-15 years of age) that resided for >5 years within industrial areas of Belgium (near a stainless-steel plant or a shredder factory). These data were then compared to age-matched controls. A significant increase in DNA damage associated with PFOA exposure was observed, as evidenced by an alkaline comet assay performed on the same blood samples. Urinary 8-hydroxydeoxyguanosine (8-OHdG) was used as a biomarker for oxidative DNA damage. While there was no significant change observed, a positive dose-response relationship with increasing PFOA concentrations was noted. The authors attributed the DNA damage to oxidative stress, but noted that urinary 8-OHdG can also indicate DNA repair. Governini et al. (2015, 3981589) collected semen samples from healthy nonsmoking men and evaluated aneuploidy, diploidy, and DNA fragmentation. The occurrence of aneuploidy and diploidy in sperm cells, which are normally haploid, was significantly higher in the PFAS-positive samples (PFOA was detected in 75% of the samples) when compared to PFAS-negative samples. This suggests that PFAS exposure is related to errors in cell division leading to aneugenicity. Additionally, fragmented chromatin levels were also significantly increased for the PFAS-positive group compared with the PFAS-negative group.

3.5.3.1.2.1.2 Animal Toxicological Studies
Studies of the genotoxicity related to PFOA exposure were conducted in rat and mouse models (Table 3-15). All of the studies presented data from micronucleus tests of bone marrow, peripheral blood, and splenocytes, with the exception of one study of DNA strand breaks. It is important to note that rat models could be ineffective for determining micronucleus formation if study authors do not use appropriate methodologies as the spleen will remove micronucleated cells (Schlegel, 1984, 10368697). However, this would generally bias studies towards the null, not result in false positives.

With the exception of one micronucleus assay, there was no evidence for PFOA-induced genotoxic effects after acute or subchronic exposures (Figure 3-15). The single study of DNA strand breakage used a comet assay in tissues from male C57Bl/6 mice administered ≤5 mg/kg/day for five weeks (Crebelli, 2019, 5381564). Analysis of the liver and testis following exposure indicated there was no change in DNA fragmentation. Acute and subchronic PFOA exposures in mouse studies found no evidence of micronuclei formation, a measure of genotoxic damage to DNA in proliferating cells and spindle formation (Hayashi, 2016, 9956921), in either peripheral blood cells or splenocytes (Crebelli, 2019, 5381564) or within erythrocytes of the bone marrow (Butenhoff, 2014, 5079860; Murli, 1995, 10228120; Murli, 1996, 10228121). NTP (2019, 5400977) assessed micronuclei formation in Sprague Dawley rats using flow cytometry to avoid the potential confounding effect of splenic filtration (Dertinger, 2004, 10328871; Schlegel, 1984, 10368697). A subchronic study in Sprague Dawley rats noted that PFOA exposure induced a slight increase in micronuclei formation in peripheral blood cells of male rats administered 10 mg/kg/day; however, the micronuclei level was within the historical control range, and there was no effect in females (NTP, 2019, 5400977).
### In Vitro Evidence

#### 3.5.3.1.2.1.3 Chromosomal Aberrations

Measurements of chromosomal aberrations have been performed using human and animal cell lines, and predominantly found that PFOA exposure does not cause alterations (Table 3-16). In human lymphocytes, PFOA did not induce chromosomal aberrations in the presence of S9 activation (3 hours) or without the addition of S9 (≤46 hours) at concentrations up to 600 µg/ml {Butenhoff, 2014, 5079860}. This evidence corroborates previous studies of human lymphocyte cells that found similar results using non-cytotoxic concentrations of PFOA {Murli, 1996, 10228126; NOTOX, 2000, 10270878} as reported in the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}.

In contrast, Butenhoff et al. (2014, 5079860) observed chromosomal aberrations after PFOA exposure (≥750 µg/ml) with S9 metabolic activation in CHO cells. These results corroborate with previously reported studies in S9 activated CHO cells {Murli, 1996, 10228125; Murli, 1996, 10228124}. Butenhoff et al. (2014, 5079860) and Murli (1996, 10228124) also reported PFOA-induced chromosomal aberrations in CHO cells without S9 metabolic activation but were unable to replicate their own results.

#### 3.5.3.1.2.1.4 DNA Double Strand Breaks

Evaluation of DNA strand breakage using comet assays and histological analysis of phosphorylated H2AX (γH2AX) yielded positive results in all of the studies reviewed (Table 3-16). PFOA exposure caused DNA breakage in a dose-dependent manner in human lymphocytes exposed to ≥250 ppm PFOA for two hours {Yahia, 2016, 2851192} and in HepG2 cells exposed to ≥100 µM PFOA for 24 hours in one study {Yao and Zhong, 2005, 5081563}, ≥10 µM PFOA for 24 hours in another study {Wielsøe, 2015, 2533367}, and at 10 and 200 µM PFOA (but not 50 or 100 µM PFOA) for 24 hours in a third study {Florentin et al., 2011, 2919235}. *Paramecium caudatum* (*P. caudatum*), a unicellular protozoa, exhibited DNA damage after exposure to 100 µM PFOA {Kawamoto, 2010, 1274162}. Peropadre et al. (2018, 5080270) observed a 4.5-fold higher level of double strand breaks in human keratinocyte cells (HaCaT) exposed to 50 µM PFOA for 24 hours, compared to controls, as evidenced by γH2AX. Eight days post-exposure, γH2AX levels were twice that of the controls, indicating that double strand breaks were not fully repaired. In contrast, a study conducted in Syrian hamster embryo (SHE) cells demonstrated no change in DNA strand breaks by the comet assay at 4.1×10⁻⁵ to 300 µM PFOA for 5 or 24 hours {Jacquet et al., 2012, 2124683}.

#### 3.5.3.1.2.1.5 Micronuclei Formation

Three studies measured micronucleus formation in cells exposed to PFOA (Table 3-16). Buhrke et al. (2013, 2325346) demonstrated that PFOA exposure (10 µM, 24 hours) did not induce micronuclei formation in Chinese hamster lung cells (V79). Studies conducted in human HepG2 cells reported conflicting results: in one study, PFOA induced micronuclei formation at concentration of ≥100 µM after 24 hours {Yao and Zhong, 2005, 5081563}, while another study reported no difference in micronuclei frequency in HepG2 cells exposed to concentrations of PFOA up to 400 µM for 24 hours compared to controls {Florentin et al., 2011, 2919235}. The micronucleus assays were performed according to the same method {Natarajan, 1991, 5143588}. 
Table 3-14. Mutagenicity Data from In Vitro Studies

<table>
<thead>
<tr>
<th>Reference</th>
<th>Cell Line or Bacterial Strain</th>
<th>Results</th>
<th>Concentration (Duration of exposure)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTP (2019, 5400977)</td>
<td><em>Salmonella typhimurium</em> (TA98, TA100)</td>
<td>Equivocal(^a) (Not reproducible)</td>
<td>100–5,000 µg/plate</td>
</tr>
<tr>
<td></td>
<td><em>Escherichia coli</em> (WP2uvrA/pKM101)</td>
<td>Negative</td>
<td>100–10,000 µg/plate</td>
</tr>
<tr>
<td>Zhao et al. (2011, 847496)</td>
<td>Human-hamster hybrid (A(_2)) cells</td>
<td>N/A</td>
<td>1–200 µM (1–16 days)</td>
</tr>
<tr>
<td></td>
<td>Mitochondrial DNA-deficient human-hamster hybrid (p(^{TA}_{A2})) cells</td>
<td>N/A</td>
<td>1–200 µM (1–16 days)</td>
</tr>
<tr>
<td>Sadhu (2002, 10270882)</td>
<td>CHO K-1</td>
<td>Negative</td>
<td>≤ 39 µg/mL (5 or 17 hours)</td>
</tr>
<tr>
<td>Butenhoff et al. (2014, 5079860)</td>
<td><em>Salmonella typhimurium</em> (TA98, TA100, TA1535, TA1537)</td>
<td>Positive(^c)</td>
<td>20–1,000 µg/plate</td>
</tr>
<tr>
<td>Buhre et al. (2015, 2850235)</td>
<td><em>Salmonella typhimurium</em> (TA98, TA100, TA1535, TA1537, TA1538)</td>
<td>Negative</td>
<td>5 µM</td>
</tr>
<tr>
<td>Fernández Friere et al. (2008, 2919390)</td>
<td><em>Salmonella typhimurium</em> (TA98, TA100, TA102, TA104)</td>
<td>Negative</td>
<td>100 or 500 µM</td>
</tr>
<tr>
<td>Lawlor (1995, 10228128)</td>
<td><em>Salmonella typhimurium</em> (TA98, TA100, TA1535, TA1537)</td>
<td>Negative</td>
<td>100–5,000 µg/plate</td>
</tr>
<tr>
<td></td>
<td><em>Salmonella typhimurium</em> (TA98, TA100, TA1535, TA1537)</td>
<td>Negative</td>
<td>100–5,000 µg/plate</td>
</tr>
<tr>
<td></td>
<td><em>Escherichia coli</em> (WP2uvrA)</td>
<td>Negative</td>
<td>100–5,000 µg/plate</td>
</tr>
<tr>
<td></td>
<td><em>Escherichia coli</em> (WP2uvrA)</td>
<td>Negative</td>
<td>6.67–5,000 µg/plate</td>
</tr>
</tbody>
</table>

Notes:
\(^a\) Mutagens were present in 1 of 3 TA98 replicate plates only.
\(^b\) Mutagens were present in cells that were exposed only to 200 µM for 16 days.
\(^c\) Mutagenicity found at cytotoxic concentrations only.

Table 3-15. DNA Damage Data from In Vivo Studies

<table>
<thead>
<tr>
<th>Reference</th>
<th>Species, Strain (Sex)</th>
<th>Tissue</th>
<th>Results</th>
<th>PFOA Concentration (Dosing Regimen)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franken et al. (2017, 3789256)</td>
<td>Human (Male and Female)</td>
<td>Peripheral Blood Cells</td>
<td>Positive</td>
<td>Average Blood Concentration of 2.55 µg/L</td>
</tr>
</tbody>
</table>

DNA Strand Breakage
<table>
<thead>
<tr>
<th>Reference</th>
<th>In Vitro Model</th>
<th>Results</th>
<th>Concentration (Duration of exposure)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>S9 Activated</td>
<td>Non-Activated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chromosomal Aberrations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butenhoff et al. (2014, 5079860)</td>
<td>Human Lymphocytes</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chinese Hamster Ovarian Cells</td>
<td>Positive</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Chinese Hamster Ovarian Cells</td>
<td>N/A</td>
<td>Positive (Not reproducible)</td>
</tr>
<tr>
<td>NOTOX (2000, 10270878)</td>
<td>Human Lymphocytes</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Murli (1996, 10228126)</td>
<td>Human Lymphocytes</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cell Transformation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jacquet et al. (2012, 2124683)</td>
<td>Syrian Hamster Embryo Cells</td>
<td>N/A</td>
<td>Negative</td>
</tr>
<tr>
<td>Garry and Nelson (1981, 10228130)</td>
<td>C3H10T½</td>
<td>N/A</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>DNA Strand Breakage</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> A slight increase in micronuclei in the male 10 mg/kg/day group was within the historical control range. No change in females.
3.5.3.2 Key Characteristic #4: Induces Epigenetic Alterations

Epigenetic alterations are modifications to the genome that do not change genetic sequence. Epigenetic alterations include DNA methylation, histone modifications, changes in chromatin structure, and dysregulated microRNA expression, all of which can affect the transcription of individual genes and/or genomic stability \(\{\text{Smith, 2016, 3160486}\}\).

### 3.5.3.2.1 In Vivo Evidence

#### 3.5.3.2.1.1 Humans

A cohort of singleton term births were recruited from Faroese hospitals over an eighteen-month period from 1986 to 1987 \(\{\text{Leung, 2018, 4633577}\}\). At delivery, samples of umbilical cord whole blood and scalp hair from the mothers were collected and used to measure toxicant levels as well as evaluation of DNA methylation. No change in CpG island methylation was correlated with PFOA levels, although changes in this epigenetic alteration were found to be significantly correlated with several other toxicants in the blood samples. Two other studies evaluated global DNA methylation patterns in cord-blood. Miura et al. (2018, 5080353) found that increased
PFOA in the cord blood was associated with a global DNA hypermethylation in a cohort from Japan. Kingsley et al. (2017, 3981315) did not observe associations between PFOA exposure in cord blood and epigenome-wide changes in methylation status. However, the authors found significant changes in methylation in seven CpG sites located in several genes, including RAS P21 Protein Activator 3 (RASA3) and Opioid Receptor Delta 1 (OPRD1). Three studies reviewed herein found no association between maternal PFOA exposure and global methylation changes in offspring [Liu, 2018, 4926233; Leung, 2018, 4633577] or placenta [Ouidir, 2020, 6833759].

A subset of adults enrolled in the C8 Health Project between August 1, 2005 and August 31, 2006 were evaluated for exposure to perfluoroalkyl acids (PFAAs) via drinking water [Watkins, 2014, 2850906]. The cross-sectional survey consisted of residents within the mid-Ohio River Valley. A second, short-term follow-up study including another sample collection was conducted in 2010 to evaluate epigenetic alterations in relation to serum PFOA concentrations. Serum concentrations of PFOA significantly decreased between enrollment (2005–2006) and follow-up (2010). However, methylation of long interspersed nuclear elements (LINE-1) transposable DNA elements in peripheral blood leukocytes was not associated with PFOA exposure at any timepoint.

Several studies detail the influence of PFOA exposure on the epigenome in humans. Specifically, in prenatal studies, PFOA exposure was associated with mixed results of increased methylation in cord blood but not in placenta. However, consistently, studies found alterations in methylation patterns in genes associated with fetal growth. For additional information, please see the developmental mechanistic section (Section 3.4.4.3; refer to the interactive Tableau for additional supporting information and study details).

### 3.5.3.2.1.2 Animals

An in vivo analysis of epigenetic modifications in an oral PFOA study (1–20 mg/kg/day; 10 days) was performed in female CD-1 mice [Rashid, 2020, 6315778]. Measurement of 5-methylcytosine (5mc) and 5-hydroxymethylcytosine (5hmC) indicated no alteration of global CpG methylation levels in the kidneys. Downregulation of DNA methyltransferase 1 (Dnmt1) mRNA was observed at ≤5 mg/kg/day PFOA, while Dnmt1 expression increased by 4- and 7-fold at doses of 10 and 20 mg/kg/day, respectively. Levels of Dnmt3a decreased at all doses, and Dnmt3b expression increased at the highest dose (20 mg/kg/day). mRNA expression of ten eleven translocation (Tet) 1/2/3 methylcytosine dioxygenases was decreased at low doses of PFOA exposure compared to controls, with no change at higher doses.

### 3.5.3.2.2 In Vitro Evidence

In vitro PFOA exposures have yielded mixed results with evidence of both hyper- and hypomethylation of DNA. Data presented here are categorized by global DNA methylation and gene-specific modifications.

#### 3.5.3.2.2.1 Global DNA Methylation

5mC expression can be used to indicate global DNA methylation. Pierozan et al. (2020, 6833637) treated MCF-10A cells with PFOA (100 µM, 72 hours) and found elevated global methylation levels in the first daughter cell subculture. However, methylation levels returned to baseline after the second passage. This study contrasts with the results of Wen et al. (2020, 6302274) in a study conducted in HepG2 cells (20–400 µM PFOA, 48 hours), and Liu and
Irudayaraj (2020, 6512127) in a study of MCF7 cells (20–400 µM PFOA, 24–48 hours). Both studies found dose-dependent reductions in 5mC after PFOA exposure.

3.5.3.2.2.2 Modification to Gene Expression

Assays evaluating gene expression modified by enzymes that regulate DNA methylation levels, such as DNMT and TET enzymes, and histone modifications have been used to assess the impact of PFOA on the epigenome. Liu and Irudayaraj (2020, 6512127) reported significantly lower levels of DNMT1 protein after PFOA exposure in both MCF7 (≥100 µM) and HepG2 (≥200 µM) cells. However, DNMT3A expression was increased in a dose-dependent manner in MCF7 cells (≥200 µM). Authors attributed PFOA-induced global demethylation to alterations of DNMT3A and subsequent enzymatic activity of DNMT. Levels of DNMT3B did not change significantly in either cell line. Wen et al. (2020, 6302274) found no significant changes to DNMT1/3A/3B gene profiles after PFOA exposure (20–400 µM, 48 hours) in HepG2 cells. Further analysis found PFOA (200 µM) decreased TET1 expression, which is strongly associated with DNA methylation, but increased TET2 and TET3. Pierozan et al. (2020, 6836363) noted that PFOA-exposed MCF-10A cells and the direct daughter cell passages contained decreased levels of histone 3 lysine 9 dimethylation (H3K9me2). H3K9me2 is a silencing epigenetic marker; thus, a decrease in H3K9me2 is indicative of transcriptional activation, and has been associated with altered gene expression in breast cancer transformation.

3.5.3.3 Key Characteristic #5: Induce Oxidative Stress

Reactive oxygen and nitrogen species (ROS and RNS, respectively) are byproducts of energy production that occur under normal physiological conditions. An imbalance in the detoxification of reactive such species can result in oxidative (or nitrosative) stress, which can play a role in a variety of diseases and pathological conditions, including cancer. The primary mechanism by which oxidative stress leads to the carcinogenic transformation of normal cells is by inducing oxidative DNA damage that leads to genomic instability and/or mutations {Smith, 2016, 3160486}.

3.5.3.3.1 In Vivo Evidence

3.5.3.3.1.1 Humans

Franken et al. (2017, 3789256) measured urinary 8-OHdG to evaluate DNA induced by oxidative stress, in adolescents (14 – 15 years of age) that resided for >5 years in industrial areas of Belgium and compared their findings to blood PFOA concentrations. While no significant change was observed in urinary 8-OHdG in the subjects when compared to that of age-matched controls, a positive dose-response relationship with increasing PFOA concentrations was noted. The authors attributed the DNA damage to oxidative stress but noted that elevated 8-OHdG could also reflect aberrant DNA repair.

3.5.3.3.1.2 Animals

Several in vivo analyses of PFOA exposure in rodents found evidence that PFOA exposure caused increased oxidative stress and markers of oxidative damage in a tissue-specific manner. Takagi et al. (1991, 2325496) performed a two-week subchronic study (0.02% powdered PFOA in the diet) in male Fischer 344 rats and evaluated the levels of 8-OHdG in the liver and kidneys after exposure. While a significant increase was noted in liver and kidney weights, elevated levels of 8-OHdG was observed only in the liver. A second subset of animals were given a single IP
injection of PFOA (100 mg/kg) and sacrificed at days 1, 3, 5, and 8. Results were comparable to that of the dietary exposure study, as PFOA significantly increased liver (by day 1) and kidney (on days 3 and 8) weights with elevated liver 8-OHdG levels (by day 3).

Minata et al. (2010, 1937251) exposed wild-type (129S4/SvImJ) and Ppara-null (129S4/SvJae-Pparαtm1Gonz/J) mice to PFOA (≤50 µmol/kg/day) for four weeks. Levels of 8-OHdG were evaluated in the liver. No increase in oxidative stress levels was noted in exposed wild-type mice. In contrast, Ppara-null mice demonstrated a dose-dependent increase in 8-OHdG levels, with a significance increase at 50 µmol/kg/day when compared to controls. The correlation between PFOA exposure and 8-OHdG was associated with increased tumor necrosis factor α (TNF-α) mRNA levels.

In a developmental toxicity study, Li et al. (2019, 5387402) exposed pregnant Kunming mice to PFOA (≤10 mg/kg/day) on gestational day (GD) 1-17. Female mice were sacrificed on postnatal day (PND) 21 and livers were assessed for oxidative damage by quantification of 8-OHdG, catalase, and superoxide dismutase (SOD). Findings indicate the PFOA caused a dose-dependent increase in oxidative DNA damage levels, which were significantly elevated after 2.5 mg/kg/day. These results were associated with increased superoxide dismutase and catalase protein levels. Together, these findings suggest that the livers of exposed mice were producing antioxidant enzymes to counteract PFOA-induced elevated oxidative stress.

The testes are particularly susceptible to oxidative stress due to high energy demand and abundance of polyunsaturated fatty acids. Liu et al. (2015, 3981571) exposed male Kunming mice to ≤10 mg/kg/day of PFOA for 14 days and examined oxidative stress in the testis and epididymis. A dose-dependent increase in lipid peroxidation and oxidative stress was observed with a significant increase at ≥5 mg/kg/day relative to controls. In contrast to the results of Li et al. (2019, 5387402), levels of the antioxidant enzymes SOD and carnitine acyltransferase (CAT), and Nrf2 expression (an oxidative stress response gene) decreased as PFOA exposure doses increased.

Several other studies measuring oxidative stress in the liver have found that PFOA induces damage through hydrogen peroxide production {Salimi, 2019, 5381528} and through PPARα activation pathways {Li, 2019, 5387402}. For additional information that PFOA induces oxidative stress in the liver, please see the hepatic mechanistic section (Section 3.4.1.3; refer to the interactive Tableau for additional supporting information and study details).

Evidence that PFOA induces oxidative stress in the immune system have been reported. Wang et al. (2014, 3860153) observed that the spleens of mice treated with PFOA had mitochondrial swelling and cavitation as well as swollen and ruptured cristae, which suggests impaired oxidative processes. For additional information that PFOA induces oxidative stress in immune cells, please see the immune mechanistic section (Section 3.4.2.3; refer to the interactive Tableau for additional supporting information and study details).

Mechanistic studies noted PFOA exposure increased oxidative stress in the heart and brain. For additional information, please see the developmental (Section 3.4.4.3) and cardiovascular (Section 3.4.3.3) mechanistic sections (refer to the interactive Tableau for additional supporting information and study details).
3.5.3.3.2 In Vitro Evidence

The ability of PFOA to induce oxidative stress has been assessed in vitro in several human, non-human primate, and animal cell lines.

PFOA exposure caused a dose-dependent increase in 8-OHdG in human lymphoblast cells (TK6), with significant results noted at ≥250 ppm (2 hours) [Yahia, 2014, 2851192]. A similar relationship was noted in HepG2 cells with significant increase in 8-OHdG levels found at PFOA concentrations ≥100 µM (3 hours) [Yao, 2005, 5081563]. Yao and Zhong [2005, 5081563] measured ROS using a 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA) assay and observed a dose-dependent increase associated with elevated 8-OHdG levels. Peropadre et al. [2018, 5080270] found 8-OHdG levels were non-significantly elevated in human HaCaT cells following 24-hour exposure to PFOA (50 µM). However, measurements taken 8 days following exposure found levels to be significantly elevated by 50%.

Panaretakis et al. [2001, 5081525] observed the peak in ROS generation three hours following PFOA exposure in HepG2 cells exposed to concentrations of 200 and 400 µM. Both concentrations significantly increased hydrogen peroxide and superoxide anions. Wielsøe et al. [2014, 2533367] noted non-significant elevated levels of ROS after HepG2 cells were exposed to PFOA (0.2–20 µM) for 24 hours. Additionally, total antioxidant capacities were reduced after exposure to 0.02–2.000 µM. These studies contrast with the findings of Florentin et al. [2011, 2919235], which found no change in ROS using a DCFH-DA test in HepG2 cells exposed to 5–400 µM PFOA for 1 or 24 hours.

Kidney cells isolated from the African green monkey (Vero) were used in a DCFH-DA assay to measure ROS production [Fernández Freire, 2008, 2919390]. Authors reported a dose-dependent increase in ROS production that reached significance at 500 µM after 24 hours. Vero cells also displayed fragmentation of mitochondrial reticulum at ≥50 µM, a morphological change consistent with defective metabolism, indicating that irregular metabolic activity may play a role in ROS production in this model and exposure scenario.

ROS production was significantly higher in Paramecium caudatum exposed to PFOA (100 µM) for 12 or 24 hours, while 8-OHdG was not affected by PFOA [Kawamoto, 2010, 1274162]. Addition of the antioxidant glutathione attenuated the PFOA-induced ROS production but not DNA damage (as measured by a comet assay), indicating that the PFOA-induced DNA damage was not associated with oxidative stress is P. caudatum.

Hocevar et al. [2020, 6833720] exposed mouse pancreatic acinar cells to PFOA (≤100 µg/mL; 6 or 24 hours) and observed an increase in intracellular calcium-induced activation of the unfolded protein response (UPR) in the endoplasmic reticulum at concentrations ≥50 µg/mL. This is a well-established oxidative stress-inducing pathway.

Zhao et al. [2010, 847496] exposed human-hamster hybrid (A1) cells to PFOA (1–200 µM; 1–16 days) and found significantly increased intracellular ROS, NO, and O2·− levels at all timepoints exposed to ≥100 µM. These increases correlated with cytotoxicity, which was significant at all timepoints at 100 and 200 µM. DNA mutagenicity was only significant at the highest concentration at the longest exposure (16 days). Effects were reversed when previously PFOA-exposed cells were treated with oxidative stress inhibitors dimethyl sulfoxide (DMSO) and NG-methyl-L-arginine (L-NMMA). When repeating the study using a mitochondrial deficient cell
line (p^0\text{A_L})\), authors reported no mutagenesis, indicating that if the increase in DNA mutation after PFOA exposure is related to ROS generation, the association is mitochondria dependent.

### 3.5.3.4 Key Characteristic #6: Induces Chronic Inflammation

The induction of chronic inflammation includes increased white blood cells, altered chemokine and/or cytokine production, and myeloperoxidase activity (Smith, 2016, 3160486). Chronic inflammation has been associated with several forms of cancer, and a role of chronic inflammation in the development of cancer has been hypothesized. However, there are biological links between inflammation and oxidative stress and genomic instability, such that the contribution of each in carcinogenic progression is not always clear.

#### 3.5.3.4.1 In Vivo Evidence

Increased inflammation and/or inflammatory markers (i.e., inflammatory cytokines) has been reported in animal toxicological studies of acute, subchronic, and chronic exposures to PFOA. NTP (2020, 7330145) used a matrix-type exposure paradigm. Pregnant Sprague-Dawley rats were administered PFOA via gavage beginning on GD 6 and exposure was continued in offspring postweaning for a total of 107 weeks. Dose groups for this report are referred to as (perinatal exposure level (ppm))/(postweaning exposure level (ppm)) and ranged from 0/0–300/300 ppm in males and 0/0–300/1,000 ppm in females. At the 16-week interim sacrifice, incidences of chronic active inflammation of the glandular stomach submucosa was significantly higher in the male 0/300 ppm group compared to the control group. No effects were seen in female rats at the interim sacrifice. At the 2-year evaluation, females in the 0/1,000 and 300/1,000 ppm groups exhibited increased incidences of ulcer, epithelial hyperplasia, and chronic active inflammation of the submucosa of the forestomach when compared to controls.

Histopathological analysis of animals exposed to PFOA (0.625–10 mg/kg) by oral gavage for 28 day exhibited nasal respiratory epithelium inflammation in both males and females, though these effects did not follow a linear dose-response {NTP, 2019, 5400977}. Similarly, olfactory epithelial inflammation and degeneration were observed in females. Increases in nasal and olfactory hyperplasia were thought to be a result of the observed epithelial degradation and/or inflammation.

Activation of the NF-κB signaling pathway plays an important role in the regulation of inflammation, including through expression of proinflammatory cytokines {Lee, 2017, 3981419; Shane, 2020, 6316911; Zhong, 2020, 6315790; Zhang, 2014, 2851150}. Modification to NF-κB expression has been observed in adult zebrafish after 7, 14, and 21 days of PFOA exposure {Zhang, 2014, 2851150; Zhong, 2020, 6315790} and in female BALB/c mice dermally exposed to PFOA for 14 days {Shane, 2020, 6316911}. Additionally, proinflammatory cytokines IL-1β, TNF-α, and others were upregulated by PFOA exposure at doses ranging from 0.002% w/w in the diet and 2.5-10 mg/kg/day by gavage for 10 or 14 days in various tissues across several mouse studies {Qazi, 2009, 1276154; Wang, 2014, 3860153; Liu, 2016, 3981762; Yang, 2014, 2850321}.

#### 3.5.3.4.2 In Vitro Evidence

Saejia et al. (2019, 5387114) noted that PFOA (1 nM, 72 hours) significantly increased activation of NF-κB in FTC133 cells. Furthermore, translocation of the phosphorylated version of NF-κB to the nucleus from the cytosol, a crucial step in inflammation cytokine production,
was observed. Inhibition of NF-κB activation was found to reduce invasive characteristics of cells, likely through reduced expression of MMP-2 and MMP-9. PFOA increased the levels of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IL-8, in a dose-responsive manner in IgE-stimulated rat mast cells (RBL-2H3 cell line) [Lee, 2017, 3981419]. It is important to note that in vitro models may be used for the evaluation of changes in inflammatory markers and response, they are generally not effective in modeling the events that are associated with chronic inflammation.

Several studies have identified the potential of PFOA to increase inflammation within various testing systems. For additional information, please see the immune (Section 3.4.2.3), hepatic (Section 3.4.1.3), and cardiovascular (Section 3.4.3.3) mechanistic sections (refer to the interactive Tableau for additional supporting information and study details).

### 3.5.3.5  **Key Characteristic #7: Is Immunosuppressive**

Immunosuppression refers to the reduction in the response of the immune system to antigen, which is important in cases of tumor antigens {Smith, 2016, 3160486}. It is important to note that immunosuppressive agents do not directly transform cells, but rather can facilitate immune surveillance escape of cells transformed through other mechanisms (e.g., genotoxicity).

Studies have identified the immunosuppressive potential of PFOA in in vivo and in vitro testing systems. The pleotropic immunomodulatory effects of PFOA, including impaired vaccine response in humans and reduction in B and T cell populations in the thymus and spleen in laboratory animals, may reflect perturbed function of B and/or T cells. At the molecular level, dysregulation of the NF-κB pathway may contribute to the immunosuppressive effects of PFOA. The NF-κB pathway facilitates initial T cell responses by supporting proliferation and regulating apoptosis, participates in the regulation of CD4+ T cell differentiation, and is involved in mediating inflammatory responses. Dysregulation of the NF-κB pathway by PFOA, potentially consequent to the induction of oxidative stress, may be a key component of the underlying mechanism of PFOA-mediated immunosuppression. Reduced NF-κB activation and consequent elevation of apoptosis is consistent with increased apoptosis in multiple cell types, the reduction of pre/pro B cell numbers, and dysregulation of pro-inflammatory cytokines and mediators of inflammation. For additional information, please see the immune mechanistic section (Section 3.4.2.3; refer to the interactive Tableau for additional supporting information and study details).

### 3.5.3.6  **Key Characteristic #8: Modulates Receptor-Mediated Effects**

Modulation of receptor-mediated effects involves the activation or inactivation of receptors (e.g., PPAR, AhR) or the modification of endogenous ligands (including hormones) {Smith, 2016, 3160486}.

#### 3.5.3.6.1  **In Vivo Evidence**

Yan et al. (2015, 2851199) exposed adult male Balb/c mice to PFOA (0.08–20 mg/kg/day) via oral gavage for four weeks. Livers were isolated and mRNA levels of several peroxisome proliferator-activated receptors (PPARs) were evaluated using RT-PCR. PPARα was found to be increased by 50% in the 0.08 and 0.31 mg/kg/day dose groups. This trend was not consistent as PPARα levels diminished at higher doses. PPARγ was found to increase in a dose-dependent
manner that reached significance at 1.25 mg/kg/day PFOA. No differences were observed in PPARβ/δ mRNA expression after exposure.

Data from studies conducted in rodent models have demonstrated PPARα activation as a mechanism for PFOA-induced hepatotoxicity, due to the association between hepatic lesions and/or increased liver weight and peroxisome proliferation downstream of PPARα activation. There is also growing evidence the PFOA activates other nuclear receptors (e.g., CAR/PXR, ERα, HNF4α) in tandem with PPARα to enact its effects. For additional information, please see the hepatic (Section 3.4.1.3) and cardiovascular (Section 3.4.3.3) mechanistic sections (refer to the interactive Tableau for additional supporting information and study details).

3.5.3.6.2 In Vitro Evidence

PPARα and PPARγ gene expression was assessed in hepatocellular carcinoma cells (Hepa 1-6) exposed to PFOA (50–200 µM; 72 hours) {Yan, 2015, 2851199}. While no significant changes were observed for these genes, PPARα target genes were significantly increased, indicating that PPARα was activated by PFOA.

Available mechanistic evidence demonstrates that PFOA has the potential to dysregulate hormone levels in hepatic cells, particularly in regard to thyroid function. Furthermore, rodent and human hepatocytes treated with PFOA demonstrated a concentration-dependent decrease in lipid accumulation that was associated with PPARα activation. For additional information, please see the hepatic mechanistic section (Section 3.4.1.3; refer to the interactive Tableau for additional supporting information and study details).

3.5.3.7 Key Characteristic #9: Causes Immortalization

Immortalization leads to tumorigenesis when cells continue to divide after sustaining DNA damage and/or shortened telomeres, events that cause cells to cease to divide in healthy or normal states (i.e., the Hayflick limit). Immortalization is a key characteristic typically observed in and associated with human DNA and RNA viruses, such as human papillomaviruses and hepatitis C virus, among others. In vitro cell transformation assays have been historically used to test carcinogenic potential of both genotoxic and non-genotoxic compounds {Creton, 2012, 8803671}, and is recognized as an assay related to key characteristic #9 {Smith et al., 2020, 6956443}.

In the case of PFOA, two studies reported no change in cell transformation in vitro in cells exposed to PFOA relative to controls. Jacquet et al. (2012, 2124683) exposed SHE cells to PFOA at concentrations ranging from 3.7×10^{-4} – 37.2 µM for 6 days with or without pre-treatment with the tumor initiator benzo-α-pyrene (BaP). PFOA exposure alone did not induce cell transformation, but PFOA did significantly induce transformation in BaP-sensitized cells, indicating that PFOA does not alone initiate cell transformation, but may have tumor promoter-like activity. A second in vitro cell transformation assay reported no evidence of transformation in C3H 10T-1/2 mouse embryo cells exposed to 0.1–200 µg/mL PFOA in a 14-day colony assay for transformation nor in a 38-day foci transformation assay {Garry and Nelson, 1981, 10228130}. 

3-285
3.5.3.8  **Key Characteristic #10: Alters Cell Proliferation, Cell Death, or Nutrient Supply**

Aberrant cellular proliferation, cell death, and/or nutrient supply is a common mechanism among carcinogens. This mechanism includes aberrant proliferation, decreased apoptosis or other evasion of terminal programming, changes in growth factors, angiogenesis, and modulation of energetics and signaling pathways related to cellular replication or cell cycle control {Smith, 2016, 3160486}.

3.5.3.8.1  **In Vivo Evidence**

To determine if PFOA exposure induced proliferation in cancer cells, Ma et al. (2016, 3981426) xenografted human endometrial adenocarcinoma (Ishikawa cell line) cells into the flanks of six-week-old female BALB/c mice. Animals were then treated with PFOA (20 mg/kg/day) by oral gavage daily for three weeks beginning the same day of the xenograft. Tumor volume was measured after five weeks, and data indicated that PFOA caused tumors to nearly triple in size. Additionally, levels of proliferating cell nuclear antigen (PCNA) and vimentin protein were both upregulated by PFOA, suggesting increased cell proliferation and invasion. E-cadherin expression was downregulated after PFOA exposure, indicating that cells were more likely to migrate and form metastases.

Treatment effects on apoptosis and cell cycle have also been observed in immune system cells of animals exposed to PFOA. Wang et al. (2014, 3860153) exposed BALB/c mice to PFOA (5–20 mg/kg/day, 14 days) via gavage and reported that the percent of apoptotic cells increased in the spleen (10–20 mg/kg/day) and in the thymus (20 mg/kg/day). Yang et al. (2002, 1332453) reported significant reductions in the proportion of thymocytes in the S and G2/M phases and significant increases in the G0/G1 phases of mice treated with PFOA, effects that were PPARα-dependent.

Additional mechanistic studies, detailed elsewhere, noted PFOA exposure alters the number of various B and T cell subsets in primary and secondary lymphoid organs, which may impact immune system development, including dysregulation of proliferation, differentiation, and/or apoptosis. For additional information, please see the immune mechanistic section (Section 3.4.2.3; refer to the interactive Tableau for additional supporting information and study details).

3.5.3.8.2  **In Vitro Evidence**

PFOA has been demonstrated to increase cell proliferation and apoptosis evasion in vitro. Evidence presented here is organized into three categories: induced proliferation, apoptosis evasion, and modification of cellular migration.

3.5.3.8.2.1  **Proliferation**

Exacerbation of proliferation in cancer cell lines is of particular concern to the development and prognosis of cancer. Several studies have utilized MTT assays to measure cellular metabolic activity to determine cell proliferation and cytotoxicity rates.

PFOA exposure (5-50 µM) increased cellular proliferation in MCF-7 human breast cancer cells and HepG2 human hepatoma (nontumorigenic) cells {Burhke, 2015, 2850235; Burhke, 2013, 2325346; Liu, 2020, 6512127}. However, predictably, proliferation rates decreased at cytotoxic
concentrations (≥100 µM PFOA) {Burhke, 2015, 2850235; Burhke, 2013, 2325346; Wen, 2020, 6302274}. Similar results were observed in the breast epithelial (nontumorigenic) cell line MCF-10A, in which PFOA exposure (50 and 100 µM; 24–72 hours) increased cell proliferation, whereas proliferation rates decreased as the PFOA concentration was increased to a cytotoxic level (250 µM) {Pierozan, 2018, 4241050}. A subsequent study by Pierozan et al. (2020, 6833637) reported that PFOA-induced (100 µM, 72 hours) proliferation persisted in MCF-10A daughter subcultures that were not exposed to PFOA. PFOA exposure (1–100 nM) in colorectal cancer cells (DLD-1) has also been shown to modify the cell cycle by causing more cells to enter S-phase and less in G1 of mitosis {Miao, 2015, 3981523}.

Several studies of the effects of low exposure to PFOA found no evidence of modification to cell proliferation rates. These studies include ovarian cancer cell line A2780 (1–200 nM, 48 hours) {Li, 2018, 5079796} Ishikawa human endometrial adenocarcinoma cells (50 nM, 48 hours) {Ma, 2016, 3981426}, and human colorectal cancer cell line DLD-1 (1–10,000 nM, 72 hours) {Miao, 2015, 3981523}.

Insulin growth factor 1 (IGF-1) expression has been implicated in governing proliferation in cancer cells. A series of experiments performed by Gogola et al. (2019, 5016947; 2020, 6316203; 2020, 6316206) used COV434 and KGN cells exposed to PFOA (0.02 ng/mL–2 µg/mL; 72 hours). All studies found increased proliferation in both cell lines. Proliferation was highest in COV434 and KGN cells at 0.02 ng/mL and 2 ng/mL, respectively. Interestingly, proliferation returned to baseline levels in both cell lines at PFOA concentration of 2 µg/mL, indicating a bell-shaped dose response. These experiments were repeated after inhibition of IGF-1 caused normalization in both cell lines after PFOA exposure. Together, these studies demonstrate the potential pathway in which PFOA induces proliferation in cancer cells.

HepG2 cells were exposed to non-cytotoxic concentrations of PFOA for 24 hours before SHP-2, a tumor suppressor protein, was immunoprecipitated from the cell lysates {Yang, 2017, 3981427}. PFOA (100 µM) slightly lowered SHP-2 mRNA expression and decreased SHP-2 enzyme activity in a concentration-dependent manner. SHP-2 protein levels were increased only at 140 µM exposure, and unchanged at other concentrations. These results indicate that PFOA inhibits SHP-2 by reducing enzyme activity, not protein content.

Rainieri et al. (2017, 3860104) evaluated the effects of PFOA on cell proliferation by quantifying the distribution of cells in different stages of the cell cycle in a human macrophage cell line (TLT cells). Significantly more cells were in G2M phase following exposure to PFOA (50–500 mg/L; 12 hours) in parallel with a lower proportion of cells in the G0/G1 phase, suggesting increased cell proliferation. For additional evidence of the effect of PFOA on cell death and cell proliferation in the immune system, please see the immune mechanistic section (Section 3.4.2.3; refer to the interactive Tableau for additional supporting information and study details).

### 3.5.3.8.2.2 Apoptosis

Evasion of programmed cell death is a characteristic of cancer cells, allowing them to continue proliferating, which can be enhanced by PFOA exposure. Dairkee et al. (2018, 4563919) evaluated several human breast cancer cell lines for apoptosis following PFOA exposure (1 or 100 nM; 7 days). Using fluorescence activated cell sorting (FACS) of Annexin V-FITC, PFOA concentrations were found to be inversely correlated with apoptosis rates. However, in HepG2 cells, PFOA exposure was found to increase metabolically-induced BAX apoptosis in a dose-
dependent manner {Wen, 2020, 6302274}. Apoptosis was also found to increase in HepG2 cells after PFOA exposure (200 or 400 µM; ≤24 hours) and was associated with an increase in caspase-9 activation after 5 hours of exposure {Panaretakis, 2001, 5081525}. Additionally, the murine spermatogonial cell line GC-1 exhibited a dose-dependent increase in apoptosis after exposure to PFOA (≥250 µM) for 24 hours that reached significance at ≥500 µM {Lin, 2020, 6833675}. Caspase protease enzymes are essential in apoptotic cell death and are frequently used to assess apoptosis. Gogola et al. (2020, 6316203; 2020, 6316206) found that PFOA (0.2–20 ng/mL; 72 hours) caused no changes to caspase 3/7 expression in COV434 and KGN cells. Additionally, PFOA (≤100 µM) had no effect on caspase 3/7 activity in HepG2 cells. Lin et al. (2020, 6833675) reported a dose-dependent increase in caspase-3 activity that correlated with apoptosis rates in GC-1 cells. Additionally, apoptosis and caspase activity were inversely correlated with Bcl-2/Bax ratios. These results indicate that PFOA may induce apoptosis through an increase in BAX expression. Hu and Hu (2009, 2919334) also suggested that PFOA could induce apoptosis by overwhelming the homeostasis of antioxidative systems, increasing ROS, impacting mitochondria, and changing expression of apoptosis gene regulators, based on their findings in studies with HepG2 cells. Overall, data are conflicting on the ability of PFOA to induce or inhibit apoptosis, with the variation likely dependent upon dose and duration of exposure.

3.5.3.8.2.3 Modulation of Migration
Cancer cells are invasive in nature due to their ability to increase mobility, reduce attachment to neighboring cells, and express proteins that break down the extracellular matrix of tissues. Wound healing assays are a common and reproducible way to inflict a ‘wound’ on a monolayer plate of cells and measure the time for the cells to re-establish confluency. Two independent studies concluded PFOA exposure increased the rate at which Ishikawa cells (50 nM, 48 hours) {Ma, 2016, 3981426} and A2780 cells (≥100 nM, 72 hours) {Li, 2018, 5079796} were able to re-establish confluency in a dose-dependent manner. Assays of migration and invasion measure the ability of a cell to travel either without inhibition or through the extracellular matrix of plated cells, respectively. Two studies investigated cellular migration after PFOA exposure and found no change after FTC133 cells were exposed to 1 nM (72 hours) {Saejia, 2019, 5387114} or 0-1 mM (24-72 hours) {Pierozan, 2018, 4241050}, while an increase in migration was found at 100 nM (72 hours) in MCF-10A cells {Pierozan, 2018, 4241050}. All studies reviewed found an increase in the invasive nature of cancer cells lines FTC133 (1 nM, 72 hours) {Saejia, 2019, 5387114}, Ishikawa (≥50 nM) {Ma, 2016, 3981426}, MCF-10A (100 nM, 72 hours) {Pierozan, 2018, 4241050}, A2780 (≥100 nM, 72 hours) {Li, 2018, 5079796}, and DLD-1 (1 nM–1 µM, 72 hours) {Miao, 2015, 3981523} after PFOA exposure. Pierozan et al. (2020, 6833637) exposed MCF-10A cells to PFOA (100 µM, 72 hours) and found that invasion and migration of daughter cell passages was elevated when compared to control. Several reports noted cell invasion and upregulated MMP2 and MMP9 expression levels, which help to break down the extracellular matrix allowing cells to move freely, indicating that cancer cells could be more likely to become invasive or metastasize after exposure to PFOA {Li, 2018, 5079796; Miao, 2015, 3981523; Saejia, 2019, 5387114}. 
Additional mechanistic studies have identified the potential of PFOA to induce aberrant cellular proliferation rates and increase apoptosis within \textit{in vitro} testing systems. For additional information, please see the immune (Section 3.4.2.3) and hepatic (Section 3.4.1.3) mechanistic sections (refer to the interactive Tableau for additional supporting information and study details).

\section*{3.5.4 \textbf{Weight Of Evidence for Carcinogenicity}}

\subsection*{3.5.4.1 \textbf{Summary of Evidence}}

The carcinogenicity of PFOA has been documented in both epidemiological and animal toxicological studies. The evidence in epidemiological studies is primarily based on the incidence of kidney and testicular cancer, as well as potential incidence of breast cancer in genetically susceptible subpopulations. Other cancer types have been observed in humans, although the evidence for these is generally limited to low confidence studies. The evidence of carcinogenicity in animal models is provided in three chronic oral animal bioassays in Sprague-Dawley rats which identified neoplastic lesions of the liver, pancreas, and testes.

\subsection*{3.5.4.1.1 \textbf{Evidence from Epidemiological Studies}}

As discussed in depth in the 2016 HESD \cite{U.S. EPA, 2016, 3603279}, two medium confidence studies involving members of the C8 Health Project showed a positive association between PFOA levels (mean at enrollment 0.024 \(\mu\)g/mL) and kidney and testicular cancers \cite{Barry, 2013, 2850946; Vieira, 2013, 2919154}. Vieira et al. \cite{2013, 2919154} investigated the relationship between PFOA exposure and cancer among the residents living near the DuPont plant in Parkersburg, West Virginia. The adjusted ORs were increased for testicular cancer and for kidney cancer (OR: 5.1, 95% CI: 1.6, 15.6; \(n = 8\) and OR: 1.7, 95% CI: 0.4, 3.3; \(n = 10\), respectively) in the Little Hocking water district of Ohio and for kidney cancer (OR: 2.0, 95% CI: 1.3, 3.1; \(n = 23\)) in the Tippers Plains water district of Ohio. Barry et al. \cite{2013, 2850946} extended this work and found significantly increased testicular cancer risk with an increase in the estimated cumulative PFOA serum level (HR: 1.34, 95% CI: 1.00, 1.79; \(n = 17\)). Increases, though nonsignificant, were also observed for kidney cancer (HR: 1.10, 95% CI: 0.98, 1.24; \(n = 105\)) and thyroid cancer (HR: 1.10, 95% CI: 0.95, 1.26; \(n = 86\)). As part of the C8 Health Project, the C8 Science Panel \cite{2012, 9642155} concluded that a probable link existed between PFOA exposure and testicular and kidney cancer \cite{Steenland, 2020, 7161469}.

Since publication of the 2016 PFOA HESD \cite{U.S. EPA, 2016, 3603279}, eight medium confidence epidemiological studies examining the carcinogenicity of PFOA have been published. Six of those studies focused specifically on breast cancer risk. One study adds support to the previous evidence of an association between PFOA and kidney cancer \cite{Shearer, 2021, 7161466}. No new epidemiological studies on testicular cancer were identified. Shearer et al. \cite{2021, 7161466} is a multi-center case-control study nested within the NCI’s PLCO. This randomized clinical trial included all the participants of the screening arm of the PLCO trial who were newly diagnosed with histopathologically confirmed RCC during the follow-up period \((n = 326)\). The authors reported a statistically significant increase in risk of RCC with pre-diagnostic serum levels of PFOA (OR = 2.63; 95% CI: 1.33, 5.20 for the highest vs. lowest quartiles; \(p\)-trend = 0.007, or per doubling of PFOA: OR: 1.71; 95% CI: 1.23, 2.37). After adjusting for other PFAS the association remained significant in analyses on a per doubling increase in PFOA. The increase in the highest exposure quartile remained and the magnitude was similar (i.e., OR = 2.63 without adjusting for other PFAS vs. 2.19 after adjusting for other factors).
PFAS), but it was no longer statistically significant. The analyses accounted for numerous confounders including BMI, smoking, history of hypertension, eGFR, previous freeze-thaw cycle, calendar and study year of blood draw, sex, race and ethnicity, study center. Statistically significant increased odds of RCC were observed in participants ages 55–59 years, and in men and in women, separately.

Notably, a recent critical review and meta-analysis of the epidemiological literature concluded that there was an increased risk for kidney (16%) and testicular (3%) tumors for every 10 ng/mL increase in serum PFOA {Bartell, 2021, 7643457}. Although the authors concluded that the associations were likely causal, they noted that there were a limited number of studies and additional studies with larger cohorts could strengthen the conclusion.

The majority of studies examining associations between PFOA and cancer outcomes were on breast cancer, with five medium confidence epidemiological studies examining the carcinogenicity of PFOA published since the 2016 assessment. Two nested case-control studies did not report an association between breast cancer and PFOA concentrations measured in maternal serum throughout pregnancy and 1–3 days after delivery {Cohn, 2020, 5412451} or in serum after case diagnosis and breast cancer {Hurley, 2018, 5080646}. Both studies were conducted in California and most breast cancer cases were obtained from the cancer registry. Two nested case-control studies found associations between PFOA and breast cancer, but only in specific genotype or estrogen receptive groups of participants {Ghisari, 2017, 3860243; Mancini, 2020, 5381529}. Ghisari et al. (2017, 3860243) reported an increased risk for breast cancer identified from the Danish cancer registry with increasing PFOA concentrations only in subjects with a CC genotype (n = 36 cases and 47 controls) in the CYP19 gene (cytochrome P450 aromatase). A nested case-control study (194 pairs of breast cancer cases and controls) within the French E3N cohort found an 86% higher risk of breast cancer in the 2nd quartile of PFOA compared to the 1st quartile in a partially adjusted model {Mancini, 2020, 5381529}. Mancini et al. (2020, 5381529) also reported that the risk for breast cancer (93% verified as pathologically confirmed from medical records after self-reported cancer diagnosis) varied by type of cancer with a statistically significant increase in ER− and progesterone receptor negative (PR−) breast cancers in the second quartile of PFOA only. The sample size was small with 26 participants having ER− breast cancers and 57 having PR− breast cancers. There was no association between PFOA and receptor-positive breast cancer risk. In Taiwan, Tsai et al. (2020, 6833693) observed a statistically significant increase in risk of breast cancer only in women younger than 50 years, and in ER+ participants aged 50 years or younger, along with a decrease in risk for ER- breast cancers in participants aged 50 years or younger. Significantly increased breast cancer risk was also observed in an NHANES population across serum PFOA quartiles with a significant dose-response trend {Omoike, 2021, 7021502}. A recent study in a Japanese population observed inverse association across serum PFOA quartiles with a significant dose-response trend {Itoh, 2021, 9959632}. The association remained significantly inverse in postmenopausal women in the highest tertile of exposure, with a significant dose-response trend. Overall, study design issues, lack of replication of the results, and a lack of mechanistic understanding of PFOA on specific breast cancer subtypes or in subpopulations limit firm conclusions regarding PFOA and breast cancer.

These findings are supported by other recent assessments and reviews {IARC, 2016, 3982387; ATSDR, 2021, 9642134; Steenland, 2021, 7491705; CalEPA, 2021, 9416932}. In their review
of the available epidemiological data, the International Agency for Research on Cancer (IARC) (2016, 3982387) concluded that the evidence for testicular cancer was “considered credible and unlikely to be explained by bias and confounding, however, the estimate was based on small numbers.” Similarly, IARC (2016, 3982387) concluded that the evidence for kidney cancer was also credible but noted that chance, bias, and confounding could not be ruled out with reasonable confidence. They considered that there was limited evidence in humans for the carcinogenicity of PFOA.

3.5.4.1.2 Evidence from Animal Bioassays

In addition to the available epidemiological data, two multi-dose bioassays and one single-dose chronic cancer bioassay are available that investigate the relationship between dietary PFOA exposure and carcinogenicity in male and female rats (Butenhoff, 2012, 2919192; NTP, 2020, 7330145; Biegel, 2001, 673581). Increased incidences of neoplastic lesions were primarily observed in male rats, though results in females are supportive of potential carcinogenicity of PFOA. Testicular LCTs were identified in both the Butenhoff et al. (2012, 2919192) and Biegel et al. (2001, 673581) studies. LCT incidence at similar dose levels was comparable between the two studies (11% and 14%). PACTs were observed in both the NTP (2020, 7330145) and Biegel et al. (2001, 673581) studies. NTP (2020, 7330145) reported increased incidences of pancreatic acinar cell adenomas in males in all treatment groups compared to their respective controls (Table 3-12). This rare tumor type was also observed in female rats from the highest dose group, though these increases did not reach statistical significance. Biegel et al. (2001, 673581) similarly reported increases in the incidence of PACTs in male rats treated with PFOA, with zero incidences observed in control animals. In addition, NTP (2020, 7330145) reported dose-dependent increases in the incidence of liver adenomas in male rats (Table 3-11), which were also observed by Biegel et al. (2001, 673581). Overall, NTP concluded that under the exposure conditions of their report, there was clear evidence of carcinogenic activity of PFOA in male Sprague Dawley rats and some evidence of carcinogenic activity of PFOA in female Sprague Dawley rats based on the observed tumor types {NTP, 2020, 7330145}.

The report from NTP (2020, 7330145) provides evidence that chronic exposure accompanied by perinatal exposure to PFOA does not increase cancer risk when compared to chronic exposure scenarios alone. There were no differences in the incidences of all tumor types examined across the treatment groups administered PFOA during both perinatal and postweaning periods compared with the postweaning-only treatment groups (see further study design details in Section 3.4.4.2.1.2). Age-dependent sensitivity to the carcinogenic effects of PFOA was previously only addressed in the study by Filgo et al. (2015, 2851085) in mice which is limited in terms of its gestational-only study design and small sample sizes.

3.5.4.2 Mode of Action Analysis

As PFOA has been associated with multi-site tumorigenesis in both epidemiological studies and animal toxicological studies, not always with site concordance, it is reasonable to assume that it may act through multiple carcinogenic MOAs. In the 2016 HESD {U.S. EPA, 2016, 3603279}, EPA suggested that the induction of tumors was likely due to interactions with nuclear receptors, perturbations in the endocrine system, interruption of intercellular communication, mitochondrial effects, and/or perturbations in the DNA replication and cell division processes. Since that time, several health agencies have reviewed the available mechanistic literature. For example,
CalEPA’s Office of Environmental Health Hazard Assessment recently concluded that PFOA “possesses several of the key characteristics of carcinogens, including the ability to induce oxidative stress, inflammation, and modulate receptor-mediated effects. Additionally, there is suggestive evidence that PFOA... is genotoxic, thus a genotoxic MOA for cancer remains plausible” {CalEPA, 2021, 9416932}. IARC (2016, 3982387) also concluded that there is moderate evidence for many potential mechanisms for PFOA-induced toxicity.

As described in the following subsections, the available mechanistic data continue to suggest that multiple MOAs could play role in the renal, testicular, pancreatic, and hepatic tumorigenesis associated with PFOA exposure in human populations as well as animal models.

3.5.4.2.1 Mode of Action for Renal Tumors
As discussed in Section 3.5.10, there is convincing evidence for an association between renal carcinogenesis and serum PFOA concentrations in epidemiological studies from both the general population and residents of high-exposure communities {Barry, 2013, 2850946; Shearer, 2021, 7161466}. However, there is limited mechanistic information from epidemiological studies explaining the observed renal carcinogenicity. Additionally, many animal models are limited in their ability to replicate kidney damage due to PFOA exposure that is observed in humans {Li, 2017, 3981403}. One factor that may be driving this inconsistency between humans and animals is the difference in renal clearance rates between human and animal models. Regardless of elimination differences, both animal toxicological studies and the limited available human biomonitoring data suggest that the kidneys may be a site of enrichment upon PFOA exposure and subsequent distribution {Shearer, 2021, 7161466}.

The few available studies focusing on PFOA-induced renal toxicity highlight several potential MOAs by which PFOA exposure may result in renal tumorigenesis, including altered cell proliferation and apoptosis, epigenetic alterations, and oxidative stress. However, due to data limitations, it is difficult to distinguish what mechanism(s) are the most relevant for PFOA-induced kidney cancer. The renal-specific evidence supporting multiple MOAs is described in the subsections below, though as described in Section 3.5.3, PFOA generally exhibits evidence of multiple key characteristics of carcinogens which may also be relevant to the MOA for PFOA-induced renal cell carcinoma.

3.5.4.2.1.1 Altered Cell Death, Cell Proliferation, or Nutrient Supply
There is evidence that relative kidney weight, particularly in male rats, is increased after PFOA treatment (see PFOA Appendix) {NTP, 2019, 5400977; Butenhoff, 2004, 1291063; NTP, 2020, 7330145}. However, these increases in kidney weight and presumably increases in cell proliferation may be due to increased need for renal transporters and not necessarily an indicator of the initial stages of carcinogenesis {U.S. EPA, 2016, 3603278}. Though there is conflicting evidence of alterations in relative kidney weight in female rats, NTP (2020, 7330145) reported increased hyperplasia of urothelium that lines the renal papilla in female rats from the 0/1,000 and 300/1,000 ppm (63.4 and 63.5 mg/kg/day, respectively) dose groups at the interim sacrifice timepoint (16 weeks) and in female rats from the 0/300 (18.2 mg/kg/day), 0/1,000, and 300/1,000 ppm dose groups at the terminal sacrifice (107 weeks). These changes were accompanied by increased incidence of renal papilla necrosis at terminal sacrifice in both 1,000 ppm postweaning groups. Though NTP (2020, 7330145) did not explore the mechanisms of toxicity underlying the observed renal effects, they note that prolonged exposure and
relatively high dose levels along with the enhanced efficiency of excretion and increased urinary concentrations of PFOA in female rats (compared to males) may have resulted in cytotoxicity and hyperplasia of the papilla.

Evidence of cytotoxicity and cell cycle disruption was also provided by a single in vitro study in Vero cells (cell line derived from monkey kidney epithelial cells) {Fernández Freire, 2008, 2919390}. Fernández Freire et al. (2008, 2919390) assessed potential cytotoxic effects and alterations in cell cycle progression in Vero cells treated with PFOA at concentrations of 50–500 µM for 24 hours. Cells treated with PFOA exhibited decreases in viability and proliferation, as indicated by alterations in mitochondrial metabolism (MTT assay) and the total number of cells (Bradford/TPC assay), though both assays exhibited a plateau in cytotoxicity at PFOA concentrations of approximately 200 µM and higher. The study also reported dose-dependent increases in the percentage of apoptotic cells with increasing PFOA concentrations. Flow cytometric analysis demonstrated G0/G1 cell cycle arrest in Vero cells treated with the maximum concentration of 500 µM PFOA. The percentage of cells in the G0–G1 stage was increased whereas the percentages of cells in the S and G2-M stages were decreased. The authors hypothesized that the observed cell cycle arrest may be linked to increased ROS and oxidative stress, further described below.

3.5.4.2.1.2 Oxidative Stress
The increases in cytotoxicity and apoptosis in Vero cells treated with up to 500 µM PFOA for 24 hours observed by Fernández Freire et al. (2008, 2919390) were accompanied by a dose-dependent increase in ROS which was statistically significant in the cells treated with 500 µM. The authors noted that severe oxidative stress could induce cell cycle arrest and apoptosis, as described previously {Fernández Freire, 2008, 2919390}. However, in the only available animal toxicological study assessing oxidative damage in the kidney, levels of 8-hydroxydeoxyguanosine (8-OH-dG) DNA damage in the kidney were unchanged in male Fischer 344 rats administered PFOA via the diet (0.02% for 2 weeks) or by IP injection (100 mg/kg single injection) {Takagi, 1991, 2325496}. Though the renal-specific evidence of PFOA-induced oxidative stress is limited, further discussion on oxidative stress in other organ systems is discussed below, as well as in Section 3.5.3.

3.5.4.2.1.3 Epigenetics
Rashid et al. (2020, 6315778) investigated epigenetic markers that could contribute to the kidney dysfunction associated with PFOA exposure. CD-1 mice were orally exposed to 1–20 mg/kg/day PFOA for 10 days and kidney tissues were evaluated for epigenetic alterations (DNA methylation and histone acetylation). Though no PFOA-induced changes in global methylation were noted (by measurements of 5-methyl cytosine and 5-hydroxy methylation levels), the study reported specific methylation changes with reduced representation bisulfite sequencing (RRBS). Overall, 879 genes were differentially methylated in the 20 mg/kg/day dose group vs. control. PFOA exposure also altered mRNA expression of several proteins that regulate DNA methylation, including DNA methyl transferases and ten eleven translocation enzymes, as well as mRNA expression of several histone deacetylases. Combined, these results suggest that PFOA exposure triggered epigenetic alterations, including DNA methylation changes and potentially histone modifications, in the kidney {Rashid, 2020, 6315778}. However, further study is needed to explore connections between the observed epigenetic changes and subsequent regulation of genes associated with kidney tumorigenesis.
3.5.4.2.2 Mode of Action for Testicular Tumors

There is both epidemiological evidence and evidence from animal bioassays of an association between increased PFOA serum concentrations or doses and testicular carcinogenesis. Testicular cancer was observed in epidemiological studies from the C8 Health Project {Barry, 2013, 2850946; Vieira, 2013, 2919154}. In addition, a recent meta-analysis concluded that there is a 3% increase in risk for testicular cancer with every 10 ng/mL increase in serum PFOA concentrations {Bartell, 2021, 7643457}. In animal models, testicular tumors (Leydig cell tumors (LCTs)) were reported in two chronic studies in male Sprague-Dawley rats {Butenhoff, 2012, 2919192; Biegel, 2001, 673581}. Combined, these results indicate that the testes are a common site of PFOA-induced tumorigenesis.

The available literature highlights several potential MOAs by which PFOA exposure may result in increased incidence of LCTs in animals, though it is unclear whether these MOAs are relevant to testicular cancers associated with PFOA exposure in humans. In a review of LCTs published by Clegg et al. (1997, 224277), a workgroup identified seven non-genotoxic hormonal MOAs (i.e., androgen receptor antagonism; testosterone biosynthesis inhibition; 5α-reductase inhibition; aromatase inhibition; estrogen agonism; GnRH agonism; and dopamine agonism), the majority of which involved downstream increases in luteinizing hormone (LH) levels and subsequent Leydig cell hyperplasia/tumorigenesis. It has been proposed that PPARα agonism potentially mediates these effects, though the evidence supporting this claim is not as strong as for other tumor types (i.e., hepatic tumors) {Klaunig, 2003, 5772415; Klaunig, 2012, 1289837}.

The testes-specific evidence for various MOAs are described in the subsections below, though, as described in Section 3.5.3, PFOA generally exhibits evidence of multiple key characteristics of carcinogens which may also be relevant to the MOA for testicular cancers associated with increased serum PFOA concentrations in humans.

3.5.4.2.2.1.1 Hormone-mediated MOAs

Clegg et al. (1997, 224277) identified five human-relevant MOAs for LCTs that involve alterations in hormone balances, steroid receptor activity, or enzymes involved in steroid metabolism (androgen receptor antagonism; testosterone biosynthesis inhibition; 5α-reductase inhibition; aromatase inhibition; estrogen agonism). In addition, some compounds have been shown to influence Leydig cell function, including steroidogenesis, via hormone-mediated MOAs that are initiated upon PPARα activation {Gazouli, 2002, 674161; Klaunig, 2003, 5772415}. Klaunig et al. (2003, 5772415) described two proposed hormone-mediated MOAs and key events by which PPARα agonists could induce LCTs in rats: one MOA which is secondary to liver PPARα induction and one MOA which involves direct inhibition of testosterone biosynthesis in the testes. These two MOAs involve associative key events such as increased aromatase activity, increased serum estradiol (E2) levels, increased TGFα levels, decreased testosterone levels, increased LH levels, and/or Leydig cell proliferation.

There is no evidence in the identified literature of PFOA treatment resulting in 5α-reductase inhibition. Similarly, the majority of the limited available in vitro studies report that PFOA does not act as an androgen receptor antagonist {McComb, 2019, 6304412; Kang, 2016, 3749062; Du, 2013, 2850983; Rosenmei, 2013, 2919164}. In vivo studies in male rats and mice generally found no effect of oral PFOA exposure on testicular aromatase activity or mRNA expression, though there was some evidence for increased hepatic microsomal aromatase activity or mRNA
expression \{Li, 2011, 1294081; Biegel, 1995, 1307447; Liu, 1996, 1307751\}. This hepatic aromatase activity provides some support for the MOA that is secondary to liver PPARα induction \{Klaunig, 2003, 5772415\}.

Although increased aromatase activity was observed indicating potential increases in the conversion of androgens to estrogens, further evidence of estrogen agonism in rodents was not robust. Biegel et al. (2001, 673581) reported consistent increases in serum E2 in male rats treated with the same concentration of PFOA that induced LCTs (300 ppm; approximately 13.6 mg/kg/day); however, the estrogen levels were too low to be accurately measured with the radioimmunoassay methods utilized in the study. Cook et al. (1992, 1306123) observed similar increases in serum E2 concentrations in male rats gavaged with 10, 25, or 50 mg/kg/day PFOA for 14 days, though the authors also used a radioimmunoassay and reported similarly low E2 concentrations. Perkins et al. (2004, 1291118) additionally reported suggestive increases in serum E2 concentrations in male rats treated with up to 6.5 mg/kg/day PFOA for 13 weeks, though this response was not statistically significant. Overall, there is not sufficient evidence to support estrogen agonism as the MOA for PFOA-induced LCTs.

Several of the available studies support an impact of PFOA on testosterone production in male rodents \{Biegel, 1995, 1307447; Cook, 1992, 1306123; Zhang, 2014, 2850230; Song, 2019, 5079725; Li, 2011, 1294081; Eggert, 2019, 5381535; Lu, 2019, 5381625; Martin, 2007, 758419\}, as well as in men from the general population or high-exposure communities from epidemiological studies \{Cui, 2020, 6833614; Petersen, 2018, 5080277; Lopez-Espinosa, 2016, 3859832\}. However, neither the subchronic nor the chronic study in male rats that measured serum testosterone reported decreases across multiple time points ranging from 1-21 months \{Perkins, 2004, 1291118; Biegel, 2001, 673581\}. Though there is evidence of PFOA-induced inhibition of testosterone biosynthesis, this lack of response in the only study that both observed LCTs and measured testosterone serum levels limits potential conclusions about whether decreased testosterone plays a role in the MOA for LCTs \{Biegel, 2001, 673581\}.

Support for at least partial PPARα mediation of testosterone production inhibition due to PFOA administration is available from one study in mice \{Li, 2011, 1295081\}. Significantly reduced plasma testosterone concentrations were observed in male wildtype PPARα mice and humanized PPARα transgenic mice. These decreases were visible but no longer statistically significant in PPARα-null mice. In addition, reduced reproductive organ weights and increased sperm abnormalities were also observed in PFOA-treated male PPARα wild-type and humanized PPARα mice but not in PPARα-null mice \{Li, 2011, 1295081\}. However, data are not currently sufficient to demonstrate that the other key steps in the postulated PPARα-mediated MOAs are present in PFOA-treated animals following exposures that lead to tumor formation. Studies are needed to demonstrate the increase of GnRH and LH in concert with the changes in aromatase and further study is needed to confirm the potential increases in serum E2. There was also no indication of increased Leydig cell proliferation at the doses that caused adenomas in the Biegel et al. (2001, 673581) study. Thus, additional research is needed to determine if the hormone testosterone-E2 imbalance is a key factor in development of LCTs as a result of PFOA exposure.

3.5.4.2.3 Mode of Action for Pancreatic Tumors
As discussed in Section 3.5.20, PACTs were identified in male rats in two 2-year chronic cancer bioassays \{Biegel, 2001, 673581; NTP, 2020, 7330145\}. In fact, NTP (2020, 7330145) reported
increased incidences of pancreatic acinar cell adenomas in males in all treatment groups, as well as increased incidence, though non-significant, in female rats from the highest dose group. A subchronic drinking water exposure study in the LSL-KRas\textsuperscript{G12D}; Pdx-1 Cre (KC) mouse model for pancreatic cancer also provides evidence that PFOA exposure promotes the growth of pancreatic lesions {Kamendulis, 2022, 10176439}.

The literature provides two hypothetical MOAs for PFOA-induced pancreatic tumors in animal models, including one study that utilizes a transgenic mouse model to mimic the histologic progression of pancreatic cancer that occurs in humans {Kamendulis, 2022, 10176439; Klaunig, 2003, 5772415; Klaunig, 2012, 1289837}. The proposed MOAs are: 1) changes in bile acid, potentially linked to activation of hepatic PPAR\(\alpha\), leading to cholestasis, a positive cholecystokinin (CCK) feedback loop, and acinar cell proliferation; and 2) oxidative stress. However, the existing database is limited in its ability to determine the relationship between PFOA exposure and these MOAs, particularly for the PACTs observed in chronic rat studies.

### 3.5.4.2.3.1 Gastric Bile Alterations

Gastric bile compositional changes or flow alterations can lead to cholestasis, a reduction or stoppage of bile flow. Cholestasis may cause an increase in CCK, a peptide hormone that stimulates digestion of fat and protein, causes increased production of hepatic bile, and stimulates contraction of the gall bladder. There is some research to suggest that pancreatic acinar cell adenomas may result from increased CCK levels resulting from blocked bile flow {Obourn, 1997, 3748746}, which may result in a CCK-activated feedback loop that leads to increased proliferation of secretory pancreatic acinar cells.

PFOA may change bile composition by competing with bile acids for biliary transport. Upregulation of MRP3 and MRP4 transporters {Maher, 2008, 2919367} and downregulation of OATPs {Cheng, 2008, 7588077} linked to PPAR\(\alpha\) activation in mice may favor excretion of PFOA from liver via bile. Minata et al. (2010, 1937251) found that PFOA levels in bile were much higher in wild-type male mice vs. PPAR\(\alpha\)-null mice, suggesting a link to PPAR\(\alpha\). In this study, male mice were dosed with 0, 5.4, 10.8, and 21.6 mg/kg/day PFOA for 4 weeks, resulting in increased total bile acid in PPAR\(\alpha\)-null mice at the highest dose, which indicated that PFOA-induced activation of PPAR\(\alpha\) may result in increased PFOA excretion. This may, in turn, result in decreased flow of bile acids that compete for the same transporters. Notably, however, these alterations in male mice occurred at relatively high dose levels compared to those that resulted in PACTs in male rats {NTP, 2020, 7330145}. There was no further evidence of cholestasis reported in the literature.

Additionally, there is no evidence of alterations in CCK in animal models or human studies. In fact, medical surveillance data from male workers at 3M’s Cottage Grove plant demonstrated a significant negative association between CCK levels and serum PFOA {Olsen, 1998, 9493903; Olsen, 2000, 1424954}. Further, cholestasis was not observed in the workers {Olsen, 2000, 1424954}. It has been suggested that the lack of a positive association may be due to PFOA levels being too low to increase CCK in humans, although it has been demonstrated that PFOA is not an agonist for the CCKA receptor that activates CCK release {Obourn, 1997, 3748746}. Overall, there is not sufficient evidence to determine whether bile acid alterations contribute to the MOA for PACTs observed after chronic PFOA exposure.
3.5.4.2.3.2 Oxidative Stress

More recent literature has suggested a potential role for oxidative stress in pancreatic carcinogenesis associated with PFOA exposure. Hocevar et al. (2020, 6833720) and Kamendulis et al. (2022, 10176439) suggest that pancreatic cancer is induced through the activation of the UPR pathway, which leads to the activation of nuclear factor erythroid 2–related factor 2 (Nrf2), a regulator of the oxidative stress response, and protein kinase-like endoplasmic reticulum kinase (PERK), a signaler of endoplasmic reticulum (ER) stress, and subsequent upregulation antioxidant responses (e.g., SOD gene expression). Activation of the UPR pathway can also stimulate ROS production. Activation of Sod1 in the mouse by the Nrf2 or PERK signaling pathways can stimulate cell proliferation through increased production of hydrogen peroxide which can then, in turn, act as a second messenger in mitogen signaling or through its elimination of ROS, leading to prevention of ROS-stimulated apoptosis {Kamendulis 2022, 10176439}. Activation of PERK through the UPR pathway may also result in increased cytosolic calcium levels through activation of the inositol 1,4,5-trisphosphate receptor (IP3R), leading to ER stress and generation of ROS {Hocevar, 2020, 6833720}.

Induction of tumors by PFOA through the UPR signaling pathway is supported by two studies. Hocevar et al. (2020, 6833720) evaluated PFOA-induced oxidative stress in mouse pancreatic acinar cells (266-6 cells) treated with 50 µg/mL PFOA for various durations. PFOA-exposed cells exhibited increased ER stress as well as activation of PERK, inositol-requiring kinase/endonuclease 1α (IRE1α), and activating transcription factor 6 (ATF6) signaling cascades of the UPR pathway. Exposure to PFOA at concentrations of 20, 50, or 100 µg/mL was also shown to result in time- and dose-dependent increases in cytosolic calcium levels, an effect that occurred predominantly through activation of IP3R. Altogether, results in this study demonstrated that PFOA increased intracellular calcium levels through activation of the IP3R, leading to ER stress, the generation of ROS and oxidative stress and subsequent PERK-dependent induction of antioxidant genes. The oxidative stress and ROS generated in response to PFOA may serve as a mechanism through which PFOA may induce pancreatic tumors.

Kamendulis et al. (2022, 10176439) evaluated the ability for PFOA to promote pancreatic cancer using the KC mouse model, which has a mutation in the KRas gene. KRAS mutations are present in over 90% of human pancreatic cancers; mutating this gene in mice results in a histologic progression of pancreatic cancer that mirrors human pancreatic cancer progression, including formation of pancreatic intraepithelial neoplasia (PanIN). KC mice were exposed to 5 ppm PFOA in drinking water for up to 7 months and effects were monitored after 4 months and 7 months of exposure. PFOA treatment was demonstrated to increase PanIN at 4 months, as well as result in a 2-fold increase in pancreatic lesion number. Significant increases in inflammation were observed in the pancreas after 7 months of exposure. PFOA exposure was associated with enhanced desmoplasia (collagen deposition) in the pancreas compared to controls and also with progressive exposure duration.

Oxidative stress was also apparent in the PFOA-treated mice {Kamendulis, 2022, 10176439}. The authors reported increases in Sod enzyme activity at 4 and 7 months, along with 3-fold increases in Sod1 protein and mRNA levels and increased pancreatic catalase and thioredoxin reductase activities at 4 months relative to control. Pancreatic malondialdehyde, a product of oxidized lipids, was increased at 7 months of exposure but not 4 months, indicating a potential accumulation of oxidative damage over time. Altogether, the results of this study demonstrated
that PFOA increased PanIN area and number at 4 months, indicating early lesion formation. The increased desmoplasia and inflammation (MDA levels) at 7-month exposure suggest PFOA exposure increased disease severity over time, potentially through prolonged oxidative stress, resulting in pancreatic cancer progression.

3.5.4.2.4 Mode of Action for Hepatic Tumors

Two high confidence chronic studies on PFOA reported an increased incidence of hepatocellular adenomas in male rats {Biegel, 2001, 673581; NTP, 2020, 7330145}, one of which also demonstrated increased incidence of hepatocellular carcinomas specific to male rats exposed to PFOA perinatally. As described in the subsections below, the available mechanistic evidence across different in vivo and in vitro models establishes that multiple modes of action (MOA) are plausible for PFOA-induced liver cancer, including PPARα activation, activation of other nuclear receptors such as CAR, and an oxidative stress-mediated MOA.

EPA previously concluded that liver tumor development in rats exposed to PFOA was not relevant to human health because it was determined to be mediated through PPARα activation. A substantial body of evidence exists suggesting that although PPARα activators cause liver tumors in rodents, they are unlikely to result in liver tumors in humans due to comparatively low hepatic PPARα expression, as well as biological differences between rodents and humans in the responses of events that are downstream of PPARα activation {Corton, 2018, 4862049; U.S. EPA, 2016, 3603279}. Specifically, there is strong consensus that the MOA for liver tumor induction by PPARα activators in rodents has limited-to-no relevance to humans, due to differences in cellular expression patterns of PPARα and related proteins (e.g., cofactors and chromatin remodelers), as well as differences in binding site affinity and availability {Corton, 2018, 4862049; Klaunig, 2003, 5772415}. However, there is also evidence that other MOAs are operative in PFOA-induced hepatic tumorigenesis (e.g., cytotoxicity {Felter, 2018, 9642149} and liver necrosis in PFOA-exposed mice and rats; see Section 3.5.2). Recently published data suggest that oxidative stress and other mechanistic key characteristics associated with carcinogens may play a role in liver tumor development, as described further below. The existence of multiple MOAs in addition to PPARα activation suggest that PFOA-induced liver cancer in rats may be more relevant to humans than previously thought.

The available literature on mechanisms related to PFOA-induced hepatic tumor development also supports EPA’s prior conclusion that PFOA-induced tumors are likely due to nongenotoxic mechanisms involving nuclear receptor activation, perturbations of the endocrine system, and/or DNA replication and cell division {U.S. EPA, 2016, 3603729}.

3.5.4.2.4.1 PPARα Activation

Exposure to several PFAS have been shown to activate PPARα, which is characterized by downstream cellular or tissue alterations in peroxisome proliferation, cell cycle control (e.g., apoptosis and cell proliferation), and lipid metabolism {U.S. EPA, 2016, 3603279}. Notably, human expression of PPARα mRNA and protein is only a fraction of what is expressed in rodent models, though there are functional variant forms of PPARα that are expressed in human liver to a greater extent than rodent models {Klaunig, 2003, 5772415; Corton, 2018, 4862049}. Therefore, for PPARα activators that act solely or primarily through PPARα-dependent mechanisms (e.g., Wyeth-14,643 or di-2-ethyl hexyl phthalate), the hepatic tumorigenesis
observed in rodents is expected to be infrequent and/or less severe in humans, or not observed at all {Klaunig, 2003, 5772415; Corton, 2014, 2215399; Corton, 2018, 4862049}.

The MOA for PPARα activator-induced rodent hepatocarcinogenesis consists of the following sequence of key events: 1) PPARα activation in hepatic cells; 2) alterations in cell growth signaling pathways (e.g., increases in Kupffer cell activation leading to increases in TNFα); 3) perturbations of hepatocyte growth and survival (i.e., increased cell proliferation and inhibition of apoptosis); and 4) selective clonal expansion of preneoplastic foci cells leading to increases in hepatocellular adenomas and carcinomas {Klaunig, 2003, 5772415; Corton, 2014, 2215399; Corton, 2018, 4862049}. Modulating factors in this MOA include increased oxidative stress and activation of NF-κB {Corton, 2018, 4862049}, both of which have been demonstrated for PFOA. This MOA is associated with, but not necessarily causally related to, non-neoplastic effects including peroxisome proliferation, hepatocellular hypertrophy, Kupffer cell-mediated events, and increased liver weight. There is also some overlap between signaling pathways and adverse outcomes, including tumorigenesis, associated with PPARα activation and the activation or degradation of other nuclear receptors, such as CAR, PXR, HNF4α, and PPARγ {Rosen, 2017, 3859803; Huck, 2018, 5079648; Beggs, 2016, 3981474; Corton, 2018, 4862049}.

The key events underlying PFOA-induced hepatic tumor development through the PPARα MOA have been demonstrated in both in vivo and in vitro studies and have been discussed in detail previously {U.S. EPA, 2016, 3603729}, as well as in Sections 3.5.2 and 3.5.3 of this document. A number of studies illustrate the potential of PFOA to activate human and rodent PPARα. For example, Buhrke et al. (2013, 232534) demonstrated PPARα activation in human Hep2G cells after 24-hour exposure to PFOA at a concentration of 25 µM. PFOA also activated mouse {Maloney, 1999, 630744; Takacs, 2007, 7922012; Li, 2019, 5387402; Yan, 2015, 3981567} and human PPARα {Takacs, 2007, 7922012} in cell transfection studies. Gene expression analyses showed that PPARα activation was required for most transcriptional changes observed in livers of mice exposed to either PFOA or the known PPARα agonist Wyeth-14,643, demonstrating PFOA’s ability to act as a PPARα agonist {Rosen, 2008, 1290828; 2008, 1290832}. Non-neoplastic (or pre-neoplastic) events that are associated with PPARα activation include peroxisome proliferation, hepatocellular hypertrophy, and increases in liver weight. Studies of PFOA exposure in rodents have reported one or more of these non-neoplastic effects (Section 3.5.2). For example, hepatocellular hypertrophy was observed in one of the two available chronic carcinogenicity studies of PFOA in rats {NTP, 2020, 7330145}, and both studies observed increases in liver weights {Biegel, 2001, 673581; NTP, 2020, 7330145}.

There is evidence from in vivo animal bioassays and in vitro studies of Kupffer cell activation, an indicator of alterations in cell growth, in response to PFOA treatment. Though this mechanism is itself PPARα-independent, factors secreted upon Kupffer cell activation may be required for increased cell proliferation by PPARα activators {Corton, 2018, 4862049}. Minata et al. (2010, 1937251) observed a correlation between PFOA exposure and increased tumor necrosis factor-alpha (TNF-α) mRNA levels in the livers of wild-type (129S4/SvImJ) and Ppara-null (129S4/SvJae-Pparαtm1Gonz/J) mice treated with PFOA (≤50 µmol/kg/day) for four weeks. TNFα is a pro-inflammatory cytokine that can be released upon activation of Kupffer cells {Corton, 2018, 4862049}. Further study is needed to understand the potential role of other mediators of Kupffer cell activation since, unlike PPARα, PPARγ is expressed in Kupffer cells and can also be activated by PFOA.
Studies in both rats and mice have demonstrated that PFOA induces peroxisome proliferation in the liver, an indication of PPARα activation {Elcombe, 2010, 2850034; Minata, 2010, 1937251; Pastoor, 1987, 3748971; Wolf, 2008, 1290827; Yang, 2001, 1014748}. Gene expression profiling of livers of PFOA-exposed rats showed changes indicative of hepatocyte cell growth and proliferation {Martin, 2007, 758419}; exposure of HepG2 cells to low PFOA concentrations (0.1 and 1 μM) was associated with increased expression of cell cycle regulators (e.g., Cyclin D1, Cyclin E1). Higher PFOA concentrations generally had no effect on these genes, but were associated with increased expression of p53, p16, and p21 cell cycle regulators {Buhrke, 2013, 232534}. Evidence for cell proliferation in the form of increased mitotic figures and/or bile duct hyperplasia as observed in PFOA-exposed male mice {Loveless, 2008, 988599}, pregnant mice {Yahia, 2010, 1332451}, male rats {Elcombe, 2010, 2850034}, and female rats {NTP, 2020, 7330145}. Buhrke et al. (2013, 2325346) also reported increased proliferation in HepG2 cells exposed to PFOA, in addition to PPARα activation. With respect to inhibition of apoptosis, there are conflicting reports, with some studies reported decreases in apoptosis following PFOA exposure {Son, 2008, 1276157}, while others report no effect or an increase in apoptosis {Blake, 2020, 6305864; Elcombe, 2010, 2850034; Minata, 2010, 1937251}. There is also evidence to support the clonal expansion key event. In an initiation-promotion study of liver tumor induction in rats, Abdellatif et al. (1990, 2328171) reported that PFOA had promoting activity and increased the incidence of hepatocellular carcinomas. Jacquet et al. (2012, 2124683) exposed SHE cells to PFOA at concentrations ranging from 3.7×10^{-4} – 37.2 μM for 6 days with or without pre-treatment with the tumor initiator benzo-α-pyrene (BaP). PFOA exposure alone did not induce cell transformation, but PFOA did significantly induce transformation in BaP-sensitized cells, indicating that PFOA does not alone initiate cell transformation, but may have tumor promoter-like activity.

Two modulating factors have been proposed as part of the PPARα activation MOA that are relevant to PFOA: increased ROS and activation of NF-κB. Although there is not enough evidence to designate these effects as key events in the MOA, they have the potential to alter the ability of PPARα activators to increase liver cancer, and are thus defined as modulating factors. PFOA exposure has been demonstrated to cause oxidative stress (detailed below).

### 3.5.4.2.4.2 Other Nuclear Receptors

In addition to PPARα, there is some evidence that other nuclear receptors, such as CAR, PXR, PPARγ, and ER, can be activated by PFOA. CAR, which has an established adverse outcome pathway of key events similar to that of PPARα, has been implicated in hepatic tumorigenesis in rodents. The key events of CAR-mediated hepatic tumors are: 1) CAR activation; 2) altered gene expression specific to CAR activation; 3) increased cell proliferation; and 4) clonal expansion leading to altered hepatic foci, leading to 5) liver tumors {Felter, 2018, 9642149}. Non-neoplastic events associated with this pathway include hypertrophy, induction of CAR-specific CYP enzymes (e.g., CYP2B), and inhibition of apoptosis. There is evidence that PFOA can activate CAR and initiate altered gene expression and associative events {Martin, 2007, 758419; Elcombe, 2010, 2850034; Rosen, 2008, 1290828; Rosen, 2008, 1290832; Rosen, 2017, 3859803}. For example, Martin et al. (2007, 758419) and Elcombe et al. (2010, 2850034) observed evidence of activation of CAR-related genes in rats following PFOA exposure, and Wen et al. (2019, 5080582) observed increased CAR activation in PFOA-exposed PPARα knock-out mice compared to wild-type. Other studies have shown altered gene expression of transcriptional targets related to CAR in wild type and PPARα knock-out mice {Rosen, 2008,
As with PPARα-mediated tumorigenesis, there are claims that CAR-mediated tumorigenesis seen in animals is not relevant to humans because CAR activators (e.g., phenobarbital) induce cell proliferation and tumors in rodents but not in human cell lines {Elcombe, 2014, 2343661}. Hall et al. {2012, 2718645} noted that there is evidence that CAR in humans is more resistant to mitogenic effects (e.g., studies showing that human hepatocytes are resistant to induction of replicative DNA synthesis).

There is also evidence that PFOA can activate other nuclear receptors, such as PXR, PPARγ, and ERα. Martin et al. (2007, 758419) and Elcombe et al. (2010, 2850034) observed evidence of PPARγ agonism and/or activation of PXR-related genes in rats following PFOA exposure, and Wen et al. (2019, 5080582) reported evidence suggesting increased ERα and PXR activation in PFOA-exposed PPARα knock-out mice compared to wild-type. PFOA has also been shown to activate PXR in human HepG2 cells {Zhang, 2017, 3604013}. Buhrke et al. (2013, 2325346) demonstrated PPARγ and PPARδ activation at PFOA concentrations of \( \geq 100 \) µM in transfected HEK293 cells, and activation of PPARγ by PFOA in HepG2 cells {Buhrke, 2015, 2850235}.

An evaluation of high-throughput screening (HTS) assay data from the ToxCast/Tox21 program provides further evidence that PFOA activates other nuclear receptors in addition to PPARα. Chiu et al. (2018, 3981309) evaluated HTS data for PFOA in the context of the ten key characteristics of carcinogens as described in Smith et al. (2016, 3160486). The assay results demonstrated PFOA activity in four ER assays (ERa, ERE, ERA_LUC, ERa_BLA), seven PPAR and PXR assays (PPARα, PPARγ, PPRE, hRRAg, PXR, PXRE, hPXR), two androgen receptor assays (rAR, AR_LUC), five enzyme assays (hBACE, hTie2, gLTB4, hORL1, hPY2), and six other assays (Nrf2, RXRb, hCYP2C9, AhR, ELG1, and TR LUC Via.) The results suggest a broad range of PFOA-induced receptor-mediated effects that were not exclusively receptor effects.

Many of the above-described nuclear receptors are known to play a role in liver homeostasis and disease and may be driving factors in the hepatotoxicity observed after PFOA exposure; however, their role in hepatic tumorigenesis is less clear.

### 3.5.4.2.4.3 Cytotoxicity

There is suggestive evidence that PFOA may act through a cytotoxic MOA. Felter et al. (2018, 9642149) identified the following key events for establishing a cytotoxicity MOA: 1) the chemical is not DNA reactive; 2) clear evidence of cytotoxicity by histopathology such as the presence of necrosis and/or increased apoptosis; 3) evidence of toxicity by increased serum enzymes indicative of cellular damage that are relevant to humans; 4) presence of increased cell proliferation as evidenced by increased labeling index and/or increased number of hepatocytes; 5) demonstration of a parallel dose response for cytotoxicity and formation of tumors; and 6) reversibility upon cessation of exposure. As discussed above in the genotoxicity section, there is some evidence that PFOA can induce DNA damage, although most of the genotoxicity data indicate that PFOA is not genotoxic. These data indicate that PFOA may be DNA reactive (either directly or indirectly), but it is not clear if DNA reactivity plays a role in tumorigenicity of PFOA. Quantitative liver histopathology is available in one study {NTP, 2020, 7330145}. Significantly increased single cell (hepatocyte) death and in necrosis in male and female was reported in Sprague-Dawley rats, with a significant dose-response trend.
In vitro results regarding apoptosis are variable. Wielsøe et al. (2015, 2533367) observed no change in LDH release, a marker for cytotoxicity, in HepG2 cells after 24-hour exposure to PFOA doses as high as 2E-5M, while Panaretakis et al. (2001, 5081525) demonstrated that PFOA exposure increased ROS generation, which led to activation of caspase-9 and induction of the apoptotic pathway in HepG2 cells.

Increased cell proliferation or markers of cell proliferation has been reported. Buhrke et al. (2013, 2325346) determined that PFOA exposures of 10 µM and 25 µM for 24 hours resulted in increased proliferation of HepG2 cells. Increases in metabolic activity were also detected at 10, 25, and 50 µM exposures. Low PFOA concentrations (0.1 and 1 µM) were associated with increased expression of cell cycle regulators Cyclin D1, Cyclin E1, and Cyclin B1 whereas higher concentrations generally had no effect on these genes (except for increased expression of Cyclin E1 at 100 µM). The higher PFOA concentration of 100 µM was associated with increased expression of p53, p16, and p21 regulators (a non-significant increase was observed at 25 µM).

Although Wen et al. (2020, 6302274) observed decreasing cell viability with increasing PFOA exposure in HepG2 cells after 48 hours of exposure (20 to 600 µM), no change in metabolic activity was observed. Wen et al. (2020, 6302274) evaluated the impact of PFOA on several genes involved in cell cycle regulation, proliferation, and apoptosis and found that the expression of the BAX gene, a regulator of apoptosis, increased at 20, 50, and 150 µM, and decreased at 100 and 200 µM. The expression of cell cycle genes CCNA2, CCNE1, and CCNB1 was altered, as was that of several genes related to cell proliferation (CDKN1A and CDK4): at lower concentrations (50 µM) of PFOA exposure, a minor increase in expression was observed, while significant decreases in expression was observed in a dose-dependent manner at concentrations >50 µM. Lipid metabolism and transport genes were also altered in the study: increased expression of lipid anabolism gene ACSL1, decreased expression of cholesterol synthesis enzyme gene HMGCR, decreased expression of fatty acid binding protein gene (FABP1), decreased expression ACOX2. There was no change in expression in the beta-oxidation acyl-CoA dehydrogenase enzyme encoding genes ACAD11 and ACADM.

3.5.4.2.4 Genotoxicity
Evidence of PFOA genotoxicity (e.g., chromosomal aberrations, DNA breakage, micronuclei formation) is mixed, whereas most of the evidence for mutagenicity is consistently negative (Table 3-16). In an in vivo study in humans, Franken et al. (2017, 3789256) observed an increase in DNA damage with increasing PFOA exposure, but the effect did not achieve statistical significance. The authors suggest that the DNA damage may have resulted from induction of oxidative stress. Additionally, Governini et al. (2015, 3981589) reported that incidence of aneuploidy and diploidy was increased in PFAS-positive semen samples from non-smokers (PFOA detected in 75% of the samples) compared to PFAS-negative samples. Of the five available animal toxicological studies that evaluated PFOA genotoxicity in vivo, only one yielded a positive result (micronuclei formation in peripheral blood cells from PFOA-exposed rats {NTP, 2019, 5400977}). A number of studies assessing genotoxicity of PFOA in vitro in both animal and human cell lines were reviewed. Results for chromosomal aberrations were negative for PFOA in human lymphocytes both with and without metabolic activation; results in CHO cells were mostly positive, both with and without activation, but the authors reported that the positive results were not reproducible. PFOA exposure induced DNA breakage in all in vitro DNA strand break assays that were reviewed, across three different human cell types. As noted
in U.S. EPA (2016, 3603279) and Fenton et al. (2021, 6988520), the clastogenic effects observed in some PFOA studies may arise from an indirect mechanism related to the physical-chemical properties of PFOA (specifically, PFOA is not subject to metabolism, it binds to proteins, it carries a net-negative electrostatic surface charge) and/or as a consequence of oxidative stress.

PFOA is non-mutagenic both with and without activation in several bacterial assays. Although three positive or equivocal results have been reported, these positive results were either exclusively at cytoxic concentrations or were not reproducible (Table 3-16).

The available evidence suggests that PFOA is not mutagenic, but that PFOA exposure may cause DNA damage, although there is currently no known mechanistic explanation for the interaction between PFOA and genetic material. Although unlikely, genotoxicity cannot be ruled out as a potential MOA for PFOA-induced hepatic tumor formation.

### 3.5.4.2.4.4.1 Consideration of Other Plausible Mode of Actions

In addition to the evidence supporting modulation of receptor-mediated effects, and potential genotoxicity, PFOA also exhibits several other key characteristics (KCs) of carcinogens (Section 3.5.3), some of which are similarly directly evident in hepatic tissues.

For example, PFOA appears to induce oxidative stress, another KC of carcinogens, particularly in hepatic tissues (Section 3.4.1.3.7). Several studies in rats and mice showed evidence of increased oxidative stress and reduced capacity for defense against oxidants and oxidative damage in hepatic tissues.

### 3.5.4.2.4.4.2 Epigenetics

In vivo and in vitro evidence suggests that PFOA induces epigenetic changes, (e.g., DNA methylation; Section 3.5.3.2) with very little liver-specific data. Two studies conducted with human cord blood reported associations between PFOA concentration and changes in DNA methylation (Miura, 2018, 5080353; Kingsley, 2017, 3981315), whereas an additional three studies reported no association between maternal PFOA exposure and global DNA methylation changes in the blood of the children or placenta (Leung, 2018, 4633577; Ouidir, 2020, 6833759; Liu, 2018, 4926233). Leung et al. (2018, 4633577), however, did report some evidence of changes in methylation at CpG sites associated with PFOA exposure in a subset of a Faroese birth cohort with a mean cord blood PFOA concentration of 2.57 µg/L. Watkins et al. (2014, 2850906) found no association between DNA methylation and PFOA in adults from the C8 Health Project.

Li et al. (2019, 5387402) observed PFOA-associated epigenetic alterations in the liver of female mouse pups following maternal exposure to PFOA. Histone acetyltransferase (HAT) levels were decreased, while histone deacetylase (HDAC) levels were increased at all dose levels. These results suggest that PFOA inhibits HAT and enhances HDAC activity, which was further demonstrated by a dose-dependent decrease in acetylation of histones H3 and H4 in the livers of PFOA-treated mice. The authors proposed that increased HDAC may activate PPARα, based upon known interactions between specific HDACs and PPARα (specifically, the class III HDAC SIRT1 deacetylates PPARα resulting in its activation), representing a regulatory role of an event included in the PPARα MOA.
In vitro studies have yielded mixed results with evidence of both hyper- and hypo-methylation of DNA in response to PFOA exposure (Section 3.5.3.2). For example, Pierozan et al. (2020, 6833637) observed increased global methylation in the first daughter cell subculture of breast epithelial MCF-10A cells exposed to PFOA, although levels returned to baseline after the second passage. Two other studies found inverse relationships between global methylation and PFOA concentration in HepG2 and MCF7 cell lines {Wen, 2020, 6302274; Liu, 2020, 6512127, respectively}.

3.5.4.2.4.4 Oxidative Stress

Results vary regarding the effect of PFOA exposure on markers of oxidative stress in in vitro and in vivo studies, both with and without a demonstrated relationship to PPARα activation.

Li et al. (2019, 5387402) observed a dose-dependent increase in 8-OHdG, as well as increases in the antioxidants catalase (CAT) and superoxide dismutase (SOD) (also indicative of oxidative stress) in the liver of female offspring of Kunming mice exposed to 1, 2.5, 5, or 10 mg/kg/day PFOA from GD 0-17, with pups sacrificed at PND 21. Serum AST and ALT levels were significantly increased in the PFOA-treated groups, indicating liver damage. Liver CAT content significantly increased in the 5 and 10 mg/kg/day dose groups. The authors propose that oxidative stress occurred through PPARα activation pathways and demonstrated changes in the mRNA level of PPARα-target genes in the same study. One such target gene is Acox1, which was significantly increased in livers of offspring of dams exposed to ≥2.5 mg/kg/day PFOA. Overexpression of Acox1 has been reported to generate excess ROS, as ACOX1 is involved in fatty acid β-oxidation and produces hydrogen peroxide as a byproduct {Kim et al., 2014, 4318185}. This aligns with oxidative stress being proposed as a modulating factor in the PPARα-activation MOA for rodent hepatic tumors {Corton, 2018, 4862049}, as discussed above. Another study observed an increase in hydrogen peroxide in the liver of PFOA-exposed NMRI mice exposed to PFOA in utero (GD 5–9) {Salimi, 2019, 5381528}. Although they did not measure PPARα targets or PPARα itself, the type of oxidative stress observed aligns with the modulating factor in the MOA.

In contrast, Minata et al. (2010, 1937251) did not observe an increase in a biomarker of oxidative stress in wild-type mice exposed to PFOA. The authors treated wild-type (129S4/SvlmJ) and Ppara-null (129S4/SvJae-Ppara<sup>tm1Gonz</sup>/J) mice with PFOA (≤50 µmol/kg/day) for four weeks, after which no changes in 8-OHdG were observed in the wild-type mice. In contrast, a dose-dependent increase in 8-OHdG levels was observed in the Ppara-null mice, with a significant increase at 50 µmol/kg/day when compared to controls. The correlation between PFOA exposure and 8-OHdG was associated with increased tumor necrosis factor-alpha (TNF-α) mRNA levels.

Takagi et al. (1991, 2325496) performed a two-week subchronic (0.02% powdered PFOA in the diet) in male Fischer 344 rats and evaluated the levels of 8-OHdG in the liver and kidneys after exposure. The 8-OHdG level was significantly higher in the liver of exposed rats relative to controls, while there was no change in the kidneys, despite increased weights of both organs. Another group of rats were administered a single IP injection of PFOA (100 mg/kg) and sacrificed at days 1, 3, 5, and 8. Results were comparable to that of the dietary exposure study, with a significant increase in 8-OHdG levels in the liver (by Day 1 following injection) as well as increased liver weight (by Day 3).
PFOA exposure caused increases in 8-OHdG, a biomarker of oxidative stress, in human lymphoblast cells (TK6) and HepG2 hepatocytes {Yahia, 2014, 2851192; Yao, 2005, 5081563}. Peropadre et al. (2018, 5080270) observed a slight elevation in 8-OHdG levels in PFOA-exposed human p53-deficient keratinocytes (HaCaT), and significantly elevated levels eight days following cessation of PFOA exposure. Several other in vitro studies reported increases in ROS in PFOA-exposed cells, including HepG2, non-human primate kidney, and human-hamster hybrid (AL) cells {Panaretakis, 2001, 5081525; Wielsøe, 2014, 2533367; Fernández Freire, 2008, 2919390; Zhao, 2010, 847496}. In contrast, Florentin et al. (2011, 2919235) did not observe increased ROS in HepG2 cells exposed to 5-400 µM PFOA for 24-hours, despite increased cytotoxicity at 200 µM PFOA and higher.

Some of the in vitro studies reported oxidative stress in relation to cell death and/or DNA damage. For example, Panaretakis et al. (2001, 5081525) investigated ROS, mitochondrial damage, and caspase-9 following PFOA exposure and determined that PFOA-induced apoptosis involved a ROS- and mitochondria-mediated pathway. ROS generation (H₂O₂ and superoxide anions) was detected in HepG2 cells following exposure to 200 and 400 µM PFOA. PFOA treatment also resulted in depolarization of the mitochondria and loss of mitochondrial transmembrane potential. A population of sub-G0/G2 phase of cell cycle was also observed. PFOA treatment was also associated with an increase in cells undergoing apoptotic DNA degradation. Caspase-9 activation was evident in cells exposed to 200 µM PFOA. The results of this study suggested that PFOA exposure increased ROS generation, which led to activation of caspase-9 and induction of the apoptotic pathway in HepG2 cells.

Wielsøe et al. (2015, 2533367) observed a significant increase in ROS production in HepG2 cells exposed to 2.0E-7, 2.0E-6, and 2.0E-5M PFOA for 24 hours, along with a dose-dependent increase in DNA damage. Total antioxidant concentration was significantly decreased after 24 hours of exposure to all PFOA concentrations tested. This study demonstrated that genotoxic effects in vitro are the result of oxidative DNA damage following excess ROS production.

3.5.4.2.4.5 Conclusions

PFOA exposure is associated with several mechanisms that can contribute to carcinogenicity. There is robust evidence that PFOA activates PPARα and initiates downstream events that lead to hepatic tumorigenesis, including key events and modulating factors of the PPARα activator-induced MOA for rodent hepatocarcinogenesis {Klaunig, 2003, 5772415; Corton, 2014, 2215399; Corton, 2018, 4862049}.

Additionally, PFOA exposure is associated with several mechanisms that can contribute to carcinogenicity, including epigenetic changes and oxidative stress, which may occur in conjunction with or independently of PPARα activation. It is plausible that these mechanisms may occur independently of PPARα-dependent mechanisms. These observations are consistent with literature reviews recently published by state health agencies which concluded that the hepatotoxic effects of PFOA may not entirely depend on PPARα activation {CalEPA, 2021, 9416932; NJDWQI, 2017, 5024840}. The existence of multiple MOAs in addition to PPARα activation suggest that PFOA-induced liver cancer in rats may be more relevant to humans than previously thought. Additional research is warranted to better characterize the MOAs for PFOA-induced hepatic tumorigenesis.
As described in the *Guidelines for Carcinogen Risk Assessment* [U.S. EPA, 2005, 6324329], “[i]n the absence of sufficiently, scientifically justifiable mode of action information, EPA generally takes public health-protective, default positions regarding the interpretation of toxicologic and epidemiologic data; animal tumor findings are judged to be relevant to humans, and cancer risks are assumed to conform with low dose linearity.” For the available data regarding the MOA of PFOA-induced hepatic carcinogenesis, there is an absence of definitive information supporting a single, scientifically justified MOA; in fact, there is evidence supporting the potential for multiple plausible MOAs. Therefore, EPA takes the health-protective approach and concludes that the hepatic tumors observed by Biegel et al. (2001, 673581) and NTP (2020, 7330145) can be relevant to human health.

### 3.5.4.3 Conclusions

The available data is limited in its ability to provide enough evidence to support conclusions about potential MOAs for PFOA-induced kidney and testicular tumors in humans. Similarly, there is limited data to support specific MOAs for PFOA-induced testicular and pancreatic tumors in rats. While there is robust evidence that PFOA activates PPARα and initiates downstream events that lead to hepatic tumorigenesis, there are also reports of PPARα-independent MOAs that could be the underlying the observed hepatocellular adenomas and carcinomas in rodents treated with PFOA. Additionally, the available *in vivo* and *in vitro* assays provide considerable support that PFOA may induce tumorigenesis through multiple mechanisms that are considered key characteristics of carcinogens.

### 3.5.5 Cancer Classification

Under the *Guidelines for Carcinogen Risk Assessment* [U.S. EPA, 2005, 6324329], EPA reviewed the weight of the evidence and determined that PFOA is *Likely to Be Carcinogenic to Humans*, as “the evidence is adequate to demonstrate carcinogenic potential to humans but does not reach the weight of evidence for the descriptor *Carcinogenic to Humans.*” This determination is based on the evidence of kidney and testicular cancer in humans and LCTs, PACTs, and hepatocellular adenomas in rats.

Since publication of the 2016 HESD [U.S. EPA, 2016, 3603279], the evidence supporting the carcinogenicity of PFOA has been strengthened. In particular, the evidence of kidney cancer from high-exposure community studies [Vieira, 2013, 2919154; Barry, 2013, 2850946] is now supported by evidence of RCC from a nested case-control study in the general population [Shearer, 2021, 7161466]. In animal models, the evidence of multi-site tumorigenesis reported in two chronic bioassays in rats [Butenhoff, 2012, 2919192; Biegel, 2001, 673581] is now supported by evidence from a second chronic bioassay in rats similarly reporting multi-site tumorigenesis [NTP, 2020, 7330145].

The *Guidelines* provide descriptions of data that may support the *Likely to Be Carcinogenic to Humans* descriptor; the available PFOA data are consistent with the following factors:

- “an agent demonstrating a plausible (but not definitively causal) association between human exposure and cancer, in most cases with some supporting biological, experimental evidence, though not necessarily carcinogenicity data from animal experiments;
- an agent that has tested positive in animal experiments in more than one species, sex, strain, site, or exposure route, with or without evidence of carcinogenicity in humans;
• a rare animal tumor response in a single experiment that is assumed to be relevant to humans;
• a positive tumor study that is strengthened by other lines of evidence, for example, either plausible (but not definitively causal) association between human exposure and cancer or evidence that the agent or an important metabolite causes events generally known to be associated with tumor formation (such as DNA reactivity or effects on cell growth control) likely to be related to the tumor response in this case” {U.S. EPA, 2005, 6324329}.

The available evidence indicates that PFOA has carcinogenic potential in humans and at least one animal model. A plausible, though not definitively causal, association exists between human exposure to PFOA and kidney and testicular cancers in the general population and highly exposed populations. As stated in the Guidelines for Carcinogen Risk Assessment, “an inference of causality is strengthened when a pattern of elevated risks is observed across several independent studies.” Two medium confidence independent studies provide evidence of an association between kidney cancer and elevated PFOA serum concentrations {Shearer, 2021, 7161466; Vieira, 2013, 2919154}, while two studies in the same cohort provide evidence of an association between testicular cancer and elevated PFOA serum concentrations {Vieira, 2013, 2919154; Barry, 2013, 2850946}. Additionally, though the Shearer et al. (2021, 7161466) study showed an increased risk of kidney cancer in the highest PFOA exposure quartile (OR = 2.63), the relationship was slightly attenuated (OR = 2.19) and not statistically significant after adjusting for other PFAS. The PFOA cancer database would benefit from additional large high confidence cohort studies in independent populations.

The evidence of carcinogenicity in animals is limited to three studies using the same strain of rat. However, the results provide evidence of increased incidence of three tumor types (LCTs, PACTs, and hepatocellular adenomas) in males administered diets contaminated with PFOA. Additionally, pancreatic acinar cell adenocarcinomas are a rare tumor type {NTP, 2020, 7330145}. Importantly, site concordance is not always assumed between humans and animal models; agents observed to produce tumors may do so at the same or different sites in humans and animals, which appears to be the case for PFOA {U.S. EPA, 2005, 6324329}.

Table 3-17. Comparison of the PFOA Carcinogenicity Database with the Likely Cancer Descriptor as Described in the Guidelines for Carcinogen Risk Assessment {U.S. EPA, 2005, 6324329}

<table>
<thead>
<tr>
<th>Likely to be Carcinogenic to Humans</th>
<th>PFOA data are consistent with this description.</th>
</tr>
</thead>
<tbody>
<tr>
<td>An agent demonstrating a plausible (but not definitively causal) association between human exposure and cancer, in most cases with some supporting biological, experimental evidence, though not necessarily carcinogenicity data from animal experiments</td>
<td>Epidemiological evidence supports a plausible association between exposure and cancer, though there are significant uncertainties regarding the MOAs for tumor types observed in humans. There is supporting experimental evidence, including carcinogenicity data from animal experiments.</td>
</tr>
<tr>
<td>An agent that has tested positive in animal experiments in more than one species, sex, strain, site, or exposure route, with or without evidence of carcinogenicity in humans</td>
<td>PFOA has tested positive in one species (rat), both sexes, and multiple sites (liver, pancreas, testes, uterus). There is also evidence of carcinogenicity in humans.</td>
</tr>
<tr>
<td>Likely to be Carcinogenic to Humans</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td>A positive tumor study that raises additional biological concerns beyond that of a statistically significant result, for example, a high degree of malignancy, or an early age at onset</td>
<td><strong>This description is not applicable to PFOA.</strong> The report by NTP (2020, 7330145) does not indicate that perinatal exposure exacerbates the carcinogenic potential of PFOA.</td>
</tr>
<tr>
<td>A rare animal tumor response in a single experiment that is assumed to be relevant to humans</td>
<td><strong>PFOA data are consistent with this description.</strong> The pancreatic adenocarcinomas observed in multiple male dose groups are a rare tumor type in this strain {NTP, 2020, 7330145}.</td>
</tr>
<tr>
<td>A positive tumor study that is strengthened by other lines of evidence, for example, either plausible (but not definitively causal) association between human exposure and cancer or evidence that the agent or an important metabolite causes events generally known to be associated with tumor formation (such as DNA reactivity or effects on cell growth control) likely to be related to the tumor response in this case</td>
<td><strong>PFOA data are consistent with this description.</strong> Multiple positive tumor studies in the same strain of rat are supported by plausible associations between human exposure and kidney and testicular cancer.</td>
</tr>
</tbody>
</table>

While reviewing the weight of evidence for PFOA, EPA evaluated consistencies of the carcinogenicity database with other cancer descriptors according to the *Guidelines for Carcinogen Risk Assessment* {U.S. EPA, 2005, 6324329}. A discussion on these findings is presented in Section 6.4.
4 Dose-Response Assessment

4.1 Non-Cancer

4.1.1 Study and Endpoint Selection

There is evidence from both epidemiological and animal toxicological studies that oral PFOA exposure may result in adverse health effects across many health outcomes (Section 3.4). Per recommendations made by the SAB and the conclusions presented in EPA’s preliminary analysis, Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) in Drinking Water, EPA has focused its toxicity value derivation efforts “on those health outcomes that have been concluded to have the strongest evidence” {U.S. EPA, 2022, 10476098}. EPA prioritized health outcomes and endpoints with the strongest overall weight of evidence (evidence demonstrates or evidence indicates) based on human and animal evidence (Section 3.4 and 3.5) for POD derivation using the systematic review methods described in Section 2 and the Appendix (see PFOA Appendix). For PFOA, these health outcomes are immunological, developmental, cardiovascular (serum lipids), and hepatic effects. EPA considered both epidemiological and animal toxicological studies for POD derivation.

In the previous section, for hazard judgment decisions (Section 3.4 and 3.5), EPA qualitatively considered high, medium, and, at times, low confidence studies to characterize the weight of evidence for each health outcome. However, given the robust database for PFOA, only well-conducted high or medium confidence human and animal toxicological studies were considered for POD derivation, as recommended in the IRIS Handbook {U.S. EPA, 2022, 10476098}. Such human epidemiological studies were available for immunotoxicity, developmental, serum lipid, and hepatic effects. Preferred animal toxicological studies consisted of medium and high confidence studies of longer exposure duration (e.g., chronic or subchronic studies vs. 28-day studies) or with exposure during sensitive windows of development (i.e., perinatal periods) with exposure levels near the lower dose range of doses tested across the evidence base, along with medium or high confidence animal toxicological studies evaluating exposure periods relevant to developmental outcomes. These types of animal toxicological studies increase the confidence in the RfD relative to other animal toxicological studies because they are based on data with relatively low risk of bias and are associated with less uncertainty related to low-dose and exposure duration extrapolations. See Section 6.3 for a discussion of animal toxicological studies and endpoints selected for POD derivation for this updated assessment compared to those selected for the 2016 PFOA HESD {U.S. EPA, 2016, 3603279}.

For all other health outcomes (e.g., reproductive, endocrine, nervous, hematological, musculoskeletal), the evidence integration summary judgment for the human and animal evidence was suggestive or inadequate and these outcomes were not assessed quantitatively. Uncertainties related to health outcomes for which the results were suggestive are discussed in the evidence profile tables provided in the Appendix (See PFOA Appendix), as well as Section 6.5.
4.1.1.1 Hepatic effects

As reviewed in Section 3.4.1.4, evidence indicates that elevated exposures to PFOA are associated with hepatic effects in humans. As described in Table 3-3, the majority of epidemiological studies assessed endpoints related to serum biomarkers of hepatic injury (9 medium confidence studies), while several studies also reported on liver disease or injury (4 medium confidence studies) and other serum markers of liver function (3 medium confidence studies). EPA prioritized endpoints related to serum biomarkers of injury for quantitative analyses as the reported effects on these endpoints, particularly ALT, were well-represented within the database and were generally consistent across the available medium confidence studies. Specifically, all 5 medium confidence studies in the recent literature reported positive associations between PFOA serum concentrations and ALT in adults, three of which reported statistically significant responses. Findings for AST and GGT in adults were generally positive and are supportive of the selection of ALT as an endpoint for dose-response modeling.

Serum ALT measures are considered a reliable indicator of impaired liver function because increased serum ALT is indicative of leakage of ALT from damaged hepatocytes {Boone, 2005, 782862; Liu, 2014, 10473988; U.S. EPA, 2002, 625713}. Additionally, evidence from both human epidemiological and animal toxicological studies indicates that increased serum ALT is associated with liver disease {Ioannou, 2006, 10473853; Ioannou, 2006, 10473854; Kwo, 2017, 10328876; Roth, 2021, 9960592}. Human epidemiological studies have demonstrated that even low magnitude increases in serum ALT can be clinically significant. For example, a Scandinavian study in people with no symptoms of liver disease observed that relatively small increases in serum ALT were associated with liver diseases such as steatosis and chronic hepatitis C {Mathiesen, 1999, 10293242}. Additionally, a study in Korea found that the use of lowered thresholds for “normal” serum ALT values showed good prediction power for liver-related adverse outcomes such as mortality and hepatocellular carcinoma {Park, 2019, 10293238}. Others have questioned the biological significance of relatively small increases in serum ALT (i.e., less than 2-fold) reported in animal toxicological studies {Hall, 2012, 2718645}, though measures of ALT in these studies can be supported by histopathological evidence of liver damage.

Additionally, numerous studies have demonstrated an association between elevated ALT and liver-related mortality (reviewed by Kwo et al. (2017, 10328876)). Furthermore, the American Association for the Study of Liver Diseases (AASLD) recognizes serum ALT as an indicator of overall human health and mortality {Kim, 2008, 7757318}. For example, as reported by Kwo et al. (2017, 10328876), Kim et al. (2004, 10473876) observed that higher serum ALT concentrations corresponded to an increased risk of liver-related death in Korean men and women; similarly, Ruhl and Everhart (2009, 3405056; 2013, 2331047) analyzed NHANES data and observed an association between elevated serum ALT and increased mortality, liver-related mortality, coronary heart disease in Americans, and Lee et al. (2008, 10293233) found that higher serum ALT was associated with higher mortality in men and women in Olmstead County, Minnesota. Furthermore, the American College of Gastroenterology (ACG) recommends that people with ALT levels greater than 33 (men) or 25 IU/L (women) undergo screenings and assessments for liver diseases, alcohol use, and hepatotoxic medication use {Kwo, 2017, 10328876}. Results of human and animal toxicological studies as well as the positions of the AASLD and the ACG demonstrate the clinical significance of increased serum ALT. It is also
important to note that while evaluation of direct liver damage is possible in animal studies, it is difficult to obtain biopsy-confirmed histological data in humans. Therefore, liver injury is typically assessed using serum biomarkers of hepatotoxicity {Costello et al, 2022, 10285082}.

Results reported in animal toxicological studies are consistent with the observed elevated ALT indicative of hepatic damage in epidemiological studies. Specifically, studies in rodents found that oral PFOA treatment resulted in increased relative liver weight (17/20 high and medium confidence studies), biologically significant alterations in levels of at least one serum biomarker of liver injury (i.e., ALT, AST, and ALP) (6/9 high and medium confidence studies), and evidence of histopathological alterations including hepatocyte degenerative or necrotic changes (12/12 high and medium confidence studies). These hepatic effects, particularly the increases in serum enzymes and histopathological evidence of liver damage are supportive of elevated ALT observed in human populations. Mechanistic studies in rodents and limited evidence from in vitro studies and animal models provide additional support for the biological plausibility and human relevance of the apical effects observed in animals and suggest possible PPARα-dependent and -independent MOA for PFOA induced liver toxicity. EPA prioritized studies that quantitatively reported histopathological evidence of hepatic damage for dose-response modeling because these endpoints are more direct measures of liver injury than serum biomarkers. However, the observed increases in liver enzymes in rodents are supportive of the hepatic damage confirmed during histopathological examinations in several studies.

Four medium confidence epidemiological studies {Gallo, 2012, 1276142; Darrow, 2016, 3749173; Lin, 2010, 1291111; Nian, 2019, 5080307} and one high and one medium confidence animal toxicological study were considered for POD derivation {NTP, 2020, 7330145; Loveless, 2008, 988599} (Table 4-1). The two largest studies of PFOA and ALT in adults are Gallo et al. (2012, 1276142) and Darrow et al. (2016, 3749173), both conducted in over 30,000 adults from the C8 Study. Gallo et al. (2012, 1276142) demonstrated a statistically significant trend in elevated ALT across deciles and Darrow et al. (2016, 3749173) provides an exposure-response gradient for PFOA. Two additional studies {Lin, 2010, 1291111; Nian, 2019, 5080307} were considered by EPA for POD derivation because they reported statistically significant associations in general populations in the United States and a highly exposed population in China, respectively. Nian et al. (2019, 5080307) examined a large population of adults in Shenyang (one of the largest fluoropolymer manufacturing centers in China) as part of the Isomers of C8 Health Project. Lin et al. (2010, 1291111) observed elevated ALT levels per log-unit increase in PFOA in an NHANES adult population and these associations remained after accounting for other PFAS in the regression models. While Lin et al. (2010, 1291111) was considered for POD derivation, several methodological limitations, including lack of clarity about base of logarithmic transformation applied to PFOS concentrations in regression models and the choice to model ALT as an untransformed variable ultimately preclude its use for POD derivation.

EPA identified two studies in male rodents, NTP (2020, 7330145), a chronic dietary study in Sprague Dawley rats (see study design details in Section 3.4.4.2.1.2), and Loveless et al. (2008, 988599), a 29-day gavage dosing study in CD-1 mice, for POD derivation. NTP (2020, 7330145) conducted histopathological examinations of liver tissue in male rats and reported dose-dependent increases in the incidence of hepatocellular single cell death and hepatocellular necrosis. As this is one of the few available chronic PFOA toxicity studies with a large sample

4-3
size (n = 50), numerous and relatively low dose levels, and a comprehensive suite of endpoints, both the single cell death and necrosis endpoints in males from the 107-week time point were considered for derivation of PODs.

Similar to the NTP study (2020, 7330145), Loveless et al. (2008, 988599) provides a comprehensive report of hepatotoxicity, with a low dose range resulting in dose-dependent increases in histopathological outcomes indicating adversity in male mice gavaged with PFOA for 29 days. Therefore, the incidences of focal cell necrosis and individual cell necrosis in male mice from Loveless et al. (2008, 988599) were also considered for the derivation of PODs.

4.1.1.2 Immunological Effects

As reviewed in Section 3.4.2.4, evidence indicates that elevated exposures to PFOA are associated with immunological effects in humans. As described in Table 3-7, the majority of epidemiological studies assessed endpoints related to immunosuppression (1 high and 15 medium confidence studies) and immune hypersensitivity (1 high and 16 medium confidence studies), while several studies (2 medium confidence) also reported on endpoints related to autoimmune disease. Endpoints related to autoimmune diseases were not further considered for quantitative assessments as there were a limited number of studies that assessed specific diseases (e.g., rheumatoid arthritis, celiac disease). Endpoints related to immune hypersensitivity were also not considered for dose-response analyses. Although the majority (6/9) of the available medium confidence studies reported consistent increases in the odds of asthma, there were inconsistencies in effects reported in the same or similar subgroups across these different studies. These inconsistencies limited the confidence needed to select particular studies and populations for dose-response modeling. Other immune hypersensitivity endpoints, such as odds of allergies and rhinoconjunctivitis, had less consistent results reported across medium and high confidence studies and were therefore excluded from further consideration, though they are supportive of an association between PFOA and altered immune function.

Evidence of immunosuppression in children reported by epidemiological studies was consistent across studies and endpoints. Specifically, epidemiological studies reported reduced humoral immune response to routine childhood immunizations, including lower levels of tetanus and anti-diphtheria antibodies {Timmerman, 2021, 9416315; Abraham, 2020, 6506041; Grandjean, 2012, 1248827; Budtz-Jørgensen, 2018, 5083631} and rubella {Granum, 2013, 1937228; Pilkerton, 2018, 5080265; Stein, 2016, 3108691} antibody titers. Reductions in antibody response were observed at multiple timepoints throughout childhood, using both prenatal and childhood exposure levels, and were consistent across study populations from medium confidence studies.

Measurement of antigen-specific antibodies following vaccinations is an overall measure of the ability of the immune system to respond to a challenge. The antigen-specific antibody response is extremely useful for evaluating the entire cycle of adaptive immunity and is a sweeping approach to detect immunosuppression across a range of cells and signals {Myers, 2018, 10473136}. The SAB’s PFAS review panel noted that reduction in the level of antibodies produced in response to a vaccine represents a failure of the immune system to respond to a challenge and is considered an adverse immunological health outcome {U.S. EPA, 2022, 10476098}. This is in line with a review by Selgrade (2007, 736210) who suggested that specific immunotoxic effects observed in children may be broadly indicative of developmental immunosuppression impacting these children’s ability to protect against a range of immune
hazards—which has the potential to be a more adverse effect that just a single immunotoxic effect. Thus, decrements in the ability to maintain effective levels of antitoxins following immunization may be indicative of wider immunosuppression in these children exposed to PFOA.

As noted by Dewitt et al. (2017, 5926400; 2019, 5080663) as well as subject matter experts on the SAB’s PFAS review panel {U.S. EPA, 2022, 10476098}, the clinical manifestation of a disease is not a prerequisite for a chemical to be classified as an immunotoxic agent and the ability to measure clinical outcomes as a result of mild to moderate immunosuppression from exposure to chemicals in traditional epidemiological studies can be challenging. Specifically, the SAB noted that “[d]ecreased antibody responses to vaccines is relevant to clinical health outcomes and likely to be predictive of risk of disease” {U.S. EPA, 2022, 10476098}. The WHO Guidance for immunotoxicity risk assessment for chemicals similarly recommends measures of vaccine response as a measure of immune effects as “childhood vaccine failures represent a significant public health concern” {WHO, 2012, 10633091}. This response is also translatable across multiple species, including rodents and humans, and extensive historical data indicate that suppression of antigen-specific antibody responses by exogenous agents is predictive of immunotoxicity.

When immunosuppression occurs during immune system development, the risks of developing infectious diseases and other immunosuppression-linked diseases may increase {Dietert, 2010, 644213}. Immunosuppression linked with chemical stressors is not the same as an immunodeficiency associated with, for example, genetic-based diseases, but still is an endpoint associated with potential health risks. Studies of individuals exposed at the extremes of age, those with existing immunodeficiencies, and those exposed to chronic stress, show that what may be considered mild to moderate immunosuppression in the general population could result in increased risk of infections in these more susceptible populations {Selgrade, 2007, 736210}. Finally, the immune system continues developing after birth; because of this continued development, exposures to PFAS may have serious and long-lasting consequences {DeWitt, 2019, 5080663; MacGillivray, 2014, 6749084; Selgrade, 2007, 736210}. Hessel et al. (2015, 5750707) reviewed the effect of exposure to nine toxicants on the developing immune system and found that the developing immune system was at least as sensitive or more sensitive than the general (developmental) toxicity parameters. Immunotoxicity that occurs in the developing organism generally occurs at doses lower than required to affect the adult immune system, thus providing a more sensitive endpoint for assessing risk {vonderEmbse, 2018, 6741321}. Luster et al. (2005, 2174509) similarly noted that responses to childhood vaccines may be sensitive enough to detect changes in populations with moderate degrees of immunosuppression, such as those exposed to an immunotoxic agent.

Results reported in animal toxicological studies are coherent with the observed immunosuppression in epidemiological studies. Specifically, studies in rodents found that oral PFOA treatment resulted in reduced immune response (i.e., reduced globulin and immunoglobulin levels upon immune challenges) (4 medium confidence studies) and altered immune cell populations (e.g., altered white blood cell counts, altered splenic and thymic cellularity) (1 high and 4 medium confidence studies). Immunosuppression evidenced by functional assessments of the immune responses, such as analyses of globulin and immunoglobulin levels after challenges, are supportive of decreased antibody responses seen in
human populations and were therefore prioritized for quantitative assessment. Studies assessing alterations in immune cell populations were not considered further as there were a limited number of studies assessing specific endpoints of interest or because effects were observed in only a single species or sex. Other immune effects observed in animals, such as altered organ weights and histopathology, were not considered for dose-response assessments as these effects may be confounded by changes in body weight, effects were not consistent across species, sexes, or studies, and/or a limited number of studies assessed specific outcomes, though overall, the results from these endpoints are consistent with evidence indicating alterations in immune function and response from animal toxicological studies.

Two medium confidence epidemiologic studies {Budtz-Jørgensen, 2018, 5083631; Timmerman, 2021, 9416315} and two medium confidence animal toxicological studies {DeWitt, 2008, 1290826; Loveless, 2008, 988599} were considered for POD derivation (Table 4-1). The candidate epidemiological studies offer data characterizing antibody responses to vaccinations in children using a variety of PFOA exposure measures across various populations and vaccinations. Budtz-Jørgensen and Grandjean (2018, 5083631) investigated anti-tetanus and anti-diphtheria responses in Faroese children aged 5–7 and Timmerman et al. (2021, 9416315) investigated anti-tetanus and anti-diphtheria responses in Greenlandic children aged 7–12. Given the mixed epidemiological results for hypersensitivity and autoimmune disease, these outcomes were not considered for derivation of PODs. In addition to the results from epidemiological studies, impaired IgM response reported in Dewitt et al. (2008, 1290826), a 15-day drinking water exposure study in female mice, and Loveless et al. (2008, 988599), a 29-day study in male mice, supported the evidence of immunosuppression in humans and were also considered for POD derivation.

### 4.1.1.3 Cardiovascular effects

As reviewed in Section 3.4.3.4, evidence indicates that elevated exposures to PFOA are associated with cardiovascular effects in humans. As described in Table 3-8, the majority of epidemiological studies assessed endpoints related to serum lipids (1 high and 20 medium confidence studies) and blood pressure and hypertension (3 high and 14 medium confidence studies), while several studies also reported on cardiovascular disease (1 high and 5 medium confidence studies) and atherosclerosis (1 high and 3 medium confidence studies). Endpoints related to cardiovascular disease and atherosclerosis were not prioritized for dose-response as they reported mixed or primarily null results. Endpoints related to blood pressure and hypertension were also not prioritized for quantitative analyses because studies reported no effects or generally mixed associations, though there was some evidence of associations between PFOA exposure and continuous measures of blood pressure and risk of hypertension in adults from the general population and high-exposure communities.

The majority of studies in adults from the general population, including high-exposure communities, reported positive associations between PFOA serum concentrations and serum lipids. Specifically, medium confidence epidemiological studies in adults reported positive associations between PFOA exposure and total cholesterol (TC) (8/10 studies), low-density lipoprotein (LDL) (6/6 studies), and triglycerides (5/9 studies). Of these three endpoints, EPA prioritized TC for quantitative assessments because the association was consistently positive in adults, with some studies reporting statistically significant ORs, this response was more consistently positive in other populations (i.e., children and pregnant women) compared to LDL
and triglycerides, and elevations in TC were reported in a marginally larger number of studies. Additionally, the positive associations with TC were supported by a recent meta-analysis restricted to 14 general population studies in adults {U.S. EPA, 2022, 10369698}.

Increased serum cholesterol is associated with changes in incidence of cardiovascular disease events such as myocardial infarction (MI, i.e., heart attack), ischemic stroke (IS), and cardiovascular mortality occurring in populations without prior CVD events {D’Agostino, 2008, 10694408; Goff, 2014, 3121148; Lloyd-Jones, 2017, 10694407}. Additionally, disturbances in cholesterol homeostasis contribute to the pathology of non-alcoholic fatty liver disease (NAFLD) and to accumulation of lipids in hepatocytes {Malhotra, 2020, 10442471}. Cholesterol is made and metabolized in the liver, and thus the evidence indicating that PFOA exposure disrupts lipid metabolism, suggests that toxic disruptions of lipid metabolism by PFOA are indications of hepatotoxicity.

Though results reported in animal toxicological studies support the alterations in lipid metabolism observed in epidemiological studies, variations in the direction of effect with dose increases the uncertainty of the biological relevance of these responses in rodents to humans. Additionally, the available mechanistic data does not help to explain the non-monotonicity of serum lipid levels and decreased serum lipid levels at higher dose levels in rodents (Section 3.4.3.2). EPA did not derive PODs for animal toxicological studies reporting cardiovascular effects, such as altered serum lipid levels, due to uncertainties about the human relevance of these responses.

Three medium confidence epidemiologic studies were considered for POD derivation (Table 4-1) {Dong, 2019, 5080195; Lin, 2019, 5187597; Steenland, 2009, 1291109}. These candidate studies offer a variety of PFOA exposure measures across various populations. Dong et al. (2019, 5080195) investigated the NHANES population (2003–2014), while Steenland et al. (2009, 1291109) investigated effects in a high-exposure community (the C8 Health Project study population). Lin et al. (2019, 5187597) collected data from prediabetic adults from the DPP and DPPOS at baseline (1996–1999). Dong et al. (2019, 5080195) and Steenland et al. (2009, 1291109) excluded individuals prescribed cholesterol medication from their analyses, a potential confounder for the total cholesterol endpoint, while Lin et al. (2019, 5187597) did not.

### 4.1.1.4 Developmental effects

As reviewed in Section 3.4.4.4, evidence indicates that elevated exposures to PFOA are associated with developmental effects in humans. As described in Table 3-10, the majority of epidemiological studies assessed endpoints related to fetal growth restriction (22 high and 14 medium confidence studies) and gestational duration (11 high and 5 medium confidence studies), while several studies also reported on endpoints related to fetal loss (2 high and 2 medium confidence studies) and birth defects (2 medium confidence studies). Findings from the small number of studies reporting on birth defects were mixed and therefore not prioritized for quantitative assessments. Although half of the available high and medium confidence studies reported increased incidence of fetal loss (2/4), EPA did not prioritize this endpoint for dose-response analyses as there were a relatively limited number of studies compared to endpoints related to gestational duration and fetal growth restriction and the evidence from high confidence studies was mixed. The impacts observed on fetal loss are supportive of an association between PFOA exposure and adverse developmental effects.
Approximately half of the available studies reporting metrics of gestational duration observed increased risk associated with PFOA exposure. Six of the fourteen medium or high confidence studies reported adverse effects on gestational age at birth and five of the eleven medium or high confidence studies reported an association with preterm birth. Gestational age was not prioritized for quantitative analyses because several studies did not report statistically significant results and some studies reported inconsistent responses across sexes. There were generally more consistent associations with adverse effects on preterm birth, particularly from the high confidence studies. However, there were some concerns with sample timing and potential influence of pregnancy hemodynamics on the observed outcomes, as the majority of studies reporting increased odds of preterm birth sampled PFOA concentrations later in pregnancy. While overall there appears to be associations between PFOA exposure and gestational duration, the inconsistencies in the database and lack of studies sampling in the first trimester of pregnancy reduce the level of confidence in the responses preferred for endpoints prioritized for dose-response modeling.

The adverse effects on gestational duration were consistent with effects on fetal growth restriction. The majority of high and medium confidence epidemiological studies (17/25) reported associations between PFOA and decreased mean birth weight in infants. Studies on changes in standardized birth weight measures (i.e., z-scores) also generally reported inverse associations (6/12 studies; 5 high and 1 medium confidence). Low birth weight is clinically defined as birth weight less than 2,500 g (approximately 5.8 lbs) and can include babies born SGA (birth weight below the 10th percentile for gestational age, sex, and parity) {JAMA, 2002, 10473200; McIntire, 1999, 15310; U.S. EPA, 2013, 4158459}. Low birth weight is widely considered a useful measure of public health {Cutland, 2017, 10473225; Lira, 1996, 10473966; Vilanova, 2019, 10474271; WHO, 2004, 10473140} and is on the World Health Organization’s (WHO’s) global reference list of core health indicators {WHO, 2014, 10473141; WHO, 2018, 10473143}.

Substantial evidence links low birth weight to a variety of adverse health outcomes at various stages of life. It has been shown to predict prenatal mortality and morbidity {Cutland, 2017, 10473225; U.S. EPA, 2013, 4158459; WHO, 2014, 10473141} and is a leading cause of infant mortality in the United States {CDC, 2021, 10473144}. Low-birth-weight infants are also more likely to have underdeveloped and/or improperly-functioning organ systems (e.g., respiratory, hepatic, cardiovascular), clinical manifestations of which can include breathing problems, red blood cell disorders (e.g., anemia), and heart failure {Guyatt, 2004, 10473298; JAMA, 2002, 10473200; U.S. EPA, 2013, 4158459; WHO, 2004, 10473140; Zeleke, 2012, 10474317}. Additionally, low-birth-weight infants evaluated at 18 to 22 months of age demonstrated impaired mental development {Laptook, 2005, 3116555}.

Low birth weight is also associated with increased risk for diseases in adulthood, including obesity, diabetes, and cardiovascular disease {Gluckman, 2008, 10473269; Osmond, 2000, 3421656; Risnes, 2011, 2738398; Smith, 2016, 10474151; Ong, 2002, 10474127, as reported in Yang \ 2022, 10176603}. Poor academic performance, cognitive difficulties {Hack, 2002, 3116212; Larroque, 2001, 10473940}, and depression {Loret de Mola, 2014, 10473992} in adulthood have also been linked to low birth weight. These associations between low birth weight and infant mortality, childhood disease, and adult disease establish low birth weight as an adverse effect. Given the known consequences of this effect, as well as the consistency of the database and large number of high confidence studies reporting statistically significant odds of
this effect, the endpoint of low birth weight in humans was considered for dose-response modeling.

Results reported in animal toxicological studies are consistent with the observed developmental toxicity in epidemiological studies. Specifically, studies in rodents found that gestational PFOA treatment resulted in reduced offspring weight (8/11 studies; 2 high and 6 medium confidence), decreased offspring survival (6/9 studies; 1 high and 5 medium confidence), reduced maternal weight (3/8 studies; 2 high and 1 medium confidence), developmental delays (2/2 studies; both medium confidence), physical abnormalities (2/2 studies; both medium confidence), and altered placental parameters (2/2 studies; both medium confidence). The developmental effects seen in the offspring of rodents treated with PFOA are supportive of low birth weight and potential consequences of low birth weight observed in human populations.

Given the large number of adverse effects identified in the animal toxicological database for the developmental health outcome, EPA considered only the most sensitive effects in pups supported by multiple studies for derivation of PODs. EPA focused on the animal toxicological studies with effects in offspring, as opposed to placental or maternal effects, because these effects provide concordance with the approximate timing of low birth weight observed in human infants. Though several studies measured birth weight in dams, there were inconsistencies across the database, with some studies reporting decreased maternal weight, some reporting no effect, and some reporting increased maternal weight due to PFOA treatment. These inconsistencies may stem from the potential confounding effect of reduced offspring weight observed in those same studies. EPA also focused on endpoints for which multiple animal toxicological studies corroborated the observed effect, thereby increasing the confidence in that effect. Multiple animal toxicological studies observed effects at low dose levels and demonstrated a dose-related response in decreased offspring weight, decreased offspring survival, and developmental delays, which therefore, were prioritized for dose-response analyses.

Six high confidence epidemiologic studies {Chu, 2020, 6315711; Govarts, 2016, 3230364; Sagiv, 2018, 4238410; Starling, 2017, 3858473; Wikström, 2020, 6311677; Yao, 2021, 9960202} and 3 medium confidence animal toxicological studies {Li, 2018, 5084746; Song, 2018, 5079725; Lau, 2006, 1276159} were considered for POD derivation (Table 4-1). The candidate epidemiological studies offer a variety of PFOA exposure measures across the fetal and neonatal window. All six studies reported their exposure metric in units of ng/mL and reported the β coefficients per ng/mL or ln(ng/mL), along with 95% confidence intervals, estimated from linear regression models. In addition, the endpoints of decreased fetal body weights in mice gestationally treated with PFOA from GD 1–17 {Li, 2018, 5084746}, decreased pup survival at PND 22 in male mice gestationally treated with PFOA from GD 1–17 {Song, 2018, 5079725}, and delayed eye opening in mice gestationally treated with PFOA from GD 1–17 {Lau, 2006, 1276159} were considered for the derivation of PODs.

Table 4-1 summarizes the studies and endpoints considered for POD derivation.
### Table 4-1. Summary of Endpoints and Studies Considered for Dose-Response Modeling and Derivation of Points of Departure for All Effects in Humans and Rodents

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Reference, Confidence</th>
<th>Strain/Species/ Sex</th>
<th>POD Derived?</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immune Effects</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduced Antibody Concentrations for Diphtheria</td>
<td>Budtz-Jørgensen and Grandjean (2018, 5083631)\textsuperscript{a}</td>
<td>Human (male and female children)</td>
<td>Yes</td>
<td>Evidence for immune effects is based on decreases in childhood antibody responses to pathogens such as diphtheria and tetanus. Reductions in antibody response were observed at multiple timepoints in childhood, using both prenatal and childhood exposure levels. Effect was large in magnitude and generally coherent with epidemiological evidence for other antibody effects.</td>
</tr>
<tr>
<td>and Tetanus</td>
<td>Timmerman et al. (2021, 9416315)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduced Antibody Concentrations for Rubella</td>
<td>Granum et al. (2013, 1937228)</td>
<td>Human (male and female children)</td>
<td>No</td>
<td>Effect was large in magnitude and generally coherent with epidemiological evidence for other antibody effects, however, the data were not suitable for application of a BMR of 1 SD and ½ SD to provide a reasonably good estimate of 10% and 5% extra risk. The Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433} explains that in a control population where 1.4% are considered to be at risk of having an adverse effect, a downward shift in the control mean of one SD results in about 10% extra risk of being at risk of having an adverse effect. Using a cut off value of 0.1 IU/mL resulted in 0.003% of the control population at risk of having an adverse effect, a value much smaller than 1.4% which in turn did not result in 10% extra risk. (see PFOA Appendix).</td>
</tr>
<tr>
<td>Reduced Antibody Concentrations for Influenza</td>
<td>Looker et al. (2014, 2850913)</td>
<td>Human (male and female adults)</td>
<td>No</td>
<td>Effect observed in adults coherent with evidence for other antibody effects in children. The study was not amenable to modeling because of inconsistent results by vaccine type, lack of dose-response trend, and imprecision of most results.</td>
</tr>
<tr>
<td>Reduced immunoglobulin M (IgM) Response</td>
<td>Loveless et al. (2008, 988599)</td>
<td>C57BL/6N mice (females), Crl:CD-1(ICR)BR mice (males)</td>
<td>Yes</td>
<td>Functional assessment indicative of immunosuppression. Immune effects were consistently observed across multiple studies including reduced spleen and thymus weights, altered immune cell populations, and decreased splenic and thymic cellularity. Reduced IgM response is coherent with epidemiological evidence of reduced immune response to vaccinations.</td>
</tr>
<tr>
<td><strong>Developmental Effects</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoint</td>
<td>Reference, Confidence</td>
<td>Strain/Species/Sex</td>
<td>POD Derived?</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------------------</td>
<td>-------------------</td>
<td>--------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Decreased Birth Weight</td>
<td>Chu et al. (2020, 6315711) High Govarts et al. (2016, 3230364) High Sagiv et al. (2018, 4238410) High Starling et al. (2017, 3858473) High Wikström et al. (2020, 6311677) High</td>
<td>Human (male and female infants)</td>
<td>Yes</td>
<td>Evidence for developmental effects is based on consistent adverse effects for FGR including birthweight measures which are the most accurate endpoint. Some deficits were consistently reported for birth weight and standardized birth weight in many high and medium confidence cohort studies. Effect was generally large in magnitude and coherent with epidemiological evidence for other biologically related effects.</td>
</tr>
<tr>
<td>Decreased Birth Weight</td>
<td>Yao et al. (2021, 9960202) High</td>
<td>Human (male and female infants)</td>
<td>No</td>
<td>Effect was supportive of epidemiological evidence for this effect, but the exposure median in this study was at least 10x higher than the other studies considered (see PFOA Appendix).</td>
</tr>
<tr>
<td>Decreased Offspring Survival</td>
<td>Song et al. (2018, 5079725) Medium</td>
<td>Kunming mice (F₁ males and females)</td>
<td>Yes</td>
<td>Effect was consistently observed across multiple studies and species. Supported by the prenatal loss observed by Lau et al. (2006, 1276159) and Wolf et al. (2007, 1332672). Lau et al. (2006, 1276159) was not amenable to benchmark dose modeling (See PFOA appendix). Song et al. (2018, 5079725) was selected over Wolf et al. (2007, 1332672) because Song et al. (2018, 5079725) had more dose groups and tested a lower dose range. BMD modeling results for Wolf et al. (2007, 1332672) are provided in the PFOA appendix for comparison purposes.</td>
</tr>
<tr>
<td>Decreased Fetal Body Weight</td>
<td>Li et al. (2018, 5084746) Medium</td>
<td>Kunming mice (F₁ males and females)</td>
<td>Yes</td>
<td>Effect was consistently observed across multiple studies and species. Supported by reduced offspring weight observed by Lau et al. (2006, 1276159), Wolf et al. (2007, 1332672), Blake et al. (2020, 6305864), and Butenhoff et al. (2004, 1291063). While the data from Lau et al. (2006, 1276159), Wolf et al. (2007, 1332672) and Li et al. (2018, 5084746) were not amenable to BMD modeling (see PFOA appendix), Li et al. (2018, 5084746) was selected because the study tested a relatively large number of dose groups and had decreased variability compared to the other studies. Note that decreases in maternal body weight were also considered for POD derivation but was not a selected endpoint because the decreased fetal body weight could be a potential confounder and was found to be a more sensitive effect.</td>
</tr>
<tr>
<td>Endpoint</td>
<td>Reference, Confidence</td>
<td>Strain/Species/ Sex</td>
<td>POD Derived?</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Delayed Time to Eye Opening</td>
<td>Lau et al. (2006, 1276159) Medium</td>
<td>CD-1 mice (F&lt;sub&gt;1&lt;/sub&gt; males and females)</td>
<td>Yes</td>
<td>Effect also observed in Wolf et al. (2007, 1332672). Lau et al. (2006, 1276159) was prioritized for dose response because this study tested more dose groups (5) with a lower dose range (1, 3, 5,10 and 20 mg/kg/day) than Wolf et al. (2007, 1332672) (2 dose groups – 3 and 5 mg/kg/day). Additionally, the data from Wolf et al. (2007, 1332762) were not amenable to BMD modeling (see PFOA Appendix).</td>
</tr>
<tr>
<td>Serum Lipid Effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased Total Cholesterol</td>
<td>Dong et al. (2019, 5080195) Medium Lin et al. (2019, 5187597) Medium Steenland et al. (2009, 1291109)&lt;sup&gt;b&lt;/sup&gt; Medium</td>
<td>Human (male and female adults)</td>
<td>Yes</td>
<td>Effect was consistent and observed across multiple populations including general population adults {Dong, 2019, 5080195; Lin, 2019, 5187597} (NHANES) and the C8 Health project high-exposure community {Steenland, 2009, 1291109}, as well as when study designs excluded individuals prescribed cholesterol medication, minimizing concerns of bias due to medical intervention {Dong, 2019, 5080195; Steenland, 2009, 1291109}.</td>
</tr>
<tr>
<td>Hepatic Effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased ALT</td>
<td>Gallo et al. (2012, 1276142) Medium Darrow et al. (2016, 3749173)&lt;sup&gt;b&lt;/sup&gt; Medium Nian et al. (2019, 5080307) Medium</td>
<td>Human (male and female adults)</td>
<td>Yes</td>
<td>Effect was consistent and observed across multiple populations including general population adults {Lin, 2010, 1291111} (NHANES) and high-exposure communities including the C8 Health Project {Darrow, 2016, 3749173; Gallo, 2012, 1276142} and Isomers of C8 Health Project in China {Nian, 2019, 5080307}.</td>
</tr>
<tr>
<td>Increased ALT</td>
<td>Lin et al. (2010, 1291111) Medium</td>
<td>Human (male and female adults)</td>
<td>No</td>
<td>While this is a large nationally representative population, several methodological limitations preclude its use for POD derivation. Limitations include lack of clarity about base of logarithmic transformation applied to PFOA concentrations in regression models, and the choice to model ALT as an untransformed variable, a departure from the typically lognormality assumed in most of the ALT literature.</td>
</tr>
<tr>
<td>Necrosis (focal, individual cell, both in the Liver)</td>
<td>Loveless et al. (2008, Crl:CD-1(ICR)BR mice (males), Medium</td>
<td></td>
<td>Yes</td>
<td>Effect was accompanied in both studies by other liver lesions including cytoplasmic alteration and apoptosis. Necrotic liver cells were also observed in male mice in Crebelli et al. (2019, 5381564) and pregnant dams in Blake et al.</td>
</tr>
<tr>
<td>Endpoint</td>
<td>Reference, Confidence</td>
<td>Strain/Species/ Sex</td>
<td>POD Derived?</td>
<td>Notes</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>--------------</td>
<td>-------</td>
</tr>
<tr>
<td>NTP (2020, 7330145) High</td>
<td>Sprague-Dawley rats (males)</td>
<td>(2020, 6305864). Effect is further supported by changes in serum ALT levels in animals and humans. Data from females were not considered for POD derivation as they appear to be less sensitive, potentially due to toxicokinetic differences between the sexes in rats.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: ALT = alanine transaminase; BMD = benchmark dose; F1 = first generation; NHANES = National Health and Nutrition Examination Survey; POD = point of departure.

a Supported by Grandjean et al. (2012, 1248827), Grandjean et al. (2017, 3858518), and Grandjean et al. (2017, 4239492).

b See Section 6.6.3 for discussion on the approach to estimating BMDs from regression coefficients.
4.1.2 Estimation or Selection of Points of Departure (PODs) for RfD Derivation

Consistent with EPA’s Benchmark Dose Technical Guidance (U.S. EPA, 2012, 1239433), the BMD and 95% lower confidence limit on the BMD (BMDL) were estimated using a BMR intended to represent a minimal, biologically significant level of change. The Benchmark Dose Technical Guidance (U.S. EPA, 2012, 1239433) describes a hierarchy by which BMRs are selected, with the first and preferred approach being the use of a biological or toxicological basis to define what minimal level of response or change is biologically significant. If that biological or toxicological information is lacking, the guidance document recommends BMRs that could be used in the absence of information about a minimal clinical or biological level of change considered to be adverse—specifically, a BMR of one standard deviation (SD) change from the control mean for continuous data or a BMR of 10% extra risk for dichotomous data. When severe or frank effects are modeled, a lower BMR can be adopted. For example, developmental effects are frequently serious effects, and the Benchmark Dose Technical Guidance suggests that studies of developmental effects can support lower BMRs. BMDs for these effects may employ a BMR of 0.5 SD change from the control mean for continuous data or a BMR of 5% for dichotomous data (U.S. EPA, 2012, 1239433). A lower BMR can also be used if it can be justified on a biological and/or statistical basis. The Benchmark Dose Technical Guidance (page 23; {U.S. EPA, 2012, 1239433}) shows that in a control population where 1.4% are considered to be at risk of having an adverse effect, a downward shift in the control mean of one SD results in a ~10% extra risk of being at risk of having an adverse effect. A BMR smaller than 0.5 SD change from the control mean is generally used for severe effects (e.g., 1% extra risk of cancer mortality).

Based on rationales described in EPA’s Benchmark Dose Technical Guidance (U.S. EPA, 2012, 1239433, the IRIS Handbook (U.S. EPA, 2022, 10476098) and past IRIS assessment precedent, BMRs were selected for dose-response modeling of PFOA-induced health effects for individual study endpoints as described below and summarized in Table 4-2 along with the rationales for their selection. For this assessment, EPA took statistical and biological considerations into account to select the BMR. For dichotomous responses, the general approach was to use 10% extra risk as the BMR for borderline or minimally adverse effects and either 5% or 1% extra risk for adverse effects, with 1% reserved for the most severe effects. For continuous responses, the preferred approach for defining the BMR was to use a preestablished cutoff for the minimal level of change in the endpoint at which the effect is generally considered to become biologically significant (e.g., greater than or equal to 42 IU/L serum ALT in human males (Valenti, 2021, 10369689)). In the absence of an established cutoff, a BMR of 1 SD change from the control mean, or 0.5 SD for effects considered to be severe, was generally selected. Specific considerations for BMR selection for endpoints under each of the priority non-cancer health outcomes are described in the subsections below. Considerations for BMR selection for cancer endpoints are described in Section 4.2.

4.1.2.1 Hepatic Effects

Modeling elevated human ALT used cutoff levels of 42 IU/L for males and 30 IU/L for females, based on the most recent sex-specific upper reference limits (Valenti, 2021, 10369689). The baseline prevalence of elevated ALT is estimated as 14% and 13% in U.S. male and female
adults (aged 20 and older), respectively (see PFOA Appendix). Therefore, the BMR was defined as a 5% increase in the number of people with ALT values above the cutoffs. Although the Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433} recommends a BMR of 10% extra risk for dichotomous data when biological information is not sufficient to identify the BMR, in this situation, such a BMR would result in a doubling of risk.

For the adverse effect of single cell and focal liver necrosis observed in rats following PFOA exposure, there is currently inadequate available biological or toxicological information to permit determination of a minimal biologically significant response level. Therefore, in accordance with EPA’s Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433}, a BMR of 10% extra risk was used (dichotomous data; see Table 4-2).

4.1.2.2 Immune Effects

For the developmental immune endpoint of decreased diphtheria and tetanus antibody response in children found to be associated with PFOA exposure, the BMD and the BMDL were estimated using a BMR of 0.5 SD change from the control mean (see Table 4-2). Consistent with EPA’s Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433}, EPA typically selects a 5% or 0.5 standard deviation (SD) benchmark response (BMR) when performing dose response modeling of data from an endpoint resulting from developmental exposure. Because Budtz-Jørgensen and Grandjean (2018, 5083631) and Timmerman et al. (2021, 9416315) assessed antibody response after PFAS exposure during gestation and childhood, these are considered developmental studies {U.S. EPA, 1991, 732120} based on EPA’s Guidelines for Developmental Toxicity Risk Assessment, which includes the following definition:

“Developmental toxicology - The study of adverse effects on the developing organism that may result from exposure prior to conception (either parent), during prenatal development, or postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the lifespan of the organism.”

EPA guidance recommends the use of a 1 or 0.5 SD change in cases where there is no accepted definition of an adverse level of change or clinical cut-off for the health outcome {U.S. EPA, 2012, 1239433}. A 0.5 SD was selected since the health outcome is developmental and there is no accepted definition of an adverse level of change or clinical cut-off for reduced antibody concentrations in response to vaccination. Therefore, EPA performed the BMDL modeling using a BMR equivalent to a 0.5 SD change in log2-transformed antibody concentrations, as opposed to a fixed change in the antibody concentration distributions {U.S. EPA, 2012, 1239433}.

For the effect of reduced IgM response, there is currently inadequate available biological or toxicological information to permit determination of a minimal biologically significant response level. Therefore, in accordance with EPA’s Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433}, a BMR of 1 SD change from the control mean was employed (see Table 4-2).

4.1.2.3 Cardiovascular Effects

Modeling human cholesterol used a cutoff level of 240 mg/dL for elevated serum total cholesterol, consistent with the American Heart Association’s definition of hypercholesterolemia {NCHS, 2019, 10369680}. Recent data (for years 2015-2018) show that the percentage of U.S. adults aged 20 and older with total cholesterol ≥240 mg/dL is 11.5% {NCHS, 2019, 10369680}.
Therefore, the BMR was defined as a 5% increase in the number of people with total cholesterol values above 240 mg/dL. Although the Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433} recommends a BMR of 10% extra risk for dichotomous data when biological information is not sufficient to identify the BMR, in this situation, such a BMR would result in a doubling of risk.

### 4.1.2.4 Developmental Effects

For the developmental endpoint of decreased birth weight in infants associated with PFOA exposure, the BMD and the BMDL were estimated using a BMR of 5% extra risk, given that this level of response is typically used when modeling developmental responses from animal toxicology studies, and that low birthweight confers increased risk for adverse health effects throughout life {Hack, 1995, 8632216; Reyes, 2005, 1065677; Tian, 2019, 8632212}. Low birth weight is clinically defined as birth weight less than 2,500 g (approximately 5.8 lbs) and can include babies born SGA (birth weight below the 10th percentile for gestational age, sex, and parity) {JAMA, 2002, 10473200; McIntire, 1999, 15310; U.S. EPA, 2013, 4158459}.

For decreased fetal and pup weights and decreased pup survival observed in animal studies, a BMR of 5% relative deviation and 0.5 SD from the control was employed, respectively (see Table 4-2). This is consistent with EPA’s Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433} and the IRIS Handbook {U.S. EPA, 2022, 10476098}, which note that studies of adverse developmental effects represent a susceptible lifestage and can support BMRs that are lower than 10% extra risk (dichotomous data) and 1 SD change from the control mean (continuous data).

A 5% relative deviation in markers of growth in gestational exposure studies (e.g., fetal weight) that do not lead to death has generally been considered an appropriate biologically significant response level and has been used as the BMR in final IRIS assessments (e.g., U.S. EPA (2003, 1290574), U.S. EPA (2004, 198783), and U.S. EPA (2012, 3114808)). Additionally, the 5% BMR selection is statistically supported by data which compared a BMR of 5% relative deviation for decreased fetal weight to NOAELs and other BMR measurements, including 0.5 standard deviation, and found they were statistically similar {Kavlock, 1995, 75837}.

For the effects time to eye opening, there is currently inadequate available biological or toxicological information to permit determination of minimal biologically significant response levels. Therefore, in accordance with EPA’s Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433}, a BMR of 1 SD change from the control mean was employed (results for this endpoint is averaged across a dose group and are therefore continuous data).

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>BMR</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune Effects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduced antibody concentrations for diphtheria and tetanus</td>
<td>0.5 SD</td>
<td>Consistent with EPA guidance. EPA typically selects a 5% or 0.5 standard deviation (SD) benchmark response (BMR) when performing dose response modeling of data from an endpoint resulting from developmental exposure and selects a 1 or 0.5 SD change in cases where there is no...</td>
</tr>
<tr>
<td>Endpoint</td>
<td>BMR</td>
<td>Rationale</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>----------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Reduced immunoglobulin M (IgM) response</td>
<td>1 SD</td>
<td>Insufficient information available to determine minimal biologically significant response level. The available biological or toxicological information does not allow for determination of a minimal biologically significant response level for this adverse effect, and so a BMR of one SD was used as per EPA guidance {U.S. EPA, 2012, 1239433}</td>
</tr>
<tr>
<td><strong>Developmental Effects</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased Birth Weight in Infants or Decreased Fetal Body Weight in Rodent Offspring</td>
<td>5% extra risk of exceeding adversity cutoff (hybrid approach)</td>
<td>Consistent with EPA guidance. EPA typically selects a 5% or 0.5 standard deviation (SD) benchmark response (BMR) when performing dose response modeling of data from an endpoint resulting from developmental exposure {U.S. EPA, 2012, 1239433}. There is biological evidence that a lower BMR of 0.5 SD will result in a highly improbable doubling of risk.</td>
</tr>
<tr>
<td>Decreased Pup Survival</td>
<td>0.5 SD</td>
<td>Consistent with EPA guidance. EPA typically selects a 5% or 0.5 standard deviation (SD) benchmark response (BMR) when performing dose response modeling of data from an endpoint resulting from developmental exposure {U.S. EPA, 2012, 1239433}.</td>
</tr>
<tr>
<td>Delayed Time to Eye Opening</td>
<td>1 SD</td>
<td>Insufficient information available to determine minimal biologically significant response level. The available biological or toxicological information does not allow for determination of a minimal biologically significant response level for this adverse effect, and so a BMR of one SD was used as per EPA guidance {U.S. EPA, 2012, 1239433}.</td>
</tr>
<tr>
<td><strong>Serum Lipids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased Cholesterol</td>
<td>5% extra risk of exceeding adversity cutoff (hybrid approach)</td>
<td>Response rate of 5% extra risk is reasonable, whereas a 10% BMR would result in a doubling of risk. Although EPA’s Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433} recommends a BMR based on a 10% extra risk for dichotomous endpoints when biological information is not sufficient to identify the BMR, in this situation such a BMR would result in a highly improbable doubling of risk.</td>
</tr>
<tr>
<td><strong>Hepatic Effects</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased ALT</td>
<td>5% extra risk of exceeding adversity cutoff (hybrid approach)</td>
<td>Response rate of 5% extra risk is reasonable, whereas a 10% BMR would result in a doubling of risk. Although EPA’s Benchmark Dose Technical Guidance {U.S. EPA, 2012, 1239433} recommends a BMR based on a 10% extra risk for dichotomous endpoints when biological information is not sufficient to identify the BMR, in this situation such a BMR would result in a highly improbable doubling of risk.</td>
</tr>
<tr>
<td>Single Cell and Focal Liver Necrosis</td>
<td>10%</td>
<td>Insufficient information available to determine minimal biologically significant response level. The available biological or toxicological information does not allow for determination of a minimal biologically significant response level for this adverse effect, and so a BMR of 10% was used as per EPA guidance {U.S. EPA, 2012, 1239433}.</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Endpoint</th>
<th>BMR</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>10% was used as per EPA guidance {U.S. EPA, 2012, 1239433}</td>
</tr>
</tbody>
</table>

Notes: ALT = alanine transaminase; BMD = benchmark dose; BMR = benchmark response; CDC = Centers for Disease Control; SD = standard deviation.

### 4.1.3 Pharmacokinetic Modeling Approaches to Convert Administered Dose to Internal Dose in Animals and Humans

#### 4.1.3.1 Pharmacokinetic Model for Animal Internal Dosimetry

Following review of the available models in the literature (see Section 3.3.2), EPA chose the Wambaugh et al. (2013, 2850932) model to describe PFOA dosimetry in experimental animals based on the following criteria:

- availability of model parameters across the species of interest,
- agreement with out-of-sample datasets (see PFOA Appendix), and
- flexibility to implement life-course modeling.

These criteria originated from the goal of accurately predicting internal dose metrics for toxicology studies that were selected for dose-response analysis. These studies involved rats, mice, and non-human primates, and these were the species of interest necessary to have available model parameters. Good agreement with out-of-sample datasets shows that the model performance is good compared to both the data used to identify model parameters and to external data. This increases confidence that the model can be used to make accurate predictions of internal dose metrics for the toxicology studies, which can also be seen as external. The ability to implement life-course modeling was necessary to properly predict internal dose metrics for developmental studies and endpoints as the animal transitioned through numerous life-stages.

In this case, an oral dosing version of the original model structure introduced by Andersen et al. (2006, 818501) and summarized in Section 3.3.2 was selected for having the fewest number of parameters that would need estimation. In addition, the Wambaugh et al. (2013, 2850932) approach allowed for a single model structure to be used for all species in the toxicological studies allowing for model consistency for the predicted dose metrics associated with LOAELs and NOAELs from 13 animal toxicological studies of PFOA.

The Wambaugh et al. (2013, 2850932) model was selected for pharmacokinetic modeling for animal internal dosimetry for several important reasons: 1) it allowed for sex-dependent concentration-time predictions for PFOA across all three species of interest, 2) it adequately predicted dosimetry of newer datasets published after model development, and 3) it was amendable to addition of a life stage component for predicting developmental study designs. These analyses are further described in the subsections below. Uncertainties and limitations of the selected modeling approach are described in Section 6.6.1.
4.1.3.1.1  Animal Model Parameters

Pharmacokinetic parameters for different species represented in the Wambaugh et al. (2013, 2850932) model are presented in Table 4-3.

<table>
<thead>
<tr>
<th>Table 4-3. PK Parameters from Wambaugh et al. (2013, 2850932) Meta-Analysis of Literature Data for PFOA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parameter</strong></td>
</tr>
<tr>
<td>Body Weight (BW)</td>
</tr>
<tr>
<td>Cardiac Output (Qeo)</td>
</tr>
<tr>
<td>Absorption Rate (ka)</td>
</tr>
<tr>
<td>Central Compartment Volume (Vcc)</td>
</tr>
<tr>
<td>Intercompartment Transfer Rate (k12)</td>
</tr>
<tr>
<td>Intercompartment Ratio (Rv2/v21)</td>
</tr>
<tr>
<td>Maximum Resorption Rate (Tmax)</td>
</tr>
<tr>
<td>Renal Resorption Affinity (Kf)</td>
</tr>
<tr>
<td>Free Fraction</td>
</tr>
<tr>
<td>Filtrate Flow Rate (Qfle)</td>
</tr>
<tr>
<td>Filtrate Volume (Vfle)</td>
</tr>
</tbody>
</table>

Notes: F = female; M = male.

Means and 95% credible intervals (in parentheses) from Bayesian analysis are reported. For some parameters, the distributions are quite wide, indicating uncertainty in that parameter (i.e., the predictions match the data equally well for a wide range of values).

* Data sets modeled for the CD1 mouse were from Lou et al. (2009, 2919359), for the C57BL/6 mouse were from DeWitt et al. (2008, 1290826), for the rat were from Kemper (2003, 6302380), and for the monkey from Butenhoff et al. (2004, 3749227).

b Estimated average body weight for species used except with Kemper (2003, 6302380) where individual rat weights were available and assumed to be constant.

c Cardiac outputs obtained from Davies and Morris (1993, 192570).
### 4.1.3.1.2 Out-of-Sample Comparisons

To evaluate the model’s ability to predict PFOA concentration-time data in the species of interest, EPA compared model fits to *in vivo* datasets either not considered in or published after the 2016 HESD (Table 4-4). For rats, this included Kudo et al. (2002, 2990271), Kim et al. (2016, 3749289), and Dzierlenga et al. (2020, 5916078). Model simulations demonstrated good agreement with available data for adult time-course PFOA PK predictions in the rat. For mice however, only one adult PFOA study was available for comparison {Fujii, 2015, 2816710} and that study only tracked PFOA concentrations through 24 hours. As mentioned when this study is discussed in Section 3.3.2.1, a 24 hr observation window is insufficient to accurately estimate the terminal excretion half-life of PFOA. Therefore, only the original study used for parameter determination, Lou et al. (2009, 2919359), was compared to model simulations. This comparison approach demonstrated agreement with the *in vivo* data.

Using the Wambaugh et al. (2013, 2850932) model, EPA predicted the half-life, $V_d$, and clearance and compared these species-specific predictions to values obtained from *in vivo* studies when data were available.

Because male mouse parameters are not available for PFOA, only female parameters are used for all PFOA modeling in mice. This assumption is addressed in Wambaugh et al. (2013, 2850932) and is based on a lack of evidence for sex-dependent PK differences in the mouse.

| Table 4-4. Model Predicted and Literature PK Parameter Comparisons for PFOA |
|---------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
|                                 | Male           |                |                | Female          |                |                |                |                |
|                                 | $t_{1/2,\alpha}$ | $t_{1/2,\beta}$ | $V_{d,\alpha}$ | $V_{d,\beta}$ | $CL$           | $t_{1/2,\alpha}$ | $t_{1/2,\beta}$ | $V_{d,\alpha}$ | $V_{d,\beta}$ | $CL$           |
| Rat                             |                |                |                |                |                |                |                |                |                |                |
| Model                           | 5.8            | 16.5           | 0.12           | 0.35           | 0.0147         | 0.16           | 2.84           | 0.16           | 2.81           | 0.686         |
| Literature                      | 1.64<sup>a</sup>, 10.25<sup>b</sup> | 0.11<sup>a,c</sup>, 0.15<sup>b,c</sup> | 0.047<sup>a</sup>, 0.013<sup>b</sup> | 0.19<sup>a</sup>, 0.22<sup>b</sup> | 0.17<sup>a,c</sup>, 0.12<sup>b,c</sup> | 0.613<sup>a</sup>, 0.81<sup>b</sup> |
| Mouse                           |                |                |                |                |                |                |                |                |                |                |
| Model                           | –              | –              | –              | –              | –              | 17.8           | 18.9           | 0.18           | 0.19           | 0.007         |
| Literature                      | –              | –              | –              | –              | –              | –              | –              | –              | –              | –              |

Notes: $CL$ = clearance; $PK$ = pharmacokinetic; $t_{1/2,\alpha}$ = initial-phase elimination half-life; $t_{1/2,\beta}$ = terminal-phase elimination half-life; $V_{d,\alpha}$ = volume of distribution during the initial phase; $V_{d,\beta}$ = volume of distribution during the terminal phase.

<sup>a</sup> Information obtained from Kim et al. (2016, 3749289).

<sup>b</sup> Information obtained from Dzierlenga et al. (2020, 5916078).

<sup>c</sup> Literature volumes of distribution represent central compartment volumes from a one-compartment or two-compartment model.

### 4.1.3.1.3 Life Course Modeling

The Wambaugh et al. (2013, 2850932) model was modified to account for gestation, lactation, and post-weaning phases (Figure 4-1). Using the original model structure and published parameters, simulations assumed that dams were dosed prior to conception and up to the date of parturition. Following parturition, a lactational phase involved PFOA transfer from the breastmilk to the suckling pup where the pup was modeled with a simple one-compartment PK model. Finally, a post-weaning phase utilized the body-weight scaled Wambaugh model to
simulate dosing to the growing pup and accounted for filtrate rate as a constant fraction of cardiac output.

Figure 4-1. Model Structure for Life Stage Modeling

Model parameters for three-compartment model are the same as those described earlier. Pup-specific parameters include milk consumption in kg milk/day (R_milk), infant-specific volume of distribution (V_d), and infant-specific half-life (t1/2).

This methodology was adapted from Kapraun et al. (2022, 9641977) and relies on the following assumptions for gestation/lactation modeling:

- During gestation and up through the instant birth occurs, the ratio of the fetal concentration (mg of substance per mL of tissue) to the maternal concentration is constant.
- Infant animal growth during the lactational period is governed by the infant growth curves outlined in Kapraun et al. (2022, 9641977).
- Rapid equilibrium between maternal serum PFOA and milk PFOA is assumed and modeled using a serum:milk partition coefficient.
- All (100%) of the substance in the breast milk ingested by the offspring is absorbed by the offspring.
- The elimination rate of the substance in offspring is proportional to the amount of substance in the body and is characterized by an infant-specific half-life that is a fixed constant for any given animal species as described in Table 4-5 below.
- Following the lactation period, infant time course concentrations are tracked using the more physiologically-based Wambaugh model to model post-weaning exposure and infant growth.

A simple one-compartment model for infant lactational exposure was chosen because of differences between PFOA Vd reported in the literature and Wambaugh et al. (2013, 2850932) model-predicted Vd following extrapolation to a relatively low infant body weight. Because Vd is assumed to be extracellular water in human, Goeden et al. (2019, 5080506) adjusts for life stage-specific changes in extracellular water using an adjustment factor where infants have 2.1 times more extracellular water than adults resulting in a larger V_d. However, this large difference in extracellular water is not observed in rats (Johanson, 1979, 9641334). Johanson (1979, 9641334) demonstrated a 5% decrease in blood water content from early postnatal life.
rate consumptions are defined as:

- *r*ᵢ<sub>₁</sub> milk, the (average) milk consumption rate (kg/d) during the first week of lactation (and nursing);
- *r*ᵢ<sub>₂</sub> milk, the (average) milk consumption rate (kg/d) during the second week of lactation; and
- *r*ᵢ<sub>₃</sub> milk, the (average) milk consumption rate (kg/d) during the third week of lactation.

Therefore, EPA used the literature reported *V*₃ for PFOA, and the species-specific *in vivo* determined half-life (*t*₁/₂) and *V*₃ for PFOA, and the species-specific milk consumption rate during lactation (*r*ᵢ<sub>ᵢ</sub> milk) for the *i*<sup>th</sup> week of lactation. Milk rate consumptions are defined as:

These developmental-specific parameters include the maternal milk:blood PFOA partition coefficient (*P*₃ milk), the ratio of the concentrations in the fetus(es) and the mother during pregnancy (*R*₃ milk), the species-specific *in vivo* determined half-life (*t*₁/₂) and *V*₃ for PFOA, and the species-specific milk consumption rate during lactation (*r*ᵢ<sub>ᵢ</sub> milk) for the *i*<sup>th</sup> week of lactation. Milk rate consumptions are defined as:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Units</th>
<th>Rat</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal Milk:Blood Partition Coefficient (<em>P</em>₃ milk)</td>
<td>Unitless</td>
<td>0.11&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>0.32&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fetus:Mother Concentration Ratio (<em>R</em>₃ milk)</td>
<td>Unitless</td>
<td>0.42&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.25&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td>Elimination Half-Life (<em>t</em>₁/₂)</td>
<td>Days</td>
<td>2.23&lt;sup&gt;c&lt;/sup&gt;</td>
<td>18.5&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
<tr>
<td>Volume of Distribution (<em>V</em>₃)</td>
<td>L/kg</td>
<td>0.18&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.2&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>Starting Milk Consumption Rate (<em>r</em>₁&lt;sub&gt;₀&lt;/sub&gt; milk)</td>
<td>kg&lt;sub&gt;milk&lt;/sub&gt;/day</td>
<td>0.001&lt;sup&gt;h&lt;/sup&gt;</td>
<td>0.0001&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
<tr>
<td>Week 1 Milk Consumption Rate (<em>r</em>₁&lt;sub&gt;₁&lt;/sub&gt; milk)</td>
<td>kg&lt;sub&gt;milk&lt;/sub&gt;/day</td>
<td>0.003&lt;sup&gt;h&lt;/sup&gt;</td>
<td>0.0003&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
<tr>
<td>Week 2 Milk Consumption Rate (<em>r</em>₁&lt;sub&gt;₂&lt;/sub&gt; milk)</td>
<td>kg&lt;sub&gt;milk&lt;/sub&gt;/day</td>
<td>0.0054&lt;sup&gt;h&lt;/sup&gt;</td>
<td>0.00054&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
<tr>
<td>Week 3 Milk Consumption Rate (<em>r</em>₁&lt;sub&gt;₃&lt;/sub&gt; milk)</td>
<td>kg&lt;sub&gt;milk&lt;/sub&gt;/day</td>
<td>0.0059&lt;sup&gt;h&lt;/sup&gt;</td>
<td>0.00059&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

**Notes:** PK = pharmacokinetic.

<sup>a</sup> Information obtained from Loccisano et al. (2013, 1326665) (derived from Hinderliter et al. (2005, 1332671)).

<sup>b</sup> Information obtained from Hinderliter et al. (2005, 1332671).

<sup>c</sup> Average of male/female half-lives reported in Dzierlenga et al. (2020, 5916078), Kim et al. (2016, 3749289), and Kemper et al. (2003, 6302380).

<sup>d</sup> Information obtained from Kim et al. (2016, 3749289) and Dzierlenga et al. (2020, 5916078).

<sup>e</sup> Information obtained from Fujii et al. (2020, 6512379).

<sup>f</sup> Information obtained from Blake et al. (2020, 6305864).

<sup>g</sup> Information obtained from Lou et al. (2009, 2919359).

<sup>h</sup> Information obtained from Kapraun et al. (2022, 9641977) (adapted from Lehmann et al. (2014, 2447276)).

<sup>i</sup> Information obtained from Kapraun et al. (2022, 9641977) (mouse value is 10% of rat based on assumption that milk ingestion rate is proportional to body mass).
where $R_{\text{milk}}$ used in the model is a piecewise linear function comprising each $r_{\text{milk}}^i$ depending on the week of lactation.

Using this gestation/lactation model, EPA simulated two studies for PFOA exposure (one in mice and one in rats) to ensure the model predicted the time-course concentration curves for both the dam and the pup. For all gestation/lactation studies, time zero represents conception followed by a gestational window (21 days for the rat, 17 days for the mouse). Dosing prior to day zero represents pre-mating exposure to PFOA.

Figure 4-2 demonstrates the model’s ability to predict gestation/lactation study design in the rat for dams exposed to 30 mg/kg/day PFOA giving birth to pups who are exposed through lactation {Hinderliter, 2005, 1332671}. Comparatively, Figure 4-3 demonstrates model fits for PFOA exposure in mice from a cross-fostering study {White, 2009, 194811}. In each case, the original Wambaugh et al. (2013, 2850932) model with increasing maternal weight predicts dam concentrations in female rats and mice while the one-compartmental lactational transfer model predicts infant concentrations for pups exposed both in utero and through lactation only.

![Figure 4-2. Gestation/Lactation Predictions of PFOA in the Rat](image)

Top panel represents time-course model predicted dam concentrations (solid line) where open diamonds (◊) represent the in vivo dam concentrations reported in Hinderliter et al. (2005, 1332671) and x’s represent the model-predicted value at the reported time. Bottom panel demonstrates the model predicted pup concentrations (solid line) where open diamonds (◊) represent the reported pup concentrations in Hinderliter et al. (2005, 1332671) with PFOA exposure is from the breast milk. Vertical dashed line represents birth.
Figure 4-3. Gestation/Lactation Predictions of PFOA in the Mouse in a Cross-Fostering Study

Top panel represents predicted dam concentrations while bottom panel represents the predicted pup concentrations from White et al. (2009, 194811). Solid lines (−) represent a 5 mg/kg/day maternal dose paired with nursing pups that were exposed to PFOA in utero and open diamonds (◊) represent the reported dam and infant concentrations for this exposure scenario. Comparatively, dot-dashed lines (•) represent the simulations from the cross-fostering study where dams were exposed to 5 mg/kg/day PFOA and pups born to the control dam were exposed through lactation. Open triangles (▷) represent the reported dam and infant concentrations for this cross-foster study.

The purpose of the animal PBPK model is to make predictions of internal dose in lab animals used in toxicity studies and extrapolate these internal dose points-of-departure to humans. Therefore, to evaluate its predictive utility for risk assessment, a number of dose-metrics across life stages were selected for simulation in a mouse, rat, monkey, or human. Concentrations of PFOA in blood were considered for all the dose-metrics. For studies in adult animals the dose-metric options were generally a maximum blood concentration (C_{max}, mg/L) and a time averaged blood concentration i.e., the area under the curve over the duration of the study (AUC, mg * day/L) or the blood concentration over the last 7 days (C_{last7}, mg/L). In developmental studies, dose-metrics were developed for the dam, the fetus (during gestation), and the pup (during lactation) for both time C_{max} and averaged blood concentrations (C_{avg}). In the dam, the C_{max} and C_{avg}, were calculated over a range of life stages: during gestation (C_{avg_dam_gest}), during lactation (C_{avg_dam_lact}), or combined gestation and lactation (C_{avg_dam_gest_lact}). In pups for C_{max}, two different life stages were calculated either during gestation or lactation (C_{max_pup_gest}, C_{max_pup_lact}). In pups for time averaged metrics, a C_{avg} was calculated during gestation, lactation, or combined gestation and lactation (C_{avg_pup_gest}, C_{avg_pup_lact}, and C_{avg_pup_gest_lact}). Finally, for NTP, 2020, 7330145, an additional dose metric was derived which averages out the concentration in the pup from conception to the end of the 2 years (C_{avg_pup_total}). Specifically, it adds the area under the curve in gestation/lactation to the area under the curve from diet (post-weaning) and then divides by two years.
4.1.3.2 Pharmacokinetic Model for Human Dosimetry

The key factors considered in model determination were to implement a human model from the literature that was able to model gestational and lactational exposure to infants, that was able to describe time course changes in serum concentration due to changes in bodyweight during growth, and that required minimal new development. Previous modeling efforts suggest that limiting model complexity helps to prevent errors and facilitates rapid implementation {Bernstein, 2021, 9639956}. For the human and animal endpoints of interests, serum concentration was identified as a suitable internal dosimetry target, which provides support for using a simpler model that did not have individual tissue dosimetry. For these reasons, EPA selected the one-compartment human developmental model published by Verner et al. (2016, 3299692). Several alternative models to EPA’s updated version of the Verner et al. (2016, 3299692) model for the calculation of PODHED from an internal POD were considered. This included consideration of full PBPK models (i.e., the Loccisano family of models {Loccisano, 2011, 787186; Loccisano, 2012, 1289830; Loccisano, 2012, 1289833; Loccisano, 2013, 1326665}), as well as other one-compartment PK models (e.g., Goeden et al. (2019, 5080506)). Discussion on the justification for selection of the Verner et al. (2016, 3299629) model as the basis for the pharmacokinetic modeling approach used for PFOA is available in Sections 6.6.2 and 6.7.

Several adjustments were undertaken to facilitate the application of the model for this use. First, the model was converted from acslX language to an R/MCSim framework. This allows the code to be more accessible to others by updating it to a contemporary modeling language, as acslX software is no longer available or supported. The starting point for the conversion to R/MCSim was another model with a similar structure that was in development by EPA at that time {Kapraun, 2022, 9641977}. Second, the modeling language conversion body weight curves for non-pregnant adults were revised based on CDC growth data for juveniles and values from EPA’s Exposure Factors Handbook in adults {Kuczmaraki, 2002, 3490881; U.S. EPA, 2011, 786546}. Linear interpolation was used to connect individual timepoints from these two sources to produce a continuous function over time. Body weight during pregnancy was defined based on selected studies of maternal body weight changes during pregnancy {Portier, 2007, 192981; Carmichael, 1997, 1060457; Thorsdottir, 1998, 4940407; Dewey, 1993, 1335605; U.S. EPA, 2011, 786546}. Age-dependent breastmilk intake rates were based on the 95th percentile estimates from EPA’s Exposure Factors Handbook and was defined relative to the infant’s bodyweight {U.S. EPA, 2011, 786546}.

A third modification was the update of parameters: the half-life, the volume of distribution (Vd), the ratio of PFOA concentration in cord blood to maternal serum, and the ratio of PFOA concentration in breastmilk and maternal serum. Details for how these parameters were updated are given in the following paragraphs. In the model, half-life and Vd are used to calculate the clearance, which is used in the model directly and is also used for calculation of steady-state concentrations in adults. Other than half-life and, because of that, clearance, the updated parameters were similar to the original parameters (Table 4-6). The results of the new R model and updated acslX model with the original parameters were essentially identical (see PFOA Appendix). With the updated parameters, the predicted PFOA serum concentrations are approximately 70% of the original values during pregnancy, and the child’s serum concentration is approximately 60% of the original values during the first year of life.
The use of the Verner model in humans presents a substantial advancement in approach for endpoints in children compared to the previous EPA assessment of PFOA (U.S. EPA, 2016, 3603279). The previous assessment did not explicitly model children, but instead applied an uncertainty factor to an RfD based on long-term adult exposure to account for the potential for increased susceptibility. The current approach explicitly models PFOA exposure to infants during nursing and the rapid growth of children, who do not reach steady state until near adulthood. This allows for a more accurate estimation of exposures associated with either serum levels in children or dose metric from developmental animal toxicological studies. The Verner model also explicitly models the mother from her birth through the end of breastfeeding which allows for the description of accumulation in the mother prior to pregnancy followed by decreasing maternal levels during pregnancy. Detailed modeling of this period is important for dose metrics based on maternal levels during pregnancy, especially near term, and on cord blood levels.

Application of the updated Verner model to three cohorts with paired maternal measurements and subsequent samples in children between ages of 6 months and 6 years showed good agreement between reported and predicted serum levels in the children (see PFOA Appendix). This suggests that the assumptions made governing lactational transfer and the selected half-life value are reasonable. A local sensitivity analysis was also performed to better understand the influence of each parameter on model output (see PFOA Appendix).

### Table 4-6. Updated and Original Chemical-Specific Parameters for PFOA in Humans

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Updated Value</th>
<th>Original Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume of Distribution (mL/kg)</td>
<td>170</td>
<td>170</td>
</tr>
<tr>
<td>Half-life (yr)</td>
<td>2.7</td>
<td>3.8</td>
</tr>
<tr>
<td>Clearance (mL/kg/d)</td>
<td>0.120</td>
<td>0.085</td>
</tr>
<tr>
<td>Cord Serum:Maternal Serum Ratio</td>
<td>0.83</td>
<td>0.79</td>
</tr>
<tr>
<td>Milk:Serum Partition Coefficient</td>
<td>0.049</td>
<td>0.058</td>
</tr>
</tbody>
</table>

**Notes:**

- a Verner et al. (2016, 3299692).
- b Thompson et al. (2010, 2919278).
- c Li et al. (2017, 9641333).
- d Calculated from half-life and volume of distribution. \( Cl = Vd \times \frac{\ln(2)}{t_{1/2}} \).
- e Average values for total PFOA Cord Serum:Maternal Serum ratios (see PFOA Appendix). This is a similar approach to that used by Verner et al. (2016, 3299692), but also includes studies made available after the publication of that model.
- f Average value of studies as reported in Table 4-7. This is a similar approach to that used by Verner et al. (2016, 3299692), but also includes studies made available after the publication of that model.

EPA selected a reported half-life value from an exposure to a study population that is demographically representative of the general population, with a clear decrease in exposure at a known time, with a high number of participants and a long follow-up time. Based on these criteria, a half-life of 2.7 years was determined for PFOA as reported in Li et al. (2017, 9641333; 2018, 4238434). This value comes from a large population (n = 455) who originally had contaminated drinking water for which the study documents the decrease in exposure levels after the installation of filtration with an average final serum sample taken 3.9 years after the beginning of water filtration. Li et al. (2018, 4238434) also reported a similar half-life of 2.7 years for PFOA in a separate community with a similar study design. In that study, serial blood samples were collected from participants after the beginning of drinking water filtration.
after a long period of exposure to drinking water contaminated with PFOA. The second study involved 106 participants with a median number of 6 samples per person but with only a two-year observation period Li et al. (2017, 9641333). The good agreement between the second study and the previous, larger study in diverse populations support the use of this value as a good estimate of the PFOA elimination half-life.

A summary of PFOA half-life values is presented in the Appendix (see PFOA Appendix). Uncertainties related to EPA’s selected half-life are discussed in Section 6.6.2.

The updated value for human $V_d$ of PFOA, 170 mL/kg, was sourced from Thompson et al. (2010, 2919278) who used a one-compartment PK model. This calculation involves several assumptions: that the participants’ serum concentrations are at steady-state, their exposure can be estimated from the drinking water concentration in their community, there is 91% bioavailability for exposure from drinking water, and the half-life of PFAS is 2.3 years, which comes from the report of Bartell et al. (2010, 379025). EPA considered updating this parameter to 200 mL/kg, which is the value that would be calculated using the EPA chosen half-life value of 2.7 years. However, the value of 2.3 years was calculated under very similar conditions as the other data in the Thompson et al. (2010, 2919278) population and 2.3 years may better reflect the clearance rate in that specific population at that time. This calculation was performed in a population with PFOA contamination. $V_d$ is a parameter that is relatively easily obtained from an analysis of PK data from controlled experimental studies, as it is related to the peak concentration observed after dosing and is expected to be similar between human and non-human primates {Mordenti, 1991, 9571900}. For comparison, the optimized $V_d$ for PFOA from oral dosing in monkeys was 140 mL/kg {Andersen, 2006, 818501}.

Another group has approached the calculation of $V_d$ by taking the average of reported animal and human values and reported values of 200 mL/kg for PFOA {Gomis, 2017, 3981280}. This calculation included the $V_d$ value from Thompson et al. (2010, 2919278) and did not include additional values derived from human data. The resulting average value shows that the value from Thompson et al. (2010, 2919278) is reasonable; EPA selected the Thompson et al. (2010, 2919278) result based on the fact that it is the only value derived from human data that EPA considers to be reliable for risk estimation in the general population.

A summary of PFOA $V_d$ values is presented in the Appendix (see PFOA Appendix). Uncertainties related to EPA’s selected $V_d$ are discussed in Section 6.6.2.

In the original model, the ratio of PFOA concentration in cord blood to maternal serum, and the ratio of PFOA concentration in breastmilk and maternal serum were based on an average of values available in the literature; here, EPA identified literature made available since the original model was published and updated those parameters with the averages of all identified values (Table 4-7). The values for cord blood to maternal serum ratio are presented in the Appendix (see PFOA Appendix). One restriction implemented on the measurements of the cord blood to maternal serum ratio was to only include reports where the ratio was reported, and not to calculate the ratio from reported mean cord and maternal serum values.
Table 4-7. Summary of Studies Reporting the Ratio of PFOA Levels in Breastmilk and Maternal Serum or Plasma

<table>
<thead>
<tr>
<th>Source</th>
<th>HERO ID</th>
<th>Milk:Maternal Plasma Ratio</th>
<th>Included in Verner et al. (2016, 3299692) Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haug et al. (2011, 2577501)</td>
<td>2577501</td>
<td>0.038</td>
<td>No</td>
</tr>
<tr>
<td>Seung-Kyu Kim et al. (2011, 2919258)</td>
<td>2919258</td>
<td>0.025</td>
<td>No</td>
</tr>
<tr>
<td>Liu et al. (2011, 2919240)</td>
<td>2919240</td>
<td>0.11</td>
<td>No</td>
</tr>
<tr>
<td>Cariou et al. (2015, 3859840)(^a)</td>
<td>3859840</td>
<td>0.034</td>
<td>Yes</td>
</tr>
<tr>
<td>Sunmi Kim et al. (2011, 1424975)(^b)</td>
<td>1424975</td>
<td>0.04</td>
<td>Yes</td>
</tr>
<tr>
<td>Verner et al. (2016, 3299692)</td>
<td>3299692</td>
<td>0.058(^c)</td>
<td>–</td>
</tr>
<tr>
<td>Additional Studies</td>
<td>–</td>
<td>0.049(^d)</td>
<td>–</td>
</tr>
</tbody>
</table>

Notes: Whether studies were included in the analysis of Verner et al. (2016, 3299692) is noted. The reported values were based on the mean of ratios in the study populations except when noted otherwise.
\(^a\) Median result based on the report of Pizzurro et al. (2019, 5387175).
\(^b\) Median result as reported by the authors.
\(^c\) Average value of milk:maternal plasma ratio used by Verner et al. (2016, 3299692).
\(^d\) Average value of milk:maternal plasma ratio with the inclusion of additional studies not in the original analysis. This value was used in the human PK model.

This updated model was used to simulate the HED from the animal PODs that were obtained from BMD modeling of the animal toxicological studies (see PFOA Appendix). It was also used to simulate selected epidemiological studies (Section 4.1.1.2) to obtain a chronic dose that would result in the internal POD obtained from dose-response modeling (see PFOA Appendix). For PODs resulting from chronic exposure, such as a long-term animal toxicological study or an epidemiological study on an adult cohort, the steady state approximation was used to calculate a POD\(_{HED}\) that would result in the same dose metric after chronic exposure. For PODs from exposure to animals in developmental scenarios, the updated Verner model was used to calculate a POD\(_{HED}\) that results in the same dose metric during the developmental window selected. The updated Verner model was also used to calculate a POD\(_{HED}\) for PODs based on epidemiological observations of maternal serum concentration during pregnancy, cord blood concentration, and serum concentrations in children.

The pharmacokinetic modeling code for both the updated Wambaugh et al. (2013, 850932) and Verner et al. (2013, 299692) models that was used to calculate human equivalence doses is available in an online repository (https://github.com/USEPA/OW-PFOS-PFOA-MCLG-support-PK-models). The model code was thoroughly QA’d through the established EPA Quality Assurance Project Plan (QAPP) for PBPK models [U.S. EPA, 2018, 4326432].

### 4.1.4 Application of Pharmacokinetic Modeling for Animal-Human Extrapolation of PFOA Toxicological Endpoints and Dosimetric Interpretation of Epidemiological Endpoints

Table 4-8 displays the POD and estimated internal and POD\(_{HEDs}\) for immune, developmental, cardiovascular (serum lipids), and hepatic endpoints from animal and/or human studies selected for the derivation of candidate RfDs. The PODs from epidemiological studies (immune, developmental, hepatic, and serum lipid endpoints) were derived using benchmark dose modeling (see PFOA Appendix) which provided an internal serum concentration in mg/L. The
internal dose PODs were converted to a POD_{HED} using the modified Verner model described in Section 4.1.3.1.3 to calculate the dose that results in the same serum concentrations. Specifically, reverse dosimetry was performed by multiplying an internal dose POD by a model predicted ratio of a standard exposure and the internal dose for that standard exposure. This expedited procedure can be performed because the human model is linear, that is, the ratio of external and internal dose is constant with dose. Additional details are provided below and in
Table 4-8.

The PODs from the animal toxicological studies were derived by first converting the administered dose to an internal dose as described in Section 4.1.3.1.1. The rationale for the internal dosimetric selected for each endpoint is described in the Appendix (see PFOA Appendix). Because a toxicological endpoint of interest results from the presence of chemical at the organ-specific site of action, dose response modeling is preferentially performed on internal doses rather than administered doses and assumes the internal dose metric is proportional to the target tissue dose. In addition, the non-linear elimination described in Wambaugh et al. (2013, 2850932) requires conversion to an internal dose as the relationship between internal and external dose will not scale linearly. The internal doses were then modeled using the Benchmark Dose Software (BMDS) (see PFOA Appendix for additional modeling details). The internal dose animal PODs were converted to a POD\(_{\text{HED}}\) using the model described in Section 4.1.3.1.3. Reverse dosimetry for the animal PODs used the ratio of standard exposure and internal dose as was applied to PODs from epidemiological data. For animal toxicological studies using the average concentration over the final week of the study (\(C_{\text{last7}}\)), the POD\(_{\text{HED}}\) is the human dose that would result in the same steady-state concentration in adults. When a concentration internal dose metric in the pup during lactation and/or gestation was selected, the POD\(_{\text{HED}}\) is the dose to the mother that results in the same average concentration in the fetus/infant over that period.

This approach for interspecies extrapolation follows the EPA’s guidance to prefer the use of a PK or PBPK model over the use of a data-derived extrapolation factor (DDEF) (EPA, 2014, 2520260). A PK model allows for predictions of dosimetry for specific exposure scenarios in animals and humans and can incorporate PK details such as maternal accumulation and subsequent gestation/lactational transfer to a fetus/infant. Using a hierarchical decision-making framework, a DDEF approach is only considered when a validated PK or PBPK model is not available. Furthermore, EPA considers DDEF values based on the ratio of maximum blood concentration from acute, high-dose exposures to likely not be protective for typical exposure scenarios to humans, chronic low-dose exposure or lactational exposure to a nursing infant (Dourson, 2019, 6316919). While a repeat dose DDEF has been presented (Dourson, 2019, 6316919), this factor relied on maximum concentrations from Elcombe et al. (2013, 10494295), for which the results are not considered relevant to the general population as discussed in Section 4.1.3.2.
### Table 4-8. PODHEDS Considered for the Derivation of Candidate RfD Values

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Reference, Confidence</th>
<th>Strain/Species/Sex</th>
<th>POD Type, Model</th>
<th>POD Internal Dose/Internal Dose Metric</th>
<th>PODHED (mg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased serum anti-tetanus antibody concentration in children</td>
<td>Budtz-Jørgensen and Grandjean (2018, 5083631)&lt;sup&gt;b&lt;/sup&gt; Medium</td>
<td>Human, male and female; PFOA concentrations at age five years and anti-tetanus antibody serum concentrations at age seven years</td>
<td>BMDL&lt;sub&gt;0.5SSD&lt;/sub&gt;, Linear</td>
<td>3.47 ng/mL</td>
<td>3.05×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Budtz-Jørgensen and Grandjean (2018, 5083631)&lt;sup&gt;b&lt;/sup&gt; Medium</td>
<td>Human, male and female; PFOA concentrations in the mother and anti-tetanus antibody serum concentrations at age 5 years</td>
<td>BMDL&lt;sub&gt;0.5SSD&lt;/sub&gt;, Linear</td>
<td>3.31 ng/mL</td>
<td>5.21×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Timmerman et al. (2021, 9416315) Medium</td>
<td>Human, male and female; PFOA concentrations and anti-tetanus antibody concentrations at ages 7–10 years</td>
<td>BMDL&lt;sub&gt;0.5SSD&lt;/sub&gt;, Linear</td>
<td>2.26 ng/mL</td>
<td>3.34×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td>Decreased serum anti-diphtheria antibody concentration in children</td>
<td>Budtz-Jørgensen and Grandjean (2018, 5083631)&lt;sup&gt;b&lt;/sup&gt; Medium</td>
<td>Human, male and female; PFOA concentrations at age five years and anti-diphtheria antibody serum concentrations at age seven years</td>
<td>BMDL&lt;sub&gt;0.5SSD&lt;/sub&gt;, Linear</td>
<td>3.32 ng/mL</td>
<td>2.92×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Budtz-Jørgensen and Grandjean (2018, 5083631)&lt;sup&gt;b&lt;/sup&gt; Medium</td>
<td>Human, male and female; PFOA concentrations in the mother and anti-diphtheria antibody serum concentrations at age 5 years</td>
<td>BMDL&lt;sub&gt;0.5SSD&lt;/sub&gt;, Piecewise</td>
<td>1.24 ng/mL</td>
<td>1.95×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Timmerman et al. (2021, 9416315) Medium</td>
<td>Human, male and female; PFOA concentrations and anti-diphtheria antibody</td>
<td>BMDL&lt;sub&gt;0.5SSD&lt;/sub&gt;, Linear</td>
<td>1.49 ng/mL</td>
<td>2.20×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td>Endpoint</td>
<td>Reference, Confidence</td>
<td>Strain/Species/Sex</td>
<td>POD Type, Model</td>
<td>POD</td>
<td>POD Internal Dose/Internal Dose Metric&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------</td>
<td>--------------------</td>
<td>-----------------</td>
<td>-----</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>Decreased IgM response to SRBC</td>
<td>Dewitt et al. (2008, 1290826) Medium</td>
<td>Mouse, female Study 1</td>
<td>BMDL&lt;sub&gt;1SD&lt;/sub&gt;, Polynomial 4</td>
<td>18.2 mg/L</td>
<td>2.18×10&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Decreased IgM response to SRBC</td>
<td>Dewitt et al. (2008, 1290826) Medium</td>
<td>Mouse, female Study 2</td>
<td>NOAEL&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1.88 mg/kg/day</td>
<td>45.3 mg/L</td>
</tr>
<tr>
<td>Decreased IgM response to SRBC</td>
<td>Loveless et al. (2008, 988599) Medium</td>
<td>Mouse, male</td>
<td>BMDL&lt;sub&gt;1SD&lt;/sub&gt;, Exponential 3</td>
<td>57.6 mg/L</td>
<td>6.91×10&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Developmental Effects</td>
<td>Chu et al. (2020, 6315711) High</td>
<td>Human, male and female; PFOA serum concentrations in third trimester</td>
<td>BMDL&lt;sub&gt;5RD&lt;/sub&gt;, Hybrid</td>
<td>2.0 ng/mL</td>
<td>3.15×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Govarts et al. (2016, 3230364) High</td>
<td>Human, male and female; PFOA concentrations in umbilical cord</td>
<td>BMDL&lt;sub&gt;5RD&lt;/sub&gt;, Hybrid</td>
<td>1.2 ng/mL</td>
<td>2.28×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Sagiv et al. (2018, 4238410) High</td>
<td>Human, male and female; PFOA serum concentrations in first trimester</td>
<td>BMDL&lt;sub&gt;5RD&lt;/sub&gt;, Hybrid</td>
<td>9.1 ng/mL</td>
<td>1.21×10&lt;sup&gt;-6&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Starling et al. (2017, 3858473) High</td>
<td>Human, male and female; PFOA serum concentrations in second and third trimesters</td>
<td>BMDL&lt;sub&gt;5RD&lt;/sub&gt;, Hybrid</td>
<td>1.8 ng/mL</td>
<td>2.65×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Wikström et al. (2020, 6311677) High</td>
<td>Human, male and female; PFOA serum concentrations in first and second trimesters</td>
<td>BMDL&lt;sub&gt;5RD&lt;/sub&gt;, Hybrid</td>
<td>2.2 ng/mL</td>
<td>2.92×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td>Decreased Offspring Survival</td>
<td>Song et al. (2018, 5079725) Medium</td>
<td>Kunming Mice, F&lt;sub&gt;1&lt;/sub&gt; males and females</td>
<td>BMDL&lt;sub&gt;0.5SD&lt;/sub&gt;, Polynomial 3rd degree</td>
<td>12.3 mg/L</td>
<td>6.40×10&lt;sup&gt;-4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Decreased Fetal Body Weight</td>
<td>Li et al. (2018, 5084746) Medium</td>
<td>Kunming Mice, F&lt;sub&gt;1&lt;/sub&gt; males and females</td>
<td>NOAEL&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1 mg/kg/day</td>
<td>8.5 mg/L</td>
</tr>
<tr>
<td>Delayed Time to Eye Opening</td>
<td>Lau et al. (2006, 1276159) Medium</td>
<td>CD-1 Mice, F&lt;sub&gt;1&lt;/sub&gt; males and females</td>
<td>BMDL&lt;sub&gt;1SD&lt;/sub&gt;, Polynomial 2</td>
<td>10.1 mg/L</td>
<td>1.71×10&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>POD Internal Dose/Internal Dose Metric: C<sub>last</sub> or C<sub>avg</sub>.

<sup>d</sup>NOAEL: No Observed Adverse Effect Level.
<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Reference, Confidence</th>
<th>Strain/Species/Sex</th>
<th>POD Type, Model</th>
<th>POD</th>
<th>POD Internal Dose/Internal Dose Metric$^a$</th>
<th>POD HED (mg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular Effects (Serum Lipids)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased Total Cholesterol</td>
<td>Dong et al. (2019, 5080195)</td>
<td>Human, male and female; excluding individuals prescribed cholesterol medication</td>
<td>BMDL$_{5RD}$, Hybrid</td>
<td>2.29 ng/mL</td>
<td>2.75×10$^{-7}$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steenland et al. (2009, 1291109)</td>
<td>Human, male and female; excluding individuals prescribed cholesterol medication</td>
<td>BMDL$_{5RD}$, Hybrid</td>
<td>4.25 ng/mL</td>
<td>5.10×10$^{-7}$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lin et al. (2019, 5187597)</td>
<td>Human, male and female</td>
<td>BMDL$_{5RD}$, Hybrid</td>
<td>5.28 ng/mL</td>
<td>6.34×10$^{-7}$</td>
<td></td>
</tr>
<tr>
<td><strong>Hepatic Effects</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elevated ALT</td>
<td>Gallo et al. (2012, 1276142)</td>
<td>Human, female</td>
<td>BMDL$_{5RD}$, Hybrid</td>
<td>17.9 ng/mL</td>
<td>2.15×10$^{-6}$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Darrow et al. (2016, 3749173)</td>
<td>Human, female</td>
<td>BMDL$_{5RD}$, Hybrid</td>
<td>66.0 ng/mL</td>
<td>7.92×10$^{-6}$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nian et al. (2019, 5080307)</td>
<td>Human, female</td>
<td>BMDL$_{5RD}$, Hybrid</td>
<td>3.76 ng/mL</td>
<td>4.51×10$^{-7}$</td>
<td></td>
</tr>
<tr>
<td>Increased Focal Necrosis</td>
<td>Loveless et al. (2008, 988599)</td>
<td>Crl:CD-1(ICR)BR mice, male</td>
<td>BMDL$_{10RD}$, Dichotomous Hill</td>
<td>10.0 mg/L</td>
<td>1.20×10$^{-3}$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Loveless et al. (2008, 988599)</td>
<td>Crl:CD-1(ICR)BR mice, male</td>
<td>BMDL$_{10RD}$, Probit</td>
<td>36.0 mg/L</td>
<td>4.32×10$^{-3}$</td>
<td></td>
</tr>
<tr>
<td>Increased Individual Cell Necrosis</td>
<td>Loveless et al. (2008, 988599)</td>
<td>Crl:CD-1(ICR)BR mice, male</td>
<td>BMDL$_{10RD}$, Multistage Degree 1</td>
<td>26.9 mg/L</td>
<td>3.23×10$^{-3}$</td>
<td></td>
</tr>
<tr>
<td>Increased Necrosis</td>
<td>NTP (2020, 7330145)</td>
<td>Sprague-Dawley rats, males; perinatal and postweaning</td>
<td>BMDL$_{10RD}$, Multistage Degree 1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: ALT = alanine aminotransferase; AUC = area under the curve; BMDL$_{0.5SD}$ = lower bound on the dose level corresponding to the 95% lower confidence limit for a change in the mean response equal to 0.5 standard deviation from the control mean; BMDL$_{5RD}$ = lower bound on the dose level corresponding to the 95% lower confidence limit for a 5% change in response; BMDL$_{10RD}$ = lower bound on the dose level corresponding to the 95% lower confidence limit for a 10% change in response; $C_{last7}$ = blood concentration over
the last 7 days; F1 = first generation; IgM = immunoglobulin M; NOAEL = no-observed-adverse-effect level; NTP = National Toxicology Program; PODHED = point-of-departure human equivalence dose; RID = reference dose; SRBC = sheep red blood cell.

a see PFOA Appendix for additional details on BMD modeling.
b Supported by Grandjean et al. (2012, 1248827), Grandjean et al. (2017, 3858518), and Grandjean et al. (2017, 4239492).
c Maternal serum concentrations were taken either in the third trimester (32 weeks) or about two weeks after the expected term date.
d No models provided adequate fit; therefore, a NOAEL/LOAEL approach was selected.
4.1.4.1 Hepatic Effects

Increased ALT in individuals aged 18 and older \{Gallo, 2012, 1276142; Darrow, 2016, 3749173; Nian, 2019, 5080307\}

The POD for increased ALT in adults was derived by quantifying a benchmark dose using a hybrid modeling approach (see PFOA Appendix) on the measured \{Gallo, 2012, 1276142; Nian, 2019, 5080307\} or modeled \{Darrow, 2016, 3749173\} PFOA serum concentrations collected from adults aged 18 years and older, which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD\(_{\text{HED}}\)), in mg/kg/day. Specifically, the POD\(_{\text{HED}}\) was calculated as the external dose that would result in a steady-state serum concentration equal to the internal serum POD. This calculation is simply the POD multiplied by the selected human clearance value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = \(V_d \times \ln(2)/t_{1/2}\)).

Focal Necrosis, Crl:CD-1(ICR)BR mice, male, C\(_{\text{last7}}\) \{Loveless, 2008, 7330145\}

Increased incidence of focal necrosis of the liver was observed in male ICR mice. Dichotomous models were used to fit dose-response data. A BMR of 10% extra risk was chosen. C\(_{\text{last7}}\) was selected for this model rather than alternate metrics such as C\(_{\text{max}}\) because the average blood concentration is expected to better correlate with an accumulation of focal necrosis in the liver. The BMDS produced a BMDL in mg/L. A POD\(_{\text{HED}}\) was calculated as the external dose that would result in a steady-state serum concentration in humans equal to the POD from the animal analysis. This calculation is simply the POD multiplied by the selected human clearance value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = \(V_d \times \ln(2)/t_{1/2}\)).

Individual Cell Necrosis, Crl:CD-1(ICR)BR mice, male, C\(_{\text{last7}}\) \{Loveless, 2008, 7330145\}

Increased incidence of individual cell necrosis of the liver was observed in male ICR mice. Dichotomous models were used to fit dose-response data. A BMR of 10% extra risk was chosen. C\(_{\text{last7}}\) was selected for this model rather than alternate metrics such as C\(_{\text{max}}\) because the average blood concentration is expected to better correlate with an accumulation of individual cell necrosis of the liver. The BMDS produced a BMDL in mg/L. A POD\(_{\text{HED}}\) was calculated as the external dose that would result in a steady-state serum concentration in humans equal to the POD from the animal analysis. This calculation is simply the POD multiplied by the selected human clearance value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = \(V_d \times \ln(2)/t_{1/2}\)).

Necrosis, Sprague-Dawley rats, males, perinatal and postweaning, male rats, C\(_{\text{avg_pup_total}}\) \{NTP, 2020, 7330145\}

Increased incidence of necrosis of the liver was observed in adult male Sprague-Dawley rats. Dichotomous models were used to fit dose-response data. A BMR of 10% extra risk was chosen. The C\(_{\text{avg_pup_total}}\) was selected for this model rather than alternate metrics such as C\(_{\text{max}}\) because the average blood concentration is expected to better correlate with an accumulation of necrosis in the liver. The BMDS produced a BMDL in mg/L. A POD\(_{\text{HED}}\) was calculated as the external dose that would result in a steady-state serum concentration in humans equal to the POD from the animal analysis. This calculation is simply the POD multiplied by the selected human clearance value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = \(V_d \times \ln(2)/t_{1/2}\)).
value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = Vd * ln(2)/t1/2)).

4.1.4.2 Immune Effects

Decreased Diphtheria and Tetanus antibody response in vaccinated children at age 7
{Budtz-Jorgensen, 2018, 5083631}

The POD for decreased antibody production at age 7 was derived by quantifying a benchmark dose (see PFOA Appendix) on the measured PFOA serum concentrations at age 5, which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD_HED), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). For this, the model was run starting at the birth of the mother, with constant exposure relative to bodyweight. Pregnancy began at 24.25 years maternal age and birth occurred at 25 years maternal age. The initial concentration in the child is governed by the observed ratio between maternal serum and cord blood at delivery. Then the model is run through the 1 year breastfeeding period, where the exposure to the child is only through lactation, which is much greater than the exposure to the mother. After 1 year, the exposure to the child, relative to bodyweight, is set to the same value as the mother. The model provides predictions up to a child age of 5 years, when the serum concentrations used to determine the POD were collected, and reverse dosimetry was used to determine the POD_HED that results in the POD serum concentration. Because of different growth curves used for male and female children used in the model, the model predicted slightly different (less than 5%) serum concentrations for them. The lower HED was then selected as it was the most health protective.

Decreased Diphtheria and Tetanus antibody response in vaccinated children at age 5
{Budtz-Jorgensen, 2018, 5083631}

The POD for decreased antibody production at age 5 was derived by quantifying a benchmark dose (see PFOA Appendix) on the measured PFOA serum concentrations collected from the mother either in the third trimester (32 weeks) or about two weeks after the expected term date, which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD_HED), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). For this, the model was run similarly to the endpoint based on antibodies at age 7, except that the model was only run until the maternal age of 25 years, when delivery occurs in the model. As the POD was based on maternal serum concentrations taken before and after birth, the time of delivery was chosen as an average of the two. Reverse dosimetry was performed on model predicted maternal serum concentration at that time to calculate the POD_HED. This metric is independent of the sex of the child in the model.

Decreased Diphtheria and Tetanus antibody response in vaccinated children at ages 7–12
{Timmerman, 2021, 9416315}

The POD for decreased antibody production in children aged 7–12 was derived by quantifying a benchmark dose (see PFOA Appendix) on the measured PFOA serum concentrations at ages 7–12, which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD_HED), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). For this, the model was run similarly to the endpoint based on antibodies at age 7 {Budtz-Jorgensen, 2018, 5083631}, but the model was run until the median
age of this cohort at blood collection, 9.9 years. Reverse dosimetry was used to calculate the POD_{HED} that resulted in a serum level equal to the POD at that age. Because of different growth curves used for male and female children, the model predicted slightly different serum concentrations for them. The lower HED was then selected as it was the most health protective.

**Decreased IgM response to SRBC, Mouse, Female, Studies 1 and 2, C_{last7} {Dewitt, 2008, 1290826}**

Decreased mean response of SRBC-specific IgM antibody titers was observed in female C57BL/6N mice (Studies 1 and 2). Using the Wambaugh et al. (2013, 2850932) model, daily exposure to PFOA in the drinking water was simulated for 15 days using female C57BL/6 mice parameters. An average concentration over the last 7 days of treatment (C_{last7}) was calculated as the internal dose metric for each dose group. Continuous models were used to fit dose-response data. A BMR of a change in the mean equal to 1 SD from the control mean was chosen per EPA’s *Benchmark Dose Technical Guidance* {U.S. EPA, 2012, 1239433}. The average concentration over the final week of study (C_{last7}) was selected for this model rather than alternate metrics such as C_{max} because the average blood concentration is expected to better correlate with an accumulation of effects leading to decreased response of SRBC-specific IgM antibody titers. The BMDS produced a BMDL in mg/L. A POD_{HED} was calculated as the external dose that would result in a steady-state serum concentration in humans equal to the POD from the animal analysis. This calculation is simply the POD multiplied by the selected human clearance value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = V_d * ln(2)/t_{1/2}).

**Decreased IgM response to SRBC, Mouse, Male, C_{last7} {Loveless, 2008, 988599}**

Decreased mean response of IgM serum titer was observed in male Crl:CD-1(ICR)BR mice. Using the Wambaugh et al. (2013, 2850932) model, daily oral gavage exposure to PFOA was simulated for 29 days using male CD1 mice parameters. An average concentration over the last 7 days of treatment (C_{last7}) was calculated as the internal dose metric for each dose group. Continuous models were used to fit dose-response data. A BMR of a change in the mean equal to 1 SD from the control mean was chosen per EPA’s *Benchmark Dose Technical Guidance* {U.S. EPA, 2012, 1239433}. C_{last7} was selected for this model rather than alternate metrics such as C_{max} because the average blood concentration is expected to better correlate with an accumulation of effect resulting in decreased mean response of IgM serum titer. The BMDS produced a BMDL in mg/L. A POD_{HED} was calculated as the external dose that would result in a steady-state serum concentration in humans equal to the POD from the animal analysis. This calculation is simply the POD multiplied by the selected human clearance value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = V_d * ln(2)/t_{1/2}).

**Cardiovascular Effects**

**Increased total cholesterol in adults aged 20–80, excluding individuals prescribed cholesterol medication {Dong, 2019, 5080195}**

The POD for increased TC in adults was derived by quantifying a benchmark dose using a hybrid modeling approach (see PFOA Appendix) on the measured PFOA serum concentrations collected from adults aged 20–80 years not prescribed cholesterol medication through the NHANES, which provided an internal serum concentration POD in mg/L. The internal serum
POD was converted to an external dose (POD_{HED}), in mg/kg/day. Specifically, the POD_{HED} was calculated as the external dose that would result in a steady-state serum concentration equal to the internal serum POD. This calculation is simply the POD multiplied by the selected human clearance value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = V_d * ln(2)/t_{1/2}).

**Increased total cholesterol in individuals aged 18 and older, excluding individuals prescribed cholesterol medication (Steenland, 2009, 1291109)**

The POD for increased TC in adults was derived by quantifying a benchmark dose using a hybrid modeling approach (see PFOA Appendix) on the measured PFOA serum concentrations collected from adults aged 18 years and older not prescribed cholesterol medication from the C8 study population, which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD_{HED}), in mg/kg/day. Specifically, the POD_{HED} was calculated as the external dose that would result in a steady-state serum concentration equal to the internal serum POD. This calculation is simply the POD multiplied by the selected human clearance value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = V_d * ln(2)/t_{1/2}).

**Increased total cholesterol in individuals aged 25 and older (Lin, 2019, 5187597)**

The POD for increased TC in adults was derived by quantifying a benchmark dose using a hybrid modeling approach (see PFOA Appendix) on the measured PFOA serum concentrations collected in adults 25 years and older who were at high risk of developing type 2 diabetes and hyperlipidemia from the Diabetes Prevention Program (DPP) and Outcomes Study (DPPOS), which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD_{HED}), in mg/kg/day. Specifically, the POD_{HED} was calculated as the external dose that would result in a steady-state serum concentration equal to the internal serum POD. This calculation is simply the POD multiplied by the selected human clearance value (0.120 mL/kg/day; calculated from half-life and volume of distribution; Cl = V_d * ln(2)/t_{1/2}).

**4.1.4.4 Developmental Effects**

**Decreased birthweight using the mother’s serum PFOA concentration collected in third trimester (Chu, 2020, 6315711)**

The POD for decreased birth weight in infants was derived by quantifying a benchmark dose using a hybrid modeling approach (see PFOA Appendix) on the measured PFOA serum concentrations collected from the mother in the third trimester (blood was collected within 3 days after delivery), which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD_{HED}), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). This calculation was performed similarly for each of the birthweight endpoints. The model was run starting at the birth of the mother, with constant exposure relative to bodyweight. Pregnancy began at 24.25 years maternal age. The model was stopped at a time to match the median gestational age of the cohort at sample time for samples taken during pregnancy, or at delivery (25 years maternal age) in the case of maternal samples at delivery or samples of cord blood. Reverse dosimetry was performed to calculate the POD_{HED} resulting in serum levels matching the POD at the model end time. For this study,
maternal blood was drawn within a few days of the birth of the child, so delivery was chosen as the model end time. This metric is independent of the sex of the child in the model.

**Decreased birthweight using the serum PFOA concentrations collected from umbilical cord samples {Govarts, 2016, 3230364}**

The POD for decreased birth weight in infants was derived by quantifying a benchmark dose using a hybrid modeling approach (see PFOA Appendix) on the measured PFOA serum concentrations collected from an umbilical cord sample, which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD$_{HED}$), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). This was performed as described for the Chu et al. (2020, 6315711) study. The model was stopped at delivery and reverse dosimetry was performed to calculate the POD$_{HED}$ that resulted in the POD serum level in cord serum. This metric is independent of the sex of the child in the model.

**Decreased birthweight using the mother’s serum PFOA concentration collected in in first trimester {Sagiv, 2018, 4238410}**

The POD for decreased birth weight in infants was derived by quantifying a benchmark dose using a hybrid modeling approach (see PFOA Appendix) on the measured PFOA serum concentrations collected from the mother in the first trimester (median gestational age of 9 weeks), which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD$_{HED}$), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). This was performed as described for the Chu et al. (2020, 6315711) study. The model was stopped at the median gestational age of this cohort, 9 weeks. The time after conception was calculated as the fraction of pregnancy competed after 9 weeks (9/39 weeks), times the pregnancy duration of 0.75 year. Reverse dosimetry was performed to calculate the POD$_{HED}$ that resulted in the POD in maternal serum at that time. This metric is independent of the sex of the child in the model.

**Decreased birthweight using the mother’s serum PFOA concentration collected in second and third trimesters {Starling, 2017, 3858473}**

The POD for decreased birth weight in infants was derived by quantifying a benchmark dose using a hybrid modeling approach (see PFOA Appendix) on the measured PFOA serum concentrations collected from the mother in the trimesters 2 and 3 (median gestational age of 27 weeks), which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD$_{HED}$), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). This was performed as described for the Chu et al. (2020, 6315711) study. The model was stopped at the median gestational age of this cohort, 27 weeks. The time after conception was calculated as the fraction of pregnancy competed after 27 weeks (27/39 weeks), times the pregnancy duration of 0.75 year. Reverse dosimetry was performed to calculate the POD$_{HED}$ that resulted in the POD in maternal serum at that time. This metric is independent of the sex of the child in the model.

**Decreased birthweight using the mother’s serum PFOA concentration collected in first and second trimesters {Wikström, 2020, 6311677}**
The POD for decreased birth weight in infants was derived by quantifying a benchmark dose using a hybrid modeling approach (see PFOA Appendix) on the measured PFOA serum concentrations collected from the mother in the trimesters 1 and 2 (median gestational age of 10 weeks), which provided an internal serum concentration POD in mg/L. The internal serum POD was converted to an external dose (POD\textsubscript{HED}), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). This was performed as described for the Chu et al. (2020, 6315711) study. The model was stopped at the median gestational age of this cohort, 10 weeks. The time after conception was calculated as the fraction of pregnancy completed at 10 weeks (10/39 weeks), times the pregnancy duration of 0.75 year. Reverse dosimetry was performed to calculate the POD\textsubscript{HED} that resulted in the POD in maternal serum at that time. This metric is independent of the sex of the child in the model.

**Decreased Offspring Survival, Kunming Mice, F\textsubscript{1} males and females, C\textsubscript{avg,pup,gest,lact} {Song, 2018, 5079725}**

Decreased mean response of number of offspring survival was observed in F\textsubscript{1} male and female Kunming mice. Continuous models were used to fit dose-response data. BMR of a change in the mean equal to 0.1 and 0.5 standard deviations from the control mean were chosen. The C\textsubscript{avg,pup,gest}, C\textsubscript{avg,pup,lact}, C\textsubscript{avg,pup,gest,lact}, C\textsubscript{max,pup,gest}, and C\textsubscript{max,pup,lact} were considered because prenatal loss could be a result of exposure during a sensitive window of development where a C\textsubscript{max} metric is expected to better correlate with the effect or an accumulation of exposure and an average concentration metric is expected to better correlate with the effect and this could occur during the gestation or lactation lifestages. The C\textsubscript{avg,pup,gest,lact} was selected for this model since an average concentration metric is expected to better correlate with the effect and this could occur during the gestation or lactation lifestages. A 0.5 standard deviation BMR was ultimately selected. The BMDS produced a BMDL in mg/L. The internal serum POD, based on the predicted average serum concentration in the pup during gestation, was converted to an external dose (POD\textsubscript{HED}), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). For this, the model was run starting at the birth of the mother, with constant exposure relative to bodyweight. Pregnancy began at 24.25 years maternal age and birth occurred at 25 years maternal age. The model was run up to the birth of the child. The average serum concentration in the infant during gestation was determined for this scenario and reverse dosimetry was used to calculate the exposure that results in the same value as the POD. Before birth, model predictions for male and female children are equivalent.

**Decreased Fetal Body Weight, Kunming Mice, F\textsubscript{1} males and females, C\textsubscript{avg,pup,gest} {Li, 2018, 5084746}**

Decreased mean response of fetal body weight was observed in F\textsubscript{1} male and female Kunming mice. Continuous models were used to fit dose-response data. A BMR of 5% extra risk was selected as described in Section 4.1.2, and a change in the mean equal to 0.5 standard deviations from the control mean was provided for comparison purposes (See PFOA Appendix). The C\textsubscript{avg,pup,gest} was selected for this model rather than alternate metrics such as C\textsubscript{max} because the average concentration normalized per day during gestation is expected to better correlate with an accumulation of effect resulting in decreased fetal body weight. The BMDS did not produce a model with adequate fit, so a NOAEL approach was taken. The internal serum POD, based on the predicted average serum concentration in the pup during gestation, was converted to an external dose (POD\textsubscript{HED}), in mg/kg/day, using the updated Verner model (described in Section
4.1.3.1.3). For this, the model was run starting at the birth of the mother, with constant exposure relative to bodyweight. Pregnancy began at 24.25 years maternal age and birth occurred at 25 years maternal age. The model was run up to the birth of the child. The average serum concentration in the infant during gestation was determined for this scenario and reverse dosimetry was used to calculate the exposure that results in the same value as the POD. Before birth, model predictions for male and female children are equivalent.

Delayed Time to Eye Opening, CD-1 Mice, F1 males and females, Cavg_pup_gest \{Lau, 2006, 1276159\}

Decreased mean response of time to eye opening was observed in F1 male and female CD-1 mice. Continuous models were used to fit dose-response data. BMR of a change in the mean equal to 1 standard deviations from the control mean was selected, and a BMR of a change in the mean equal to 0.5 standard deviations from the control mean is provided for comparison purposes (See PFOA Appendix). The average concentration normalized per day during gestation, (Cavg_pup_gest), average concentration normalized per day during lactation (Cavg_pup_lact), maximum fetal concentration during gestation (Cmax_pup_gest), and maximum pup concentration during lactation (Cmax_pup_lact) were all considered because time to eye opening could be a result of exposure during a sensitive window of development where a Cmax metric is expected to better correlate with the effect or an accumulation of exposure where an average concentration metric is expected to better correlate with the effect and time to eye opening could be due to exposure during the gestation or lactation lifestages. The Cavg_pup_gest was selected for this model. The BMDS produced a BMDL in mg/L. The internal serum POD, based on the predicted average serum concentration in the pup during gestation and lactation, was converted to an external dose (POD_HED), in mg/kg/day, using the updated Verner model (described in Section 4.1.3.1.3). For this, the model was run starting at the birth of the mother, with constant exposure relative to bodyweight. Pregnancy began at 24.25 years maternal age and birth occurred at 25 years maternal age. The initial concentration in the child was governed by the observed ratio between maternal serum and cord blood at delivery. Then the model was run through the 1 year breastfeeding period. The average serum concentration in the infant through gestation and lactation was determined for this scenario and reverse dosimetry was used to calculate the exposure that results in the same value as the POD. Because of different growth curves used for male and female children, the model predicted slightly different serum concentrations for them. The lower HED was selected to be more health protective.

4.1.5 Derivation of Candidate Chronic Oral Reference Doses (RfDs)

Though multiple POD_HEDS were derived for multiple health systems from both epidemiological and animal toxicological studies, EPA selected the POD_HEDS with the greatest strength of evidence and the lowest risk of bias represented by high or medium confidence studies for candidate RfD derivation, as described below. As presented in Table 4-9, epidemiological data representing the four prioritized health outcomes represented the most sensitive effects after PFOA exposure in the lower dose range. Four endpoints from epidemiological studies representing the four health outcomes were considered for candidate RfD derivation. These endpoints are decreased antibody response, low birth weight, increased total cholesterol, and
elevated ALT. As described in the subsections below, EPA further evaluated studies within each endpoint to determine those most suitable for candidate RfD derivation.

EPA also further evaluated animal toxicological studies to determine which were the most suitable for candidate RfD derivation. Factors considered included study confidence (i.e., high confidence studies were prioritized over medium confidence studies), amenability to benchmark dose modeling, and health effects observed after exposure in the lower dose range among the animal toxicological studies. As described in the subsections below, this examination led to the exclusion a number of studies considered for POD derivation, including both epidemiological and animal toxicological studies, from further consideration.

### 4.1.5.1 Hepatic Effects

Three medium confidence epidemiological studies were carried forward for candidate RfD determination {Gallo, 2012, 1276142; Darrow, 2016, 3749173; Nian, 2019, 5080307}. EPA considered all three studies as they represented the low-dose range of effects across hepatic endpoints and provided data from relatively large populations, including U.S. populations.

One high confidence animal toxicological study was carried forward for candidate RfD determination {NTP, 2020, 7330145}. NTP (2020, 7330145) was prioritized for candidate RfD development because it was determined to be a high confidence study and it used a chronic exposure duration that encompassed sensitive periods of development whereas Loveless et al. (2008, 988599) was a medium confidence study that used a short-term (28 day) exposure duration and predated current criteria for hepatic histopathological assessment of cell death {Elmore, 2016, 10671182}.

### 4.1.5.2 Immune Effects

Two medium confidence epidemiological studies were carried forward for candidate RfD determination {Budtz-Jørgensen, 2018, 5083631; Timmerman, 2021, 9416315}. EPA considered both studies as they both represented the low-dose range of effects across immunological endpoints and provided data regarding sensitive populations (i.e., children). Although EPA derived PODHEDS for two time points reported by Budtz-Jørgensen and Grandjean (2018, 5083631) (i.e., PFOA serum concentrations at age 5 and antibody concentrations at age 7; PFOA serum concentrations in the mother during the third trimester or approximately 2 weeks after the expected term date and antibody concentrations at age 5), EPA did not carry forward PODHEDS based on serum PFOA concentrations measured in the mother for candidate RfD derivation because of concerns surrounding bias due to pregnancy-related hemodynamic effects.

One medium confidence animal toxicological study was carried forward for candidate RfD determination {Dewitt, 2008, 1290826}. Study quality evaluations and further consideration did not identify notable characteristics distinguishing the two candidate studies {Dewitt, 2008, 1290826; Loveless, 2008, 988599}, but because the PODHEDS of reduced IgM response in rodents represented effects at the highest dose range of responses and because the observed effects were from medium confidence less-than-chronic studies, EPA selected the most health protective PODHED for candidate RfD derivation.
4.1.5.3  **Cardiovascular Effects**

Two medium confidence epidemiological studies were carried forward for candidate RfD determination {Dong, 2019, 5080195; Steenland, 2009, 1291109}. Of the three studies for which PODHEDs were derived, Dong et al. (2019, 5080195) and Steenland et al. (2009, 1291109) exclude individuals who were prescribed cholesterol medication, minimizing concerns surrounding confounding due to the medical intervention altering serum total cholesterol levels. Therefore, these two studies were considered further for candidate RfD derivation.

4.1.5.4  **Developmental Effects**

Two high confidence epidemiological studies were carried forward for candidate RfD determination for the endpoint of low birth weight {Sagiv, 2018, 4238410; Wikström, 2020, 6311677}. Of the six epidemiological studies for which PODHEDs were derived, Sagiv et al. (2018, 4238410) and Wikström et al. (2020, 6311677) assessed maternal PFOA serum concentrations primarily or exclusively in the first trimester, minimizing concerns surrounding bias due to pregnancy-related hemodynamic effects. Therefore, these two studies were considered further for candidate RfD derivation.

Two medium confidence animal toxicological studies were carried forward for candidate RfD determination {Lau, 2006, 1276159; Song, 2018, 5079725}. These two studies were amenable to benchmark dose modeling, unlike Li et al. (2018, 5084746), which had a NOAEL as the basis of the PODHED. As the endpoints reported by Lau et al. (2006, 1276159) and Song et al. (2018, 5079725) encompass sensitive populations (i.e., fetuses and pups), these two studies were considered further for candidate RfD derivation.

4.1.5.5  **Application of Uncertainty Factors (UFs)**

To calculate the candidate RfD values, EPA applied UFs to the PODHEDs derived from selected epidemiological and animal toxicological studies (Table 4-9 and Table 4-10). UFs were applied according to methods described in EPA’s *Review of the Reference Dose and Reference Concentration Processes* {U.S. EPA, 2002, 88824}.

<table>
<thead>
<tr>
<th>UF</th>
<th>Value</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>UF_A</td>
<td>1</td>
<td>A UF_A of 1 is applied to effects observed in epidemiological studies as the study population is humans.</td>
</tr>
<tr>
<td>UF_H</td>
<td>10</td>
<td>A UF_H of 10 is applied when information is not available relative to variability in the human population.</td>
</tr>
<tr>
<td>UF_S</td>
<td>1</td>
<td>A UF_S of 1 is applied when effects are observed in adult human populations that are assumed to have been exposed to a contaminant over the course of many years. A UF_S of 1 is applied for developmental effects because the developmental period is recognized as a susceptible life stage when exposure during a time window of development is more relevant to the induction of developmental effects than lifetime exposure {U.S. EPA, 1991, 732120}.</td>
</tr>
<tr>
<td>UF_L</td>
<td>1</td>
<td>A UF_L of 1 is applied for LOAEL to NOAEL extrapolation when the POD is a BMDL or a NOAEL.</td>
</tr>
</tbody>
</table>
An interspecies UF (UF_A) of 1 was applied to POD_{HED_{S}} derived from epidemiological studies because the dose response information from these studies is directly relevant to humans. There is no need to account for uncertainty in extrapolating from laboratory animals to humans.

An intraspecies UF (UF_H) of 10 was applied to POD_{HED_{S}} derived from epidemiological studies to account for variability in the responses within the human populations because of both intrinsic (toxicokinetic, toxicodynamic, genetic, life stage, and health status) and extrinsic (lifestyle) factors that can influence the response to dose. No information to support a UF_H other than 10 was available to quantitatively characterize interindividial and age-related variability in the toxicokinetics or toxicodynamics.

A LOAEL-to-NOAEL extrapolation UF (UF_L) of 1 was applied to POD_{HED_{S}} derived from epidemiological studies because a BMDL is used as the basis for the POD_{HED_{S}} derivation. When the POD type is a BMDL, the current approach is to address this factor as one of the considerations in selecting a BMR for BMD modeling.

A UF for extrapolation from a subchronic to a chronic exposure duration (UF_S) of 1 was applied to POD_{HED_{S}} derived from epidemiological studies. A UF_S of 1 was applied to the hepatic and cardiovascular endpoints because the effects were observed in adult populations that were assumed to have been exposed to PFOA over the course of many years. A UF_S of 1 was applied to the developmental endpoints because the developmental period is recognized as a susceptible life stage when exposure during a time window of development is more relevant to the induction of developmental effects than lifetime exposure (U.S. EPA, 1991, 732120). A UF_S of 1 was also applied to the immune endpoints in children because the developing immune system is recognized as a susceptible lifestage; therefore, exposure during this time window can be considered more relevant than lifetime exposure (U.S. EPA, 1991, 732120). According to the WHO/International Programme on Chemical Safety (IPCS) Immunotoxicity Guidance for Risk Assessment, developmental immunotoxicity encompasses the prenatal, neonatal, juvenile and adolescent life stages and should be viewed differently from the immune system of adults from a risk assessment perspective (IPCS, 2012, 1249755).

A database UF (UF_D) of 1 was applied to account for deficiencies in the database for PFOA. In animals, comprehensive oral short term, subchronic, and chronic studies in three species and several strains of laboratory animals have been conducted and published in the peer reviewed literature. Additionally, there are several neurotoxicity studies (including developmental neurotoxicity) and several reproductive (including one- and two-generation reproductive toxicity studies) and developmental toxicity studies including assessment of immune effects following developmental exposure. Moreover, there is a robust epidemiological database which was used
quantitatively in this assessment. Typically, the specific study types lacking in a chemical’s database that influence the value of the UF to the greatest degree are developmental toxicity and multigenerational reproductive toxicity studies. Effects identified in developmental and multigenerational reproductive toxicity studies have been quantitatively considered in this assessment.

The total UF that was applied to candidate RfDs derived from all of the epidemiological studies were the same value (UF_C = 10) (Table 4-9).

Increased uncertainty is associated with the use of animal toxicological studies as the basis of candidate RfDs. The UFs applied to animal toxicological studies considered for candidate RfD derivation were either one of two values, depending on the duration of exposure (i.e., chronic vs. subchronic) or exposure window (e.g., gestational) (Table 4-10).

### Table 4-10. Uncertainty Factors for the Development of the Candidate Chronic RfD Values from Animal Toxicological Studies [U.S. EPA, 2002, 88824]

<table>
<thead>
<tr>
<th>UF</th>
<th>Value</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>UF_A</td>
<td>3</td>
<td>A UF_A of 3 is applied for the extrapolation from animal models to humans due to the implementation of a PK model for animal POD_HED derivation.</td>
</tr>
<tr>
<td>UF_H</td>
<td>10</td>
<td>A UF_H of 10 is applied when information is not available relative to variability in the human population.</td>
</tr>
<tr>
<td>UF_S</td>
<td>1 or 10</td>
<td>A UF_S of 10 is applied for the extrapolation of subchronic to chronic exposure durations. A UF_S of 1 is applied to studies with chronic exposure durations or that encompass a developmental period (i.e., gestation). The developmental period is recognized as a susceptible life stage when exposure during a time window of development is more relevant to the induction of developmental effects than lifetime exposure [U.S. EPA, 1991, 732120].</td>
</tr>
<tr>
<td>UF_L</td>
<td>1</td>
<td>A UF_L of 1 is applied for LOAEL to NOAEL extrapolation when the POD is a BMDL or a NOAEL.</td>
</tr>
<tr>
<td>UF_D</td>
<td>1</td>
<td>A UF_D of 1 is applied when the database for a contaminant contains a multitude of studies of adequate quality that encompass a comprehensive array of endpoints in various life stages and populations and allow for a complete characterization of the contaminant’s toxicity.</td>
</tr>
<tr>
<td>UF_C</td>
<td>30 or 300</td>
<td>Composite UF_C = UF_A × UF_H × UF_S × UF_L × UF_D</td>
</tr>
</tbody>
</table>

Notes: BMDL = benchmark dose level; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; POD = point of departure; UF_A = interspecies uncertainty factor; UF_D = database uncertainty factor; UF_H = intraspecies uncertainty factor; UF_L = LOAEL-to-NOAEL extrapolation uncertainty factor; UF_S = uncertainty factor for extrapolation from a subchronic to a chronic exposure duration; UF_C = total uncertainty factors.

A UF_A of 3 was applied to POD_HEDS derived from animal toxicological studies to account for uncertainty in extrapolating from laboratory animals to humans (i.e., interspecies variability). The 3-fold factor is applied to account for toxicodynamic differences between the animals and humans. The HEDs were derived using a model that accounted for PK differences between animals and humans.

A UF_H of 10 was applied to POD_HEDS derived from animal toxicological studies to account for variability in the responses within human populations because of both intrinsic (toxicokinetic, toxicodynamic, genetic, life stage, and health status) and extrinsic (lifestyle) factors can

4-45
influence the response to dose. No information to support a UF_H other than 10 was available to characterize interindividual and age-related variability in the toxicokinetics or toxicodynamics.

A UF_L of 1 was applied to POD_HEDs derived from animal toxicological studies because a BMDL is used as the basis for the POD_HED derivation. When the POD type is a BMDL, the current approach is to address this factor as one of the considerations in selecting a BMR for BMD modeling.

A UF_S of 1 was applied to POD_HEDs derived from chronic animal toxicological studies as well as animal toxicological studies that encompass a developmental period (i.e., gestation). A UF_S of 1 was applied to developmental endpoints because the developmental period is recognized as a susceptible life stage when exposure during a time window of development is more relevant to the induction of developmental effects than lifetime exposure \{U.S. EPA, 1991, 732120\}. A UF_S of 10 was applied to POD_HEDs derived from studies that implemented a less-than-chronic exposure duration because extrapolation is required to translate from a subchronic POD_HED to a chronic RfD.

A database UF (UF_D) of 1 was applied to account for deficiencies in the database for PFOA. In animals, comprehensive oral short term, subchronic, and chronic studies in three species and several strains of laboratory animals have been conducted and published in the peer reviewed literature. Additionally, there are several neurotoxicity studies (including developmental neurotoxicity) and several reproductive (including one- and two-generation reproductive toxicity studies) and developmental toxicity studies including assessment of immune effects following developmental exposure. Moreover, there is a robust epidemiological database which was used quantitatively in this assessment. Typically, the specific study types lacking in a chemical’s database that influence the value of the UF_D to the greatest degree are developmental toxicity and multigenerational reproductive toxicity studies. Effects identified in developmental and multigenerational reproductive toxicity studies have been quantitatively considered in this assessment.

4.1.5.6 Candidate RfDs

Table 4-11 shows the UFs applied to each candidate study to subsequently derive the candidate RfDs.
<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Study, Confidence</th>
<th>Strain/Species/Sex</th>
<th>POD&lt;sub&gt;HED&lt;/sub&gt; (mg/kg/day)</th>
<th>UFA</th>
<th>UFH</th>
<th>UF&lt;sub&gt;S&lt;/sub&gt;</th>
<th>UF&lt;sub&gt;L&lt;/sub&gt;</th>
<th>UF&lt;sub&gt;D&lt;/sub&gt;</th>
<th>UF&lt;sub&gt;C&lt;/sub&gt;</th>
<th>Candidate RfD&lt;sup&gt;a&lt;/sup&gt; (mg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immune Effects</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased serum anti-tetanus antibody concentration in children</td>
<td>Budtz-Jørgensen and Grandjean (2018, 5083631)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Human, male and female</td>
<td>3.05×10&lt;sup&gt;-7&lt;/sup&gt;</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>3.05×10&lt;sup&gt;-8&lt;/sup&gt; = 3×10&lt;sup&gt;-8&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Timmerman et al. (2021, 9416315)</td>
<td>Human, male and female</td>
<td>3.34×10&lt;sup&gt;-7&lt;/sup&gt;</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>3.34×10&lt;sup&gt;-8&lt;/sup&gt; = 3×10&lt;sup&gt;-8&lt;/sup&gt;</td>
</tr>
<tr>
<td>Decreased serum anti-diphtheria antibody concentration in children</td>
<td>Budtz-Jørgensen and Grandjean (2018, 5083631)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Human, male and female</td>
<td>2.92×10&lt;sup&gt;-7&lt;/sup&gt;</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>2.92×10&lt;sup&gt;-8&lt;/sup&gt; = 3×10&lt;sup&gt;-8&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Timmerman et al. (2021, 9416315)</td>
<td>Human, male and female</td>
<td>2.20×10&lt;sup&gt;-7&lt;/sup&gt;</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>2.20×10&lt;sup&gt;-8&lt;/sup&gt; = 2×10&lt;sup&gt;-8&lt;/sup&gt;</td>
</tr>
<tr>
<td>Decreased IgM response to SRBC</td>
<td>Dewitt et al. (2008, 1290826)</td>
<td>Mouse, Female Study 1</td>
<td>2.18×10&lt;sup&gt;-3&lt;/sup&gt;</td>
<td>3</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>300</td>
<td>7.27×10&lt;sup&gt;-6&lt;/sup&gt; = 7×10&lt;sup&gt;-6&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Developmental Effects</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low Birth Weight</td>
<td>Sagiv et al. (2018, 4238410)</td>
<td>Human, male and female</td>
<td>1.21×10&lt;sup&gt;-6&lt;/sup&gt;</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>1.21×10&lt;sup&gt;-7&lt;/sup&gt; = 1×10&lt;sup&gt;-7&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Wikström et al. (2020, 6311677)</td>
<td>Human, male and female</td>
<td>2.92×10&lt;sup&gt;-7&lt;/sup&gt;</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>2.92×10&lt;sup&gt;-8&lt;/sup&gt; = 3×10&lt;sup&gt;-8&lt;/sup&gt;</td>
</tr>
<tr>
<td>Decreased Offspring Survival</td>
<td>Song et al. (2018, 5079725)</td>
<td>Kunming Mice, F&lt;sub&gt;1&lt;/sub&gt; males and females</td>
<td>6.40×10&lt;sup&gt;-4&lt;/sup&gt;</td>
<td>3</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>30</td>
<td>2.13×10&lt;sup&gt;-5&lt;/sup&gt; = 2×10&lt;sup&gt;-5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Delayed Time to Eye Opening</td>
<td>Lau et al. (2006, 1276159)</td>
<td>CD-1 Mice, F&lt;sub&gt;1&lt;/sub&gt; males and females</td>
<td>1.71×10&lt;sup&gt;-3&lt;/sup&gt;</td>
<td>3</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>30</td>
<td>5.70×10&lt;sup&gt;-5&lt;/sup&gt; = 6×10&lt;sup&gt;-5&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
### Cardiovascular Effects

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Study, Confidence</th>
<th>Strain/Species/Sex</th>
<th>POD$^{\text{HED}}$ (mg/kg/day)</th>
<th>UFA</th>
<th>UFH</th>
<th>UF$^S$</th>
<th>UF$^L$</th>
<th>UF$^D$</th>
<th>UF$^C$</th>
<th>Candidate RfD$^a$ (mg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased Serum Total Cholesterol</td>
<td>Dong et al. (2019, 5080195) Medium</td>
<td>Human, male and female, excluding individuals prescribed cholesterol medication</td>
<td>2.75×10$^{-7}$</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>2.75×10$^{-8}$ = 3×10$^{-8}$</td>
</tr>
<tr>
<td></td>
<td>Steenland et al. (2009, 1291109) Medium</td>
<td>Human, male and female, excluding individuals prescribed cholesterol medication</td>
<td>5.10×10$^{-7}$</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>5.10×10$^{-8}$ = 5×10$^{-8}$</td>
</tr>
</tbody>
</table>

### Hepatic Effects

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Study, Confidence</th>
<th>Strain/Species/Sex</th>
<th>POD$^{\text{HED}}$ (mg/kg/day)</th>
<th>UFA</th>
<th>UFH</th>
<th>UF$^S$</th>
<th>UF$^L$</th>
<th>UF$^D$</th>
<th>UF$^C$</th>
<th>Candidate RfD$^a$ (mg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased Serum ALT</td>
<td>Gallo et al. (2012, 1276142) Medium</td>
<td>Human, female</td>
<td>2.15×10$^{-6}$</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>2.15×10$^{-7}$ = 2×10$^{-7}$</td>
</tr>
<tr>
<td></td>
<td>Darrow et al. (2016, 3749173) Medium</td>
<td>Human, female</td>
<td>7.92×10$^{-6}$</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>7.92×10$^{-7}$ = 8×10$^{-7}$</td>
</tr>
<tr>
<td></td>
<td>Nian et al. (2019, 5080307) Medium</td>
<td>Human, female</td>
<td>4.51×10$^{-7}$</td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>10</td>
<td>4.51×10$^{-8}$ = 5×10$^{-8}$</td>
</tr>
<tr>
<td>Necrosis</td>
<td>NTP (2020, 7330145) High</td>
<td>Sprague-Dawley rats, perinatal and postweaning, male</td>
<td>3.23×10$^{-3}$</td>
<td>3</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>30</td>
<td>1.08×10$^{-4}$ = 1×10$^{-4}$</td>
</tr>
</tbody>
</table>

Notes: ALT = alanine aminotransferase; NTP = National Toxicology Program; POD$^{\text{HED}}$ = point-of-departure human equivalence dose; RfD = reference dose; SRBC = sheep red blood cells; UFA = interspecies uncertainty factor; UFH = intraspecies uncertainty factor; UF$^S$ = subchronic-to-chronic extrapolation uncertainty factor; UF$^L$ = extrapolation from a LOAEL to NOAEL uncertainty factor; UF$^D$ = database uncertainty factor; UF$^C$ = composite uncertainty factor.

$^a$RfDs were rounded to one significant figure.

$^b$Supported by Grandjean et al. (2012, 1248827), Grandjean et al. (2017, 3858518), and Grandjean et al. (2017, 4239492).
4.1.6 RfD Selection

As presented in Section 4.1.5 (Table 4-11), EPA derived and considered multiple candidate RfDs across the four non-cancer health outcomes that EPA determined had the strongest weight of evidence (i.e., immune, cardiovascular, hepatic, and developmental). EPA derived candidate RfDs based on both epidemiological and animal toxicological studies. As depicted in Figure 4-4, the candidate RfDs derived from epidemiological studies were all within 1 order of magnitude of each other (10^{-7} to 10^{-8} mg/kg/day), regardless of endpoint, health outcome, or study population.

Candidate RfDs derived from animal toxicological studies were generally 2-3 orders of magnitude higher than candidate RfDs derived from epidemiological studies. However, EPA does not necessarily expect concordance between animal and epidemiological studies in terms of the adverse effect(s) observed, as well as the dose level that elicits the adverse effect(s). For example, EPA’s Guidelines for Developmental Toxicity Risk Assessment states that “the fact that every species may not react in the same way could be due to species-specific differences in critical periods, differences in timing of exposure, metabolism, developmental patterns, placentation, or mechanisms of action” {U.S. EPA, 1991, 732120}. Additionally, for developmental effects, the guidance says that “the experimental animal data were generally predictive of adverse developmental effects in humans, but in some cases, the administered dose or exposure level required to achieve these adverse effects was much higher than the effective dose in humans” {U.S. EPA, 1991, 732120}.

As shown in Table 4-11 and Figure 4-4, there is greater uncertainty associated with the use of animal toxicological studies as the basis of RfDs than human epidemiological studies. Though there are some uncertainties in the use of epidemiological studies for quantitative dose-response analyses (see Section 6.1), human data eliminate the uncertainties associated with interspecies extrapolation and the toxicokinetic differences between species which are major uncertainties associated with the PFOA animal toxicological studies due to the half-life differences and sex-specific toxicokinetic differences in rodent species. These uncertainties may explain why the candidate RfDs derived from animal toxicological studies were several orders of magnitude higher in value than the candidate RfDs derived from epidemiological studies. Moreover, the human epidemiological studies also have greater relevance of exposure to human exposure because they directly measure environmental or serum concentrations of PFOA. In accordance with EPA’s current best practices for systematic review, “animal studies provide supporting evidence when adequate human studies are available, and they are considered to be the studies of primary interest when adequate human studies are not available” {U.S. EPA, 2022, 10476098}. For these reasons, EPA determined that candidate RfDs based on animal toxicological studies would not be further considered for health outcome-specific RfD selection or overall RfD selection. See Section 6.2 for further comparisons between toxicity values derived from epidemiological and animal toxicological studies.
Figure 4-4. Comparison of Candidate RfDs Resulting from the Application of Uncertainty Factors to PODHEDs Derived from Epidemiological and Animal Toxicological Studies
As described in the subsections below, EPA selected amongst the candidate RfDs to identify an RfD representative of each of the four prioritized health outcomes (i.e., health outcome-specific RfDs), as well as an overall RfD that is protective of the effects of PFOA on all health outcomes and endpoints (Figure 4-5).

**4.1.6.1 Health Outcome-Specific RfDs**

**4.1.6.1.1 Hepatic Effects**

Three medium confidence epidemiological studies were selected as candidates for RfD derivation for the endpoint of elevated ALT \{Gallo, 2012, 1276142; Darrow, 2016, 3749173; Nian, 2019, 5080307\}. The two largest studies of PFOA and ALT in adults, Gallo et al. (2012, 1276142) and Darrow et al. (2016, 3749173), were both conducted in over 30,000 adults from the C8 Study. Gallo et al. (2012) reported measured serum ALT levels, unlike Darrow et al. (2016) which reported a modeled regression coefficient as the response variable. Another difference between the two studies is reflected in exposure assessment: Gallo et al. (2012, 1276142) includes measured PFOA serum concentrations, while Darrow et al. (2016, 3749173) based PFOA exposure on modeled PFOA serum levels. The third study by Nian et al. (2019, 5080307) examined a large population of adults in Shenyang (one of the largest fluoropolymer manufacturing centers in China) as part of the Isomers of C8 Health Project and observed significant increases in lognormal ALT per each ln-unit increase in PFOA, as well significant increases in ORs of elevated ALT. While both Nian et al. (2019, 5080307) and Gallo et al. (2012, 1276142) provide measured PFOA serum concentrations and a measure of serum ALT levels, the RfD for increased ALT from Gallo et al. (2012, 1276142) was ultimately selected for the hepatic outcome as it was conducted in a community exposed predominately to PFOA, whereas Nian et al. (2019, 5080307) was in a community exposed predominately to PFOS, which reduces concerns about confounding from other PFAS. The resulting health outcome-specific RfD is \(2 \times 10^{-7}\) mg/kg/day (Figure 4-5).

**4.1.6.1.2 Immune Effects**

Two medium confidence epidemiological studies were considered for RfD derivation for the endpoint of decreased antibody production in response to various vaccinations in children \{Budtz-Jørgensen, 2018, 5083631; Timmerman, 2021, 9416315\}. These candidate studies offer a variety of PFOA exposure measures across various populations and various vaccinations. Budtz-Jørgensen and Grandjean (2018, 5083631) investigated anti-tetanus and anti-diptheria responses in Faroese children aged 5–7 and Timmerman et al. (2021, 9416315) investigated anti-tetanus and anti-diphtheria responses in Greenlandic children aged 7–12. Though the Timmerman et al. (2021, 9416315) study is also a medium confidence study, the study by Budtz-Jørgensen and Grandjean (2018, 5083631) has two additional features that strengthen the confidence in this RfD: 1) the response reported by this study was more precise in that it reached statistical significance, and 2) the analysis considered co-exposures of other PFAS. The RfDs for anti-tetanus response in 7-year-old Faroese children and anti-diphtheria response in 7-year-old Faroese children, both from Budtz-Jørgensen and Grandjean (2018, 5083631) were ultimately selected for the immune outcome as they are the same value and have no distinguishing characteristics that would facilitate selection of one over the other. The resulting health outcome-specific RfD is \(3 \times 10^{-8}\) mg/kg/day (Figure 4-5). Note that all candidate RfDs based on epidemiological studies for the immune outcome were within one order of magnitude of the selected health outcome-specific RfD.
4.1.6.1.3 Cardiovascular Effects

Two medium confidence epidemiological studies were considered for RfD derivation for the endpoint of increased TC {Dong, 2019, 5080195; Steenland, 2009, 1291109}. These candidate studies offer a variety of PFOA exposure measures across various populations. Dong et al. (2019, 5080195) investigated the NHANES population (2003–2014), while Steenland et al. (2009, 1291109) investigated effects in a high-exposure community (the C8 Health Project study population). Both of these studies excluded individuals prescribed cholesterol medication which minimizes concerns of confounding due to medical intervention. The RfD for increased TC from Dong et al. (2019, 5080195) was ultimately selected for the health outcome-specific RfD for cardiovascular effects as there is marginally increased confidence in the modeling from this study. Steenland et al. (2009, 1291109) presented analyses using both PFOA and TC as categorical and continuous variables. The results using the natural log transformed TC and the natural log transformed PFOA were stated to fit the data slightly better than the ones using untransformed PFOA. However, the dramatically different changes in regression slopes between the two analyses by Steenland et al. (2009, 1291109) resulting in extremely different PODs raise concerns about the appropriateness of using this data. Therefore, the resulting health outcome-specific RfD based on results from Dong et al. (2019, 5080195) is $3 \times 10^{-8}$ mg/kg/day (Figure 4-5). Note that both candidate RfDs for the cardiovascular outcome were within one order of magnitude of the selected health outcome-specific RfD.

4.1.6.1.4 Developmental Effects

Two high confidence epidemiological studies were considered for RfD derivation for the endpoint of low birth weight {Sagiv, 2018, 4238410; Wikström, 2020, 6311677}. These candidate studies assessed maternal PFOA serum concentrations primarily or exclusively in the first trimester, minimizing concerns surrounding bias due to pregnancy-related hemodynamic effects. Both were high confidence prospective cohort studies with many study strengths including sufficient study sensitivity and sound methodological approaches, analysis, and design, as well as no evidence of bias. The RfD for low birth weight from Wikström et al. (2020, 6311677) was selected as the basis for the health outcome-specific RfD for developmental effects as it was the lowest and therefore most health protective candidate RfD from these two studies. The resulting health outcome-specific RfD is $3 \times 10^{-8}$ mg/kg/day (Figure 4-5). Note that both candidate RfDs based on epidemiological studies for the developmental outcome were within one order of magnitude of the selected health outcome-specific RfD.
4.1.6.2 Overall RfD

The available evidence indicates there are effects across immune, developmental, cardiovascular, and hepatic organ systems at the same or approximately the same level of PFOA exposure. In fact, candidate RfDs within the immune, developmental, and cardiovascular outcomes are the same value (i.e., $3 \times 10^{-8}$ mg/kg/day). Therefore, EPA has selected an overall RfD for PFOA of $3 \times 10^{-8}$ mg/kg/day. The immune, developmental, and cardiovascular RfDs based on endpoints of decreased anti-tetanus and anti-diphtheria antibody concentrations in children, low birth weight, and increased total cholesterol, respectively, serve as co-critical effects for this RfD. Notably, the RfD is protective of effects that may occur in sensitive populations (i.e., infants and children; see Section 6.8), as well as hepatic effects in adults that may result from PFOA exposure. As two of the co-critical effects identified for PFOA are developmental endpoints and can potentially result...
from a short-term exposure during critical periods of development, EPA concludes that the overall RfD for PFOA is applicable to both short-term and chronic risk assessment scenarios.

The critical studies that serve as the basis of the RfD are all medium or high confidence epidemiological studies. The critical studies are supported by multiple other medium or high confidence studies in both humans and animal models and have health outcome databases for which EPA determined that either evidence indicates or evidence demonstrates that oral PFOA exposure is associated with adverse effects. Additionally, the selected critical effects can lead to clinical outcomes in a sensitive lifestage (children) and/or yield the lowest PODHED and candidate RfDs and therefore, is expected to be protective of all other health effects in humans.

4.2 Cancer

4.2.1 Animal Toxicological Studies

4.2.1.1 Study and Endpoint Selection

Three chronic studies are available that investigate the relationship between dietary PFOA exposure and carcinogenicity in male and female rats {Butenhoff, 2012, 2919192; NTP, 2020, 7330145; Biegel, 2001, 673581}. Biegel et al. (2001, 673581) was not considered for dose-response modeling because it is a single-dose study. Butenhoff et al. (2012, 2919192) and NTP (2020, 7330145) are medium and high confidence multi-dose chronic cancer bioassays, respectively, and were used for the cancer dose-response assessment.

Increased incidences of neoplastic lesions were primarily observed in male rats, though results in females are supportive of potential carcinogenicity of PFOA. Butenhoff et al. (2012, 2919192) and Biegel et al. (2001, 673581) reported dose-dependent increases in testicular LCTs. Additionally, LCT incidence at similar dose levels was comparable between the two studies (11 and 14%, respectively). PACTs were observed in both the NTP (2020, 7330145) and Biegel et al. (2001, 673581) studies. NTP (2020, 7330145) reported increased incidences of pancreatic acinar cell adenomas in males in all treatment groups compared to their respective controls. This rare tumor type was also observed in female rats from the highest dose group, though the increased incidence did not reach statistical significance. Biegel et al. (2001, 673581) reported increases in the incidence of PACTs in male rats treated with PFOA, with zero incidences observed in control animals. In addition, both NTP (2020, 7330145) and Biegel et al. (2001, 673581) reported dose-dependent increases in the incidence of liver adenomas in male rats. Therefore, testicular LCTs, pancreatic acinar cell adenomas, and liver adenomas in male rats were considered for CSF derivation.

NTP (2020, 7330145) observed marginally increased incidences of uterine adenocarcinomas in female Sprague-Dawley rats during the extended evaluation (i.e., uterine tissue which included cervical, vaginal, and uterine tissue remnants). The accompanying incidences of uterine hyperplasia did not follow a dose-response relationship. Uterine adenocarcinomas were not considered for CSF derivation because “the strength of the response was marginal and there was a low concurrent control incidence that lowered confidence in the response” {NTP, 2020, 7330145}. Butenhoff et al. (2012, 2919192) identified mammary fibroadenomas and ovarian tubular adenomas in female rats, though there were no statistical differences in incidence rates between PFOA-treated groups and controls. These tumor types were also not considered for CSF.
derivation because the incidences were not statistically significant and the tumors were not observed by NTP (2020, 7330145).

4.2.1.2 CSF Derivation

In the 2016 HESD for PFOA {U.S. EPA, 2016, 3603279}, a CSF based on LCTs reported by Butenhoff et al. (2012, 2919192) was calculated to determine if a lifetime Health Advisory derived from the RfD would be protective for the cancer endpoint. At that time, the dose-response relationship for the LCTs observed by Butenhoff et al. (2012, 2919192) was modeled using EPA’s Benchmark Dose Software (BMDS) Version 2.3.1. The multistage cancer model predicted the dose at which a 4% increase in tumor incidence would occur. The 4% increase was chosen as the low-end of the observed response range within the Butenhoff et al. (2012, 2919192) results. The CSF presented in the 2016 PFOA HESD of 0.07 (mg/kg/day) was derived from the BMDL of 1.99 mg/kg/day after converting the animal BMDL to a HED using body weights to the ¾ power. The resultant 0.5 μg/L value was greater than the lifetime Health Advisory (0.070 μg/L) based on noncancer effects {U.S. EPA, 2016, 3982042}, indicating that the Health Advisory derived based on the developmental endpoint was protective for the cancer endpoint.

EPA has reevaluated the LCTs reported by Butenhoff et al. (2012, 2919192) in the current effort using the updated animal and human PK models described in Section 4.1.3. These modeling results are described in the Appendix (see PFOA Appendix). To duplicate the findings from the 2016 PFOA HESD, a BMR of 4% was chosen as the low end of the observed response range within the study results. EPA also derived CSFs for the tumor types observed in the NTP study that provide further evidence of carcinogenic activity of PFOA in male Hsd:Sprague DawleySD rats: hepatocellular neoplasms (hepatocellular adenomas and carcinomas) and acinar cell adenomas of the pancreas {NTP, 2020, 7330145} (Table 4-12). A BMR of 10% was selected for these tumor types, consistent with the BMD Technical Guidance {U.S. EPA, 2012, 1239433}. For all tumor types, dichotomous models were used to fit dose-response data. For LCTs reported by Butenhoff et al. (2012, 2919192), the area under the curve (AUC) for duration of the study was selected for this model because the AUC accounts for the accumulation of effects expected to precede the increased incidence of Leydig cell adenomas. For tumor types reported by NTP (2020, 7330145), the Cavg_pup_total was selected for this model to account for the perinatal window of exposure. The Cavg_pup_total metric averages out the concentration in the pup from conception to the end of the 2 years by adding the area under the curve in gestation/lactation to the area under the curve from diet (post-weaning) and dividing by two years. The BMDS produced BMDLs in mg/L for all tumor types. The animal PODs were converted to POD_HED by multiplying the POD by the human clearance value (Table 4-6). This POD_HED is equivalent to the constant exposure, per body weight, that would result in serum concentration equal to the POD at steady state. The CSF is then calculated by dividing the BMR by the POD_HED. These modeling results are described further in the Appendix (see PFOA Appendix).
Table 4-12. Cancer Slope Factors based on Animal Toxicological Data

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Reference, Confidence</th>
<th>Strain/Species/Sex</th>
<th>POD Type, Model</th>
<th>POD Internal Dose/Internal Dose Metrica</th>
<th>POD\textsubscript{HED}</th>
<th>CSF (BMR/POD\textsubscript{HED})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leydig Cell Adenomas in the Testes</td>
<td>Butenhoff et al. (2012, 2919192) Medium</td>
<td>Male Sprague-Dawley Rats</td>
<td>BMDL\textsubscript{4RD}, Multistage Degree 1</td>
<td>27.089.3 ( (\text{mg/kg/day}) )</td>
<td>4.75×10^{-3} ( (\text{mg/kg/day}) )</td>
<td>8.42 ( (mg/kg/day)^{-1} )</td>
</tr>
<tr>
<td>Hepatocellular Adenomas or Carcinoma</td>
<td>NTP (2020, 7330145) High</td>
<td>F1 Male Sprague-Dawley Rats, Perinatal and Postweaning Exposure</td>
<td>BMDL\textsubscript{10RD}, Multistage Degree 2</td>
<td>88.7 ( (\text{C}_{\text{avg,pup, total}} \text{ in mg/L}) )</td>
<td>1.06×10^{-2} ( (mg/kg/day) )</td>
<td>9.4 ( (mg/kg/day)^{-1} )</td>
</tr>
<tr>
<td>Pancreatic Acinar Cell Adenoma</td>
<td>NTP (2020, 7330145) High</td>
<td>F1 Male Sprague-Dawley Rats, Perinatal and Postweaning Exposure</td>
<td>BMDL\textsubscript{10RD}, Multistage Degree 1</td>
<td>15.7 ( (\text{C}_{\text{avg,pup, total}} \text{ in mg/L}) )</td>
<td>1.88×10^{-3} ( (mg/kg/day) )</td>
<td>53.2 ( (mg/kg/day)^{-1} )</td>
</tr>
</tbody>
</table>

\textbf{Notes:} AUC = area under the curve; BMDL\textsubscript{4RD} = benchmark dose level corresponding to the 95\% lower confidence limit of a 4\% change; BMDL\textsubscript{10RD} = lower bound on the dose level corresponding to the 95\% lower confidence limit for a 10\% change; BMR = benchmark response; CSF = cancer slope factor; NTP = National Toxicology Program.

\[ a \] see PFOA Appendix for additional details on benchmark dose modeling.

### 4.2.2 Epidemiological Studies

#### 4.2.2.1 Study and Endpoint Selection

This updated review indicated that there is an increase in risk for kidney or RCC and testicular cancers and PFOA exposure {Shearer, 2021, 7161466; Chang, 2014, 2850282; Bartell, 2021, 7643457}. Although newer studies generally show no association with breast cancer in the general population, there is some evidence that PFOA may be associated with breast cancer risk in participants with specific polymorphisms or specific types of tumors {Ghisari, 2017, 3860243; Mancini, 2019, 5381529}. Two occupational studies {Steenland, 2015, 2851015; Girardi, 2019, 6315730} support an increase in risk for liver cancer and malignant neoplasm of the lymphatic and hematopoietic tissue, as well as an increasing trend in prostate cancer that did not reach statistical significance. No associations were found for colorectal cancer in either the general population or occupational studies, or for lung cancer in occupational studies.

Results are most consistent for kidney cancer in adults based on a new nested case-control study {Shearer, 2021, 7161466}, two C8 Health Project studies {Barry, 2013, 2850946; Vieira, 2013, 2919154}, and an occupational mortality study {Steenland, 2012, 2919168} described in the 2016 PFOA Health Advisory {U.S. EPA, 2016, 3982042}.

For dose-response modeling, Shearer et al. (2021, 7161466) was selected as the key study. Shearer et al. (2021, 7161466) is a multi-center case-control study nested within NCI’s PLCO. The PLCO is a randomized clinical trial of the use of serum biomarkers for cancer screening. The cases in this study {Shearer 2021, 7161466} included all the participants of the screening arm of the PLCO trial who were newly diagnosed with RCC during the follow-up period (N = 326). All cases were histopathologically confirmed. Controls were selected from among participants of the PLCO trial screening arm who had never had RCC. Controls were individually matched to the RCC cases by age at enrollment, sex, race/ethnicity, study center,
and year of blood draw. PFOA concentrations were measured in the baseline serum samples collected between 1993 and 2002. Median PFOA levels in controls was 5.0 ng/mL, comparable with 4.8 ng/mL in adults 60 and over from NHANES 1999–2000. The analyses accounted for numerous confounders including BMI, smoking, history of hypertension, eGFR, previous freeze-thaw cycle, calendar and study year of blood draw, sex, race and ethnicity, study center. Socio-economic status was not explicitly considered in the analyses.

There was a statistically significant increase in odds of RRC per doubling of PFOA (OR = 1.71, 95% CI: 1.23, 2.37) and in the highest vs. lowest quartile (OR = 2.63, 95% CI: 1.33, 5.2). Although non-significant elevated risks were observed in the second and third quartiles, there was a statistically significant increasing trend with increasing PFOA exposure across quartiles (p-trend = 0.007). Statistically significant increased odds of RCC were observed in participants ages 55–59 years, and in men and in women, separately.

For sensitivity analyses, EPA also considered the C8 Health Project study {Vieira, 2013, 2919154} and those results can be found in the Appendix (see PFOA Appendix). Shearer et al. (2021, 7161466) was selected as the critical study over Vieira et al. (2013, 2919154) due to multiple study design considerations. Specifically, study design advantages of Shearer et al. (2021, 7161466) compared with the Vieira et al. (2013, 2919154) include specificity in the health outcome considered (RCC vs. any kidney cancer), the type of exposure assessment (serum biomarker vs. modeled exposure), source population (multi-center vs. Ohio and West Virginia regions), and study size (324 cases and 324 matched controls vs. 59 cases and 7,585 registry-based controls).

The high exposure occupational study by Steenland and Woskie (2012, 2919168) evaluated kidney cancer mortality in workers from West Virginia and observed significant elevated risk of kidney cancer death in the highest exposure quartile (> 2,384 ppm-years). This study was limited by the small number of observed cancer cases (six kidney cancer deaths). This study was not used for dose-response analysis because information on a range of exposures more relevant to the general population were available from the Shearer et al. (2021, 7161466) and Vieira et al. (2013, 2919154). The study by Barry et al. (2013, 2850946) was not used for dose-response analysis because it was performed in the same study area as the Vieira et al. (2013, 2919154) study and these two studies likely involved a number of the same participants. In addition, Barry et al. (2013, 2850946) could not be used in the sensitivity analysis because it lacked the necessary exposure measurements for CSF calculation. In this study, estimated PFOA concentrations are provided in Table 2 for community level and worker level. However, combined exposure levels of each quartile of the overall study population were not reported. Without overall exposure data in each quartile, CSF calculations are not feasible.

The study by Raleigh et al. (2014, 2850270) was not selected because of the concerns of exposure assessment methods and study quality. This study used modeled estimates of PFOA air concentrations in the workplace rather than biomonitoring measurements. This is a concern because the assessment lack of information about the degree to which inhaled PFOA is absorbed in humans and factors that may affect the absorption, as well as PFOA exposure data in non-production workers was not based on actual measurements. In addition, this study did not observe an association between PFOA and kidney cancer. The possible reasons of this study could have missed to identify the association between PFOA, and kidney cancer include
relatively small numbers of cases, lack of information adjustment on risk factors of kidney cancer such as smoking status and BMI, and the methods for exposure assessment

### 4.2.2.2 CSF Derivation

EPA calculated CSFs for RCC from Shearer et al. (2021, 7161466) based on the method used in CalEPA (2021, 9416932) and for its Public Health Goals for Arsenic in Drinking Water [OEHHA, 2004, 10369748]. Details are provided in the Appendix (see PFOA Appendix). The underlying model involves a linear regression between PFOA exposure and cancer relative risk used to estimate the dose-response between PFOA and RCC risk. This was calculated using a weighted linear regression of the quartile specific RRs, with the weights defined as the inverse of the variance of each RR. Since the incidence of kidney cancer is relatively low and because the cases and controls were matched on age, the ORs represent a good approximation of the underlying RRs. The CSF is then calculated as the excess cancer risk associated with each ng/mL increase in serum PFOA (internal CSF). The internal CSF was calculated by first converting the linear regression model discussed above from the RR scale to the absolute risk scale. This was done assuming a baseline risk ($R_0$) of RCC or kidney cancer in an unexposed or lower exposure reference group. Since this is not available in a case-control study, the lifetime risk of RCC in U.S. males is used. The lifetime RCC risk was estimated by multiplying the lifetime risk of kidney cancer in U.S. males [American Cancer Society, 2020, 9642148] by the percentage of all kidney cancers that are the RCC subtype (90%). This gives an $R_0$ of $0.0202 \times 90\% = 0.0182$. The internal CSF was then calculated as either the product of the upper 95% CI or the central tendency of the dose-response slope and $R_0$ and represents the excess cancer risk associated with each ng/mL increase in serum PFOA. The internal serum CSF was converted to an external dose CSF, which describes the increase in cancer risk per 1 ng/(kg-day) increase in dose. This was done by dividing the internal serum CSF by the selected clearance value, which is equivalent to dividing by the change in external exposure that results in a 1 ng/mL increase in serum concentration at steady-state. The clearance value used was the same as that used in the updated Verner model for endpoints related to developmental exposure (Table 4-6). The results of the modeling and the CSFs derived are presented in Table 4-13.

### Table 4-13. Cancer Slope Factors based on Epidemiological Data

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Reference, Confidence</th>
<th>Strain/Species/Sex</th>
<th>POD Type, Model</th>
<th>Internal CSF – Increase in cancer risk per 1 ng/mL serum increase</th>
<th>CSF – Increase in cancer risk per 1 ng/(kg*d) increase in dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal cell carcinoma (RCC)</td>
<td>Shearer et al. (2021, 7161466) Medium</td>
<td>Human, male and female 55–74 years</td>
<td>CSF serum in adults (per ng/mL of serum PFOA); upper limit of the 95% CI</td>
<td>$3.52 \times 10^{-3}$ (ng/mL)$^{-1}$ (see PFOA Appendix for additional detail)</td>
<td>0.0293 (ng/kg/day)$^{-1}$</td>
</tr>
<tr>
<td>Kidney cancer</td>
<td>Vieira et al. (2013, 2919154) Medium</td>
<td>Human, male and female</td>
<td>CSF serum in adults (per ng/mL of serum PFOA); upper limit of the 95% CI, highest</td>
<td>$4.81 \times 10^{-4}$ (ng/mL)$^{-1}$ (see PFOA Appendix for additional detail)</td>
<td>0.00401 (ng/kg/day)$^{-1}$</td>
</tr>
</tbody>
</table>
4.2.3 **CSF Selection**

Overall, new data and the candidate CSFs indicate that PFOA is a more potent carcinogen than previously understood and described in the 2016 HESD {U.S. EPA, 2016, 3603279}. To select an overall CSF, EPA focused on the CSFs derived from the epidemiological data consistent with the draft ORD Staff Handbook which states “when both laboratory animal data and human data with sufficient information to perform exposure-response modeling are available, human data are generally preferred for the derivation of toxicity values” {U.S. EPA, 2022, 10476098}. EPA selected the critical effect of renal cell carcinomas in human males reported by Shearer et al. (2021, 7161466) as the basis of the CSF for PFOA because it is a multi-center case-control epidemiological study nested within NCI’s PLCO with median PFOA levels relevant to the general U.S. population.

Study design advantages of the Shearer et al. (2021, 7161466) study compared with the Vieira et al. (2013, 2919154) study include specificity in the health outcome considered (RCC vs. any kidney cancer), the type of exposure assessment (serum biomarker vs. modeled exposure), source population (multi-center vs. Ohio and West Virginia regions), and study size (324 cases and 324 matched controls vs. 59 cases and 7,585 registry-based controls). The resulting CSF is 0.0293 (ng/kg/day)^{-1}.

Selection of renal cell carcinomas as the critical effect is supported by other studies of a highly exposed community {Barry, 2013, 2850946; Vieira, 2013, 2919154}, an occupational kidney cancer mortality study {Steenland, 2012, 2919168}, as well as a meta-analysis of epidemiological literature that concluded that there was an increased risk of kidney tumors correlated with increased PFOA serum concentrations {Bartell, 2021, 7643457}.

4.2.4 **Application of Age-Dependent Adjustment Factors**

EPA’s *Guidelines for Carcinogen Risk Assessment* and *Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens* require the consideration of applying age-dependent adjustment factors (ADAFs) to CSFs to address potential increased risk for cancer due to early life stage susceptibility to chemical exposure {U.S. EPA, 2005, 6324329; U.S. EPA 2005, 88823}. ADAFs are only to be used for carcinogenic chemicals with a mutagenic MOA when chemical-specific data about early-life susceptibility are lacking. For carcinogens with any MOA, including mutagens and non-mutagens, but with available chemical specific data for early-life exposure, those data should be used.

As described in Section 3.5.3.1.1, most of the studies assessing mutagenicity following PFOA exposure were negative and therefore, PFOA is unlikely to cause tumorigenesis via a mutagenic MOA. Given the lack of evidence of a mutagenic MOA, EPA does not recommend applying ADAFs when quantitatively determining the cancer risk for PFOA {U.S. EPA, 2011, 783747}. 
EPA additionally evaluated whether there are chemical specific data for early-life exposure to PFOA and determined that there is insufficient information available from epidemiological and animal toxicological studies to adequately determine whether exposure during early-life periods, per EPA’s above-referenced supplemental guidance, may increase incidence or reduce latency for cancer compared with adult-only exposure. No current studies allow for comparisons of cancer incidence after early-life vs. adult-only PFOA exposure. However, there are two studies that assessed cancer risk after PFOA exposure during various developmental stages.

An NTP cancer bioassay in rats chronically exposed to PFOA both perinatally and post-weaning did not report an increased cancer risk compared to chronic postweaning-only exposure (see further study design details in Section 3.4.4.2.1.2 and study results in Section 3.5.2), which suggests no increased cancer risk as a result of lifetime exposure compared to postweaning-only exposure. The NTP cancer bioassay does not include dose groups that were only exposed during early-life stages (i.e., only during development), the findings of the NTP cancer bioassay do not provide a basis for quantitatively estimating the difference in susceptibility between early-life and adult exposures. The other study, by Filgo et al. (2015, 2851085), reported equivocal evidence of hepatic tumors in three strains of F1 female mice perinatally treated with PFOA (gestational exposure from GD 1-17 and potential exposure through lactation) and necropsied at 18 months of age. This study is also limited in that there was no adult-only exposure comparison group, and the authors only assessed female mice and only histopathologically examined the liver [Filgo, 2015, 2851085]. In summary, the available studies do not provide information on whether early-life PFOA exposures result in increased cancer incidence compared with adult-only exposure. Due to the lack of evidence supporting postnatal early life susceptibility to PFOA exposure, EPA did not adjust the risk value using chemical-specific data.
5 MCLG Derivation

Consistent with the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005, 6324329), EPA reviewed the weight of the evidence and determined that PFOA is Likely to Be Carcinogenic to Humans, as “the evidence is adequate to demonstrate carcinogenic potential to humans but does not reach the weight of evidence for the descriptor Carcinogenic to Humans.” This determination is based on the evidence of kidney and testicular cancer in humans and Leydig cell tumors, pancreatic acinar cell tumors, and hepatocellular adenomas in rats as described in Section 3.5. As previously noted, there is additional evidence supporting the carcinogenicity of PFOA since the publication of the prior PFOA 2016 HESD (U.S. EPA, 2016, 3603729). In particular, the evidence of kidney cancer in humans from high-exposure community studies (Vieira, 2013, 2919154; Barry, 2013, 2850946) is corroborated by associations between PFOA serum concentrations and risk of renal cell carcinoma from a nested case-control study in the general population (Shearer, 2021, 7161466). In addition, in animal models, the evidence of multi-site tumorigenesis reported in two chronic bioassays in rats (Butenhoff, 2012, 2919192; Biegel, 2001, 673581) is now further supported by similar findings of multi-site tumorigenesis from a third chronic bioassay in rats (NTP, 2020, 7330145).

Unless a non-linear mode of action is determined, EPA establishes MCLGs of zero for carcinogens classified as Carcinogenic to Humans or Likely to be Carcinogenic to Humans consistent with the statutory definition of MCLG, which requires EPA to establish MCLGs at a level where there are “no known or anticipated adverse effects” on public health and with “an adequate margin of safety.” Under SDWA, where there is insufficient information to determine that a carcinogen has a threshold below which there are no carcinogenic effects, EPA takes the health-protective approach of assuming that there is no such threshold and that carcinogenic effects should therefore be extrapolated linearly to zero (U.S. EPA, 1985, 9207; U.S. EPA, 1991, 5499; U.S. EPA, 2016, 6557097). This approach, known as the linear default extrapolation approach, ensures that the MCLG is set at a level where there are no adverse health effects with a margin of safety. EPA has determined that PFOA is Likely to be Carcinogenic to Humans based on sufficient evidence of carcinogenicity in humans and animals, that there is not sufficient evidence of a threshold for PFOA, and that therefore a linear default extrapolation approach is appropriate (U.S. EPA, 2005, 6324329). Based upon a consideration of the best available peer reviewed science and a consideration of an adequate margin of safety, EPA proposes a MCLG of zero for PFOA in drinking water.
6 Effects Characterization

6.1 Addressing Uncertainties in the Use of Epidemiological Studies for Quantitative Dose-Response Analyses

In the 2016 PFOA HESD and Drinking Water Health Advisory (U.S. EPA, 2016, 3603279; U.S. EPA, 2016, 3982042), EPA qualitatively considered epidemiological studies as a supporting line of evidence but did not quantitatively consider them for POD derivation, citing the following as reasons to exclude the epidemiological data that were available at that time from quantitative analyses:

- inconsistencies in the epidemiological database,
- the use of mean serum PFOA concentrations rather than estimates of exposure,
- declining serum PFOA values in the U.S. general population over time (CDC, 2017, 4296146),
- uncertainties related to potential exposure to additional PFAS, telomer alcohols that metabolically break down into PFOA, and other bio-persistent contaminants, and
- uncertainties related to the clinical significance of effects observed in epidemiological studies.

Since 2016, EPA has identified many additional epidemiology studies that have increased the database of information for PFOA (see Sections 3.1.1, 3.4, and 3.5). Further, new tools that have facilitated the use of study quality evaluation as part of systematic review have enabled EPA to systematically assess study quality in a way that includes consideration of confounding. As a result, EPA is now in a position to be able to quantitatively consider epidemiological studies for POD derivation in this assessment.

In this assessment EPA has assessed the strength of epidemiological and animal evidence systematically, a process that was not followed in 2016. By performing an updated assessment using systematic review methods, EPA determined that five health outcomes and five epidemiological endpoints within these outcomes (i.e., decreased antibody response to vaccination in children, decreased birthweight, elevated total cholesterol, elevated ALT, and increased risk of kidney cancer) have sufficient weight of evidence to consider quantitatively. Each endpoint quantified in this assessment has consistent evidence from multiple medium and/or high confidence epidemiological and animal toxicological studies supporting an association between PFOA exposure and the adverse effect. Each of the endpoints were also specifically supported by multiple epidemiological studies in different populations, including general and highly exposed populations. Several of these supporting studies have been published since 2016 and have strengthened the weight of evidence for this assessment.

As described in Section 4.1.3, EPA has improved upon the pharmacokinetic modeling technique used in 2016. Though there are challenges in estimations of human dosimetry from measured or modeled serum concentrations (see Section 6.6.2), EPA has evaluated the available literature and developed a pharmacokinetic model that estimates PFOA exposure concentrations from the
serum PFOA concentrations provided in epidemiological studies, which reduces uncertainties related to exposure estimations in humans. This new approach is supplemented with the UF accounting for intraspecies variation of 10x applied to each POD_{HED}, which accounts for the sensitivities of specific populations, including those that may have increased susceptibility to PFOA toxicity due to differential toxicokinetics.

An additional source of uncertainty in using epidemiological data for POD derivation is the documented declined in human serum PFOA levels over time, which raises concerns about whether one-time serum PFOA measurements are a good representation of lifetime peak exposure. Because of PFOA’s long half-life in serum, however, one-time measurements likely reflect several years of exposure (Lorber, 2011, 2914150). Importantly, EPA considered multiple time periods when estimating PFOA exposure, ranging from the longest period with available data on PFOA serum levels within the U.S. population (1999-2018) to the shortest and most recent period (2017-2018) (see Table E-17 in PFOA Appendix), when performing dose-response modeling of the ALT and TC endpoints in the epidemiological data. EPA selected PODs for these two endpoints using PFOA exposure estimates based on the serum PFOA data for 1999–2018, which is likely to capture the peak PFOA exposures in the U.S. which occurred in the 1990s (Dong, 2019, 5080195). The modeling results show that the BMDL estimates for increased TC derived using these exposure data are consistently lower than those based on the 2017–2018 PFOA exposure data whereas for ALT, the BMDL estimates using data from the longest exposure period are consistently higher than those based on the 2017–2018 PFOA exposure data. Based on these analyses, it appears that selection of one exposure time-period over another does not predictably impact the modeling results. Therefore, for this assessment, EPA decided to consistently select the time periods more likely to capture peak PFOA exposures (e.g., 1999-2018) as the basis of BMDL estimates for all endpoints of interest (see PFOA Appendix E).

It is plausible that observed associations between adverse health effects and PFOA exposure could be explained in part by confounding from other PFAS exposures, including the metabolism of precursor compounds to PFOA in the human body. However, for four of the five priority health outcomes, at least one available study performed multi-pollutant modeling. For example, for the decreased antibody production endpoint, Budtz-Jørgensen and Grandjean (2018, 5083631) performed a follow-up analysis of the study by Grandjean et al. (2012, 1248827) in which results were additionally adjusted for PFOS, and there was no notable attenuation of the observed association between PFOA exposure and decreased antibody response. Similarly, Lin et al. (2010, 1291111) performed multipollutant modeling for the effects on serum ALT and found that when PFOS, PFHxS, and PFNA were simultaneously added in the fully adjusted regression models, the associations remained and were slightly larger; one unit increase in serum log-PFOA concentration was associated with a 2.19 unit (95% CI: 1.40, 2.98) increase in serum ALT concentration compared to an increase of 1.86 units (95% CI: 1.24, 2.48). For an extended review of the uncertainties associated with PFAS co-exposures, see Systematic Review Protocol for the PFBA, PFHxA, PFHxS, PFNA, and PFDA (anionic and acid forms) IRIS Assessments {U.S. EPA, 2020, 8642427}.

Additionally, there is uncertainty about the magnitude of the contribution of PFAS precursors to PFOA serum concentrations, especially as biotransformation efficiency appears to vary depending on the precursor of interest {Lorber, 2011, 2914150; Mcdonough, 2022, 10412593;
Vestergren, 2008, 2558842; D’eon, 2011, 2903650. The contributions of PFAS precursors to serum concentrations also varies between populations with differing PFAS exposure histories (i.e., individuals living at or near sites with AFFF use may have different precursor PFOA contributions than the general population).

In addition, some populations may be disproportionately exposed to other contaminants, such as polychlorobiphenyls and methylmercury. To address this, EPA quantified associations between PFOA serum concentrations and endpoints of interest in populations with varying exposure histories, including the general population and high-exposure communities. EPA observed associations for several endpoints in populations known to have been predominantly exposed to PFOA (e.g., C8 Health Project participants), reducing the uncertainty related to potential confounding of other contaminants, including PFAS precursor compounds. These sensitivity analyses are supportive of EPA’s conclusions regarding the effects of PFOA reported across many epidemiological studies.

In this assessment, studies were not excluded from consideration based primarily on lack of or incomplete adjustments for potential confounders including socioeconomic status (SES) or race/ethnicity. A small number of studies examining PFAS serum levels across SES and racial/ethnic groups were identified, many of which reported on a national scale (e.g., using NHANES data). The identified studies (most from the early-mid 2000s) reported that serum concentrations of PFOA were lower among people of color on average nationwide (Buekers, 2018, 5080471; Kato, 2014, 2851230; Nelson, 2012, 4904674; Calafat, 2007, 1290899).

However, certain races/ethnicities may have relatively higher serum concentrations than others depending on the geographic location and the specific PFAS sampled (Park, 2019, 5381560). EPA acknowledges that in observational epidemiologic studies, potential residual confounding may result from SES and racial/ethnic disparities. Additional racially and ethnically diverse studies in multiple U.S. communities are needed to fill this important data gap. The PFOA Appendix provides detailed information on the available epidemiological studies and identifies the study-specific confounding variables that were considered, such as SES.

Lastly, the potential uncertainty related to the clinical significance of effects observed in the PFOA epidemiological studies is sometimes cited for dismissing the epidemiological data quantitatively. However, as described in section 4.1.1, increased ALT levels, decreased antibody responses in children, increased serum cholesterol levels, and decreased birthweight are clinically meaningful effects, and EPA’s A Review of the Reference Dose and Reference Concentration Processes, states that a RfD should be based on an adverse effect or a precursor to an adverse effect (e.g., increased risk of an adverse effect occurring) (U.S. EPA, 2002, 88824).

Briefly, evidence from both human epidemiological and animal toxicological studies indicates that increased serum ALT is associated with increased risk for liver disease (Ioannou, 2006, 10473853; Ioannou, 2006, 10473854; Kwo, 2017, 10328876; Roth, 2021, 9960592). Human epidemiological studies have also demonstrated that even low magnitude increases in serum ALT can be clinically significant (See section 4.1.1.1). It is also important to note that while evaluation of direct liver damage is possible in animal studies, it is difficult to obtain biopsy-confirmed histological data in humans. Therefore, liver injury is typically assessed using serum biomarkers of hepatotoxicity (Costello et al, 2022, 10285082). The SAB’s PFAS review panel noted that reduction in the level of antibodies produced in response to a vaccine represents a failure of the immune system to respond to a challenge and is considered an adverse
immunological health outcome {U.S. EPA, 2022, 10476098}. Further, a review by Selgrade (2007, 736210) suggests that specific immunotoxic effects, such as antibody response, observed in children may be broadly indicative of developmental immunosuppression impacting these children’s ability to protect against a range of immune hazards.

Additionally, increased serum cholesterol is associated with changes in incidence of cardiovascular disease events such as myocardial infarction (MI, i.e., heart attack), ischemic stroke (IS), and cardiovascular mortality occurring in populations without prior CVD events {D’Agostino, 2008, 10694408; Goff, 2014, 3121148; Lloyd-Jones, 2017, 10694407}. Moreover, disturbances in cholesterol homeostasis contribute to the pathology of non-alcoholic fatty liver disease (NAFLD) and to accumulation of lipids in hepatocytes {Malhotra, 2020, 10442471}, providing further evidence of effects in the liver. Finally, substantial evidence links low birth weight to a variety of adverse health outcomes at various stages of life. It has been shown to predict prenatal mortality and morbidity {Cutland, 2017, 10473225; U.S. EPA, 2013, 4158459; WHO, 2014, 10473141} and is a leading cause of infant mortality in the United States {CDC, 2020, 10473144}. Low birth weight is also associated with increased risk for diseases in adulthood, including obesity, diabetes, and cardiovascular disease {Gluckman, 2008, 10473269; Osmond, 2000, 3421656; Risnes, 2011, 2738398; Smith, 2016, 10474151; Ong, 2002, 10474127, as reported in Yang et al. (2022, 10176603).

There are challenges associated with quantitative use of epidemiological data for risk assessment {Deener, 2018, 6793519} as described above; however, improvements such as methodological advancements that minimize bias and confounding, strengthened methods to estimate and measure exposure, and updated systematic review practices facilitate the use of epidemiological studies to quantitatively inform risk.

### 6.2 Comparisons Between Toxicity Values Derived from Animal Toxicological Studies and Epidemiological studies

As recommended by the SAB {U.S. EPA, 2022, 10476098}, EPA derived candidate RfDs and CSFs for multiple health outcomes using data from both epidemiological and animal toxicological studies. Candidate RfDs from epidemiological and animal toxicological studies within a health outcome differed by approximately two to three orders of magnitude (see Figure 4-4. Comparison of Candidate RfDs Resulting from the Application of Uncertainty Factors to PODHEDS Derived from Epidemiological and Animal Toxicological Studies, with epidemiological studies producing lower values. EPA does not necessarily expect concordance between animal and epidemiological studies in terms of the adverse effect(s) observed, as well as the dose level that elicits the adverse effect(s). For example, EPA’s Guidelines for Developmental Toxicity Risk Assessment states that “the fact that every species may not react in the same way could be due to species-specific differences in critical periods, differences in timing of exposure, metabolism, developmental patterns, placentation, or mechanisms of action” {U.S. EPA, 1991, 732120}. EPA further describes these factors in relation to this assessment below.

First, there are well-established differences in the toxicokinetics between humans and animal models such as rats and mice. As described in Section 3.3.1.4.5, PFOA half-life estimates vary considerably by species, being lowest in rodents (hours to days) and several orders of magnitude higher in humans (years). All candidate toxicity values based on animal toxicological studies
were derived from studies conducted in rats or mice, adding a potential source of uncertainty related to toxicokinetic differences in these species compared to humans. To address this potential source of uncertainty, EPA utilized a PK model to estimate the internal dosimetry of each animal model and convert the values into predicted levels of human exposure that would result in the corresponding observed health effects. However, the outputs of these models are estimates and may not fully account for species-specific toxicokinetic differences, particularly differences in excretion. The application of uncertainty factors (i.e., UFₐ) also may not precisely reflect animal-human toxicokinetic differences.

Second, candidate toxicity values derived from epidemiological studies are based on responses associated with actual environmental exposure levels, whereas animal toxicological studies are limited to the tested dose levels which are often several orders of magnitude higher than the ranges of exposure levels in humans. Extrapolation from relatively high experimental doses to environmental exposure levels introduces a potential source of uncertainty for toxicity values derived from animal toxicological studies; exposures at higher dose levels could result in different responses, perhaps due to differences in mechanisms activated, compared to responses to lower dose levels. One example of this is the difference between epidemiological and animal toxicological studies in the effect of PFOA exposure on serum lipid levels (i.e., potential non-monotonic dose-response relationships that are not easily assessed in animal studies due to low dose levels needed to elicit the same response observed in humans).

Third, there may be differences in mechanistic responses between humans and animal models. One example of this is the PPARα response. It is unclear to what extent PPARα influences the responses to PFOA exposure observed in humans, though it has been shown that the rodent PPARα response is greater than that observed in humans (see Section 3.4.1.3.1). Mechanistic differences could influence dose-response relationships and subsequently result in differences between toxicity values derived from epidemiological and animal toxicological studies. There may be additional mechanisms that differ between humans and animal models that could contribute to the magnitude of responses and doses required to elicit responses across species.

The factors described above represent some but not all potential contributors that may explain the differences between toxicity values derived from epidemiological and animal toxicological studies. In this assessment, EPA prioritized epidemiological studies of medium or high confidence for the selection of health outcome-specific and overall RfDs and CSFs (see Section 4.1.6). The use of human data to derive toxicity values removes uncertainties and assumptions about human relevance inherent in extrapolating from and interpreting animal toxicological data in quantitative risk assessment.

6.3 Updated Approach to Animal Toxicological RfD Derivation Compared to the 2016 PFOA HESD

For POD derivation in this assessment, EPA considered the studies identified in the recent literature searches and also re-examined the candidate RfDs derived in the 2016 PFOA HESD {U.S. EPA, 2016, 3603279} and the animal toxicological studies and endpoints on which they were based. The updated approach used for hazard identification and dose response in the current assessment as compared to the 2016 HESD led to some differences between animal toxicological studies and endpoints used as the basis of candidate RfDs for each assessment. These updates and the resulting differences are further described below.
For the 2016 PFOA HESD, EPA did not use BMD modeling to derive PODs, and instead relied on the NOAEL/LOAEL approach for all candidate studies and endpoints [U.S. EPA, 2016, 3603279]. The NOAEL/LOAEL approach allows for the incorporation of multiple endpoints from a single study to derive a single POD, if the endpoints have the same NOAEL and/or LOAEL. For example, in the 2016 PFOA HESD, EPA derived a candidate RfD based on the endpoints of decreased parental body weight and increased parental absolute and relative kidney weight reported by Butenhoff et al. (2004, 1291063), all of which shared a common POD (LOAEL). For the current assessment, EPA preferentially used BMD modeling to derive PODs because it allows for greater precision than the NOAEL/LOAEL approach and considers the entire dose-response curve. This approach requires the consideration of endpoints on an individual basis and further examination of the weight of evidence for particular endpoints, as well as the dose-response trend reported for each endpoint, in order to derive a BMDL. When considering an effect on a standalone basis rather than together with other effects occurring at the same exposure level, EPA sometimes determined the weight of evidence was not sufficient to consider an individual endpoint for POD derivation. For the current assessment, EPA used a systematic review approach consistent with the IRIS Handbook {U.S. EPA, 2022, 10476098} to consider the weight of evidence for both the health outcomes as well as for individual endpoints of interest when selecting endpoints and studies for dose-response modeling. In the case of the endpoints selected in 2016 from the Butenhoff et al. (2004, 1291063) study, systemic effects such as body weight and renal effects such as kidney weight were reevaluated and determined to have evidence suggestive of an association with PFOA exposure. As described in Section 4.1.1 of this assessment, EPA derived PODs only for endpoints from health outcomes with evidence indicating or evidence demonstrating an association with PFOA exposure.

Additionally, for the current assessment, EPA preferentially selected endpoints for which there were a greater number of studies supporting the observed effect. For example, for the 2016 PFOA HESD, EPA derived a candidate RfD based on the co-critical effect of accelerated male puberty reported by Lau et al. (2006, 1276159). Results of the current assessment’s literature search showed that no high or medium confidence studies supporting that observed effect have been published since 2016. As Lau et al. (2006, 1276159) was also the only study identified in 2016 that reported an acceleration of male puberty (a second study reported a delay in male puberty {Butenhoff, 2004, 1291063}) and there were several other developmental endpoints (e.g., reduced offspring weight and survival; delayed eye opening) that were supported by multiple studies, EPA did not further consider this endpoint from Lau et al. (2006, 1276159) for POD derivation in the present assessment. Similarly, upon further evaluation during the current assessment of the co-critical effects of reduced forelimb and hindlimb ossification in pups reported by Lau et al. (2006, 1276159), it was determined that an unexplained non-linear dose-response trend adds uncertainty to selection of the LOAEL as the POD. As reduced ossification was only observed at the highest dose tested (10 mg/kg/day) by the one other study {Yahia, 2010, 1332451} that tested dose levels close to the LOAEL from Lau et al. (2006, 1276159) (1 mg/kg/day) and because no studies identified during literature searches for the current assessment reported this effect, EPA relied on other endpoints from Lau et al. (2006, 1276159) that were amenable to BMD modeling, exhibited dose-dependent response trends, and were supported by at least one other study in the available literature. For several studies considered in the 2016 PFOA HESD, EPA performed BMD modeling for specific endpoints, but the efforts did not produce viable model fits (see PFOA Appendix).
For some health effects that served as the basis for candidate RfDs in the 2016 PFOA HESD, new studies published since 2016 provide more information about these same endpoints. For example, in 2016, EPA derived a candidate RfD based on increased liver weight and necrosis in rats reported by Perkins et al. (2004, 1291118). Since that time, NTP (2020, 7330145) published an animal bioassay that has more strengths than the older study based on study design and study quality evaluation results. Specifically, the NTP (2020, 7330145) study was identified as a high confidence study that used a chronic (rather than 14-week) exposure duration, larger sample sizes (n = 50), and a dose range that was more sensitive to the histopathological effects in both male and female rats. Therefore, EPA considered liver necrosis data as reported by NTP (2020, 7330145) for POD derivation rather than data from the medium confidence study by Perkins et al. (2004, 1291118).

For transparency, EPA has provided a comparison of studies and endpoints used to derive candidate RfDs for both the 2016 PFOA HESD and the present assessment (Table 6-1).

<table>
<thead>
<tr>
<th>Studies and Effects Used in 2016 for Candidate RfD Derivation</th>
<th>Studies and Effects Used in 2023 for Candidate RfD Derivation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dewitt et al. (2008, 1290826), medium confidence – reduced immunoglobulin M (IgM) response</td>
<td>Dewitt et al. (2008, 1290826), medium confidence – reduced immunoglobulin M (IgM) response</td>
</tr>
<tr>
<td>Lau et al. (2006, 1276159), medium confidence – reduced pup ossification (forelimb and hindlimb) and accelerated male puberty (preputial separation)</td>
<td>Lau et al. (2006, 1276159), medium confidence – delayed time to eye opening</td>
</tr>
<tr>
<td>Wolf et al. (2007, 1332672), medium confidence – decreased pup body weight</td>
<td>Song et al. (2018, 5079725), medium confidence – decreased offspring survival</td>
</tr>
<tr>
<td>Perkins et al. (2004, 1291118), medium confidence – increased liver weight and necrosis</td>
<td>NTP (2020, 7330145), high confidence – liver necrosis</td>
</tr>
</tbody>
</table>

Notes: RfD = reference dose; IgM = immunoglobulin M; NTP = National Toxicology Program.

a Note that candidate RfDs for the fourth priority health outcome (i.e., cardiovascular) are not presented in this table because candidate RfDs based on animal toxicological studies representing this health outcome were not derived in the 2016 HESD or the current assessment.

b Candidate RfDs from the 2016 PFOA HESD that correspond to non-prioritized health outcomes (e.g., renal) are not presented here.

### 6.4 Consideration of Alternative Conclusions Regarding the Weight of Evidence of PFOA Carcinogenicity

In the 2016 PFOA HESD, EPA determined that the available carcinogenicity database for PFOA at that time was consistent with the descriptions for Suggestive Evidence of Carcinogenic Potential [U.S. EPA, 2016, 3603279]. Upon reevaluation for this assessment, EPA identified several new studies reporting on cancer outcomes and subsequently determined the currently
available carcinogenicity database is consistent with the descriptions for *Likely to be Carcinogenic to Humans* according to the *Guidelines for Carcinogen Risk Assessment* [U.S. EPA, 2005, 6324329] (see Section 3.5.5). More specifically, the available data for PFOA surpass many of the descriptions for *Suggestive Evidence of Carcinogenic Potential* provided in the *Guidelines for Carcinogen Risk Assessment* [U.S. EPA, 2005, 6324329]. The examples for which the PFOA database exceeds the descriptions include:

- “a small, and possibly not statistically significant, increase in tumor incidence observed in a single animal or human study that does not reach the weight of evidence for the descriptor "Likely to Be Carcinogenic to Humans." The study generally would not be contradicted by other studies of equal quality in the same population group or experimental system (see discussions of conflicting evidence and differing results, below);
- a small increase in a tumor with a high background rate in that sex and strain, when there is some but insufficient evidence that the observed tumors may be due to intrinsic factors that cause background tumors and not due to the agent being assessed;
- evidence of a positive response in a study whose power, design, or conduct limits the ability to draw a confident conclusion (but does not make the study fatally flawed), but where the carcinogenic potential is strengthened by other lines of evidence (such as structure-activity relationships); or
- a statistically significant increase at one dose only, but no significant response at the other doses and no overall trend” [U.S. EPA, 2005, 6324329].

There are multiple *medium or high* confidence human and animal toxicological studies that provide evidence of multiple tumor types resulting from exposure to PFOA. The observed tumor types are generally consistent across human subpopulations (i.e., kidney and testicular) or studies within the same species of rat (i.e., testicular, pancreatic, and hepatic) and there is no indication that a high background incidence or other intrinsic factors related to these tumor types are driving the observed responses. The SAB PFAS Review Panel agreed that: “a) the evidence for potential carcinogenicity of PFOA has been strengthened since the 2016 HESD; b) the results of human and animal studies of PFOA are consistent with the examples provided above and support a designation of “likely to be carcinogenic to humans”; and c) the data exceed the descriptors for the three designations lower than “likely to be carcinogenic” [U.S. EPA, 2022, 10476098].

While the SAB panel agreed that the data for PFOA exceed a *Suggestive* cancer descriptor, the final report also recommends “explicit description of how the available data for PFOA do not meet the criteria for the higher designation as “carcinogenic” [U.S. EPA, 2022, 10476098]. After reviewing the descriptions of the descriptor *Carcinogenic to Humans*, EPA has determined that at this time, the evidence supporting the carcinogenicity of PFOA does not warrant a descriptor exceeding *Likely to be Carcinogenic to Humans*. As discussed in Section 3.5.5, there is not convincing epidemiological evidence supporting a causal association between human exposure to PFOA and cancer. The *Guidelines* also indicate that a chemical agent can be deemed *Carcinogenic to Humans* if it meets all of the following conditions:

- “there is strong evidence of an association between human exposure and either cancer or the key precursor events of the agent's mode of action but not enough for a causal association, and
• there is extensive evidence of carcinogenicity in animals, and
• the mode(s) of carcinogenic action and associated key precursor events have been identified in animals, and
• there is strong evidence that the key precursor events that precede the cancer response in animals are anticipated to occur in humans and progress to tumors, based on available biological information” {U.S. EPA, 2005, 6324329}.

Though the available evidence indicates that there are positive associations between PFOA and multiple cancer types, there is significant uncertainty regarding the carcinogenic MOA(s) of PFOA, particularly for renal cell carcinomas and testicular cancer in humans. The evidence of carcinogenicity in animals is limited to a single strain of rat, although PFOA tested positive for multi-site tumorigenesis. The animal database does not provide significant clarity on the MOA of PFOA in humans, though there is some evidence supporting hormone-mediated MOAs for testicular tumors and oxidative stress-mediated MOAs for pancreatic tumors. Overall, there is significant uncertainty that key events in animals are anticipated to occur in humans and progress to tumors. The SAB similarly concluded that “the available epidemiologic data do not provide convincing evidence of a causal association but rather provide evidence of a plausible association, and thus do not support a higher designation of ‘carcinogenic to humans’” {U.S. EPA, 2022, 10476098}.

Table 6-2 depicts comparisons of the PFOA carcinogenicity database with the Suggestive and Known cancer descriptors.

Table 6-2. Comparison of the PFOA Carcinogenicity Database with Cancer Descriptors as Described in the Guidelines for Carcinogen Risk Assessment {U.S. EPA, 2005, 6324329}

<table>
<thead>
<tr>
<th>Comparison of Evidence for Carcinogenic and Suggestive Cancer Descriptors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carcinogenic to Humans</strong></td>
</tr>
<tr>
<td>This descriptor is appropriate when there is convincing epidemiologic evidence of a causal association between human exposure and cancer.</td>
</tr>
<tr>
<td><strong>PFOA data are not consistent with this description.</strong></td>
</tr>
<tr>
<td>There is evidence of a plausible association between PFOA exposure and cancer in humans, however, the database is limited to only two independent populations, there is uncertainty regarding the potential confounding of other PFAS, and there is limited mechanistic information that could contribute to the determination of a causal relationship. The database would benefit from additional large high confidence cohort studies in independent populations.</td>
</tr>
</tbody>
</table>

Or, this descriptor may be equally appropriate with a lesser weight of epidemiologic evidence that is strengthened by other lines of evidence. It can be used when *all* of the following conditions are met:

| There is strong evidence of an association between human exposure and either cancer or the key precursor events of the agent's mode of action but not enough for a causal association |
| **PFOA data are not consistent with this description.** |
| There is evidence of an association between human exposure and cancer, however, there is limited mechanistic information that could contribute to the determination of a causal relationship. |

| There is extensive evidence of carcinogenicity in animals |
| **PFOA data are not consistent with this description.** |
| While there are three chronic cancer bioassays available, each testing positive in at least one tumor type, they were all conducted in the same strain of rat. The... |
Comparison of Evidence for Carcinogenic and Suggestive Cancer Descriptors

<table>
<thead>
<tr>
<th>Evidence Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinogenic</td>
<td>The mode(s) of carcinogenic action and associated key precursor events have been identified in animals. The database would benefit from high confidence chronic studies in other species and/or strains.</td>
</tr>
<tr>
<td></td>
<td>PFOA data are not consistent with this description. A definitive MOA has not been identified for each of the PFOA-induced tumor types identified in rats.</td>
</tr>
<tr>
<td></td>
<td>There is strong evidence that the key precursor events that precede the cancer response in animals are anticipated to occur in humans and progress to tumors, based on available biological information.</td>
</tr>
<tr>
<td></td>
<td>PFOA data are not consistent with this description. The animal database does not provide significant clarity on the MOA(s) of PFOA in humans, though there is some evidence supporting hormone-mediated MOAs for testicular tumors and oxidative stress-mediated MOAs for pancreatic tumors.</td>
</tr>
</tbody>
</table>

Suggestive Evidence of Carcinogenic Potential

<table>
<thead>
<tr>
<th>Evidence Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A small, and possibly not statistically significant, increase in tumor incidence observed in a single animal or human study that does not reach the weight of evidence for the descriptor “Likely to Be Carcinogenic to Humans.” The study generally would not be contradicted by other studies of equal quality in the same population group or experimental system.</td>
</tr>
<tr>
<td></td>
<td>PFOA data exceed this description. Statistically significant increases in tumor incidence of multiple tumor types were observed across several human and animal toxicological studies.</td>
</tr>
<tr>
<td></td>
<td>A small increase in a tumor with a high background rate in that sex and strain, when there is some but insufficient evidence that the observed tumors may be due to intrinsic factors that cause background tumors and not due to the agent being assessed.</td>
</tr>
<tr>
<td></td>
<td>This description is not applicable to the tumor types observed after PFOA exposure.</td>
</tr>
<tr>
<td></td>
<td>Evidence of a positive response in a study whose power, design, or conduct limits the ability to draw a confident conclusion (but does not make the study fatally flawed), but where the carcinogenic potential is strengthened by other lines of evidence (such as structure-activity relationships).</td>
</tr>
<tr>
<td></td>
<td>PFOA data exceed this description. The studies from which carcinogenicity data are available were determined to be high or medium confidence during study quality evaluation.</td>
</tr>
<tr>
<td></td>
<td>A statistically significant increase at one dose only, but no significant response at the other doses and no overall trend</td>
</tr>
<tr>
<td></td>
<td>PFOA data exceed this description. Increases in kidney cancer in humans were statistically significant in two exposure groups in one study {Vieira, 2013, 2919154} and there was a statistically significant increasing trend across exposure quartiles in a second study {Shearer, 2021, 7161466}. Increases in hepatic and pancreatic tumors in male rats were observed in multiple dose groups with a statistically significant trend overall {NTP, 2020, 7330145}.</td>
</tr>
</tbody>
</table>

Notes: MOA = mode of action.

6.5 Health Outcomes with Evidence Integration Judgments of Evidence Suggests Bordering on Evidence Indicates

EPA evaluated sixteen non-cancer health outcomes as part of this assessment. In accordance with recommendations from the SAB {U.S. EPA, 2022, 10476098} and the IRIS Handbook {U.S. EPA, 2022, 10476098}, for both quantitative and qualitative analyses in the current assessment, EPA prioritized health outcomes with either evidence demonstrating or evidence indicating associations between PFOA exposure and adverse health effects. Health outcomes reaching these tiers of judgment were the hepatic, immune, developmental, cardiovascular, and cancer.
outcomes. Some other health outcomes were determined to have *evidence suggestive* of associations between PFOA and adverse health effects as well as some characteristics associated with the *evidence indicates* tier, and EPA made judgments on these health outcomes as described below.

For PFOA, two health outcomes that had characteristics of both *evidence suggests* and *evidence indicates* were the reproductive and endocrine outcomes. Endpoints relevant to these two health outcomes had been previously considered for POD derivation in the *Proposed Approaches to the Derivation of a Draft Maximum Contaminant Level Goal for Perfluorooctanoic Acid (PFOA) (CASRN 335-67-1) in Drinking Water*. However, upon further examination using the protocols for evidence integration outlined in the PFOA Appendix and Section 2.1.5, EPA concluded that the available epidemiological and animal toxicological evidence did not meet the criteria necessary for subsequent quantitative dose-response analyses. Although these health outcomes were not prioritized in the current assessment, based on the available data, EPA concluded that PFOA exposure may cause adverse reproductive or endocrine effects.

Epidemiological studies considered for evidence integration for adverse endocrine effects included many *high* and *medium* confidence studies. There was *slight evidence* to suggest human endocrine toxicity, including associations between PFOA exposure and changes in serum thyroxine (T4) in children, though there was considerable uncertainty in the results due to inconsistencies across sexes and age groups and a limited number of studies. Animal toxicological studies considered for evidence integration included 8 *high* or *medium* confidence studies. Collectively, the animal evidence for an association between PFOA exposure and effects on the endocrine system was considered *moderate*, based on observed alterations in thyroid and adrenocortical hormone levels, increased thyroid gland weight, and increased thyroid follicular cell hypertrophy. Overall, the available evidence was *suggestive* but not *indicative* of adverse endocrine effects due to PFOA exposure. Therefore, EPA did not prioritize this health outcome for dose-response modeling. See Appendix C for a detailed description of endocrine evidence synthesis and integration.

Epidemiological studies considered for evidence integration for adverse reproductive effects included many *high* and *medium* confidence studies. There was *slight evidence* to suggest human male reproductive toxicity, including for effects on testosterone levels and sperm parameters, the associations were inconsistent and it was difficult to assess the impacts of the alterations. Animal toxicological studies considered for evidence integration included 3 *high* confidence studies and 5 *medium* confidence studies. The available animal data provided *slight evidence* that exposure to PFOA results in adverse effects to the male reproductive system, including changes to the testes and epididymis. However, the evidence from animal studies was inconsistent. Therefore, this health outcome was not prioritized for dose-response modeling. See Appendix C for a detailed description of male reproductive evidence synthesis and integration.

Female reproductive epidemiological studies considered for evidence integration included 1 *high* confidence study and 10 *medium* confidence studies. See Appendix C for a detailed description of female reproductive evidence synthesis and integration.
2017, 3856459; Kim, 2020, 6833596; Timmermann, 2017, 3981439; Ernst, 2019, 5080529; Wang, 2019, 5080598; Lopez-Espinosa, 2016, 3859832; Donley, 2019, 5381537; Romano, 2016, 3981728}. Although there was slight evidence to suggest human female reproductive toxicity, including preeclampsia and gestational hypertension, there was conflicting evidence on altered puberty onset and limited data suggesting reduced fertility and fecundity. The associations were inconsistent across reproductive hormone parameters, and it was difficult to assess the adversity of these alterations. Animal toxicological studies considered for evidence integration included 1 high confidence study {NTP, 2019, 5400977} and 3 medium confidence studies {Zhang, 2020, 6505878; Chen, 2017, 3981369; Butenhoff, 2012, 2919192}. The available animal data provided slight evidence that exposure to PFOA can result in alterations in ovarian physiology and hormonal parameters in adult female rodents following exposure to doses as low as 1 mg/kg/day. However, as with the available epidemiological studies, the evidence from animal studies was inconsistent. Therefore, this health outcome was not prioritized for dose-response modeling. See Appendix C for a detailed description of female reproductive evidence synthesis and integration.

Similar adverse reproductive and endocrine effects have been observed among the family of PFAS. For example, the developing fetus and thyroid were identified as targets following oral exposure to PFBS {U.S. EPA, 2021, 7310530}, though the observed reproductive effects were considered equivocal. Additionally, EPA’s 2021 assessment of GenX chemicals identified the reproductive system as a potential toxicological target {U.S. EPA, 2021, 9960186}. Additionally, the draft IRIS Toxicological Review of PFBA concluded that the available evidence indicates that the observed thyroid effects were likely due to PFBA exposure {U.S. EPA, 2021, 10064222}. Given the similarities across PFAS, these findings support potential associations between PFOA and reproductive and endocrine effects.

As the databases for endocrine and reproductive outcomes were suggestive of human health effects resulting from PFOA exposure, they were not prioritized during the updated literature review conducted in February 2022. However, EPA acknowledges that future studies of these currently “borderline” associations could impact the strength of the association and the weight of evidence for these health outcomes. The currently available studies indicate the potential for endocrine and reproductive effects after PFOA exposure. Studies on endocrine and reproductive health outcomes represent two important research needs.

6.6 Challenges and Uncertainty in Modeling

6.6.1 Modeling of Animal Internal Dosimetry

There are several limitations and uncertainties associated with using pharmacokinetic models in general and estimating animal internal dosimetry. In this assessment, EPA utilized the Wambaugh et al. (2013, 2850932) animal internal dosimetry model because it had availability of model parameters across all species of interest, agreement with out-of-sample datasets (see PFOA Appendix), and flexibility to implement life-course modeling (see Section 4.1.3.1). However, there were some limitations to this approach.

First, posterior parameter distributions summarized in Table 4-3 for each sex/species combination were determined using a single study. Therefore, uncertainty in these parameters represents only uncertainty in fitting that single study; any variability between studies or differences in study design were not accounted for in the uncertainty of these parameters.
Second, issues with parameter identifiability for some sex/species combinations resulted in substantial uncertainty for some parameters. For example, filtrate volume (Vfil) represents a parameter with poor identifiability when determined using only serum data, due to lack of sensitivity to serum concentrations (see PFOA Appendix). Measurements in additional matrices, such as urine, would help inform this parameter and reduce the uncertainty reflected in the wide confidence intervals of the posterior distribution. These parameters with wide posterior CIs represent parameters that are not sensitive to the concentration-time datasets on which the model was trained (see PFOA Appendix). However, these uncertain model parameters did not impact the median prediction used for BMD modeling and simply demonstrate that the available data are unable to identify all parameters across every species over the range of doses used for model calibration. Finally, the model is only parameterized using adult, single dose, PFOA study designs. Gestational and lactational PK modeling parameters were later identified from numerous sources (Table 4-5) to allow for the modeling of these life stages, with a more detailed description of the life course modeling in Section 4.1.3.1.3.

The Wambaugh et al. (2013, 2850932) model fit the selected PFOA developmental study data well, though there are additional limitations to using this method to model developmental life stages. First, perinatal fetal concentrations assume instantaneous equilibration across the placenta and do not account for the possibility of active transporters mediating distribution to the fetus. Second, clearance in the pup during lactation is assumed to be a first-order process governed by a single half-life. At low doses, this assumption is in line with adult clearance, but it is unclear how physiological changes during development impact the infant half-life. Finally, PFOA concentrations in breast milk are assumed to partition passively from the maternal blood. This assumption does not account for the presence of active transport in the mammary gland or time-course changes for PFOA uptake to the milk. Despite these limitations, the incorporation of model parameters related to developmental life stages is a significant improvement over the model used in the 2016 PFOA HESD which did not implement life course modeling {U.S. EPA, 2016, 3603279}.

6.6.2 Modeling of Human Dosimetry

Uncertainties may stem from efforts to model human dosimetry. One limitation is that the clearance parameter, which is a function of the measured half-life and Vd values, is difficult to estimate in the human general population. Specifically for PFOA, the measurement of half-life is hindered by slow excretion and ongoing exposure. Additionally, it is unclear whether some of the variability in measured half-life values reflects actual variability in the population as opposed to uncertainty in the measurement of the value.

In the Verner et al. (2016, 3299692) model, half-life, Vd, and hence clearance values are assumed to be constant across ages and sexes. The excretion of PFOA in children and infants is not well understood. The ontogeny of renal transporters, age-dependent changes in overall renal function, and the amount of protein binding (especially in serum) could all play a role in PFOA excretion and could vary between children and adults. It is even difficult to predict the overall direction of change in excretion in children (higher or lower than in adults) without a clear understanding of these age-dependent differences. Vd is also expected to be different in children. Children have a higher body water content, which results in a greater distribution of hydrophilic chemicals to tissues compared to blood in neonates and infants compared to adults {Fernandez, 2011, 9641878}. This is well known for pharmaceuticals, but PFOA is unlike most pharmaceuticals in
that it undergoes extensive protein interaction, such that its distribution in the body is driven primarily by protein binding and active transport. Hence, it is difficult to infer the degree to which increased body water content might impact the distribution of PFOA.

The updated half-life value was developed based upon a review of recent literature (see Section 3.3.1.4.5). Many half-life values have been reported for the clearance of PFOA in humans (see PFOA Appendix). The slow excretion of PFOA requires measurement of a small change in serum concentration over a long time; the difficulties associated with making these measurements may represent one reason for the variance in reported values. Another challenge is the ubiquity of PFOA exposure. Ongoing exposure will result in a positive bias in observed half-life values if not considered (Russell, 2015, 2851185). In studies that calculate the half-life in a population with greatly decreased PFOA exposures, typically due to the end of occupational exposure or the introduction of drinking water filtration, the amount of bias due to continuing exposure will depend on the ratio of the prior and ongoing exposures. That is, for a given ongoing exposure, a higher prior exposure may be less likely to overestimate half-life compared to a lower prior exposure. However, a half-life value determined from a population with very high exposure may not be informative of the half-life in typical exposure scenarios because of non-linearities in PK that may occur due to the saturation of PFAS-protein interactions. This will likely take the form of an under-estimation of the half-life that is relevant to lower levels, which are more representative of the general population due to saturation of renal resorption and increased urinary clearance in the study population. One probable example of this is the elimination half-life of approximately 120 or 200 days reported by Dourson and Gadagbui (2021, 9641867), who analyzed a clinical trial with exposures to PFOA of between 50 and 1200 mg weekly for a period of 6 weeks. In this study, the average plasma level after 6 weeks ranged from 34 ug/mL at 0.1 mg/kg/day to 492.7 ug/mL at 2.3 mg/kg/day (Dourson, 2019, 6316919). This is orders of magnitude greater than the blood levels seen in the general population (the NHANES 2007-08 95th percentile serum PFOA concentration was 9.7 ng/mL (Kato, 2011, 1290883)) and is in the range of the maximum values seen at the peak of PFOA manufacturing (Post, 2012, 1290868). The high exposure and short follow-up time may be the source of the short half-life observed in this population. In addition, this study was also carried out in patients with advanced cancer, which may have an effect on the rate of PFOA excretion.

A recent review publication (Campbell, 2022, 10492319) addressing the variation in reported half-life values for PFOA promoted a half-life value of 1.3 years, based on the authors’ analysis of half-life values estimated from paired blood and urine samples (Zhang, 2013, 3859849). The rationale for this was the exclusion of studies that may be biased upward by ongoing exposure, and studies that did not analyze linear and branched isomers of PFOA separately. A commentary in response to the review disputed this conclusion and the approach used to make it (Post, 2022, 10492320). The authors pointed out two citations that explore the effect of explicitly correcting for background exposure: Russell et al. (2015, 2851185) and Bartell (2012, 2919207). Both estimated half-lives >2 years after accounting for ongoing exposure. They go on to list several high-quality studies that estimated half-lives much longer than the value calculated from Zhang et al. (2013, 3859849). They also pointed out methodological limitations of Zhang et al. (2013, 3859849) and noted that another estimate of renal clearance using the same approach resulted in a considerably different value (Gao, 2015, 2850134). EPA is aware of two other studies estimating renal clearance of PFOA from measurements in urine, and both estimated longer half-lives than the value calculated by Zhang et al. (2013, 3859849). Fu et al. (2016, 3859819)
estimated a half-life of 4.1 years and Fujii et al. (2015, 2816710) estimated a renal clearance value of 0.044 mL/kg/day, equivalent to a half-life of 7.3 years. These additional measurements of PFOA half-life using a similar study design show that Campbell et al. (2022, 10492319) selected an outlier study, both from other urinary clearance studies and from direct-observation studies.

Another factor EPA considered when evaluating Zhang et al. (2013, 3859849) was that the estimated value for the half-life of PFOS, geometric mean of 5.8 years for young females and 18 years for males and older females, is higher than is typically estimated. This result for PFOS illustrates that there are uncertainties in any single estimate. Campbell et al. (2022, 10492319) selected an outlier study for the half-life of PFOA, both from other urinary clearance studies and from direct-observation studies. The range of results from among various studies represents a range of uncertainty and EPA has chosen a half-life based on study quality (i.e., representative population, environmentally relevant exposure, and multiple sampling of each individual) that results in a value intermediate among the published estimates.

There are few reported V_d values for humans because this parameter requires knowledge of the total dose or exposure, and V_d values are difficult to determine from environmental exposures. In addition to the V_d reported by Thompson et al. (2010, 5082271), which was selected by EPA for model parameterization, Dourson and Gadagbui (2021, 9641867) reported a human V_d of 91 mL/kg from a clinical trial on PFOA. This value is much lower than other reported values across mammalian species and may reflect an earlier initial distribution step rather than the distribution observed after chronic exposure. Chronic exposure may result in a greater distribution to tissues relative to the plasma, and this process may be slowed by extensive binding of PFOA to plasma proteins. Additionally, the exposure levels used in the clinical trial are much higher than typically seen in the general population, which could result in a different distribution profile.

Lastly, the description of breastfeeding in the updated Verner et al. (2016, 3299692) model relied on a number of assumptions: that infants were exclusively breastfed for one year, that there was a constant relationship between maternal serum and breastmilk PFOA concentrations, and that weaning was an immediate process with the infant transitioning from a breastmilk-only diet to the background exposure at one year. This is a relatively long duration of breastfeeding: only 27% of children in the U.S. are being breastfed at one year of age {CDC, 2013, 1936457}. Along with using the 95th percentile of breastmilk consumption, this provides a scenario of high but realistic lactational exposure. Lactational exposure to the infant is much greater than background exposure, so the one-year breastfeeding duration is a conservative approach and will result in a lower POD_{HED} than a scenario with earlier weaning. Children in the U.S. are very unlikely to be exclusively breastfed for up to one year, and this approach does not account for potential PFOA exposure via the introduction to solid foods. However, since lactational exposure is much greater than exposure after weaning, a breastfeeding scenario that does not account for potential PFOA exposure from introduction of infants to solid foods is not expected to introduce substantial error.

### 6.6.3 Approach of Estimating a Benchmark Dose from a Regression Coefficient

EPA identified several epidemiological studies (e.g., Steenland et al. (2009, 1291109), Darrow et al. (2016, 3749173)) that reported associations between PFOA exposure and diseases or clinical
outcomes as regression coefficients. BMD modeling of regression coefficients results in a non-traditional BMD, where the BMR is associated with a change in the regression coefficient of the response variable rather than the measured biological response variable. As a result, there is some uncertainty about the biological relevance of this non-traditional BMD associated with a regression coefficient. However, as this regression coefficient is associated with a change in the biological response variable, it is biological meaningful and EPA concluded that it can therefore be used for POD derivation. EPA modeled these regression coefficients using the same approach that EPA used to model for studies that reported measured response variables which is similar to the approach followed by CalEPA in their draft Public Health Goal for PFOA (CalEPA, 2021, 9416932).

To evaluate this potential uncertainty, EPA obtained the measured dose response data across exposure deciles from Steenland et al. (2009, 1291109) (kindly provided to EPA on June 30, 2022 via email communication with the corresponding study author) and conducted sensitivity analyses to compare BMDs produced by the reported regression coefficients with the measured response variable (i.e., mean total cholesterol and odds ratios of elevated total cholesterol). For PFOA, the analyses did not generate viable models and therefore the comparison could not be made. These analyses are presented in detail in the PFOA Appendix.

For PFOS, however, BMDL5 values estimated using the regression coefficient and using the measured response variable were 9.52 ng/L and 26.39 ng/L, respectively. The two BMDL estimates from the two approaches are within an order of magnitude, less than a 3-fold difference, and the RfD allows for an order of magnitude (10-fold or 1,000%) uncertainty in the estimate. Therefore, EPA is confident in its use regression coefficients as the basis of PODHEDs.

6.7 Human Dosimetry Models: Consideration of Alternate Modeling Approaches

PBPK models are typically preferred over a one-compartment approach because they can provide individual tissue information and have a one-to-one correspondence with the biological system that can be used to incorporate additional features of pharmacokinetics, including tissue-specific internal dosimetry and local metabolism. In addition, though PBPK models are more complex than one-compartment models, many of the additional parameters are chemical-independent and have widely accepted values. Even some of the chemical-dependent values can be extrapolated from animal toxicological studies when parameterizing a model for humans, where data are typically scarcer.

The decision to select a non-physiologically based model as opposed to one of the PBPK models was influenced in part by past issues identified during evaluation of the application of PBPK models to other PFAS for the purpose of risk assessment. During the process of adapting a published PBPK model for EPA needs, models are subjected to an extensive EPA internal QA review. During initial review of the Loccisano family of models (Loccisano, 2011, 787186; Loccisano, 2012, 1289830; Loccisano, 2012, 1289833; Loccisano, 2013, 1326665), an unusual implementation of PFOA plasma binding appeared to introduce a mass balance error. Due to the stated goal of minimizing new model development (see Section 4.1.3.2), EPA did not pursue resolution of the discrepancies, which would have required modifications to one of these models for application in this assessment.
Due to the previous issues that EPA encountered for other PFAS when implementing PBPK models and the known issue with the Loccisano model and the models based upon it, EPA selected a one-compartment model because it was the most robust available approach for this effort. Based on the consideration and analysis of different models, EPA concluded that a one-compartment model is sufficient to predict blood (or serum/plasma) concentrations. Serum/plasma is a good biomarker for exposure, because a major proportion of the PFOA in the body is found in serum/plasma due to albumin binding \cite{Forsthuber, 2020, 6311640}. There were no other specific tissues that were considered essential to describing the dosimetry of PFOA.

The two one-compartment approaches identified in the literature for PFOA was the model of Verner et al. \cite{Verner, 2016, 3299692} and the model developed by the Minnesota Department of Health (MDH model) \cite{Goeden, 2019, 5080506}. These two models are structurally very similar, with a single compartment each for mother and child, first-order excretion from those compartments, and a similar methodology for describing lactational transfer from mother to child. The following paragraphs describe the slight differences in model implementations, but it is first worth emphasizing the similarity in the two approaches.

One advantage of the Verner model is that it explicitly models the mother from birth through the end of breastfeeding. The MDH model, however, is limited to predictions for the time period after the birth of the child with maternal levels set to an initial steady-state level. An explicit description of maternal blood levels allows for the description of accumulation in the mother prior to pregnancy followed by decreasing maternal levels during pregnancy, as has been observed for serum PFOA in serial samples from pregnant women \cite{Glynn, 2012, 1578498}. This decrease occurs due to the relatively rapid increase in body weight during pregnancy (compared to the years preceding pregnancy) and the increase in blood volume that occurs to support fetal growth \cite{Sibai, 1995, 1101373}. Detailed modeling of this period is important for dose metrics based on maternal levels during pregnancy, especially near term, and on cord blood levels.

Another distinction of the Verner model is that it is written in terms of rates of change in mass rather than concentrations, as in the MDH model. This approach includes the effect of dilution of PFOA during childhood growth without the need for an explicit term in the equations. Not accounting for growth will result in the overprediction of serum concentrations in individuals exposed during growth. Despite this, PFOA concentration in infants at any specific time is driven more by recent lactational exposure than by earlier exposure (either during pregnancy or early breastfeeding), which tends to minimize the impact of growth dilution. Additionally, this structural consideration best matches the approach taken in our animal model, presenting a harmonized approach. These structural considerations favor the application of the updated Verner model over the MDH model.

EPA evaluated two other factors that were present in the MDH model: the application of a scaling factor to increase the $V_d$ in children and the treatment of exposure as a drinking water intake rather than a constant exposure relative to bodyweight. After testing these features within the updated Verner model structure, EPA determined that neither of these features were appropriate for this assessment, primarily because they did not meaningfully improve the comparison of model predictions to validation data.
In the MDH model, $V_d$ in children starts at 2.4 times the adult $V_d$ and decreases relatively quickly to 1.5 times the adults $V_d$ between 6 and 12 months, reaching the adult level at 10 years of age. These scaling values originated from measurements of body water content relative to weight compared to the adult value. There is no chemical-specific information to suggest that $V_d$ is larger in children compared to adults for PFOA. However, it is generally accepted in pharmaceutical research that hydrophilic chemicals have greater $V_d$ in children [Batchelor, 2015, 3223516], which is attributed to increased body water. Still, PFOA is amphiphilic, not simply hydrophilic, and its distribution is driven by interactions with binding proteins and transporters, not by passive diffusion with body water. While it is plausible that $V_d$ is larger in children, it is unknown to what degree.

Since increased $V_d$ in children is plausible but neither supported nor contradicted by direct evidence, EPA evaluated the effect of variable $V_d$ by implementing this change the updated Verner model and comparing the results with constant and variable $V_d$ (see PFOA Appendix). This resulted in reduced predictions of serum concentrations, primarily during their peak in early childhood. The model with variable $V_d$ did not decrease the average relative error or the average absolute value of relative error compared to the model with constant $V_d$ (with PFOA and PFOS results combined). Since the model with constant $V_d$ had marginally better performance and was an overall simpler solution, EPA did not implement variable $V_d$ in the application of the model for PODHED calculation.

The other key difference between the MDH model and the updated Verner model is that instead of constant exposure relative to body weight, exposure in the MDH model was based on drinking water consumption, which is greater relative to bodyweight in young children compared to adults. Drinking water consumption is also greater in lactating women. To evaluate the potential impact of calculating a drinking water concentration directly, bypassing the RfD step, EPA implemented drinking water consumption in the modified Verner model (See PFOA Appendix). EPA evaluated this decision for PFOA and PFOS together because the choice of units used for human exposure represents a substantial difference in risk assessment methodology. For reasons explained below, EPA ultimately decided to continue to calculate an RfD in terms of constant exposure, with an MCLG calculated thereafter using life-stage specific drinking water consumption values.

When comparing exposure based on drinking water consumption to the traditional RfD approach, the impact on the serum concentrations predicted by the updated Verner model differed between PFOA and PFOS. For PFOA, the predicted serum concentration in the child was qualitatively similar, with the main effect seen in overprediction of timepoints that occur later in childhood. These timepoints are more susceptible to changes in exposure, as early childhood exposure is dominated by lactational exposure. Lactational exposure is slightly increased in this scenario, because of increased drinking water consumption during lactation. However, the main source of PFOA or PFOS in breastmilk in the model with exposure based on drinking water consumption is that which accumulated over the mother’s life prior to childbirth, not that which was consumed during lactation. For PFOS, the increased exposure predicted based on children’s water intake results in much greater levels in later childhood compared to the model with constant exposure relative to bodyweight. Use of water ingestion rates to adjust for dose in the Verner model fails to match the decrease in PFOS concentration present in the reported data with multiple timepoints and overestimates the value for the Norwegian Mother,
Father, and Child Cohort Study (MoBa) cohort with a single timepoint. There is a much greater effect on PFOS model results relative to PFOA. This comparison suggests that incorporating variations in drinking water exposure in this way is not appropriate for the updated Verner model.

In addition to the comparison with reported data, EPA’s decision to use the Verner model was also considered in the context of the effect on the derivation of MCLGs. The epidemiological endpoints can be placed into three categories based on the age of the individuals: adults, children, and pregnant women. Because increased drinking water exposure is only applied to children and lactating women, the group of endpoints in children are the only ones that would be affected. While the RfD estimated using the updated Verner model assumed constant exposure, the MCLG is an algebraic calculation that incorporates the RfD, RSC, and drinking water intake. The drinking water intake used for the MCLG calculation is chosen based on the target population relevant to the critical effect that serves as the basis of the RfD. Therefore, even if the RfD does not incorporate increased drinking water intake in certain lifestages, the subsequent MCLG calculation does take this into account. Furthermore, the derivation of an RfD is useful for general assessment of risk and not limited to drinking water exposure.

For these reasons and based on EPA’s analyses, EPA determined that the updated Verner model was the most appropriate model structure for PODHED calculation for PFOA. Including the determination that assuming V_d in children equal to the adult values was appropriate, and that calculating an RfD assuming a constant dose (mg/kg/day) was appropriate for this assessment.

### 6.8 Sensitive Populations

Some populations may be more susceptible to the potential adverse health effects of toxic substances such as PFOA. These potentially susceptible populations include populations exhibiting a greater response than others despite similar PFOA exposure due to increased biological sensitivity, as well as populations exhibiting a greater response due to higher PFOA exposure and/or exposure to other chemicals or non-chemical stressors. Populations with greater biological sensitivity may include pregnant women and their developing fetuses, lactating women, the elderly, and people with certain underlying medical conditions (see Section 6.8.1). Additionally, some available data indicates that there may be sex-specific differences in sensitivity to potential effects of PFOA (see Section 6.8.2). Populations that could exhibit a greater response to PFOA exposure due to higher exposures to PFOA or other chemicals include communities overburdened by chemical exposures or non-chemical stressors such as communities with environmental justice concerns (see Section 6.8.3).

The potential health effects after PFOA exposure have been evaluated in some sensitive populations (e.g., pregnant women, children) and a small number of studies have assessed differences in exposure to PFOA across populations to assess whether racial/ethnic or socioeconomic differences are associated with greater PFOA exposure. However, the available research on PFOA’s potential impacts on sensitive populations is limited and more research is needed. Health effects differences in sensitivity to PFOA exposure have not allowed for the identification or characterization of all potentially sensitive subpopulations. This lack of knowledge about susceptibility to PFOA represents a potential source of uncertainty in the assessment of PFOA.
6.8.1 Fetuses, Infants, Children

One of the more well-studied sensitive populations to PFOA exposure is developing fetuses, infants, and children. Both animal toxicological and epidemiological data suggest that the developing fetus is particularly sensitive to PFOA-induced toxicity. As described in Section 3.4.4.1, results of some epidemiological studies indicate an association between PFOA exposure during pregnancy and adverse birth outcomes such as low birth weight, and studies of PFOA exposure during early childhood, which may also reflect in utero exposure, suggest an association between PFOA exposure and effects on development, including immune system development (Section 3.4.2.1). The available animal toxicological data lend support to these findings; as described in Section 3.4.4.2, numerous studies in rodents report effects similar to those seen in humans (e.g., decreased body weights in offspring exposed to PFOA during gestation). Additionally, PFOA exposure to humans during certain life stages or exposure windows (e.g., prenatal or early postnatal exposure windows) may be more consequential than others, and these potentially different effects in different populations and/or exposure windows have not been fully characterized. More research is needed to fully understand the specific critical windows of exposure during development.

With respect to the decreased antibody production endpoint, children who have autoimmune diseases (e.g., juvenile arthritis) or are taking medications that weaken the immune system would be expected to be more likely to mount a low antibody response and would therefore represent potentially susceptible populations for PFOA exposure. There are also concerns about declines in vaccination status {Smith, 2011, 9642143; Bramer, 2020, 9642145} for children overall, and the possibility that diseases which are considered eradicated (such as diphtheria or tetanus) could return to the United States {Hotez, 2019, 9642144}. As noted by Dietert et al. (2010, 644213), the risks of developing infectious diseases may increase if immunosuppression occurs in the developing immune system.

6.8.2 Sex Differences

In humans, potential sex differences in the disposition of PFOA in the body, as well as in the potential for adverse health effects in response to PFOA exposure, have not been fully elucidated. With respect to sex differences in the development of adverse health effects in response to PFOA exposure, the available epidemiological data are insufficient to draw conclusions, although some studies reported sex differences (e.g., an association between PFOA exposure and serum ALT in girls but not boys {Attanasio, 2019, 5412069; Mora, 2018, 4239224}). In some studies in rats, males appeared to be more sensitive to some effects than females, even when females received much higher PFOA doses {Butenhoff, 2004, 1291063; NTP, 2020, 7330145}.

With respect to ADME, research in humans indicates that PFOA half-lives in males are generally longer than those in females {Fu, 2016, 3859819; Gomis, 2017, 3981280; Li, 2017, 4238434}. Some animal studies (in rats in particular) show the same sex difference, but additional research is needed to determine whether the underlying mechanisms identified in rats are relevant to humans. Female rats have been shown to absorb PFOA faster than male rats {Kim, 2016, 3749289}, and PFOA may distribute to some compartments (i.e., liver cytosol) to a greater extent in female rats compared to males {Han, 2005, 5081570}. Several studies have demonstrated that female rats and rabbits eliminate PFOA from the body faster than males.
Several studies have been conducted to elucidate the cause of the sex difference in the elimination of PFOA by rats {Kudo, 2002, 2990271; Cheng, 2006, 6551310; Hinderliter, 2006, 3749132}. Many of the studies have focused on the role of transporters in the kidney tubules, especially the OATs and OATPs located in the proximal portion of the descending tubule {Nakagawa, 2007, 2919370; Nakagawa, 2009, 2919342; Yang, 2009, 2919328; Yang, 2010, 2919288}. Generally, both in vivo and in vitro studies reported differences in renal transporters that are regulated by sex hormones and show consistent results indicating increased resorption of PFOA in male rats (see Section 3.3.1 and Appendix B). Hinderliter et al. (2006, 3749132) found that a developmental change in renal transport occurs in rats between 3 and 5 weeks of age that allows for expedited excretion of PFOA in females and an inverse development in males. When considered together, the studies of the transporters suggest that female rats are efficient in transporting PFOA across the basolateral and apical membranes of the proximal kidney tubules into the glomerular filtrate, but male rats are not.

Although sex differences in rats have been relatively well studied, sex differences observed in mice were less pronounced {Lau, 2006, 1276159; Lou, 2009, 2919359} and were actually reversed in cynomolgus monkeys and hamsters {Butenhoff, 2004, 3749227; Hundley, 2006, 3749054}, indicating species-specific factors impacting elimination across sexes.

Although there is some evidence to suggest sex differences in humans exposed to PFOA, the mechanisms for these potential differences have not been fully explored. For example, postmenopausal females and adult males have longer PFOA elimination half-lives than premenopausal adult females {Zhang, 2013, 3859849}. Partitioning to the placenta, amniotic fluid, fetus, menstruation, and breast milk represent important routes of elimination in humans and may account for some of the sex differences observed for blood and urinary levels of PFOA by sex and age. It is unclear whether hormone-dependent renal transporters play an additional role in the observed sex differences in PFOA half-life in humans. Additional research is needed to further elucidate these sex differences and their implications, and to ascertain whether the sex differences observed in some animal species are relevant to humans. This data gap represents a source of uncertainty in the elucidation of the risks of PFOA to humans.

### 6.8.3 Other Susceptible Populations

As noted in the SAB PFAS review panel’s final report {U.S. EPA, 2022, 10476098}, there is uncertainty about whether there are susceptible populations, such as certain racial/ethnic groups, that might be more sensitive to the health effects of PFOA exposure because of either greater biological sensitivity or higher exposure to PFOA and/or other environmental chemicals. Although some studies have evaluated differences in PFAS exposure levels across SES and racial/ethnic groups (see Section 6.1), studies of differential health effects incidence and PFOA exposure are limited. To fully address equity and environmental justice concerns about PFOA, these data gaps regarding differential exposure and health effects after PFOA exposure need to be addressed. In the development of the proposed PFAS NPDWR, EPA conducted an analysis to evaluate potential environmental justice impacts of the proposed regulation (See Chapter 8 of the Economic Analysis for the Proposed PFAS National Primary Drinking Water Regulation {U.S.
EPA, 2023, 10692765}). EPA acknowledges that exposure to PFOA, and PFAS in general, may have a disproportionate impact on certain communities (e.g., low SES communities; tribal communities; minority communities; communities in the vicinity of areas of historical PFOA manufacturing and/or contamination) and that studies of these communities are high priority research needs.
7 References


Abdallah, MA; Wemken, N; Drage, DS; Tlustos, C; Cellarius, C; Cleere, K; Morrison, JJ; Daly, S; Coggins, MA; Harrad, S. (2020). Concentrations of perfluoroalkyl substances in human milk from Ireland: Implications for adult and nursing infant exposure. Chemosphere 246: 125724. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6316215


Abraham, K; Mielke, H; Fromme, H; Völkel, W; Menzel, J; Peiser, M; Zepp, F; Willich, SN; Weikert, C. (2020). Internal exposure to perfluoroalkyl substances (PFASs) and biological markers in 101 healthy 1-year-old children: associations between levels of perfluorooctanoic acid (PFOA) and vaccine response. Arch Toxicol 94: 2131-2147. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6506041

Agier, L; Basagaña, X; Maitre, L; Granum, B; Bird, PK; Casas, M; Oftedal, B; Wright, J; Andrusaitye, S; de Castro, M; Cequier, E; Chatzi, L; Donaire-Gonzalez, D; Grazuleviciene, R; Haug, LS; Sakhi, AK; Leventakou, V; Mceachan, R; Nieuwenhuijsen, M; Pettraviciene, I; Robinson, O; Roumeliotaki, T; Sunyer, J; Tamayo-Uria, I; Thomsen, C; Urquiza, J; Valentin, A; Slama, R; Vrijheid, M; Si Roumeliotaki T; Slama, R; Vrijheid, M; Si Roumeliotaki T. (2019). Early-life exposome and lung function in children in Europe: an analysis of data from the longitudinal, population-based HELIX cohort. The Lancet Planetary Health 3: e81-e92. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5043613


Ashley-Martin, J; Dodds, L; Arbuckle, TE; Bouchard, MF; Fisher, M; Morriset, AS; Monnier, P; Shapiro,


Bao, WW; Qian, ZM; Geiger, SD; Liu, E; Liu, Y; Wang, SQ; Lawrence, WR; Yang, BY; Hu, LW; Zeng, XW; Dong, GH. (2017). Gender-specific associations between serum isomers of perfluoroalkyl substances and blood pressure among Chinese: Isomers of C8 Health Project in China.


Bartell, SM; Calafat, AM; Lyu, C; Kato, K; Ryan, PB; Steenland, K. (2010). Rate of Decline in Serum PFOA Concentrations after Granular Activated Carbon Filtration at Two Public Water Systems in Ohio and West Virginia. Environ Health Perspect 118: 222-228.


Bassler, J; Ducatman, A; Elliott, M; Wen, S; Wahlang, B; Barnett, J; Cave, MC. (2019). Environmental perfluoroalkyl acid exposures are associated with liver disease characterized by apoptosis and altered serum adipocytokines. Environ Pollut 247: 1055-1063.


Beck, IH; Timmermann, CAG; Nielsen, F; Schoeters, G; Jøhnk, C; Kyhl, HB; Høst, A; Jensen, TK. (2019). Association between prenatal exposure to perfluoroalkyl substances and asthma in 5-year-old children in the Odense Child Cohort. Environ Health 18: 97.


Benskin, JP; Muir, DCG; Scott, BF; Spencer, C; De Silva, AO; Kylin, H; Martin, JW; Morris, A;


Blake, BE; Cope, HA; Hall, SM; Keys, RD; Mahler, BW; Mccord, J; Scott, B; Stapleton, HM; Strynar, MJ; Elmore, SA; Fenton, SE. (2020). Evaluation of Maternal, Embryo, and Placental Effects in CD-1 Mice following Gestational Exposure to Perfluorooctanoic Acid (PFOA) or Hexafluoropropylene Oxide Dimer Acid (HFPO-DA or GenX). Environ Health Perspect 128: 27006. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6305864


Bogdanska, J; Borg, D; Bergström, U; Mellring, M; Bergman, Å; Depierre, J; Nobel, S. (2020). Tissue
distribution of 14C-labelled perfluorooctanoic acid in adult mice after 1-5 days of dietary exposure to an experimental dose or a lower dose that resulted in blood levels similar to those detected in exposed humans. Chemosphere 239: 124755.


Borghese, MM; Walker, M; Helewa, ME; Fraser, WD; Arbuckle, TE. (2020). Association of perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC study. Environ Int 141: 105789.


Bouwmeester, MC; Ruiter, S; Lommelaars, T; Sippel, J; Hodemaekers, HM; van den Brandhof, EJ; Pennings, JL; Kamstra, JH; Jelinek, J; Issa, JP; Legler, J; van der Ven, LT. (2016). Zebrafish embryos as a screen for DNA methylation modifications after compound exposure. Toxicol Appl Pharmacol 291: 84-96.


Braun, JM; Chen, A; Romano, ME; Calafat, AM; Webster, GM; Yolton, K; Lanphear, BP. (2016). Prenatal perfluoroalkyl substance exposure and child adiposity at 8 years of age: The HOME study. Obesity (Silver Spring) 24: 231-237.

Braun, JM; Kalkbrenner, AE; Just, AC; Yolton, K; Calafat, AM; Sjödin, A; Hauser, R; Webster, GM; Chen, A; Lanphear, BP. (2014). Gestational exposure to endocrine-disrupting chemicals and reciprocal social, repetitive, and stereotypic behaviors in 4- and 5-year-old children: the HOME study. Environ Health Perspect 122: 513-520.

Brede, E; Wilhelm, M; Göen, T; Müller, J; Rauchfuss, K; Kraft, M; Hölzer, J. (2010). Two-year follow-


Buck, RC; Franklin, J; Berger, U; Conder, JM; Cousins, IT; de Voogt, P; Jensen, AA; Kannan, K; Mabury, SA; van Leeuwen, SP. (2011). Perfluoroalkyl and polyfluoroalkyl substances in the environment: terminology, classification, and origins [Review]. Integr Environ Assess Manag 7: 513-541. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/4771046


Butenhoff, J; Costa, G; Elcombe, C; Farrar, D; Hansen, K; Iwai, H; Jung, R; Kennedy, G; Lieder, P; Olsen, G; Thomford, P. (2002). Toxicity of ammonium perfluoroctanoate in male cynomolgus...
monkeys after oral dosing for 6 months. Toxicol Sci 69: 244-257.

Butenhoff, JL; Kennedy, GL; Chang, SC; Olsen, GW. (2012). Chronic dietary toxicity and
carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. Toxicology

Butenhoff, JL; Kennedy, GL; Frame, S. R.; O'Conner, JC; York, RG. (2004). The reproductive

Butenhoff, JL; Kennedy, GL; Hinderliter, PM; Lieder, PH; Jung, R; Hansen, KJ; Gorman, GS; Noker,
PE; Thomford, PJ. (2004). Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys.

Butenhoff, JL; Kennedy, GL; Jung, R; Chang, SC. (2014). Evaluation of perfluorooctanoate for potential
genotoxicity. Toxicol Rep 1: 252-270.

Butt, CM; Berger, U; Bossi, R; Tomy, GT. (2010). Levels and trends of poly- and perfluorinated
compounds in the arctic environment [Review]. Sci Total Environ 408: 2936-2965.

Byrne, S; Seguinot-Medina, S; Miller, P; Waghiji, V; von Hippel, FA; Buck, CL; Carpenter, DO. (2017).
Exposure to polybrominated diphenyl ethers and perfluoroalkyl substances in a remote population of

Byrne, SC; Miller, P; Seguinot-Medina, S; Waghiji, V; Buck, CL; von Hippel, FA; Carpenter, DO.
(2018). Exposure to perfluoroalkyl substances and associations with serum thyroid hormones in a


C8 Science Panel. (2012). C8 study results - Status reports. Available online at
http://www.c8sciencepanel.org/study_results.html 1430770

Cai, D; Li, QQ; Chu, C; Wang, SZ; Tang, YT; Appleton, AA; Qiu, RL; Yang, BY; Hu, LW; Dong, GH;
Zeng, XW. (2020). High trans-placental transfer of perfluoralkyl substances alternatives in the
matched maternal-cord blood serum: Evidence from a birth cohort study. Sci Total Environ 705:

Calafat, AM; Kato, K; Hubbard, K; Jia, T; Botelho, JC; Wong, LY. (2019). Legacy and alternative per-
and polyfluoroalkyl substances in the U.S. general population: Paired serum-urine data from the

Calafat, AM; Wong, LY; Kuklenyik, Z; Reidy, JA; Needham, LL. (2007). Polyfluoroalkyl chemicals in
the US population: Data from the National Health and Nutrition Examination Survey (NHANES)

CalEPA. (2021). Public Health Goals: Perfluorooctanoic Acid and Perfluorooctane Sulfonic Acid in
Drinking Water (First Public Review Draft ed.). California Environmental Protection Agency,
Office of Environmental Health Hazard Assessment, Pesticide and Environmental Toxicology

Campbell, J; Clewell, H; Cox, T; Dourson, M; Ethridge, S; Forsberg, N; Gadagbui, B; Hamade, A; Naidu,
R; Pechacek, N; Peixe, TS; Prueitt, R; Rachamalla, M; Rhomberg, L; Smith, J; Verma, N. (2022).
The Conundrum of the PFOA human half-life, an international collaboration. Regul Toxicol
Pharmacol 132: 105185.

Canova, C; Barbieri, G; Zare Jeddi, M; Gion, M; Fabricio, A; Daprà, F; Russo, F; Fletcher, T; Pitter, G. (2020). Associations between perfluoroalkyl substances and lipid profile in a highly exposed young adult population in the Veneto Region. Environ Int 145: 106117. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/7021512


Canova, C; Barbieri, G; Zare Jeddi, M; Gion, M; Fabricio, A; Daprà, F; Russo, F; Fletcher, T; Pitter, G. (2020). Associations between perfluoroalkyl substances and lipid profile in a highly exposed young adult population in the Veneto Region. Environ Int 145: 106117. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/7021512


Cavallini, G; Donati, A; Taddei, M; Bergamini, E. (2017). Peroxisomes proliferation and pharmacological stimulation of autophagy in rat liver: evidence to support that autophagy may remove the "older" peroxisomes. Mol Cell Biochem 431: 97-102.
Cellesi, C; Michelangeli, C; Rossolini, GM; Giovannoni, F; Rossolini, A. (1989). Immunity to diphtheria, six to 15 years after a basic three-dose immunization schedule. Journal of Biological Standardization 17: 29-34.
Chang, CJ; Barr, DB; Ryan, PB; Panuwet, P; Smarr, MM; Liu, K; Kannan, K; Yakimavets, V; Tan, Y; Ly, V; Marsit, CJ; Jones, DP; Corwin, EJ; Dunlop, AL; Liang, D. (2022). Per- and polyfluoroalkyl substance (PFAS) exposure, maternal metabolic perturbation, and fetal growth in African American women: A meet-in-the-middle approach. Environ Int 158: 106964.
Chang, S; Parker, GA; Kleinschmidt, SE; Olsen, GW; Ley, CA; Taiwo, OA. (2020). A Pathology Review of the Lower Gastrointestinal Tract in Relation to Ulcerative Colitis in Rats and Cynomolgus Macaques Treated With Ammonium Perfluorooctanoate. Toxicol Pathol192623320911606.
Chen, A; Jandarov, R; Zhou, L; Calafat, AM; Zhang, G; Urbina, EM; Sarac, J; Augustin, DH; Caric, T; Bockor, L; Petranovic, MZ; Novokmet, N; Missoni, S; Rudan, P; Deka, R. (2019). Association of perfluoroalkyl substances exposure with cardiometabolic traits in an island population of the eastern Adriatic coast of Croatia. Sci Total Environ 683: 29-36.
Chen, MH; Ha, EH; Liao, HF; Jeng, SF; Su, YN; Wen, TW; Lien, GW; Chen, CY; Hsieh, WS; Chen, PC. (2013). Perfluorinated compound levels in cord blood and neurodevelopment at 2 years of age. Epidemiology 24: 800-808.
Chen, Q; Zhang, X; Zhao, Y; Lu, W; Wu, J; Zhao, S; Zhang, J; Huang, L. (2019). Prenatal exposure to perfluorobutanesulfonic acid and childhood adiposity: A prospective birth cohort study in Shanghai, China. Chemosphere 226: 17-23.
Chen, Y; Zhou, L; Xu, J; Zhang, L; Li, M; Xie, X; Xie, Y; Luo, D; Zhang, D; Yu, X; Yang, B; Kuang, H.
Maternal exposure to perfluorooctanoic acid inhibits luteal function via oxidative stress and apoptosis in pregnant mice. Reprod Toxicol 69: 159-166.


Christensen, KY; Maisonet, M; Rubin, C; Holmes, A; Calafat, AM; Kato, K; Flanders, WD; Heron, J; Mcgeehin, MA; Marcus, M. (2011). Exposure to polyfluoroalkyl chemicals during pregnancy is not associated with offspring age at menarche in a contemporary British cohort. Environ Int 37: 129-135. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/1290803


Christensen, KY; Raymond, M; Thompson, BA; Anderson, HA. (2016). Perfluoroalkyl substances in older male anglers in Wisconsin. Environ Int 91: 312-318.

Christensen, KY; Raymond, MR; Thompson, BA; Anderson, HA. (2016). Fish consumption, levels of nutrients and contaminants, and endocrine-related health outcomes among older male anglers in Wisconsin. J Occup Environ Med 58: 668-675.


Chu, C; Zhou, Y; Li, QQ; Bloom, MS; Lin, S; Yu, YJ; Chen, D; Yu, HY; Hu, LW; Yang, BY; Zeng, XW; Dong, GH. (2020). Are perfluorooctane sulfonate alternatives safer? New insights from a birth cohort study. Environ Int 135: 105365.


Clegg, ED; Cook, JC; Chapin, RE; Foster, PMD; Daston, GP. (1997). Leydig cell hyperplasia and

Cluett, R; Seshasayee, SM; Rokoff, LB; Rifas-Shiman, SL; Ye, X; Calafat, AM; Gold, DR; Coull, B; Gordon, CM; Rosen, CJ; Oken, E; Sagiv, SK; Fleisch, AF. (2019). Per- and Polyfluoroalkyl Substance Plasma Concentrations and Bone Mineral Density in Midchildhood: A Cross-Sectional Study (Project Viva, United States). Environ Health Perspect 127: 87006. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5412438


Cohn, BA; La Merrill, MA; Krigbaum, NY; Wang, M; Park, JS; Petreas, M; Yeh, G; Hovey, RC; Zimmermann, L; Cirillo, PM. (2020). In utero exposure to poly- and perfluoroalkyl substances (PFASs) and subsequent breast cancer. Reprod Toxicol 92: 112-119. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5412451


Cong, J; Chu, C; Li, QQ; Zhou, Y; Qian, ZM; Geiger, SD; Vaughn, MG; Zeng, XW; Liu, RQ; Hu, LW; Yang, BY; Chen, G; Zeeshan, M; Sun, X; Xiang, M; Dong, GH. (2021). Associations of perfluorooctane sulfonate alternatives and serum lipids in Chinese adults. Environ Int 155: 106596. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/8442223


Cope, HA; Blake, BE; Love, C; McCord, J; Elmore, SA; Harvey, JB; Chappell, VA; Fenton, SE. (2021). Latent, sex-specific metabolic health effects in CD-1 mouse offspring exposed to PFOA or HFPO-DA (GenX) during gestation. Emerging Contaminants 7: 219-235. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/10176465


Corton, JC; Cunningham, ML; Hummer, BT; Lau, C; Meek, B; Peters, JM; Popp, JA; Rhomberg, L; Seed, J; Klaunig, JE. (2014). Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study [Review]. Crit Rev
Costello, E; Rock, S; Stratakis, N; Eckel, SP; Walker, DI; Valvi, D; Cserbik, D; Jenkins, T; Xanthakos, SA; Kohli, R; Sisley, S; Vasiliou, V; La Merrill, MA; Rosen, H; Conti, DV; Mcconnell, R; Chatzi, L. (2022). Exposure to per- and Polyfluoroalkyl Substances and Markers of Liver Injury: A Systematic Review and Meta-Analysis [Review]. Environ Health Perspect 130: 46001.
Crebelli, R; Caiola, S; Conti, L; Cordelli, E; De Luca, G; Dellatte, E; Eleuteri, P; Iacovella, N; Leopardi, P; Marcon, F; Sanchez, M; Sestili, P; Siniscalchi, E; Villani, P. (2019). Can sustained exposure to PFAS trigger a genotoxic response? A comprehensive genotoxicity assessment in mice after subacute oral administration of PFOA and PFBA. Regul Toxicol Pharmacol 106: 169-177.
Creton, S; Aardema, MJ; Carmichael, PL; Harvey, JS; Martin, FL; Newbold, RF; O'Donovan, MR; Pant, K; Poth, A; Sakai, A; Sasaki, K; Scott, AD; Schechtm, LM; Shen, RR; Tanaka, N; Yasaki, H. (2012). Cell transformation assays for prediction of carcinogenic potential: State of the science and future research needs. Mutagenesis 27: 93-101.
Cui, Q; Pan, Y; Wang, J; Liu, H; Yao, B; Dai, J. (2020). Exposure to per- and polyfluoroalkyl substances (PFASs) in serum versus semen and their association with male reproductive hormones. Environ Pollut 266 Pt. 2: 115330. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6833614
Cui, R; Li, C; Wang, J; Dai, J. (2019). Induction of hepatic miR-34a by perfluorooctanoic acid regulates metabolism-related genes in mice. Environ Pollut 244: 270-278.


Dalla Zuanna, T; Savitz, DA; Barbieri, G; Pitter, G; Zare Jeddi, M; Daprà, F; Fabricio, ASC; Russo, F; Fletcher, T; Canova, C. (2021). The association between perfluorooalkyl substances and lipid profile in exposed pregnant women in the Veneto region, Italy. Ecotoxicol Environ Saf 209: 111805. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/7277682


De Silvaa, AO; Armitage, JM; Bruton, TA; Dassuncaco, C; Heiger-Bernays, W; Hu, XC; Kärrman, A; Kelly, B; Ng, C; Robuck, A; Sun, M; Webster, TF; Sunderland, EM. (2021). PFAS Exposure Pathways for Humans and Wildlife: A Synthesis of Current Knowledge and Key Gaps in Understanding [Review]. Environ Toxicol Chem 40: 631-657.

De Toni, L; Radu, CM; Sabovic, I; Di Nisio, A; Dall’Acqua, S; Guidolin, D; Spampinato, S; Campello, E; Simioni, P; Foresta, C. (2020). Increased cardiovascular risk associated with chemical sensitivity to perfluoro-octanoic acid: role of impaired platelet aggregation. International Journal of Molecular Sciences 21: 399.

Deener, KC; Sacks, JD; Kirrane, EF; Glenn, BS; Gwinn, MR; Bateson, TF; Burke, TA. (2018). Epidemiology: a foundation of environmental decision making [Review]. J Expo Sci Environ Epidemiol 28: 515-521.


Dertinger, SD; Camphausen, K; Macgregor, JT; Bishop, ME; Torous, DK; Avlasevich, S; Cairns, S; Tometsko, CR; Menard, C; Muanza, T; Chen, Y; Miller, RK; Cederbrant, K; Sandelin, K; Pontén, J; Bolcsfoldi, G. (2004). Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood. Environ Mol Mutagen 44: 427-435.


Donat-Vargas, C; Bergdahl, IA; Tornevi, A; Wennberg, M; Sommar, J; Koponen, J; Kiviranta, H;


Duan, Y; Sun, H; Yao, Y; Meng, Y; Li, Y. (2020). Distribution of novel and legacy per-/polyfluoroalkyl substances in serum and its associations with two glycemic biomarkers among Chinese adult men and women with normal blood glucose levels. Environ Int 134: 105295. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5918597


Dzierlenga, AL; Robinson, VG; Waidyanatha, S; Devito, MJ; Eifrid, MA; Gibbs, ST; Granville, CA; Blystone, CR. (2019). Toxicokinetics of perfluorohexanoic acid (PFHxA), perfluorooctanoic acid (PFOA) and perfluorodecanoic acid (PFDA) in male and female Hsd:Sprague dawley SD rats following intravenous or gavage administration. Xenobiotica 50: 1-11. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5916078


Dzierlenga, MW; Moreau, M; Song, G; Mallick, P; Ward, PL; Campbell, JL; Housand, C; Yoon, M; Allen, BC; Clewell, HJ; Longnecker, MP. (2020). Quantitative bias analysis of the association between subclinical thyroid disease and two perfluoroalkyl substances in a single study. Environ Res 182: 109017. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6315786


Ebert, A; Allendorf, F; Berger, U; Goss, KU; Ulrich, N. (2020). Membrane/water partitioning and permeabilities of perfluoroalkyl acids and four of their alternatives and the effects on toxicokinetic behavior. Environ Sci Technol 54: 5051-5061.


Eggert, A; Cisneros-Montalvo, S; Anandan, S; Musili, S; Stukenborg, JB; Adamsson, A; Nurmi, M; Toppari, J. (2019). The effects of perfluorooctanoic acid (PFOA) on fetal and adult rat testis. Reprod Toxicol 90: 68-76.

Ehresman, DJ; Froehlich, JW; Olsen, GW; Chang, SC; Butenhoff, JL. (2007). Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ Res 103: 176-184.

Eick, SM; Enright, EA; Geiger, SD; Dzwilewski, KLC; DeMicco, E; Smith, S; Park, JS; Aguiar, S; Woodruff, TJ; Morello-Frosch, R; Schantz, SL. (2021). Associations of maternal stress, prenatal exposure to per- and polyfluoroalkyl substances (PFAS), and demographic risk factors with birth outcomes and offspring neurodevelopment: An overview of the ECO.CA.IL prospective birth cohorts [Review]. Int J Environ Res Public Health 18: 742.


Elcombe, CR; Elcombe, BM; Foster, JR; Farrar, DG; Jung, R; Chang, SC; Kennedy, GL; Butenhoff, JL. (2010). Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARα and CAR/PXR. Arch Toxicol 84: 787-798.


Elmore, SA; Dixon, D; Hailey, JR; Harada, H; Herbert, RA; Maronpot, RR; Nolte, T; Rehg, JE; Rittinghausen, S; Rosol, TJ; Satoh, H; Vidal, JD; Willard-Mack, CL; Creasy, DM. (2016). Recommendations from the INHAND Apoptosis/Necrosis Working Group. Toxicol Pathol 44. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/10671182


Eriksen, KT; Raaschou-Nielsen, O; Mclaughlin, JK; Lipworth, L; Tjønneland, A; Overvad, K; Sørensen, M. (2013). Association between plasma PFOA and PFOS levels and total cholesterol in a middle-aged Danish population. PLoS ONE 8: e56969.

Eriksen, KT; Sørensen, M; Mclaughlin, JK; Lipworth, L; Tjønneland, A; Overvad, K; Raaschou-Nielsen, O. (2009). Perfluorooctanoate and perfluorooctanesulfonate plasma levels and risk of cancer in the general Danish population. J Natl Cancer Inst 101: 605-609.

Erol, E; Kumar, LS; Cline, GW; Shulman, GI; Kelly, DP; Binas, B. (2004). Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPARalpha in fasting mice. FASEB J 18: 347-349.


Fan, Y; Lu, C; Li, X; Xu, Q; Zhang, Y; Yang, X; Han, X; Du, G; Xia, Y; Wang, X. (2020). Serum albumin mediates the effect of multiple per- and polyfluoroalkyl substances on serum lipid levels. Environ Pollut 266 Pt 2: 115138.


Feng, Y; Bai, Y; Lu, Y; Chen, M; Fu, M; Guan, X; Cao, Q; Yuan, F; Jie, J; Li, M; Meng, H; Wang, C; Hong, S; Zhou, Y; Zhang, X; He, M; Guo, H. (2022). Plasma perfluoroalkyl substance exposure and incidence risk of breast cancer: A case-cohort study in the Dongfeng-Tongji cohort. Environ Pollut 306: 119345. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/10328872


Fenton, SE; Reiner, JL; Nakayama, SF; Delinsky, AD; Stanko, JP; Hines, EP; White, SS; Lindstrom, AB;


Fitz-Simon, N; Fletcher, T; Luster, MI; Steenland, K; Calafat, AM; Kato, K; Armstrong, B. (2013). Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid. Epidemiology 24: 569-576.

Fleisch, AF; Rfas-Shiman, SL; Mora, AM; Calafat, AM; Ye, X; Luttmann-Gibson, H; Gillman, MW; Oken, E; Sagiv, SK. (2017). Early-life exposure to perfluoroalkyl substances and childhood metabolic function. Environ Health Perspect 125: 481-487.

Fletcher, T; Galloway, TS; Melzer, D; Holcroft, P; Cipelli, R; Pilling, LC; Mondal, D; Luster, M; Harries, LW. (2013). Associations between PFOA, PFOS and changes in the expression of genes involved in cholesterol metabolism in humans. Environ Int 57-58: 2-10.


Forns, J; Izazz, N; White, RA; Mandal, S; Sabarezdovic, A; Lamoree, M; Thomsen, C; Haug, LS; Stigum, H; Eggshø, M. (2015). Perfluoroalkyl substances measured in breast milk and child neuropsychological development in a Norwegian birth cohort study. Environ Int 83: 176-182.


Fragki, S; Dirven, H; Fletcher, T; Grasl-Kraupp, B; Bjerve Gützkow, K; Hoogenboom, R; Kersten, S; Lindeman, B; Louisse, J; Peijnenburg, A; Piersma, AH; Princen, HMG; Uhl, M; Westerhout, J; Zeilmaker, MJ; Luijten, M. (2021). Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not? Crit Rev Toxicol 141-164.

Franco, ME; Fernandez-Luna, MT; Ramirez, AJ; Lavado, R. (2020). Metabolomic-based assessment


Fu, J; Gao, Y; Cui, L; Wang, T; Liang, Y; Qu, G; Yuan, B; Wang, Y; Zhang, A; Jiang, G. (2016). Occurrence, temporal trends, and half-lives of perfluoroalkyl acids (PFAAs) in occupational workers in China. Sci Rep 6: 38039.


Gallo, V; Leonardi, G; Brayne, C; Armstrong, B, en; Fletcher, T. (2013). Serum perfluoroalkyl acids concentrations and memory impairment in a large cross-sectional study. BMJ Open 3.

Gallo, V; Leonardi, G; Genser, B; Lopez-Espinosa, MJ; Frisbee, SJ; Karlsson, L; Ducatman, AM; Fletcher, T. (2012). Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. Environ Health Perspect 120: 655-660.

Gannon, SA; Fasano, WJ; Mawn, MP; Nabb, DL; Buck, RC; Buxton, LW; Jepson, GW; Frame, SR. (2016). Absorption, distribution, metabolism, excretion, and kinetics of 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)propanoic acid ammonium salt following a single dose in rat, mouse, and cynomolgus monkey. Toxicology 340: 1-9.


Gao, K; e; Zhuang, T; Liu, X; Fu, J; Zhang, J; Fu, J; ie; Wang, L; Zhang, A; Liang, Y; Song, M; Jiang, G. (2019). Prenatal Exposure to Per- and Polyfluoroalkyl Substances (PFASs) and Association between the Placental Transfer Efficiencies and Dissociation Constant of Serum Proteins-PFAS Complexes. Environ Sci Technol 53: 6529-6538.

Gao, X; Ni, W; Zhu, S; Wu, Y; Cui, Y; Ma, J; Liu, Y; Qiao, J; Ye, Y; Yang, P; Liu, C; Zeng, F. (2021). Per- and polyfluoroalkyl substances exposure during pregnancy and adverse pregnancy and birth outcomes: A systematic review and meta-analysis. Environ Res 201: 111632.

Gao, Y; Fu; J; Cao, H; Wang, Y; Zhang, A; Liang, Y; Wang, T; Zhao, C; Jiang, G. (2015). Differential Accumulation and Elimination Behavior of Perfluoroalkyl Acid Isomers in Occupational Workers in a Manufactory in China. Environ Sci Technol 49: 6953-6962.


Gaylord, A; Berger, KI; Naidu, M; Attina, TM; Gilbert, J; Koshy, TT; Han, X; Marmor, M; Shao, Y; Giusti, R; Goldring, RM; Kannan, K; Trasande, L. (2019). Serum perfluoroalkyl substances and lung function in adolescents exposed to the World Trade Center disaster. Environ Res 172: 266-272.


Gazouli, M; Yao, ZX; Boujrad, N; Corton, JC; Culty, M; Papadopoulos, V. (2002). Effect of peroxisome proliferators on Leydig cell peripheral-type benzodiazepine receptor gene expression, hormone-stimulated cholesterol transport, and steroidogenesis: Role of the peroxisome proliferator-activator receptor alpha. Endocrinology 143: 2571-2583.


Glassmeyer, ST; Furlong, ET; Kolpin, DW; Batt, AL; Benson, R; Boone, JS; Conerly, O; Donohue, MJ; King, DN; Kostich, MS; Mash, HE; Pfaller, SL; Schenck, KM; Simmons, JE; Varughese, EA; Vesper, SJ; Villegas, EN; Wilson, VS. (2017). Nationwide reconnaissance of contaminants of emerging concern in source and treated drinking waters of the United States. Sci Total Environ 581-582: 909-922. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3454569

Gleason, JA; Cooper, KR; Klots, JB; Post, GB; Van Orden, G; New Jersey Drinking Water Quality Institute (NJDWQI). (2017). Health-based maximum contaminant level support document: Perfluorooctanoic acid (PFOA): Appendix A.


Goff, DC; Lloyd-Jones, DM; Bennett, G; Coady, S; D'Agostino, RB; Gibbons, R; Greenland, P; Lackland, DT; Levy, D; O'Donnell, CJ; Robinson, JG; Schwartz, JS; Shero, ST; Smith, SC; Sorlie, P; Stone, NJ; Wilson, PW. (2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129: S49-S73. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6316203


Goodrich, JA; Walker, D; Lin, X; Wang, H; Lim, T; Mcconnell, R; Conti, DV; Chatzi, L; Setiawan, VW. (2022). Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort. 4: 100550.


Graber, JM; Alexander, C; Laumbach, RJ; Black, K; Strickland, PO; Georgopoulos, PG; Marshall, EG; Shendell, DG; Alderson, D; Mi, Z; Mascari, M; Weisel, CP. (2019). Per and polyfluoroalkyl substances (PFAS) blood levels after contamination of a community water supply and comparison with 2013-2014 NHANES. J Expo Sci Environ Epidemiol 29: 172-182. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5080653


Granum, B; Haug, LS; Namork, E; Stølevik, SB; Thomsen, C; Aaberger, IS; van Loveren, H; Løvik, M;


Guo, H; Wang, J; Yao, J; Sun, S; Sheng, N; Zhang, X; Guo, X; Guo, Y; Sun, Y; Dai, J. (2019). Comparative hepatotoxicity of novel PFOA alternatives (perfluoropolyether carboxylic acids) on male mice. Environ Sci Technol 53: 3929-3937.


Gyllenhammar, I; Benskin, JP; Sandblom, O; Berger, U; Ahrens, L; Lignell, S; Wiberg, K; Glynn, A. (2018). Perfluoroalkyl acids (PFAAs) in serum from 2-4-month-old infants: Influence of maternal serum concentration, gestational age, breast-feeding, and contaminated drinking water. Environ Sci Technol 52: 7101-7110.


Gyllenhammar, I; Diderholm, B; Gustafsson, J; Berger, U; Ridefelt, P; Benskin, JP; Lignell, S; Lamp, A; Glynn, A. (2018). Perfluorooctyl acid levels in first-time mothers in relation to offspring weight gain and growth. Environ Int 111: 191-199.


Hagenaars, A; Vergauwen, L; Benoot, D; Laukens, K; Knappen, D. (2013). Mechanistic toxicity study of perfluorooctanoic acid in zebrafish suggests mitochondrial dysfunction to play a key role in PFOA toxicity. Chemosphere 91: 844-856.

Hammer, T; Lophaven, SN; Nielsen, KR; Petersen, MS; Munkholm, P; Weihe, P; Burisch, J; Lynge, E. (2019). Dietary risk factors for inflammatory bowel diseases in a high-risk population: Results from the Faroese IBD study. 7: 924-932. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/8776815


Han, W; Gao, Y; Yao, Q; Yuan, T; Wang, Y; Zhao, S; Shi, R; Bonefeld-Jorgensen, EC; Shen, X; Tian, Y. (2018). Perfluoroalkyl and polyfluoroalkyl substances in matched parental and cord serum in Shandong, China. Environ Int 116: 206-213. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5080230


Han, X; Meng, L; Zhang, G; Li, Y; Shi, Y; Zhang, Q; Jiang, G. (2021). Exposure to novel and legacy per- and polyfluoroalkyl substances (PFASs) and associations with type 2 diabetes: A case-control study in East China. Environ Int 156: 106637. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/7762348


Hanvatananukul, P; Prasarakke, C; Sarachai, S; Aurpibul, L; Sintupat, K; Khampan, R; Saheng, J; Sudjaritruk, T. (2020). Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents. Int J Infect Dis 96: 422-430.


Hardell, E; Kärrman, A; van Bavel, B; Bao, J; Carlberg, M; Hardell, L. (2014). Case-control study on perfluorinated alkyl acids (PFAAs) and the risk of prostate cancer. Environ Int 63: 35-39.


Harris, MH; Oken, E; Rifas-Shiman, SL; Calafat, AM; Ye, X; Bellinger, DC; Webster, TF; White, RF; Sagiv, SK. (2018). Prenatal and childhood exposure to per- and polyfluoroalkyl substances (PFASs) and child cognition. Environ Int 115: 358-369.


Hines, EP; White, SS; Stanko, JP; Flournoy, EAG; Lau, C; Fenton, SE. (2009). Phenotypic dichotomy


Huang, H; Yu, K; Zeng, X; Chen, Q; Liu, Q; Zhao, Y; Zhang, J; Zhang, X; Huang, L. (2020). Association
between prenatal exposure to perfluoroalkyl substances and respiratory tract infections in preschool children. Environ Res 191: 110156.


Huang, Q; Zhang, J; Peng, S; Du, M; Ow, S; Pu, H; Pan, C; Shen, H. (2014). Proteomic analysis of perfluorooctane sulfonate-induced apoptosis in human hepatic cells using the iTRAQ technique. J Appl Toxicol 34: 1342-1351.

Huang, R; Chen, Q; Zhang, L; Luo, K; Chen, L; Zhao, S; Feng, L; Zhang, J. (2019). Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and the risk of hypertensive disorders of pregnancy. Environ Health 18: 5.


Huo, X; Huang, R; Gan, Y; Luo, K; Aimuzi, R; Nian, M; Ao, J; Feng, L; Tian, Y; Wang, W; Ye, W; Zhang, J. (2020). Perfluoroalkyl substances in early pregnancy and risk of hypertensive disorders of pregnancy: A prospective cohort study. Environ Int 138: 105656.

Hurley, S; Goldberg, D; Wang, M; Park, JS; Petreas, M; Bernstein, L; Anton-Culver, H; Nelson, DO; Reynolds, P. (2018). Breast cancer risk and serum levels of per- and poly-fluoroalkyl substances: a case-control study nested in the California Teachers Study. Environ Health 17: 83.


ILEPA. Title 35: Environmental Protection. Subtitle: Public Water Supplies. Chapter I: Pollution Control

Innes, KE; Wimsatt, JH; Frisbee, S; Ducatman, AM. (2014). Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population. BMC Cancer 14: 45. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5918599


Itoh, S; Araki, A; Miyashita, C; Yamazaki, K; Goudarzi, H; Minatoya, M; Ait Bami, Y; Kobayashi, S; Okada, E; Kashino, I; Yuasa, M; Baba, T; Kishi, R. (2019). Association between perfluoroalkyl substance exposure and thyroid hormone/thyroid antibody levels in maternal and cord blood: The Hokkaido Study. Environ Int 133: 105139. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5915990

Iwabuchi, K; Senzaki, N; Mazawa, D; Sato, I; Hara, M; Ueda, F; Liu, W; Tsuda, S. (2017). Tissue toxicokinetics of perfluoro compounds with single and chronic low doses in male rats. J Toxicol


Jensen, RC; Andersen, MS; Larsen, PV; Glintborg, D; Dalgård, C; Timmermann, CAG; Nielsen, F; Sandberg, MB; Andersen, HR; Christesen, HT; Grandjean, P; Jensen, TK. (2020). Prenatal Exposures to Perfluoroalkyl Acids and Associations with Markers of Adiposity and Plasma Lipids in Infancy: An Odense Child Cohort Study. Environ Health Perspect 128: 77001. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6833719

Jensen, RC; Glintborg, D; Gade Timmermann, CA; Nielsen, F; Kyhl, HB; Frederiksen, H; Andersson, AM; Juul, A; Sidellman, JJ; Andersen, HR; Grandjean, P; Andersen, MS; Jensen, TK. (2020). Prenatal exposure to perfluorodecanoic acid is associated with lower circulating concentration of adrenal steroid metabolites during mini puberty in human female infants. The odense child cohort. Environ Res 182: 109101. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6311643


Jiang, W; Zhang, Y; Zhu, L; Deng, J. (2014). Serum levels of perfluoroalkyl acids (PFAAs) with isomer analysis and their associations with medical parameters in Chinese pregnant women. Environ Int

Jin, R; Mcconnell, R; Catherine, C; Xu, S; Walker, DI; Stratakis, N; Jones, DP; Miller, GW; Peng, C; Conti, DV; Vos, MB; Chatzi, L. (2020). Perfluoroalkyl substances and severity of nonalcoholic fatty liver in Children: An untargeted metabolomics approach. Environ Int 134: 105220.


Joensen, UN; Veyrand, B; Antignac, JP; Jensen, MB; Petersen, JH; Marchand, P; Skakkebæk, NE; Andersson, AM; Le Bizec, B; Jørgensen, N. (2014). PFOS (perfluorooctanesulfonate) in serum is negatively associated with testosterone levels, but not with semen quality, in healthy men. Hum Reprod 29: 1600-1600.


Johnson, PI; Sutton, P; Atchley, DS; Koustas, E; Lam, J; Sen, S; Robinson, KA; Axelrad, DA; Woodruff, TJ. (2014). The navigation guide - evidence-based medicine meets environmental health: Systematic review of human evidence for PFOA effects on fetal growth [Review]. Environ Health Perspect 122: 1028-1039.

Jusko, TA; Oktapodas, M; Palkovičová Murinová, L; Babinská, K; Babjaková, J; Verner, MA; Dewitt, JC; Thevenet-Morrison, K; Čonka, K; Drobná, B; Chovancová, J; Thurston, SW; Lawrence, BP; Dozier, AM; Järvinen, KM; Patayová, H; Trnovec, T; Legler, J; Hertz-Picciotto, I; Lamoree, MH. (2016). Demographic, reproductive, and dietary determinants of perfluorooctane sulfonic (PFOS) and perfluorooctanoic acid (PFOA) concentrations in human colostrum. Environ Sci Technol 50: 7152-7162. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3981718


7-37


Kim, SK; Lee, KT; Kang, CS; Tao, L; Kannan, K; Kim, KR; Kim, CK; Lee, JS; Park, PS; Yoo, YW; Ha, JY; Shin, YS; Lee, JH. (2011). Distribution of perfluorochemicals between sera and milk from the same mothers and implications for prenatal and postnatal exposures. Environ Pollut 159: 169-174. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2919258


Kim, YR; White, N; Bräunig, J; Vijayasarathy, S; Mueller, JF; Knox, CL; Harden, FA; Pacella, R; Toms, LL. (2020). Per- and poly-fluoroalkyl substances (PFASs) in follicular fluid from women experiencing infertility in Australia. Environ Res 190: 109963. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6833596


https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/1289837


Konwick, BJ; Tomy, GT; Ismail, N; Peterson, JT; Fauver, RJ; Higginbotham, D; Fisk, AT. (2008). Concentrations and patterns of perfluoroalkyl acids in Georgia, USA surface waters near and distant to a major use source. Environ Toxicol Chem 27: 2011-2018.

Koshy, TT; Attina, TM; Ghassabian, A; Gilbert, J; Burdine, LK; Marmor, M; Honda, M; Chu, DB; Han, X; Shao, Y; Kannan, K; Urbina, EM; Trasande, L. (2017). Serum perfluoroalkyl substances and cardiometabolic consequences in adolescents exposed to the World Trade Center disaster and a matched comparison group. Environ Int 109: 128-135.


Kotlarz, N; McLeod, J; Collier, D; Lea, CS; Strynar, M; Lindstrom, AB; Wilkie, AA; Islam, JY; Matney, K; Tarte, P; Polera, ME; Burdette, K; Dewitt, J; May, K; Smart, RC; Knappe, DR; Hoppin, JA. (2020). Measurement of Novel, Drinking Water-Associated PFAS in Blood from Adults and Children in Wilmington, North Carolina. Environ Health Perspect 128: 77005.

Kuczmarski, RJ; Ogden, CL; Guo, SS; Grummer-Strawn, LM; Flegal, KM; Mei, Z; Wei, R; Curtin, LR; Roche, AF; Johnson, CL. (2002). 2000 CDC growth charts for the United States: Methods and development. (Vital and Health Statistics: Series 11, No. 246). Hyattsville, MD: National Center for Health Statistics. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3490881


Lebeaux, RM; Doherty, BT; Gallagher, LG; Zoeller, RT; Hoofnagle, AN; Calafat, AM; Karagas, MR; Yolton, K; Chen, A; Lanphear, BP; Braun, JM; Romano, ME. (2020). Maternal serum perfluoroalkyl substance mixtures and thyroid hormone concentrations in maternal and cord sera: The HOME Study. Environ Res 185: 109395. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6356361


Lehmann, GM; Verner, MA; Luukinen, B; Henning, C; Assimon, SA; Lakind, JS; Mclanahan, ED; Phillips, LJ; Davis, MH; Powers, CM; Hines, EP; Haddad, S; Longnecker, MP; Poulsen, MT; Farrer, DG; Marchitti, SA; Tan, YM; Swartout, JC; Sagiv, SK; Welsh, C; Campbell, JL; Foster, WG; Yang, RS; Fenton, SE; Tornero-Velez, R; Francis, BM; Barnett, JB; El-Masri, HA; Simmons, JE. (2014). Improving the risk assessment of lipophilic persistent environmental chemicals in breast milk [Review]. Crit Rev Toxicol 44: 600-617. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2447276


Lenters, V; Portengen, L; Rignell-Hydborn, A; Jönsson, BA; Lindh, CH; Piersma, AH; Toft, G; Bonde,


Leter, G; Consales, C; Eleuteri, P; Uccelli, R; Specht, IO; Toft, G; Moccia, T; Budillon, A; Jönsson, BA; Lindh, CH; Giwercman, A; Pedersen, HS; Ludwicki, JK; Zviezdai, V; Heederik, D; Bonde, JP; Spanò, M. (2014). Exposure to perfluoroalkyl substances and sperm DNA global methylation in Arctic and European populations. Environ Mol Mutagen 55: 591-600. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2967406


Li, H; Hammarstrand, S; Midberg, B; Xu, Y; Li, Y; Olsson, DS; Fletcher, T; Jakobsson, K; Andersson, EM. (2022). Cancer incidence in a Swedish cohort with high exposure to perfluoroalkyl substances in drinking water. Environ Res 204: 112217. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/9961926


Li, K; Sun, J; Yang, J; Roberts, SM; Zhang, X; Cui, X; Wei, S; Ma, LQ. (2017). Molecular Mechanisms of Perfluorooctanoate-Induced Hepatocyte Apoptosis in Mice Using Proteomic Techniques. Environ Sci Technol 51: 11380-11389. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/4238518


Li, MC. (2020). Serum Per- and Polyfluoroalkyl Substances Are Associated with Increased Hearing
Li, N; Liu, Y; Papandonatos, GD; Calafat, AM; Eaton, CB; Kelsey, KT; Cecil, KM; Kalkwarf, HJ; Yolton, K; Lanphear, BP; Chen, A; Braun, JM. (2021). Gestational and childhood exposure to per- and polyfluoroalkyl substances and cardiometabolic risk at age 12 years. Environ Int 147: 106344. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/7404102
Li, X; Wang, Z; Klaunig, JE. (2019). The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice. Toxicology 416: 1-14.
Li, Y; Barregard, L; Xu, Y; Scott, K; Pineda, D; Lindh, CH; Jakobsson, K; Fletcher, T. (2020). Associations between perfluoroalkyl substances and serum lipids in a Swedish adult population with contaminated drinking water. Environ Health 19: 33.
Li, Y; Mucs, D; aniel; Scott, K, ristin; Lindh, C, hristin; Tallving, P, ia; Fletcher, T, ony; Jakobsson, K, ristina. (2017). Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water. (2:2017). Gothenburg, Sweden: Gothenburg University, Unit for Occupational & Environmental Medicine.
Li, Y; Oliver, DP; Kookana, RS. (2018). A critical analysis of published data to discern the role of soil and sediment properties in determining sorption of per and polyfluoroalkyl substances (PFASs) [Review]. Sci Total Environ 628-629: 110-120.
Liang, JL; Tiwari, T; Moro, P; Messonnier, NE; Reingold, A; Sawyer, M; Clark, TA. (2018). Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 67: 1-44.
Liang, L; Pan, Y; Bin, L; Liu, Y; Huang, W; Li, R; Lai, KP. (2021). Immunotoxicity mechanisms of perfluorinated compounds PFOA and PFOS [Review]. Chemosphere 291: 132892.
Liang, X; Xie, G; Wu, X; Su, M; Yang, B. (2019). Effect of prenatal PFOS exposure on liver cell


Lin, CY; Lin, LY; Wen, TW; Lien, GW; Chien, KL; Hsu, SH; Liao, CC; Sung, FC; Chen, PC; Su, TC. (2013). Association between levels of serum perfluorooctane sulfate and carotid artery intima-media thickness in adolescents and young adults. Int J Cardiol 168: 3309-3316. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2850967

Lin, CY; Wen, LL; Lin, LY; Wen, TW; Lien, GW; Hsu, SH; Chien, KL; Liao, CC; Sung, FC; Chen, PC; Su, TC. (2013). The associations between serum perfluorinated chemicals and thyroid function in adolescents and young adults. J Hazard Mater 244-245: 637-644. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/1332458

Lin, HW; Feng, HX; Chen, L; Yuan, XJ; Tan, Z. (2020). Maternal exposure to environmental endocrine


Lin, TW; Chen, MK; Lin, CC; Chen, MH; Tsai, MS; Chan, DC; Hung, KY; Chen, PC. (2020). Association between exposure to perfluoroalkyl substances and metabolic syndrome and related outcomes among older residents living near a Science Park in Taiwan. Int J Hyg Environ Health 230: 113607. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6988476


Liu, G; Zhang, B; Hu, Y; Rood, J; Liang, L; Qi, L; Bray, GA; Dejonge, L; Coull, B; Grandjean, P; Furtado, JD; Sun, Q. (2020). Associations of Perfluoroalkyl substances with blood lipids and Apolipoproteins in lipoprotein subspecies: the POUNDS-lost study. Environ Health 19: 5. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6318644

Liu, H; Pan, Y; Jin, S; Li, Y; Zhao, L; Sun, X; Cui, Q; Zhang, B; Zheng, T; Xia, W; Zhou, A; Campana, AM; Dai, J; Xu, S. (2020). Associations of per-/polyfluoroalkyl substances with glucocorticoids and progestogens in newborns. Environ Int 140: 105636. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6569227


Liu, J; Liu, S; Huang, Z; Fu, Y; Fei, J; Liu, X; He, Z. (2020). Associations between the serum levels of PFOS/PFOA and IgG N-glycosylation in adult or children. Environ Pollut 265: 114285. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6833599


Liu, W; Xu, C; Sun, X; i; Kuang, H; Kuang, X; Zou, W; Yang, B, ei; Wu, L, ei; Liu, F; Zou, T; Zhang, D. (2016). Grape seed proanthocyanidin extract protects against perfluorooctanoic acid-induced hepatotoxicity by attenuating inflammatory response, oxidative stress and apoptosis in mice. Toxicology Research 5: 224-234. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3981762


Lopez-Espinosa, MJ; Mondal, D; Armstrong, BG; Eskenazi, B; Fletcher, T. (2016). Perfluoroalkyl Substances, Sex Hormones, and Insulin-like Growth Factor-1 at 6-9 Years of Age: A Cross-


Louis, GMB; Peterson, CM; Chen, Z; Hediger, ML.; Croughan, MS; Sundaram, R; Stanford, JB; Fujimoto, VY; Varner, MW; Giudice, LC; Kennedy, A; Sun, L; Wu, Q; Kannan, K. (2012). Perfluorochemicals and endometriosis: The ENDO study. Epidemiology 23: 799-805. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/1597490

Louisse, J; Rijkers, D; Stoopen, G; Janssen, A; Staats, M; Hoogenboom, R; Kersten, S; Peijnenburg, A. (2020). Perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), and perfluorononanoic acid (PFNA) increase triglyceride levels and decrease cholesterogenic gene expression in human HepaRG liver cells. Arch Toxicol 94: 3137-3155. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6833626


Luster, MI; Johnson, VJ; Yucsesoy, B; Simeonova, PP. (2005). Biomarkers to assess potential


Lyngsø, J; Ramlau-Hansen, CH; Høyer, BB; Støvring, H; Bonde, JP; Jönsson, BA; Lindh, CH; Pedersen, HS; Ludwicki, JK; Zviezdai, V; Toft, G. (2014). Menstrual cycle characteristics in fertile women from Greenland, Poland and Ukraine exposed to perfluorinated chemicals: a cross-sectional study. Hum Reprod 29: 359-367. 

Ma, S; Xu, C; Ma, J; Wang, Z; Zhang, Y; Shu, Y; Mo, X. (2019). Association between perfluoroalkyl substance concentrations and blood pressure in adolescents. Environ Pollut 254: 112971. 

Ma, Z; Liu, X; Li, F; Wang, Y; Xu, Y; Zhang, M; Zhang, X; Ying, X; Zhang, X. (2016). Perfluorooctanoic acid induces human Ishikawa endometrial cancer cell migration and invasion through activation of ERK/mTOR signaling. Oncot 7: 66558-66568. 


Macon, MB; Villanueva, LR; Tatum-Gibbs, K; Zehr, RD; Strynar, MJ; Stanko, JP; White, SS; Helfant, L; Fenton, SE. (2011). Prenatal perfluorooctanoic acid exposure in CD-1 mice: low-dose developmental effects and internal dosimetry. Toxicol Sci 122: 134-145. 

Maekawa, R; Ito, R; Iwasaki, Y; Saito, K; Akutsu, K; Takatori, S; Ishii, R; Kondo, F; Arai, Y; Ohgane, J; Shiota, K; Makino, T; Sugino, N. (2017). Evidence of exposure to chemicals and heavy metals during pregnancy in Japanese women. Reproductive Medicine and Biology 16: 337-348. 


Maher, JM; Aleksunes, LM; Dieter, MZ; Tanaka, Y; Peters, JM; Manautou, JE; Klaassen, CD. (2008). Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 106: 319-328. 

Maisonet, M; Calafat, AM; Marcus, M; Jaakkola, JI; Lashen, H. (2015). Prenatal exposure to perfluoroalkyl acids and serum testosterone concentrations at 15 years of age in female ALSPAC study participants. Environ Health Perspect 123: 1325-1330.


Mamsen, LS; Björvang, RD; Mucs, D; Vinnars, MT; Papadogiannakis, N; Lindh, CH; Andersen, CY; Damdimopoulou, P. (2019). Concentrations of perfluoroalkyl substances (PFASs) in human embryonic and fetal organs from first, second, and third trimester pregnancies. Environ Int 124: 482-492. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5080595


Mancini, FR; Rajaobelina, K; Praud, D; Dow, C; Antignac, JP; Kvaskoff, M; Severi, G; Bonnet, F; Boutron-Ruault, MC; Fagherazzi, G. (2018). Nonlinear associations between dietary exposures to perfluorooctanoic acid (PFOA) or perfluorooctane sulfonate (PFOS) and type 2 diabetes risk in women: Findings from the E3N cohort study. Int J Hyg Environ Health 221: 1054-1060. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5079710


Manzano-Salgado, CB; Casas, M; Lopez-Espinos, MJ; Ballester, F; Iniguez, C; Martinez, D; Romaguera, D; Fernández-Barrés, S; Santa-Marina, L; Basterretxea, M; Schettgen, T; Valvi, D; Vioque, J; Sunyer, J; Vrijheid, M. (2017). Prenatal exposure to perfluoroalkyl substances and cardiometabolic risk in children from the Spanish INMA birth cohort study. Environ Health Perspect 125: 097018. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/4238509


Martin, MT; Brennan, RJ; Hu, W; Ayanoglu, E; Lau, C; Ren, H; Wood, CR; Corton, JC; Kavlock, RJ;


Matkowskyj, KA; Bai, H; Liao, J; Zhang, W; Li, H; Rao, S; Omary, R; Yang, GY. (2014). Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. Hum Pathol 45: 834-843. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3859607


McComb, J; Mills, IG; Berntsen, HF; Ropstad, E; Verhaegen, S; Connolly, L. (2019). Human-based exposure levels of perfluoroalkyl acids may induce harmful effects to health by disrupting major components of androgen receptor signalling in vitro. Exposure and Health 12: 527-538. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3858475

Mccoy, JA; Bangma, JT; Reiner, JL; Bowden, JA; Schnorr, J; Slowey, M; O'Leary, T; Guillette, LJ; Parrott, BB. (2017). Associations between perfluorinated alkyl acids in blood and ovarian follicular fluid and ovarian function in women undergoing assisted reproductive treatment. Sci Total Environ 605-606: 9-17. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/9418094

Mcdonough, CA; Li, W; Bischel, HN; De Silva, AO; Dewitt, JC. (2022). Widening the Lens on PFASs: Direct Human Exposure to Perfluoroalkyl Acid Precursors (pre-PFAs). Environ Sci Technol 56: 6004-6013. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/10412593


Melnikov, F; Botta, D; White, CC; Schmuck, SC; Winfough, M; Schaupp, CM; Gallagher, E; Brooks, BW; Williams, ES; Coish, P; Anastas, PT; Vountchkoval, A; Kostal, J; Kavanaugh, TJ. (2018). Kinetics of Glutathione Depletion and Antioxidant Gene Expression as Indicators of Chemical
Mi, X; Yang, YQ; Zeeshan, M; Wang, ZB; Zeng, XY; Zhou, Y; Yang, BY; Hu, LW; Yu, HY; Zeng, XW; Liu, RQ; Dong, GH. (2020). Serum levels of per- and polyfluoroalkyl substances alternatives and blood pressure by sex status: Isomers of C8 health project in China. Chemosphere 261: 127691.
Miao, C; Ma, J; Zhang, Y; Chu, Y; Li, J; Kuai, R; Wang, S; Peng, H. (2020). Serum levels of per- and polyfluoroalkyl substances alternatives and blood pressure by sex status: Isomers of C8 health project in China. Chemosphere 261: 127691.
Midic, U; Goheen, B; Vincent, KA; Vandervoort, CA; Latham, KE. (2018). Changes in gene expression following long-term in vitro exposure of macaca mulatta trophoblast stem cells to biologically relevant levels of endocrine disruptors. Reprod Toxicol 77: 154-165.
Mitro, SD; Sagiv, SK; Fleisch, AF; Jaacks, LM; Williams, PL; Rifas-Shiman, SL; Calafat, AM; Hivert, MF; Oken, E; James-Todd, TM. (2020). Pregnancy per- and polyfluoroalkyl substance concentrations and postpartum health in project viva: A prospective cohort. J Clin Endocrinol Metab 105: e3415–e3426.
Mobacke, I; Lind, L; Dunder, L; Salihovic, S; Lind, PM. (2018). Circulating levels of perfluoroalkyl substances and left ventricular geometry of the heart in the elderly. Environ Int 115: 295-300.
Mogensen, UB; Grandjean, P; Nielsen, F; Weihe, P; Budtz-Jørgensen, E. (2015). Breastfeeding as an


Mora, AM; Fleisch, AF; Rifas-Shiman, SL; Woo Baidal, JA; Pardo, L; Webster, TF; Calafat, AM; Ye, X; Oken, E; Sagiv, SK. (2018). Early life exposure to per- and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. Environ Int 111: 1-13. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/4239224

Mora, AM; Oken, E; Rifas-Shiman, SL; Webster, TF; Gillman, MW; Calafat, AM; Ye, X; Sagiv, SK. (2017). Prenatal exposure to perfluoroalkyl substances and adiposity in early and mid-childhood. Environ Health Perspect 125: 467-473. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3859823


New Hampshire DES. (2019). Technical background report for the June 2019 proposed maximum contaminant levels (MCLs) and ambient groundwater quality standards (AGQSs) for perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorohexane sulfonic acid (PFHxS). https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5949029

Nguea, G; Longnecker, MP; Yoon, M; Ruark, CD; Clewell, HJ; Andersen, ME; Verner, MA. (2017). Quantitative bias analysis of a reported association between perfluoroalkyl substances (PFAS) and endometriosis: The influence of oral contraceptive use. Environ Int 104: 118-121. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3860773

Nguyen, TMH; Bräunig, J; Thompson, K; Thompson, J; Kabiri, S; Navarro, DA; Kookana, RS; Grimison, C; Barnes, CM; Higgins, CP; Mclaughlin, MJ; Mueller, JF. (2020). Influences of

Nian, M; Li, QQ; Bloom, M; Qian, ZM; Syberg, KM; Vaughn, MG; Wang, SQ; Wei, Q; Zeeshan, M; Gurram, N; Chu, C; Wang, J; Tian, YP; Hu, LW; Liu, KK; Yang, BY; Liu, RQ; Feng, D; Zeng, XW; Dong, GH. (2019). Liver function biomarkers disorder is associated with exposure to perfluoroalkyl acids in adults: Isomers of C8 Health Project in China. Environ Res 172: 81-88.

Nielsen, C; Andersson Hall, U; Lindh, C; Ekström, U; Xu, Y; Li, Y; Holmäng, A; Jakobsson, K. (2020). Pregnancy-induced changes in serum concentrations of perfluoroalkyl substances and the influence of kidney function. Environ Health 19: 80.

Niu, J; Liang, H; Tian, Y; Yuan, W; Xiao, H; Hu, H; Sun, X; Song, X; Wen, S; Yang, L; Ren, Y; Miao, M. (2019). Prenatal plasma concentrations of Perfluoroalkyl and polyfluoroalkyl substances and neuropsychological development in children at four years of age. Environ Health 18: 53.


NTP. (2019). NTP technical report on the toxicity studies of perfluorooalkyl carboxylates (perfluoroundecanoic acid, perfluorooctanoic acid, perfluororobutanoic acid, and perfluorodecanoic acid) administrated by gavage to Sprague Dawley (Hsd:Sprague Dawley SD) rats [NTP]. (Toxicity Report 97). Research Triangle Park, NC.

NTP. (2019). NTP technical report on the toxicity studies of perfluorooalkyl sulfonates (perfluorobutane sulfonic acid, perfluorohexane sulfonate potassium salt, and perfluoroctane sulfonic acid) administrated by gavage to Sprague Dawley (Hsd:Sprague Dawley SD) rats. (Toxicity Report 96). Research Triangle Park, NC.


Olsen, GW; Ehresman, DJ; Buehrer, BD; Gibson, BA; Butenhoff, JL; Zobel, LR. (2012). Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities. J Occup Environ Med 54: 974-983.


Olsen, GW; Zobel, LR. (2007). Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health 81: 231-246.


Onishchenko, N; Fischer, C; Wan Ibrahim, WN; Negri, S; Spulber, S; Cottica, D; Ceccatelli, S. (2011). Prenatal exposure to PFOS or PFOA alters motor function in mice in a sex-related manner. Neurotox Res 19: 452-461.


Oshida, K; Vasani, N; Jones, C; Moore, T; Hester, S; Nesnow, S; Auerbach, S; Geter, DR; Aleksunes, LM; Thomas, RS; Applegate, D; Klaassen, CD; Corton, JC. (2015). Identification of chemical modulators of the constitutive activated receptor (CAR) in a gene expression compendium. Nuclear Receptor Signaling 13: e002. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2850125


Osorio-Yáñez, C; Sanchez-Guerra, M; Cardenas, A; Lin, PID; Hauser, R; Gold, DR; Kleinman, KP; Hivert, MF; Fleisch, AF; Calafat, AM; Webster, TF; Horton, ES; Oken, E. (2021). Per- and polyfluoroalkyl substances and calcifications of the coronary and aortic arteries in adults with prediabetes: Results from the diabetes prevention program outcomes study. Environ Int 151: 106446. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/7542684


Pan, Y; Zhu, Y; Zheng, T; Cui, Q; Buka, SL; Zhang, B; Guo, Y; Xia, W; Yeung, LW; Li, Y; Zhou, A; Qiu, L; Liu, H; Jiang, M; Wu, C; Xu, S; Dai, J. (2017). Novel Chlorinated Polyfluorinated Ether Sulfonates and Legacy Per-/Polyfluoroalkyl Substances: Placental Transfer and Relationship with Serum Albumin and Glomerular Filtration Rate. Environ Sci Technol 51: 634-644. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3981900


Papadopoulou, E; Stratakis, N; Basagaña, X; Brantsaeter, AL; Casas, M; Fossati, S; Gražulevičienė, R; Småstuen Haug, L; Heude, B; Maître, L; Mceachan, RRC; Robinson, O; Roumeliotaki, T; Sabidó, E; Borràs, E; Urquiza, J; Vafeiadi, M; Zhao, Y; Slama, R; Wright, J; Conti, DV; Vrijheid, M; Chatzi, L. (2021). Prenatal and postnatal exposure to PFAS and cardiometabolic factors and inflammation status in children from six European cohorts. Environ Int 157: 106853. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/9960593


Pecquet, AM; Maier, A; Kasper, S; Sumanas, S; Yadav, J. (2020). Exposure to perfluorooctanoic acid...


Pinney, SM; Windham, GC; Xie, C; Herrick, RL; Calafat, AM; Mcwhorter, K; Fassler, CS; Hiatt, RA; Kushi, LH; Biro, FM. (2019). Perfluorooctanoate and changes in anthropometric parameters with


Pirali, B; Negri, S; Chytiris, S; Perissi, A; Villani, L; La Manna, L; Cottica, D; Ferrari, M; Imbriani, M; Rotondi, M; Chiovato, L. (2009). Perfluorooctane sulfonate and perfluorooctanoic acid in surgical thyroid specimens of patients with thyroid diseases. Thyroid 19: 1407-1412.


Pitter, G; Zare Jedd, M; Barbieri, G; Gion, M; Fabricio, ASC; Daprà, F; Russo, F; Fletcher, T; Canova, C. (2020). Perfluoroalkyl substances are associated with elevated blood pressure and hypertension in highly exposed young adults. Environ Health 19: 102.


Podder, A, ; Sadmani, A, ; Reinhart, D, ; Chang, N, ; Goel, R, ; (2021). Per and poly-fluoroalkyl substances (PFAS) as a contaminant of emerging concern in surface water: A transboundary review of their occurrences and toxicity effects. J Hazard Mater 419: 126361.


Pouwer, MG; Pieterman, EJ; Chang, SC; Olsen, GW; Caspers, MPM; Verschuren, L; Jukema, JW; Princen, HMG. (2019). Dose effects of ammonium perfluorooctanoate on lipoprotein metabolism in apoe*3-LEIDEN.CETP mice. Toxicol Sci 168: 519-534.


Preston, EV; Rifas-Shiman, SL; Hivert, MF; Zota, AR; Sagiv, SK; Calafat, AM; Oken, E; James-Todd, T. (2020). Associations of per- and polyfluoroalkyl substances (PFAS) with glucose tolerance during pregnancy in project viva. J Clin Endocrinol Metab 105: E2864-E2876.

Preston, EV; Webster, TF; Oken, E; Claus Henn, B; Mcclean, MD; Rifas-Shiman, SL; Pearce, EN; Braverman, LE; Calafat, AM; Ye, X; Sagiv, SK. (2018). Maternal plasma per- and polyfluoroalkyl substance concentrations in early pregnancy and maternal and neonatal thyroid function in a prospective birth cohort: Project Viva (USA). Environ Health Perspect 126: 027013.


Quazi, MR; Abedi, MR; Nelson, BD; Depierre, JW; Abedi-Valugerdi, M. (2010). Dietary exposure to perfluorooctanoate or perfluorooctane sulfonate induces hypertrophy in centrilobular hepatocytes and alters the hepatic immune status in mice. Int Immunopharmacol 10: 1420-1427.

Quazi, MR; Bogdanska, J; Butenhoff, JL; Nelson, BD; Depierre, JW; Abedi-Valugerdi, M. (2009). High-dose, short-term exposure of mice to perfluorooctanesulfonate (PFOS) or perfluorooctanoate (PFOA) affects the number of circulating neutrophils differently, but enhances the inflammatory responses of macrophages to lipopolysaccharide (LPS) in a similar fashion. Toxicology 262: 207-214.

Qazi, MR; Nelson, BD; Depierre, JW; Abedi-Valugerdi, M. (2012). High-dose dietary exposure of mice to perfluorooctanoate or perfluorooctane sulfonate exerts toxic effects on myeloid and B-lymphoid cells in the bone marrow and these effects are partially dependent on reduced food consumption. Food Chem Toxicol 50: 2955-2963.


Qin, XD; Qian, Z; Vaughn, MG; Huang, J; Ward, P; Zeng, XW; Zhou, Y; Zhu, Y; Yuan, P; Li, M; Bai, Z; Paul, G; Hao, YT; Chen, W; Chen, PC; Dong, GH; Lee, YL. (2016). Positive associations of serum perfluoroalkyl substances with uric acid and hyperuricemia in children from Taiwan. Environ Pollut 212: 519-524.

Qu, A; Cao, T; Li, Z; Wang, W; Liu, R; Wang, X; Nie, Y; Sun, S; Liu, X; Zhang, X. (2021). The association between maternal perfluoroalkyl substances exposure and early attention deficit hyperactivity disorder in children: a systematic review and meta-analysis. Environ Sci Pollut Res Int 28: 67066-67081.
Raleigh, KK; Alexander, BH; Olsen, GW; Ramachandran, G; Morey, SZ; Church, TR; Logan, PW; Scott, LL; Allen, EM. (2014). Mortality and cancer incidence in ammonium perfluorooctanoate production workers. Occup Environ Med 71: 500-506.
Rantakokko, P; Männistö, V; Airaksinen, R; Koponen, J; Viluksela, M; Kiviranta, H; Pihlajamäki, J. (2015). Persistent organic pollutants and non-alcoholic fatty liver disease in morbidly obese patients: A cohort study. Environ Health 14: 79.
Rashid, F; Ahmad, S; Irudayaraj, JMK. (2020). Effect of Perfluorooctanoic Acid on the Epigenetic and Tight Junction Genes of the Mouse Intestine. Toxics 8: 64.
Reardon, AJF; Khodayari Moez, E; Dinu, I; Goruk, S; Field, CJ; Kinniburgh, DW; Macdonald, AM; Martin, JW; Study, A. (2019). Longitudinal analysis reveals early-pregnancy associations between perfluoroalkyl sulfonates and thyroid hormone status in a Canadian prospective birth cohort. Environ Int 129: 389-399.
Rebholz, SL; Jones, T; Herrick, RL; Xie, C; Calafat, AM; Pinney, SM; Woollett, LA. (2016). Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice. Toxicol Rep 3: 46-54.
Rigden, M; Pelletier, G; Poon, R; Zhu, J; Auray-Blais, C; Gagnon, R; Kubwabo, C; Kosarac, I; Lalonde,


Rose, K; Wolf, KK; Ukaiiro, O; Moore, A; Gaffney, J; Bradford, BU; Wetmore, BA; Andersen, ME; LeCluyse, EL. (2016). Nuclear Receptor-Mediated Gene Expression Changes in a Human Hepatic Micropatterned Coculture Model After Treatment with Hepatotoxic Compounds. Applied In Vitro Toxicology 2: 8-16. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/9959775


Ruark, CD; Song, G; Yoon, M; Verner, MA; Andersen, ME; Clewell, HJ; Longnecker, MP. (2017).


Salihovic, S; Stubleski, J; Kärrman, A; Larsson, A; Fall, T; Lind, L; Lind, PM. (2018). Changes in markers of liver function in relation to changes in perfluoroalkyl substances - A longitudinal study. Environ Int 117: 196-203.
dysfunction in brain, liver, and heart of mouse fetus: An explanation for perfluorooctanoic acid induced abortion and developmental toxicity. Environ Toxicol 34: 878-885.


Sanchez Garcia, D; Sjödin, M; Hellstrandh, M; Norinder, U; Nikiforova, V; Lindberg, J; Wincent, E; Bergman, Å; Cotgreave, I; Munic Kos, V. (2018). Cellular accumulation and lipid binding of perfluorinated alkylated substances (PFASs) - A comparison with lysosomotropic drugs. Chem Biol Interact 281: 1-10.

Savitz, DA; Stein, CR; Bartell, SM; Elston, B; Gong, J; Shin, HM; Wellenius, GA. (2012). Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community. Epidemiology 23: 386-392.

Savitz, DA; Stein, CR; Elston, B; Wellenius, GA; Bartell, SM; Shin, HM; Viera, VM; Fletcher, T. (2012). Relationship of perfluorooctanoic Acid exposure to pregnancy outcome based on birth records in the mid-ohio valley. Environ Health Perspect 120: 1201-1207.


Schecter, A; Colacino, J; Haffner, D; Patel, K; Opel, M; Päpke, O; Birnbaum, L. (2010). Perfluorinated compounds, polychlorinated biphenyls, and organochlorine pesticide contamination in composite food samples from Dallas, Texas, USA. Environ Health Perspect 118: 796-802.


Schumann, G; Bonora, R; Cериotti, F; Férad, G; Ferrero, CA; Franck, PFH; Gella, FJ; Hoelzel, W; Jørgensen, PJ; Kanno, T; Kessner, A; Klauke, R; Kristiansen, N; Lessinger, JM; Linsinger, TPJ; Misaki, H; Panteghini, M; Pauwels, J; Schiele, F; Schimmel, HG. (2002). IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at


Seo, SH; Son, MH; Choi, SD; Lee, DH; Chang, YS. (2018). Influence of exposure to perfluoroalkyl substances (PFASs) on the Korean general population: 10-year trend and health effects. Environ Int 113: 149-161. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/4238334


Shao, X; Ji, F; Wang, Y; Zhu, L; Zhang, Z; Du, X; Chung, ACK; Hong, Y; Zhao, Q; Cai, Z. (2018). Integrative Chemical Proteomics-Metabolomics Approach Reveals Acaca/Acacb as Direct Molecular Targets of PFOA. Anal Chem 90: 11092-11098.


Shapiro, GD; Dodds, L; Arbuckle, TE; Ashley-Martin, J; Ettinger, AS; Fisher, M; Taback, S; Bouchard, MF; Monnier, P; Dallaire, R; Morisset, AS; Fraser, W. (2016). Exposure to organophosphorus and organochlorine pesticides, perfluoroalkyl substances, and polychlorinated biphenyls in pregnancy and the association with impaired glucose tolerance and gestational diabetes mellitus: The MIREC Study. Environ Res 147: 71-81.


Shearer, JJ; Callahan, CL; Calafat, AM; Huang, WY; Jones, RR; Sаббисетти, VS; Freedman, ND; Sampson, JN; Silverman, DT; Purdue, MP; Hofmann, JN. (2021). Serum concentrations of per- and polfluoroalkyl substances and risk of renal cell carcinoma. J Natl Cancer Inst 113: 580-587.


Shen, M; Xiao, Y; Huang, Y; Jing, D; Su, J; Luo, D; Duan, Y; Xiao, S; Li, J; Chen, X. (2022).
Perfluoroalkyl substances are linked to incident chronic spontaneous urticaria: A nested case-control study. Chemosphere 287: 132358.


Sheng, N; Cui, R; Wang, J; Guo, Y; Wang, J; Dai, J. (2018). Cytotoxicity of novel fluorinated alternatives to long-chain perfluoroalkyl substances to human liver cell line and their binding capacity to human liver fatty acid binding protein. Arch Toxicol 92: 359-369.


Shin, HM; Vieira, VM; Ryan, PB; Steenland, K; Bartell, SM. (2011). Retrospective exposure estimation and predicted versus observed serum perfluorooctanoic acid concentrations for participants in the C8 Health Project. Environ Health Perspect 119: 1760-1765.


Shrestha, S; Bloom, MS; Yucel, R; Seegal, RF; Rej, R; Mccaffrey, RJ; Wu, Q; Kannan, K; Fitzgerald, EF. (2017). Perfluoroalkyl substances, thyroid hormones, and neuropsychological status in older adults. Int J Hyg Environ Health 220: 679-685.


Shrestha, S; Bloom, MS; Yucel, R; Seegal, RF; Wu, Q; Kannan, K; Rej, R; Fitzgerald, EF. (2015). Perfluoroalkyl substances and thyroid function in older adults. Environ Int 75: 206-214.


Singer, AB; Whitworth, KW; Haug, LS; Sabaredzovic, A; Impinen, A; Papadopoulou, E; Longnecker, MP. (2018). Menstrual cycle characteristics as determinants of plasma concentrations of perfluoroalkyl substances (PFASs) in the Norwegian Mother and Child Cohort (MoBa study). Environ Res 166: 78-85.


Sinisalu, L; Sen, P; Salihović, S; Virtanen, SM; Hyöty, H; Ikonen, J; Toppari, J; Veijola, R; Orešič, M; Knip, M; Hyötyläinen, T. (2020). Early-life exposure to perfluorinated alkyl substances
modulates lipid metabolism in progression to celiac disease. Environ Res 188: 109864.

Sinisalu, L; Yeung, LWY; Wang, J; Pan, Y; Dai, J; Hyötyläinen, T. (2021). Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood.
Metabolomics 17: 103.


Skuladottir, M; Ramel, A; Ryttner, D; Haug, LS; Sabaredzovic, A; Bech, BH; Henrikson, TB; Olsen, SF; Hallgdorsson, TI. (2015). Examining confounding by diet in the association between perfluoroalkyl acids and serum cholesterol in pregnancy. Environ Res 143: 33-38.

Smit, LA; Lenters, V; Høyer, BB; Lindh, CH; Pedersen, HS; Liermontova, I; Jönsson, BA; Piersma, AH; Bonde, JP; Toft, G; Vermeulen, R; Heediker, D. (2015). Prenatal exposure to environmental chemical contaminants and asthma in school-age children. Allergy 70: 653-660.


Smith, MT; Guyton, KZ; Gibbons, CF; Fritz, JM; Portier, CJ; Rusyn, I; DeMarini, DM; Caldwell, JC; Kaylock, RJ; Lambert, PF; Hecht, SS; Bucher, JR; Stewart, BW; Baan, RA; Cogliano, VJ; Straif, K. (2016). Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis [Review]. Environ Health Perspect 124: 713-721.

Smith, MT; Guyton, KZ; Kleinreuter, N; Borrel, A; Cardenas, A; Chiu, WA; Felscher, DW; Gibbons, CF; Goodson, WH; Houck, KA; Kane, AB; La Merrill, MA; Lebrec, H; Lowe, L; Mchale, CM; Minocherhomji, S; Rieswijk, L; Sandy, MS; Sone, H; Wang, A; Zhang, L; Zeise, L; Fiedler, M. (2020). The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them [Editorial]. Cancer Epidemiol Biomarkers Prev. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6956443

Smith, PJ; Humiston, SG; Marcuse, EK; Zhao, Z; Dorell, CG; Howes, C; Hibbs, B. (2011). Parental delay or refusal of vaccine doses, childhood vaccination coverage at 24 months of age, and the Health Belief Model. 126: 135-146.


Sobolewski, M; Conrad, K; Allen, JL; Weston, H; Martin, K; Lawrence, BP; Cory-Slechta, DA. (2014). Sex-specific enhanced behavioral toxicity induced by maternal exposure to a mixture of low dose endocrine-disrupting chemicals. Neurotoxicology 45: 121-130.

Son, HY; Kim, SH; Shin, HI; Bae, HI; Yang, JH. (2008). Perfluorooctanoic acid-induced hepatic toxicity following 21-day oral exposure in mice. Arch Toxicol 82: 239-246.

Son, HY; Lee, S; Tak, EN; Cho, HS; Shin, HI; Kim, SH; Yang, JH. (2009). Perfluorooctanoic acid alters T lymphocyte phenotypes and cytokine expression in mice. Environ Toxicol 24: 580-588.


Starling, AP; Engel, SM; Richardson, DB; Baird, DD; Haug, LS; Stuebe, AM; Klungsoyr, K; Harmon, Q; Becher, G; Thomsen, C; Sabaredzovic, A; Eggesbo, M; Hoppin, JA; Travlos, GS; Wilson, RE; Trogstad, LI; Magnus, P, er; Longnecker, MP. (2014). Perfluoroalkyl Substances During Pregnancy and Validated Preeclampsia Among Nulliparous Women in the Norwegian Mother and Child Cohort Study. Am J Epidemiol 179: 824-833. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2446669

Starling, AP; Engel, SM; Whitworth, KW; Richardson, DB; Stuebe, AM; Daniels, JL; Haug, LS; Eggesbø, M; Becher, G; Sabaredzovic, A; Thomsen, C; Wilson, RE; Travlos, GS; Hoppin, JA; Baird, DD; Longnecker, MP. (2014). Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study. Environ Int 62: 104-112. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2850928


Stratakis, N; Rock, S; La Merrill, MA; Saez, M; Robinson, O; Fecht, D; Vrijheid, M; Valvi, D; Conti, DV; McConnell, R; Chatzi, VL. (2022). Prenatal exposure to persistent organic pollutants and childhood obesity: A systematic review and meta-analysis of human studies. Obes Rev 23(S1): e13383. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/10176437


Thayer, KA; Angrish, M; Arzuaga, X; Carlson, LM; Davis, A; Dishaw, L; Druwe, I; Gibbons, C; Glenn, B; Jones, R; Kaiser, JP; Keshava, C; Keshava, N; Kraft, A; Lizarroga, L; Persad, A; Radke, EG; Rice, G; Schulz, B; Shaffer, R; T, S; Shapiro, A; Thacker, S; Vulimiri, S; Williams, AJ; Woodall, G; Yost, E; Blain, R; Duke, K; Goldstone, AE; Hartman, P; Hobbie, K; Ingle, B; Lemeris, C; Lin, C; Lindahl, A; McKinley, K; Soleymani, P; Vetter, N. (2022). Systematic evidence map (SEM) template: report format and methods used for the US EPA integrated risk information system (iris) program, provisional peer reviewed toxicity value (PPRTV) program, and other “fit for purpose” literature-based human health analyses (manuscript-in-progress) (pp. 1-69). Thayer,


Tian, YP; Zeng, XW; Bloom, MS; Lin, S; Wang, SQ; Yim, SHL; Yang, M; Chu, C; Gurram, N; Hu, LW; Liu, KK; Yang, BY; Feng, D; Liu, RQ; Nian, M; Dong, GH. (2019). Isomers of perfluoroalkyl substances and overweight status among Chinese by sex status: Isomers of C8 Health Project in China. Environ Int 124: 130-138. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5080586


Tsai, MS; Chang, SH; Kuo, WH; Kuo, CH; Li, SY; Wang, MY; Chang, DY; Lu, YS; Huang, CS; Cheng, AL; Lin, CH; Chen, PC. (2020). A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women. Environ Int 142: 105850. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6833693
Tsai, MS; Lin, CY; Lin, CC; Chen, MH; Hsu, SH; Chien, KL; Sung, FC; Chen, PC; Su, TC. (2015). Association between perfluoroalkyl substances and reproductive hormones in adolescents and young adults. Int J Hyg Environ Health 218: 437-443. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2850160


Vagi, SJ; Azziz-Baumgartner, E; Sjödin, A; Calafat, AM; Dumesic, D; Gonzalez, L; Kato, K; Silva, MJ; Ye, X; Azziz, R. (2014). Exploring the potential association between brominated diphenyl ethers, polychlorinated biphenyls, organochlorine pesticides, perfluorinated compounds, phthalates, and bisphenol a in polycystic ovary syndrome: a case-control study. BMC Endocrine Disorders 14:
Valenti, L; Pelusi, S; Bianco, C; Ceriotti, F; Berzuini, A; Iogna Prat, L; Trottì, R; Malvestiti, F; D’Ambrosio, R; Lampertico, P; Colli, A; Colombo, M; Tsochatzis, E; Fraquelli, M; Prati, D. (2021). Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatology Communications 5: 1824-1832.


van der Veen, I; Hanning, AC; Stare, A; Leonards, PEG; de Boer, J; Weiss, JM. (2020). The effect of weathering on per- and polyfluoroalkyl substances (PFASs) from durable water repellent (DWR) clothing. Chemosphere 249: 126100.

Varshavsky, JR; Robinson, JF; Zhou, Y; Puckett, KA; Kwan, E; Buarpung, S; Aburajab, R; Gaw, SL; Sen, S; Gao, S; Smith, SC; Park, JS; Zakharievich, I; Gerona, RR; Fisher, SJ; Woodruff, TJ. (2021). Organophosphate Flame Retardants, Highly Fluorinated Chemicals, and Biomarkers of Placental Development and Disease during Mid-Gestation. Toxicol Sci 181: 215-228.


Verner, MA; Loccisano, AE; Morken, NH; Yoon, M; Wu, H; Mcdougall, R; Maisonet, M; Marcus, M; Kishi, R; Miyashita, C; Chen, MH; Hsieh, WS; Andersen, ME; Clewell, HJ; Longnecker, MP. (2015). Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK). Environ Health Perspect 123: 1317-1324.


Vested, A; Ramlau-Hansen, CH; Olsen, SF; Bonde, JP; Kristensen, SL; Halldorsson, TF; Becher, G; Haug, LS; Ernst, EH; Toft, G. (2013). Associations of in utero exposure to perfluorinated alkyl acids with human semen quality and reproductive hormones in adult men. Environ Health Perspect 121: 453-458, 458e451-455.
precursor compounds in consumer exposure to PFOS and PFOA. Chemosphere 73: 1617-1624.


Vieira, VM; Hoffman, K; Shin, HM; Weinberg, JM; Webster, TF; Fletcher, T. (2013). Perfluorooctanoic acid exposure and cancer outcomes in a contaminated community: a geographic analysis. Environ Health Perspect 121: 318-323.


Vuong, A; Yolton, K; Webster, GM; Sjodin, A; Calafat, AM; Braun, JM; Dietrich, K; Lanphear, BP; Chen, A. (2016). Prenatal polybrominated diphenyl ether and perfluoroalkyl substance exposures and executive function in school-age children. Environ Res 147: 556-564.

Vuong, AM; Braun, JM; Yolton, K; Wang, Z; Xie, C; Webster, GM; Ye, X; Calafat, AM; Dietrich, KN; Lanphear, BP; Chen, A. (2018). Prenatal and childhood exposure to perfluorooalkyl substances (PFAS) and measures of attention, impulse control, and visual spatial abilities. Environ Int 119: 413-420.

Vuong, AM; Xie, C; Jandarov, R; Dietrich, KN; Zhang, H; Sjödin, A; Calafat, AM; Lanphear, BP; Mccandless, L; Braun, JM; Yolton, K; Chen, A. (2020). Prenatal exposure to a mixture of persistent organic pollutants (POPs) and child reading skills at school age. Int J Hyg Environ Health 228: 113527.

Vuong, AM; Yolton, K; Braun, JM; Sjodin, A; Calafat, AM; Xu, Y; Dietrich, KN; Lanphear, BP; Chen, A. (2020). Polybrominated diphenyl ether (PBDE) and poly- and perfluoroalkyl substance (PFAS) exposures during pregnancy and maternal depression. Environ Int 139: 105694.

Wambaugh, JF; Setzer, RW; Pitruzzello, AM; Liu, J; Reif, DM; Kleinstreuer, NC; Wang, NC; Sipes, N; Martin, M; Das, K; Dewitt, JC; Strynar, M; Judson, R; Houck, KA; Lau, C. (2013). Dosimetric anchoring of in vivo and in vitro studies for perfluoroctanoate and perfluorooctanesulfonate. Toxicol Sci 136: 308-327.

Wan, C; Han, R; Liu, L; Zhang, F; Li, F; Xiang, M; Ding, W. (2016). Role of miR-155 in fluorooctane sulfonate-induced oxidative hepatic damage via the Nrf2-dependent pathway. Toxicol Appl Pharmacol 295: 85-93.


Wang, J; Zeng, XW; Bloom, MS; Qian, Z; Hinyard, LJ; Belue, R; Lin, S; Wang, SQ; Tian, YP; Yang, M; Chu, C; Gurram, N; Hu, LW; Liu, KK; Yang, BY; Feng, D; Liu, RQ; Dong, GH. (2019). Renal function and isomers of perfluoroctanoate (PFOA) and perfluorooctanesulfonate (PFOS): Isomers of C8 Health Project in China. Chemosphere 218: 1042-1049. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5080583


Wang, Y; Rogan, WJ; Chen, PC; Lien, GW; Chen, HY; Tseng, YC; Longnecker, MP; Wang, SL. (2014). Association between maternal serum perfluoroalkyl substances during pregnancy and maternal


Wang, Z; Shi, R; Ding, G; Yao, Q; Pan, C; Gao, Y; Tian, Y. (2022). Association between maternal serum concentration of perfluoroalkyl substances (PFASs) at delivery and acute infectious diseases in infancy. Chemosphere 289: 133235.

Wearembourg, C; Maitre, L, ea; Tamayo-Uria, I; Fossati, S; Roumeliotaki, T; Aasvang, GM; Andrusaityte, S; Casas, M; Cequier, E; Chatzi, L; Dedele, A; Gonzalez, J. R.; Grazuleviciene, R; Haug, LS; Hernandez-Ferrer, C; Heude, B; Karachaliou, M; Krog, NH; Mceachan, R; Nieuwenhuijsen, M; Petraviciene, I; Quentin, J; Robinson, O; Sakhi, AK; Slama, R; Thomsen, C; Vafeiadi, M; West, J; Wright, J; Vrijheid, M; Basagana, X. (2019). Early-life environmental exposures and blood pressure in children. J Am Coll Cardiol 74: 1317-1328. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5881345


Weisskopf, MG; Seals, RM; Webster, TF. (2018). Bias amplification in epidemiologic analysis of exposure to mixtures. Environ Health Perspect 126.


Woodcroft, MW; Ellis, DA; Rafferty, SP; Burns, DC; March, RE; Stock, NL; Trumpour, KS; Yee, J; Munro, K. (2010). Experimental characterization of the mechanism of perfluorocarboxylic acids' liver protein bioaccumulation: the key role of the neutral species. Environ Toxicol Chem 29: 1669-1677. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2919284

Workman, CE; Becker, AB; Azad, MB; Moraes, TJ; Mandhane, PJ; Turvey, SE; Subbarao, P; Brook, JR; Sears, MR; Wong, CS. (2019). Associations between concentrations of perfluoroalkyl substances in human plasma and maternal, infant, and home characteristics in Winnipeg, Canada. Environ Pollut 249: 758-766. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5387046


Wu, H; Yoon, M; Verner, MA; Xue, J; Luo, M, an; Andersen, ME; Longnecker, MP; Clewell, HJ, III. (2015). Can the observed association between serum perfluoroalkyl substances and delayed menarche be explained on the basis of puberty-related changes in physiology and pharmacokinetics? Environ Int 82: 61-68. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3223290


Wu, XM; Bennett, DH; Calafat, AM; Kato, K; Strynar, M; Andersen, E; Moran, RE; Tancredi, DJ; Tulve, NS; Hertz-Picciotto, I. (2014). Serum concentrations of perfluorinated compounds (PFC) among selected populations of children and Adults in California. Environ Res 136C: 264-273. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/2533322


Xu, H; Zhou, Q; Zhang, J; Chen, X; Zhao, H; Lu, H; Ma, B; Wang, Z; Wu, C; Ying, C; Xiong, Y; Zhou, Z; Li, X. (2020). Exposure to elevated per- and polyfluoroalkyl substances in early pregnancy is related to increased risk of gestational diabetes mellitus: A nested case-control study in Shanghai, China. Environ Int 143: 105952. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6833677


Xu, Y; Li, Y; Scott, K; Lindh, CH; Jakobsson, K; Fletcher, T; Ohlsson, B; Andersson, EM. (2020). Inflammatory bowel disease and biomarkers of gut inflammation and permeability in a community with high exposure to perfluoroalkyl substances through drinking water. Environ Res 181: 108923. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6315709


Yang, D; Han, J; Hall, DR; Sun, J; Fu, J; Kutarna, S; Houck, KA; Lalone, CA; Doering, JA; Ng, CA; Peng, H. (2020). Nontarget Screening of Per- and Polyfluoroalkyl Substances Binding to Human Liver Fatty Acid Binding Protein. Environ Sci Technol 54: 5676-5686. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6356370


Yao, Q; Shi, R; Wang, C; Han, W; Gao, Y; Zhang, Y; Zhou, Y; Ding, G; Tian, Y. (2019). Cord blood per- and polyfluoroalkyl substances, placental steroidogenic enzyme, and cord blood reproductive hormone. Environ Int 129: 573-582. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/5187556


Yu, S; Feng, WR; Liang, ZM; Zeng, XY; Bloom, MS; Hu, GC; Zhou, Y; Ou, YQ; Chu, C; Li, QQ; Yu, Y; Zeng, XW; Dong, GH. (2021). Perfluorooctane sulfonate alternatives and metabolic syndrome in adults: New evidence from the Isomers of C8 Health Project in China. Environ Pollut 283: 117078. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/8453076


Yusoff, AF; Mohd Sharani, ZZ; Kee, CC; Md Iderus, NH; Md Zamri, ASS; Nagalingam, T; Mohamad Bashabaidin, MS; Wan Ibadullah, WAH; Ghazali, SM; Yusof, AY; Ching, YM; Mohamed Nor, N; Kamarudin, B; Ahmad, N; Arip, M. (2021). Seroprevalence of diphtheria toxoid IgG antibodies in the Malaysian population. BMC Infect Dis 21: 581. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/9642157


Zeeshan, M; Yang, Y; Zhou, Y; Huang, W; Wang, Z; Zeng, XY; Liu, RQ; Yang, BY; Hu, LW; Zeng, XW; Sun, X; Yu, Y; Dong, GH. (2020). Incidence of ocular conditions associated with perfluoroalkyl substances exposure: Isomers of C8 Health Project in China. Environ Int 137: 105555. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6315698


Zeng, X; Chen, Q; Zhang, X; Li, H; Liu, Q; Li, C; Ma, M; Zhang, J; Zhang, W; Zhang, J; Huang, L. (2019). Association between prenatal exposure to perfluoroalkyl substances and asthma-related diseases in preschool children. Environ Sci Pollut Res Int 26: 29639-29648.
Zeng, XW; Bloom, MS; Dharmage, SC; Lodge, CJ; Chen, D; Li, S; Guo, Y; Roponen, M; Jalava, P; Hirvonen, MR; Ma, H; Hao, YT; Chen, W; Yang, M; Chu, C; Li, QQ; Hu, LW; Liu, KK; Yang, BY; Liu, S; Fu, C; Dong, GH. (2019). Prenatal exposure to perfluoroalkyl substances is associated with lower hand, foot and mouth disease viruses antibody response in infancy: Findings from the Guangzhou Birth Cohort Study. Sci Total Environ 663: 60-67. 


Zeng, XW; Li, QQ; Chu, C; Ye, WL; Yu, S; Ma, H; Zeng, XY; Zhou, Y; Yu, HY; Hu, LW; Yang, BY; Dong, GH. (2020). Alternatives of perfluoroalkyl acids and hepatitis B virus surface antibody in adults: Isomers of C8 Health Project in China. Environ Pollut 259: 113857. 


Zeng, XW; Lodge, CJ; Dharmage, SC; Bloom, MS; Yu, Y; Yang, M; Chu, C; Li, QQ; Hu, LW; Liu, KK; Yang, BY; Dong, GH. (2019). Isomers of per- and polyfluoroalkyl substances and uric acid in adults: Isomers of C8 Health Project in China. Environ Int 133: 105160. 


Zhang, C; Sundaram, R; Maisog, J; Calafat, AM; Barr, DB; Buck Louis, GM. (2015). A prospective study of prepregnancy serum concentrations of perfluorochemicals and the risk of gestational diabetes. Fertil Steril 103: 184-189. 


Zhang, H; Fang, W; Wang, D; Gao, N; Ding, Y; Chen, C. (2014). The role of interleukin family in perfluorooctanoic acid (PFOA)-induced immunotoxicity. J Hazard Mater 280: 552-560. 


Zhang, H; Yolton, K; Webster, GM; Ye, X; Calafat, AM; Dietrich, KN; Xu, Y; Xie, C; Braun, JM; Lanphear, BP; Chen, A. (2018). Prenatal and childhood perfluoroalkyl substances exposures and children's reading skills at ages 5 and 8 years. Environ Int 111: 224-231. 


Zhang, S; Kang, Q; Peng, H; Ding, M; Zhao, F; Zhou, Y; Dong, Z; Zhang, H; Yang, M; Tao, S; Hu, J. (2019). Relationship between perfluorooctanoate and perfluorooctane sulfonate blood concentrations in the general population and routine drinking water exposure. Environ Int 126: 54-60. 


Zhang, Y; Cao, X; Chen, L; Qin, Y; Xu, Y; Tian, Y; Chen, L. (2020). Exposure of female mice to perfluorooctanoic acid suppresses hypothalamic kisspeptin-reproductive endocrine system through enhanced hepatic fibroblast growth factor 21 synthesis, leading to ovulation failure and prolonged dioestrus. J Neuroendocrinol 32: e12848. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/9944433

Zhang, Y; Pan, C; Ren, Y; Wang, Z; Luo, J; Ding, G; Vinturache, A; Wang, X; Shi, R; Ouyang, F; Zhang, J; Li, J; Gao, Y; Tian, Y. (2022). Association of maternal exposure to perfluoroalkyl and polyfluoroalkyl substances with infant growth from birth to 12 months: A prospective cohort study. Sci Total Environ 806: 151303. https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/9944433


Zhao, W; Zitzow, JD; Weaver, Y; Ehresman, DJ; Chang, SC; Butenhoff, JL; Hagenbuch, B. (2017).


Zhong, Y; Shen, L; Ye, X; Zhou, D; He, Y; Zhang, H. (2020). Mechanism of immunosuppression in zebrafish (Danio rerio) spleen induced by environmentally relevant concentrations of perfluorooctanoic acid. Chemosphere 249: 126200. 

Zhong, Y; Shen, L; Ye, X; Zhou, D; He, Y; Zhang, H. (2020). Mechanism of immunosuppression in zebrafish (Danio rerio) spleen induced by environmentally relevant concentrations of perfluorooctanoic acid. Chemosphere 249: 126200. 

Zhong, Y; Shen, L; Ye, X; Zhou, D; He, Y; Zhang, H. (2020). Mechanism of immunosuppression in zebrafish (Danio rerio) spleen induced by environmentally relevant concentrations of perfluorooctanoic acid. Chemosphere 249: 126200. 


Zhou, W; Zhang, L; Tong, C; Fang, F; Zhao, S; Tian, Y; Tao, Y; Zhang, J. (2017). Plasma perfluoroalkyl and polyfluoroalkyl substances concentration and menstrual cycle characteristics in preconception women. Environ Health Perspect 125: 067012. 

Zhou, Y; Bao, WW; Qian, ZM; Dee Geiger, S; Parrish, KL; Yang, BY; Lee, YL; Dong, GH. (2017). Perfluorooalkyl substance exposure and urine CC16 levels among asthmatics: A case-control study of children. Environ Res 159: 158-163. 

Zhou, Y; Hu, LW; Qian, ZM; Chang, JJ; King, C; Paul, G; Lin, S; Chen, PC; Lee, YL; Dong, GH. (2016). Association of perfluoroalkyl substances exposure with reproductive hormone levels in adolescents: By sex status. Environ Int 94: 189-195. 

Zhou, Y; Hu, LW; Qian, ZM; Geiger, SD; Parrish, KL; Dharmage, SC; Campbell, B; Roponen, M; Jalava, P; Hirvonen, MR; Heinrich, J; Zeng, XW; Yang, BY; Qin, XD; Lee, YL; Dong, GH. (2017). Interaction effects of polyfluoroalkyl substances and sex steroid hormones on asthma among children. Sci Rep 7: 899. 

Zhu, Y; Qin, XD; Zeng, XW; Paul, G; Morawska, L; Su, MW; Tsai, CH; Wang, SQ; Lee, YL; Dong, GH. (2016). Associations of serum perfluoroalkyl acid levels with T-helper cell-specific cytokines in children: By gender and asthma status. Sci Total Environ 559: 166-173. 